[{"title01":"Early Intensification with bendamustine supercharge plus brentuximab vedotinfollowing failure to obtain complete metabolic remission after two cycles of ABVD inpatients aged ","title02":"Early Intensification with bendamustine supercharge plus brentuximab vedotinfollowing failure to obtain complete metabolic remission after two cycles of ABVD inpatients aged <\/=60 years with classic Hodgkin lymphoma. Comment on:\"Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkinlymphoma: the LYSA real-world experience\".","journal":"Haematologica","issue":"2026 June 18. doi: 10.3324\/haematol.2026.301273. Online ahead of print","author":"Giordano C, Picardi M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42312413"},{"title01":"Phase II study of lenalidomide maintenance after rituximab-methotrexatebased induction therapy in primary central nervous system lymphoma.","title02":"Phase II study of lenalidomide maintenance after rituximab-methotrexatebased induction therapy in primary central nervous system lymphoma.","journal":"Haematologica","issue":"2026 June 18. doi: 10.3324\/haematol.2026.300790. Online ahead of print","author":"Lee JY, Kim SA, Yang DH, Eum HS, Lee MW, Lee HJ, Kwak JY, Park YH, Do YR, Lee JO","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42312406"},{"title01":"Response-adapted consolidation and salvage strategies in secondary central nervous system lymphoma: Insights from a multicentre cohort.","title02":"Response-adapted consolidation and salvage strategies in secondary central nervous system lymphoma: Insights from a multicentre cohort.","journal":"Br J Haematol","issue":"2026 June 25. doi: 10.1111\/bjh.70633. Online ahead of print","author":"Eigendorff F, Gorke F, Zeremski V, Wollnitza S, Shumilov E, Lenz G, Obstfelder E, Hilgendorf I, Vucinic V, Hochhaus A, Schnetzke U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42351369"},{"title01":"Plasmin-mediated fibrinolysis is required for hematopoietic recovery after 5-FU-induced myeloablation.","title02":"Plasmin-mediated fibrinolysis is required for hematopoietic recovery after 5-FU-induced myeloablation.","journal":"Blood advances","issue":"2026 June 18. doi: 10.1182\/bloodadvances.2025019416. Online ahead of print","author":"Nguyen TPL, Jiang YG, Ogan BM, Doyle AD, Tran DT, Ward JM, Zhang A, Ferrer de Oliveira R, Ferraresso F, Bledsoe JR, Kastrup CJ, Flick MJ, Rowe RG, Bugge TH, Silva LM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42314039"},{"title01":"Single-Cell Analysis of Adaptive NK and CMV-Specific T Cell Dynamics after Allogeneic HSCT.","title02":"Single-Cell Analysis of Adaptive NK and CMV-Specific T Cell Dynamics after Allogeneic HSCT.","journal":"Blood advances","issue":"2026 June 23. doi: 10.1182\/bloodadvances.2026019733. Online ahead of print","author":"Hakkinen AE, Huuhtanen J, Lundgren S, Niittyvuopio R, Salmenniemi U, Lahdesmaki H, Keranen MAI, Myllymaki M, Mustjoki S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42335212"},{"title01":"Outcomes of Adolescents and Young Adults with AML Treated on Pediatric vs Adult Protocols.","title02":"Outcomes of Adolescents and Young Adults with AML Treated on Pediatric vs Adult Protocols.","journal":"Blood advances","issue":"2026 June 18. doi: 10.1182\/bloodadvances.2026020372. Online ahead of print","author":"Krayem B, Biswas J, Derkach A, Rafizadeh M, Ciervo JR, Famulare CA, Abdel-Wahab O, Shukla NN, Trippett T, Forlenza CJ, Ramaswamy K, Tallman MS, Geyer MB, Sulis ML, Stein EM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42314040"},{"title01":"Incidence and Risk Factors for CNS Relapse in Adult ALL after Allogeneic Hematopoietic Cell Transplantation.","title02":"Incidence and Risk Factors for CNS Relapse in Adult ALL after Allogeneic Hematopoietic Cell Transplantation.","journal":"Blood advances","issue":"2026 June 24. doi: 10.1182\/bloodadvances.2026020594. Online ahead of print","author":"Le CTK, Zhang A, Vyas RD, Otani J, Russell K, Cassaday RD, Muffly LS, Liang EC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42348785"},{"title01":"WT1 peptide vaccines of post-allogeneic HSCT maintenance immunotherapy for pediatric acute leukemias: a phase II study.","title02":"WT1 peptide vaccines of post-allogeneic HSCT maintenance immunotherapy for pediatric acute leukemias: a phase II study.","journal":"Blood advances","issue":"2026 June 16. doi: 10.1182\/bloodadvances.2025019352. Online ahead of print","author":"Hashii Y, Oka Y, Sakata N, Hirayama M, Oji Y, Hosen N, Hattori S, Nakajima H, Nakata J, Fujiki F, Morimoto S, Fuji S, Nishida S, Noguchi M, Hino M, Sato A, Tabuchi K, Atsuta Y, Ozono K, Tsuboi A, Sugiyama H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42308229"},{"title01":"Endothelial activation and damage associated with steroid-refractory aGVHD are counteracted by ruxolitinib.","title02":"Endothelial activation and damage associated with steroid-refractory aGVHD are counteracted by ruxolitinib.","journal":"Blood advances","issue":"2026 June 23; 10(12):4379-4389. doi: 10.1182\/bloodadvances.2026019704","author":"De Moner B, Martinez-Sanchez J, Escribano-Serrat S, Moreno-Castano AB, Charry P, Cid J, Lozano M, Arellano-Rodrigo E, Salas MQ, Rovira M, Martinez C, Escolar G, Carreras E, Alvarez-Larran A, Diaz-Ricart M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42048573"},{"title01":"Eligibility versus appropriateness in allogeneic HCT.","title02":"Eligibility versus appropriateness in allogeneic HCT.","journal":"Blood advances","issue":"2026 June 23; 10(12):4117-4119. doi: 10.1182\/bloodadvances.2026020278","author":"Sorror ML, Artz AS, Olin RL, Ramlal R, Giralt SA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41954617"},{"title01":"Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.","title02":"Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.","journal":"Blood advances","issue":"2026 June 23; 10(12):4144-4159. doi: 10.1182\/bloodadvances.2025017738","author":"Levis MJ, Erba HP, Montesinos P, Patkowska E, Cortes J, Perl AE, Dombret H, Amadori S, Wang J, Schlenk RF, Liu L, Mostafa Kamel Y, Imadalou K, Laadem A, Burns K, Sekeres MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41949390"},{"title01":"Nonmyeloablative HLA-identical sibling transplant for sickle cell disease in children: a multicenter prospective study.","title02":"Nonmyeloablative HLA-identical sibling transplant for sickle cell disease in children: a multicenter prospective study.","journal":"Blood advances","issue":"2026 June 23; 10(12):4160-4170. doi: 10.1182\/bloodadvances.2025019567","author":"Nickel RS, Abraham A, Chiang KY, Ali M, Rangarajan HG, Chaudhury S, Kent M, Odinakachukwu M, Kukadiya D, Malloy J, Zhang A, Hardy SJ, Guilcher GMT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41945757"},{"title01":"Supportive care interventions in hematopoietic stem cell transplantation: a systematic review and meta-analysis.","title02":"Supportive care interventions in hematopoietic stem cell transplantation: a systematic review and meta-analysis.","journal":"Blood advances","issue":"2026 June 23; 10(12):4227-4265. doi: 10.1182\/bloodadvances.2026019724","author":"Schaefer DA, Guo M, Keane EP, Song MT, Larizza IS, Adri FN, Wolfe ED, Saadeh N, Boardman AC, Acharya NB, Waldman LP, Monahan JA, Ramirez-Gomero AF, Gonzalez-Colmenero FD, Watson J, Cronin AE, Celano CM, Brown L, Lee SJ, Stoto MA, Gudenkauf LM, Amonoo HL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41925563"},{"title01":"Iron in HSCs: too much of a good thing.","title02":"Iron in HSCs: too much of a good thing.","journal":"Blood","issue":"2026 June 25; 147(26):3131-3132. doi: 10.1182\/blood.2026033923","author":"Stolla MC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42348232"},{"title01":"Immune-mediated side effects of cancer immunotherapies.","title02":"Immune-mediated side effects of cancer immunotherapies.","journal":"Blood","issue":"2026 June 18; 147(25):3001-3024. doi: 10.1182\/blood.2025030059","author":"Braun LM, Naidoo J, Zeiser R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41802111"},{"title01":"Expanded antigen-specific donor regulatory T cells for GVHD prevention.","title02":"Expanded antigen-specific donor regulatory T cells for GVHD prevention.","journal":"Blood","issue":"2026 June 18. doi: 10.1182\/blood.2025030663. Online ahead of print","author":"Pidala JA, Cieri N, Schell MJ, Song X, Shao Y, Cao B, Du D, Thapa R, Betts BC, Janssen W, Cubitt C, Yoder SJ, O'Leary MF, Beato F, Veerapathran A, Menges MA, Burton M, Bejanyan N, Castaneda-Puglianini OA, Elmariah H, Faramand RG, Fernandez HF, Hansen DK, Jain MD, Khimani F, Lazaryan A, Liu HD, Locke FL, Mirza AS, Mishra A, Nieder M, Nishihori T, Ochoa L, Perez LE, Perna F, Ramlal R, Torres NE, Anasetti C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42322116"},{"title01":"Translational Regulation of Sf1 Integrates Alternative Splicing and Hematopoietic Stem Cell Fate.","title02":"Translational Regulation of Sf1 Integrates Alternative Splicing and Hematopoietic Stem Cell Fate.","journal":"Blood","issue":"2026 June 23. doi: 10.1182\/blood.2025032484. Online ahead of print","author":"Liudkovska V, Ciolek M, Grygorowicz D, Kumari A, Binias SI, Mikolajczyk J, Lenkiewicz AM, Konturek-Ciesla A, Szade A, Wojtas B, Serwa R, Turowski TW, Bryder D, Szade K, Ciesla M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42345356"},{"title01":"Niche-targeted therapy via YAP\/TAZ activation enhances hematopoietic regeneration.","title02":"Niche-targeted therapy via YAP\/TAZ activation enhances hematopoietic regeneration.","journal":"Blood","issue":"2026 June 22. doi: 10.1182\/blood.2025030831. Online ahead of print","author":"Uemura S, Yamashita M, Yokomizo-Nakano T, Aihara A, Iwawaki T, Koide S, Nakajima-Takagi Y, Oshima M, Omatsu Y, Matsumoto Y, Kubota Y, Rahmutulla B, Kaneda A, Nishio M, Suzuki A, Nagasawa T, Kagaya K, Nishino T, Iwama A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42329810"},{"title01":"Retinoic acid-driven expansion of CD16hiCD177+ neutrophils mediates steroid-resistant GI-GVHD.","title02":"Retinoic acid-driven expansion of CD16hiCD177+ neutrophils mediates steroid-resistant GI-GVHD.","journal":"Blood","issue":"2026 June 18. doi: 10.1182\/blood.2025032193. Online ahead of print","author":"Liang W, Xu D, Zhang L, Qu Y, Li L, Zhong K, Yao M, Zhu J, Wang S, Tan L, Ding W, Zhang R, Wang F, Zhou W, Bai F, Jiang H, Zhang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42322118"},{"title01":"Iron overload damages mitochondria and induces metabolic rewiring of hematopoietic stem cells toward glycolysis.","title02":"Iron overload damages mitochondria and induces metabolic rewiring of hematopoietic stem cells toward glycolysis.","journal":"Blood","issue":"2026 June 25; 147(26):3217-3230. doi: 10.1182\/blood.2025031552","author":"Sighinolfi S, Cassina L, Lidonnici MR, Beretta S, Stefanoni D, Storto M, Mayerhofer C, Kristiansen TA, Scadden DT, Merelli I, Boletta A, Aprile A, Ferrari G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41878806"},{"title01":"Targeting the METTL1\/m7G axis as a therapeutic strategy in myeloid leukemia.","title02":"Targeting the METTL1\/m7G axis as a therapeutic strategy in myeloid leukemia.","journal":"Blood","issue":"2026 June 18; 147(25):3069-3085. doi: 10.1182\/blood.2025030336","author":"Ren L, Zhang H, Bobileva O, Nai F, Bi H, Chan A, Baker GE, Dong L, Guarin D, Hu W, Li W, Leite I, Wang X, Zhang X, Xue M, Wang H, Qin H, Wu X, Ghoda L, Xu L, Zhang B, Li L, Wunderlich M, Mulloy JC, Jones CL, O'Leary SE, Li H, Rosen ST, Chen CD, Heisterkamp N, Perry JJP, Nam Y, Chen J, Caflisch A, Li X, Su R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42247311"},{"title01":"CD4+CD25+FOXP3+ Regulatory T Cells to Protect Against Graft Versus Host Disease.","title02":"CD4+CD25+FOXP3+ Regulatory T Cells to Protect Against Graft Versus Host Disease.","journal":"Blood","issue":"2026 June 30. doi: 10.1182\/blood.2025029805. Online ahead of print","author":"Negrin RS, Meyer E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42378229"},{"title01":"Female reproductive health-what the classical haematologist needs to know.","title02":"Female reproductive health-what the classical haematologist needs to know.","journal":"Lancet Haematol","issue":"2026 June 16. doi: 10.1016\/S2352-3026(26)00110-9. Online ahead of print","author":"Bannow BS, Akpan I, Baldwin MK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42302802"},{"title01":"Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE).","title02":"Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE).","journal":"J Clin Oncol","issue":"2026 June 20; 44(18):1709-1719. doi: 10.1200\/JCO-25-02835","author":"McKay RR, Xie W, Ajmera A, Araneta A, Jamieson C, Folefac E, Hussain A, Kyriakopoulos CE, Manning DK, Olson A, Parikh M, Parikh R, Saraiya B, Pasquina LW, Madison R, Clifford S, Childress M, Gasco A, Ivy P, Van Allen E, Kochupurakkal B, Shapiro GI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42096662"},{"title01":"Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I\/Ib Trial.","title02":"Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I\/Ib Trial.","journal":"J Clin Oncol","issue":"2026 June 20; 44(18):1697-1708. doi: 10.1200\/JCO-25-02027","author":"Hanna GJ, Zandberg DP, Wong DJ, Sherman E, Sacco AG, Yilmaz E, Hernando-Calvo A, Reiners RD, Bohr D, Salazar RL, O'Connell BC, Raben D, Schulten J, Chung CH, Kaczmar J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42102329"},{"title01":"Bone marrow transplant in aplastic anemia: the horse served us well, but is it still the best ride?","title02":"Bone marrow transplant in aplastic anemia: the horse served us well, but is it still the best ride?","journal":"Haematologica","issue":"2026 June 18. doi: 10.3324\/haematol.2026.301191. Online ahead of print","author":"On YB, Ram R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42312417"},{"title01":"The N6-methyladenosine (m(6)A) methyltransferase Wilms tumour 1-associating protein promotes erythropoiesis via stabilization of STAT5 mRNA.","title02":"The N6-methyladenosine (m(6)A) methyltransferase Wilms tumour 1-associating protein promotes erythropoiesis via stabilization of STAT5 mRNA.","journal":"Br J Haematol","issue":"2026 June 19. doi: 10.1111\/bjh.70613. Online ahead of print","author":"Wu X, Ye W, Ling Y, Wang X, Wang F, Liu X, Yan T, Gong Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42321011"},{"title01":"Delayed Recognition and Significant Morbidity in Adults with Non-Transfusion-Dependent Thalassemia.","title02":"Delayed Recognition and Significant Morbidity in Adults with Non-Transfusion-Dependent Thalassemia.","journal":"Blood advances","issue":"2026 June 18. doi: 10.1182\/bloodadvances.2026020059. Online ahead of print","author":"Cheng AN, Peslak SA, Sheth S, Sayani FA, Lal A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42314035"},{"title01":"Sutimlimab vs B-cell-targeted therapy in cold agglutinin disease: which is the optimal approach?","title02":"Sutimlimab vs B-cell-targeted therapy in cold agglutinin disease: which is the optimal approach?","journal":"Blood","issue":"2026 June 25; 147(26):3135-3143. doi: 10.1182\/blood.2026033150","author":"Fattizzo B, Miyakawa Y, Broome C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41911068"},{"title01":"Arterial iron regulates vasodilation during anemia via endothelial holo alpha-globin.","title02":"Arterial iron regulates vasodilation during anemia via endothelial holo alpha-globin.","journal":"Blood","issue":"2026 June 29. doi: 10.1182\/blood.2025032905. Online ahead of print","author":"Dunaway LS, Nyshadham S, Loeb SA, O'Donnell BL, Abib N, Schug WJ, Juskiewicz ZJ, Luse MA, Stahl ME, Sveeggen TM, Bagher P, Allen JD, Toldo S, Goldfarb AN, Isakson BE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42371808"},{"title01":"Academic point-of-care anti-CD19 CAR T-cell therapy induces durable remission and transient paroxysmal nocturnal hemoglobinuria-type cell expansion in a patient with multi-refractory immune thrombocytopenia.","title02":"Academic point-of-care anti-CD19 CAR T-cell therapy induces durable remission and transient paroxysmal nocturnal hemoglobinuria-type cell expansion in a patient with multi-refractory immune thrombocytopenia.","journal":"Haematologica","issue":"2026 June 25. doi: 10.3324\/haematol.2026.300887. Online ahead of print","author":"Plumer KA, Horster K, Teichert M, Reinhardt HC, Tzalavras A, Roth A, Von Tresckow B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42345064"},{"title01":"A randomized trial of GVHD prophylaxis in haploidentical PBSC transplantation: ATG, PTCy, and low-dose combination therapy.","title02":"A randomized trial of GVHD prophylaxis in haploidentical PBSC transplantation: ATG, PTCy, and low-dose combination therapy.","journal":"Blood","issue":"2026 June 25; 147(26):3168-3178. doi: 10.1182\/blood.2025032569","author":"Yang J, Jia Y, Hu X, Zhou F, Ni X, Wan J, Ding Y, Kang M, Yu X, Jiang C, Wang L, Wan L, Cai Y, Huang C, Qiu H, Ding X, Tong Y, Dong B, Zhou K, Song X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41849227"},{"title01":"Aberrant splicing of MBD1 reshapes the epigenome to drive convergent myeloerythroid defects in MDS.","title02":"Aberrant splicing of MBD1 reshapes the epigenome to drive convergent myeloerythroid defects in MDS.","journal":"Blood","issue":"2026 June 18. doi: 10.1182\/blood.2025030731. Online ahead of print","author":"Chen HTT, Joshi P, Cathelin S, Tazehkand SJ, Adeel SA, Xu J, Tsao E, Mo Y, Kealy D, Dowle A, Balde Z, Xuan M, Gowlett-Park D, Czibere K, Misura A, Bigun O, Sasso R, Lin A, Kundu N, Chadwick D, Usta S, Khazaee T, Chow S, Tsui H, Minden MD, Holding AN, Bridge KS, Zheng G, Hope K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42322117"},{"title01":"Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial.","title02":"Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial.","journal":"Blood","issue":"2026 June 23. doi: 10.1182\/blood.2025032681. Online ahead of print","author":"Knapper S, Thomas A, Hills RK, King S, Thomas I, Marquez-Almuina N, Burns S, Gilkes AF, Irwin S, Sellar RS, Green S, Overgaard UM, Mehta P, Dennis M, Freeman SD, Russell NH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42345353"},{"title01":"Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.","title02":"Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.","journal":"J Clin Oncol","issue":"2026 June 20; 44(18):1730-1744. doi: 10.1200\/JCO-25-02351","author":"Dierickx D, Heimovaara JH, Bellido M, Van Calsteren K, Cardonick E, Garcia AC, Baten A, Evens AM, Ferber A, Fumagalli M, Lampka E, Specht L, Vandecaveye V, Vogelius IR, Alber M, Amant F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42030539"},{"title01":"Resolving diagnostic uncertainty in rare MPL and CALR variants: A practical framework for the haematology clinic.","title02":"Resolving diagnostic uncertainty in rare MPL and CALR variants: A practical framework for the haematology clinic.","journal":"Br J Haematol","issue":"2026 June 18. doi: 10.1111\/bjh.70630. Online ahead of print","author":"Singh S, Dhillon BK, Pandita RM, Jain K, Singh J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42312542"},{"title01":"Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms.","title02":"Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms.","journal":"Blood","issue":"2026 June 23. doi: 10.1182\/blood.2025032631. Online ahead of print","author":"He F, Lin S, Kong T, Fisher DAC, Kim AB, Ramesh V, Brakhane M, Letson CT, Grodzielski M, Cox MJ, Fulbright MC, Xiong Y, Yu L, Yu Y, Ashworth KJ, Siner J, Engeler A, Laranjeira ABA, Sykes SM, Di Paola J, Oh ST","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42345360"},{"title01":"Response-adapted consolidation and salvage strategies in secondary central nervous system lymphoma: Insights from a multicentre cohort.","title02":"Response-adapted consolidation and salvage strategies in secondary central nervous system lymphoma: Insights from a multicentre cohort.","journal":"Br J Haematol","issue":"2026 June 25. doi: 10.1111\/bjh.70633. Online ahead of print","author":"Eigendorff F, Gorke F, Zeremski V, Wollnitza S, Shumilov E, Lenz G, Obstfelder E, Hilgendorf I, Vucinic V, Hochhaus A, Schnetzke U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42351369"},{"title01":"Metabolic heterogeneity-based radiomic model predicts treatment outcomes of primary mediastinal B-cell lymphoma patients in the IELSG37 study.","title02":"Metabolic heterogeneity-based radiomic model predicts treatment outcomes of primary mediastinal B-cell lymphoma patients in the IELSG37 study.","journal":"Br J Haematol","issue":"2026 June 16. doi: 10.1111\/bjh.70614. Online ahead of print","author":"Ceriani L, Milan L, Cascione L, Di Rocco A, Kryachok I, Davies AJ, Stathis A, Rossi D, Johnson PWM, Martelli M, Zucca E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42304704"},{"title01":"Scaffold-free three-dimensional culture of chronic lymphocytic leukaemia preserves B-T-cell cross-talk and enables drug response profiling.","title02":"Scaffold-free three-dimensional culture of chronic lymphocytic leukaemia preserves B-T-cell cross-talk and enables drug response profiling.","journal":"Br J Haematol","issue":"2026 June 26. doi: 10.1111\/bjh.70635. Online ahead of print","author":"Playa-Albinyana H, Giro A, Pineyroa JA, Araujo-Ayala F, Dobano-Lopez C, Otin-Sanchez S, Campo E, Bezombes C, Perez-Galan P, Colomer D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42360285"},{"title01":"Renoir phase III Rituximab-Lenalidomide vs Rituximab as Maintenance Treatment in Relapsed\/Refractory Follicular Lymphoma.","title02":"Renoir phase III Rituximab-Lenalidomide vs Rituximab as Maintenance Treatment in Relapsed\/Refractory Follicular Lymphoma.","journal":"Blood advances","issue":"2026 June 25. doi: 10.1182\/bloodadvances.2025018732. Online ahead of print","author":"Botto B, Boccomini C, Evangelista A, Zilioli VR, Anastasia A, Cavallo F, Merli F, Zanni M, Tani M, Chiarenza A, Liberati AM, Conconi A, Rusconi C, Bari A, Del Giudice I, Gaidano G, Spina M, Maschio N, Castellino C, Rota-Scalabrini D, Puccini B, Arcari A, Bigliardi S, Matta GME, Bianchi B, Mannina D, Marino D, Galieni P, Ciambelli F, Musuraca G, Muzi C, Bottelli C, Genuardi E, Meli E, Ferrero S, Luminari S, Ladetto M, Ciccone G, Vitolo U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42349017"},{"title01":"A practical approach to risk stratification of incidental T cell clonality.","title02":"A practical approach to risk stratification of incidental T cell clonality.","journal":"Blood advances","issue":"2026 June 18. doi: 10.1182\/bloodadvances.2026020090. Online ahead of print","author":"Wilk AJ, Khodadoust MS, Oak JS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42314037"},{"title01":"Anti-CD19 CAR-T in transformed indolent lymphoma versus de novo large B-cell lymphoma: a meta-analysis of 5,006 patients.","title02":"Anti-CD19 CAR-T in transformed indolent lymphoma versus de novo large B-cell lymphoma: a meta-analysis of 5,006 patients.","journal":"Blood advances","issue":"2026 June 18. doi: 10.1182\/bloodadvances.2025019087. Online ahead of print","author":"Zhang MY, Lu KJ, Zhu XQ, Shen LJ, Du J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42314038"},{"title01":"Loss of miR-146a-5p contributes to ibrutinib resistance in mantle cell lymphoma.","title02":"Loss of miR-146a-5p contributes to ibrutinib resistance in mantle cell lymphoma.","journal":"Blood advances","issue":"2026 June 23. doi: 10.1182\/bloodadvances.2025016640. Online ahead of print","author":"Kersy O, Cohen N, Salmon-Divon M, Klener P, Mekin K, Zvida T, Silva MG, Moita F, Cabecadas JM, Trneny M, Basood M, Dreyling M, Durham BH, Abdel-Wahab O, Shpilberg O, Hershkovitz-Rokah O","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42335205"},{"title01":"Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma.","title02":"Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma.","journal":"Blood advances","issue":"2026 June 16. doi: 10.1182\/bloodadvances.2026019675. Online ahead of print","author":"Xu-Monette ZY, Wang C, Wu D, Tzankov A, Moller MB, Visco C, Hsi ED, Zhao X, Lv B, Wang B, Cao X, Yao S, Chiu A, Dybkaer K, Bhagat G, Zu Y, Montes-Moreno S, Pan Z, Bernal-Mizrachi L, van Krieken JHJ, Choi WWL, Tam W, Chen W, Ponzoni M, Ferreri AJM, Parsons BMM, Khajouei F, Sikkink K, Li Y, Hastie AR, Schmitt AD, Young KH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42308239"},{"title01":"Meta-analysis of survival by phased-variant ctDNA and PET response in large B-cell lymphoma.","title02":"Meta-analysis of survival by phased-variant ctDNA and PET response in large B-cell lymphoma.","journal":"Blood advances","issue":"2026 June 24. doi: 10.1182\/bloodadvances.2026020988. Online ahead of print","author":"Gordon MJ, Choo-Wosoba H, Ozcan G, Lakhotia R, Hill E, Melani C, Wilson WH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42341324"},{"title01":"LySeqST: a targeted sequencing assay for robust genomic classification of diffuse large B-cell lymphoma.","title02":"LySeqST: a targeted sequencing assay for robust genomic classification of diffuse large B-cell lymphoma.","journal":"Blood advances","issue":"2026 June 23; 10(12):4208-4214. doi: 10.1182\/bloodadvances.2026020105","author":"Hilton LK, Gillis S, Y-Moayyed F, Bridgers J, Alduaij W, Jiang A, Ben-Neriah S, Collinge B, Wong JCH, Boyle M, Meissner B, Slack GW, Farinha P, Craig JW, Gerrie AS, Villa D, Savage KJ, Sehn LH, Karsan A, Wright GW, Staudt LM, Morin RD, Steidl C, Scott DW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41985007"},{"title01":"E Lesion or Stage IV disease? An Ongoing Unsettled Issue in Pediatric Hodgkin Lymphoma.","title02":"E Lesion or Stage IV disease? An Ongoing Unsettled Issue in Pediatric Hodgkin Lymphoma.","journal":"Blood advances","issue":"2026 June 26. doi: 10.1182\/bloodadvances.2026019753. Online ahead of print","author":"Seelisch J, Mauz-Koerholz C, Kelly KM, Link MP, Punnett A, Stoevesandt D, Palese M, Kaste SC, McCarten KM, Kurch L, Hoppe BS, Flerlage JE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42361346"},{"title01":"Risk factor analysis of 115 children and adolescents with primary mediastinal B-cell lymphoma treated with DA-EPOCH-R.","title02":"Risk factor analysis of 115 children and adolescents with primary mediastinal B-cell lymphoma treated with DA-EPOCH-R.","journal":"Blood advances","issue":"2026 June 23; 10(12):4370-4374. doi: 10.1182\/bloodadvances.2025019553","author":"Meyer-Wentrup F, Jonas SF, Knoerr F, Auperin A, Alexander S, Andres M, Attarbaschi A, Burke GAA, Burkhardt B, Ceppi F, Gross T, Kabickova E, Klapper W, Miles RR, Taj M, Zimmermann M, Minard-Colin V, Woessmann W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41979343"},{"title01":"Invasive fungal infections after Bruton tyrosine kinase inhibitor treatment: a systematic review and meta-analysis.","title02":"Invasive fungal infections after Bruton tyrosine kinase inhibitor treatment: a systematic review and meta-analysis.","journal":"Blood advances","issue":"2026 June 23; 10(12):4171-4182. doi: 10.1182\/bloodadvances.2025019221","author":"Srisurapanont K, Meejun T, Manothummetha K, Li LX, Baddley JW, Schulz CA, Dioverti-Prono MV, Zhang SX, Avery RK, Kates OS, Permpalung N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41954633"},{"title01":"ASH\/ISTH 2026 guidelines for anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism.","title02":"ASH\/ISTH 2026 guidelines for anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism.","journal":"Blood advances","issue":"2026 June 23; 10(12):4303-4333. doi: 10.1182\/bloodadvances.2025019415","author":"Betensky M, Azzam M, Bercovitz R, Bhat RV, Biss T, Branchford B, Brandao LR, Chan AKC, Faustino EVS, Hamarsha Q, Jaffray J, Jones S, Kawtharany H, Kerlin BA, Khawandi J, Krider G, Kucine N, Kumar R, Male C, Monagle P, Pelland-Marcotte MC, Raffini L, Raulji C, Sartain SE, Takemoto CM, Tarango C, Heleen van Ommen C, Velez MC, Vesely SK, Wiernikowski J, Williams S, Wilson HP, Woods G, Mustafa RA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41949461"},{"title01":"Late cytopenia after CD19 chimeric antigen receptor T cell in large B cell lymphoma: A Cell Therapy Consortium Analysis.","title02":"Late cytopenia after CD19 chimeric antigen receptor T cell in large B cell lymphoma: A Cell Therapy Consortium Analysis.","journal":"Blood advances","issue":"2026 June 24. doi: 10.1182\/bloodadvances.2026019953. Online ahead of print","author":"Wudhikarn K, Bromberg M, Brower J, Seshan VE, Bachanova V, Ahmed S, McGuirk JP, Manu G, Maziarz RT, Oluwole OO, Schuster SJ, Porter DL, Bishop MR, Riedell PA, Perales MA, Dahi PB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42341321"},{"title01":"Radiotherapy for indolent primary cutaneous B-cell lymphoma: an international multicenter ILROG analysis.","title02":"Radiotherapy for indolent primary cutaneous B-cell lymphoma: an international multicenter ILROG analysis.","journal":"Blood","issue":"2026 June 18; 147(25):3051-3060. doi: 10.1182\/blood.2025032050","author":"Oertel M, Dabaja B, Gorlich D, Thomas BR, Sim V, Johnstone P, Hashmi A, Levis M, Ackerson B, Hague C, Weil CR, Plastaras J, Roos D, Kirova Y, Fietkau R, Fang PQ, Ng A, Bock F, Tseng YD, Linde P, Dunst J, Terezakis S, Easwaran T, Peeken JC, Wittig A, Yoon HI, Tao R, Illidge T, Kelsey CR, Ricardi U, Binkley MS, Campbell BA, Morris S, Elsayad K, Storck M, Hoppe RT, Eich HT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41824381"},{"title01":"Metabolic plasticity under chronic acidotic stress promotes biphasic adaptive resistance and defines a clinically relevant biomarker signature in multiple myeloma.","title02":"Metabolic plasticity under chronic acidotic stress promotes biphasic adaptive resistance and defines a clinically relevant biomarker signature in multiple myeloma.","journal":"Haematologica","issue":"2026 June 18. doi: 10.3324\/haematol.2026.300533. Online ahead of print","author":"Chen HL, Tsai PC, Lin SC, Tsai FY, Jiang SS, Teng CJ, Chang WW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42312397"},{"title01":"Prognostic impact of Dmax on baseline FDG-PET\/CT in newly diagnosed multiple myeloma.","title02":"Prognostic impact of Dmax on baseline FDG-PET\/CT in newly diagnosed multiple myeloma.","journal":"Haematologica","issue":"2026 June 18. doi: 10.3324\/haematol.2025.300090. Online ahead of print","author":"Raffy L, Etchegaray C, Hindie E, Saut O, Hulin C, Schmitt A, Mesguich C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42312402"},{"title01":"Clinical and immunological effects of adding cyclophosphamide to pomalidomide-dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trial.","title02":"Clinical and immunological effects of adding cyclophosphamide to pomalidomide-dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trial.","journal":"Br J Haematol","issue":"2026 June 16. doi: 10.1111\/bjh.70611. Online ahead of print","author":"Hall A, Croft J, Walker K, Boyd K, Roberts S, Holroyd A, Garg M, Ferris E, Cook G, Pierceall WE, Thakurta A, Gandhi A, Pawlyn C, Brown SR, Kaiser M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42299497"},{"title01":"Measurable residual disease assessment in apheresis product from multiple myeloma patients: Correlation with biology, depth of response and survival.","title02":"Measurable residual disease assessment in apheresis product from multiple myeloma patients: Correlation with biology, depth of response and survival.","journal":"Br J Haematol","issue":"2026 June 18. doi: 10.1111\/bjh.70606. Online ahead of print","author":"Puertas B, Padilla I, Alejo E, Serra-Toral F, Garcia-Mateo A, Lopez-Lopez R, Barez A, Alonso-Alonso JM, Aguilar-Franco C, de Cabo E, Cantalapiedra-Diez A, Garcia-Coca A, Hernandez R, Rey-Bua B, Fonseca-Santos M, Lopez-Parra M, Lopez-Corral L, Gutierrez NC, Vidriales-Vicente MB, Perez JJ, Gonzalez-Calle V, Mateos MV, Escalante F, Flores-Montero J, Puig N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42312383"},{"title01":"BCMA\/CD19 dual-targeting CAR T-cell therapy in older patients with newly diagnosed multiple myeloma: a phase 1 study.","title02":"BCMA\/CD19 dual-targeting CAR T-cell therapy in older patients with newly diagnosed multiple myeloma: a phase 1 study.","journal":"Blood advances","issue":"2026 June 23; 10(12):4134-4143. doi: 10.1182\/bloodadvances.2025019036","author":"Liu J, Fan X, Peng L, Liu J, He H, Qiang W, Jin L, Shi L, Lu J, Guo P, Shah N, Zhang Q, Shen L, Du J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41925575"},{"title01":"A multicenter study of progression risk and outcomes in solitary bone plasmacytoma with and without marrow involvement.","title02":"A multicenter study of progression risk and outcomes in solitary bone plasmacytoma with and without marrow involvement.","journal":"Blood advances","issue":"2026 June 23; 10(12):4286-4295. doi: 10.1182\/bloodadvances.2025019136","author":"Lim KJC, Steinhardt M, Rees MJ, Greipp P, Kelemen K, Dispenzieri A, Jevremovic D, Baughn L, Buadi FK, Dingli D, Hayman SR, Kapoor P, Muchtar E, Leung N, Fonder A, Hobbs M, Hwa YL, Warsame R, Kourelis TV, Cook J, Binder M, Abdallah N, Zanwar S, Lin Y, Go RS, Siddiqui MA, Parrondo RD, Ailawadi S, Roy V, Cooke R, Dun K, Zordan A, Ninkovic S, Best SH, Alatorre GA, Wiedmeier-Nutor JE, Kortum KM, Einsele H, Chhabra S, Bergsagel PL, Kyle RA, Gertz MA, Kumar SK, Rajkumar SV, Fonseca R, Gonsalves WI, Yadav U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42018661"},{"title01":"Clinical Course, Risk Factors, and Therapeutic Response in Multiple Myeloma with Central Nervous System Involvement.","title02":"Clinical Course, Risk Factors, and Therapeutic Response in Multiple Myeloma with Central Nervous System Involvement.","journal":"Blood advances","issue":"2026 June 24. doi: 10.1182\/bloodadvances.2026020668. Online ahead of print","author":"Xiao A, Zanwar SS, Lin Y, Kapoor P, Abdallah N, Baudi F, Binder M, Dispenzieri A, Dingli D, Gertz MA, Gonsalves WI, Hayman SR, Kourelis TV, Leung N, Muchtar E, Siddiqui M, Tan MS, Warsame R, Rajkumar SV, Kumar SK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42348786"},{"title01":"IRF2 is an essential transcription factor with pathogenic and prognostic impact in multiple myeloma.","title02":"IRF2 is an essential transcription factor with pathogenic and prognostic impact in multiple myeloma.","journal":"Blood","issue":"2026 June 25; 147(26):3195-3208. doi: 10.1182\/blood.2025029422","author":"Gomez-Echarte N, Carrasco-Leon A, Maiques-Diaz A, Barrena N, Miranda E, Garate L, Amundarain A, San Martin-Uriz P, Charalampopoulou S, Valcarcel LV, Ariceta B, Rodriguez-Marquez P, Rodriguez-Madoz JR, Ishiguro K, Planes FJ, Rodriguez-Otero P, Mitsiades CS, Martin-Subero JI, San Jose-Eneriz E, Prosper F, Agirre X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42247308"},{"title01":"Multinucleated plasma cells and IgG lambda myeloma in a patient with TEMPI syndrome and renal cell carcinoma.","title02":"Multinucleated plasma cells and IgG lambda myeloma in a patient with TEMPI syndrome and renal cell carcinoma.","journal":"Blood","issue":"2026 June 18; 147(25):3122. doi: 10.1182\/blood.2025032992","author":"Lyle A, Li P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42313435"},{"title01":"Albumin-derived pseudo-Dutcher bodies in nonsecretory myeloma.","title02":"Albumin-derived pseudo-Dutcher bodies in nonsecretory myeloma.","journal":"Blood","issue":"2026 June 25; 147(26):3253. doi: 10.1182\/blood.2026033553","author":"Luo H, Peng S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42348226"},{"title01":"In search of dependencies in myeloma, consider IRF2 too.","title02":"In search of dependencies in myeloma, consider IRF2 too.","journal":"Blood","issue":"2026 June 25; 147(26):3128-3129. doi: 10.1182\/blood.2026033775","author":"Taiana E, Bolli N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42348229"},{"title01":"NSD2 Degradation Remediates the Oncogenic Cistrome in t(4;14) Multiple Myeloma.","title02":"NSD2 Degradation Remediates the Oncogenic Cistrome in t(4;14) Multiple Myeloma.","journal":"Blood","issue":"2026 June 29. doi: 10.1182\/blood.2025031998. Online ahead of print","author":"Hu B, Edwards J, Modi H, Gamez J, Echeagaray OE, Hess K, Ren Y, Anderson D, Larrayoz M, Zhu J, Johnson SA, Deb G, Jankeel D, Janardhanan P, Leisten J, Peng S, Christoforou A, Stong N, Fontanillo C, Bjorklund CC, Hagner PR, Gandhi AK, Martinez-Climent JA, Narla RK, Lopez-Girona A, Rolfe M, Bence N, Mortensen DS, Groocock L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42371798"},{"title01":"Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation.","title02":"Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation.","journal":"J Clin Oncol","issue":"2026 June 25; JCO2600113. doi: 10.1200\/JCO-26-00113. Online ahead of print","author":"Fleischhauer K, Toffalori C, Cugnata F, Hofmann JA, Orofino G, Lorentino F, Ahci-Hanci M, Lange V, Muller CR, Kunadt D, Bornhauser M, Sanz G, Soiffer R, Waterhouse M, Giaccone L, Ali H, Nachtkamp K, Bacigalupo A, Bonifazi F, Luznik L, Facchini L, Bramanti S, Nagler A, Saccardi R, Milano F, Zallio F, Pierini A, Mohty M, Flomenberg N, Takaori-Kondo A, Vey N, Teshima T, Kroger N, Laperche CM, Andreani M, Lupo Stanghellini MT, Peccatori J, Di Serio C, Kobbe G, Al Malki MM, Bruno B, Zeiser R, Lindsley RC, Sanz J, Beelen D, Stolzel F, Sauter J, Schmidt AH, Ciceri F, Vago L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42348822"},{"title01":"Bone marrow transplant in aplastic anemia: the horse served us well, but is it still the best ride?","title02":"Bone marrow transplant in aplastic anemia: the horse served us well, but is it still the best ride?","journal":"Haematologica","issue":"2026 June 18. doi: 10.3324\/haematol.2026.301191. Online ahead of print","author":"On YB, Ram R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42312417"},{"title01":"Prognostic impact of t(9;11) and del(7q) as intermediate-risk abnormalities in acute myeloid leukemia following allo-transplant: an Acute Leukemia Working Party study from the European Society for Blood and Marrow Transplantation.","title02":"Prognostic impact of t(9;11) and del(7q) as intermediate-risk abnormalities in acute myeloid leukemia following allo-transplant: an Acute Leukemia Working Party study from the European Society for Blood and Marrow Transplantation.","journal":"Haematologica","issue":"2026 June 25. doi: 10.3324\/haematol.2025.289080. Online ahead of print","author":"Dalle IA, Galimard JE, Bazarbachi A, De Latour RP, Chevallier P, Dreger P, Olesen G, Yakoub-Agha I, Versluis J, Kuball J, Blau IW, Loron S, Heinicke T, Schneidawind D, Holderried TAW, Wilson K, Schroeder T, Baron F, Brissot E, Esteve J, Nagler A, Mohty M, Ciceri F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42345045"},{"title01":"Measurable residual disease assessment in apheresis product from multiple myeloma patients: Correlation with biology, depth of response and survival.","title02":"Measurable residual disease assessment in apheresis product from multiple myeloma patients: Correlation with biology, depth of response and survival.","journal":"Br J Haematol","issue":"2026 June 18. doi: 10.1111\/bjh.70606. Online ahead of print","author":"Puertas B, Padilla I, Alejo E, Serra-Toral F, Garcia-Mateo A, Lopez-Lopez R, Barez A, Alonso-Alonso JM, Aguilar-Franco C, de Cabo E, Cantalapiedra-Diez A, Garcia-Coca A, Hernandez R, Rey-Bua B, Fonseca-Santos M, Lopez-Parra M, Lopez-Corral L, Gutierrez NC, Vidriales-Vicente MB, Perez JJ, Gonzalez-Calle V, Mateos MV, Escalante F, Flores-Montero J, Puig N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42312383"},{"title01":"Eligibility versus appropriateness in allogeneic HCT.","title02":"Eligibility versus appropriateness in allogeneic HCT.","journal":"Blood advances","issue":"2026 June 23; 10(12):4117-4119. doi: 10.1182\/bloodadvances.2026020278","author":"Sorror ML, Artz AS, Olin RL, Ramlal R, Giralt SA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41954617"},{"title01":"Endothelial activation and damage associated with steroid-refractory aGVHD are counteracted by ruxolitinib.","title02":"Endothelial activation and damage associated with steroid-refractory aGVHD are counteracted by ruxolitinib.","journal":"Blood advances","issue":"2026 June 23; 10(12):4379-4389. doi: 10.1182\/bloodadvances.2026019704","author":"De Moner B, Martinez-Sanchez J, Escribano-Serrat S, Moreno-Castano AB, Charry P, Cid J, Lozano M, Arellano-Rodrigo E, Salas MQ, Rovira M, Martinez C, Escolar G, Carreras E, Alvarez-Larran A, Diaz-Ricart M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42048573"},{"title01":"WT1 peptide vaccines of post-allogeneic HSCT maintenance immunotherapy for pediatric acute leukemias: a phase II study.","title02":"WT1 peptide vaccines of post-allogeneic HSCT maintenance immunotherapy for pediatric acute leukemias: a phase II study.","journal":"Blood advances","issue":"2026 June 16. doi: 10.1182\/bloodadvances.2025019352. Online ahead of print","author":"Hashii Y, Oka Y, Sakata N, Hirayama M, Oji Y, Hosen N, Hattori S, Nakajima H, Nakata J, Fujiki F, Morimoto S, Fuji S, Nishida S, Noguchi M, Hino M, Sato A, Tabuchi K, Atsuta Y, Ozono K, Tsuboi A, Sugiyama H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42308229"},{"title01":"Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.","title02":"Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.","journal":"Blood advances","issue":"2026 June 23; 10(12):4144-4159. doi: 10.1182\/bloodadvances.2025017738","author":"Levis MJ, Erba HP, Montesinos P, Patkowska E, Cortes J, Perl AE, Dombret H, Amadori S, Wang J, Schlenk RF, Liu L, Mostafa Kamel Y, Imadalou K, Laadem A, Burns K, Sekeres MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41949390"},{"title01":"Nonmyeloablative HLA-identical sibling transplant for sickle cell disease in children: a multicenter prospective study.","title02":"Nonmyeloablative HLA-identical sibling transplant for sickle cell disease in children: a multicenter prospective study.","journal":"Blood advances","issue":"2026 June 23; 10(12):4160-4170. doi: 10.1182\/bloodadvances.2025019567","author":"Nickel RS, Abraham A, Chiang KY, Ali M, Rangarajan HG, Chaudhury S, Kent M, Odinakachukwu M, Kukadiya D, Malloy J, Zhang A, Hardy SJ, Guilcher GMT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41945757"},{"title01":"HLA-E single-chain trimer shields gene-edited allogeneic CAR T cells from NK cell attack.","title02":"HLA-E single-chain trimer shields gene-edited allogeneic CAR T cells from NK cell attack.","journal":"Blood advances","issue":"2026 June 23; 10(12):4266-4280. doi: 10.1182\/bloodadvances.2025016927","author":"Apodaca KM, Xu C, Stanton KL, Baroja ML, Alfaro Doblado AR, Engel NW, Wellhausen N, Cox A, Berjis A, Ji M, Bushara O, Perez DM, Welch C, Banerjee E, Assenmacher CA, Sheppard NC, Scholler J, June CH, Carreno BM, Linette GP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41945756"},{"title01":"Characterization of hematopoietic stem cell-derived microglia-like cells in nonhuman primates.","title02":"Characterization of hematopoietic stem cell-derived microglia-like cells in nonhuman primates.","journal":"Blood advances","issue":"2026 June 18. doi: 10.1182\/bloodadvances.2025019337. Online ahead of print","author":"Petty NE, Wolf CB, Kanestrom G, Mendoza M, Swing K, Murnane RD, Tong A, Starrs M, Fields E, Madhu R, Nelson V, Bennett FC, Furlan SN, Loeb KR, Radtke S, Kiem HP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42314036"},{"title01":"Plasmin-mediated fibrinolysis is required for hematopoietic recovery after 5-FU-induced myeloablation.","title02":"Plasmin-mediated fibrinolysis is required for hematopoietic recovery after 5-FU-induced myeloablation.","journal":"Blood advances","issue":"2026 June 18. doi: 10.1182\/bloodadvances.2025019416. Online ahead of print","author":"Nguyen TPL, Jiang YG, Ogan BM, Doyle AD, Tran DT, Ward JM, Zhang A, Ferrer de Oliveira R, Ferraresso F, Bledsoe JR, Kastrup CJ, Flick MJ, Rowe RG, Bugge TH, Silva LM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42314039"},{"title01":"Outcomes of Adolescents and Young Adults with AML Treated on Pediatric vs Adult Protocols.","title02":"Outcomes of Adolescents and Young Adults with AML Treated on Pediatric vs Adult Protocols.","journal":"Blood advances","issue":"2026 June 18. doi: 10.1182\/bloodadvances.2026020372. Online ahead of print","author":"Krayem B, Biswas J, Derkach A, Rafizadeh M, Ciervo JR, Famulare CA, Abdel-Wahab O, Shukla NN, Trippett T, Forlenza CJ, Ramaswamy K, Tallman MS, Geyer MB, Sulis ML, Stein EM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42314040"},{"title01":"Supportive care interventions in hematopoietic stem cell transplantation: a systematic review and meta-analysis.","title02":"Supportive care interventions in hematopoietic stem cell transplantation: a systematic review and meta-analysis.","journal":"Blood advances","issue":"2026 June 23; 10(12):4227-4265. doi: 10.1182\/bloodadvances.2026019724","author":"Schaefer DA, Guo M, Keane EP, Song MT, Larizza IS, Adri FN, Wolfe ED, Saadeh N, Boardman AC, Acharya NB, Waldman LP, Monahan JA, Ramirez-Gomero AF, Gonzalez-Colmenero FD, Watson J, Cronin AE, Celano CM, Brown L, Lee SJ, Stoto MA, Gudenkauf LM, Amonoo HL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41925563"},{"title01":"Incidence and Risk Factors for CNS Relapse in Adult ALL after Allogeneic Hematopoietic Cell Transplantation.","title02":"Incidence and Risk Factors for CNS Relapse in Adult ALL after Allogeneic Hematopoietic Cell Transplantation.","journal":"Blood advances","issue":"2026 June 24. doi: 10.1182\/bloodadvances.2026020594. Online ahead of print","author":"Le CTK, Zhang A, Vyas RD, Otani J, Russell K, Cassaday RD, Muffly LS, Liang EC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42348785"},{"title01":"Single-Cell Analysis of Adaptive NK and CMV-Specific T Cell Dynamics after Allogeneic HSCT.","title02":"Single-Cell Analysis of Adaptive NK and CMV-Specific T Cell Dynamics after Allogeneic HSCT.","journal":"Blood advances","issue":"2026 June 23. doi: 10.1182\/bloodadvances.2026019733. Online ahead of print","author":"Hakkinen AE, Huuhtanen J, Lundgren S, Niittyvuopio R, Salmenniemi U, Lahdesmaki H, Keranen MAI, Myllymaki M, Mustjoki S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42335212"},{"title01":"A randomized trial of GVHD prophylaxis in haploidentical PBSC transplantation: ATG, PTCy, and low-dose combination therapy.","title02":"A randomized trial of GVHD prophylaxis in haploidentical PBSC transplantation: ATG, PTCy, and low-dose combination therapy.","journal":"Blood","issue":"2026 June 25; 147(26):3168-3178. doi: 10.1182\/blood.2025032569","author":"Yang J, Jia Y, Hu X, Zhou F, Ni X, Wan J, Ding Y, Kang M, Yu X, Jiang C, Wang L, Wan L, Cai Y, Huang C, Qiu H, Ding X, Tong Y, Dong B, Zhou K, Song X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41849227"},{"title01":"Immune-mediated side effects of cancer immunotherapies.","title02":"Immune-mediated side effects of cancer immunotherapies.","journal":"Blood","issue":"2026 June 18; 147(25):3001-3024. doi: 10.1182\/blood.2025030059","author":"Braun LM, Naidoo J, Zeiser R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41802111"},{"title01":"Retinoic acid-driven expansion of CD16hiCD177+ neutrophils mediates steroid-resistant GI-GVHD.","title02":"Retinoic acid-driven expansion of CD16hiCD177+ neutrophils mediates steroid-resistant GI-GVHD.","journal":"Blood","issue":"2026 June 18. doi: 10.1182\/blood.2025032193. Online ahead of print","author":"Liang W, Xu D, Zhang L, Qu Y, Li L, Zhong K, Yao M, Zhu J, Wang S, Tan L, Ding W, Zhang R, Wang F, Zhou W, Bai F, Jiang H, Zhang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42322118"},{"title01":"Expanded antigen-specific donor regulatory T cells for GVHD prevention.","title02":"Expanded antigen-specific donor regulatory T cells for GVHD prevention.","journal":"Blood","issue":"2026 June 18. doi: 10.1182\/blood.2025030663. Online ahead of print","author":"Pidala JA, Cieri N, Schell MJ, Song X, Shao Y, Cao B, Du D, Thapa R, Betts BC, Janssen W, Cubitt C, Yoder SJ, O'Leary MF, Beato F, Veerapathran A, Menges MA, Burton M, Bejanyan N, Castaneda-Puglianini OA, Elmariah H, Faramand RG, Fernandez HF, Hansen DK, Jain MD, Khimani F, Lazaryan A, Liu HD, Locke FL, Mirza AS, Mishra A, Nieder M, Nishihori T, Ochoa L, Perez LE, Perna F, Ramlal R, Torres NE, Anasetti C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42322116"},{"title01":"A randomized trial of GVHD prophylaxis in haploidentical PBSC transplantation: ATG, PTCy, and low-dose combination therapy.","title02":"A randomized trial of GVHD prophylaxis in haploidentical PBSC transplantation: ATG, PTCy, and low-dose combination therapy.","journal":"Blood","issue":"2026 June 25; 147(26):3168-3178. doi: 10.1182\/blood.2025032569","author":"Yang J, Jia Y, Hu X, Zhou F, Ni X, Wan J, Ding Y, Kang M, Yu X, Jiang C, Wang L, Wan L, Cai Y, Huang C, Qiu H, Ding X, Tong Y, Dong B, Zhou K, Song X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41849227"},{"title01":"CD4+CD25+FOXP3+ Regulatory T Cells to Protect Against Graft Versus Host Disease.","title02":"CD4+CD25+FOXP3+ Regulatory T Cells to Protect Against Graft Versus Host Disease.","journal":"Blood","issue":"2026 June 30. doi: 10.1182\/blood.2025029805. Online ahead of print","author":"Negrin RS, Meyer E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42378229"},{"title01":"Role of endothelial Dlc1 in embryonic vascular development and adult bone marrow hematopoiesis.","title02":"Role of endothelial Dlc1 in embryonic vascular development and adult bone marrow hematopoiesis.","journal":"Leukemia","issue":"2026 June 25. doi: 10.1038\/s41375-026-03013-1. Online ahead of print","author":"Feng JX, Durkin ME, Yang MT, Li L, Lake R, Li C, Livak F, Tessarollo L, Kruhlak M, Lowy DR, Tosato G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42350604"},{"title01":"Immunological mechanisms and therapeutic advances in chronic myeloid leukemia.","title02":"Immunological mechanisms and therapeutic advances in chronic myeloid leukemia.","journal":"Leukemia","issue":"2026 June 25. doi: 10.1038\/s41375-026-03006-0. Online ahead of print","author":"Ybarra TK, Sathianathen RS, Hamidi R, Hijiya N, Shah NP, Sakamoto KM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42350605"},{"title01":"Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation.","title02":"Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation.","journal":"J Clin Oncol","issue":"2026 June 25; JCO2600113. doi: 10.1200\/JCO-26-00113. Online ahead of print","author":"Fleischhauer K, Toffalori C, Cugnata F, Hofmann JA, Orofino G, Lorentino F, Ahci-Hanci M, Lange V, Muller CR, Kunadt D, Bornhauser M, Sanz G, Soiffer R, Waterhouse M, Giaccone L, Ali H, Nachtkamp K, Bacigalupo A, Bonifazi F, Luznik L, Facchini L, Bramanti S, Nagler A, Saccardi R, Milano F, Zallio F, Pierini A, Mohty M, Flomenberg N, Takaori-Kondo A, Vey N, Teshima T, Kroger N, Laperche CM, Andreani M, Lupo Stanghellini MT, Peccatori J, Di Serio C, Kobbe G, Al Malki MM, Bruno B, Zeiser R, Lindsley RC, Sanz J, Beelen D, Stolzel F, Sauter J, Schmidt AH, Ciceri F, Vago L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42348822"},{"title01":"Prognostic impact of t(9;11) and del(7q) as intermediate-risk abnormalities in acute myeloid leukemia following allo-transplant: an Acute Leukemia Working Party study from the European Society for Blood and Marrow Transplantation.","title02":"Prognostic impact of t(9;11) and del(7q) as intermediate-risk abnormalities in acute myeloid leukemia following allo-transplant: an Acute Leukemia Working Party study from the European Society for Blood and Marrow Transplantation.","journal":"Haematologica","issue":"2026 June 25. doi: 10.3324\/haematol.2025.289080. Online ahead of print","author":"Dalle IA, Galimard JE, Bazarbachi A, De Latour RP, Chevallier P, Dreger P, Olesen G, Yakoub-Agha I, Versluis J, Kuball J, Blau IW, Loron S, Heinicke T, Schneidawind D, Holderried TAW, Wilson K, Schroeder T, Baron F, Brissot E, Esteve J, Nagler A, Mohty M, Ciceri F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42345045"},{"title01":"Response-adapted consolidation and salvage strategies in secondary central nervous system lymphoma: Insights from a multicentre cohort.","title02":"Response-adapted consolidation and salvage strategies in secondary central nervous system lymphoma: Insights from a multicentre cohort.","journal":"Br J Haematol","issue":"2026 June 25. doi: 10.1111\/bjh.70633. Online ahead of print","author":"Eigendorff F, Gorke F, Zeremski V, Wollnitza S, Shumilov E, Lenz G, Obstfelder E, Hilgendorf I, Vucinic V, Hochhaus A, Schnetzke U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42351369"},{"title01":"Characterization of hematopoietic stem cell-derived microglia-like cells in nonhuman primates.","title02":"Characterization of hematopoietic stem cell-derived microglia-like cells in nonhuman primates.","journal":"Blood advances","issue":"2026 June 18. doi: 10.1182\/bloodadvances.2025019337. Online ahead of print","author":"Petty NE, Wolf CB, Kanestrom G, Mendoza M, Swing K, Murnane RD, Tong A, Starrs M, Fields E, Madhu R, Nelson V, Bennett FC, Furlan SN, Loeb KR, Radtke S, Kiem HP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42314036"},{"title01":"Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL.","title02":"Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL.","journal":"Blood advances","issue":"2026 June 25. doi: 10.1182\/bloodadvances.2026020707. Online ahead of print","author":"Othman T, Roloff GW, Miller K, Zhang A, Sutherland KC, Faramand RG, Hill LC, Muhsen IN, Jeyakumar N, Ladha A, Sasine JP, Lin C, Kopmar NE, Tsai SB, O'Connor TE, Hilal T, Solh MM, Guzowski C, Tan V, Majhail NS, Battiwalla M, Malik SA, Mathews J, Shaughnessy PJ, Mountjoy L, Dykes KC, Logan AC, Schwartz MS, Connor MP, Wang J, Vasu S, Kumaran M, Hoeg RT, Tracy SI, Yalniz FF, Yaghmour G, Pullarkat VA, Cassaday RD, Leonard JT, Shah BD, Frey NV, Muffly LS, Aldoss I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42349018"},{"title01":"NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.","title02":"NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.","journal":"Blood advances","issue":"2026 June 23; 10(12):4113-4116. doi: 10.1182\/bloodadvances.2026020243","author":"Bazinet A, Ferrajoli A, Jain N, Burger J, Yilmaz M, Swaminathan M, Kantarjian H, Keating M, Thompson PA, Wierda WG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41879712"},{"title01":"DLK1 is a GATA1s-driven dependency and therapeutic target in Down syndrome-associated myeloid leukemia.","title02":"DLK1 is a GATA1s-driven dependency and therapeutic target in Down syndrome-associated myeloid leukemia.","journal":"Blood advances","issue":"2026 June 23; 10(12):4120-4133. doi: 10.1182\/bloodadvances.2025018830","author":"Verboon LJ, Barwe SP, Tavenner M, Faust JR, Issa H, Goncalves-Dias J, Schuschel K, Bhayadia R, van Berkel PH, Sebastian A, Ries RE, Paczesny S, Meshinchi S, Hitzler J, Pikman Y, Kolb EA, Heckl D, Klusmann JH, Gopalakrishnapillai A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41945753"},{"title01":"Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.","title02":"Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.","journal":"Blood advances","issue":"2026 June 23; 10(12):4144-4159. doi: 10.1182\/bloodadvances.2025017738","author":"Levis MJ, Erba HP, Montesinos P, Patkowska E, Cortes J, Perl AE, Dombret H, Amadori S, Wang J, Schlenk RF, Liu L, Mostafa Kamel Y, Imadalou K, Laadem A, Burns K, Sekeres MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41949390"},{"title01":"ASH\/ISTH 2026 guidelines for anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism.","title02":"ASH\/ISTH 2026 guidelines for anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism.","journal":"Blood advances","issue":"2026 June 23; 10(12):4303-4333. doi: 10.1182\/bloodadvances.2025019415","author":"Betensky M, Azzam M, Bercovitz R, Bhat RV, Biss T, Branchford B, Brandao LR, Chan AKC, Faustino EVS, Hamarsha Q, Jaffray J, Jones S, Kawtharany H, Kerlin BA, Khawandi J, Krider G, Kucine N, Kumar R, Male C, Monagle P, Pelland-Marcotte MC, Raffini L, Raulji C, Sartain SE, Takemoto CM, Tarango C, Heleen van Ommen C, Velez MC, Vesely SK, Wiernikowski J, Williams S, Wilson HP, Woods G, Mustafa RA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41949461"},{"title01":"Single-cell tracking of the fittest in AML.","title02":"Single-cell tracking of the fittest in AML.","journal":"Blood","issue":"2026 June 25; 147(26):3129-3131. doi: 10.1182\/blood.2026034221","author":"Thijssen R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42348231"},{"title01":"CD49d: beyond a prognostic marker in CLL.","title02":"CD49d: beyond a prognostic marker in CLL.","journal":"Blood","issue":"2026 June 25; 147(26):3126-3127. doi: 10.1182\/blood.2026033672","author":"Nguyen PH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42348230"},{"title01":"NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab.","title02":"NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab.","journal":"Blood","issue":"2026 June 23. doi: 10.1182\/blood.2025031693. Online ahead of print","author":"Rubio-Gayarre A, Vinyoles M, Tejedor JR, Guerrero-Murillo M, Fernandez-Fuentes N, Caracuel-Peramos R, Plaza-Calonge MC, Martinez-Moreno A, Roca-Ho H, Petazzi P, Panella-Alferez A, Meseguer-Giron A, Vrenken KS, Fraga MF, Leoz Allegretti P, Palacio-Garcia C, Velasco P, Fuster JL Sr, Stam RW, Rodriguez-Manzaneque JC, Bustelo XR, Robles-Valero J, Menendez P, Bueno C, Lopez-Millan B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42345361"},{"title01":"Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial.","title02":"Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial.","journal":"Blood","issue":"2026 June 23. doi: 10.1182\/blood.2025032681. Online ahead of print","author":"Knapper S, Thomas A, Hills RK, King S, Thomas I, Marquez-Almuina N, Burns S, Gilkes AF, Irwin S, Sellar RS, Green S, Overgaard UM, Mehta P, Dennis M, Freeman SD, Russell NH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42345353"},{"title01":"The prevalence and clinical significance of clonal monocytosis.","title02":"The prevalence and clinical significance of clonal monocytosis.","journal":"Blood","issue":"2026 June 18; 147(25):3039-3050. doi: 10.1182\/blood.2025031883","author":"Dunn WG, Sachs MC, Maggi M, Gu M, Quiros PM, Batta K, Andersen CL, Fabre MA, Chevassut T, Mohorianu I, Wiseman DH, Vassiliou GS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41802133"},{"title01":"Ibrutinib in early stage CLL: Genetic risk factors and treatment outcome in the GCLLSG CLL12 trial.","title02":"Ibrutinib in early stage CLL: Genetic risk factors and treatment outcome in the GCLLSG CLL12 trial.","journal":"Blood","issue":"2026 June 18. doi: 10.1182\/blood.2025032806. Online ahead of print","author":"Riecke A, Robrecht S, Yosifov DY, Schneider C, Giza A, Muller L, Vehling-Kaiser U, Eckart MJ, Freier W, Schottker B, Gaska T, Reiser M, Fink AM, Fischer K, Eichhorst BF, Hallek MJ, Langerbeins P, Stilgenbauer S, Tausch E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42322115"},{"title01":"Frontline CLL: lessons from the final analysis of CLL13-GAIA.","title02":"Frontline CLL: lessons from the final analysis of CLL13-GAIA.","journal":"Blood","issue":"2026 June 18; 147(25):2989-2990. doi: 10.1182\/blood.2026033777","author":"Castonguay M, Anderson MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42313445"},{"title01":"Signal AML stem cells to home: written and sent by METTL1.","title02":"Signal AML stem cells to home: written and sent by METTL1.","journal":"Blood","issue":"2026 June 18; 147(25):2994-2996. doi: 10.1182\/blood.2026033731","author":"Nguyen DTT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42313443"},{"title01":"Targeting the METTL1\/m7G axis as a therapeutic strategy in myeloid leukemia.","title02":"Targeting the METTL1\/m7G axis as a therapeutic strategy in myeloid leukemia.","journal":"Blood","issue":"2026 June 18; 147(25):3069-3085. doi: 10.1182\/blood.2025030336","author":"Ren L, Zhang H, Bobileva O, Nai F, Bi H, Chan A, Baker GE, Dong L, Guarin D, Hu W, Li W, Leite I, Wang X, Zhang X, Xue M, Wang H, Qin H, Wu X, Ghoda L, Xu L, Zhang B, Li L, Wunderlich M, Mulloy JC, Jones CL, O'Leary SE, Li H, Rosen ST, Chen CD, Heisterkamp N, Perry JJP, Nam Y, Chen J, Caflisch A, Li X, Su R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42247311"},{"title01":"Genotype-immunophenotype relationships in NPM1-mutated AML clonal evolution uncovered by single-cell multiomic analysis.","title02":"Genotype-immunophenotype relationships in NPM1-mutated AML clonal evolution uncovered by single-cell multiomic analysis.","journal":"Blood","issue":"2026 June 25; 147(26):3209-3216. doi: 10.1182\/blood.2025030772","author":"Drucker M, Lee D, Bowman M, Zhang X, Kain BN, Nicolet D, Bandopadhyay R, Singh V, Wang Z, Stone RM, Saygin C, Mrozek K, Carroll AJ, Starczynowski DT, Levine RL, Byrd JC, Salomonis N, Skuli SJ, Grimes HL, Eisfeld AK, Bowman RL, Miles LA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41950000"},{"title01":"Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13\/GAIA trial.","title02":"Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13\/GAIA trial.","journal":"Blood","issue":"2026 June 18; 147(25):3025-3038. doi: 10.1182\/blood.2025032160","author":"Furstenau M, Niemann CU, Robrecht S, Rotbain EC, Eurelings L, Giza A, von Tresckow J, Zhang C, Gregor M, Thornton P, Staber PB, Tadmor T, Lindstrom V, Juliusson G, Janssens A, da Cunha-Bang C, Schneider C, Herishanu Y, O'Shea D, Baumann M, Widmer A, Nosslinger T, Poulsen CB, Frederiksen H, Lotfi K, Ranti J, Enggaard L, Velders G, Vekemans MC, de Heer K, Snijders TF, Siemes C, Wendtner CM, Knauf W, Kroeber A, Zahn MO, Illmer T, Schottker B, Simon F, Fink A, Fischer K, D'Brot R, Holmes E, Kreuzer KA, Ritgen M, Bruggemann M, Tausch E, Stilgenbauer S, Levin MD, Hallek M, Kater AP, Eichhorst B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41911073"},{"title01":"A randomized trial of GVHD prophylaxis in haploidentical PBSC transplantation: ATG, PTCy, and low-dose combination therapy.","title02":"A randomized trial of GVHD prophylaxis in haploidentical PBSC transplantation: ATG, PTCy, and low-dose combination therapy.","journal":"Blood","issue":"2026 June 25; 147(26):3168-3178. doi: 10.1182\/blood.2025032569","author":"Yang J, Jia Y, Hu X, Zhou F, Ni X, Wan J, Ding Y, Kang M, Yu X, Jiang C, Wang L, Wan L, Cai Y, Huang C, Qiu H, Ding X, Tong Y, Dong B, Zhou K, Song X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41849227"},{"title01":"Phosphorylated DEK sustains leukemia stem cells by enabling PBX3-driven transcriptional reprogramming.","title02":"Phosphorylated DEK sustains leukemia stem cells by enabling PBX3-driven transcriptional reprogramming.","journal":"Blood","issue":"2026 June 30. doi: 10.1182\/blood.2025032710. Online ahead of print","author":"Lei Y, Lai Y, Li Y, Wang Y, Fan H, Gong Q, Wu F, Yan Q, Zeng H, Deng J, Hou Y, Chen Z","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42378254"},{"title01":"Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.","title02":"Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.","journal":"N Engl J Med","issue":"2026 June 25; 394(24):2440-2448. doi: 10.1056\/NEJMoa2518035","author":"Ruella M, Paruzzo L, Chong ER, Chong EA, Landsburg DJ, Nasta SD, Devi P, Michener P, Stella F, Carturan A, Napier EB, Van Deerlin VM, Porazzi P, Levine BL, Frey N, Porter DL, Fraietta JA, Svoboda J, June CH, Schuster SJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42341302"},{"title01":"Immunosuppression-Associated Peripheral T-Cell Lymphoma.","title02":"Immunosuppression-Associated Peripheral T-Cell Lymphoma.","journal":"N Engl J Med","issue":"2026 June 18; 394(23):2356. doi: 10.1056\/NEJMicm2501877","author":"Cliff ERS, Kenealy M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42294861"},{"title01":"CircZBTB46, a promising therapeutic target in crizotinib resistant ALK-positive T lymphomas.","title02":"CircZBTB46, a promising therapeutic target in crizotinib resistant ALK-positive T lymphomas.","journal":"Leukemia","issue":"2026 June 26. doi: 10.1038\/s41375-026-03018-w. Online ahead of print","author":"Babin L, Andraos E, Fuchs S, Bessiere C, Colras L, Dailhau S, Quelen C, Pinto C, Daoudi I, Pfeifer R, Zamani A, Bousquet M, Pyronnet S, Gaspin C, Lamant L, Meggetto F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42362808"},{"title01":"Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.","title02":"Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.","journal":"Lancet","issue":"2026 June 20; 407(10547):2528-2541. doi: 10.1016\/S0140-6736(26)00866-4","author":"Lenz G, Trneny M, Burke JM, Nowakowski GS, Fox CP, Chiappella A, Duell J, Jeon YW, Cheah CY, Westin J, Ye JZ, Caguioa PB, Belada D, Shin HJ, Oh SY, Amorim S, Ku M, Mocikova H, Jimenez JL, Gaidano G, Rosenwald A, Chiarle R, Colucci P, Ioannidis S, Cheng L, Vitolo U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42217458"},{"title01":"Moving beyond R-CHOP in large B-cell lymphoma.","title02":"Moving beyond R-CHOP in large B-cell lymphoma.","journal":"Lancet","issue":"2026 June 20; 407(10547):2480-2482. doi: 10.1016\/S0140-6736(26)01069-X","author":"Nijland M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42217459"},{"title01":"Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.","title02":"Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.","journal":"J Clin Oncol","issue":"2026 June 20; 44(18):1730-1744. doi: 10.1200\/JCO-25-02351","author":"Dierickx D, Heimovaara JH, Bellido M, Van Calsteren K, Cardonick E, Garcia AC, Baten A, Evens AM, Ferber A, Fumagalli M, Lampka E, Specht L, Vandecaveye V, Vogelius IR, Alber M, Amant F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42030539"},{"title01":"Glofitamab plus polatuzumab vedotin: a novel safe, and highly effective chemotherapy-free regimen for pediatric relapsed\/refractory B-cell non-Hodgkin lymphoma.","title02":"Glofitamab plus polatuzumab vedotin: a novel safe, and highly effective chemotherapy-free regimen for pediatric relapsed\/refractory B-cell non-Hodgkin lymphoma.","journal":"Haematologica","issue":"2026 June 18. doi: 10.3324\/haematol.2026.300836. Online ahead of print","author":"Dong S, Wang M, Luo Z, Wu W, Huang H, Yang J, Liang Y, Jiang H, Qiu L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42312407"},{"title01":"Phase II study of lenalidomide maintenance after rituximab-methotrexatebased induction therapy in primary central nervous system lymphoma.","title02":"Phase II study of lenalidomide maintenance after rituximab-methotrexatebased induction therapy in primary central nervous system lymphoma.","journal":"Haematologica","issue":"2026 June 18. doi: 10.3324\/haematol.2026.300790. Online ahead of print","author":"Lee JY, Kim SA, Yang DH, Eum HS, Lee MW, Lee HJ, Kwak JY, Park YH, Do YR, Lee JO","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42312406"},{"title01":"Gradient of CD79B expression in diffuse large B-cell lymphoma corresponds to stages of germinal center B-cell differentiation.","title02":"Gradient of CD79B expression in diffuse large B-cell lymphoma corresponds to stages of germinal center B-cell differentiation.","journal":"Haematologica","issue":"2026 June 25. doi: 10.3324\/haematol.2025.300248. Online ahead of print","author":"Naoi Y, Chijimatsu R, Urata T, Sunami K, Imai T, Nawa Y, Hiramatsu Y, Yamamoto K, Fujii S, Yoshida I, Yano T, Ikeuchi K, Kobayashi H, Murakami H, Ujiie H, Tani K, Kondo K, Inoue H, Tomida S, Yamamoto A, Seike K, Fujiwara H, Asada N, Fujii K, Fujii N, Matsuoka KI, Boyle M, Jiang A, Farinha P, Takata K, Sato Y, Yoshino T, Maeda Y, Scott DW, Ennishi D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42345068"},{"title01":"The RELEVANCE of long-term follow-up in follicular lymphoma.","title02":"The RELEVANCE of long-term follow-up in follicular lymphoma.","journal":"Blood","issue":"2026 June 18; 147(25):2993-2994. doi: 10.1182\/blood.2026034016","author":"Falconer J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42313442"},{"title01":"Less is more in primary cutaneous indolent B-cell lymphoma.","title02":"Less is more in primary cutaneous indolent B-cell lymphoma.","journal":"Blood","issue":"2026 June 18; 147(25):2992-2993. doi: 10.1182\/blood.2026033604","author":"Specht L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42313441"},{"title01":"Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.","title02":"Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.","journal":"Blood","issue":"2026 June 18; 147(25):3061-3068. doi: 10.1182\/blood.2026033126","author":"Gower N, Feugier P, Westin J, Schiano De Colella JM, Tilly H, Palomba ML, Julia E, Damaj GL, Durand A, Flinn I, Lemonnier F, Morineau N, Ysebaert L, Bartlett N, Thieblemont C, Ribrag V, Gastinne T, Dony A, Fouillet L, Guidez S, Houot R, Da Silva MG, Barnes J, Bijou F, Cartron G, Garcia-Sancho AM, Eradat H, Cheminant M, Guillermo AL, Abrisqueta P, Abraham J, Sarkozy C, Izutsu K, Crochet G, Sehn LH, Gkasiamis A, Yge ML, Chartier L, Fowler N, Xerri L, Salles G, Morschhauser F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41915772"},{"title01":"Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy.","title02":"Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy.","journal":"Blood","issue":"2026 June 25; 147(26):3248-3252. doi: 10.1182\/blood.2026033090","author":"Vodicka P, El-Galaly TC, Prochazka V, Flowers CR, Villa D, Dietrich CE, Jakobsen LH, Ghesquieres H, Clausen MR, Kridel R, Cheah CY, Hawkes EA, Wahlin B, Gandhi MK, Larson MC, Cahn EJ, Friedberg JW, Martin P, Chihara D, Cohen JB, Habermann TM, Casulo C, Wang Y, de Nully Brown P, Mou E, Belada D, Janikova A, Mocikova H, Burack R, Lossos IS, Kahl BS, Smedby KE, Sehn LH, Trneny M, Cerhan JR, Maurer MJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41980013"},{"title01":"Gonadal function and fertility after Hodgkin lymphoma treatment with nivolumab-AVD in the phase 2 GHSG NIVAHL trial.","title02":"Gonadal function and fertility after Hodgkin lymphoma treatment with nivolumab-AVD in the phase 2 GHSG NIVAHL trial.","journal":"Blood","issue":"2026 June 18; 147(25):3118-3121. doi: 10.1182\/blood.2025031809","author":"Robertz AS, Buhnen I, Meissner J, Trautmann-Grill K, Herhaus P, Halbsguth TV, Schaub V, Kerkhoff A, Mathas S, Bormann M, Dickhut A, Jaworek CP, Fuchs M, Kobe C, Baues C, Borchmann P, von Tresckow B, Behringer K, Brockelmann PJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41926569"},{"title01":"A single-cell atlas identifies oncogenic transcriptional programs and immune escape mechanisms in CTCL.","title02":"A single-cell atlas identifies oncogenic transcriptional programs and immune escape mechanisms in CTCL.","journal":"Blood","issue":"2026 June 30. doi: 10.1182\/blood.2025032507. Online ahead of print","author":"Wang C, Geng X, Abdelrahman S, Fu Y, Kady N, Rauf MA, Hristov A, Tejasvi T, Murga-Zamalloa C, Tsoi L, Welch J, Fox J, Carty SA, Gudjonsson JE, Wilcox RA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42378251"},{"title01":"Targeted degradation of CBP\/p300 by CBPD-409 exhibits robust anti-myeloma activity.","title02":"Targeted degradation of CBP\/p300 by CBPD-409 exhibits robust anti-myeloma activity.","journal":"Leukemia","issue":"2026 June 16. doi: 10.1038\/s41375-026-03004-2. Online ahead of print","author":"Corradini S, Maksimos M, Azab F, Arsalani S, Nwarunma E, Watt G, Soutar R, Powell M, Henderson R, Travers J, Chen Z, Wang S, Azab AK, Williams MTS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42303771"},{"title01":"Will mezigdomide find its place in the T-cell redirecting treatment landscape for relapsed multiple myeloma?","title02":"Will mezigdomide find its place in the T-cell redirecting treatment landscape for relapsed multiple myeloma?","journal":"Lancet","issue":"2026 June 17. doi: 10.1016\/S0140-6736(26)01199-2. Online ahead of print","author":"Maura F, Firestone R, Usmani SZ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42309119"},{"title01":"Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.","title02":"Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.","journal":"J Clin Oncol","issue":"2026 June 20; 44(18):1730-1744. doi: 10.1200\/JCO-25-02351","author":"Dierickx D, Heimovaara JH, Bellido M, Van Calsteren K, Cardonick E, Garcia AC, Baten A, Evens AM, Ferber A, Fumagalli M, Lampka E, Specht L, Vandecaveye V, Vogelius IR, Alber M, Amant F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42030539"},{"title01":"Plasticity under pressure: biology and detection of lineage switch in acute leukemia.","title02":"Plasticity under pressure: biology and detection of lineage switch in acute leukemia.","journal":"Leukemia","issue":"2026 June 26. doi: 10.1038\/s41375-026-03020-2. Online ahead of print","author":"Kovach AE, Ding YY, Lamble AJ, Bernt K, Bomken S, Brodersen LE, Buldini B, Colon DD, Coorens THH, Gladden RG, Gu Z, Hu S, Jacoby E, Janssens D, Kurzer JH, Mejstrikova E, Raikar SS, Rheingold SR, Silbert SK, Tan K, Yuan CM, Wang HW, Ghorashian S, Shah NN, Davis KL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42362807"},{"title01":"From data to evidence: why administrative databases alone cannot measure real-world effectiveness in rare diseases &#8211; the case of chronic myeloid leukaemia.","title02":"From data to evidence: why administrative databases alone cannot measure real-world effectiveness in rare diseases &#8211; the case of chronic myeloid leukaemia.","journal":"Leukemia","issue":"2026 June 26. doi: 10.1038\/s41375-026-03037-7. Online ahead of print","author":"Mucherino S, Menditto E, Orlando V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42362804"},{"title01":"Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study.","title02":"Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study.","journal":"Leukemia","issue":"2026 June 18. doi: 10.1038\/s41375-026-03001-5. Online ahead of print","author":"Rinaldetti S, Chepeleva M, Hedblom A, Sticht C, Muciek M, Panayiotidis P, Richter J, Olsson-Stromberg U, Nowak D, Nowak V, Ljungman P, von Bubnoff N, Lotfi K, Stenke L, Brummendorf TH, Hjorth-Hansen H, Gedde-Dahl T, Majeed W, Burchert A, Nazarov PV, Felde E, Tarnopolscaia I, Hoelting C, Fabarius A, Hofmann WK, Mahon FX, Saussele S, Pfirrmann M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42315627"},{"title01":"MYD88 variants in chronic lymphocytic leukemia exhibit distinct biological behaviors and prognostic implications.","title02":"MYD88 variants in chronic lymphocytic leukemia exhibit distinct biological behaviors and prognostic implications.","journal":"Leukemia","issue":"2026 June 26. doi: 10.1038\/s41375-026-03019-9. Online ahead of print","author":"Yan Y, Zhou Y, Chen W, Wang J, Wang T, Yu Y, Xiong W, Jia Y, Yu Z, Zou D, An G, Qiu L, Li F, Yi S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42362806"},{"title01":"Retraction Note: MEK1\/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia.","title02":"Retraction Note: MEK1\/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia.","journal":"Leukemia","issue":"2026 June 24. doi: 10.1038\/s41375-026-03026-w. Online ahead of print","author":"Mazzera L, Abeltino M, Lombardi G, Cantoni AM, Jottini S, Corradi A, Ricca M, Rossetti E, Armando F, Peli A, Ferrari A, Martinelli G, Scupoli MT, Visco C, Bonifacio M, Ripamonti A, Gambacorti-Passerini C, Bonati A, Perris R, Lunghi P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42342852"},{"title01":"Small interfering RNA-mediated silencing of mutant NPM1 suppresses acute myeloid leukemia via reversing KAT7 and p300-mediated histone acetylation.","title02":"Small interfering RNA-mediated silencing of mutant NPM1 suppresses acute myeloid leukemia via reversing KAT7 and p300-mediated histone acetylation.","journal":"Leukemia","issue":"2026 June 26. doi: 10.1038\/s41375-026-03014-0. Online ahead of print","author":"Hou Y, Xing Y, Chen C, Su D, Zhou Z, Ye Y, Lai Z, Peng Z, Cai H, Sun M, Liu Y, Yang B, Huang H, Li Z, Li J, Li J, Gao H, Li J, Zhao H, Shi Y, Chen Q, Long J, Hu J, Zhou D, Chen L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42362805"},{"title01":"Outcomes of patients with chronic lymphocytic leukemia discontinuing covalent Bruton tyrosine kinase inhibitors due to adverse events.","title02":"Outcomes of patients with chronic lymphocytic leukemia discontinuing covalent Bruton tyrosine kinase inhibitors due to adverse events.","journal":"Leukemia","issue":"2026 June 25. doi: 10.1038\/s41375-026-03005-1. Online ahead of print","author":"Mansour AG, Huang Y, Pemberton JP, Alsouqi A, Kittai AS, Byrd JC, Grever MR, Miller C, Lozanski G, Wiczer T, Lundberg J, Rosen L, Crawford C, Everhart T, Moran M, Lucas M, Hinton S, Grantier C, Hoffman C, Reid M, Rogers KA, Bhat SA, Woyach JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42350607"},{"title01":"Genomic landscape of acute myeloid leukemia in adolescents and young adults.","title02":"Genomic landscape of acute myeloid leukemia in adolescents and young adults.","journal":"Leukemia","issue":"2026 June 25. doi: 10.1038\/s41375-026-03010-4. Online ahead of print","author":"Vasseur L, Duployez N, Lambert J, Lapillonne H, De Botton S, Marceau-Renaut A, Lengline E, Recher C, Strullu M, Saultier P, Jourdan E, Gardin C, Balsat M, Cornillet-Lefebvre P, Penther D, Luquet I, Cuccuini W, Leverger G, Petit A, Preudhomme C, Boissel N, Fenwarth L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42350606"},{"title01":"Immunological mechanisms and therapeutic advances in chronic myeloid leukemia.","title02":"Immunological mechanisms and therapeutic advances in chronic myeloid leukemia.","journal":"Leukemia","issue":"2026 June 25. doi: 10.1038\/s41375-026-03006-0. Online ahead of print","author":"Ybarra TK, Sathianathen RS, Hamidi R, Hijiya N, Shah NP, Sakamoto KM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42350605"},{"title01":"Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.","title02":"Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.","journal":"J Clin Oncol","issue":"2026 June 20; 44(18):1730-1744. doi: 10.1200\/JCO-25-02351","author":"Dierickx D, Heimovaara JH, Bellido M, Van Calsteren K, Cardonick E, Garcia AC, Baten A, Evens AM, Ferber A, Fumagalli M, Lampka E, Specht L, Vandecaveye V, Vogelius IR, Alber M, Amant F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42030539"},{"title01":"Dual CDK2 and CDK4\/6 inhibition suppresses Rb\/E2F signaling and enhances anti-leukemic activity in acute myeloid leukemia.","title02":"Dual CDK2 and CDK4\/6 inhibition suppresses Rb\/E2F signaling and enhances anti-leukemic activity in acute myeloid leukemia.","journal":"Haematologica","issue":"2026 June 18. doi: 10.3324\/haematol.2026.300728. Online ahead of print","author":"Weisberg E, Chowdhury B, Garg S, Akatsu T, Ni W, Gokhale PC, Eschle BK, Grant S, Sattler M, DeCaprio JA, Noltner L, Garcia J, Marinchev K, Galinsky I, Nath A, Stone RM, Griffin JD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42312423"},{"title01":"Scaffold-free three-dimensional culture of chronic lymphocytic leukaemia preserves B-T-cell cross-talk and enables drug response profiling.","title02":"Scaffold-free three-dimensional culture of chronic lymphocytic leukaemia preserves B-T-cell cross-talk and enables drug response profiling.","journal":"Br J Haematol","issue":"2026 June 26. doi: 10.1111\/bjh.70635. Online ahead of print","author":"Playa-Albinyana H, Giro A, Pineyroa JA, Araujo-Ayala F, Dobano-Lopez C, Otin-Sanchez S, Campo E, Bezombes C, Perez-Galan P, Colomer D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42360285"},{"title01":"Comparative atrial fibrillation risk across Bruton&#8217;s tyrosine kinase inhibitors in B-cell malignancies: A nationwide population-based study.","title02":"Comparative atrial fibrillation risk across Bruton&#8217;s tyrosine kinase inhibitors in B-cell malignancies: A nationwide population-based study.","journal":"Br J Haematol","issue":"2026 June 23. doi: 10.1111\/bjh.70634. Online ahead of print","author":"Zelmat Y, Ysebaert L, Gautier P, Sommet A, Lafaurie M, Despas F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42334369"},{"title01":"Diagnosis and management of neutropenia in adults: Expert guidance.","title02":"Diagnosis and management of neutropenia in adults: Expert guidance.","journal":"Br J Haematol","issue":"2026 June 29. doi: 10.1111\/bjh.70640. Online ahead of print","author":"Welte K, Zeidler C, Skokowa J, Mellor-Heineke S, Bolyard AA, Dale D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42366919"},{"title01":"Rapid and Reproducible Karyotyping with Long Read Sequencing in AML Patients.","title02":"Rapid and Reproducible Karyotyping with Long Read Sequencing in AML Patients.","journal":"Blood advances","issue":"2026 June 25. doi: 10.1182\/bloodadvances.2026019960. Online ahead of print","author":"Heuser M, Dolnik A, Arnhardt I, Lai CK, Jahn E, Salim M, Gohring G, Behrens Y, Luhmann JL, Steinemann D, Neugebohren M, Schrezenmeier JF, Alwie Y, Kloos A, Baurmann G, Westermann J, Damm F, Dohner H, Ganser A, Thol FR, Blau O, Dohner K, Bullinger L, Gabdoulline R, Strang JE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42349015"},{"title01":"Low-Dose Vemurafenib Plus Rituximab in Front-Line and Relapsed or Refractory Hairy Cell Leukemia: The Scripps Regimen.","title02":"Low-Dose Vemurafenib Plus Rituximab in Front-Line and Relapsed or Refractory Hairy Cell Leukemia: The Scripps Regimen.","journal":"Blood advances","issue":"2026 June 16. doi: 10.1182\/bloodadvances.2025019243. Online ahead of print","author":"Hermel DJ, Saven A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42308249"},{"title01":"Minimal Residual Disease by High-Throughput Sequencing in Standard Risk-Favorable Pediatric B-Lymphoblastic Leukemia.","title02":"Minimal Residual Disease by High-Throughput Sequencing in Standard Risk-Favorable Pediatric B-Lymphoblastic Leukemia.","journal":"Blood advances","issue":"2026 June 24. doi: 10.1182\/bloodadvances.2026020975. Online ahead of print","author":"Fries C, Ji L, Devidas M, Rabin KR, Loh ML, Lee LW, Kirsch IR, Teachey DT, Gupta S, Wood BL, Rau RE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42348788"},{"title01":"Incidence and Risk Factors for CNS Relapse in Adult ALL after Allogeneic Hematopoietic Cell Transplantation.","title02":"Incidence and Risk Factors for CNS Relapse in Adult ALL after Allogeneic Hematopoietic Cell Transplantation.","journal":"Blood advances","issue":"2026 June 24. doi: 10.1182\/bloodadvances.2026020594. Online ahead of print","author":"Le CTK, Zhang A, Vyas RD, Otani J, Russell K, Cassaday RD, Muffly LS, Liang EC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42348785"},{"title01":"Mining single-cell transcriptomic data reveals distinct T-cell population in pediatric B-ALL and AML at diagnosis.","title02":"Mining single-cell transcriptomic data reveals distinct T-cell population in pediatric B-ALL and AML at diagnosis.","journal":"Blood advances","issue":"2026 June 23; 10(12):4199-4205. doi: 10.1182\/bloodadvances.2025019565","author":"Tian L, Gottschalk S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41979357"},{"title01":"CAR T Cell Therapy as a Definitive Consolidation for Older Adults with B-ALL in First Complete Remission.","title02":"CAR T Cell Therapy as a Definitive Consolidation for Older Adults with B-ALL in First Complete Remission.","journal":"Blood advances","issue":"2026 June 24. doi: 10.1182\/bloodadvances.2026020963. Online ahead of print","author":"Aldoss I, Goldberg L, Zhang J, Artz AS, Clark MC, Guan M, Espinosa R, Abimannan T, Wu J, Garcia B, Haas ER, Pathak KV, Lovell B, Pirrotte P, Agrawal V, Sanani N, Kasten S, Tilakawardane D, Wagner JR, Paul J, Shan H, Khaled S, Budde LE, Koller PB, Stein AS, Pullarkat VA, Salhotra A, Aribi A, Marcucci G, Wang X, Forman SJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42341322"},{"title01":"Adding induction intrathecal cytarabine in newly diagnosed CNS2 B-acute lymphoblastic leukemia does not improve outcomes.","title02":"Adding induction intrathecal cytarabine in newly diagnosed CNS2 B-acute lymphoblastic leukemia does not improve outcomes.","journal":"Blood advances","issue":"2026 June 23; 10(12):4184-4192. doi: 10.1182\/bloodadvances.2026019660","author":"Lee-Miller CA, Kairalla JA, Hibbitts E, Winick NJ, Rabin KR, Angiolillo A, Schore RJ, Salzer WL, Burke MJ, Loh ML, Raetz EA, Hunger SP, Devidas M, Teachey DT, Gupta S, McNeer JL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41984995"},{"title01":"SAVE, Safe Accelerated Venetoclax Escalation: A phase Ib study of obinutuzumab plus venetoclax with daily ramp-up in CLL.","title02":"SAVE, Safe Accelerated Venetoclax Escalation: A phase Ib study of obinutuzumab plus venetoclax with daily ramp-up in CLL.","journal":"Blood advances","issue":"2026 June 23. doi: 10.1182\/bloodadvances.2026020392. Online ahead of print","author":"Crombie JL, Ahn IE, Ren Y, Tyekucheva S, Carey C, Kniezewski M, Normilus S, Solomon S, Montegaard J, Kim AI, Merryman RW, Armand P, Fisher DC, Brown JR, Davids MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42335220"},{"title01":"Chromosome 15q deletions confer inferior outcomes among children with ETV6::RUNX1 B-cell acute lymphoblastic leukemia.","title02":"Chromosome 15q deletions confer inferior outcomes among children with ETV6::RUNX1 B-cell acute lymphoblastic leukemia.","journal":"Blood advances","issue":"2026 June 23; 10(12):4109-4112. doi: 10.1182\/bloodadvances.2026019599","author":"Wang'ondu R, Kairalla JA, Shago M, Angiolillo AL, Breidenbach H, Burke MJ, Carroll AJ, Rabin KR, Salzer WL, Schore RJ, Wang C, Hunger SP, Teachey DT, Raetz EA, Loh ML, Davis KL, Rau RE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41985005"},{"title01":"WT1 peptide vaccines of post-allogeneic HSCT maintenance immunotherapy for pediatric acute leukemias: a phase II study.","title02":"WT1 peptide vaccines of post-allogeneic HSCT maintenance immunotherapy for pediatric acute leukemias: a phase II study.","journal":"Blood advances","issue":"2026 June 16. doi: 10.1182\/bloodadvances.2025019352. Online ahead of print","author":"Hashii Y, Oka Y, Sakata N, Hirayama M, Oji Y, Hosen N, Hattori S, Nakajima H, Nakata J, Fujiki F, Morimoto S, Fuji S, Nishida S, Noguchi M, Hino M, Sato A, Tabuchi K, Atsuta Y, Ozono K, Tsuboi A, Sugiyama H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42308229"},{"title01":"Treatment-Free Remission and Immune Profiling after Frontline Second-Generation TKI Therapy in CML.","title02":"Treatment-Free Remission and Immune Profiling after Frontline Second-Generation TKI Therapy in CML.","journal":"Blood advances","issue":"2026 June 18. doi: 10.1182\/bloodadvances.2026020915. Online ahead of print","author":"Takahashi N, Minami Y, Fujioka Y, Ohtake S, Atsuta Y, Kurata M, Ono T, Sato S, Yano S, Fujimaki K, Maeda T, Ozawa Y, Sakaida E, Kondo T, Yamamoto M, Iriyama N, Miyamoto T, Kiyoi H, Miyazaki Y, Matsumura I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42314090"},{"title01":"Caution in Interpreting Prognostic Genomic Factors in Underpowered Subgroups of Children with T-ALL.","title02":"Caution in Interpreting Prognostic Genomic Factors in Underpowered Subgroups of Children with T-ALL.","journal":"Blood advances","issue":"2026 June 18. doi: 10.1182\/bloodadvances.2026019613. Online ahead of print","author":"Simonin M, Baruchel A, Asnafi V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42314087"},{"title01":"Outcomes of Adolescents and Young Adults with AML Treated on Pediatric vs Adult Protocols.","title02":"Outcomes of Adolescents and Young Adults with AML Treated on Pediatric vs Adult Protocols.","journal":"Blood advances","issue":"2026 June 18. doi: 10.1182\/bloodadvances.2026020372. Online ahead of print","author":"Krayem B, Biswas J, Derkach A, Rafizadeh M, Ciervo JR, Famulare CA, Abdel-Wahab O, Shukla NN, Trippett T, Forlenza CJ, Ramaswamy K, Tallman MS, Geyer MB, Sulis ML, Stein EM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42314040"},{"title01":"Treatment duration matters in frontline CLL comparisons.","title02":"Treatment duration matters in frontline CLL comparisons.","journal":"Blood advances","issue":"2026 June 25. doi: 10.1182\/bloodadvances.2026021200. Online ahead of print","author":"Mao G, Lan H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42349014"},{"title01":"FGF18 mediates fibroblast-leukemia crosstalk to promote acute myeloid leukemia progression.","title02":"FGF18 mediates fibroblast-leukemia crosstalk to promote acute myeloid leukemia progression.","journal":"Blood","issue":"2026 June 26. doi: 10.1182\/blood.2026033125. Online ahead of print","author":"Zhang W, Ye Z, Zhou X, Xiong P, Pan Y, Qiu J, Li M, Shen J, Li Y, Lu \u59da, Chen Y, Bai X, Xie X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42360909"},{"title01":"Menin-MLL inhibitors enhance JUND activity in MLLr leukemic cells contributing to tumorigenesis and therapy resistance.","title02":"Menin-MLL inhibitors enhance JUND activity in MLLr leukemic cells contributing to tumorigenesis and therapy resistance.","journal":"Blood","issue":"2026 June 29. doi: 10.1182\/blood.2025032363. Online ahead of print","author":"Ozyerli-Goknar E PhD, Nizamuddin S, Fetsch V, Biniossek ML, Hartmann A, Perner F, McGeehan GM, Armstrong SA, Zeiser R, Timmers HTM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42371796"},{"title01":"CD49d governs immune synapse formation through actin rearrangements and synchronizes BCR signaling in CLL.","title02":"CD49d governs immune synapse formation through actin rearrangements and synchronizes BCR signaling in CLL.","journal":"Blood","issue":"2026 June 25; 147(26):3179-3194. doi: 10.1182\/blood.2024027753","author":"Polcik L, Pethe A, Ashok D, Tissino E, Fernandez-Rego A, Pozzo F, Danner DJ, Holst M, Martines C, Hofmann K, Dimovski AJ, Kissel S, Harzschel A, Li L, Bittolo T, Andrieux G, Haslauer T, Hopner JP, Zaborsky N, Greil R, Miething C, Duque-Afonso J, Kohler N, Boerries M, Bomben R, Duyster J, Grosse R, Gaidano G, Zamo A, Zucchetto A, Carrasco YR, Efremov DG, Gattei V, Hartmann TN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41790574"},{"title01":"Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.","title02":"Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.","journal":"N Engl J Med","issue":"2026 June 25; 394(24):2440-2448. doi: 10.1056\/NEJMoa2518035","author":"Ruella M, Paruzzo L, Chong ER, Chong EA, Landsburg DJ, Nasta SD, Devi P, Michener P, Stella F, Carturan A, Napier EB, Van Deerlin VM, Porazzi P, Levine BL, Frey N, Porter DL, Fraietta JA, Svoboda J, June CH, Schuster SJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42341302"},{"title01":"Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation.","title02":"Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation.","journal":"J Clin Oncol","issue":"2026 June 25; JCO2600113. doi: 10.1200\/JCO-26-00113. Online ahead of print","author":"Fleischhauer K, Toffalori C, Cugnata F, Hofmann JA, Orofino G, Lorentino F, Ahci-Hanci M, Lange V, Muller CR, Kunadt D, Bornhauser M, Sanz G, Soiffer R, Waterhouse M, Giaccone L, Ali H, Nachtkamp K, Bacigalupo A, Bonifazi F, Luznik L, Facchini L, Bramanti S, Nagler A, Saccardi R, Milano F, Zallio F, Pierini A, Mohty M, Flomenberg N, Takaori-Kondo A, Vey N, Teshima T, Kroger N, Laperche CM, Andreani M, Lupo Stanghellini MT, Peccatori J, Di Serio C, Kobbe G, Al Malki MM, Bruno B, Zeiser R, Lindsley RC, Sanz J, Beelen D, Stolzel F, Sauter J, Schmidt AH, Ciceri F, Vago L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42348822"},{"title01":"Prognostic impact of t(9;11) and del(7q) as intermediate-risk abnormalities in acute myeloid leukemia following allo-transplant: an Acute Leukemia Working Party study from the European Society for Blood and Marrow Transplantation.","title02":"Prognostic impact of t(9;11) and del(7q) as intermediate-risk abnormalities in acute myeloid leukemia following allo-transplant: an Acute Leukemia Working Party study from the European Society for Blood and Marrow Transplantation.","journal":"Haematologica","issue":"2026 June 25. doi: 10.3324\/haematol.2025.289080. Online ahead of print","author":"Dalle IA, Galimard JE, Bazarbachi A, De Latour RP, Chevallier P, Dreger P, Olesen G, Yakoub-Agha I, Versluis J, Kuball J, Blau IW, Loron S, Heinicke T, Schneidawind D, Holderried TAW, Wilson K, Schroeder T, Baron F, Brissot E, Esteve J, Nagler A, Mohty M, Ciceri F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42345045"},{"title01":"Combining inotuzumab ozogamicin with the p38 inhibitor BIRB 796 and venetoclax exerts synergistic cytotoxicity in B-cell precursor acute lymphoblastic leukemia including very high risk t(17;19) acute lymphoblastic leukemia.","title02":"Combining inotuzumab ozogamicin with the p38 inhibitor BIRB 796 and venetoclax exerts synergistic cytotoxicity in B-cell precursor acute lymphoblastic leukemia including very high risk t(17;19) acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 June 25. doi: 10.3324\/haematol.2026.300519. Online ahead of print","author":"Fleischer L, Kirchhoff H, Schoenherr C, Heidenreich O, Scherr M, Eder M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42345047"},{"title01":"Sunburned blasts: ultraviolet imprints on aneuploid pediatric leukemia.","title02":"Sunburned blasts: ultraviolet imprints on aneuploid pediatric leukemia.","journal":"Haematologica","issue":"2026 June 18. doi: 10.3324\/haematol.2026.301185. Online ahead of print","author":"Ntziachristos P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42312390"},{"title01":"Prime salvage treatment for pediatric acute myeloid leukemia.","title02":"Prime salvage treatment for pediatric acute myeloid leukemia.","journal":"Haematologica","issue":"2026 June 18. doi: 10.3324\/haematol.2026.300975. Online ahead of print","author":"Kaspers GJL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42312394"},{"title01":"Second-line bosutinib for chronic phase chronic myeloid leukemia after imatinib: final, 10-year results of a phase I\/II study.","title02":"Second-line bosutinib for chronic phase chronic myeloid leukemia after imatinib: final, 10-year results of a phase I\/II study.","journal":"Haematologica","issue":"2026 June 18. doi: 10.3324\/haematol.2025.300221. Online ahead of print","author":"Gambacorti-Passerini C, Brummendorf TH, Kim DW, Goh YT, Dyagil I, Pagnano K, Batai A, Turkina AG, Leip E, Purcell S, Leone J, Viqueira A, Cortes JE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42312395"},{"title01":"The gap narrows but shifts. Response to Comment on: &#8220;Mind the gap: anti-PD-1 salvage before autologous transplantation in classical Hodgkin lymphoma&#8221;.","title02":"The gap narrows but shifts. Response to Comment on: &#8220;Mind the gap: anti-PD-1 salvage before autologous transplantation in classical Hodgkin lymphoma&#8221;.","journal":"Haematologica","issue":"2026 June 4. doi: 10.3324\/haematol.2026.301293. Online ahead of print","author":"Noerenberg D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42237766"},{"title01":"Reply to: &#8220;Liberalized Diets During Neutropenia: Ongoing Uncertainty in Hematopoietic Stem-Cell Transplantation&#8221; and &#8220;Impact of Transplant Type on Infection Risk in Studies of Neutropenic Diets&#8221;.","title02":"Reply to: &#8220;Liberalized Diets During Neutropenia: Ongoing Uncertainty in Hematopoietic Stem-Cell Transplantation&#8221; and &#8220;Impact of Transplant Type on Infection Risk in Studies of Neutropenic Diets&#8221;.","journal":"J Clin Oncol","issue":"2026 June 1; JCO2600696. doi: 10.1200\/JCO-26-00696. Online ahead of print","author":"Wingard JR, Lee JH, Li D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42224639"},{"title01":"Another &#8220;one stone hit two birds&#8221; candidate in chronic GVHD.","title02":"Another &#8220;one stone hit two birds&#8221; candidate in chronic GVHD.","journal":"Blood","issue":"2026 June 4; 147(23):2711-2712. doi: 10.1182\/blood.2026033671","author":"Wolff D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42241042"},{"title01":"A novel CD7-directed antibody-drug conjugate targeting BCL-XL with potent anti-leukemic activity in T-cell acute lymphoblastic leukemia.","title02":"A novel CD7-directed antibody-drug conjugate targeting BCL-XL with potent anti-leukemic activity in T-cell acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 June 8. doi: 10.1038\/s41375-026-02998-z. Online ahead of print","author":"Oliveira ML, Nuantang K, Hure G, Avila-Avila A, Bresson L, Haumont S, Kostova V, Novak T, Le Toumelin-Braizat G, Guerlesquin J, Demarles D, Merdas M, Cauquil N, Goundiam O, Rocchetti F, Courtade-Gaiani S, Valour D, Zerhouni M, Artus R, Douillet-Michel E, Laurent I, Denis A, Ovreiu A, Duvauchelle B, Ecsedi M, Colland F, Geneste O, Maragno AL, Ghysdael J, Tran Quang C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42260111"},{"title01":"Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines Committee.","title02":"Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines Committee.","journal":"Lancet Haematol","issue":"2026 June; 13(6):e408-e417. doi: 10.1016\/S2352-3026(26)00046-3","author":"Gurnari C, Armstrong C, Battipaglia G, Bentolila G, Brissot E, Chalandon Y, Barroso Duarte F, Drozd-Sokolowska J, Funke V, Gagelmann N, Guillaume T, Hasserjian R, Hernandez-Boluda JC, Hiwase D, Jerez A, Loschi M, Medjugorac M, Moonim MT, Polverelli N, Quarchioni M, Scheid C, Sockel K, Wiseman DH, Onida F, Raj K, Ruggeri A, Sanchez-Ortega I, Garcia NA, Cazzola M, Ciceri F, Czerw T, Maciejewski JP, Pagliuca S, Pleyer L, Sobieralski P, Versluis J, Voso MT, McLornan DP, Yakoub-Agha I, Robin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42242262"},{"title01":"Liberalized Diets During Neutropenia: Ongoing Uncertainty in Hematopoietic Stem-Cell Transplantation.","title02":"Liberalized Diets During Neutropenia: Ongoing Uncertainty in Hematopoietic Stem-Cell Transplantation.","journal":"J Clin Oncol","issue":"2026 June 1; JCO2600254. doi: 10.1200\/JCO-26-00254. Online ahead of print","author":"Pham B, New J, Tzachanis D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42224641"},{"title01":"Reply to: &#8220;Liberalized Diets During Neutropenia: Ongoing Uncertainty in Hematopoietic Stem-Cell Transplantation&#8221; and &#8220;Impact of Transplant Type on Infection Risk in Studies of Neutropenic Diets&#8221;.","title02":"Reply to: &#8220;Liberalized Diets During Neutropenia: Ongoing Uncertainty in Hematopoietic Stem-Cell Transplantation&#8221; and &#8220;Impact of Transplant Type on Infection Risk in Studies of Neutropenic Diets&#8221;.","journal":"J Clin Oncol","issue":"2026 June 1; JCO2600696. doi: 10.1200\/JCO-26-00696. Online ahead of print","author":"Wingard JR, Lee JH, Li D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42224639"},{"title01":"Sequential therapy with allogeneic HCT in patients aged >\/=70 years with active AML: a single-center retrospective analysis.","title02":"Sequential therapy with allogeneic HCT in patients aged >\/=70 years with active AML: a single-center retrospective analysis.","journal":"Haematologica","issue":"2026 June 1; 111(6):2061-2069. doi: 10.3324\/haematol.2025.300184","author":"Amit O, Fridberg G, Moshe Y, Ospovat I, Sherf Y, Tshernichovsky D, Karni C, Avivi I, Ram R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568537"},{"title01":"Long-term follow-up: blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia.","title02":"Long-term follow-up: blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 June 4. doi: 10.3324\/haematol.2026.300873. Online ahead of print","author":"Miatech J, Milton DR, Gaballa MR, Banerjee P, Jiang X, Ganesh C, Khazal S, Nandivada V, Islam S, Kaplan M, Daher M, Basar R, Alousi A, Mehta R, Al-Atrash G, Khouri I, Oran B, Marin D, Popat U, Olson A, Tewari P, Jain N, Jabbour E, Ravandi-Kashani F, Chen K, Champlin R, Shpall E, Rezvani K, Kebriaei P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42237781"},{"title01":"Ligature-induced periodontitis promotes Dnmt3a(R878H)-driven clonal hematopoiesis.","title02":"Ligature-induced periodontitis promotes Dnmt3a(R878H)-driven clonal hematopoiesis.","journal":"Haematologica","issue":"2026 June 1; 111(6):2047-2060. doi: 10.3324\/haematol.2025.288827","author":"Yuan Q, Liao M, Zhuang Z, Huang C, Chen R, Song Y, Wu Y, Zou P, Li L, Nie H, Zhang M, Song S, Li Y, Yan F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568536"},{"title01":"A pilot randomized clinical trial of a peer support intervention for hematopoietic stem cell transplantation.","title02":"A pilot randomized clinical trial of a peer support intervention for hematopoietic stem cell transplantation.","journal":"Blood advances","issue":"2026 June 9; 10(11):3987-3997. doi: 10.1182\/bloodadvances.2025018918","author":"Amonoo HL, Keane EP, Guo M, Gudenkauf LM, Boardman AC, Larizza IS, Wolfe ED, Mate-Kole MN, Healy BC, Cutler C, Jim HS, Lee SJ, Greer JA, Huffman JC, El-Jawahri A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42241036"},{"title01":"The evolution of hematopoietic models through a clonal lens.","title02":"The evolution of hematopoietic models through a clonal lens.","journal":"Blood","issue":"2026 June 4; 147(23):2740-2748. doi: 10.1182\/blood.2024028189","author":"Tomei S, Weber TS, Naik SH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42089925"},{"title01":"Long-term stability of posttranscriptional genetic silencing of BCL11A using a shmiR vector in Sickle Cell Disease.","title02":"Long-term stability of posttranscriptional genetic silencing of BCL11A using a shmiR vector in Sickle Cell Disease.","journal":"Blood","issue":"2026 June 2. doi: 10.1182\/blood.2026033871. Online ahead of print","author":"Esrick EB, Lehmann L, Federico A, Vincon H, Liu B, Daley H, Dansereau C, De Oliveira S, Everett JK, Kao PC, Moore TB, Morris E, Trebeden-Negre H, Shaw KL, Roach GD, Ritz J, Roche AM, Silva O, Grant PE, Bushman FD, Kohn DB, Jain A, London WB, Justus DG, Armant M, Manis JP, Williams DA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42233421"},{"title01":"Type I interferon-activated NK cells control polycythemia vera in vivo.","title02":"Type I interferon-activated NK cells control polycythemia vera in vivo.","journal":"Blood","issue":"2026 June 2. doi: 10.1182\/blood.2026033951. Online ahead of print","author":"Lossa J, Schnoder TM, Ronge Z, Haasch N, Hodapp K, Marini F, Abassi N, Gaida MM, Lee SJ, Henrich A, Hohne-Wiechmann MN, Thull Mogollon C, Schutze K, Klein M, Bopp T, Schild H, Sasca D, Crodel CC, Heidel FH, Koschmieder S, Probst HC, Radsak MP, Muth S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42233405"},{"title01":"Therapeutic Targeting of IL-17A-Driven PTGS2\/NLRP3 Inflammasome Activation in Juvenile Myelomonocytic Leukemia.","title02":"Therapeutic Targeting of IL-17A-Driven PTGS2\/NLRP3 Inflammasome Activation in Juvenile Myelomonocytic Leukemia.","journal":"Blood","issue":"2026 June 2. doi: 10.1182\/blood.2025032588. Online ahead of print","author":"Pasupuleti SK, Ramdas B, Padam KSR, Kanumuri R, Palam LR, Kumar R, Ho TC, Lee AG, Clapp W, Qu CK, Stieglitz E, Yang K, Kapur R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42233403"},{"title01":"Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis.","title02":"Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis.","journal":"Blood","issue":"2026 June 2. doi: 10.1182\/blood.2025032290. Online ahead of print","author":"Chetlapalli K, Ito S, Ng DQ, Sra MS, Wang D, Krumholz H, Krishnamurti L, Pandya A, Goshua G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42227898"},{"title01":"Targeting ABCD1 inhibits peroxisomal fatty acid oxidation to selectively eliminate acute myeloid leukemia cells.","title02":"Targeting ABCD1 inhibits peroxisomal fatty acid oxidation to selectively eliminate acute myeloid leukemia cells.","journal":"Blood","issue":"2026 June 11; 147(24):2930-2943. doi: 10.1182\/blood.2025031202","author":"Parfenova EN, Vrdoljak N, Mosca DA, Aristizabal-Henao JJ, Kiebish MA, Minden MD, Spagnuolo PA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41746867"},{"title01":"[211At]Astatine-Based Conditioning with a Humanized CD45 Antibody for Autologous Hematopoietic Stem Cell Gene Therapy.","title02":"[211At]Astatine-Based Conditioning with a Humanized CD45 Antibody for Autologous Hematopoietic Stem Cell Gene Therapy.","journal":"Blood","issue":"2026 June 1. doi: 10.1182\/blood.2026033789. Online ahead of print","author":"Radtke S, Laszlo GS, Swing K, Repele A, Barton JW, King DJ, Pande D, Enstrom MR, Li J, Wolf CB, Reevey L, Petty NE, Kanestrom G, Loeb KR, Pettenger-Willey CM, Othus M, Kehret AR, Cole FM, Lunn-Halbert MC, Hamlin DK, Wilbur DSS, Sandmaier BM, Kiem HP, Walter RB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42224345"},{"title01":"FAP-1 loss impairs megakaryocyte demarcation membrane system and platelet function with myelofibrosis-like features.","title02":"FAP-1 loss impairs megakaryocyte demarcation membrane system and platelet function with myelofibrosis-like features.","journal":"Blood","issue":"2026 June 15. doi: 10.1182\/blood.2025031490. Online ahead of print","author":"Chiu MF, Yeh KH, Chen PJ, Chou WC, Lin CW, Chang K, Lin CC, Yeh SH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42296014"},{"title01":"Remodeling of the bone marrow vasculature induced by venetoclax and azacitidine damage.","title02":"Remodeling of the bone marrow vasculature induced by venetoclax and azacitidine damage.","journal":"Blood","issue":"2026 June 11; 147(24):2905-2915. doi: 10.1182\/blood.2025030055","author":"Ngo S, D'Agostino G, Papazoglou D, Mohamad Nor F, Finsterbusch K, Habel K, Ferrelli A, Anjos-Afonso F, Bonnet D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610429"},{"title01":"Clonal tracing of blood stem cells across mouse and human lifespans.","title02":"Clonal tracing of blood stem cells across mouse and human lifespans.","journal":"Blood","issue":"2026 June 4; 147(23):2728-2739. doi: 10.1182\/blood.2024028195","author":"Rodriguez-Fraticelli AE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40983030"},{"title01":"Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial.","title02":"Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial.","journal":"Lancet Oncol","issue":"2026 June 15. doi: 10.1016\/S1470-2045(26)00090-2. Online ahead of print","author":"Li Z, Hu J, Chen J, Yu Y, Meng X, Dong X, Hu Y, Ji Y, Liu H, Wang W, Ning F, Zhang Z, Liu C, Zhang Z, Wang Q, Zheng W, Wang H, Qu X, Chen Z, Fan S, Zhang X, Lu S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42296979"},{"title01":"Postpartum haemorrhage: epidemiology, consequences, and missed opportunities.","title02":"Postpartum haemorrhage: epidemiology, consequences, and missed opportunities.","journal":"Lancet","issue":"2026 June 12. doi: 10.1016\/S0140-6736(26)00902-5. Online ahead of print","author":"Coomarasamy A, Sindhu KN, Gallos I, Periyathambi N, Price MJ, Yunas I, Qureshi Z, Muriithi FG, Williams CR, Fawcus S, George A, Althabe F, Titulaer P, Aswat A, Cresswell JA, Arulkumaran S, Scott N, Devall AJ, Oladapo OT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42285119"},{"title01":"Prevention of postpartum haemorrhage: from evidence to implementation at scale.","title02":"Prevention of postpartum haemorrhage: from evidence to implementation at scale.","journal":"Lancet","issue":"2026 June 12. doi: 10.1016\/S0140-6736(26)00903-7. Online ahead of print","author":"Gallos ID, Sindhu KN, Yunas I, Sobhy S, Mavrides E, Sheikh L, Escobar MF, Al-Beity FA, Bohren MA, Evans C, Bouthors AS, Francisco AA, Papageorghiou AT, Podesek M, Lissauer D, Ntirushwa D, Rulisa S, Chandan JS, Devall AJ, Oladapo OT, Coomarasamy A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42285117"},{"title01":"EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in HER2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer.","title02":"EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in HER2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer.","journal":"J Clin Oncol","issue":"2026 June 1; 101200JCO2601072. doi: 10.1200\/JCO-26-01072. Online ahead of print","author":"Nakayama I, Ryu MH, Lim SH, Kim JG, Omori T, Oh SC, Kim JY, Rha SY, Lee KW, Machida N, Sym SJ, Narita Y, Park YI, Hara H, Hosaka H, Kang B, Kim IH, Bai LY, Hirashima Y, Hagihara S, Yamamoto T, Shitara K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42223130"},{"title01":"Selinexor Plus Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis: Phase 3 SENTRY Trial.","title02":"Selinexor Plus Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis: Phase 3 SENTRY Trial.","journal":"J Clin Oncol","issue":"2026 June 2; 101200JCO2601080. doi: 10.1200\/JCO-26-01080. Online ahead of print","author":"Bose P, Ali H, Al-Ali HK, Garcia-Gutierrez V, Grosicki S, Grudeva-Popova Z, Harrison C, Hong J, Hou HA, Kwiatek M, Loschi M, Passamonti F, Patriarca A, Podoltsev N, Rampal R, Tantravahi S, Urian LG, Chai Y, Taverna P, Mark T, Sadiq A, Rangwala R, Vachhani P, Mascarenhas J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42241036"},{"title01":"Clinical features and maternal-fetal outcome of pregnancy with aplastic anaemia: A single-centre retrospective study.","title02":"Clinical features and maternal-fetal outcome of pregnancy with aplastic anaemia: A single-centre retrospective study.","journal":"Br J Haematol","issue":"2026 June; 208(6):2222-2228. doi: 10.1111\/bjh.70464","author":"Wu X, Yang Z, Zhang X, Lu S, Sun A, Wu D, Zhou H, Miao M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41937249"},{"title01":"A genetic risk score based on BCL11A and HBS1L-MYB variants predicts clinical severity in Brazilian sickle cell anaemia patients.","title02":"A genetic risk score based on BCL11A and HBS1L-MYB variants predicts clinical severity in Brazilian sickle cell anaemia patients.","journal":"Br J Haematol","issue":"2026 June; 208(6):2203-2211. doi: 10.1111\/bjh.70489","author":"Arcanjo GS, Silva AP, Diniz MV, Domingos IF, Pereira-Martins DA, Araujo AB, Franca TSS, Anjos AC, Araujo AS, Belini-Junior E, Saad STO, Costa FF, Lucena-Araujo AR, Bezerra MAC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41989145"},{"title01":"Short-course blood transfusion therapy with hydroxyurea, a functional strategy in the management of stroke in children with sickle cell disease.","title02":"Short-course blood transfusion therapy with hydroxyurea, a functional strategy in the management of stroke in children with sickle cell disease.","journal":"Br J Haematol","issue":"2026 June; 208(6):2194-2202. doi: 10.1111\/bjh.70399","author":"Temiye E, Akinsete A, Joacquim A, Fakile U, Ashefor O, Ogamba C, Ogbenna A, Adeyemo N, Okodugha O, Edokpolo E, Elemo O, Salako A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41937419"},{"title01":"Paediatric-onset autoimmune cytopenia: How can we reduce the long-term mortality?","title02":"Paediatric-onset autoimmune cytopenia: How can we reduce the long-term mortality?","journal":"Br J Haematol","issue":"2026 June 9. doi: 10.1111\/bjh.70599. Online ahead of print","author":"Aladjidi N, Leblanc T, Fernandes H, Picard C, Bustamante J, Rieux-Laucat F, Fusaro M, Tusseau M, Durand-Teyssier C, Cohendy E, Granel J, Ducassou S, Escudier A, Moshous D, Michel M, Godeau B, Heritier S, Fahd M, Bader-Meunier B, Fischer A, Leverger G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42262305"},{"title01":"Sirolimus for Refractory\/relapsed Warm Autoimmune Hemolytic Anemia and Evans&#8217; syndrome: A Prospective Study.","title02":"Sirolimus for Refractory\/relapsed Warm Autoimmune Hemolytic Anemia and Evans&#8217; syndrome: A Prospective Study.","journal":"Blood advances","issue":"2026 June 9. doi: 10.1182\/bloodadvances.2026019844. Online ahead of print","author":"Wang Q, Liu Z, Yang C, Li J, Chen M, Han B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42263666"},{"title01":"PT\/Cy-based alloBMT platform as a curative, accessible alternative for pediatric and young adult severe aplastic anemia.","title02":"PT\/Cy-based alloBMT platform as a curative, accessible alternative for pediatric and young adult severe aplastic anemia.","journal":"Blood advances","issue":"2026 June 10. doi: 10.1182\/bloodadvances.2025019581. Online ahead of print","author":"Dionysiou M, Ktena YP, Bonifant CL, Chen AR, Llosa NJ, Zambidis ET, DeZern AE, Jones RJ, Symons HJ, Cooke KR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42269078"},{"title01":"Real-world safety profile of twice a day deferiprone in patients with thalassemia, sickle cell disease, or other anemias.","title02":"Real-world safety profile of twice a day deferiprone in patients with thalassemia, sickle cell disease, or other anemias.","journal":"Blood advances","issue":"2026 June 4. doi: 10.1182\/bloodadvances.2025019368. Online ahead of print","author":"Sheth S, Lal A, Appiah-Kubi A, Peslak SA, Toiber Temin N, Chen MA, Coates TD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42241705"},{"title01":"Transthyretin V122I variant and protein affect cardiac severity and mortality in sickle cell disease.","title02":"Transthyretin V122I variant and protein affect cardiac severity and mortality in sickle cell disease.","journal":"Blood advances","issue":"2026 June 9; 10(11):4000-4008. doi: 10.1182\/bloodadvances.2026019698","author":"Li H, Gao S, Wang X, Asomaning N, Conrey A, Kruah B, Joo J, Wu CO, Sachdev V, Thein SL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41921073"},{"title01":"Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis.","title02":"Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis.","journal":"Blood","issue":"2026 June 2. doi: 10.1182\/blood.2025032290. Online ahead of print","author":"Chetlapalli K, Ito S, Ng DQ, Sra MS, Wang D, Krumholz H, Krishnamurti L, Pandya A, Goshua G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42227898"},{"title01":"Renin-Angiotensin-Aldosterone System Inhibition Exacerbates Anemia in Sickle Cell Disease.","title02":"Renin-Angiotensin-Aldosterone System Inhibition Exacerbates Anemia in Sickle Cell Disease.","journal":"Blood","issue":"2026 June 1. doi: 10.1182\/blood.2026033813. Online ahead of print","author":"Eskandari N, Pappano E, Ruiz MAD, Mahmud N, Ren G, Ivy ZK, Gaitonde S, Gordeuk VR, Gladwin MT, Malik P, Quinn CT, Saraf SL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42224366"},{"title01":"Blinatumomab-induced remission of refractory immune thrombocytopenia in pediatric acute lymphoblastic leukemia: a case report.","title02":"Blinatumomab-induced remission of refractory immune thrombocytopenia in pediatric acute lymphoblastic leukemia: a case report.","journal":"Haematologica","issue":"2026 June 1; 111(6):2175-2179. doi: 10.3324\/haematol.2025.288558","author":"Ao Y, Zheng H, Huang Y, Kang S, Zhang Q, Huang C, Wu X, Zeng Y, Zhou D, Fang J, Fu Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42241036"},{"title01":"Thrombosis in immune thrombocytopenia.","title02":"Thrombosis in immune thrombocytopenia.","journal":"Br J Haematol","issue":"2026 June; 208(6):1924-1927. doi: 10.1111\/bjh.70474","author":"Garabet L, Ghanima W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952648"},{"title01":"Chimeric antigen receptor T cells for autoimmune diseases, in particular immune thrombocytopenia.","title02":"Chimeric antigen receptor T cells for autoimmune diseases, in particular immune thrombocytopenia.","journal":"Br J Haematol","issue":"2026 June; 208(6):1928-1930. doi: 10.1111\/bjh.70482","author":"Soff SP, Ruder S, Bussel JB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41989015"},{"title01":"HLA profile in paediatric ITP: Comparison with healthy controls and prognostic implications.","title02":"HLA profile in paediatric ITP: Comparison with healthy controls and prognostic implications.","journal":"Br J Haematol","issue":"2026 June; 208(6):2175-2184. doi: 10.1111\/bjh.70483","author":"Gonzalez de Pablo J, Molina YL, Vicario JL, Moreno Hidalgo MA, de la Cruz A, Galan A, Zubicaray J, Lopez de Hontanar G, Sanz A, Marin L, Verdejo de Antonio J, Sevilla J, Sebastian E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42051172"},{"title01":"Integrated proteomic and metabolomic profiling reveals sex-stratified biomarkers predicting chronicity in paediatric primary immune thrombocytopenia.","title02":"Integrated proteomic and metabolomic profiling reveals sex-stratified biomarkers predicting chronicity in paediatric primary immune thrombocytopenia.","journal":"Br J Haematol","issue":"2026 June; 208(6):1954-1964. doi: 10.1111\/bjh.70521","author":"Xue Y, Zhang R, Liang D, Xu Y, Tian Z, Dai X, Xu W, Cao Q, Zhu H, Wang Y, Yuan Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42070774"},{"title01":"Real-world treatment patterns and outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL-AVA 3.5 study.","title02":"Real-world treatment patterns and outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL-AVA 3.5 study.","journal":"Br J Haematol","issue":"2026 June; 208(6):2185-2193. doi: 10.1111\/bjh.70531","author":"Piatek C, Oladapo A, Kolodny S, Vredenburg M, Lucht S, Bland E, Pathak P, Feinberg B, Maitland H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42136034"},{"title01":"Clinical profiling and outcomes of ischaemic stroke patients with immune thrombocytopenia: A multicentre retrospective study.","title02":"Clinical profiling and outcomes of ischaemic stroke patients with immune thrombocytopenia: A multicentre retrospective study.","journal":"Br J Haematol","issue":"2026 June 1. doi: 10.1111\/bjh.70572. Online ahead of print","author":"Cao L, Wu J, An Z, Zhou F, Li D, Ji L, Gong Y, Yu Z, Cai K, Zhang G, Xie Y, Zhou Z, Cheng Y, Lu Y, Cheng P, Ma L, Yan Z, Fu H, Zhu X, Huang Q, He Y, Zhao X, Chang Y, Huang X, Zhang X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42223019"},{"title01":"Paediatric-onset autoimmune cytopenia: How can we reduce the long-term mortality?","title02":"Paediatric-onset autoimmune cytopenia: How can we reduce the long-term mortality?","journal":"Br J Haematol","issue":"2026 June 9. doi: 10.1111\/bjh.70599. Online ahead of print","author":"Aladjidi N, Leblanc T, Fernandes H, Picard C, Bustamante J, Rieux-Laucat F, Fusaro M, Tusseau M, Durand-Teyssier C, Cohendy E, Granel J, Ducassou S, Escudier A, Moshous D, Michel M, Godeau B, Heritier S, Fahd M, Bader-Meunier B, Fischer A, Leverger G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42262305"},{"title01":"Association between vaccine-induced immune thrombocytopenia and thrombosis and human leucocyte antigen loci: Yes, no or maybe?","title02":"Association between vaccine-induced immune thrombocytopenia and thrombosis and human leucocyte antigen loci: Yes, no or maybe?","journal":"Br J Haematol","issue":"2026 June 10. doi: 10.1111\/bjh.70605. Online ahead of print","author":"Petito E, Bury L, Heck LA, Di Paola J, Gresele P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42267856"},{"title01":"Complement activation profile in adult primary immune thrombocytopenia.","title02":"Complement activation profile in adult primary immune thrombocytopenia.","journal":"Blood","issue":"2026 June 11; 147(24):2958-2969. doi: 10.1182\/blood.2025032255","author":"Nakata K, Onami I, Kato H, Kosugi S, Tomiyama Y, Matsushita H, Kurata A, Sato K, Takahashi K, Sawamura F, Ohmine K, Ohtomo S, Hosen N, Kashiwagi H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41915761"},{"title01":"A step towards guided complement-targeted therapy in ITP?","title02":"A step towards guided complement-targeted therapy in ITP?","journal":"Blood","issue":"2026 June 11; 147(24):2859-2861. doi: 10.1182\/blood.2026034015","author":"Audia S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42275124"},{"title01":"Pre-diagnostic clonal hematopoiesis of indeterminate potential among patients with a primary cancer and risk of second cancers.","title02":"Pre-diagnostic clonal hematopoiesis of indeterminate potential among patients with a primary cancer and risk of second cancers.","journal":"Leukemia","issue":"2026 June; 40(6):1240-1246. doi: 10.1038\/s41375-026-02946-x","author":"Liu X, Adami HO, Boberg E, Smedby KE, Wei H, Fang F, Liu Q","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41981103"},{"title01":"Not guilty by association: myelodysplasia-related mutations in AML.","title02":"Not guilty by association: myelodysplasia-related mutations in AML.","journal":"Leukemia","issue":"2026 June; 40(6):1340-1341. doi: 10.1038\/s41375-026-02936-z","author":"Venugopal S, Sekeres MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42020780"},{"title01":"Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.","title02":"Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.","journal":"Leukemia","issue":"2026 June 15. doi: 10.1038\/s41375-026-02996-1. Online ahead of print","author":"Lee D, Abu-Shihab Y, Plas K, Nicolet D, Mrozek K, Routbort MJ, Patel KP, Walker CJ, Buss J, Stiff AR, Laganson A, DiNardo CD, Daver NG, Kadia TM, Ravandi F, Carroll AJ, Kolitz JE, Powell BL, Blum WG, Baer MR, Marcucci G, Uy GL, Stock W, Stone RM, Medeiros LJ, Byrd JC, Blachly JS, Bowman RL, Tyner JW, Loghavi S, Eisfeld AK, Miles LA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42297916"},{"title01":"Isolated KRAS and NRAS mutations in adults with monocytosis and\/or cytopenia(s).","title02":"Isolated KRAS and NRAS mutations in adults with monocytosis and\/or cytopenia(s).","journal":"Haematologica","issue":"2026 June 1; 111(6):2070-2079. doi: 10.3324\/haematol.2025.288906","author":"Wang SA, Ok CY, Tsai HK, Loayza N, Daneshpajouhnejad P, Seth N, Cantu MD, Bagg A, Tam W, Weinberg O, Barone PD, Geyer JT, Lindsley CR, Montalban-Bravo G, Simon CR, Arber DA, Bueso-Ramos CE, Hsi ED, Foucar K, Orazi A, Patnaik MM, Hasserjian RP, Reichard KK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42241036"},{"title01":"Clinical outcomes of venetoclax combined with hypomethylating agents versus hypomethylating agents alone in TP53-mutated myelodysplastic syndromes.","title02":"Clinical outcomes of venetoclax combined with hypomethylating agents versus hypomethylating agents alone in TP53-mutated myelodysplastic syndromes.","journal":"Haematologica","issue":"2026 June 1; 111(6):2159-2163. doi: 10.3324\/haematol.2025.289268","author":"Aldapt M, Wang YH, Shah KJ, El Kettani M, Foran J, Kharfan-Dabaja M, Murthy H, Al-Kali A, Shah MV, Alkhateeb H, Saliba AN, Hogan W, Yi CA, Sproat L, Punwani N, Khera N, Palmer J, Litzow M, Tefferi A, Gangat N, Patnaik MM, Badar T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41504247"},{"title01":"Evolution to complex karyotype disease in mono-allelic TP53-mutated myelodysplastic syndrome\/acute myeloid leukemia: a cohort study.","title02":"Evolution to complex karyotype disease in mono-allelic TP53-mutated myelodysplastic syndrome\/acute myeloid leukemia: a cohort study.","journal":"Haematologica","issue":"2026 June 11. doi: 10.3324\/haematol.2026.300734. Online ahead of print","author":"Fernandes P, Pasca S, Jain T, Levis MJ, Ambinder AJ, Walsh L, Gojo I, Smith DB, Webster J, Ghiaur G, Dalton WB, Prince G, Jones RJ, DeZern AE, Gondek LP, Karantanos T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42273942"},{"title01":"Luspatercept in myelodysplastic syndrome with ring sideroblasts: a case report of intrapulmonary vascular dilatation syndrome causing protracted inexplicable hypoxia.","title02":"Luspatercept in myelodysplastic syndrome with ring sideroblasts: a case report of intrapulmonary vascular dilatation syndrome causing protracted inexplicable hypoxia.","journal":"Haematologica","issue":"2026 June 11. doi: 10.3324\/haematol.2026.300865. Online ahead of print","author":"Warsi A, Faughnan ME, Buckstein R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42273959"},{"title01":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: A 25-year nationwide study.","title02":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: A 25-year nationwide study.","journal":"Br J Haematol","issue":"2026 June; 208(6):2143-2155. doi: 10.1111\/bjh.70463","author":"Itonaga H, Miyazaki Y, Tachi N, Kurosawa S, Marumo A, Konuma T, Ebina T, Doki N, Uchida N, Fukuda T, Nishida T, Katayama Y, Asada N, Sakurai M, Maeda T, Eto T, Tanaka M, Nakamae H, Onizuka M, Kawamura K, Kanda Y, Atsuta Y, Tachibana T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41937388"},{"title01":"Contrasting impacts of pretransplant cytoreduction and post-transplant maintenance on outcomes of allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromes: Real-world multicentre evidence.","title02":"Contrasting impacts of pretransplant cytoreduction and post-transplant maintenance on outcomes of allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromes: Real-world multicentre evidence.","journal":"Br J Haematol","issue":"2026 June; 208(6):2156-2167. doi: 10.1111\/bjh.70477","author":"Chen Y, Zhang X, Shen N, Zhang J, Guo R, Xing H, Han L, Liu Y, Tian W, Wang M, Xie X, Jiang Z, Wan D, Zhou X, Xu H, Qin L, Shi W, Cao W, Bian Z","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41960892"},{"title01":"Not all Tregs in MDS are created equal.","title02":"Not all Tregs in MDS are created equal.","journal":"Br J Haematol","issue":"2026 June; 208(6):2332-2334. doi: 10.1111\/bjh.70503","author":"Selig M, Penter L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42025585"},{"title01":"High frequency of CD95(+)\/CD45RA(-) regulatory T cells defines an immunosuppressive profile associated with MDS progression.","title02":"High frequency of CD95(+)\/CD45RA(-) regulatory T cells defines an immunosuppressive profile associated with MDS progression.","journal":"Br J Haematol","issue":"2026 June; 208(6):1993-2003. doi: 10.1111\/bjh.70504","author":"Vazquez R, Deredec N, Boussaid I, Boncoeur P, Knosp C, Houvert A, Zalmai L, Friedrich C, Almire C, Dussiau C, Willems L, Birsen R, Decroocq J, Bouscary D, Kosmider O, Kordasti S, Fontenay M, Simoni Y, Chapuis N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42080308"},{"title01":"Impact of blood donor, component and recipient variables on antigen-specific alloantibodies.","title02":"Impact of blood donor, component and recipient variables on antigen-specific alloantibodies.","journal":"Br J Haematol","issue":"2026 June; 208(6):2212-2221. doi: 10.1111\/bjh.70536","author":"Wang D, Zhou L, Hendrickson JE, Karafin MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42128430"},{"title01":"Hematologic Responses Achieved with Luspatercept in Higher-Risk Myelodysplastic Syndromes.","title02":"Hematologic Responses Achieved with Luspatercept in Higher-Risk Myelodysplastic Syndromes.","journal":"Blood advances","issue":"2026 June 4. doi: 10.1182\/bloodadvances.2025019244. Online ahead of print","author":"Leonard D, Sallman DA, Pugh K, Bell C, Al Ali NH, Borate U, Komrokji RS, Brunner AM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42247344"},{"title01":"Myelodysplastic Syndromes in VEXAS.","title02":"Myelodysplastic Syndromes in VEXAS.","journal":"Blood advances","issue":"2026 June 12. doi: 10.1182\/bloodadvances.2025018827. Online ahead of print","author":"Patel BA, Calvo KR, Reichard KK, Patnaik MM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42284697"},{"title01":"A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alpha.","title02":"A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alpha.","journal":"Leukemia","issue":"2026 June; 40(6):1122-1136. doi: 10.1038\/s41375-026-02882-w","author":"Silver RT, Hasselbalch HC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41951941"},{"title01":"Pre-diagnostic clonal hematopoiesis of indeterminate potential among patients with a primary cancer and risk of second cancers.","title02":"Pre-diagnostic clonal hematopoiesis of indeterminate potential among patients with a primary cancer and risk of second cancers.","journal":"Leukemia","issue":"2026 June; 40(6):1240-1246. doi: 10.1038\/s41375-026-02946-x","author":"Liu X, Adami HO, Boberg E, Smedby KE, Wei H, Fang F, Liu Q","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41981103"},{"title01":"MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasms.","title02":"MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasms.","journal":"Leukemia","issue":"2026 June; 40(6):1111-1121. doi: 10.1038\/s41375-026-02975-6","author":"Al-Ali HK, Heidel ST, Palandri F, Heidel FH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42086932"},{"title01":"Artificial intelligence triage tool for bone marrow fibrosis in myeloproliferative neoplasms using complete blood counts.","title02":"Artificial intelligence triage tool for bone marrow fibrosis in myeloproliferative neoplasms using complete blood counts.","journal":"Lancet Haematol","issue":"2026 June; 13(6):e355-e357. doi: 10.1016\/S2352-3026(26)00129-8","author":"Fan BE, Lam BD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42241036"},{"title01":"Prediction of bone marrow fibrosis from complete blood count in myeloproliferative neoplasms (FIBOM-AI): a multicentre machine learning model development and validation study.","title02":"Prediction of bone marrow fibrosis from complete blood count in myeloproliferative neoplasms (FIBOM-AI): a multicentre machine learning model development and validation study.","journal":"Lancet Haematol","issue":"2026 June; 13(6):e396-e407. doi: 10.1016\/S2352-3026(26)00099-2","author":"Donzel M, Khedimallah S, Barriere S, Gouband A, Aubert C, Bosselut N, Poullot E, Bezsera SM, Mansier O, Yilmaz N, Syrykh C, Hittinger X, Momenkhan S, Barraco F, Gilis L, Labussiere-Wallet H, Brehon M, Chin-Yee B, Hsia C, Wang L, Zouaghi S, Sujobert P, Eveillard M, De Mas V, Tavitian S, Legros L, Parrens M, Flandrin-Gresta P, Meunier M, Freynet N, Roy L, Meignin V, Drevon L, Ranta D, Pagliuca S, Lippert E, Ianotto JC, Jallades L, Burroni B, Luque Paz D, Traverse-Glehen A, Chevalier S, Alcazer V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42242261"},{"title01":"Erratum to: &#8220;Multilevel defects in the hematopoietic niche in essential thrombocythemia&#8221;.","title02":"Erratum to: &#8220;Multilevel defects in the hematopoietic niche in essential thrombocythemia&#8221;.","journal":"Haematologica","issue":"2026 June 1; 111(6):2180-2181. doi: 10.3324\/haematol.2026.289416","author":"Sun T, Ju M, Dai X, Dong H, Gu W, Gao Y, Fu R, Liu X, Huang Y, Liu W, Ch Y, Wang W, Li H, Zhou Y, Shi L, Yang R, Zhang L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42231802"},{"title01":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: A 25-year nationwide study.","title02":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: A 25-year nationwide study.","journal":"Br J Haematol","issue":"2026 June; 208(6):2143-2155. doi: 10.1111\/bjh.70463","author":"Itonaga H, Miyazaki Y, Tachi N, Kurosawa S, Marumo A, Konuma T, Ebina T, Doki N, Uchida N, Fukuda T, Nishida T, Katayama Y, Asada N, Sakurai M, Maeda T, Eto T, Tanaka M, Nakamae H, Onizuka M, Kawamura K, Kanda Y, Atsuta Y, Tachibana T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41937388"},{"title01":"Ropeginterferon alfa-2b for prefibrotic myelofibrosis and lower-risk myelofibrosis requiring cytoreduction.","title02":"Ropeginterferon alfa-2b for prefibrotic myelofibrosis and lower-risk myelofibrosis requiring cytoreduction.","journal":"Blood advances","issue":"2026 June 9; 10(11):3920-3930. doi: 10.1182\/bloodadvances.2026019612","author":"Gill H, Au L, Yim R, Lee P, Li V, Chin L, Zhang Q, Chan PY, Lee CYY, Wu TKY, Leung GMK, Kwong YL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41875235"},{"title01":"Phase 2a randomized study to evaluate sapablursen in patients with non-transfusion dependent beta-thalassemia intermedia.","title02":"Phase 2a randomized study to evaluate sapablursen in patients with non-transfusion dependent beta-thalassemia intermedia.","journal":"Blood advances","issue":"2026 June 4. doi: 10.1182\/bloodadvances.2026019799. Online ahead of print","author":"Taher A, Diamantidis MD, Kattamis A, Aydinok Y, Kaplan ZS, Dibble A, Dorow S, Doherty S, Mathews J, Jung S, Goldberg YP, Tami J, Bhanot S, Schneider E, Monia BP, Barrett TD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42241700"},{"title01":"A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib.","title02":"A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib.","journal":"Blood advances","issue":"2026 June 11. doi: 10.1182\/bloodadvances.2026020255. Online ahead of print","author":"Palandri F, Dedola A, Caocci G, Rossi E, Elli EM, Sartor C, Latagliata R, Pugliese N, Morsia E, Binotto G, Mendicino F, Tieghi A, Benevolo G, Martino B, D'Addio A, Tiribelli M, Cilloni D, Crugnola M, Cavalca F, Scalzulli E, Lanza F, Pane F, Palumbo GA, Heidel FH, De Stefano V, Breccia M, Branzanti F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42275537"},{"title01":"Therapeutic Targeting of IL-17A-Driven PTGS2\/NLRP3 Inflammasome Activation in Juvenile Myelomonocytic Leukemia.","title02":"Therapeutic Targeting of IL-17A-Driven PTGS2\/NLRP3 Inflammasome Activation in Juvenile Myelomonocytic Leukemia.","journal":"Blood","issue":"2026 June 2. doi: 10.1182\/blood.2025032588. Online ahead of print","author":"Pasupuleti SK, Ramdas B, Padam KSR, Kanumuri R, Palam LR, Kumar R, Ho TC, Lee AG, Clapp W, Qu CK, Stieglitz E, Yang K, Kapur R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42233403"},{"title01":"Type I interferon-activated NK cells control polycythemia vera in vivo.","title02":"Type I interferon-activated NK cells control polycythemia vera in vivo.","journal":"Blood","issue":"2026 June 2. doi: 10.1182\/blood.2026033951. Online ahead of print","author":"Lossa J, Schnoder TM, Ronge Z, Haasch N, Hodapp K, Marini F, Abassi N, Gaida MM, Lee SJ, Henrich A, Hohne-Wiechmann MN, Thull Mogollon C, Schutze K, Klein M, Bopp T, Schild H, Sasca D, Crodel CC, Heidel FH, Koschmieder S, Probst HC, Radsak MP, Muth S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42233405"},{"title01":"FAP-1 loss impairs megakaryocyte demarcation membrane system and platelet function with myelofibrosis-like features.","title02":"FAP-1 loss impairs megakaryocyte demarcation membrane system and platelet function with myelofibrosis-like features.","journal":"Blood","issue":"2026 June 15. doi: 10.1182\/blood.2025031490. Online ahead of print","author":"Chiu MF, Yeh KH, Chen PJ, Chou WC, Lin CW, Chang K, Lin CC, Yeh SH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42296014"},{"title01":"CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation.","title02":"CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation.","journal":"Blood","issue":"2026 June 4; 147(23):2786-2792. doi: 10.1182\/blood.2025030207","author":"Minnie SA, Ho K, Boiko JR, Adams RC, Ensbey KS, Nemychenkov NS, Legg SRW, Schmidt CR, Comstock ML, Lyons JM, Sekiguchi T, Koyama M, Spencer A, Green DJ, Hill GR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41770790"},{"title01":"A velocity-informed framework for resolving functional stratification in rare human stem cells.","title02":"A velocity-informed framework for resolving functional stratification in rare human stem cells.","journal":"Leukemia","issue":"2026 June; 40(6):1284-1295. doi: 10.1038\/s41375-026-02956-9","author":"Jarczak J, Ratajczak MZ, Kucia M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42014860"},{"title01":"A novel CD7-directed antibody-drug conjugate targeting BCL-XL with potent anti-leukemic activity in T-cell acute lymphoblastic leukemia.","title02":"A novel CD7-directed antibody-drug conjugate targeting BCL-XL with potent anti-leukemic activity in T-cell acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 June 8. doi: 10.1038\/s41375-026-02998-z. Online ahead of print","author":"Oliveira ML, Nuantang K, Hure G, Avila-Avila A, Bresson L, Haumont S, Kostova V, Novak T, Le Toumelin-Braizat G, Guerlesquin J, Demarles D, Merdas M, Cauquil N, Goundiam O, Rocchetti F, Courtade-Gaiani S, Valour D, Zerhouni M, Artus R, Douillet-Michel E, Laurent I, Denis A, Ovreiu A, Duvauchelle B, Ecsedi M, Colland F, Geneste O, Maragno AL, Ghysdael J, Tran Quang C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42260111"},{"title01":"Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trial.","title02":"Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trial.","journal":"Lancet Haematol","issue":"2026 June; 13(6):e365-e375. doi: 10.1016\/S2352-3026(26)00014-1","author":"Stein A, Wang Y, Malki MMA, Aldoss I, Ali H, Aribi A, Artz A, Ball B, Dandapani S, Farol L, Han C, Liu A, Pullarkat V, Radany E, Sahebi F, Sanchez JF, Sandhu K, Salhotra A, Smith E, Spielberger R, Hui S, Marcucci G, Nakamura R, Forman SJ, Palmer J, Wong J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42150590"},{"title01":"Umbilical Cord Blood and Nonengrafting Allogeneic Cell Therapies.","title02":"Umbilical Cord Blood and Nonengrafting Allogeneic Cell Therapies.","journal":"J Clin Oncol","issue":"2026 June 4; JCO2600673. doi: 10.1200\/JCO-26-00673. Online ahead of print","author":"Wynn RF, Jeffreys N, Nierkens S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42241672"},{"title01":"Liberalized Diets During Neutropenia: Ongoing Uncertainty in Hematopoietic Stem-Cell Transplantation.","title02":"Liberalized Diets During Neutropenia: Ongoing Uncertainty in Hematopoietic Stem-Cell Transplantation.","journal":"J Clin Oncol","issue":"2026 June 1; JCO2600254. doi: 10.1200\/JCO-26-00254. Online ahead of print","author":"Pham B, New J, Tzachanis D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42224641"},{"title01":"Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.","title02":"Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.","journal":"J Clin Oncol","issue":"2026 June; 44(16):1529-1539. doi: 10.1200\/JCO-25-03104","author":"Cutler C, Kim HT, El Banna H, Halloran E, Matozel E, Ho VT, Koreth J, Gooptu M, Shapiro R, Kelkar A, Gibson C, Nikiforow S, Nageshwar P, Reynolds C, Ansuinelli M, Tamada R, Au C, Panaro K, Gervais C, DeFilipp Z, El-Jawahri A, Chen YB, El Jurdi N, Weisdorf D, Couriel D, Lee C, Arai S, Sahaf B, Bacigalupi J, Ji K, Soiffer R, Miklos D, Antin JH, Ritz J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42060875"},{"title01":"Autologous stem cell transplantation for newly diagnosed multiple myeloma &#8211; real-world data from 2,149 Czech patients.","title02":"Autologous stem cell transplantation for newly diagnosed multiple myeloma &#8211; real-world data from 2,149 Czech patients.","journal":"Haematologica","issue":"2026 June 11. doi: 10.3324\/haematol.2025.300225. Online ahead of print","author":"Popkova T, Pour L, Spicka I, Radocha J, Jungova A, Minarik J, Pavlicek P, Jelinek T, Krejci M, Straub J, Maisnar V, Dekojova T, Pika T, Soukup J, Pospisilova L, Zihala D, Hajek R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42273953"},{"title01":"The prognostic factors and immune microenvironment of primary plasma cell leukemia: the KMMWP-2204 study.","title02":"The prognostic factors and immune microenvironment of primary plasma cell leukemia: the KMMWP-2204 study.","journal":"Haematologica","issue":"2026 June 11. doi: 10.3324\/haematol.2026.300772. Online ahead of print","author":"Kim M, Jang HC, Ahn JS, Cho H, Lee JJ, Cho HJ, Kim DS, Jung J, Lee JH, Kim K, Byun JM, Yoon DH, Choi YS, Jo JC, Yhim HY, Lee MW, Lim SN, Lee JH, Park SS, Min CK, Jung SH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42273949"},{"title01":"Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns.","title02":"Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns.","journal":"Haematologica","issue":"2026 June 11. doi: 10.3324\/haematol.2026.300853. Online ahead of print","author":"Stuver R, Moore ZR, Barta SK, Bhansali RS, Choa R, Epstein-Peterson ZD, Ganesan N, Ghione P, Jain S, Jacobsen E, Johnson WT, Lukowski JD, Lunning M, McCabe S, Merrill M, Moskowitz AJ, Singh S, Taranto E, Yahalom J, Savage KJ, Imber BS, Horwitz SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42273944"},{"title01":"Sustained molecular clearance of the MYD88 p.L265P-mutant clone preceding resolution of cold agglutinin syndrome after autologous stem cell transplantation.","title02":"Sustained molecular clearance of the MYD88 p.L265P-mutant clone preceding resolution of cold agglutinin syndrome after autologous stem cell transplantation.","journal":"Haematologica","issue":"2026 June 4. doi: 10.3324\/haematol.2026.300719. Online ahead of print","author":"Yokoyama K, Yusa N, Jimbo K, Takahashi A, Ogami K, Shimizu E, Imoto S, Nagamura-Inoue T, Nannya Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42237787"},{"title01":"Sequential therapy with allogeneic HCT in patients aged >\/=70 years with active AML: a single-center retrospective analysis.","title02":"Sequential therapy with allogeneic HCT in patients aged >\/=70 years with active AML: a single-center retrospective analysis.","journal":"Haematologica","issue":"2026 June 1; 111(6):2061-2069. doi: 10.3324\/haematol.2025.300184","author":"Amit O, Fridberg G, Moshe Y, Ospovat I, Sherf Y, Tshernichovsky D, Karni C, Avivi I, Ram R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568537"},{"title01":"Platelet recovery delay and survival in patients with myelofibrosis undergoing allogeneic hemopoietic stem cell transplantation.","title02":"Platelet recovery delay and survival in patients with myelofibrosis undergoing allogeneic hemopoietic stem cell transplantation.","journal":"Haematologica","issue":"2026 June 1; 111(6):2080-2086. doi: 10.3324\/haematol.2025.288371","author":"Sora' F, Bacigalupo A, Giammarco S, Metafuni E, Frioni F, Galli E, Limongiello MA, Sica S, Chiusolo P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537336"},{"title01":"Contrasting impacts of pretransplant cytoreduction and post-transplant maintenance on outcomes of allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromes: Real-world multicentre evidence.","title02":"Contrasting impacts of pretransplant cytoreduction and post-transplant maintenance on outcomes of allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromes: Real-world multicentre evidence.","journal":"Br J Haematol","issue":"2026 June; 208(6):2156-2167. doi: 10.1111\/bjh.70477","author":"Chen Y, Zhang X, Shen N, Zhang J, Guo R, Xing H, Han L, Liu Y, Tian W, Wang M, Xie X, Jiang Z, Wan D, Zhou X, Xu H, Qin L, Shi W, Cao W, Bian Z","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41960892"},{"title01":"Endothelial activation and stress index score as a predictor of transplant-associated thrombotic microangiopathy in patients with sickle cell disease.","title02":"Endothelial activation and stress index score as a predictor of transplant-associated thrombotic microangiopathy in patients with sickle cell disease.","journal":"Br J Haematol","issue":"2026 June; 208(6):2315-2319. doi: 10.1111\/bjh.70465","author":"Krishnan R, Sankaran H, Jacobsohn D, Nickel R, Snelling K, Vatsayan A, Dreyzin A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924942"},{"title01":"Significant clinical impact of immunosuppressive therapy termination after allogeneic haematopoietic stem cell transplantation.","title02":"Significant clinical impact of immunosuppressive therapy termination after allogeneic haematopoietic stem cell transplantation.","journal":"Br J Haematol","issue":"2026 June; 208(6):2168-2174. doi: 10.1111\/bjh.70450","author":"Fuji S, Ohmoto A, Najima Y, Yoshimura K, Uchida N, Tanaka M, Hasegawa Y, Fukuda T, Asada N, Sawa M, Sakata-Yanagimoto M, Ishimura M, Onizuka M, Nishida T, Doki N, Kawamura K, Hino M, Kanda Y, Atsuta Y, Yakushijin K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41866833"},{"title01":"Front-line systemic treatment outcomes in POEMS syndrome.","title02":"Front-line systemic treatment outcomes in POEMS syndrome.","journal":"Br J Haematol","issue":"2026 June; 208(6):2087-2095. doi: 10.1111\/bjh.70436","author":"Tomkins O, Khwaja J, Koay S, Japzon N, Keh R, Keddie S, Wechalekar A, Kirkwood A, Carr A, Lunn M, D'Sa S, Sive J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41871552"},{"title01":"Inclusion of Thiotepa in Myeloablative Regimens Improves Donor Chimerism in Children with Inborn Errors of Immunity or Inherited Metabolic Disorders.","title02":"Inclusion of Thiotepa in Myeloablative Regimens Improves Donor Chimerism in Children with Inborn Errors of Immunity or Inherited Metabolic Disorders.","journal":"Br J Haematol","issue":"2026 June; 208(6):2293-2297. doi: 10.1111\/bjh.70486","author":"McComb C, Pai V, Stanek J, Rankin AW, Lamb M, Bhunia N, Bajwa R, Abu-Arja R, Rangarajan HG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41983326"},{"title01":"Optimizing treatment selection and timing of allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia with concurrent feline McDonough sarcoma (FMS)-like tyrosine kinase 3 internal tandem duplication, nucleophosmin 1 and deoxyribonucleic acid (DNA) methyltransferase 3 alpha mutations.","title02":"Optimizing treatment selection and timing of allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia with concurrent feline McDonough sarcoma (FMS)-like tyrosine kinase 3 internal tandem duplication, nucleophosmin 1 and deoxyribonucleic acid (DNA) methyltransferase 3 alpha mutations.","journal":"Br J Haematol","issue":"2026 June 2. doi: 10.1111\/bjh.70593. Online ahead of print","author":"Li R, Yao Y, Yang D, Mao L, Lou Y, He Y, Meng H, Yu W, Pang A, Feng S, Tong H, Han M, Jin J, Tang M, Jiang E, Wang H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42230972"},{"title01":"Cesni-cel (ARI0002h) in ultra-high-risk multiple myeloma with plasma cell leukaemia or central nervous system involvement.","title02":"Cesni-cel (ARI0002h) in ultra-high-risk multiple myeloma with plasma cell leukaemia or central nervous system involvement.","journal":"Br J Haematol","issue":"2026 June 4. doi: 10.1111\/bjh.70586. Online ahead of print","author":"Jimenez-Mira C, Tovar N, Martinez-Cibrian N, Gonzalez-Calle V, Albiol N, Lopez-Munoz N, Oliver-Caldes A, Gonzalez A, Mateos JM, Espanol-Rego M, Rosinol L, Juan M, Charry P, Sanchez-Pina JM, Navarro S, Munarriz D, Lopez-Corral L, Ortiz-Maldonado V, Varea S, Olesti E, Delgado J, Urbano-Ispizua A, Martinez-Lopez J, Mateos MV, Rodriguez-Lobato LG, Fernandez de Larrea C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42237881"},{"title01":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: A 25-year nationwide study.","title02":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: A 25-year nationwide study.","journal":"Br J Haematol","issue":"2026 June; 208(6):2143-2155. doi: 10.1111\/bjh.70463","author":"Itonaga H, Miyazaki Y, Tachi N, Kurosawa S, Marumo A, Konuma T, Ebina T, Doki N, Uchida N, Fukuda T, Nishida T, Katayama Y, Asada N, Sakurai M, Maeda T, Eto T, Tanaka M, Nakamae H, Onizuka M, Kawamura K, Kanda Y, Atsuta Y, Tachibana T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41937388"},{"title01":"Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data.","title02":"Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data.","journal":"Br J Haematol","issue":"2026 June; 208(6):2134-2142. doi: 10.1111\/bjh.70490","author":"Goel U, Dragomirescu C, Zanwar S, Cassano RC, Cicero KI, Cowan AJ, Banerjee R, Anwer F, Khouri J, Dima D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42023513"},{"title01":"Recombinant zoster vaccine induces superior immunogenicity compared with live varicella vaccine in allogeneic haematopoietic stem cell transplantation recipients.","title02":"Recombinant zoster vaccine induces superior immunogenicity compared with live varicella vaccine in allogeneic haematopoietic stem cell transplantation recipients.","journal":"Br J Haematol","issue":"2026 June; 208(6):2288-2292. doi: 10.1111\/bjh.70500","author":"Ono T, Okada T, Ikeda R, Yamashita M, Koyauchi K, Takagi F, Adachi M, Takemura T, Mitsui K, Nagata Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42007689"},{"title01":"Impact of novel therapies on the efficacy of posttransplantation brentuximab vedotin maintenance in Hodgkin lymphoma.","title02":"Impact of novel therapies on the efficacy of posttransplantation brentuximab vedotin maintenance in Hodgkin lymphoma.","journal":"Blood advances","issue":"2026 June 9; 10(11):3833-3844. doi: 10.1182\/bloodadvances.2025018683","author":"Falade AS, Redd R, Desai SH, Moskowitz AJ, Shah H, Geyer SM, Ganesan N, Chang T, Othman T, Shah GL, Nedved A, Durani U, Ng LS, Baron K, Ong SY, Yoon K, Ansell SM, Iyengar S, Micallef I, Stuver R, Herrera AF, Mei M, Armand P, Merryman RW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41894690"},{"title01":"Telomere length and clonal hematopoiesis interact to influence outcomes in hematopoietic stem cell transplantation.","title02":"Telomere length and clonal hematopoiesis interact to influence outcomes in hematopoietic stem cell transplantation.","journal":"Blood advances","issue":"2026 June 9; 10(11):3909-3919. doi: 10.1182\/bloodadvances.2025018279","author":"Tobin J, Stelmach P, Richter S, Xu D, Sauer S, Raab MS, Gu M, Dunn WG, Fabre MA, Muller-Tidow C, Vassiliou GS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41860374"},{"title01":"Glofitamab plus gemcitabine and oxaliplatin for relapsed\/refractory DLBCL: 3-year follow-up of STARGLO.","title02":"Glofitamab plus gemcitabine and oxaliplatin for relapsed\/refractory DLBCL: 3-year follow-up of STARGLO.","journal":"Blood advances","issue":"2026 June 10. doi: 10.1182\/bloodadvances.2026019764. Online ahead of print","author":"Abramson JS, Townsend W, Fox CP, Ku M, Hertzberg M, Huang HQ, Zhang H, Yoon DH, Kim WS, Abdulhaq H, Herbaux C, Zaucha JM, Zhang QY, Chang H, Liu Y, Cheah CY, Ghesquieres H, Mulvihill ES, Kesavan M, Kallemeijn M, Ta R, Choeurng V, Belousov A, Relf J, Bottos A, Lundberg L, Gregory GP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42269085"},{"title01":"PT\/Cy-based alloBMT platform as a curative, accessible alternative for pediatric and young adult severe aplastic anemia.","title02":"PT\/Cy-based alloBMT platform as a curative, accessible alternative for pediatric and young adult severe aplastic anemia.","journal":"Blood advances","issue":"2026 June 10. doi: 10.1182\/bloodadvances.2025019581. Online ahead of print","author":"Dionysiou M, Ktena YP, Bonifant CL, Chen AR, Llosa NJ, Zambidis ET, DeZern AE, Jones RJ, Symons HJ, Cooke KR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42269078"},{"title01":"Peri-transplant molecular MRD monitoring by targeted NGS in patients with FLT3-ITD mutated acute myeloid leukemia.","title02":"Peri-transplant molecular MRD monitoring by targeted NGS in patients with FLT3-ITD mutated acute myeloid leukemia.","journal":"Blood advances","issue":"2026 June 9. doi: 10.1182\/bloodadvances.2026020264. Online ahead of print","author":"Hu X, Zhao Y, Jiang C, Fan Y, Shi J, Luo Y, Yu J, Lai X, Liu L, Ye Y, Liang J, Huang X, Zheng Z, Huang H, Shi W, Zhao Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42263741"},{"title01":"Plant-based whole-food diets are feasible during auto-HCT and are associated with dose-dependent microbiome modulation.","title02":"Plant-based whole-food diets are feasible during auto-HCT and are associated with dose-dependent microbiome modulation.","journal":"Blood advances","issue":"2026 June 9. doi: 10.1182\/bloodadvances.2026020270. Online ahead of print","author":"Ueland K, Elahi T, Rasmussen M, Wolfe AE, Purcell H, Chakka SR, Mirimo-Martinez M, Persinger H, Johnson K, Boynton AM, McMillen K, Byelykh M, Biernacki MA, Yeh AC, Ali N, Manjappa S, Wuliji N, Fredricks D, Bleakley M, Holmberg LA, Peled JU, Schenk J, Raftery D, Ma J, Hill GR, Neuhouser ML, Lee SJ, Markey KA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42263665"},{"title01":"Antigen-specific T-cell responses to SARS-CoV-2 vaccination after hematopoietic cell transplant or CAR T-cell therapy.","title02":"Antigen-specific T-cell responses to SARS-CoV-2 vaccination after hematopoietic cell transplant or CAR T-cell therapy.","journal":"Blood advances","issue":"2026 June 9; 10(11):3945-3959. doi: 10.1182\/bloodadvances.2026019614","author":"Einarsdottir S, Fei T, Singh K, Martens M, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Shahid Z, Armistead P, Westervelt P, McCarty J, McGuirk J, Hamadani M, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, Horowitz MM, Riches ML, Hosszu K, Hill JA, DeWolf S, Perales MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42241036"},{"title01":"A pilot randomized clinical trial of a peer support intervention for hematopoietic stem cell transplantation.","title02":"A pilot randomized clinical trial of a peer support intervention for hematopoietic stem cell transplantation.","journal":"Blood advances","issue":"2026 June 9; 10(11):3987-3997. doi: 10.1182\/bloodadvances.2025018918","author":"Amonoo HL, Keane EP, Guo M, Gudenkauf LM, Boardman AC, Larizza IS, Wolfe ED, Mate-Kole MN, Healy BC, Cutler C, Jim HS, Lee SJ, Greer JA, Huffman JC, El-Jawahri A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41945755"},{"title01":"Management of relapsed\/refractory AL amyloidosis.","title02":"Management of relapsed\/refractory AL amyloidosis.","journal":"Blood advances","issue":"2026 June 9; 10(11):3799-3810. doi: 10.1182\/bloodadvances.2025019223","author":"Ling J, Sidiqi MH, Gertz M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41894688"},{"title01":"TA-TMA and GVHD are distinct consequences of endothelial injury: A MIDAS consortium study.","title02":"TA-TMA and GVHD are distinct consequences of endothelial injury: A MIDAS consortium study.","journal":"Blood advances","issue":"2026 June 3. doi: 10.1182\/bloodadvances.2026019747. Online ahead of print","author":"Hahn T, Zhao Q, Miller EG, Elder P, Langenberg L, Luebbering N, Abdullah S, Neidemire-Colley L, Holtan SG, Cataland SR, Ranganathan P, Davies SM, Bejanyan N, Vasu S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42234937"},{"title01":"Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment Trial.","title02":"Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment Trial.","journal":"Blood advances","issue":"2026 June 5. doi: 10.1182\/bloodadvances.2026020355. Online ahead of print","author":"Bashey A, Logan BR, Hill LC, Symons HJ, Farhadfar N, Grunwald MR, Pidala JA, Dehn JG, Brunstein C, Arai S, Leifer E, He N, Shaw BE, Juckett MB, Devine SM, Uberti J, Westervelt P, Srour SA, Pusic I, Vasu S, Hayes-Lattin B, Ciurea SO, Horowitz MM, Lee SJ, Hogan WJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42263667"},{"title01":"Therapeutic Targeting of IL-17A-Driven PTGS2\/NLRP3 Inflammasome Activation in Juvenile Myelomonocytic Leukemia.","title02":"Therapeutic Targeting of IL-17A-Driven PTGS2\/NLRP3 Inflammasome Activation in Juvenile Myelomonocytic Leukemia.","journal":"Blood","issue":"2026 June 2. doi: 10.1182\/blood.2025032588. Online ahead of print","author":"Pasupuleti SK, Ramdas B, Padam KSR, Kanumuri R, Palam LR, Kumar R, Ho TC, Lee AG, Clapp W, Qu CK, Stieglitz E, Yang K, Kapur R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42233403"},{"title01":"Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis.","title02":"Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis.","journal":"Blood","issue":"2026 June 2. doi: 10.1182\/blood.2025032290. Online ahead of print","author":"Chetlapalli K, Ito S, Ng DQ, Sra MS, Wang D, Krumholz H, Krishnamurti L, Pandya A, Goshua G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42227898"},{"title01":"BET inhibition blunts antibody production and macrophage-mediated fibrosis to restore lung function in murine cGVHD.","title02":"BET inhibition blunts antibody production and macrophage-mediated fibrosis to restore lung function in murine cGVHD.","journal":"Blood","issue":"2026 June 4; 147(23):2828-2844. doi: 10.1182\/blood.2025031983","author":"Kumar R, Neidemire-Colley L, Garfinkle EAR, Steere C, Surana S, Murray A, Giordano G, Martin O, Woodbury ED, Rivaldi A, Singh S, Corps K, Lederer K, Karunasiri M, Gorr MW, Wold LE, Sehgal L, Oestreich KJ, Grieselhuber NR, de Lima MJ, Blazar BR, Maillard I, Miller KE, Choe HK, Ranganathan P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41770848"},{"title01":"CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation.","title02":"CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation.","journal":"Blood","issue":"2026 June 4; 147(23):2786-2792. doi: 10.1182\/blood.2025030207","author":"Minnie SA, Ho K, Boiko JR, Adams RC, Ensbey KS, Nemychenkov NS, Legg SRW, Schmidt CR, Comstock ML, Lyons JM, Sekiguchi T, Koyama M, Spencer A, Green DJ, Hill GR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41770790"},{"title01":"A novel triple-knockout allogeneic BCMA CAR T cell therapy (CT0590) in multiple myeloma: preclinical and phase I study.","title02":"A novel triple-knockout allogeneic BCMA CAR T cell therapy (CT0590) in multiple myeloma: preclinical and phase I study.","journal":"Blood","issue":"2026 June 11. doi: 10.1182\/blood.2025032112. Online ahead of print","author":"Jin S, Liao Z, Yan S, Yan L, Yao W, Shang J, Tang F, Zhu Z, Wu D, Rajakumaraswamy N, Luo Y, Yuan D, Jiang H, Li Z, Fu C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42275247"},{"title01":"Exa-cel in Children with Transfusion-Dependent beta-Thalassemia or Sickle Cell Disease.","title02":"Exa-cel in Children with Transfusion-Dependent beta-Thalassemia or Sickle Cell Disease.","journal":"N Engl J Med","issue":"2026 June 11. doi: 10.1056\/NEJMoa2603387. Online ahead of print","author":"Frangoul H, de la Fuente J, Chopra Y, Meisel R, Amrolia PJ, Algeri M, Sharma A, Cappellini MD, Corbacioglu S, Kattamis A, Lobitz S, de Montalembert M, Rondelli D, Sheth S, Steinberg MH, Walters MC, Boerner K, Liu T, Zairis S, Hobbs W, Grupp SA, Locatelli F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42274009"},{"title01":"Pre-diagnostic clonal hematopoiesis of indeterminate potential among patients with a primary cancer and risk of second cancers.","title02":"Pre-diagnostic clonal hematopoiesis of indeterminate potential among patients with a primary cancer and risk of second cancers.","journal":"Leukemia","issue":"2026 June; 40(6):1240-1246. doi: 10.1038\/s41375-026-02946-x","author":"Liu X, Adami HO, Boberg E, Smedby KE, Wei H, Fang F, Liu Q","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41981103"},{"title01":"Allogeneic hematopoietic cell transplantation for T-cell\/histiocyte-rich large B-cell lymphoma: An EBMT lymphoma working party study.","title02":"Allogeneic hematopoietic cell transplantation for T-cell\/histiocyte-rich large B-cell lymphoma: An EBMT lymphoma working party study.","journal":"Leukemia","issue":"2026 June 15. doi: 10.1038\/s41375-026-02993-4. Online ahead of print","author":"Renders S, Ngoya M, de Leval L, Finel H, Khvedelidze I, Pocock R, Ram R, Gedde-Dahl T, Serroukh Y, Bug G, Kroger N, Nagler A, Pabst T, Rabitsch W, Yakoub-Agha I, Eder M, Ratip S, Scheid C, Perez-Simon JA, Wagner-Drouet EM, Sureda A, Schmitz N, Glass B, Bazarbachi A, Dreger P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42297918"},{"title01":"Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trial.","title02":"Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trial.","journal":"Lancet Haematol","issue":"2026 June; 13(6):e365-e375. doi: 10.1016\/S2352-3026(26)00014-1","author":"Stein A, Wang Y, Malki MMA, Aldoss I, Ali H, Aribi A, Artz A, Ball B, Dandapani S, Farol L, Han C, Liu A, Pullarkat V, Radany E, Sahebi F, Sanchez JF, Sandhu K, Salhotra A, Smith E, Spielberger R, Hui S, Marcucci G, Nakamura R, Forman SJ, Palmer J, Wong J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42150590"},{"title01":"Multicolor detection of chronic myeloid leukemia stem cells, including novel marker CD69, predicts survival and early hematological toxicity.","title02":"Multicolor detection of chronic myeloid leukemia stem cells, including novel marker CD69, predicts survival and early hematological toxicity.","journal":"Haematologica","issue":"2026 June 11. doi: 10.3324\/haematol.2025.300293. Online ahead of print","author":"Culen M, Romzova M, Smitalova D, Loja T, Busa D, Venglar O, Herudkova Z, Kassa S, Radova L, Borsky M, Reigl T, Plevova K, Smejkal J, Zackova D, Stejskal L, Mayer J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42273943"},{"title01":"Platelet recovery delay and survival in patients with myelofibrosis undergoing allogeneic hemopoietic stem cell transplantation.","title02":"Platelet recovery delay and survival in patients with myelofibrosis undergoing allogeneic hemopoietic stem cell transplantation.","journal":"Haematologica","issue":"2026 June 1; 111(6):2080-2086. doi: 10.3324\/haematol.2025.288371","author":"Sora' F, Bacigalupo A, Giammarco S, Metafuni E, Frioni F, Galli E, Limongiello MA, Sica S, Chiusolo P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537336"},{"title01":"Mmrn1 expression defines a novel subset of hematopoietic stem cells and leukemia stem cells with great self-renewal potential.","title02":"Mmrn1 expression defines a novel subset of hematopoietic stem cells and leukemia stem cells with great self-renewal potential.","journal":"Haematologica","issue":"2026 June 1; 111(6):2032-2046. doi: 10.3324\/haematol.2025.287609","author":"Chen N, Yang L, Chen F, Zeng H, Zhong X, Liu Y, Chen Z, Yao M, Lu Y, Shen M, Chen M, Xu Y, Wang S, Zhang X, Wang J, Hu M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568470"},{"title01":"Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data.","title02":"Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data.","journal":"Br J Haematol","issue":"2026 June; 208(6):2134-2142. doi: 10.1111\/bjh.70490","author":"Goel U, Dragomirescu C, Zanwar S, Cassano RC, Cicero KI, Cowan AJ, Banerjee R, Anwer F, Khouri J, Dima D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42023513"},{"title01":"Cesni-cel (ARI0002h) in ultra-high-risk multiple myeloma with plasma cell leukaemia or central nervous system involvement.","title02":"Cesni-cel (ARI0002h) in ultra-high-risk multiple myeloma with plasma cell leukaemia or central nervous system involvement.","journal":"Br J Haematol","issue":"2026 June 4. doi: 10.1111\/bjh.70586. Online ahead of print","author":"Jimenez-Mira C, Tovar N, Martinez-Cibrian N, Gonzalez-Calle V, Albiol N, Lopez-Munoz N, Oliver-Caldes A, Gonzalez A, Mateos JM, Espanol-Rego M, Rosinol L, Juan M, Charry P, Sanchez-Pina JM, Navarro S, Munarriz D, Lopez-Corral L, Ortiz-Maldonado V, Varea S, Olesti E, Delgado J, Urbano-Ispizua A, Martinez-Lopez J, Mateos MV, Rodriguez-Lobato LG, Fernandez de Larrea C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42237881"},{"title01":"Optimizing treatment selection and timing of allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia with concurrent feline McDonough sarcoma (FMS)-like tyrosine kinase 3 internal tandem duplication, nucleophosmin 1 and deoxyribonucleic acid (DNA) methyltransferase 3 alpha mutations.","title02":"Optimizing treatment selection and timing of allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia with concurrent feline McDonough sarcoma (FMS)-like tyrosine kinase 3 internal tandem duplication, nucleophosmin 1 and deoxyribonucleic acid (DNA) methyltransferase 3 alpha mutations.","journal":"Br J Haematol","issue":"2026 June 2. doi: 10.1111\/bjh.70593. Online ahead of print","author":"Li R, Yao Y, Yang D, Mao L, Lou Y, He Y, Meng H, Yu W, Pang A, Feng S, Tong H, Han M, Jin J, Tang M, Jiang E, Wang H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42230972"},{"title01":"High frequency of CD95(+)\/CD45RA(-) regulatory T cells defines an immunosuppressive profile associated with MDS progression.","title02":"High frequency of CD95(+)\/CD45RA(-) regulatory T cells defines an immunosuppressive profile associated with MDS progression.","journal":"Br J Haematol","issue":"2026 June; 208(6):1993-2003. doi: 10.1111\/bjh.70504","author":"Vazquez R, Deredec N, Boussaid I, Boncoeur P, Knosp C, Houvert A, Zalmai L, Friedrich C, Almire C, Dussiau C, Willems L, Birsen R, Decroocq J, Bouscary D, Kosmider O, Kordasti S, Fontenay M, Simoni Y, Chapuis N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42080308"},{"title01":"Improvements over time in survival after post-transplant relapse of adult T-cell leukaemia\/lymphoma and trends of salvage therapy in a real-world experience.","title02":"Improvements over time in survival after post-transplant relapse of adult T-cell leukaemia\/lymphoma and trends of salvage therapy in a real-world experience.","journal":"Br J Haematol","issue":"2026 June 15. doi: 10.1111\/bjh.70631. Online ahead of print","author":"Itonaga H, Fukushima T, Kato K, Muranushi H, Tokunaga M, Miyazono T, Ito A, Eto T, Suehiro Y, Kato T, Fujioka M, Kawakita T, Uchida N, Mori Y, Yoshimitsu M, Nakamae H, Morichika K, Ishitsuka K, Kanda J, Fukuda T, Atsuta Y, Fuji S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42298882"},{"title01":"Recombinant zoster vaccine induces superior immunogenicity compared with live varicella vaccine in allogeneic haematopoietic stem cell transplantation recipients.","title02":"Recombinant zoster vaccine induces superior immunogenicity compared with live varicella vaccine in allogeneic haematopoietic stem cell transplantation recipients.","journal":"Br J Haematol","issue":"2026 June; 208(6):2288-2292. doi: 10.1111\/bjh.70500","author":"Ono T, Okada T, Ikeda R, Yamashita M, Koyauchi K, Takagi F, Adachi M, Takemura T, Mitsui K, Nagata Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42007689"},{"title01":"Significant clinical impact of immunosuppressive therapy termination after allogeneic haematopoietic stem cell transplantation.","title02":"Significant clinical impact of immunosuppressive therapy termination after allogeneic haematopoietic stem cell transplantation.","journal":"Br J Haematol","issue":"2026 June; 208(6):2168-2174. doi: 10.1111\/bjh.70450","author":"Fuji S, Ohmoto A, Najima Y, Yoshimura K, Uchida N, Tanaka M, Hasegawa Y, Fukuda T, Asada N, Sawa M, Sakata-Yanagimoto M, Ishimura M, Onizuka M, Nishida T, Doki N, Kawamura K, Hino M, Kanda Y, Atsuta Y, Yakushijin K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41866833"},{"title01":"Inclusion of Thiotepa in Myeloablative Regimens Improves Donor Chimerism in Children with Inborn Errors of Immunity or Inherited Metabolic Disorders.","title02":"Inclusion of Thiotepa in Myeloablative Regimens Improves Donor Chimerism in Children with Inborn Errors of Immunity or Inherited Metabolic Disorders.","journal":"Br J Haematol","issue":"2026 June; 208(6):2293-2297. doi: 10.1111\/bjh.70486","author":"McComb C, Pai V, Stanek J, Rankin AW, Lamb M, Bhunia N, Bajwa R, Abu-Arja R, Rangarajan HG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41983326"},{"title01":"Contrasting impacts of pretransplant cytoreduction and post-transplant maintenance on outcomes of allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromes: Real-world multicentre evidence.","title02":"Contrasting impacts of pretransplant cytoreduction and post-transplant maintenance on outcomes of allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromes: Real-world multicentre evidence.","journal":"Br J Haematol","issue":"2026 June; 208(6):2156-2167. doi: 10.1111\/bjh.70477","author":"Chen Y, Zhang X, Shen N, Zhang J, Guo R, Xing H, Han L, Liu Y, Tian W, Wang M, Xie X, Jiang Z, Wan D, Zhou X, Xu H, Qin L, Shi W, Cao W, Bian Z","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41960892"},{"title01":"Monitoring of haematopoietic stem cell mobilization by targeted DNA methylation analysis.","title02":"Monitoring of haematopoietic stem cell mobilization by targeted DNA methylation analysis.","journal":"Br J Haematol","issue":"2026 June; 208(6):2284-2287. doi: 10.1111\/bjh.70446","author":"Hubens WHG, Diehlmann A, Wuchter P, Wagner W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41844549"},{"title01":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: A 25-year nationwide study.","title02":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: A 25-year nationwide study.","journal":"Br J Haematol","issue":"2026 June; 208(6):2143-2155. doi: 10.1111\/bjh.70463","author":"Itonaga H, Miyazaki Y, Tachi N, Kurosawa S, Marumo A, Konuma T, Ebina T, Doki N, Uchida N, Fukuda T, Nishida T, Katayama Y, Asada N, Sakurai M, Maeda T, Eto T, Tanaka M, Nakamae H, Onizuka M, Kawamura K, Kanda Y, Atsuta Y, Tachibana T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41937388"},{"title01":"High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT.","title02":"High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT.","journal":"Blood advances","issue":"2026 June 12. doi: 10.1182\/bloodadvances.2026020219. Online ahead of print","author":"Kauer J, Kramer I, Derigs P, Blank MF, Dietrich S, Meissner J, Kehl N, Friedrich MJ, Schubert ML, Ho AD, Schmitt A, Kobbe G, Muller-Tidow C, Schmitt M, Dreger P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42284699"},{"title01":"Modulation of the bone marrow microenvironment by acute B-cell lymphoblastic leukemia-derived large oncosomes.","title02":"Modulation of the bone marrow microenvironment by acute B-cell lymphoblastic leukemia-derived large oncosomes.","journal":"Blood advances","issue":"2026 June 10. doi: 10.1182\/bloodadvances.2025018905. Online ahead of print","author":"Samangan F, Krack T, Kerman FD, Bravo J, Witzler CL, Gregorz B, Ruf W, Krause DS, Minciacchi VR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42268930"},{"title01":"Peri-transplant molecular MRD monitoring by targeted NGS in patients with FLT3-ITD mutated acute myeloid leukemia.","title02":"Peri-transplant molecular MRD monitoring by targeted NGS in patients with FLT3-ITD mutated acute myeloid leukemia.","journal":"Blood advances","issue":"2026 June 9. doi: 10.1182\/bloodadvances.2026020264. Online ahead of print","author":"Hu X, Zhao Y, Jiang C, Fan Y, Shi J, Luo Y, Yu J, Lai X, Liu L, Ye Y, Liang J, Huang X, Zheng Z, Huang H, Shi W, Zhao Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42263741"},{"title01":"Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment Trial.","title02":"Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment Trial.","journal":"Blood advances","issue":"2026 June 5. doi: 10.1182\/bloodadvances.2026020355. Online ahead of print","author":"Bashey A, Logan BR, Hill LC, Symons HJ, Farhadfar N, Grunwald MR, Pidala JA, Dehn JG, Brunstein C, Arai S, Leifer E, He N, Shaw BE, Juckett MB, Devine SM, Uberti J, Westervelt P, Srour SA, Pusic I, Vasu S, Hayes-Lattin B, Ciurea SO, Horowitz MM, Lee SJ, Hogan WJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42263667"},{"title01":"Plant-based whole-food diets are feasible during auto-HCT and are associated with dose-dependent microbiome modulation.","title02":"Plant-based whole-food diets are feasible during auto-HCT and are associated with dose-dependent microbiome modulation.","journal":"Blood advances","issue":"2026 June 9. doi: 10.1182\/bloodadvances.2026020270. Online ahead of print","author":"Ueland K, Elahi T, Rasmussen M, Wolfe AE, Purcell H, Chakka SR, Mirimo-Martinez M, Persinger H, Johnson K, Boynton AM, McMillen K, Byelykh M, Biernacki MA, Yeh AC, Ali N, Manjappa S, Wuliji N, Fredricks D, Bleakley M, Holmberg LA, Peled JU, Schenk J, Raftery D, Ma J, Hill GR, Neuhouser ML, Lee SJ, Markey KA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42263665"},{"title01":"CRISPR application in hematological disorders: from bench to bedside.","title02":"CRISPR application in hematological disorders: from bench to bedside.","journal":"Blood advances","issue":"2026 June 5. doi: 10.1182\/bloodadvances.2025017417. Online ahead of print","author":"Ladisa F, Morelli E, Soncini D, Garibotto M, Munshi NC, Fulciniti M, Cea M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42263664"},{"title01":"Telomere length and clonal hematopoiesis interact to influence outcomes in hematopoietic stem cell transplantation.","title02":"Telomere length and clonal hematopoiesis interact to influence outcomes in hematopoietic stem cell transplantation.","journal":"Blood advances","issue":"2026 June 9; 10(11):3909-3919. doi: 10.1182\/bloodadvances.2025018279","author":"Tobin J, Stelmach P, Richter S, Xu D, Sauer S, Raab MS, Gu M, Dunn WG, Fabre MA, Muller-Tidow C, Vassiliou GS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41860374"},{"title01":"Real-world experience with tabelecleucel within and beyond the approval label.","title02":"Real-world experience with tabelecleucel within and beyond the approval label.","journal":"Blood advances","issue":"2026 June 9; 10(11):4097-4106. doi: 10.1182\/bloodadvances.2025019207","author":"Farid KMN, Kocher F, Arnold T, Fauser J, Henze E, Schultze-Florey C, Herling CD, Vucinic V, Reicherts C, Stelljes M, Stadelmann R, Scheid C, Holtick U, Masouridi-Levrat S, Wehrli M, Novak U, Schnitzler P, Ben-Salah C, Kramer I, Schmitt A, Muller-Tidow C, Luft T, Dreger P, Schmitt M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41879713"},{"title01":"TA-TMA and GVHD are distinct consequences of endothelial injury: A MIDAS consortium study.","title02":"TA-TMA and GVHD are distinct consequences of endothelial injury: A MIDAS consortium study.","journal":"Blood advances","issue":"2026 June 3. doi: 10.1182\/bloodadvances.2026019747. Online ahead of print","author":"Hahn T, Zhao Q, Miller EG, Elder P, Langenberg L, Luebbering N, Abdullah S, Neidemire-Colley L, Holtan SG, Cataland SR, Ranganathan P, Davies SM, Bejanyan N, Vasu S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42234937"},{"title01":"Antigen-specific T-cell responses to SARS-CoV-2 vaccination after hematopoietic cell transplant or CAR T-cell therapy.","title02":"Antigen-specific T-cell responses to SARS-CoV-2 vaccination after hematopoietic cell transplant or CAR T-cell therapy.","journal":"Blood advances","issue":"2026 June 9; 10(11):3945-3959. doi: 10.1182\/bloodadvances.2026019614","author":"Einarsdottir S, Fei T, Singh K, Martens M, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Shahid Z, Armistead P, Westervelt P, McCarty J, McGuirk J, Hamadani M, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, Horowitz MM, Riches ML, Hosszu K, Hill JA, DeWolf S, Perales MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41941698"},{"title01":"Statistical considerations in the comparison of immunotherapy and chemotherapy for POD24 follicular lymphoma.","title02":"Statistical considerations in the comparison of immunotherapy and chemotherapy for POD24 follicular lymphoma.","journal":"Br J Haematol","issue":"2026 June; 208(6):2326. doi: 10.1111\/bjh.70522","author":"Yan C, Liu J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42099098"},{"title01":"Hepatitis C virus and hepatitis B virus in indolent lymphomas: Prospective data from the international observational NF10 study.","title02":"Hepatitis C virus and hepatitis B virus in indolent lymphomas: Prospective data from the international observational NF10 study.","journal":"Br J Haematol","issue":"2026 June; 208(6):2229-2234. doi: 10.1111\/bjh.70439","author":"Arcaini L, Merli M, Rattotti S, Nizzoli ME, Tarantino V, Consoli C, Talami A, Murru R, Deodato M, Cencini E, Re F, Visco C, Duffles G, Spina M, Annibali O, Pulsoni A, Ferreri AJM, Stelitano C, Pennese E, Varettoni M, Cappello E, Favrin G, La Fauci M, Marcheselli L, Paulli M, Luminari S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41905881"},{"title01":"Are CHOP-plus really CHOP-minus propositions in the treatment of PTCL? A comprehensive assessment of the strategy.","title02":"Are CHOP-plus really CHOP-minus propositions in the treatment of PTCL? A comprehensive assessment of the strategy.","journal":"Blood advances","issue":"2026 June 9; 10(11):3867-3877. doi: 10.1182\/bloodadvances.2025018042","author":"Saleh ND, O'Connor OA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671456"},{"title01":"Real-world outcomes and toxicities of CAR-T in relapsed\/refractory follicular lymphoma: a multicenter cohort study.","title02":"Real-world outcomes and toxicities of CAR-T in relapsed\/refractory follicular lymphoma: a multicenter cohort study.","journal":"Blood advances","issue":"2026 June 9; 10(11):3757-3768. doi: 10.1182\/bloodadvances.2025019115","author":"Sharp J, Strati P, Bhatta S, Huang JJ, Thomas C, Elghawy O, Reef D, Gorzewski A, Wang J, Shouse G, Reinert C, Teferra A, Velez ET, Pelcovits A, Ollila T, Clark W, Yazbeck V, Maakaron J, Kamdar M, Fitzgerald L, Danilov A, Karmali R, Grover NS, Barta SK, Voorhees TJ, Chen AI, Shadman M, Ahmed S, Epperla N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41747197"},{"title01":"Real-World Treatment Patterns of Patients with Large B-cell Lymphoma Over Time and into a Post-CAR T Approval Era.","title02":"Real-World Treatment Patterns of Patients with Large B-cell Lymphoma Over Time and into a Post-CAR T Approval Era.","journal":"Blood advances","issue":"2026 June 3. doi: 10.1182\/bloodadvances.2025019064. Online ahead of print","author":"Perales MA, McGuirk JP, Fesen MR, Snider J, Adamson B, Proli AJ, Hsu H, Adedokun B, Patel AR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42234934"},{"title01":"\u200bEuroNet-PHL-LP1: Complete resection or low-dose chemo for pediatric low-risk nodular lymphocyte-predominant Hodgkin lymphoma.","title02":"\u200bEuroNet-PHL-LP1: Complete resection or low-dose chemo for pediatric low-risk nodular lymphocyte-predominant Hodgkin lymphoma.","journal":"Blood advances","issue":"2026 June 3. doi: 10.1182\/bloodadvances.2026019765. Online ahead of print","author":"Shankar AG, Landman-Parker J, Mascarin M, Attarbaschi A, Boudjemaa S, Burnelli R, Beishuizen A, Cepelova M, Ceppi F, Georgi T, Hall GW, Klapper W, Kluge R, Lopci E, Metzger ML, Ramsay AG, Steglich J, Stoevesandt D, Kurch L, Korholz D, Hasenclever D, Mauz-Koerholz C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42234940"},{"title01":"Analysis of cell-free DNA in lymphomas: from sample collection to genotyping and minimal residual disease monitoring.","title02":"Analysis of cell-free DNA in lymphomas: from sample collection to genotyping and minimal residual disease monitoring.","journal":"Blood advances","issue":"2026 June 12. doi: 10.1182\/bloodadvances.2024015609. Online ahead of print","author":"Piffaretti D, Consoli C, Rossi D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42284698"},{"title01":"Phase 1 study of zanubrutinib plus lenalidomide for patients with relapsed\/refractory diffuse large B-cell lymphoma.","title02":"Phase 1 study of zanubrutinib plus lenalidomide for patients with relapsed\/refractory diffuse large B-cell lymphoma.","journal":"Blood advances","issue":"2026 June 9; 10(11):3897-3908. doi: 10.1182\/bloodadvances.2025018482","author":"Song Z, Cheng Y, Yang H, Zhang L, Zou L, Guo Y, Cao J, Huang H, Wang Z, Huang S, Fang Y, Lyu J, Zhang Y, Liu Y, Zhou K, Zhang H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41824782"},{"title01":"A phase 1\/2 study of duvelisib plus venetoclax in patients with relapsed\/refractory CLL\/SLL or Richter transformation.","title02":"A phase 1\/2 study of duvelisib plus venetoclax in patients with relapsed\/refractory CLL\/SLL or Richter transformation.","journal":"Blood advances","issue":"2026 June 9; 10(11):3811-3819. doi: 10.1182\/bloodadvances.2025018878","author":"Crombie JL, Ryan CE, Ren Y, Tyekucheva S, Carey C, Zou A, Normilus S, Montegaard J, Bhandari S, Alencar A, Soumerai JD, Arnason JE, Kim AI, Parry EM, Armand P, Fisher DC, Brown JR, Davids MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41886642"},{"title01":"Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma.","title02":"Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma.","journal":"Blood advances","issue":"2026 June 9; 10(11):3777-3786. doi: 10.1182\/bloodadvances.2026019802","author":"Kuhnl A, Kirkwood AA, Northend M, Alajangi R, Uttenthal B, Norman J, Hiew H, Seymour F, Maybury BD, Osborne W, Sillito F, Abdulgawad A, Jones C, Delaney A, Townsend W, Panopoulou A, Gribben JG, Bataillard E, Mathew A, Martinez-Calle N, Gajendran L, Davies AJ, Chavda N, Kumar E, Sanderson R, Kamat S, Petrides G, Roddie C, Menne T, Chaganti S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41894687"},{"title01":"Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapy.","title02":"Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapy.","journal":"Blood advances","issue":"2026 June 9; 10(11):3845-3855. doi: 10.1182\/bloodadvances.2025016688","author":"Xu R, Wu G, Rice S, Booker M, Weekes J, Bell H, Gao Y, Nirmal AJ, Liu H, Ciantra Z, Luo Q, Fortune A, Whalen K, Guanci T, Wan Y, Louissaint A Jr, Nordberg JJ, Lin JR, Hemann M, Manalis SR, Armand P, Smith E, Jacobson CA, Tolstorukov M, Murakami MA, Sorger PK, Weinstock DM, Song L, Lane AA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41855504"},{"title01":"Final phase 2 study results of acalabrutinib in treatment-naive and relapsed\/refractory chronic lymphocytic leukemia.","title02":"Final phase 2 study results of acalabrutinib in treatment-naive and relapsed\/refractory chronic lymphocytic leukemia.","journal":"Blood advances","issue":"2026 June 9; 10(11):3931-3941. doi: 10.1182\/bloodadvances.2025018310","author":"Furman RR, Wierda WG, Patten PEM, Chaves JM, Brown JR, Munir T, Martin P, Awan FT, Stephens DM, Ghia P, Barrientos JC, Patel K, Woyach JA, de Borja M, Wang MH, Jain N, O'Brien SM, Byrd JC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41915892"},{"title01":"Glofitamab plus gemcitabine and oxaliplatin for relapsed\/refractory DLBCL: 3-year follow-up of STARGLO.","title02":"Glofitamab plus gemcitabine and oxaliplatin for relapsed\/refractory DLBCL: 3-year follow-up of STARGLO.","journal":"Blood advances","issue":"2026 June 10. doi: 10.1182\/bloodadvances.2026019764. Online ahead of print","author":"Abramson JS, Townsend W, Fox CP, Ku M, Hertzberg M, Huang HQ, Zhang H, Yoon DH, Kim WS, Abdulhaq H, Herbaux C, Zaucha JM, Zhang QY, Chang H, Liu Y, Cheah CY, Ghesquieres H, Mulvihill ES, Kesavan M, Kallemeijn M, Ta R, Choeurng V, Belousov A, Relf J, Bottos A, Lundberg L, Gregory GP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42269085"},{"title01":"Brentuximab Vedotin after AlloSCT for Relapsed\/Refractory Hodgkin Lymphoma: GHSG BV-ALLO Phase II Trial.","title02":"Brentuximab Vedotin after AlloSCT for Relapsed\/Refractory Hodgkin Lymphoma: GHSG BV-ALLO Phase II Trial.","journal":"Blood advances","issue":"2026 June 10. doi: 10.1182\/bloodadvances.2026020136. Online ahead of print","author":"Scheid C, Jablonski J, Kerkhoff A, Stelljes M, Trautmann-Grill K, Bornhauser M, Tischer J, von Bergwelt-Baildon M, Janson D, Ayuk FA, Kroger N, Holtick U, Richardson T, von Tresckow B, Fuchs M, Borchmann P, Brockelmann PJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42241036"},{"title01":"Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma.","title02":"Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma.","journal":"Blood advances","issue":"2026 June 10. doi: 10.1182\/bloodadvances.2025019264. Online ahead of print","author":"Sanchez-Salinas MA, Varela-Gonzalez-Aller J, Iacoboni G, Navarro V, Troconiz IF, Carpio C, Alonso-Martinez C, Carreras-Soler MJ, Farriols-Danes A, Guerra-Gonzalez M, Rivas-Delgado A, Rivera Sanchez L, Feijoo S, Bosch F, Valdivia C, Miarons M, Barba P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42269079"},{"title01":"Impact of novel therapies on the efficacy of posttransplantation brentuximab vedotin maintenance in Hodgkin lymphoma.","title02":"Impact of novel therapies on the efficacy of posttransplantation brentuximab vedotin maintenance in Hodgkin lymphoma.","journal":"Blood advances","issue":"2026 June 9; 10(11):3833-3844. doi: 10.1182\/bloodadvances.2025018683","author":"Falade AS, Redd R, Desai SH, Moskowitz AJ, Shah H, Geyer SM, Ganesan N, Chang T, Othman T, Shah GL, Nedved A, Durani U, Ng LS, Baron K, Ong SY, Yoon K, Ansell SM, Iyengar S, Micallef I, Stuver R, Herrera AF, Mei M, Armand P, Merryman RW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41894690"},{"title01":"Prognostic factors and survival outcomes in relapsed\/refractory aggressive B-cell lymphomas treated with epcoritamab.","title02":"Prognostic factors and survival outcomes in relapsed\/refractory aggressive B-cell lymphomas treated with epcoritamab.","journal":"Blood advances","issue":"2026 June 5. doi: 10.1182\/bloodadvances.2026020171. Online ahead of print","author":"Bock AM, Feng L, Chauhan A, Falchi L, Merryman RW, Godbole S, Kambhampati Thiruvengadam S, Jallouk AP, Major A, D'Angelo CR, Ayers A, Baron K, Farahat O, Shouse G, Danilov AV, Bair SM, Lunning MA, Bhaskar S, Herrera AF, Sawalha Y, Flowers CR, Crombie JL, Salles GA, Epperla N, Ahmed S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42263668"},{"title01":"Digital spatial profiling uncovers transcriptomic features of distinct plasma cell-like phenotypes in diffuse large B-cell lymphoma.","title02":"Digital spatial profiling uncovers transcriptomic features of distinct plasma cell-like phenotypes in diffuse large B-cell lymphoma.","journal":"Blood advances","issue":"2026 June 9; 10(11):3966-3982. doi: 10.1182\/bloodadvances.2025018014","author":"Xie Z, Qin Y, Xue X, Chen X, Xie T, Zhu H, Huang L, Yang S, Yang J, Liu P, Gui L, Tang L, Feng X, Shi Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41886633"},{"title01":"From breakthroughs to blueprints: evolving evidence and future directions in relapsed and refractory large B-cell lymphoma.","title02":"From breakthroughs to blueprints: evolving evidence and future directions in relapsed and refractory large B-cell lymphoma.","journal":"Blood","issue":"2026 June 11; 147(24):2879-2894. doi: 10.1182\/blood.2025030859","author":"Kamdar M, Bartlett NL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41871044"},{"title01":"Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.","title02":"Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.","journal":"Lancet","issue":"2026 June 14. doi: 10.1016\/S0140-6736(26)01088-3. Online ahead of print","author":"Dimopoulos MA, Schjesvold F, Fu C, Hartley-Brown MA, Gomez C, Reece D, Mikala G, Alkharabsheh O, Parrish C, de Queiroz Crusoe E, Galvez K, Idrobo H, White D, Gupta R, Lee C, Liu CJ, Quach H, Wang Y, Cerchione C, Forsyth C, Hungria V, Kalaskar P, Graklanov V, Ho PJ, Klaiber-Hakimi M, Kwong YL, Louzada M, Mazumder A, Miles O, Nagarajan C, Prasad SVSS, Raab MS, Varga G, von der Heyde E, Xia Z, Ochoa PA, Oriol A, Yuda J, Kuroda J, Gong J, Zhou Z, Maciag P, Yu B, Rocci A, Koo P, Katz J, Richardson PG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42289183"},{"title01":"Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.","title02":"Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.","journal":"J Clin Oncol","issue":"2026 June 8; JCO2601346. doi: 10.1200\/JCO-26-01346. Online ahead of print","author":"Jin JX, Ginde VR, Huhn S, Reichert P, Bertsch U, Fenk R, Besemer B, Boquoi A, Schroers R, von Metzler I, Hanel M, Mann C, Leypoldt LB, Heilmeier B, Scheid C, Peters-Regehr T, Blau IW, Muller-Tidow C, Luntz S, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Muller M, Shumilov E, Knauf W, Michel CS, Geer T, Riesenberg H, Lutz C, Raab MS, Weinhold N, Hoffmann M, Benner A, Findeisen P, Weisel KC, Salwender HJ, Mai EK, Goldschmidt H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42258800"},{"title01":"Autologous stem cell transplantation for newly diagnosed multiple myeloma &#8211; real-world data from 2,149 Czech patients.","title02":"Autologous stem cell transplantation for newly diagnosed multiple myeloma &#8211; real-world data from 2,149 Czech patients.","journal":"Haematologica","issue":"2026 June 11. doi: 10.3324\/haematol.2025.300225. Online ahead of print","author":"Popkova T, Pour L, Spicka I, Radocha J, Jungova A, Minarik J, Pavlicek P, Jelinek T, Krejci M, Straub J, Maisnar V, Dekojova T, Pika T, Soukup J, Pospisilova L, Zihala D, Hajek R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42273953"},{"title01":"Longitudinal mechanisms of response, resistance and relapse to teclistamab in multiple myeloma: results from MajesTEC-1.","title02":"Longitudinal mechanisms of response, resistance and relapse to teclistamab in multiple myeloma: results from MajesTEC-1.","journal":"Haematologica","issue":"2026 June 11. doi: 10.3324\/haematol.2026.300526. Online ahead of print","author":"Vishwamitra D, Skerget S, Cortes-Selva D, Perova T, Lau O, Davis C, Boominathan R, Patel J, Berge KVD, Guo Y, Miao X, Stephenson T, Hodin C, Uhlar C, Pei L, Trancucci D, Zuppa AF, Chastain K, Banerjee A, Kobos R, Bahlis NJ, Van de Donk NWCJ, Verona RI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42273947"},{"title01":"Impact of the plasma cell quantification method on the International Myeloma Working Group diagnostic criteria for MGUS\/SMM.","title02":"Impact of the plasma cell quantification method on the International Myeloma Working Group diagnostic criteria for MGUS\/SMM.","journal":"Haematologica","issue":"2026 June 1; 111(6):2149-2153. doi: 10.3324\/haematol.2025.289176","author":"Uehara A, Sakuma H, Fujii F, Toho M, Tabata R, Narita K, Takeuchi M, Matsuda R, Isuge D, Ikeda D, Miyamoto T, Takamatsu H, Matsue K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41414966"},{"title01":"NEAT1: a multifaceted long non-coding RNA in multiple myeloma.","title02":"NEAT1: a multifaceted long non-coding RNA in multiple myeloma.","journal":"Haematologica","issue":"2026 June 1; 111(6):1936-1948. doi: 10.3324\/haematol.2025.289258","author":"Benini G, Taranto S, Sciume M, Rigali F, Marcheselli R, Abate A, Mitola S, Sigala S, Sacco A, Roccaro AM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41414960"},{"title01":"Promoter hypermethylation as a reversible mechanism of resistance to GPRC5D-directed therapy in multiple myeloma.","title02":"Promoter hypermethylation as a reversible mechanism of resistance to GPRC5D-directed therapy in multiple myeloma.","journal":"Haematologica","issue":"2026 June 1; 111(6):2145-2148. doi: 10.3324\/haematol.2025.289162","author":"Han S, Munawar U, Truger M, Gerhard-Hartmann E, Verbruggen C, Pfeiffer L, Hainold AS, Kurian S, Nerreter S, Besant E, Vogt C, Rein N, Koppel M, Lehmann J, Schmitt F, Tamamushi Y, Zhou X, Steinbrunn T, Haferlach C, Rosenwald A, Einsele H, Rasche L, Waldschmidt JM, Kortum MK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41504227"},{"title01":"Single-cell dissection of plasma cell clonal evolution to smoldering multiple myeloma after CD19 CAR-T cell therapy in B-cell acute lymphoblastic leukemia.","title02":"Single-cell dissection of plasma cell clonal evolution to smoldering multiple myeloma after CD19 CAR-T cell therapy in B-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 June 1; 111(6):2164-2170. doi: 10.3324\/haematol.2025.300240","author":"Yu H, Zhang G, Gong B, Li S, Guo C, Liu Y, Gu R, Xu Y, An G, Wei H, Wang M, Rao Q, Liu W, Wang J, Qiu S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41676912"},{"title01":"Late-onset progressive multifocal leukoencephalopathy after teclistamab in multiple myeloma: extending the timeline of infectious risk.","title02":"Late-onset progressive multifocal leukoencephalopathy after teclistamab in multiple myeloma: extending the timeline of infectious risk.","journal":"Haematologica","issue":"2026 June 1; 111(6):2171-2174. doi: 10.3324\/haematol.2025.300331","author":"Chizzoniti D, Ciambelli F, Latargia ML, Canziani L, Godi C, Pavesi F, Zambrotta GMP, Lotesoriere I, Appio L, Bertolli V, Santamaria C, Ballardini F, Cecchetti C, Todisco E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41709740"},{"title01":"Post-dose observation after subcutaneous daratumumab: A service evaluation of safety and capacity impact.","title02":"Post-dose observation after subcutaneous daratumumab: A service evaluation of safety and capacity impact.","journal":"Br J Haematol","issue":"2026 June 4. doi: 10.1111\/bjh.70604. Online ahead of print","author":"Sharpley F, Miller H, Pealing J, Loughran C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42237870"},{"title01":"Real-world outcomes of idecabtagene vicleucel in relapsed\/refractory multiple myeloma: A single-centre experience.","title02":"Real-world outcomes of idecabtagene vicleucel in relapsed\/refractory multiple myeloma: A single-centre experience.","journal":"Br J Haematol","issue":"2026 June 2. doi: 10.1111\/bjh.70602. Online ahead of print","author":"Kikuchi T, Kondo U, Sugita S, Watanabe M, Matsumoto C, Nomura-Yogo M, Kunisada K, Sato K, Takei T, Abe Y, Hosoya O, Ishida T, Tsukada N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42227265"},{"title01":"Safety profile of chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma: A systematic review and meta-analysis of proportions from clinical trials.","title02":"Safety profile of chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma: A systematic review and meta-analysis of proportions from clinical trials.","journal":"Br J Haematol","issue":"2026 June 15. doi: 10.1111\/bjh.70624. Online ahead of print","author":"Filippatos C, Ntanasis-Stathopoulos I, Voulomenou A, Malandrakis P, Kastritis E, Gavriatopoulou M, Dimopoulos MA, Terpos E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42297741"},{"title01":"Enostosis 100 days post-transplant in multiple myeloma.","title02":"Enostosis 100 days post-transplant in multiple myeloma.","journal":"Br J Haematol","issue":"2026 June; 208(6):1905-1906. doi: 10.1111\/bjh.70412","author":"Browner C, Erber W, Cirillo M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41797418"},{"title01":"Real-world application of the International Myeloma Society (IMS)\/International Myeloma Working Group (IMWG) consensus on genomic staging for high-risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases Registry.","title02":"Real-world application of the International Myeloma Society (IMS)\/International Myeloma Working Group (IMWG) consensus on genomic staging for high-risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases Registry.","journal":"Br J Haematol","issue":"2026 June 7. doi: 10.1111\/bjh.70609. Online ahead of print","author":"Lim KJC, Ashrafi E, Wellard C, Moore EM, Gration B, Augustson B, Mollee P, Zhang J, Doo NW, Dun K, Cooke R, Ringkowski S, Bryant A, McCaughan G, Wood E, McQuilten Z, Ho PJ, Quach H, Spencer A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42252849"},{"title01":"Cost-effective analysis of teclistamab and daratumumab versus ciltacabtagene autoleucel in relapsed multiple myeloma.","title02":"Cost-effective analysis of teclistamab and daratumumab versus ciltacabtagene autoleucel in relapsed multiple myeloma.","journal":"Br J Haematol","issue":"2026 June 7. doi: 10.1111\/bjh.70607. Online ahead of print","author":"Irfan S, Jamil MA, Abid MB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42252797"},{"title01":"Cesni-cel (ARI0002h) in ultra-high-risk multiple myeloma with plasma cell leukaemia or central nervous system involvement.","title02":"Cesni-cel (ARI0002h) in ultra-high-risk multiple myeloma with plasma cell leukaemia or central nervous system involvement.","journal":"Br J Haematol","issue":"2026 June 4. doi: 10.1111\/bjh.70586. Online ahead of print","author":"Jimenez-Mira C, Tovar N, Martinez-Cibrian N, Gonzalez-Calle V, Albiol N, Lopez-Munoz N, Oliver-Caldes A, Gonzalez A, Mateos JM, Espanol-Rego M, Rosinol L, Juan M, Charry P, Sanchez-Pina JM, Navarro S, Munarriz D, Lopez-Corral L, Ortiz-Maldonado V, Varea S, Olesti E, Delgado J, Urbano-Ispizua A, Martinez-Lopez J, Mateos MV, Rodriguez-Lobato LG, Fernandez de Larrea C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42237881"},{"title01":"Crystalline masquerade: Pseudo-Auer rods in multiple myeloma.","title02":"Crystalline masquerade: Pseudo-Auer rods in multiple myeloma.","journal":"Br J Haematol","issue":"2026 June 3. doi: 10.1111\/bjh.70547. Online ahead of print","author":"Peng C, Sun M, Chen H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42231727"},{"title01":"Recognising disease progression in MGUS and smouldering myeloma: Biomarkers, symptom monitoring and imaging.","title02":"Recognising disease progression in MGUS and smouldering myeloma: Biomarkers, symptom monitoring and imaging.","journal":"Br J Haematol","issue":"2026 June; 208(6):2079-2086. doi: 10.1111\/bjh.70492","author":"Haslam A, Iqbal G, Drayson M, Pratt G, Yong K, Dunn J, Atkin C, Bunce C, Howe D, Bowcock S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42162568"},{"title01":"Circulating levels of insulin-like growth factor I (IGF-I) and risk of multiple myeloma: An observational and Mendelian randomisation study.","title02":"Circulating levels of insulin-like growth factor I (IGF-I) and risk of multiple myeloma: An observational and Mendelian randomisation study.","journal":"Br J Haematol","issue":"2026 June; 208(6):1942-1953. doi: 10.1111\/bjh.70444","author":"Benavente Y, Hermosa S, Papadimitriou N, Clay-Gilmour A, Brown EE, Hofmann JN, Rothman N, Lan Q, Berndt SI, Albanes D, Purdue M, Machiela MJ, Chanock SJ, Bhatti P, Cozen W, Norman A, Slager SL, Cerhan JR, Rajkumar V, Kumar SK, Vachon CM, Novak AJ, Habermann TM, Link BK, Salles G, Ghesquieres H, Bracci PM, Holly E, Griffin RG, Hildebrandt MAT, Vermeulen RCH, Kolijn PM, Hjalgrim H, Smedby KE, Jayasekara H, Cheah S, Monnereau A, Chen Y, Arslan A, Zhang Y, Camp NJ, Sborov DW, Osman AEG, Ziv E, De Vivo I, Joseph V, Teras LR, Patel AV, Kane E, Vajdic CM, Guilloteau A, Cocco P, Alemany L, Sainz J, McKay J, Birmann BM, Casabonne D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41873017"},{"title01":"MRD-negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in >\/=VGPR\/MRD-positive after first-line therapy: Final analysis of the open-label, single-arm multicentric phase 2 trial DART4MM.","title02":"MRD-negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in >\/=VGPR\/MRD-positive after first-line therapy: Final analysis of the open-label, single-arm multicentric phase 2 trial DART4MM.","journal":"Br J Haematol","issue":"2026 June; 208(6):2069-2078. doi: 10.1111\/bjh.70448","author":"Gozzetti A, Pacelli P, Caroni F, Raspadori D, Bestoso E, Antonioli E, Buda G, Ciofini S, Santoni A, Puccetti L, Bacchiarri F, Pengue L, Tocci D, Attucci I, Del Giudice ML, Ruggieri M, Lombardo A, Liberati AM, Candi V, Sammartano V, Cartocci A, Sicuranza A, Galimberti S, Vannucchi AM, Bocchia M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41888038"},{"title01":"HAT-PCR is non-inferior to NGS when quantifying measurable residual disease for myeloma.","title02":"HAT-PCR is non-inferior to NGS when quantifying measurable residual disease for myeloma.","journal":"Br J Haematol","issue":"2026 June; 208(6):2256-2259. doi: 10.1111\/bjh.70478","author":"Hughes E, Blombery P, Kannan S, Khong T, Spencer A, Morley A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41947647"},{"title01":"Elranatamab therapy in relapsed refractory multiple myeloma patients with chronic kidney disease: A case series.","title02":"Elranatamab therapy in relapsed refractory multiple myeloma patients with chronic kidney disease: A case series.","journal":"Br J Haematol","issue":"2026 June; 208(6):2265-2268. doi: 10.1111\/bjh.70510","author":"Marron G, Warrier N, Chan K, Augustson B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42051159"},{"title01":"Biochemical bone biomarkers in plasma cell dyscrasias.","title02":"Biochemical bone biomarkers in plasma cell dyscrasias.","journal":"Br J Haematol","issue":"2026 June; 208(6):1909-1923. doi: 10.1111\/bjh.70467","author":"Nador G, Vijjhalwar R, Javaid MK, Edwards CM, Ramasamy K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41948808"},{"title01":"A critical view of the BJH publication on the lack of benefit of second-line daratumumab in patients with functional high-risk multiple myeloma.","title02":"A critical view of the BJH publication on the lack of benefit of second-line daratumumab in patients with functional high-risk multiple myeloma.","journal":"Br J Haematol","issue":"2026 June; 208(6):2330-2331. doi: 10.1111\/bjh.70516","author":"Schnog JB, Erjavec Z, Van Dijck R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42032249"},{"title01":"Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data.","title02":"Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data.","journal":"Br J Haematol","issue":"2026 June; 208(6):2134-2142. doi: 10.1111\/bjh.70490","author":"Goel U, Dragomirescu C, Zanwar S, Cassano RC, Cicero KI, Cowan AJ, Banerjee R, Anwer F, Khouri J, Dima D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42023513"},{"title01":"Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial.","title02":"Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial.","journal":"Br J Haematol","issue":"2026 June; 208(6):2260-2264. doi: 10.1111\/bjh.70479","author":"Delimpasi S, Spicka I, Butler JP, Stevens DA, Mesa MG, Bygrave C, Merlo GM, la Porte C, Dimopoulos MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41978554"},{"title01":"Early diagnosis of AL amyloidosis in haematology, cardiology, neurology, renal and general clinics: A British Society for Haematology Guideline.","title02":"Early diagnosis of AL amyloidosis in haematology, cardiology, neurology, renal and general clinics: A British Society for Haematology Guideline.","journal":"Br J Haematol","issue":"2026 June; 208(6):1931-1938. doi: 10.1111\/bjh.70472","author":"Garg M, Choudhuri S, Parrish C, Hawkins S, Lachmann H, Clayton L, Richardson J, Chan YLT, Wechalekar A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42099096"},{"title01":"Telomere length and clonal hematopoiesis interact to influence outcomes in hematopoietic stem cell transplantation.","title02":"Telomere length and clonal hematopoiesis interact to influence outcomes in hematopoietic stem cell transplantation.","journal":"Blood advances","issue":"2026 June 9; 10(11):3909-3919. doi: 10.1182\/bloodadvances.2025018279","author":"Tobin J, Stelmach P, Richter S, Xu D, Sauer S, Raab MS, Gu M, Dunn WG, Fabre MA, Muller-Tidow C, Vassiliou GS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41860374"},{"title01":"Plant-based whole-food diets are feasible during auto-HCT and are associated with dose-dependent microbiome modulation.","title02":"Plant-based whole-food diets are feasible during auto-HCT and are associated with dose-dependent microbiome modulation.","journal":"Blood advances","issue":"2026 June 9. doi: 10.1182\/bloodadvances.2026020270. Online ahead of print","author":"Ueland K, Elahi T, Rasmussen M, Wolfe AE, Purcell H, Chakka SR, Mirimo-Martinez M, Persinger H, Johnson K, Boynton AM, McMillen K, Byelykh M, Biernacki MA, Yeh AC, Ali N, Manjappa S, Wuliji N, Fredricks D, Bleakley M, Holmberg LA, Peled JU, Schenk J, Raftery D, Ma J, Hill GR, Neuhouser ML, Lee SJ, Markey KA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42263665"},{"title01":"IL-6-driven POU2AF1 and ELL2 are key regulators of multiple myeloma-distinct transcriptional and splicing programs.","title02":"IL-6-driven POU2AF1 and ELL2 are key regulators of multiple myeloma-distinct transcriptional and splicing programs.","journal":"Blood advances","issue":"2026 June 9; 10(11):4049-4066. doi: 10.1182\/bloodadvances.2025018710","author":"Ohguchi Y, Ajiro M, Ogiya D, Masuda T, Kawano Y, Usuki S, Koga T, Hino S, Harada T, Takahashi S, Okada S, Yasunaga JI, Sashida G, Ohtsuki S, Nakao M, Minami T, Yoshimi A, Ohguchi H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41925579"},{"title01":"Counterpoint: Bispecific antibodies are becoming the preferred standard of care in relapsed\/refractory multiple myeloma.","title02":"Counterpoint: Bispecific antibodies are becoming the preferred standard of care in relapsed\/refractory multiple myeloma.","journal":"Blood advances","issue":"2026 June 12. doi: 10.1182\/bloodadvances.2026020073. Online ahead of print","author":"Janakiram M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42284703"},{"title01":"Bispecific antibody therapy in multiple myeloma and risk of progressive multifocal leukoencephalopathy.","title02":"Bispecific antibody therapy in multiple myeloma and risk of progressive multifocal leukoencephalopathy.","journal":"Blood advances","issue":"2026 June 12. doi: 10.1182\/bloodadvances.2026020556. Online ahead of print","author":"Le Henaff JR, Le Guennec L, Schiro P, Bihan K, Gasnault J, Stankoff B, Taoufik Y, Treiner E, Bensoussan D, Lhomme S, L'Honneur AS, Bonneville F, Shor N, Pourcher V, Pignolet B, Lievin B, Javaux C, Le Guen J, Brissot E, Limouzin PA, Richaud C, Lioure B, Wirth T, Petitgas P, Herbel S, Coustilleres F, Rusu EC, Maerten L, Perrot A, Sommet A, Roos-Weil D, Lafaurie M, Weiss N, Martin-Blondel G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42284702"},{"title01":"FDG-PET medullary total tumor volume highlights high-risk patients with newly diagnosed multiple myeloma in CASSIOPEIA trial.","title02":"FDG-PET medullary total tumor volume highlights high-risk patients with newly diagnosed multiple myeloma in CASSIOPEIA trial.","journal":"Blood advances","issue":"2026 June 9; 10(11):3787-3798. doi: 10.1182\/bloodadvances.2025019465","author":"Jamet B, Ahrari S, Zweegman S, Perrot A, Hulin C, Caillot D, Facon T, Leleu X, Belhadj K, Itti E, Karlin L, Bailly C, Levin MD, Minnema MC, Bodet-Milin C, de Keizer B, Corre J, Sonneveld P, Mateus D, Moreau P, Touzeau C, Kraeber-Bodere F, Carlier T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41894685"},{"title01":"Idecabtagene vicleucel manufacturing and clinical value of out-of-specification products in relapsed and refractory MM.","title02":"Idecabtagene vicleucel manufacturing and clinical value of out-of-specification products in relapsed and refractory MM.","journal":"Blood advances","issue":"2026 June 9; 10(11):3769-3776. doi: 10.1182\/bloodadvances.2025017186","author":"Sidana S, Lin Y, Cowan AJ, Rodriguez-Otero P, Scheid C, Mueller PJ, Broussard C, Krengel P, Li Y, Piault R, Corrao A, Ho C, Patel K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41894689"},{"title01":"Engineering a TACIxCD3 Bispecific Antibody to Redirect T Cells Against Multiple Myeloma.","title02":"Engineering a TACIxCD3 Bispecific Antibody to Redirect T Cells Against Multiple Myeloma.","journal":"Blood advances","issue":"2026 June 3. doi: 10.1182\/bloodadvances.2025018210. Online ahead of print","author":"Zhang M, Leong WF, Huo J, Ngoh EZX, Loh H, Chen Q, Toh SHM, de Mel S, Ooi MG, Soekojo CY, Chng WJ, Yang Y, Lam KP, Xu S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42241036"},{"title01":"Daratumumab in Transplant-Ineligible or -Deferred Newly Diagnosed Multiple Myeloma: Minimal Residual Disease in CEPHEUS.","title02":"Daratumumab in Transplant-Ineligible or -Deferred Newly Diagnosed Multiple Myeloma: Minimal Residual Disease in CEPHEUS.","journal":"Blood advances","issue":"2026 June 3. doi: 10.1182\/bloodadvances.2026019937. Online ahead of print","author":"Zweegman S, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M, Pour L, Marti J, Basu S, Cohen YC, Matsumoto M, Suzuki K, Hulin C, Legiec WM, Beksac M, Maiolino A, Takamatsu H, Perrot A, Turgut M, Liu W, Wang J, Van Brummelen E, Krevvata M, Lopez-Masi L, Carey J, Borgsten F, Rowe M, Carson R, Usmani SZ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42234958"},{"title01":"Study of NSD2 using a dTAG system reveals its molecular mechanism and oncogenic implications in t(4;14) multiple myeloma.","title02":"Study of NSD2 using a dTAG system reveals its molecular mechanism and oncogenic implications in t(4;14) multiple myeloma.","journal":"Blood","issue":"2026 June 11; 147(24):2916-2929. doi: 10.1182\/blood.2025031663","author":"Wang Y, Liu S, Ghamlouch H, Gagler DC, Blaney P, Nabet B, Davies FE, Morgan GJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758961"},{"title01":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study.","title02":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study.","journal":"Blood","issue":"2026 June 4; 147(23):2760-2769. doi: 10.1182\/blood.2025030120","author":"Orlowski RZ, Dimopoulos MA, Leleu X, Facon T, Ishida T, Hajek R, Spicka I, Romejko-Jarosinska J, Vorobyev V, Besemer B, Besisik SK, Robak P, Jelinek T, Goldschmidt H, Martin T, Mohty M, Mace S, Kodas E, Tekle C, Shafer AT, Moreau P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758929"},{"title01":"Measurable residual disease in myeloma: a MyRiaD of findings.","title02":"Measurable residual disease in myeloma: a MyRiaD of findings.","journal":"Blood","issue":"2026 June 4; 147(23):2702-2703. doi: 10.1182\/blood.2025032857","author":"Puig N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42241041"},{"title01":"How does NSD2 fuel multiple myeloma?","title02":"How does NSD2 fuel multiple myeloma?","journal":"Blood","issue":"2026 June 11; 147(24):2855-2856. doi: 10.1182\/blood.2026033562","author":"Samur MK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42275120"},{"title01":"A novel triple-knockout allogeneic BCMA CAR T cell therapy (CT0590) in multiple myeloma: preclinical and phase I study.","title02":"A novel triple-knockout allogeneic BCMA CAR T cell therapy (CT0590) in multiple myeloma: preclinical and phase I study.","journal":"Blood","issue":"2026 June 11. doi: 10.1182\/blood.2025032112. Online ahead of print","author":"Jin S, Liao Z, Yan S, Yan L, Yao W, Shang J, Tang F, Zhu Z, Wu D, Rajakumaraswamy N, Luo Y, Yuan D, Jiang H, Li Z, Fu C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42275247"},{"title01":"Product-Intrinsic NF-kappaB-Driven Transcriptional Programs Connote Durability of CAR-T Response in Multiple Myeloma.","title02":"Product-Intrinsic NF-kappaB-Driven Transcriptional Programs Connote Durability of CAR-T Response in Multiple Myeloma.","journal":"Blood","issue":"2026 June 11. doi: 10.1182\/blood.2025031843. Online ahead of print","author":"Noble JD, Peixoto BC, Menges MA, Abraham-Miranda J, Savid-Frontera C, Sawyer W, Sorathia VD, Cuadrado Delgado LA, Corallo SA, Llanos JC, Merritt EC, De Avila G, Castaneda-Puglianini OA, Liu HD, Alsina M, Nishihori T, Shain KH, Siqueira Silva AS, Baz RC, Blue BJ, Grajales-Cruz AF, Hansen DK, Cleveland JL, Perna F, Lynch CC, Binning JM, Atkins RM, Song X, Locke FL, Freeman CL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42275255"},{"title01":"PKMYT1 is a Targetable Vulnerability in del(17p) High-Risk Multiple Myeloma.","title02":"PKMYT1 is a Targetable Vulnerability in del(17p) High-Risk Multiple Myeloma.","journal":"Blood","issue":"2026 June 3. doi: 10.1182\/blood.2026033819. Online ahead of print","author":"Schavgoulidze A, Cui J, Encinas J, Favasuli VK, Talluri S, Maheo S, Cerutti C, Shammas MA, Primo D, Vicente C, Larrayoz M, Martinez-Climent JA, Anderson KC, Aktas Samur A, Samur MK, Avet-Loiseau H, Corre J, Munshi NC, Fulciniti M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42237635"},{"title01":"Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed\/refractory multiple myeloma.","title02":"Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed\/refractory multiple myeloma.","journal":"Blood","issue":"2026 June 2. doi: 10.1182\/blood.2025030750. Online ahead of print","author":"Bal S, Htut M, Nadeem O, Anderson LD Jr, Gregory T, Kocoglu M, Rossi AC, Martin TG, Egan DN, Costa LJ, Hu H, Chen J, Li S, Kelly LM, Sarkis N, Ziyad S, Jordahl KM, Kao WM, Kaeding AJ, Burgess MR, Berdeja JG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42233419"},{"title01":"Improvements over time in survival after post-transplant relapse of adult T-cell leukaemia\/lymphoma and trends of salvage therapy in a real-world experience.","title02":"Improvements over time in survival after post-transplant relapse of adult T-cell leukaemia\/lymphoma and trends of salvage therapy in a real-world experience.","journal":"Br J Haematol","issue":"2026 June 15. doi: 10.1111\/bjh.70631. Online ahead of print","author":"Itonaga H, Fukushima T, Kato K, Muranushi H, Tokunaga M, Miyazono T, Ito A, Eto T, Suehiro Y, Kato T, Fujioka M, Kawakita T, Uchida N, Mori Y, Yoshimitsu M, Nakamae H, Morichika K, Ishitsuka K, Kanda J, Fukuda T, Atsuta Y, Fuji S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42298882"},{"title01":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: A 25-year nationwide study.","title02":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: A 25-year nationwide study.","journal":"Br J Haematol","issue":"2026 June; 208(6):2143-2155. doi: 10.1111\/bjh.70463","author":"Itonaga H, Miyazaki Y, Tachi N, Kurosawa S, Marumo A, Konuma T, Ebina T, Doki N, Uchida N, Fukuda T, Nishida T, Katayama Y, Asada N, Sakurai M, Maeda T, Eto T, Tanaka M, Nakamae H, Onizuka M, Kawamura K, Kanda Y, Atsuta Y, Tachibana T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41937388"},{"title01":"Prognostic impact of variant allele frequency in intensively treated patients with NPM1-mutated AML: a PETHEMA study.","title02":"Prognostic impact of variant allele frequency in intensively treated patients with NPM1-mutated AML: a PETHEMA study.","journal":"Blood","issue":"2026 June 8. doi: 10.1182\/blood.2026033576. Online ahead of print","author":"Gil JV, Sargas C, Ayala R, Gutierrez NC, Perez-Simon JA, Gomez-Casares MT, Larrayoz MJ, Prados de la Torre E, Cano-Ferri I, Navarro I, Gil C, Bernal Del Castillo T, Rodriguez-Arboli E, Perez Santaolalla E, Colmenares R, Tormo M, Bergua Burgues JM, Amigo ML, Rodriguez-Medina C, Serrano J, Oliva A, Alonso-Dominguez JM, Noriega V, Algarra JL, Olave MT, Garcia Perez MJ, Couto MDC, Almela-Gallego A, Garcia-Fortes M, Madrigal-Toscano DD, Hermosin L, Colorado M, Garcia-Boyero R, Ibanez-Alis F, Sole-Rodriguez M, Martinez Chamorro C, Mateos MC, Garcia Garay MDC, Solana-Altabella A, Martin-Herreros B, Martinez-Lopez J, Chillon MC, Soria E, Bilbao-Sieyro C, Calasanz MJJ, Sanchez-Garcia J, Barragan E, Montesinos P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42258402"},{"title01":"T-ALL: the origin story.","title02":"T-ALL: the origin story.","journal":"Blood","issue":"2026 June 4; 147(23):2706-2707. doi: 10.1182\/blood.2025032944","author":"Blombery P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42241045"},{"title01":"United forces bring down menin resistance in AML.","title02":"United forces bring down menin resistance in AML.","journal":"Blood","issue":"2026 June 4; 147(23):2707-2709. doi: 10.1182\/blood.2026033473","author":"Braun T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42241040"},{"title01":"ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia.","title02":"ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia.","journal":"Blood","issue":"2026 June 3. doi: 10.1182\/blood.2026033569. Online ahead of print","author":"Hourigan CS, Beugelink L, Othman J, Gui G, Ivey A, Dillon RJ, Thiede C, Levis MJ, Dillon LW, Wei AH, Tiong IS, Loo S, Dohner K, Arnhardt I, Kowalik A, Potter N, Kim DDH, Preudhomme C, Duployez N, Heuser M, Valk PJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42237660"},{"title01":"Homeodomain-driven oncogenic diversion to a gammadeltaTCR phenotype in T-cell acute lymphoblastic leukemia.","title02":"Homeodomain-driven oncogenic diversion to a gammadeltaTCR phenotype in T-cell acute lymphoblastic leukemia.","journal":"Blood","issue":"2026 June 4; 147(23):2793-2808. doi: 10.1182\/blood.2025030626","author":"Pinton A, Courtois L, Delafoy M, Bonnet M, Cieslak A, Lhermitte L, Simonin M, Dourthe ME, Touzart A, Andrieu GP, Dombret H, Baruchel A, Spicuglia S, Payet-Bornet D, Boissel N, Macintyre E, Asnafi V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592282"},{"title01":"Therapeutic Targeting of IL-17A-Driven PTGS2\/NLRP3 Inflammasome Activation in Juvenile Myelomonocytic Leukemia.","title02":"Therapeutic Targeting of IL-17A-Driven PTGS2\/NLRP3 Inflammasome Activation in Juvenile Myelomonocytic Leukemia.","journal":"Blood","issue":"2026 June 2. doi: 10.1182\/blood.2025032588. Online ahead of print","author":"Pasupuleti SK, Ramdas B, Padam KSR, Kanumuri R, Palam LR, Kumar R, Ho TC, Lee AG, Clapp W, Qu CK, Stieglitz E, Yang K, Kapur R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42233403"},{"title01":"Ziftomenib with venetoclax and azacitidine in relapsed\/refractory NPM1-mutated acute myeloid leukemia.","title02":"Ziftomenib with venetoclax and azacitidine in relapsed\/refractory NPM1-mutated acute myeloid leukemia.","journal":"Blood","issue":"2026 June 2. doi: 10.1182\/blood.2026034043. Online ahead of print","author":"Wang ES, Erba HP, Zeidan AM, Roboz GJ, Altman JK, Advani AS, Lin TL, Strickland SA, Juckett MB, Pratz KW, Mangan JK, McMahon CM, Alsfeld LC, Balasubramanian SK, Guru Murthy GS, Rotta M, Palmisiano N, McCloskey J, Saliba AN, Khawandanah M, Madanat YF, Naqvi K, Qasrawi AH, Schiller GJ, Badar T, Gojo I, Yaghmour G, Osman D, Zhang H, Tian Y, Soifer HS, Riches M, Corum D, Leoni M, Fathi AT, Issa GC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42227701"},{"title01":"Overcoming menin inhibitor resistance in AML cells with combinations including BET proteins and a dual BRG1\/BRM inhibitor.","title02":"Overcoming menin inhibitor resistance in AML cells with combinations including BET proteins and a dual BRG1\/BRM inhibitor.","journal":"Blood","issue":"2026 June 4; 147(23):2809-2820. doi: 10.1182\/blood.2025031486","author":"Fiskus W, Mill CP, Issa GC, Piel J, Collins M, Hentemann M, Cuglievan B, Hou H, Jain A, Malovannaya A, Kadia TM, Daver N, Sasaki K, Takahashi K, Hammond D, Senapati J, Loghavi S, Flores LB, Su X, DiNardo CD, Bhalla KN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41734382"},{"title01":"Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study.","title02":"Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study.","journal":"Lancet Haematol","issue":"2026 June 12. doi: 10.1016\/S2352-3026(26)00128-6. Online ahead of print","author":"Efficace F, Zinzani PL, Bonifazi F, Cutini I, Botto B, Chiappella A, Tisi MC, Bramanti S, Puglia S, Tartaglia F, Donzelli L, Farina M, Martino M, Gambella M, Ragaini S, Orciuolo E, Martelli M, Corradini P, Fazi P, Vignetti M, Rocco AD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42285114"},{"title01":"Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial.","title02":"Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial.","journal":"Lancet Haematol","issue":"2026 June 12. doi: 10.1016\/S2352-3026(26)00112-2. Online ahead of print","author":"Vitolo U, Burgues JMB, Duell J, Kwiatek M, Belada D, Jurczak W, Maerevoet M, Sibon D, Greil R, Kumode T, Lopez-Jimenez J, Meert C, Cia JS, Thieblemont C, Alcaide SO, Kim WS, Cordoba R, Wielgos-Bonvallet M, Jiang T, Wang Y, McGoldrick S, Guo E, Morschhauser F, Woei-A-Jin FJSH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42285113"},{"title01":"Diagnosis of primary CNS lymphoma through molecular and immune biomarkers in cerebrospinal fluid (PRICELUS): a multicentre, prospective, cohort study.","title02":"Diagnosis of primary CNS lymphoma through molecular and immune biomarkers in cerebrospinal fluid (PRICELUS): a multicentre, prospective, cohort study.","journal":"Lancet Haematol","issue":"2026 June; 13(6):e376-e385. doi: 10.1016\/S2352-3026(26)00098-0","author":"van Rooij JLM, Wessels PH, Niers JM, Bromberg JEC, Gijtenbeek JMM, van Haastert R, Ruven HJT, Meek B, Verbeek MM, Solleveld-Westerink N, de Leng WWJ, Muhlebner A, Langerak AW, Berendsen S, Knol EF, van Alkemade H, Seute T, Minnema MC, Nierkens S, Snijders TJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42242260"},{"title01":"Erratum: Lenalidomide Plus Rituximab for Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.","title02":"Erratum: Lenalidomide Plus Rituximab for Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.","journal":"J Clin Oncol","issue":"2026 June 10; 44(17):1655. doi: 10.1200\/JCO-26-01085","author":"Leonard JP, Trneny M, Zhang H, Nowakowski GS, Izutsu K, Fowler N, Thieblemont C, Zinzani PL, Gkasiamis A, Ahn JR, Gribben JG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42127332"},{"title01":"End of Methotrexate for CNS Prophylaxis in Diffuse Large B-Cell Lymphoma.","title02":"End of Methotrexate for CNS Prophylaxis in Diffuse Large B-Cell Lymphoma.","journal":"J Clin Oncol","issue":"2026 June 11; JCO2601188. doi: 10.1200\/JCO-26-01188. Online ahead of print","author":"Friedberg JW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42274643"},{"title01":"Lenalidomide Plus Rituximab for Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.","title02":"Lenalidomide Plus Rituximab for Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.","journal":"J Clin Oncol","issue":"2026 June; 44(16):1483-1489. doi: 10.1200\/JCO-25-01770","author":"Leonard JP, Trneny M, Zhang H, Nowakowski GS, Izutsu K, Fowler N, Thieblemont C, Zinzani PL, Gkasiamis A, Ahn JR, Gribben JG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41990300"},{"title01":"High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.","title02":"High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.","journal":"J Clin Oncol","issue":"2026 June 11; JCO2600947. doi: 10.1200\/JCO-26-00947. Online ahead of print","author":"Wilson MR, Lewis KL, Kirkwood AA, Cwynarski K, Cheah CY, El-Galaly TC, Villa D, Savage KJ, Ghione P, Bobillo S, Smedby KE, Harrysson S, Trneny M, Klanova M, Puckrin R, Fox CP, Bishton M, Thanarajasingam G, Wong Doo N, Hapgood G, Soussain C, Choquet S, Dickinson M, Talaulikar D, de Mel S, Preston G, Ahearne M, Hawkes EA, Schorb E, Clavert A, Ku M, Guidetti A, Narkhede M, Calimeri T, Durot E, Smith J, Renaud L, McKay P, Eyre TA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42274647"},{"title01":"Cytotoxic T-cell lymphoma with muscle involvement and germline variants in inborn error of immunity-related genes: clinical and genetic insights from a case series.","title02":"Cytotoxic T-cell lymphoma with muscle involvement and germline variants in inborn error of immunity-related genes: clinical and genetic insights from a case series.","journal":"Haematologica","issue":"2026 June 4. doi: 10.3324\/haematol.2026.300669. Online ahead of print","author":"Wei C, Zhao D, Jia C, Shen K, Zhang W, Zhou D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42237767"},{"title01":"Immune checkpoint therapy in pediatric and adolescent lymphomas.","title02":"Immune checkpoint therapy in pediatric and adolescent lymphomas.","journal":"Haematologica","issue":"2026 June 4. doi: 10.3324\/haematol.2026.300531. Online ahead of print","author":"Hoogstra DJ, Xavier AC, Harker-Murray P, Alexander S, Giulino-Roth L, Hernandez TA, Cairo MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42237783"},{"title01":"Locally manufactured versus commercial CAR T therapy for large B-cell lymphoma: a multicenter propensity scorematched analysis.","title02":"Locally manufactured versus commercial CAR T therapy for large B-cell lymphoma: a multicenter propensity scorematched analysis.","journal":"Haematologica","issue":"2026 June 1; 111(6):2023-2031. doi: 10.3324\/haematol.2025.288419","author":"Marcus R, Avigdor A, Greenbaum U, Brown S, Fried S, Golan-Accav N, Shem-Tov N, Yerushalmi R, Danylesko I, Jacoby E, Nagler A, Shimoni A, Itzhaki O, Esensten J, Valid OB, Ballweg A, Deschenes-Simard X, Luttwak E, Shah G, Scordo M, Dahi P, Perales MA, Zuckerman T, Devlin SM, Yehudai-Ofir D, Khatib H, Shibly N, Shouval R, Beyar-Katz O","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437832"},{"title01":"Improving the predictive value of end-of-treatment PET\/ CT in diffuse large B-cell lymphoma.","title02":"Improving the predictive value of end-of-treatment PET\/ CT in diffuse large B-cell lymphoma.","journal":"Haematologica","issue":"2026 June 1; 111(6):2087-2096. doi: 10.3324\/haematol.2025.288821","author":"Bes AL, Zwezerijnen GJC, Heymans MW, Duhrsen U, Eertink JJ, Wiegers SE, Lugtenburg PJ, Huttmann A, Kurch L, Hanoun C, Mikhaeel GN, Ceriani L, Zucca E, Czibor S, Gyorke T, Chamuleau MED, Fanti S, Lee ST, Hoekstra OS, Zijlstra JM, Barrington SF, Boellaard R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41504226"},{"title01":"Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns.","title02":"Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns.","journal":"Haematologica","issue":"2026 June 11. doi: 10.3324\/haematol.2026.300853. Online ahead of print","author":"Stuver R, Moore ZR, Barta SK, Bhansali RS, Choa R, Epstein-Peterson ZD, Ganesan N, Ghione P, Jain S, Jacobsen E, Johnson WT, Lukowski JD, Lunning M, McCabe S, Merrill M, Moskowitz AJ, Singh S, Taranto E, Yahalom J, Savage KJ, Imber BS, Horwitz SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42273944"},{"title01":"Clonal expansion of CAR-T cells harboring lentivector integration in the PLAAT4 gene following anti-CD19 CAR T-cell therapy in a context of cutaneous T-cell lymphoma.","title02":"Clonal expansion of CAR-T cells harboring lentivector integration in the PLAAT4 gene following anti-CD19 CAR T-cell therapy in a context of cutaneous T-cell lymphoma.","journal":"Haematologica","issue":"2026 June 11. doi: 10.3324\/haematol.2026.300851. Online ahead of print","author":"Guiraud V, Bravetti C, Guihot A, Denis JA, Legrand R, Charlotte F, Le Garff-Tavernier M, Parizot C, Fouquet B, Houot R, Dulery R, Marcelin AG, Calvez V, Barete S, Todesco E, Choquet S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42273948"},{"title01":"T-cell engagement in practice: bispecifics in large B-cell lymphoma.","title02":"T-cell engagement in practice: bispecifics in large B-cell lymphoma.","journal":"Haematologica","issue":"2026 June 11. doi: 10.3324\/haematol.2026.301265. Online ahead of print","author":"Stanchina MD, Alderuccio JP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42273965"},{"title01":"Machine learning-driven investigation on liquid-liquid phase separation-related prognostic signature in diffuse large B-cell lymphoma.","title02":"Machine learning-driven investigation on liquid-liquid phase separation-related prognostic signature in diffuse large B-cell lymphoma.","journal":"Br J Haematol","issue":"2026 June 5. doi: 10.1111\/bjh.70601. Online ahead of print","author":"Zhou ZZ, Lu JC, Wang Z, Chen RH, Li HL, Chen WT, Deng YN, Zhang HJ, Wang Y, Zhang XY, Huang WJ, Tian XP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42246608"},{"title01":"Where next for BTKi-BCL2i combinations in mantle cell lymphoma?","title02":"Where next for BTKi-BCL2i combinations in mantle cell lymphoma?","journal":"Br J Haematol","issue":"2026 June 14. doi: 10.1111\/bjh.70621. Online ahead of print","author":"Eyre TA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42289297"},{"title01":"Response alone does not define optimal bridging before brexucabtagene autoleucel in mantle cell lymphoma.","title02":"Response alone does not define optimal bridging before brexucabtagene autoleucel in mantle cell lymphoma.","journal":"Br J Haematol","issue":"2026 June 14. doi: 10.1111\/bjh.70615. Online ahead of print","author":"Zhang M, Chen Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42289300"},{"title01":"Minimal residual disease in diffuse large B-cell lymphoma after first-line therapy: Defining the continuum from metabolic remission to molecular clearance.","title02":"Minimal residual disease in diffuse large B-cell lymphoma after first-line therapy: Defining the continuum from metabolic remission to molecular clearance.","journal":"Br J Haematol","issue":"2026 June 14. doi: 10.1111\/bjh.70619. Online ahead of print","author":"Caserta S, Martino EA, Vigna E, Bruzzese A, Skafi M, Amodio N, Lucia E, Olivito V, Labanca C, Mendicino F, Alvaro ME, Morabito F, Gentile M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42289802"},{"title01":"Cow hooves and clover: Unusual morphology of peripheral T-cell lymphoma.","title02":"Cow hooves and clover: Unusual morphology of peripheral T-cell lymphoma.","journal":"Br J Haematol","issue":"2026 June 2. doi: 10.1111\/bjh.70566. Online ahead of print","author":"Lu Y, Preston G, Laing G, Scott P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42231097"},{"title01":"Concurrent antiviral-immunochemotherapy strategy safely overcomes high hepatitis B viral load barrier in diffuse large B-cell lymphoma: A multicentre cohort study.","title02":"Concurrent antiviral-immunochemotherapy strategy safely overcomes high hepatitis B viral load barrier in diffuse large B-cell lymphoma: A multicentre cohort study.","journal":"Br J Haematol","issue":"2026 June 2. doi: 10.1111\/bjh.70584. Online ahead of print","author":"Zhao Y, Guo J, Wang X, Cao L, Xia Y, Shen H, Li R, Wu P, Mi H, Zhang J, Li J, Liu H, Qu X, Fan L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42226728"},{"title01":"Evolution of the drug sensitivity landscape of chronic lymphocytic leukaemia.","title02":"Evolution of the drug sensitivity landscape of chronic lymphocytic leukaemia.","journal":"Br J Haematol","issue":"2026 June 10. doi: 10.1111\/bjh.70603. Online ahead of print","author":"Hermansen JU, Yin Y, Tjonnfjord GE, Mato AR, Skanland SS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42267774"},{"title01":"Improvements over time in survival after post-transplant relapse of adult T-cell leukaemia\/lymphoma and trends of salvage therapy in a real-world experience.","title02":"Improvements over time in survival after post-transplant relapse of adult T-cell leukaemia\/lymphoma and trends of salvage therapy in a real-world experience.","journal":"Br J Haematol","issue":"2026 June 15. doi: 10.1111\/bjh.70631. Online ahead of print","author":"Itonaga H, Fukushima T, Kato K, Muranushi H, Tokunaga M, Miyazono T, Ito A, Eto T, Suehiro Y, Kato T, Fujioka M, Kawakita T, Uchida N, Mori Y, Yoshimitsu M, Nakamae H, Morichika K, Ishitsuka K, Kanda J, Fukuda T, Atsuta Y, Fuji S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42298882"},{"title01":"Development and validation of a novel prognostic index for mantle cell lymphoma integrating TP53 mutations (MIPI53).","title02":"Development and validation of a novel prognostic index for mantle cell lymphoma integrating TP53 mutations (MIPI53).","journal":"Br J Haematol","issue":"2026 June; 208(6):2004-2015. doi: 10.1111\/bjh.70535","author":"Bastos-Boente M, Medina-Herrera A, Navarro-Bailon A, Ferrero S, Sarasquete ME, Jimenez C, Garcia-Alvarez M, Anton A, Balanzategui A, Moia R, Re A, Boccomini C, Balzarotti M, Zilioli VR, da Silva MG, Diaz-Galvez FJ, Gonzalez-Mena B, Penarrubia MJ, Fernandez-Ferrero S, de Ramon C, Blanco O, Cabero A, Ladetto M, Garcia-Sanz R, Gutierrez NC, Martin Garcia-Sancho A, Alcoceba M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42134850"},{"title01":"Fibrin-associated large B-cell lymphoma occurring in an ancient retroperitoneal schwannoma.","title02":"Fibrin-associated large B-cell lymphoma occurring in an ancient retroperitoneal schwannoma.","journal":"Br J Haematol","issue":"2026 June; 208(6):1901-1902. doi: 10.1111\/bjh.70408","author":"Hwang YY, Au-Yeung R, Kwong YL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41787739"},{"title01":"Renal dysfunction in symptomatic Waldenstrom macroglobulinaemia: A nationwide Italian multicentre study.","title02":"Renal dysfunction in symptomatic Waldenstrom macroglobulinaemia: A nationwide Italian multicentre study.","journal":"Br J Haematol","issue":"2026 June; 208(6):2059-2068. doi: 10.1111\/bjh.70424","author":"Danesin N, Autore F, Frustaci AM, Favrin G, Cencini E, Noto A, Dogliotti I, Olivieri J, Riva M, Ferrarini I, Barbui AM, Steffanoni S, Marino D, Puccini B, Stefani PM, Rizzi R, Merli M, Ferrari A, Luminari S, Visco C, Trentin L, Visentin A, Conconi A, Ferrero S, Varettoni M, Tedeschi A, Laurenti L, Piazza F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41796393"},{"title01":"Fibrin-associated large B-cell lymphoma presenting in a renal transplant patient.","title02":"Fibrin-associated large B-cell lymphoma presenting in a renal transplant patient.","journal":"Br J Haematol","issue":"2026 June; 208(6):1903-1904. doi: 10.1111\/bjh.70417","author":"Nasibov T, Cunningham A, Sarpong L, Smyth E, O'Brien O, Quinn J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41806113"},{"title01":"Limited diagnostic utility of bone marrow sampling in PET-defined limited-stage follicular lymphoma.","title02":"Limited diagnostic utility of bone marrow sampling in PET-defined limited-stage follicular lymphoma.","journal":"Br J Haematol","issue":"2026 June; 208(6):2235-2238. doi: 10.1111\/bjh.70440","author":"Solow M, Owen C, Stewart C, Cao JQ, Balogh A, Perry S, Shafey M, Street L, Puckrin R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41841763"},{"title01":"Mediastinal grey zone lymphomas: Results of the expert pathological review analysis of a case series enrolled in the multicentre BIOGZL-2020 study in Italy.","title02":"Mediastinal grey zone lymphomas: Results of the expert pathological review analysis of a case series enrolled in the multicentre BIOGZL-2020 study in Italy.","journal":"Br J Haematol","issue":"2026 June; 208(6):2016-2025. doi: 10.1111\/bjh.70432","author":"Sabattini E, Ascani S, Ciavarella S, Di Napoli A, Facchetti F, Lazzi S, Leoncini L, Lorenzi L, Lucioni M, Motta G, Nassi L, Parisi A, Paulli M, Pileri S, Ponzoni M, Tripodo C, Righi S, Agostinelli C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41844512"},{"title01":"Choosing between Nivo-AVD and BrECADD: Hodgkin lymphoma&#8217;s new era.","title02":"Choosing between Nivo-AVD and BrECADD: Hodgkin lymphoma&#8217;s new era.","journal":"Br J Haematol","issue":"2026 June; 208(6):2239-2242. doi: 10.1111\/bjh.70451","author":"Cliff ERS, McKeague S, Dickinson MJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41871830"},{"title01":"Response to &#8216;Statistical considerations in the comparison of immunotherapy and chemotherapy for POD24 follicular lymphoma&#8217;.","title02":"Response to &#8216;Statistical considerations in the comparison of immunotherapy and chemotherapy for POD24 follicular lymphoma&#8217;.","journal":"Br J Haematol","issue":"2026 June; 208(6):2327-2328. doi: 10.1111\/bjh.70523","author":"Serna A, Navarro V, Abrisqueta P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42112530"},{"title01":"Early prediction of adult lymphoma-associated haemophagocytic lymphohistiocytosis using an interpretable machine learning model.","title02":"Early prediction of adult lymphoma-associated haemophagocytic lymphohistiocytosis using an interpretable machine learning model.","journal":"Br J Haematol","issue":"2026 June; 208(6):2047-2058. doi: 10.1111\/bjh.70447","author":"Luan M, Jia R, Wang D, Zhang F, Han X, Sheng X, Li S, Zhou Q, Li B, Ning C, Ji C, Ye J, Zang S, Lu F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41871894"},{"title01":"Decreased renal function predicts severe cytokine release syndrome after CAR-T-cell therapy for large B-cell lymphoma.","title02":"Decreased renal function predicts severe cytokine release syndrome after CAR-T-cell therapy for large B-cell lymphoma.","journal":"Br J Haematol","issue":"2026 June; 208(6):2124-2133. doi: 10.1111\/bjh.70488","author":"Arai Y, Jo T, Sato T, Sakurai M, Kaji D, Kitawaki T, Shimada K, Shimoyama T, Yoshihara S, Makita S, Fujii N, Yamamoto G, Kataoka K, Sakaida E, Goto H, Nakashima Y, Yoshida A, Umezawa Y, Kim H, Kato M, Atsuta Y, Kato K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41986280"},{"title01":"Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naive follicular lymphoma: Results from the phase II &#8216;FLUORO&#8217; study.","title02":"Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naive follicular lymphoma: Results from the phase II &#8216;FLUORO&#8217; study.","journal":"Br J Haematol","issue":"2026 June; 208(6):2026-2035. doi: 10.1111\/bjh.70468","author":"Martynchyk A, Chong G, Khor R, Lee D, Lee ST, Scott AM, Grobler AC, Campbell BA, Thachil T, Manos K, Douglas G, Romano A, Palmer JB, Burgess M, Keane C, Hawkes EA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41949430"},{"title01":"Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR-T) for relapsed\/refractory large B-cell lymphoma (CRC01-01).","title02":"Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR-T) for relapsed\/refractory large B-cell lymphoma (CRC01-01).","journal":"Blood","issue":"2026 June 12. doi: 10.1182\/blood.2025032636. Online ahead of print","author":"Kim WS, Kim SJ, Yoon DH, Cho H, Yoon SE, Yang DH, Shin HJ, Eom HS, Lee E, Byun JM, Koh Y, Lee H, Jung J, Yoon SS, Song GY, Kim DY, Hong J, Park Y, Han S, Cho SH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42284198"},{"title01":"Patient-derived lymphoma spheroids reveal predictive markers of glofitamab resistance in relapsed\/refractory B-NHL.","title02":"Patient-derived lymphoma spheroids reveal predictive markers of glofitamab resistance in relapsed\/refractory B-NHL.","journal":"Blood","issue":"2026 June 4; 147(23):2770-2785. doi: 10.1182\/blood.2025031309","author":"Marcoux P, Gava F, Tosolini M, Gravelle P, Schniederjohann C, Quertinmont S, Serrat N, Bouquet F, Herter S, Tarte K, Roussel M, Sesques P, Bret C, Rossi C, Aubert P, Morschhauser F, Cartron G, Huber W, Dietrich S, Ysebaert L, Brousset P, Bruch PM, Perez-Galan P, Bezombes C, Laurent C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41746860"},{"title01":"Differential role of CREBBP missense and truncating mutations in germinal center development and lymphomagenesis.","title02":"Differential role of CREBBP missense and truncating mutations in germinal center development and lymphomagenesis.","journal":"Blood","issue":"2026 June 4; 147(23):2713-2727. doi: 10.1182\/blood.2025031181","author":"Yu C, Holloman M, Kim A, Chang Y, Meyer SN, Holmes AB, Cai B, Mo T, Basso K, Dreval K, Morin RD, Bhagat G, Mullighan CG, Dalla-Favera R, Pasqualucci L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41746257"},{"title01":"Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.","title02":"Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.","journal":"N Engl J Med","issue":"2026 June 13. doi: 10.1056\/NEJMoa2604657. Online ahead of print","author":"Mina R, Beksac M, Rodriguez-Otero P, Chen W, Mateos MV, Li J, Moreau P, Cohen YC, Min CK, Jelinek T, Ye JC, Magen H, Rubinstein SM, Fu W, Hungria V, Cengiz Seval G, Farias JS, Radocha J, Maral S, Turgut M, Koh Y, O'Leary D, Schmidt Filho J, Thertulien R, An G, Huang SY, Grosicki S, Tyczynska A, Banerjee R, Pianko MJ, Martinez-Lopez J, Steckiewicz P, Maruyama D, Fukushima K, Oriol A, Lopez Pardo J, Goldschmidt H, Pawlyn C, Perrot A, Zamagni E, Dimopoulos MA, Rasche L, Tolbert J, Terry W, Courtoux C, Liu X, Vasey SY, Connors K, Festa M, Heuck C, Langlois A, O'Rourke L, Zhou J, Qin X, Lu J, Gong J, Vieyra D, Voorhees PM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42294841"},{"title01":"Response kinetics as a dynamic prognostic marker in patients with multiple myeloma.","title02":"Response kinetics as a dynamic prognostic marker in patients with multiple myeloma.","journal":"Leukemia","issue":"2026 June 15. doi: 10.1038\/s41375-026-03007-z. Online ahead of print","author":"Cho HJ, Lee MW, Lee JH, Eom HS, Jung J, Yhim HY, Yoon DH, Cho H, Yoon SS, Byun JM, Do YR, Kim HJ, Lee JH, Lim SN, Kang HJ, Lee HS, Kim Y, Lee HJ, Lee SM, Kim K, Moon JH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42297915"},{"title01":"Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy.","title02":"Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy.","journal":"Leukemia","issue":"2026 June; 40(6):1227-1239. doi: 10.1038\/s41375-026-02920-7","author":"Munawar U, Thurner J, Nerreter S, Nerreter T, Leipold AM, Han S, Verbruggen C, Gerhard-Hartmann E, Vogt C, Grams B, Kurian S, Besant E, Roth S, Weingart J, Eiring P, Truger M, Afrin N, Steinbrunn T, Tamamushi Y, Zhou X, Rein N, Lehmann J, Koppel M, Rosenwald A, Haferlach C, Hudecek M, Saliba AE, Rasche L, Sauer M, Einsele H, Kuster B, Waldschmidt J, Kortum KM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41917280"},{"title01":"Comprehensive landscape of secondary cytogenetic and molecular genetic events in multiple myeloma patients at diagnosis.","title02":"Comprehensive landscape of secondary cytogenetic and molecular genetic events in multiple myeloma patients at diagnosis.","journal":"Leukemia","issue":"2026 June 8. doi: 10.1038\/s41375-026-02999-y. Online ahead of print","author":"Wobst J, Truger M, Wossidlo N, Hutter S, Meggendorfer M, Kern W, Haferlach T, Haferlach C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42260112"},{"title01":"Multiple myeloma with concomitant chronic lymphocytic leukemia: evidence for independent clonal origin.","title02":"Multiple myeloma with concomitant chronic lymphocytic leukemia: evidence for independent clonal origin.","journal":"Leukemia","issue":"2026 June; 40(6):1311-1313. doi: 10.1038\/s41375-026-02918-1","author":"Wobst J, Ruge H, Senk S, Muller H, Truger M, Ecker V, Tsamadou C, Baldi A, Hoermann G, Haferlach T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41851472"},{"title01":"CD70\/CD27 signaling promotes the pathogenesis of multiple myeloma and represents a promising therapeutic target.","title02":"CD70\/CD27 signaling promotes the pathogenesis of multiple myeloma and represents a promising therapeutic target.","journal":"Leukemia","issue":"2026 June; 40(6):1163-1175. doi: 10.1038\/s41375-026-02899-1","author":"Forster S, Reinhardt C, Boy M, Wegmuller A, Hinrichsen A, Schurch CM, Bruhl FK, Fend F, Tzankov A, Kronig MN, Rommele M, Gluck A, Luscher B, Legros M, Bacher U, Seipel K, Pabst T, Radpour R, Riether C, Ochsenbein AF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41872502"},{"title01":"Smoldering multiple myeloma in transition: redefining early myeloma in the modern era.","title02":"Smoldering multiple myeloma in transition: redefining early myeloma in the modern era.","journal":"Leukemia","issue":"2026 June; 40(6):1137-1141. doi: 10.1038\/s41375-026-02979-2","author":"Landgren O","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42086933"},{"title01":"How unfitness criteria can make a difference in treating AML patients with hypomethylating agents and venetoclax.","title02":"How unfitness criteria can make a difference in treating AML patients with hypomethylating agents and venetoclax.","journal":"Br J Haematol","issue":"2026 June 8. doi: 10.1111\/bjh.70569. Online ahead of print","author":"Delia M, Gagliardi VP, Tarantini F, Strippoli L, Ruga L, Attolico I, Carluccio P, Albano F, Musto P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42257484"},{"title01":"Flow cytometry-guided ex vivo drug sensitivity testing informs venetoclax-based therapy in acute undifferentiated leukaemia.","title02":"Flow cytometry-guided ex vivo drug sensitivity testing informs venetoclax-based therapy in acute undifferentiated leukaemia.","journal":"Br J Haematol","issue":"2026 June; 208(6):2275-2279. doi: 10.1111\/bjh.70499","author":"Xu L, Wang J, Zhao W, Wang Y, Hu Y, Li Y, Lai W, Yong J, Gao C, Liu D, Gao X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41995597"},{"title01":"Single-cell transcriptional consequences of leukaemogenic SETBP1 mutations.","title02":"Single-cell transcriptional consequences of leukaemogenic SETBP1 mutations.","journal":"Br J Haematol","issue":"2026 June; 208(6):2269-2274. doi: 10.1111\/bjh.70452","author":"Trinh MK, Anderson ND, Young MD, Whitfield HJ, Parks C, Ogbonnah T, Oszlanczi A, Zhou D, Robertson ER, Hodder A, Thomas R, Straathof K, Adams S, Bartram J, Summerfield N, Behjati S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41881778"},{"title01":"Frailty and health resource utilization in 5450 adults with acute myeloid leukaemia: A population-based study from Ontario, Canada.","title02":"Frailty and health resource utilization in 5450 adults with acute myeloid leukaemia: A population-based study from Ontario, Canada.","journal":"Br J Haematol","issue":"2026 June 8. doi: 10.1111\/bjh.70600. Online ahead of print","author":"Gupta G, Podolsky S, Liu N, Cheung MC, Bankar A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42259647"},{"title01":"Improved real-world outcomes of patients with acute promyelocytic leukaemia treated with first-line arsenic trioxide in specialized centres in Portugal through a 24\/7 phone-based referral.","title02":"Improved real-world outcomes of patients with acute promyelocytic leukaemia treated with first-line arsenic trioxide in specialized centres in Portugal through a 24\/7 phone-based referral.","journal":"Br J Haematol","issue":"2026 June 8. doi: 10.1111\/bjh.70608. Online ahead of print","author":"Infante JB, Aguiar E, Sa I, Marques I, Neto M, Almeida C, Nascimento T, Pereira M, Cortesao E, Sapinho G, Esteves G, Monteiro-Bras T, Regadas L, Vieira I, Saraiva F, Alikhanov G, Santos J, Ribeiro P, Trigo F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42259659"},{"title01":"Improved survival with fludarabine-based therapies in mixed phenotype acute leukaemia: A population-based study using the WHO 2022 classification.","title02":"Improved survival with fludarabine-based therapies in mixed phenotype acute leukaemia: A population-based study using the WHO 2022 classification.","journal":"Br J Haematol","issue":"2026 June; 208(6):2104-2112. doi: 10.1111\/bjh.70491","author":"Christensen LM, Simonsen MR, Jensen JF, Kristensen DT, Dybkaer K, Gronbaek K, El-Galaly TC, Ettrup MS, Ommen HB, Sorensen ALT, Hansen DL, Severinsen MT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41992976"},{"title01":"Genetic characterization of AML defined by differentiation shows a high frequency of DDX41 mutations.","title02":"Genetic characterization of AML defined by differentiation shows a high frequency of DDX41 mutations.","journal":"Br J Haematol","issue":"2026 June; 208(6):2280-2283. doi: 10.1111\/bjh.70484","author":"Huber S, Kornauth C, Hutter S, Meggendorfer M, Summerer I, Kern W, Haferlach T, Pohlkamp C, Hoermann G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41979368"},{"title01":"Evolution of the drug sensitivity landscape of chronic lymphocytic leukaemia.","title02":"Evolution of the drug sensitivity landscape of chronic lymphocytic leukaemia.","journal":"Br J Haematol","issue":"2026 June 10. doi: 10.1111\/bjh.70603. Online ahead of print","author":"Hermansen JU, Yin Y, Tjonnfjord GE, Mato AR, Skanland SS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42267774"},{"title01":"Cesni-cel (ARI0002h) in ultra-high-risk multiple myeloma with plasma cell leukaemia or central nervous system involvement.","title02":"Cesni-cel (ARI0002h) in ultra-high-risk multiple myeloma with plasma cell leukaemia or central nervous system involvement.","journal":"Br J Haematol","issue":"2026 June 4. doi: 10.1111\/bjh.70586. Online ahead of print","author":"Jimenez-Mira C, Tovar N, Martinez-Cibrian N, Gonzalez-Calle V, Albiol N, Lopez-Munoz N, Oliver-Caldes A, Gonzalez A, Mateos JM, Espanol-Rego M, Rosinol L, Juan M, Charry P, Sanchez-Pina JM, Navarro S, Munarriz D, Lopez-Corral L, Ortiz-Maldonado V, Varea S, Olesti E, Delgado J, Urbano-Ispizua A, Martinez-Lopez J, Mateos MV, Rodriguez-Lobato LG, Fernandez de Larrea C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42237881"},{"title01":"BRAF inhibitor plus rituximab in classical hairy cell leukaemia: A retrospective multicentre real-life study.","title02":"BRAF inhibitor plus rituximab in classical hairy cell leukaemia: A retrospective multicentre real-life study.","journal":"Br J Haematol","issue":"2026 June; 208(6):2243-2247. doi: 10.1111\/bjh.70476","author":"Tauveron-Jalenques U, Inchiappa L, Paillassa J, Maitre E, Willems L, Stocker N, Merabet F, Lok A, Lara D, Bijou F, Herbaux C, Ramos I, Guieze R, Tomowiak C, Troussard X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41958072"},{"title01":"Optimizing treatment selection and timing of allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia with concurrent feline McDonough sarcoma (FMS)-like tyrosine kinase 3 internal tandem duplication, nucleophosmin 1 and deoxyribonucleic acid (DNA) methyltransferase 3 alpha mutations.","title02":"Optimizing treatment selection and timing of allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia with concurrent feline McDonough sarcoma (FMS)-like tyrosine kinase 3 internal tandem duplication, nucleophosmin 1 and deoxyribonucleic acid (DNA) methyltransferase 3 alpha mutations.","journal":"Br J Haematol","issue":"2026 June 2. doi: 10.1111\/bjh.70593. Online ahead of print","author":"Li R, Yao Y, Yang D, Mao L, Lou Y, He Y, Meng H, Yu W, Pang A, Feng S, Tong H, Han M, Jin J, Tang M, Jiang E, Wang H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42230972"},{"title01":"Masked critical thrombocytopenia in hypercellular acute myeloid leukaemia.","title02":"Masked critical thrombocytopenia in hypercellular acute myeloid leukaemia.","journal":"Br J Haematol","issue":"2026 June 2. doi: 10.1111\/bjh.70548. Online ahead of print","author":"Lam WK, Wong KKW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42231068"},{"title01":"Improvements over time in survival after post-transplant relapse of adult T-cell leukaemia\/lymphoma and trends of salvage therapy in a real-world experience.","title02":"Improvements over time in survival after post-transplant relapse of adult T-cell leukaemia\/lymphoma and trends of salvage therapy in a real-world experience.","journal":"Br J Haematol","issue":"2026 June 15. doi: 10.1111\/bjh.70631. Online ahead of print","author":"Itonaga H, Fukushima T, Kato K, Muranushi H, Tokunaga M, Miyazono T, Ito A, Eto T, Suehiro Y, Kato T, Fujioka M, Kawakita T, Uchida N, Mori Y, Yoshimitsu M, Nakamae H, Morichika K, Ishitsuka K, Kanda J, Fukuda T, Atsuta Y, Fuji S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42298882"},{"title01":"High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT.","title02":"High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT.","journal":"Blood advances","issue":"2026 June 12. doi: 10.1182\/bloodadvances.2026020219. Online ahead of print","author":"Kauer J, Kramer I, Derigs P, Blank MF, Dietrich S, Meissner J, Kehl N, Friedrich MJ, Schubert ML, Ho AD, Schmitt A, Kobbe G, Muller-Tidow C, Schmitt M, Dreger P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42284699"},{"title01":"ZMYM3 mutations modulate histone acetylation and cooperate with NOTCH1 mutations in chronic lymphocytic leukemia.","title02":"ZMYM3 mutations modulate histone acetylation and cooperate with NOTCH1 mutations in chronic lymphocytic leukemia.","journal":"Blood advances","issue":"2026 June 10. doi: 10.1182\/bloodadvances.2025019501. Online ahead of print","author":"Rodriguez-Sanchez A, Perez-Carretero C, Corchete Sanchez LA, Miguel-Garcia C, Santos-Minguez S, Villaverde Ramiro A, Davila-Valls J, Garcia de Coca A, Galende J, Juanes-Velasco P, Fuentes M, Benito R, Rodriguez-Vicente AE, Quijada Alamo M, Hernandez-Rivas JM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42269081"},{"title01":"Modulation of the bone marrow microenvironment by acute B-cell lymphoblastic leukemia-derived large oncosomes.","title02":"Modulation of the bone marrow microenvironment by acute B-cell lymphoblastic leukemia-derived large oncosomes.","journal":"Blood advances","issue":"2026 June 10. doi: 10.1182\/bloodadvances.2025018905. Online ahead of print","author":"Samangan F, Krack T, Kerman FD, Bravo J, Witzler CL, Gregorz B, Ruf W, Krause DS, Minciacchi VR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42268930"},{"title01":"AR expression in AML cells is same in female vs male patients.","title02":"AR expression in AML cells is same in female vs male patients.","journal":"Blood advances","issue":"2026 June 9; 10(11):4107. doi: 10.1182\/bloodadvances.2025019246","author":"Taussig DC, Miraki-Moud F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41719448"},{"title01":"Carfilzomib plus induction chemotherapy in children with relapsed or refractory acute lymphoblastic leukemia.","title02":"Carfilzomib plus induction chemotherapy in children with relapsed or refractory acute lymphoblastic leukemia.","journal":"Blood advances","issue":"2026 June 3. doi: 10.1182\/bloodadvances.2025019356. Online ahead of print","author":"Locatelli F, Karakukcu M, Huynh V, Gonzalez-Martinez B, Mendes Lins M, Lu MY, Sulis ML, Pauly M, Morris CL, Braunlin M, Talpes M, Gore L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42234929"},{"title01":"HMA+VEN triplet regimens for the initial treatment of AML in adults (PRO).","title02":"HMA+VEN triplet regimens for the initial treatment of AML in adults (PRO).","journal":"Blood advances","issue":"2026 June 4. doi: 10.1182\/bloodadvances.2025018557. Online ahead of print","author":"DiNardo CD, Lachowiez CA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42247345"},{"title01":"MSLN expression predicts a high risk of EMD in AML by promoting cell adhesion and metastasis via interaction with MUC16.","title02":"MSLN expression predicts a high risk of EMD in AML by promoting cell adhesion and metastasis via interaction with MUC16.","journal":"Blood advances","issue":"2026 June 9; 10(11):3878-3896. doi: 10.1182\/bloodadvances.2025017325","author":"Wang L, Zhan Q, Luo J, Li J, He C, Zhu Y, Pei C, Chen Y, Tang NN, Yin J, Su L, Chen J, Xie M, Liu L, Luo XH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41824794"},{"title01":"Similar androgen receptor expression in male and female AML.","title02":"Similar androgen receptor expression in male and female AML.","journal":"Blood advances","issue":"2026 June 9; 10(11):4108. doi: 10.1182\/bloodadvances.2026020008","author":"Prabhu KS, Qian F, Sarkar D, Zheng H, Paulson RF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41921074"},{"title01":"Conventional therapy vs HMA or LDAC with or without venetoclax in older adults with AML: systematic review and meta-analysis.","title02":"Conventional therapy vs HMA or LDAC with or without venetoclax in older adults with AML: systematic review and meta-analysis.","journal":"Blood advances","issue":"2026 June 9; 10(11):4067-4081. doi: 10.1182\/bloodadvances.2025016877","author":"Ibrahim S, Burgos-Mansilla B, Roldan Y, Oliveros MJ, Bhogal G, Bravo-Soto G, Bagherianlemraski M, Movahed H, Gutierrez-Arias R, Mulazzani F, Khorrami Taj T, Hadeiy SK, Qureshi M, Chowdhury SR, Couban R, Artz A, Fletcher L, Gilberto L, Mattison R, Sekeres MA, Brignardello-Petersen R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671437"},{"title01":"Final phase 2 study results of acalabrutinib in treatment-naive and relapsed\/refractory chronic lymphocytic leukemia.","title02":"Final phase 2 study results of acalabrutinib in treatment-naive and relapsed\/refractory chronic lymphocytic leukemia.","journal":"Blood advances","issue":"2026 June 9; 10(11):3931-3941. doi: 10.1182\/bloodadvances.2025018310","author":"Furman RR, Wierda WG, Patten PEM, Chaves JM, Brown JR, Munir T, Martin P, Awan FT, Stephens DM, Ghia P, Barrientos JC, Patel K, Woyach JA, de Borja M, Wang MH, Jain N, O'Brien SM, Byrd JC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41915892"},{"title01":"A phase 1\/2 study of duvelisib plus venetoclax in patients with relapsed\/refractory CLL\/SLL or Richter transformation.","title02":"A phase 1\/2 study of duvelisib plus venetoclax in patients with relapsed\/refractory CLL\/SLL or Richter transformation.","journal":"Blood advances","issue":"2026 June 9; 10(11):3811-3819. doi: 10.1182\/bloodadvances.2025018878","author":"Crombie JL, Ryan CE, Ren Y, Tyekucheva S, Carey C, Zou A, Normilus S, Montegaard J, Bhandari S, Alencar A, Soumerai JD, Arnason JE, Kim AI, Parry EM, Armand P, Fisher DC, Brown JR, Davids MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41886642"},{"title01":"Minimal residual disease in CLL: when does it really matter?","title02":"Minimal residual disease in CLL: when does it really matter?","journal":"Blood","issue":"2026 June 11; 147(24):2852-2854. doi: 10.1182\/blood.2026033673","author":"Cuneo A, Ghia P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42275122"},{"title01":"Hitting AML where it breathes: the peroxisome fat trap.","title02":"Hitting AML where it breathes: the peroxisome fat trap.","journal":"Blood","issue":"2026 June 11; 147(24):2856-2857. doi: 10.1182\/blood.2026033659","author":"Brenet F, Sarry JE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42275119"},{"title01":"Magnificent Seven? CD7 CARTs take a surprise shot at AML.","title02":"Magnificent Seven? CD7 CARTs take a surprise shot at AML.","journal":"Blood","issue":"2026 June 11; 147(24):2863-2864. doi: 10.1182\/blood.2026033581","author":"Omer B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42275123"},{"title01":"Acquisition of Philadelphia chromosome at relapse in a case of Ph-like B-ALL.","title02":"Acquisition of Philadelphia chromosome at relapse in a case of Ph-like B-ALL.","journal":"Blood","issue":"2026 June 11; 147(24):2986. doi: 10.1182\/blood.2025033043","author":"Aldoss I, Song JY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42275116"},{"title01":"MYB activity drives emergent enhancer activation and enhancer-promoter interactions in acute lymphoblastic leukemia.","title02":"MYB activity drives emergent enhancer activation and enhancer-promoter interactions in acute lymphoblastic leukemia.","journal":"Blood","issue":"2026 June 11; 147(24):2865-2878. doi: 10.1182\/blood.2025030424","author":"Lau IJ, Bloye G, Smith AL, Harman JR, Hamley JC, Sharlandjieva V, Denny N, Chahrour C, Li H, Jackson NE, Vyas P, Davies JOJ, Hughes JR, Crump NT, Milne TA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41949410"},{"title01":"Targeting ABCD1 inhibits peroxisomal fatty acid oxidation to selectively eliminate acute myeloid leukemia cells.","title02":"Targeting ABCD1 inhibits peroxisomal fatty acid oxidation to selectively eliminate acute myeloid leukemia cells.","journal":"Blood","issue":"2026 June 11; 147(24):2930-2943. doi: 10.1182\/blood.2025031202","author":"Parfenova EN, Vrdoljak N, Mosca DA, Aristizabal-Henao JJ, Kiebish MA, Minden MD, Spagnuolo PA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41746867"},{"title01":"Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.","title02":"Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.","journal":"Blood","issue":"2026 June 1. doi: 10.1182\/blood.2025032466. Online ahead of print","author":"Kennedy VE, Peretz CAC, Walia A, Chyla B, Sun Y, Hill JE, Tran E, Koh AD, Ferng TT, Pintar S, Jones M, Popescu B, Lomeli I, Chehab F, Murad N, John A, Roy RP, Olshen AB, Berryhill CA, Davis C, Angus SP, Rivera JM, Meshulam A, Stieglitz E, Joshi SK, Traer E, Dail M, Hamidi H, Altman JK, Daver NG, Levis MJ, McCloskey J, Perl AE, Smith CC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42224378"},{"title01":"Fixed-duration VenO vs FCR\/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial.","title02":"Fixed-duration VenO vs FCR\/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial.","journal":"Blood","issue":"2026 June 11; 147(24):2895-2904. doi: 10.1182\/blood.2025030630","author":"Sharman JP, Laurenti L, Ferrant E, Casado Montero LF, Mulligan SP, Harrup R, Opat S, Ibatici A, Marasca R, Sportoletti P, Thadani-Mulero M, Cazares O, Huang W, Jiang Y, Clark E, Jin HY, Boyer M, Morschhauser F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41770817"},{"title01":"Anti-CD7 fratricide-resistant chimeric antigen receptor T cells for relapsed\/refractory acute myeloid leukemia.","title02":"Anti-CD7 fratricide-resistant chimeric antigen receptor T cells for relapsed\/refractory acute myeloid leukemia.","journal":"Blood","issue":"2026 June 11; 147(24):2981-2985. doi: 10.1182\/blood.2025032299","author":"Becilli M, Merli P, Algeri M, Del Bufalo F, Pagliara D, Bertaina V, Agrati C, Rosignoli C, Cefalo MG, Boccieri E, Di Cecca S, Iaffaldano L, Lee Y, De Angelis B, Meshinchi S, Quintarelli C, Campana D, Locatelli F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41774512"},{"title01":"Shrouded in a starry sky: a case of AML-MRC with KMT2A amplification mimicking Burkitt-like morphology.","title02":"Shrouded in a starry sky: a case of AML-MRC with KMT2A amplification mimicking Burkitt-like morphology.","journal":"Blood","issue":"2026 June 4; 147(23):2845. doi: 10.1182\/blood.2026033109","author":"Chiriac R, Alcazer V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42241038"},{"title01":"Immunosuppression-Associated Peripheral T-Cell Lymphoma.","title02":"Immunosuppression-Associated Peripheral T-Cell Lymphoma.","journal":"N Engl J Med","issue":"2026 June 18; 394(23):2356. doi: 10.1056\/NEJMicm2501877","author":"Cliff ERS, Kenealy M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42294861"},{"title01":"Loss of systemic anti-viral immunity and LMP1-driven suppressive myeloid tumour niches converge to shape the immunobiology of Epstein-Barr virus-positive diffuse large B-cell lymphoma.","title02":"Loss of systemic anti-viral immunity and LMP1-driven suppressive myeloid tumour niches converge to shape the immunobiology of Epstein-Barr virus-positive diffuse large B-cell lymphoma.","journal":"Leukemia","issue":"2026 June 10. doi: 10.1038\/s41375-026-02994-3. Online ahead of print","author":"Fennell E, Law SC, Dowell AC, Pugh MR, Enright CM, Ross AM, Hennessy AS, Leahy CI, Nikulina N, Richter AG, Mundo L, Leoncini L, Lazzi S, Siciliano MC, Dojcinov SD, Quintanilla-Martinez L, Young KH, Gandhi MK, Taylor GS, Murray PG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42271039"},{"title01":"Allogeneic hematopoietic cell transplantation for T-cell\/histiocyte-rich large B-cell lymphoma: An EBMT lymphoma working party study.","title02":"Allogeneic hematopoietic cell transplantation for T-cell\/histiocyte-rich large B-cell lymphoma: An EBMT lymphoma working party study.","journal":"Leukemia","issue":"2026 June 15. doi: 10.1038\/s41375-026-02993-4. Online ahead of print","author":"Renders S, Ngoya M, de Leval L, Finel H, Khvedelidze I, Pocock R, Ram R, Gedde-Dahl T, Serroukh Y, Bug G, Kroger N, Nagler A, Pabst T, Rabitsch W, Yakoub-Agha I, Eder M, Ratip S, Scheid C, Perez-Simon JA, Wagner-Drouet EM, Sureda A, Schmitz N, Glass B, Bazarbachi A, Dreger P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42297918"},{"title01":"Editorial Expression of Concern: Discovery of a BTK\/MNK dual inhibitor for lymphoma and leukemia.","title02":"Editorial Expression of Concern: Discovery of a BTK\/MNK dual inhibitor for lymphoma and leukemia.","journal":"Leukemia","issue":"2026 June; 40(6):1342. doi: 10.1038\/s41375-026-02980-9","author":"Wu H, Hu C, Wang A, Weisberg EL, Chen Y, Yun CH, Wang W, Liu Y, Liu X, Tian B, Wang J, Zhao Z, Liang Y, Li B, Wang L, Wang B, Chen C, Buhrlage SJ, Qi Z, Zou F, Nonami A, Li Y, Fernandes SM, Adamia S, Stone RM, Galinsky IA, Wang X, Yang G, Griffin JD, Brown JR, Eck MJ, Liu J, Gray NS, Liu Q","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42092047"},{"title01":"PRMT5 inhibition sensitizes B-cell lymphoma cells to ferroptosis.","title02":"PRMT5 inhibition sensitizes B-cell lymphoma cells to ferroptosis.","journal":"Leukemia","issue":"2026 June; 40(6):1247-1260. doi: 10.1038\/s41375-026-02932-3","author":"Liu Y, Chen R, Gao X, Zhu F, Ni Q, Bates PD, Wu S, Zai Z, Obernberger VA, Weerawardhene K, Tourdot TK, Petta S, Conyers MJ, Capitini CM, Rui L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41998301"},{"title01":"Prognostic significance of clinical risk models and genomic alterations in Waldenstrom macroglobulinemia before or after the BTK inhibitor era.","title02":"Prognostic significance of clinical risk models and genomic alterations in Waldenstrom macroglobulinemia before or after the BTK inhibitor era.","journal":"Leukemia","issue":"2026 June; 40(6):1203-1213. doi: 10.1038\/s41375-026-02919-0","author":"Yan Y, Chen W, Yu Y, Li Y, Xiong W, Zhang X, Wang T, Liu W, Sui W, Yu Z, Hao M, An G, Zou D, Qiu L, Yi S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41912911"},{"title01":"RAG1\/2 expression in IGH-switched follicular lymphoma associated with transformation to high-grade B-cell lymphoma.","title02":"RAG1\/2 expression in IGH-switched follicular lymphoma associated with transformation to high-grade B-cell lymphoma.","journal":"Leukemia","issue":"2026 June; 40(6):1306-1310. doi: 10.1038\/s41375-026-02896-4","author":"Lonardi S, Cancila V, Morello G, Varano G, Balzarini P, Pellegrini V, Albertini E, Giampaolo S, Pietrini I, Thanasi H, Sindaco P, Piazza F, Manni S, Lorenzini D, Pruneri G, Dei Tos AP, Ponzoni M, Facchetti F, Pizzi M, Lorenzi L, Tripodo C, Casola S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41792441"},{"title01":"Targeting UHRF1 induces regression of aggressive mantle cell lymphoma.","title02":"Targeting UHRF1 induces regression of aggressive mantle cell lymphoma.","journal":"Leukemia","issue":"2026 June; 40(6):1176-1188. doi: 10.1038\/s41375-026-02915-4","author":"Yang Y, Tang Z, Hu Q, Yang P, Zhang W, Wang J, Jing H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41876725"},{"title01":"Nodular lymphocyte-predominant Hodgkin lymphoma controversy and insights: a global NLPHL one working group summit report.","title02":"Nodular lymphocyte-predominant Hodgkin lymphoma controversy and insights: a global NLPHL one working group summit report.","journal":"Leukemia","issue":"2026 June 10. doi: 10.1038\/s41375-026-02990-7. Online ahead of print","author":"Flerlage JE, Palese M, Birz S, Campo E, de Jong D, Eichenauer DA, Hartmann S, Hoppe RT, Jaffe ES, Natkunam Y, Quintanilla-Martinez L, Martins W, Binkley MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42271037"},{"title01":"Pre-diagnostic clonal hematopoiesis of indeterminate potential among patients with a primary cancer and risk of second cancers.","title02":"Pre-diagnostic clonal hematopoiesis of indeterminate potential among patients with a primary cancer and risk of second cancers.","journal":"Leukemia","issue":"2026 June; 40(6):1240-1246. doi: 10.1038\/s41375-026-02946-x","author":"Liu X, Adami HO, Boberg E, Smedby KE, Wei H, Fang F, Liu Q","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41981103"},{"title01":"Double trouble: sequential lymphomas.","title02":"Double trouble: sequential lymphomas.","journal":"Lancet Haematol","issue":"2026 June; 13(6):e426. doi: 10.1016\/S2352-3026(26)00063-3","author":"Torres-Saavedra F, Diaz de la Pinta FJ, Torre-Castro J, Caballero Hernaez J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42242264"},{"title01":"Defining the acute BTK-loss transcriptional program in CLL using a BTK degrader.","title02":"Defining the acute BTK-loss transcriptional program in CLL using a BTK degrader.","journal":"Leukemia","issue":"2026 June; 40(6):1314-1317. doi: 10.1038\/s41375-026-02926-1","author":"Sherpa MG, Sinha S, Han W, Darby HC, Parikh SA, Kay NE, Wang Z","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41862595"},{"title01":"Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors.","title02":"Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors.","journal":"Leukemia","issue":"2026 June 2. doi: 10.1038\/s41375-026-02982-7. Online ahead of print","author":"Chatterjee A, Mustafa Ali MK, Bailey CM, Liu Y, Small D, Smith CC, Traer E, Wang Y, Silvestri G, Baer MR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42230959"},{"title01":"Inotuzumab ozogamicin in individuals with Down syndrome and acute lymphoblastic leukemia.","title02":"Inotuzumab ozogamicin in individuals with Down syndrome and acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 June 3. doi: 10.1038\/s41375-026-02997-0. Online ahead of print","author":"Li AM, Aftandilian C, Annesley C, Colace S, Faulk KE, Goldman JW, Guest E, Hayani A, Ho R, Jabbour E, Khanna-Farber A, Kyono W, Leger K, Maloney K, McCall D, Miller T, Pacenta HL, Quigg TC, Rubinstein JD, Schafer E, Rheingold SR, Bhojwani D, O'Brien MM, Rabin KR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42236968"},{"title01":"Prolonged BCR::ABL1 induction in the SCL-tTA mouse recapitulates gene expression signatures and therapeutic vulnerabilities of primary imatinib-resistant chronic myeloid leukaemia.","title02":"Prolonged BCR::ABL1 induction in the SCL-tTA mouse recapitulates gene expression signatures and therapeutic vulnerabilities of primary imatinib-resistant chronic myeloid leukaemia.","journal":"Leukemia","issue":"2026 June 8. doi: 10.1038\/s41375-026-02988-1. Online ahead of print","author":"Shyamsunder P, Lee KL, Chan ZE, Chuah C, Yu M, Thever HP, Nah GSS, Sulaimi FNB, Krishnan V, Ong ST","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42260110"},{"title01":"Curing acute promyelocytic leukemia: no boost from immunity needed.","title02":"Curing acute promyelocytic leukemia: no boost from immunity needed.","journal":"Haematologica","issue":"2026 June 1; 111(6):1930-1932. doi: 10.3324\/haematol.2025.300055","author":"Tallman MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195516"},{"title01":"When fibrinogen stops clotting and starts plotting: discovery of a new miRNA-GPCR axis in acute myeloid leukemia progression.","title02":"When fibrinogen stops clotting and starts plotting: discovery of a new miRNA-GPCR axis in acute myeloid leukemia progression.","journal":"Haematologica","issue":"2026 June 11. doi: 10.3324\/haematol.2026.301296. Online ahead of print","author":"Lee BY, Salmena L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42273955"},{"title01":"The prognostic factors and immune microenvironment of primary plasma cell leukemia: the KMMWP-2204 study.","title02":"The prognostic factors and immune microenvironment of primary plasma cell leukemia: the KMMWP-2204 study.","journal":"Haematologica","issue":"2026 June 11. doi: 10.3324\/haematol.2026.300772. Online ahead of print","author":"Kim M, Jang HC, Ahn JS, Cho H, Lee JJ, Cho HJ, Kim DS, Jung J, Lee JH, Kim K, Byun JM, Yoon DH, Choi YS, Jo JC, Yhim HY, Lee MW, Lim SN, Lee JH, Park SS, Min CK, Jung SH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42273949"},{"title01":"Evolution to complex karyotype disease in mono-allelic TP53-mutated myelodysplastic syndrome\/acute myeloid leukemia: a cohort study.","title02":"Evolution to complex karyotype disease in mono-allelic TP53-mutated myelodysplastic syndrome\/acute myeloid leukemia: a cohort study.","journal":"Haematologica","issue":"2026 June 11. doi: 10.3324\/haematol.2026.300734. Online ahead of print","author":"Fernandes P, Pasca S, Jain T, Levis MJ, Ambinder AJ, Walsh L, Gojo I, Smith DB, Webster J, Ghiaur G, Dalton WB, Prince G, Jones RJ, DeZern AE, Gondek LP, Karantanos T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42273942"},{"title01":"Long-term follow-up: blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia.","title02":"Long-term follow-up: blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 June 4. doi: 10.3324\/haematol.2026.300873. Online ahead of print","author":"Miatech J, Milton DR, Gaballa MR, Banerjee P, Jiang X, Ganesh C, Khazal S, Nandivada V, Islam S, Kaplan M, Daher M, Basar R, Alousi A, Mehta R, Al-Atrash G, Khouri I, Oran B, Marin D, Popat U, Olson A, Tewari P, Jain N, Jabbour E, Ravandi-Kashani F, Chen K, Champlin R, Shpall E, Rezvani K, Kebriaei P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42237781"},{"title01":"Multicolor detection of chronic myeloid leukemia stem cells, including novel marker CD69, predicts survival and early hematological toxicity.","title02":"Multicolor detection of chronic myeloid leukemia stem cells, including novel marker CD69, predicts survival and early hematological toxicity.","journal":"Haematologica","issue":"2026 June 11. doi: 10.3324\/haematol.2025.300293. Online ahead of print","author":"Culen M, Romzova M, Smitalova D, Loja T, Busa D, Venglar O, Herudkova Z, Kassa S, Radova L, Borsky M, Reigl T, Plevova K, Smejkal J, Zackova D, Stejskal L, Mayer J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42273943"},{"title01":"Immune intervention is dispensable for retinoic acid\/ arsenic therapy of murine acute promyelocytic leukemia.","title02":"Immune intervention is dispensable for retinoic acid\/ arsenic therapy of murine acute promyelocytic leukemia.","journal":"Haematologica","issue":"2026 June 1; 111(6):2124-2127. doi: 10.3324\/haematol.2025.288562","author":"Esnault C, Fortin G, Qiu F, Soilihi H, Souquere S, Niwa-Kawakita M, Lanchais K, Dirami T, Pierron G, De The H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931862"},{"title01":"Blinatumomab-induced remission of refractory immune thrombocytopenia in pediatric acute lymphoblastic leukemia: a case report.","title02":"Blinatumomab-induced remission of refractory immune thrombocytopenia in pediatric acute lymphoblastic leukemia: a case report.","journal":"Haematologica","issue":"2026 June 1; 111(6):2175-2179. doi: 10.3324\/haematol.2025.288558","author":"Ao Y, Zheng H, Huang Y, Kang S, Zhang Q, Huang C, Wu X, Zeng Y, Zhou D, Fang J, Fu Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609024"},{"title01":"Multicenter upfront randomized phase II trial of quizartinib and high-dose cytarabine plus mitoxantrone in relapsed\/refractory acute myeloid leukemia with FMSlike tyrosine kinase 3 internal tandem duplication.","title02":"Multicenter upfront randomized phase II trial of quizartinib and high-dose cytarabine plus mitoxantrone in relapsed\/refractory acute myeloid leukemia with FMSlike tyrosine kinase 3 internal tandem duplication.","journal":"Haematologica","issue":"2026 June 1; 111(6):2114-2117. doi: 10.3324\/haematol.2025.288362","author":"Jaramillo S, Krisam J, Le Cornet L, Kratzmann M, Baumann L, Kayser S, Schliemann C, Kaufmann M, Kieser M, Platzbecker U, Muller-Tidow C, Schlenk RF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262039"},{"title01":"Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed\/refractory B-cell acute lymphoblastic leukemia.","title02":"Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed\/refractory B-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 June 1; 111(6):1999-2010. doi: 10.3324\/haematol.2025.288587","author":"Jabbour E, Sandhu KS, Shaughnessy P, Logan AC, Abedi M, Shah BD, Bishop MR, Park JH, DeAngelo DJ, Tholouli E, Yallop D, Chaganti S, Hodby K, Barba P, Guerreiro M, Menne T, Shang J, Lao-Sirieix P, Brugger W, Roddie C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41504229"},{"title01":"NKX2-1 regulates cell survival, maturation, and DNAdamage responses as a cofactor of RUNX1 in T-cell acute lymphoblastic leukemia.","title02":"NKX2-1 regulates cell survival, maturation, and DNAdamage responses as a cofactor of RUNX1 in T-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 June 1; 111(6):1969-1983. doi: 10.3324\/haematol.2025.287966","author":"Van Aerschot L, Demeyer S, Timcheva K, Heylen E, Verstraete P, De Groote D, Caruso M, Lauwereins L, Veloso A, Kampen KR, Pepe D, Boeckx N, Royaert J, Verbeeck J, Segers H, Cools J, De Keersmaecker K, Granados DC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41504233"},{"title01":"Don&#8217;t forget about thrombosis in acute promyelocytic leukemia.","title02":"Don&#8217;t forget about thrombosis in acute promyelocytic leukemia.","journal":"Haematologica","issue":"2026 June 1; 111(6):1919-1921. doi: 10.3324\/haematol.2025.300189","author":"Tallman MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537346"},{"title01":"QKI dysregulation induces extensive splicing changes in T-cell acute lymphoblastic leukemia.","title02":"QKI dysregulation induces extensive splicing changes in T-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 June 1; 111(6):1953-1968. doi: 10.3324\/haematol.2025.287809","author":"Palhais B, Sharma ND, Fijalkowski I, Pieters T, Deforce D, Nieuwerburgh FV, Mestdagh P, Ntziachristos P, Matlawska-Wasowska K, Vlierberghe PV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537349"},{"title01":"Isolated KRAS and NRAS mutations in adults with monocytosis and\/or cytopenia(s).","title02":"Isolated KRAS and NRAS mutations in adults with monocytosis and\/or cytopenia(s).","journal":"Haematologica","issue":"2026 June 1; 111(6):2070-2079. doi: 10.3324\/haematol.2025.288906","author":"Wang SA, Ok CY, Tsai HK, Loayza N, Daneshpajouhnejad P, Seth N, Cantu MD, Bagg A, Tam W, Weinberg O, Barone PD, Geyer JT, Lindsley CR, Montalban-Bravo G, Simon CR, Arber DA, Bueso-Ramos CE, Hsi ED, Foucar K, Orazi A, Patnaik MM, Hasserjian RP, Reichard KK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437825"},{"title01":"Mmrn1 expression defines a novel subset of hematopoietic stem cells and leukemia stem cells with great self-renewal potential.","title02":"Mmrn1 expression defines a novel subset of hematopoietic stem cells and leukemia stem cells with great self-renewal potential.","journal":"Haematologica","issue":"2026 June 1; 111(6):2032-2046. doi: 10.3324\/haematol.2025.287609","author":"Chen N, Yang L, Chen F, Zeng H, Zhong X, Liu Y, Chen Z, Yao M, Lu Y, Shen M, Chen M, Xu Y, Wang S, Zhang X, Wang J, Hu M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568470"},{"title01":"Two episodes of Ph(+) acute leukemia with divergent Ig\/TCR rearrangements in two patients with persistent BCR::ABL1 positivity: a 17-year follow-up.","title02":"Two episodes of Ph(+) acute leukemia with divergent Ig\/TCR rearrangements in two patients with persistent BCR::ABL1 positivity: a 17-year follow-up.","journal":"Haematologica","issue":"2026 June 1; 111(6):2128-2132. doi: 10.3324\/haematol.2025.288671","author":"Rubio-San-Simon A, Salzer E, Luesink M, Sonneveld E, Van der Sluis I, Pieters R, Hoogerbrugge PM, Zwaan MC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437812"},{"title01":"A small molecule inhibitor of RNA-binding protein IGF2BP3 shows anti-leukemic activity.","title02":"A small molecule inhibitor of RNA-binding protein IGF2BP3 shows anti-leukemic activity.","journal":"Haematologica","issue":"2026 June 1; 111(6):1984-1998. doi: 10.3324\/haematol.2025.288221","author":"Jaiswal AK, Scherer GM, Thaxton ML, Sorrentino JP, Yuen C, Mehta MM, Sharma G, Lin TL, Tran TM, Cohen A, Ritter AJ, Kotecha RS, Sanford JR, Damoiseaux RD, Garg NK, Rao DS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307127"},{"title01":"Optimal management of elderly\/old Ph(+) acute lymphoblastic leukemia patients.","title02":"Optimal management of elderly\/old Ph(+) acute lymphoblastic leukemia patients.","journal":"Haematologica","issue":"2026 June 1; 111(6):1949-1952. doi: 10.3324\/haematol.2025.300060","author":"Foa R, Chiaretti S, Ferrara F, Pizzolo G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568523"},{"title01":"Sequential therapy with allogeneic HCT in patients aged >\/=70 years with active AML: a single-center retrospective analysis.","title02":"Sequential therapy with allogeneic HCT in patients aged >\/=70 years with active AML: a single-center retrospective analysis.","journal":"Haematologica","issue":"2026 June 1; 111(6):2061-2069. doi: 10.3324\/haematol.2025.300184","author":"Amit O, Fridberg G, Moshe Y, Ospovat I, Sherf Y, Tshernichovsky D, Karni C, Avivi I, Ram R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568537"},{"title01":"Venetoclax with intensive induction chemotherapy in newly diagnosed adult acute myeloid leukemia: early outcomes from a real-world experience.","title02":"Venetoclax with intensive induction chemotherapy in newly diagnosed adult acute myeloid leukemia: early outcomes from a real-world experience.","journal":"Haematologica","issue":"2026 June 1; 111(6):2141-2144. doi: 10.3324\/haematol.2025.289048","author":"Naik A, Kataria B, Sharma V, Sharma A, Batra A, Bhatia K, Singh B, Chopra A, Rout D, Sagiraju H, Talukdar R, Tiwari S, Kumar A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437831"},{"title01":"Single-cell dissection of plasma cell clonal evolution to smoldering multiple myeloma after CD19 CAR-T cell therapy in B-cell acute lymphoblastic leukemia.","title02":"Single-cell dissection of plasma cell clonal evolution to smoldering multiple myeloma after CD19 CAR-T cell therapy in B-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 June 1; 111(6):2164-2170. doi: 10.3324\/haematol.2025.300240","author":"Yu H, Zhang G, Gong B, Li S, Guo C, Liu Y, Gu R, Xu Y, An G, Wei H, Wang M, Rao Q, Liu W, Wang J, Qiu S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41676912"},{"title01":"Impact of insertion\/deletion mutations affecting the ABL1 gene in Ph-positive leukemias.","title02":"Impact of insertion\/deletion mutations affecting the ABL1 gene in Ph-positive leukemias.","journal":"Haematologica","issue":"2026 June 1; 111(6):1933-1935. doi: 10.3324\/haematol.2025.300345","author":"Lucini C, Lion T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41676918"},{"title01":"Accurate automated diagnosis of B-acute lymphoblastic leukemia using deep learning and flow cytometry.","title02":"Accurate automated diagnosis of B-acute lymphoblastic leukemia using deep learning and flow cytometry.","journal":"Haematologica","issue":"2026 June 1; 111(6):2107-2113. doi: 10.3324\/haematol.2025.288277","author":"Chalise S, Roshal M, Roshal S, Baik J, Gao Q, Li A, Dogan A, Veeraraghavan H, Zhu ML","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41504225"},{"title01":"Deletion mutations of the ABL1 gene in Philadelphia chromosome-positive acute lymphoblastic leukemia: high prevalence with limited clinical impact.","title02":"Deletion mutations of the ABL1 gene in Philadelphia chromosome-positive acute lymphoblastic leukemia: high prevalence with limited clinical impact.","journal":"Haematologica","issue":"2026 June 1; 111(6):2137-2140. doi: 10.3324\/haematol.2025.288739","author":"Takano H, Takagi S, Kato K, Watanabe O, Yamaguchi K, Kageyama K, Kaji D, Taya Y, Nishida A, Ishiwata K, Yamamoto H, Asano-Mori Y, Yamamoto G, Wake A, Taniguchi S, Uchida N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262038"},{"title01":"A scoring system to predict life-threatening thromboischemic events in patients with acute promyelocytic leukemia: the PETHEMA\/PALG study.","title02":"A scoring system to predict life-threatening thromboischemic events in patients with acute promyelocytic leukemia: the PETHEMA\/PALG study.","journal":"Haematologica","issue":"2026 June 1; 111(6):2011-2022. doi: 10.3324\/haematol.2025.288112","author":"Rodriguez-Veiga R, Gil C, Sobas M, Torres-Minana L, Botella C, De la Serna J, Bernal T, Salamero O, Otero C, Navarro-Vicente I, De Miguel C, Garrido A, Vives S, Bergua J, Perez-Encinas M, Algarra L, Gonzalez-Campos J, Gomez MDMC, Prates MV, Benavente C, Tormo M, Cervera M, Fazio P, Amutio ME, Garcia R, Pomares H, Vidriales B, Serrano J, Amigo ML, Rubio V, Almela A, Barrios M, Sossa-Melo CL, Paluszewska M, Novo A, Gromek T, Rodriguez-Macias G, Oleksiuk J, Lloret-Madrid P, Montesinos P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41230704"},{"title01":"The myeloid cell leukaemia-1 inhibitor MIK665 is a potent therapy in preclinical models of paediatric acute myeloid leukaemia.","title02":"The myeloid cell leukaemia-1 inhibitor MIK665 is a potent therapy in preclinical models of paediatric acute myeloid leukaemia.","journal":"Br J Haematol","issue":"2026 June 4. doi: 10.1111\/bjh.70596. Online ahead of print","author":"Connerty P, Colgan JN, El-Najjar F, Henry E, Xie J, Idais D, Gentile C, Mao J, Dolman MEM, Marshall GM, Lock RB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42237892"},{"title01":"Central nervous system involvement and relapse in adult acute lymphoblastic leukaemia-a population-based analysis in 2007-2022.","title02":"Central nervous system involvement and relapse in adult acute lymphoblastic leukaemia-a population-based analysis in 2007-2022.","journal":"Br J Haematol","issue":"2026 June 1. doi: 10.1111\/bjh.70589. Online ahead of print","author":"Boberg E, Lubking A, Lennmyr EB, Dietrich CE, Joelsson J, Smedby KE, Wasterlid T, Hallbook H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42223251"},{"title01":"AKT inhibitor capivasertib reverses EVI1-driven resistance to venetoclax in acute myeloid leukaemia.","title02":"AKT inhibitor capivasertib reverses EVI1-driven resistance to venetoclax in acute myeloid leukaemia.","journal":"Br J Haematol","issue":"2026 June 4. doi: 10.1111\/bjh.70530. Online ahead of print","author":"Zhou J, Kui X, Huang D, Zhang X, Hao Y, Xie F, Lou J, Yan J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42241446"},{"title01":"BCL-2 and MCL1 co-inhibition enhances glucocorticoid therapy in preclinical models of infant KMT2A-rearranged acute lymphoblastic leukaemia.","title02":"BCL-2 and MCL1 co-inhibition enhances glucocorticoid therapy in preclinical models of infant KMT2A-rearranged acute lymphoblastic leukaemia.","journal":"Br J Haematol","issue":"2026 June 5. doi: 10.1111\/bjh.70598. Online ahead of print","author":"Karsa M, Karsa A, Spurling D, Xiao L, Ronca E, Bongers A, Gao W, Gifford AJ, El-Ayoubi A, Cheung LC, Kotecha RS, Lock RB, Teh CE, Lessene G, Norris MD, Wei A, Haber M, Henderson MJ, Moujalled DM, Somers K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42246204"},{"title01":"A novel JAK1 variant in chronic eosinophilic leukaemia with response to benralizumab.","title02":"A novel JAK1 variant in chronic eosinophilic leukaemia with response to benralizumab.","journal":"Br J Haematol","issue":"2026 June 8. doi: 10.1111\/bjh.70487. Online ahead of print","author":"Vallecillo-Viejo IC, Claiborne MD, Anderson CF, Shafer S, Saven A, Seifert BA, Similuk M, Walkiewicz M, Maric I, Crespo PR, Broderick L, White AA, Klion AD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42253119"},{"title01":"Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs.","title02":"Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs.","journal":"Blood advances","issue":"2026 June 11. doi: 10.1182\/bloodadvances.2026019701. Online ahead of print","author":"Ono T, Okada T, Takahashi N, Minami Y, Nakaseko C, Iriyama N, Fujimaki K, Kakihana K, Ogasawara Y, Okada M, Tauchi T, Atsuta Y, Ohtake S, Miyamoto T, Ohnishi K, Sakaida E, Fujisawa S, Kobayashi Y, Kiyoi H, Miyazaki Y, Matsumura I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42275565"},{"title01":"No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d-positive CLL mainly expressed in trisomy 12.","title02":"No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d-positive CLL mainly expressed in trisomy 12.","journal":"Blood advances","issue":"2026 June 9; 10(11):3983-3986. doi: 10.1182\/bloodadvances.2025018640","author":"Laurenti L, Guglielmi F, Mosca A, Vitale C, Montalbano MC, Favrin G, Ferrarini I, Galitzia A, Pasquale R, Moratti M, Catania G, Murru R, Giannarelli D, Martino EA, Moia R, Zucchetto A, Tissino E, Autore F, Tomasso A, Stirparo L, Quaranta T, Abbate PL, Gattei V, Gaidano G, Gentile M, Krampera M, Farina G, Visentin A, Innao V, Varettoni M, Coscia M, Innocenti I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41925576"},{"title01":"Peri-transplant molecular MRD monitoring by targeted NGS in patients with FLT3-ITD mutated acute myeloid leukemia.","title02":"Peri-transplant molecular MRD monitoring by targeted NGS in patients with FLT3-ITD mutated acute myeloid leukemia.","journal":"Blood advances","issue":"2026 June 9. doi: 10.1182\/bloodadvances.2026020264. Online ahead of print","author":"Hu X, Zhao Y, Jiang C, Fan Y, Shi J, Luo Y, Yu J, Lai X, Liu L, Ye Y, Liang J, Huang X, Zheng Z, Huang H, Shi W, Zhao Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42263741"},{"title01":"PLCG2 Exon-Skipped Variants: Insights into Their Potential Role in Chronic Lymphocytic Leukemia.","title02":"PLCG2 Exon-Skipped Variants: Insights into Their Potential Role in Chronic Lymphocytic Leukemia.","journal":"Blood advances","issue":"2026 June 5. doi: 10.1182\/bloodadvances.2025019077. Online ahead of print","author":"Qi J, Li W, Dheenadayalan RP, Yosifov DY, Drewes C, Wist M, Wieczorek M, Schmid V, Hobeika E, Gao X, Endres S, Schneider C, Riecke A, Barth H, Gierschik P, Siebert R, Tausch E, Stilgenbauer S, Jebaraj BMC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42263669"},{"title01":"Patient and oncologist expectations of functional prognosis among older adults with acute myeloid leukemia.","title02":"Patient and oncologist expectations of functional prognosis among older adults with acute myeloid leukemia.","journal":"Blood advances","issue":"2026 June 11. doi: 10.1182\/bloodadvances.2025019276. Online ahead of print","author":"Jensen-Battaglia M, Mortaz Hedjri S, Blumberg R, Oh E, Fallone-Sharma C, Wang Y, Nafis L, Mendler JH, Rodenbach R, Huselton EJ, Liesveld JL, Terhune J, Terhune J, Agree EM, Block RC, Seplaki CL, Mohile SG, Loh KP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42275539"},{"title01":"Antileukemic therapies for older adults with AML ineligible for conventional therapy: systematic review and meta-analysis.","title02":"Antileukemic therapies for older adults with AML ineligible for conventional therapy: systematic review and meta-analysis.","journal":"Blood advances","issue":"2026 June 9; 10(11):4082-4093. doi: 10.1182\/bloodadvances.2025016879","author":"Oliveros MJ, Chowdhury SR, Roldan Y, Ibrahim S, Bravo-Soto G, Foucar CE, Bhogal G, Burgos-Mansilla B, Bagherianlemraski M, Movahed H, Gutierrez-Arias R, Khorrami Taj T, Chang Y, Hadeiy SK, Couban R, Demichelis-Gomez R, Malcovati L, Loh KP, Platzbecker U, Gilberto L, Treitz J, Baer MR, Marini BL, Mattison R, Sekeres MA, Brignardello-Petersen R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538293"},{"title01":"Chronic Myeloid Leukemia in Low- and Middle-Income Countries.","title02":"Chronic Myeloid Leukemia in Low- and Middle-Income Countries.","journal":"N Engl J Med","issue":"2026 June 4; 394(21):2175. doi: 10.1056\/NEJMc2605636","author":"Mahon FX, Rea D, Rousselot P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42235030"},{"title01":"All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.","title02":"All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.","journal":"N Engl J Med","issue":"2026 June 4; 394(21):2107-2116. doi: 10.1056\/NEJMoa2510223","author":"Roboz GJ, Zeidan AM, Mannis GN, Montesinos P, Arnan M, Savona MR, Odenike O, McCloskey JK, Amin HV, Fathi AT, Bernal Del Castillo T, Rodriguez-Macias G, Liesveld JL, Im AP, Cerny J, Gentile TC, Oganesian A, Chan D, Wan Y, Dijkstra M, Keer HN, Griffiths EA, DiNardo CD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42235013"},{"title01":"Chronic Myeloid Leukemia in Low- and Middle-Income Countries. Reply.","title02":"Chronic Myeloid Leukemia in Low- and Middle-Income Countries. Reply.","journal":"N Engl J Med","issue":"2026 June 4; 394(21):2175-2176. doi: 10.1056\/NEJMc2605636","author":"Annamalay A, Radich J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42235031"},{"title01":"Editorial Expression of Concern: Discovery of a BTK\/MNK dual inhibitor for lymphoma and leukemia.","title02":"Editorial Expression of Concern: Discovery of a BTK\/MNK dual inhibitor for lymphoma and leukemia.","journal":"Leukemia","issue":"2026 June; 40(6):1342. doi: 10.1038\/s41375-026-02980-9","author":"Wu H, Hu C, Wang A, Weisberg EL, Chen Y, Yun CH, Wang W, Liu Y, Liu X, Tian B, Wang J, Zhao Z, Liang Y, Li B, Wang L, Wang B, Chen C, Buhrlage SJ, Qi Z, Zou F, Nonami A, Li Y, Fernandes SM, Adamia S, Stone RM, Galinsky IA, Wang X, Yang G, Griffin JD, Brown JR, Eck MJ, Liu J, Gray NS, Liu Q","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42092047"},{"title01":"Overcoming MEN1-mediated resistance with menin inhibitor switching in KMT2A-rearranged acute myeloid leukemia.","title02":"Overcoming MEN1-mediated resistance with menin inhibitor switching in KMT2A-rearranged acute myeloid leukemia.","journal":"Leukemia","issue":"2026 June; 40(6):1331-1334. doi: 10.1038\/s41375-026-02959-6","author":"Chin KK, Abdul-Hay M, Shukla M, Geyer MB, Tamari R, Ko KH, Xiao W, Stein EM, Cai SF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41963592"},{"title01":"TP53 deficiency in AML induces resistance to T-cell engagers through an immunosuppressive secretome.","title02":"TP53 deficiency in AML induces resistance to T-cell engagers through an immunosuppressive secretome.","journal":"Leukemia","issue":"2026 June 1. doi: 10.1038\/s41375-026-02991-6. Online ahead of print","author":"Winter L, Pawlowsky L, Muth A, Neumann AS, White K, Kazerani M, Nixdorf D, Brauchle B, Rohrbacher L, Hanel G, Petrera A, Briem E, Hoffmann GV, Janert T, Carlini E, Gottschlich A, Spiekermann K, Straub T, Kischel R, Kobold S, Andreeff M, Buecklein VL, Subklewe M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42225967"},{"title01":"From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia.","title02":"From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia.","journal":"Leukemia","issue":"2026 June; 40(6):1092-1110. doi: 10.1038\/s41375-026-02984-5","author":"Hochhaus A, Talpaz M, Saglio G, Cortes JE, Hughes T, Apperley J, Hantschel O, Rea D, Schuld P, Kantarjian H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42174092"},{"title01":"Immunophenotypic changes following menin inhibition in acute myeloid leukemia.","title02":"Immunophenotypic changes following menin inhibition in acute myeloid leukemia.","journal":"Leukemia","issue":"2026 June; 40(6):1142-1150. doi: 10.1038\/s41375-026-02905-6","author":"Loghavi S, Farhat A, Jamison TJ, El Hajjar G, Bataller A, Wang SA, Wang W, Tang G, Quesada AE, Bazinet A, Cuglievan B, DiNardo CD, Montalban-Bravo G, Takahashi K, Short NJ, Abbas HA, Kadia T, Ravandi F, Daver N, Jabbour E, Borthakur G, Andreeff M, Medeiros LJ, Kantarjian HM, Issa GC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41814014"},{"title01":"Multiple myeloma with concomitant chronic lymphocytic leukemia: evidence for independent clonal origin.","title02":"Multiple myeloma with concomitant chronic lymphocytic leukemia: evidence for independent clonal origin.","journal":"Leukemia","issue":"2026 June; 40(6):1311-1313. doi: 10.1038\/s41375-026-02918-1","author":"Wobst J, Ruge H, Senk S, Muller H, Truger M, Ecker V, Tsamadou C, Baldi A, Hoermann G, Haferlach T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41851472"},{"title01":"Targeting BMP and TAZ\/TEAD mechanotransduction pathways impairs acute myeloid leukemia chemoresistance.","title02":"Targeting BMP and TAZ\/TEAD mechanotransduction pathways impairs acute myeloid leukemia chemoresistance.","journal":"Leukemia","issue":"2026 June; 40(6):1151-1162. doi: 10.1038\/s41375-026-02904-7","author":"Barral L, Lespinasse N, Martin Cardozo C, Jeanpierre S, Bourgeois A, Rosel K, Beillard E, Laurent D, Peyrouze P, Belhabri A, Guillermin Y, Mazurier F, Cheok M, Audry-Deschamps MC, Faivre M, Maguer-Satta V, Lefort S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41851473"},{"title01":"2001-2026: LEUKEMIA celebrates 25 years of tyrosine kinase inhibitors.","title02":"2001-2026: LEUKEMIA celebrates 25 years of tyrosine kinase inhibitors.","journal":"Leukemia","issue":"2026 June; 40(6):1087-1091. doi: 10.1038\/s41375-026-02981-8","author":"Gale RP, Hochhaus A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42174091"},{"title01":"The impact of periconceptional folate on the DNA methylome of acute lymphoblastic leukemia.","title02":"The impact of periconceptional folate on the DNA methylome of acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 June; 40(6):1189-1202. doi: 10.1038\/s41375-026-02866-w","author":"Nickels EM, Morimoto LM, Kang AY, Metayer C, Wiemels JL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41876728"},{"title01":"ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors.","title02":"ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors.","journal":"Leukemia","issue":"2026 June; 40(6):1296-1305. doi: 10.1038\/s41375-026-02965-8","author":"Hochhaus A, le Coutre P, Milojkovic D, Kim DDH, Lim SM, Pavlovsky C, Nguyen T, Nicolini FE, Moiraghi B, Grosicki S, Phu CD, Etienne G, Marco de Lucas F, Ayala Diaz RM, Breccia M, Chuah C, Abi Rached R, Pokhriyal H, Ic A, Schuld P, Pilipovic V, Alisch F, Boquimpani CM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42026180"},{"title01":"Not guilty by association: myelodysplasia-related mutations in AML.","title02":"Not guilty by association: myelodysplasia-related mutations in AML.","journal":"Leukemia","issue":"2026 June; 40(6):1340-1341. doi: 10.1038\/s41375-026-02936-z","author":"Venugopal S, Sekeres MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42020780"},{"title01":"PRMT1 facilitates the tumorigenesis of chronic lymphocytic leukemia by regulating methylation of MAST1.","title02":"PRMT1 facilitates the tumorigenesis of chronic lymphocytic leukemia by regulating methylation of MAST1.","journal":"Leukemia","issue":"2026 June; 40(6):1214-1226. doi: 10.1038\/s41375-026-02935-0","author":"Tian Z, Gao P, Zhang Y, Ma J, Hu X, Wang H, Lu L, Zhang Y, Wang X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41912914"},{"title01":"Genomic fusion breakpoints for DNA-based measurable residual disease monitoring in pediatric acute lymphoblastic leukemia.","title02":"Genomic fusion breakpoints for DNA-based measurable residual disease monitoring in pediatric acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 June; 40(6):1261-1270. doi: 10.1038\/s41375-026-02958-7","author":"Houtman AH, Arfeuille C, Strullu M, Baruchel A, Cave H, Caye-Eude A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42014859"},{"title01":"HDAC8 inhibition targets STAT3-MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute myeloid leukemia.","title02":"HDAC8 inhibition targets STAT3-MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute myeloid leukemia.","journal":"Leukemia","issue":"2026 June; 40(6):1271-1283. doi: 10.1038\/s41375-026-02950-1","author":"Zhang L, Guo W, Fu YH, Wu D, Li M, Chen YC, Tseng CY, Hua WK, Nguyen LXT, He X, Dong H, Zhang L, Zhang B, Li L, Marcucci G, Kuo YH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42014858"},{"title01":"Can natural killer cells cure leukemia?","title02":"Can natural killer cells cure leukemia?","journal":"Leukemia","issue":"2026 June 15. doi: 10.1038\/s41375-026-02992-5. Online ahead of print","author":"Cichocki F, Felices M, Matson AW, Lee MJ, Miller JS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42297917"},{"title01":"Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.","title02":"Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.","journal":"Leukemia","issue":"2026 June 15. doi: 10.1038\/s41375-026-02996-1. Online ahead of print","author":"Lee D, Abu-Shihab Y, Plas K, Nicolet D, Mrozek K, Routbort MJ, Patel KP, Walker CJ, Buss J, Stiff AR, Laganson A, DiNardo CD, Daver NG, Kadia TM, Ravandi F, Carroll AJ, Kolitz JE, Powell BL, Blum WG, Baer MR, Marcucci G, Uy GL, Stock W, Stone RM, Medeiros LJ, Byrd JC, Blachly JS, Bowman RL, Tyner JW, Loghavi S, Eisfeld AK, Miles LA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42297916"},{"title01":"Organelle proteomics reveals novel metabolic vulnerabilities in FLT3-ITD cells.","title02":"Organelle proteomics reveals novel metabolic vulnerabilities in FLT3-ITD cells.","journal":"Leukemia","issue":"2026 June 9. doi: 10.1038\/s41375-026-03000-6. Online ahead of print","author":"Bica V, Pacile AF, Boettcher M, Marano V, Marabitti V, Nazio F, Cortese M, Fischer T, Perfetto L, Mougiakakos D, Massacci G, Sacco F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42265194"},{"title01":"A novel CD7-directed antibody-drug conjugate targeting BCL-XL with potent anti-leukemic activity in T-cell acute lymphoblastic leukemia.","title02":"A novel CD7-directed antibody-drug conjugate targeting BCL-XL with potent anti-leukemic activity in T-cell acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 June 8. doi: 10.1038\/s41375-026-02998-z. Online ahead of print","author":"Oliveira ML, Nuantang K, Hure G, Avila-Avila A, Bresson L, Haumont S, Kostova V, Novak T, Le Toumelin-Braizat G, Guerlesquin J, Demarles D, Merdas M, Cauquil N, Goundiam O, Rocchetti F, Courtade-Gaiani S, Valour D, Zerhouni M, Artus R, Douillet-Michel E, Laurent I, Denis A, Ovreiu A, Duvauchelle B, Ecsedi M, Colland F, Geneste O, Maragno AL, Ghysdael J, Tran Quang C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42260111"},{"title01":"Low-normal immunoglobulin suggests monoclonal B-cell lymphocytosis and constitutional CLL susceptibility: a dual-mechanism analysis.","title02":"Low-normal immunoglobulin suggests monoclonal B-cell lymphocytosis and constitutional CLL susceptibility: a dual-mechanism analysis.","journal":"Leukemia","issue":"2026 June 10. doi: 10.1038\/s41375-026-02987-2. Online ahead of print","author":"Cohen R, Nemet S, Bezalel-Rosenberg S, Asher I, Mahlab-Guri K, Raanani P, Elbirt D, Hofstetter L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42271038"},{"title01":"mRNA vaccination targeting AML1::ETO fusion gene eliminates leukemia cells via activating T cells.","title02":"mRNA vaccination targeting AML1::ETO fusion gene eliminates leukemia cells via activating T cells.","journal":"Leukemia","issue":"2026 June; 40(6):1335-1339. doi: 10.1038\/s41375-026-02940-3","author":"Zhou C, Bian S, Pang J, Bian H, Cheng T, Koyama H, Liu B, Li B, Tse W, Liu S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41963593"},{"title01":"Normal life expectancy after all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia.","title02":"Normal life expectancy after all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia.","journal":"Leukemia","issue":"2026 June 8. doi: 10.1038\/s41375-026-02989-0. Online ahead of print","author":"Piciocchi A, Talone A, Messina M, de Fabritiis P, Marsili G, Sargentini V, Soddu S, Cicconi L, Guarnera L, Divona MD, Musto P, Ferrara F, D'Ardia S, Borlenghi E, Buccisano F, Breccia M, Efficace F, Fazi P, Venditti A, Coco FL, Platzbecker U, Vignetti M, Voso MT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42260109"},{"title01":"[(177)Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trial.","title02":"[(177)Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trial.","journal":"Lancet Oncol","issue":"2026 June; 27(6):699-710. doi: 10.1016\/S1470-2045(26)00108-7","author":"Baudin E, Durand A, Beron A, Smith D, Deandreis D, Taieb D, Ansquer C, Dierickx L, Deshayes E, Hentic O, Moalla S, Menu Y, Lebtahi R, Assenat E, Touchefeu Y, Guimbaud R, Dahan L, Lamartina L, Cheurfa N, Quak E, Bouhier-Leporrier K, Haissaguerre M, Hindie E, Cao CD, Lombard-Bohas C, Jannin A, Walter T, Ducreux M, Chaib S, Hadoux J, Foulon S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42225102"},{"title01":"Functional time in chronic lymphocytic leukaemia.","title02":"Functional time in chronic lymphocytic leukaemia.","journal":"Lancet Haematol","issue":"2026 June; 13(6):e362. doi: 10.1016\/S2352-3026(26)00108-0","author":"Haritha C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42242257"},{"title01":"Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trial.","title02":"Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trial.","journal":"Lancet Haematol","issue":"2026 June; 13(6):e365-e375. doi: 10.1016\/S2352-3026(26)00014-1","author":"Stein A, Wang Y, Malki MMA, Aldoss I, Ali H, Aribi A, Artz A, Ball B, Dandapani S, Farol L, Han C, Liu A, Pullarkat V, Radany E, Sahebi F, Sanchez JF, Sandhu K, Salhotra A, Smith E, Spielberger R, Hui S, Marcucci G, Nakamura R, Forman SJ, Palmer J, Wong J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42150590"},{"title01":"Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial.","title02":"Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial.","journal":"Lancet Haematol","issue":"2026 June 15. doi: 10.1016\/S2352-3026(26)00104-3. Online ahead of print","author":"Peccatori N, Locatelli F, Ammerlaan ACJ, Jiang Y, van der Velden VHJ, Lissat A, Nilsson A, Bielorai B, Moerloose B, Rives S, Rubio-San-Simon A, Dirksen U, Engstler G, Bruno B, Diaz-de-Heredia C, Brethon B, Sirvent FB, Rialland F, Sramkova L, Pasquet M, Nysom K, Bertorello N, Bader P, Buechner J, van der Sluis IM, Beverloo B, Sleight B, Stackelberg AV, Zwaan CM, Brivio E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42296977"},{"title01":"Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML.","title02":"Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML.","journal":"J Clin Oncol","issue":"2026 June 10; 44(17):1648. doi: 10.1200\/JCO-25-02702","author":"Shibusawa M, Tanimoto T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41894645"},{"title01":"From Molecular Complexity to Personalized Care in Chronic Myelomonocytic Leukemia.","title02":"From Molecular Complexity to Personalized Care in Chronic Myelomonocytic Leukemia.","journal":"J Clin Oncol","issue":"2026 June 10; 44(17):1567-1570. doi: 10.1200\/JCO-26-00635","author":"Wiseman DH, Batta K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42096663"},{"title01":"The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE).","title02":"The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE).","journal":"J Clin Oncol","issue":"2026 June 11; 101200JCO2601159. doi: 10.1200\/JCO-26-01159. Online ahead of print","author":"Issa GC, Cuglievan B, El Hajjar G, Jen WY, Bataller A, Short NJ, DiNardo CD, Alvarado Y, Loghavi S, Duose DY, Zhang B, Furudate K, Ning J, Xiao L, Mouhayar E, Pinto A, Bidikian A, Thompson E, Daver N, Garcia-Manero G, Farhat A, McCall D, Kadia TM, Abbas HA, Tan S, Bazinet A, Jabbour E, Montalban-Bravo G, Ravandi F, Takahashi K, Andreeff M, Kantarjian HM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42272166"},{"title01":"Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia.","title02":"Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia.","journal":"J Clin Oncol","issue":"2026 June 10; 44(17):1608-1623. doi: 10.1200\/JCO-25-02116","author":"Lanino L, Hunter AM, Gagelmann N, Robin M, Dall'Olio D, Flamigni A, Sala C, Gurnari C, Wang YH, Pleyer L, Xicoy B, Montalban-Bravo G, Shih LY, Alsugair A, Fathima S, Gregorio C, Rollo C, Palomo L, Platzbecker AS, Asti G, Itzykson R, Sallman DA, Fariselli P, Kern W, Garcia-Manero G, Platzbecker U, Sole F, Diez-Campelo M, Maciejewski J, Bejar R, Thol F, Kroger N, Savona M, Fenaux P, Sanz G, Kordasti S, Santini V, Fontenay M, Zeidan AM, Komrokji RS, Haferlach T, Germing U, Castellani G, D'Amico S, Patnaik M, Ieva F, Solary E, Tefferi A, Padron E, Della Porta MG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41894646"},{"title01":"Reply to: Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML.","title02":"Reply to: Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML.","journal":"J Clin Oncol","issue":"2026 June 10; 44(17):1648-1651. doi: 10.1200\/JCO-26-00338","author":"Montesinos P, Labrador J, Lloret-Madrid P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41894642"},{"title01":"Whole genome sequencing in acute myeloid leukemia.","title02":"Whole genome sequencing in acute myeloid leukemia.","journal":"Haematologica","issue":"2026 June 1; 111(6):1914-1916. doi: 10.3324\/haematol.2026.289418","author":"Haferlach T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42231801"},{"title01":"Blinatumomab and ponatinib with central nervous system treatment intensification for adolescents and young adults with Philadelphia-positive B-cell acute lymphoblastic leukemia.","title02":"Blinatumomab and ponatinib with central nervous system treatment intensification for adolescents and young adults with Philadelphia-positive B-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 June 4. doi: 10.3324\/haematol.2026.301051. Online ahead of print","author":"Aleid M, Altuwayjiri H, Alhumaid M, Marei MA, Hanbali A, Alahmari A, Alkhaldi H, Alotaibi AS, Albanyan O, Ahmed SO, Alzahrani H, Aljurf M, Saad A, Alfayez M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42237786"},{"title01":"Response to Comment on: &#8220;Novel ligand-binding domain truncated CPSF7::RARA::CPSF7 tripartite fusion confers primary ATRA resistance in atypical acute promyelocytic leukemia&#8221;.","title02":"Response to Comment on: &#8220;Novel ligand-binding domain truncated CPSF7::RARA::CPSF7 tripartite fusion confers primary ATRA resistance in atypical acute promyelocytic leukemia&#8221;.","journal":"Haematologica","issue":"2026 May 21. doi: 10.3324\/haematol.2026.301167. Online ahead of print","author":"Dong K, Liu H, Xu Z, Wang H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42163717"},{"title01":"IDH2-mutated acute myeloid leukemia in older adults: prognostic signal is not regimen selection. Comment on: &#8220;IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy&#8221;.","title02":"IDH2-mutated acute myeloid leukemia in older adults: prognostic signal is not regimen selection. Comment on: &#8220;IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy&#8221;.","journal":"Haematologica","issue":"2026 May 21. doi: 10.3324\/haematol.2026.301220. Online ahead of print","author":"Wang Y, Lu J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42163718"},{"title01":"Overcoming metabolic plasticity and microenvironmental rescue when targeting SLC25A1 in acute myeloid leukemia. Comment on: &#8220;SLC25A1 reprograms mitochondrial and fatty acid metabolism to promote the progression of acute myeloid leukemia&#8221;.","title02":"Overcoming metabolic plasticity and microenvironmental rescue when targeting SLC25A1 in acute myeloid leukemia. Comment on: &#8220;SLC25A1 reprograms mitochondrial and fatty acid metabolism to promote the progression of acute myeloid leukemia&#8221;.","journal":"Haematologica","issue":"2026 May 21. doi: 10.3324\/haematol.2026.301161. Online ahead of print","author":"Li R, Liu Z, Wu X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42163769"},{"title01":"On closing the gap: anti-PD-1-based salvage in relapsed\/refractory classical Hodgkin lymphoma. Comment on: &#8220;Mind the gap: anti-PD-1 salvage before autologous transplantation in classical Hodgkin lymphoma&#8221;.","title02":"On closing the gap: anti-PD-1-based salvage in relapsed\/refractory classical Hodgkin lymphoma. Comment on: &#8220;Mind the gap: anti-PD-1 salvage before autologous transplantation in classical Hodgkin lymphoma&#8221;.","journal":"Haematologica","issue":"2026 May 28. doi: 10.3324\/haematol.2026.301234. Online ahead of print","author":"Tharmaseelan H, Von Tresckow B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42206440"},{"title01":"Response to Comment on: &#8220;Is it time to reduce the doxorubicin dosage in Hodgkin lymphoma therapy?&#8221;.","title02":"Response to Comment on: &#8220;Is it time to reduce the doxorubicin dosage in Hodgkin lymphoma therapy?&#8221;.","journal":"Haematologica","issue":"2026 May 28. doi: 10.3324\/haematol.2026.301249. Online ahead of print","author":"Dann EJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42206426"},{"title01":"Orca-T as a force multiplier for HCT immune tolerance.","title02":"Orca-T as a force multiplier for HCT immune tolerance.","journal":"Blood","issue":"2026 May 21; 147(21):2422-2423. doi: 10.1182\/blood.2026033563","author":"Riwes M, Magenau J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42166206"},{"title01":"CD117-targeted HCT preconditioning in AML and MDS.","title02":"CD117-targeted HCT preconditioning in AML and MDS.","journal":"Blood","issue":"2026 May 28; 147(22):2559-2560. doi: 10.1182\/blood.2026033642","author":"Manz MG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42207548"},{"title01":"Ten Years of Hydroxyurea for Ugandan Children with Sickle Cell Anemia.","title02":"Ten Years of Hydroxyurea for Ugandan Children with Sickle Cell Anemia.","journal":"N Engl J Med","issue":"2026 May 28; 394(20):2059-2061. doi: 10.1056\/NEJMc2603063","author":"Ware RE, Opoka RO, Latham T, Kasirye P, Kasembo P, Hume H, Birungi I, Kadde N, Wambaka B, Nakafeero M, Conroy AL, Tomlinson G, Lane A, John C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42202328"},{"title01":"First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.","title02":"First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.","journal":"N Engl J Med","issue":"2026 May 29. doi: 10.1056\/NEJMoa2604461. Online ahead of print","author":"Zhou C, Greillier L, Liu G, John T, Xing L, Kowalski D, Memmott RM, Yazici O, Sun M, Shu C, Pons-Tostivint E, Fan Y, Fernandez-Hinojal G, Shum E, Wang M, Bertolini F, Camidge DR, Zhou C, Doucet L, Hong Q, Fang J, Huang D, Jin B, Yu Y, Antonuzzo L, Moro-Sibilot D, Bennouna J, de Castro G Jr, Zheng L, Heymach JV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42212913"},{"title01":"Autoimmune cytopenias following alemtuzumab-induced renal transplant: clinical features and treatment outcomes.","title02":"Autoimmune cytopenias following alemtuzumab-induced renal transplant: clinical features and treatment outcomes.","journal":"Haematologica","issue":"2026 May 28. doi: 10.3324\/haematol.2025.288549. Online ahead of print","author":"Lucchini E, Kamuriwo L, Gleeson S, Ademokun C, Atta M, Luqmani A, Deplano S, Layton M, Hart A, Sohal M, Okoli S, Vladescu C, Paul D, Saputil R, Szydlo R, Kousios A, Charif R, Cooper N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42206430"},{"title01":"Cold agglutinin disease.","title02":"Cold agglutinin disease.","journal":"Br J Haematol","issue":"2026 May 17. doi: 10.1111\/bjh.70570. Online ahead of print","author":"Berentsen S, Vos JMI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42144314"},{"title01":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.","title02":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.","journal":"Blood advances","issue":"2026 May 26; 10(10):3676-3689. doi: 10.1182\/bloodadvances.2025017519","author":"Gotlib J, Reiter A, Radia DH, Alvarez-Twose I, Deininger MW, George TI, Panse J, Mital A, Pettit KM, Vannucchi AM, Platzbecker U, Hermine O, Elshoury A, Livideanu CB, Mesa R, Ustun C, Triggiani M, Dybedal I, Jurcic JG, Zanotti R, Oh ST, Yacoub A, Hexner EO, Bose P, Lee SG, Sperr WR, Griffiths EA, Butler M, Lubke J, Bidollari I, Lin HM, Rylova S, Dimitrijevic S, Munoz-Gonzalez JI, DeAngelo DJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41604606"},{"title01":"Impact of iron overload on hematopoietic stem cell transplantation in pediatric patients with nonmalignant hematological disorders.","title02":"Impact of iron overload on hematopoietic stem cell transplantation in pediatric patients with nonmalignant hematological disorders.","journal":"Blood advances","issue":"2026 May 26; 10(10):3324-3334. doi: 10.1182\/bloodadvances.2025017942","author":"Gibson NM, Nguyen N, Amaral S, Hsu J, Haney M, Heimbruch KE, Sabulski A, Zurawel A, Davidow KA, Lind KT, Scanlon S, Alva H, Hall L, Bailey LC, Olson TS, Kwiatkowski JL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637630"},{"title01":"Selinexor plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: a multicenter, open-label, phase 1 study.","title02":"Selinexor plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: a multicenter, open-label, phase 1 study.","journal":"Blood advances","issue":"2026 May 26; 10(10):3383-3397. doi: 10.1182\/bloodadvances.2025018706","author":"Ali H, Mohan S, Kishtagari A, Prchal JT, Maher K, Chai Y, Gudi G, Taverna P, Mark T, Tantravahi SK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785311"},{"title01":"Clinical Heterogeneity and Outcome of acquired PRCA: a Multicenter European Study.","title02":"Clinical Heterogeneity and Outcome of acquired PRCA: a Multicenter European Study.","journal":"Blood advances","issue":"2026 May 27. doi: 10.1182\/bloodadvances.2025019525. Online ahead of print","author":"Versino F, Michel M, Vidler J, Payan-Pernia S, Trikha R, Gandhi SA, Gogoi S, Wimalachandra M, Racchi O, Lupo-Stanghellini MT, Giammarco S, Arguello Marina M, Memoli M, Glenthoj A, Merati G, Wickramasinghe YW, Chitharanjan A, Hemmer M, Napolitano M, Jimenez-Jambrina M, Brioschi F, Palma-Vallelano A, Gonzalez-Lopez TJ, Clissa C, Bortolotti M, Pedone GL, Croci GA, Passamonti F, Barcellini W, Kulasekararaj AG, Fattizzo B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42200581"},{"title01":"A retrospective, real-world study of IV iron use to treat iron deficiency anemia during acute infection.","title02":"A retrospective, real-world study of IV iron use to treat iron deficiency anemia during acute infection.","journal":"Blood","issue":"2026 May 21; 147(21):2518-2529. doi: 10.1182\/blood.2025031965","author":"Sohail H, Collins JE, Chan KH, Alamgir MA, Kamran A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592284"},{"title01":"Stag2 dependent chromatin remodeling enforces the erythroid-specific Gata1 cistrome.","title02":"Stag2 dependent chromatin remodeling enforces the erythroid-specific Gata1 cistrome.","journal":"Blood","issue":"2026 May 18. doi: 10.1182\/blood.2025030554. Online ahead of print","author":"Sudunagunta VS, Stewart EM, Chen Y, Yan H, Fernando S, Scoca V, Pantazi J, Deng R, Xu JJ, Mohandas N, Viny AD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42148659"},{"title01":"Thymoma-associated aplastic anemia with concurrent Good syndrome.","title02":"Thymoma-associated aplastic anemia with concurrent Good syndrome.","journal":"Blood","issue":"2026 May 21; 147(21):2554. doi: 10.1182\/blood.2025031953","author":"Holland H, Boothby A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42166196"},{"title01":"Biallelic loss-of-function mutations in BPNT1 cause vitamin B12-dependent megaloblastic anemia.","title02":"Biallelic loss-of-function mutations in BPNT1 cause vitamin B12-dependent megaloblastic anemia.","journal":"Blood","issue":"2026 May 21. doi: 10.1182\/blood.2026033550. Online ahead of print","author":"Zeng YH, Li YH, Yuan RY, Zuo DD, Zheng XS, Xiao WH, Fang MK, Lin BB, Cao CY, Cheng XW, Wang N, Yang T, Luo W, Chen WJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42166360"},{"title01":"L-Carnitine Regulates Regeneration of Human Hematopoietic Stem and Progenitor Cells.","title02":"L-Carnitine Regulates Regeneration of Human Hematopoietic Stem and Progenitor Cells.","journal":"Blood","issue":"2026 May 26. doi: 10.1182\/blood.2025032136. Online ahead of print","author":"Duan H, Wang B, Zheng Y, Lv Y, Lu T, Li H, Li P, Li R, Xie X, Yang Z, Sun G, Zhao X, Yang M, He Y, Xu C, Pu S, Zhang L, Shi J, Jiang E, Cheng T, Hu Z, Cheng H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42189862"},{"title01":"Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS.","title02":"Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS.","journal":"Blood","issue":"2026 May 28; 147(22):2610-2620. doi: 10.1182\/blood.2025031858","author":"Muffly L, Lee CJ, Gandhi A, Varma A, Scott BL, Patel SS, Shiraz P, Youn M, Yanagiba C, Arulprakasam J, Le A, Kwon HS, Long-Boyle J, Shizuru JA, Pang WW, Artz AS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785374"},{"title01":"Stag2 dependent chromatin remodeling enforces the erythroid-specific Gata1 cistrome.","title02":"Stag2 dependent chromatin remodeling enforces the erythroid-specific Gata1 cistrome.","journal":"Blood","issue":"2026 May 18. doi: 10.1182\/blood.2025030554. Online ahead of print","author":"Sudunagunta VS, Stewart EM, Chen Y, Yan H, Fernando S, Scoca V, Pantazi J, Deng R, Xu JJ, Mohandas N, Viny AD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42148659"},{"title01":"CD117-targeted HCT preconditioning in AML and MDS.","title02":"CD117-targeted HCT preconditioning in AML and MDS.","journal":"Blood","issue":"2026 May 28; 147(22):2559-2560. doi: 10.1182\/blood.2026033642","author":"Manz MG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42207548"},{"title01":"From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia.","title02":"From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia.","journal":"Leukemia","issue":"2026 May 22. doi: 10.1038\/s41375-026-02984-5. Online ahead of print","author":"Hochhaus A, Talpaz M, Saglio G, Cortes JE, Hughes T, Apperley J, Hantschel O, Rea D, Schuld P, Kantarjian H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42174092"},{"title01":"Clonal dynamics and therapeutic pressure in myeloproliferative neoplasm with concomitant chronic myeloid leukemia: Potential implications of JAK2-directed therapy and additional mutations.","title02":"Clonal dynamics and therapeutic pressure in myeloproliferative neoplasm with concomitant chronic myeloid leukemia: Potential implications of JAK2-directed therapy and additional mutations.","journal":"Leukemia","issue":"2026 May 29. doi: 10.1038\/s41375-026-02983-6. Online ahead of print","author":"Fujita M, Ureshino H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42215726"},{"title01":"Response to Comment on: &#8220;Clonal megakaryocyte dysplasia with normal blood values: a covert, thrombosis-prone, early myeloproliferative neoplasm.&#8221;.","title02":"Response to Comment on: &#8220;Clonal megakaryocyte dysplasia with normal blood values: a covert, thrombosis-prone, early myeloproliferative neoplasm.&#8221;.","journal":"Haematologica","issue":"2026 May 21. doi: 10.3324\/haematol.2026.301242. Online ahead of print","author":"Barosi G, Rosti V, Malcovati L, Gale RP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42163773"},{"title01":"Low serum cholesterol is a biomarker of advanced disease and poor outcomes in myeloproliferative neoplasms.","title02":"Low serum cholesterol is a biomarker of advanced disease and poor outcomes in myeloproliferative neoplasms.","journal":"Blood advances","issue":"2026 May 26; 10(10):3746-3755. doi: 10.1182\/bloodadvances.2025019152","author":"Leiva O, Soo S, Liu OC, You V, Palmer A, Kahla J, Murtaza Y, Odenike O, Patel A, DeCara J, Dubielecka PM, Petersen M, Lee MH, How J, Hobbs G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779966"},{"title01":"Validation of ICC hierarchical classification in secondary AML.","title02":"Validation of ICC hierarchical classification in secondary AML.","journal":"Blood advances","issue":"2026 May 26; 10(10):3347-3356. doi: 10.1182\/bloodadvances.2025018188","author":"Attardi E, Cipriani M, Guarnera L, Savi A, Fabiani E, Mallegni F, Moretti F, Silvestrini G, Awada H, Durmaz A, Ferrari I, Maggioni G, Memoli M, Visconte V, Venditti A, Della Porta MG, Gurnari C, Piciocchi A, Maciejewski JP, Voso MT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785326"},{"title01":"Chewing the fat: the role of total cholesterol in MPN management.","title02":"Chewing the fat: the role of total cholesterol in MPN management.","journal":"Blood advances","issue":"2026 May 26; 10(10):3744-3745. doi: 10.1182\/bloodadvances.2026020072","author":"Brunner AM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42189565"},{"title01":"Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy for patients with myelofibrosis.","title02":"Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy for patients with myelofibrosis.","journal":"Blood advances","issue":"2026 May 26; 10(10):3543-3553. doi: 10.1182\/bloodadvances.2025018695","author":"Mascarenhas J, Fogliatto L, Green S, Corvalan I, Traer E, Kirito K, Chuah H, Sakatoku K, Hoeg R, Khawandanah M, Lavie D, Hunter Z, Quinn D, Wang Y, Harb J, Zha J, Malyankar U, Ritchie E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41843794"},{"title01":"Dexamethasone prophylaxis for excessive lymphocyte expansion after cilta-cel in multiple myeloma.","title02":"Dexamethasone prophylaxis for excessive lymphocyte expansion after cilta-cel in multiple myeloma.","journal":"Blood advances","issue":"2026 May 26; 10(10):3629-3639. doi: 10.1182\/bloodadvances.2025018639","author":"Forsberg PA, Turner JA, Meyer M, Abbott D, Nicholson S, Schade H, Matous J, Gregory T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41894686"},{"title01":"Anti-BCMA\/GPRC5D CAR T in relapsed or refractory multiple myeloma patients with extraosseous extramedullary disease.","title02":"Anti-BCMA\/GPRC5D CAR T in relapsed or refractory multiple myeloma patients with extraosseous extramedullary disease.","journal":"Blood","issue":"2026 May 21. doi: 10.1182\/blood.2026033506. Online ahead of print","author":"Zhou D, Qi Y, Ma S, Sun Q, Gu W, Xia J, Zhang X, Chen W, Cheng H, Qi K, Zhu F, Xia F, Zhu L, Li H, Zhang H, Yan D, Qiu T, Zhang Y, Peng S, Sang W, Li D, Chang AH, Pan B, Yan Z","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42166352"},{"title01":"Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trial.","title02":"Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trial.","journal":"Lancet Haematol","issue":"2026 May 18. doi: 10.1016\/S2352-3026(26)00014-1. Online ahead of print","author":"Stein A, Wang Y, Malki MMA, Aldoss I, Ali H, Aribi A, Artz A, Ball B, Dandapani S, Farol L, Han C, Liu A, Pullarkat V, Radany E, Sahebi F, Sanchez JF, Sandhu K, Salhotra A, Smith E, Spielberger R, Hui S, Marcucci G, Nakamura R, Forman SJ, Palmer J, Wong J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42150590"},{"title01":"Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4.5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.","title02":"Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4.5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.","journal":"Lancet","issue":"2026 May 16; 407(10542):1953-1967. doi: 10.1016\/S0140-6736(26)00362-4","author":"Dreyling M, Doorduijn J, Gine E, Jerkeman M, Walewski J, Hutchings M, Mey U, Riise J, Trneny M, Vergote VKJ, Shpilberg O, da Silva MG, Leppa S, Jiang L, Stilgenbauer S, Kerkhoff A, Jachimowicz RD, Hess G, Meerten TV, Wirths S, Herhaus P, Novak U, Dierlamm J, Hanel M, Hanoun C, Sonnevi K, Visco C, Donnarumma D, Ferreri AJM, Patti C, Stefani PM, Pott C, Klapper W, Schmidt C, Unterhalt M, Tix T, Ladetto M, Hoster E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42134356"},{"title01":"Is It Time to Move Beyond Graft-Versus-Host Disease-Free, Relapse-Free Survival as a Primary End Point in Clinical Trials for Hematopoietic Cell Transplantation?","title02":"Is It Time to Move Beyond Graft-Versus-Host Disease-Free, Relapse-Free Survival as a Primary End Point in Clinical Trials for Hematopoietic Cell Transplantation?","journal":"J Clin Oncol","issue":"2026 May 20; 44(15):1389-1394. doi: 10.1200\/JCO-25-02130","author":"Kelkar AH, Abel GA, Cutler CS, Lee SJ, Soiffer RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41564387"},{"title01":"Next generation sequencing-based measurable residual disease detection predicts outcomes in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.","title02":"Next generation sequencing-based measurable residual disease detection predicts outcomes in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.","journal":"Haematologica","issue":"2026 May 28. doi: 10.3324\/haematol.2025.300432. Online ahead of print","author":"Krauss SM, Holloway T, Weigert A, Bischof L, Backhaus D, Brauer D, Ussmann J, Franke GN, Vucinic V, Platzbecker U, Schwind S, Jentzsch M, Metzeler KH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42206448"},{"title01":"Umbilical cord-blood transplantation in adults: will it be coming back?","title02":"Umbilical cord-blood transplantation in adults: will it be coming back?","journal":"Haematologica","issue":"2026 May 28. doi: 10.3324\/haematol.2026.301174. Online ahead of print","author":"Shimoni A, Nagler A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42206433"},{"title01":"Allogeneic stem cell transplantation in T-cell prolymphocytic leukemia: final disappointment or a chance for cure?","title02":"Allogeneic stem cell transplantation in T-cell prolymphocytic leukemia: final disappointment or a chance for cure?","journal":"Haematologica","issue":"2026 May 28. doi: 10.3324\/haematol.2026.301173. Online ahead of print","author":"Shumilov E, Schmitz N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42206428"},{"title01":"Unrelated cord blood transplantation and post-transplant cyclophosphamide.","title02":"Unrelated cord blood transplantation and post-transplant cyclophosphamide.","journal":"Haematologica","issue":"2026 May 28. doi: 10.3324\/haematol.2026.300530. Online ahead of print","author":"Chiusolo P, Bacigalupo A, Giammarco S, Metafuni E, Sora' F, Limongiello MA, Frioni F, Di Marino L, Rossi M, Pellegrino C, Valentini CG, Ruggeri A, Teofili L, Sica S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42206422"},{"title01":"Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS.","title02":"Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS.","journal":"Blood","issue":"2026 May 28; 147(22):2610-2620. doi: 10.1182\/blood.2025031858","author":"Muffly L, Lee CJ, Gandhi A, Varma A, Scott BL, Patel SS, Shiraz P, Youn M, Yanagiba C, Arulprakasam J, Le A, Kwon HS, Long-Boyle J, Shizuru JA, Pang WW, Artz AS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785374"},{"title01":"Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.","title02":"Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.","journal":"Blood","issue":"2026 May 21. doi: 10.1182\/blood.2025032829. Online ahead of print","author":"Duployez N, Joudinaud R, Boudry A, Hunault M, Fenwarth L, Tavernier E, Pautas C, Bertoli S, Tavitian S, Raffoux E, Hospital MA, Marchand T, Heiblig M, Chantepie SP, Carre M, Peterlin P, Gallego-Hernanz MP, Guieze R, Simand C, Turlure P, Huynh A, Lemasle E, Gabellier L, Lambert J, Suarez F, Chraibi S, Sanhes L, Celli-Lebras K, Mineur A, Gardin C, Ifrah N, Vey N, Peffault de Latour R, Rigolot L, Luquet I, Penther D, Itzykson RA, Delabesse E, Hamel-Broza JF, de Botton S, Pigneux A, Dombret H, Recher C, Preudhomme C, Dumas PY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42166362"},{"title01":"Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS.","title02":"Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS.","journal":"Blood","issue":"2026 May 28; 147(22):2610-2620. doi: 10.1182\/blood.2025031858","author":"Muffly L, Lee CJ, Gandhi A, Varma A, Scott BL, Patel SS, Shiraz P, Youn M, Yanagiba C, Arulprakasam J, Le A, Kwon HS, Long-Boyle J, Shizuru JA, Pang WW, Artz AS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785374"},{"title01":"Regulatory-like FOXP3+Helios+CD4+ T conventional cells correlate with T-cell activation after Orca-T immunotherapy.","title02":"Regulatory-like FOXP3+Helios+CD4+ T conventional cells correlate with T-cell activation after Orca-T immunotherapy.","journal":"Blood","issue":"2026 May 21; 147(21):2489-2502. doi: 10.1182\/blood.2025031545","author":"Bader CS, Killian S, Iliopoulou BP, Chen PI, Pathak S, Le CT, Villar-Prados A, Ji X, Jensen KP, Negrin RS, Meyer EH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758930"},{"title01":"Hematopoietic Stem-Cell Gene Therapy for Cystinosis. Reply.","title02":"Hematopoietic Stem-Cell Gene Therapy for Cystinosis. Reply.","journal":"N Engl J Med","issue":"2026 May 28; 394(20):2065-2066. doi: 10.1056\/NEJMc2603539","author":"Barshop BA, Ahmed I, Cherqui S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42202332"},{"title01":"Hematopoietic Stem-Cell Gene Therapy for Cystinosis.","title02":"Hematopoietic Stem-Cell Gene Therapy for Cystinosis.","journal":"N Engl J Med","issue":"2026 May 28; 394(20):2065. doi: 10.1056\/NEJMc2603539","author":"Caliment A, Niel O","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42202331"},{"title01":"Hematopoietic Stem-Cell Gene Therapy for Cystinosis.","title02":"Hematopoietic Stem-Cell Gene Therapy for Cystinosis.","journal":"N Engl J Med","issue":"2026 May 28; 394(20):2064-2065. doi: 10.1056\/NEJMc2603539","author":"Kucuk H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42202330"},{"title01":"Resolution of PML after Treatment with Virus-Specific T Cells and HCT.","title02":"Resolution of PML after Treatment with Virus-Specific T Cells and HCT.","journal":"N Engl J Med","issue":"2026 May 28; 394(20):2061-2064. doi: 10.1056\/NEJMc2514186","author":"Gonzalez CE, Fletcher A, Jenkins TL, Zahraeifard S, Peterson R, Taylor M, Jones C, Urban A, Avila D, Campillay M, Wilhelm J, Soldatos A, Kuhle J, Jain P, Corey S, Bergerson JRE, Reich DS, Highfill S, Stroncek D, Dinh A, Pittaluga S, Kong HH, Su HC, Notarangelo LD, Pai SY, Grimley M, Freeman AF, Cortese I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42202329"},{"title01":"Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trial.","title02":"Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trial.","journal":"Lancet Haematol","issue":"2026 May 18. doi: 10.1016\/S2352-3026(26)00014-1. Online ahead of print","author":"Stein A, Wang Y, Malki MMA, Aldoss I, Ali H, Aribi A, Artz A, Ball B, Dandapani S, Farol L, Han C, Liu A, Pullarkat V, Radany E, Sahebi F, Sanchez JF, Sandhu K, Salhotra A, Smith E, Spielberger R, Hui S, Marcucci G, Nakamura R, Forman SJ, Palmer J, Wong J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42150590"},{"title01":"Is It Time to Move Beyond Graft-Versus-Host Disease-Free, Relapse-Free Survival as a Primary End Point in Clinical Trials for Hematopoietic Cell Transplantation?","title02":"Is It Time to Move Beyond Graft-Versus-Host Disease-Free, Relapse-Free Survival as a Primary End Point in Clinical Trials for Hematopoietic Cell Transplantation?","journal":"J Clin Oncol","issue":"2026 May 20; 44(15):1389-1394. doi: 10.1200\/JCO-25-02130","author":"Kelkar AH, Abel GA, Cutler CS, Lee SJ, Soiffer RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41564387"},{"title01":"Next generation sequencing-based measurable residual disease detection predicts outcomes in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.","title02":"Next generation sequencing-based measurable residual disease detection predicts outcomes in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.","journal":"Haematologica","issue":"2026 May 28. doi: 10.3324\/haematol.2025.300432. Online ahead of print","author":"Krauss SM, Holloway T, Weigert A, Bischof L, Backhaus D, Brauer D, Ussmann J, Franke GN, Vucinic V, Platzbecker U, Schwind S, Jentzsch M, Metzeler KH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42206448"},{"title01":"Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in acute myeloid leukemia in first complete remission: CIBMTR analysis.","title02":"Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in acute myeloid leukemia in first complete remission: CIBMTR analysis.","journal":"Haematologica","issue":"2026 May 28. doi: 10.3324\/haematol.2026.300764. Online ahead of print","author":"Tettero JM, Zhang MJ, Liu W, Nawas MT, Milano F, Bejanyan N, Bachanova V, Broglie L, Saber W, Gui G, Dillon LW, Walter RB, Page KM, Hourigan CS, El Chaer F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42206435"},{"title01":"Venetoclax and azacytidine in childhood primary advanced myelodysplastic syndromes, refractory\/relapsed acute myeloid leukemia and therapy-related myeloid neoplasms.","title02":"Venetoclax and azacytidine in childhood primary advanced myelodysplastic syndromes, refractory\/relapsed acute myeloid leukemia and therapy-related myeloid neoplasms.","journal":"Haematologica","issue":"2026 May 21. doi: 10.3324\/haematol.2026.300775. Online ahead of print","author":"Baccelli F, Merli P, Pigazzi M, Buldini B, Becilli M, Girardi K, Paganelli V, Pagano G, Leardini D, Muratore E, Vendemini F, Beneduce G, Tumino M, Saglio F, Sieni E, Mastrodicasa E, Maffeis M, Tambaro FP, Masetti R, Locatelli F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42163725"},{"title01":"Outcomes of an optimized ciclosporin-free haploidentical HSCT protocol in paediatric patients with cerebral adrenoleukodystrophy.","title02":"Outcomes of an optimized ciclosporin-free haploidentical HSCT protocol in paediatric patients with cerebral adrenoleukodystrophy.","journal":"Br J Haematol","issue":"2026 May 18. doi: 10.1111\/bjh.70561. Online ahead of print","author":"Ye F, Fu B, Chen K, Xia X, Li Y, Wang L, Yang H, Deng W, Wang Z, Yang L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42152527"},{"title01":"Long-term outcomes after allogeneic versus autologous haematopoietic stem cell transplantation for T-lymphoblastic lymphoma.","title02":"Long-term outcomes after allogeneic versus autologous haematopoietic stem cell transplantation for T-lymphoblastic lymphoma.","journal":"Br J Haematol","issue":"2026 May 24. doi: 10.1111\/bjh.70581. Online ahead of print","author":"Cheng Q, Zhu Y, Sheng K, Zhou J, You T, Wang Q, Lu Q, Chen J, Wu D, Huang H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42178614"},{"title01":"Transplantation outcomes in patients with Down syndrome-associated acute lymphoblastic leukaemia: Implications for treatment intensity and the use of novel therapies.","title02":"Transplantation outcomes in patients with Down syndrome-associated acute lymphoblastic leukaemia: Implications for treatment intensity and the use of novel therapies.","journal":"Br J Haematol","issue":"2026 May 24. doi: 10.1111\/bjh.70583. Online ahead of print","author":"Ishida H, Okamoto Y, Sakaguchi H, Arai Y, Ueda T, Yamamoto S, Yano M, Yokosuka T, Okada K, Sato M, Karakawa S, Kobayashi R, Kato K, Koh K, Fujiki T, Goi K, Saito S, Takita J, Miyamura T, Koga Y, Yoshida N, Sato A, Hino M, Tabuchi K, Arakawa Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42178886"},{"title01":"Advances in the diagnosis and classification of B-ALL: comparative insights from updated guidelines.","title02":"Advances in the diagnosis and classification of B-ALL: comparative insights from updated guidelines.","journal":"Blood advances","issue":"2026 May 26; 10(10):3640-3652. doi: 10.1182\/bloodadvances.2025017301","author":"Chen X, Yuan L, Ma X, Wang F, Zhang Y, Fang J, Cao P, Wang T, Chen J, Zhou X, Long J, Liu H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41886641"},{"title01":"Refining busulfan exposure enhances pediatric ALL HSCT outcomes: insights from the International FORUM study.","title02":"Refining busulfan exposure enhances pediatric ALL HSCT outcomes: insights from the International FORUM study.","journal":"Blood advances","issue":"2026 May 26; 10(10):3719-3730. doi: 10.1182\/bloodadvances.2025019142","author":"Ben Hassine K, Gloor Y, Dupanloup I, Uppugunduri CRS, Mlakar V, Gonzales F, Gungor T, Ifversen M, Shaw PJ, Buechner J, Truong TH, Bittencourt H, Teague L, Toporski J, Sedlacek P, Poetschger U, Krajinovic M, Kalwak K, Balduzzi A, Algeri M, Bader P, Peters C, Dalle JH, Ansari M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779961"},{"title01":"Deferasirox 6 months after allo-HSCT in AML\/MDS: a prospective propensity-matched study.","title02":"Deferasirox 6 months after allo-HSCT in AML\/MDS: a prospective propensity-matched study.","journal":"Blood advances","issue":"2026 May 26; 10(10):3705-3714. doi: 10.1182\/bloodadvances.2025018894","author":"Buono R, Huynh A, Forcade E, Labussiere H, Ceballos P, Cornillon J, Cabrera Q, D'Aveni M, Robin M, Devillier R, Raus N, Michallet M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41811968"},{"title01":"A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS\/AML including TP53-mutated disease.","title02":"A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS\/AML including TP53-mutated disease.","journal":"Blood advances","issue":"2026 May 20. doi: 10.1182\/bloodadvances.2025019380. Online ahead of print","author":"Naji NS, Ahmedna TS, Zeng X, An Y, Hemani Y, Perkins B, Thompson Z, Nichakawade TD, Wang Y, Lee BS, Watson E, Chatzilygeroudi T, Luo LZ, Paun B, Klausner M, Supeanu TD, Gojo I, Ghiaur G, DeZern AE, Levis MJ, Resar LMS, Jones RJ, Peske JD, Karanika S, Paul S, Karantanos T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42160756"},{"title01":"Pediatric-inspired regimens and HSCT for adolescents and young adults with acute lymphoblastic leukemia.","title02":"Pediatric-inspired regimens and HSCT for adolescents and young adults with acute lymphoblastic leukemia.","journal":"Blood advances","issue":"2026 May 26; 10(10):3664-3675. doi: 10.1182\/bloodadvances.2025018736","author":"Sereda Y, Mai HJ, Kanaan G, Melson JW, Terasawa T, Cheung MC, Stock W, Wolfson JA, Saldanha IJ, Balk EM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610329"},{"title01":"Impact of iron overload on hematopoietic stem cell transplantation in pediatric patients with nonmalignant hematological disorders.","title02":"Impact of iron overload on hematopoietic stem cell transplantation in pediatric patients with nonmalignant hematological disorders.","journal":"Blood advances","issue":"2026 May 26; 10(10):3324-3334. doi: 10.1182\/bloodadvances.2025017942","author":"Gibson NM, Nguyen N, Amaral S, Hsu J, Haney M, Heimbruch KE, Sabulski A, Zurawel A, Davidow KA, Lind KT, Scanlon S, Alva H, Hall L, Bailey LC, Olson TS, Kwiatkowski JL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637630"},{"title01":"Long-term MAPK inhibition of childhood refractory-Langerhans cell histiocytosis: an observational study of 288 patients.","title02":"Long-term MAPK inhibition of childhood refractory-Langerhans cell histiocytosis: an observational study of 288 patients.","journal":"Blood advances","issue":"2026 May 26; 10(10):3733-3743. doi: 10.1182\/bloodadvances.2025018651","author":"Donadieu J, Evseev D, Pegoraro F, Sieni E, Slater O, Hutter C, Astigarraga I, Lehrnbecher T, van den Bos C, Simonin M, Ahlmann M, Barkaoui M, Le Louet S, Chevallier A, Chalard F, Nguyen T, Holzhauer S, Beutel K, Haenicke H, Escherich G, Garcia-Obregon S, Valero-Arrese L, Ruano D, Moreno MA, Habes D, Lacaille F, McLin V, Bomken S, Bishop H, Penn A, Naeije L, Kabbara N, Milne P, Helias-Rodzewicz Z, Kolenova A, Renard C, Berard PM, Thalhammer J, Pagnier A, Salmon A, Aladjidi N, Olivier L, Saultier P, Blanc L, Gandemer V, Schneider P, Hessissen L, Golan M, Elitzur S, Ben Arush M, Lustig DA, Dvir R, Raciborska A, Malas Z, Diallo S, Levy G, Efremova V, Munthe-Kaas MC, von Bahr Greenwood T, Felizzia G, Braier J, Boudiaf H, Ben Fraj I, Svojgr K, Krenova Z, Bernard F, Adam C, Karaoli E, Kristensen IA, Dahl C, Trambusti I, Gaspari S, De Fusco C, Chiaravalli S, Corti P, Todesco A, Papadakis V, Luz I, Costa V, Osipova D, Lyudovskikh E, Maschan M, Bronin G, Burcev E, Idbaih A, Larabi IA, Bellouard M, Alvarez JC, Novosad O, Collin M, Henter JI, Emile JF, Heritier S, Minkov M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41678955"},{"title01":"BCL2 overexpression in donor lymphocytes reduces the risk of graft-versus-host disease.","title02":"BCL2 overexpression in donor lymphocytes reduces the risk of graft-versus-host disease.","journal":"Blood advances","issue":"2026 May 26; 10(10):3572-3586. doi: 10.1182\/bloodadvances.2025017700","author":"Bejarano-Garcia JA, Nufer M, Palacios-Barea MJ, Guijarro-Albaladejo B, Sierro-Martinez B, Bella A, Robles-Benitez C, Garcia-Guerrero E, Carrasco-Brocal I, Lara-Chica M, Sanoja-Flores L, Mendendez NV, Caballero-Velazquez T, Rodriguez-Gil A, Perez-Simon JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41915889"},{"title01":"Baricitinib for refractory chronic graft-versus-host-disease: Results of a phase 1\/2 study.","title02":"Baricitinib for refractory chronic graft-versus-host-disease: Results of a phase 1\/2 study.","journal":"Blood advances","issue":"2026 May 27. doi: 10.1182\/bloodadvances.2025018898. Online ahead of print","author":"Holtzman NG, Im A, Curtis LM, Schulz E, Sharma R, Pirsl F, Berman A, Ostojic A, Magone MT, Cowen EW, Mays JW, Comis LE, Joe G, Peer CJ, Figg WD, Rose JJ, El Jurdi N, Pouzolles M, Hakim FT, Taylor N, Pavletic SZ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42200447"},{"title01":"Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML.","title02":"Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML.","journal":"Blood advances","issue":"2026 May 27. doi: 10.1182\/bloodadvances.2026019841. Online ahead of print","author":"Short NJ, Kantarjian HM, Daver NG, Azevedo RS, Karrar O, DiNardo CD, Kadia TM, Yilmaz M, Maroun MM, Hachem MCR, Borthakur G, Issa GC, Shpall EJ, Popat UR, Huang X, Qiao W, Nasr LF, Macaron W, Abramova R, Garcia-Manero G, Konopleva M, Ravandi F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42200455"},{"title01":"Low serum cholesterol is a biomarker of advanced disease and poor outcomes in myeloproliferative neoplasms.","title02":"Low serum cholesterol is a biomarker of advanced disease and poor outcomes in myeloproliferative neoplasms.","journal":"Blood advances","issue":"2026 May 26; 10(10):3746-3755. doi: 10.1182\/bloodadvances.2025019152","author":"Leiva O, Soo S, Liu OC, You V, Palmer A, Kahla J, Murtaza Y, Odenike O, Patel A, DeCara J, Dubielecka PM, Petersen M, Lee MH, How J, Hobbs G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779966"},{"title01":"Immunologic Dream Team: BiTEs peri-allotransplant to redirect donor lymphocytes towards GVL.","title02":"Immunologic Dream Team: BiTEs peri-allotransplant to redirect donor lymphocytes towards GVL.","journal":"Blood advances","issue":"2026 May 20. doi: 10.1182\/bloodadvances.2026020530. Online ahead of print","author":"Iovino L, Shadman M, Milano F, Gopal AK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42160762"},{"title01":"Regulatory-like FOXP3+Helios+CD4+ T conventional cells correlate with T-cell activation after Orca-T immunotherapy.","title02":"Regulatory-like FOXP3+Helios+CD4+ T conventional cells correlate with T-cell activation after Orca-T immunotherapy.","journal":"Blood","issue":"2026 May 21; 147(21):2489-2502. doi: 10.1182\/blood.2025031545","author":"Bader CS, Killian S, Iliopoulou BP, Chen PI, Pathak S, Le CT, Villar-Prados A, Ji X, Jensen KP, Negrin RS, Meyer EH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758930"},{"title01":"Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS.","title02":"Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS.","journal":"Blood","issue":"2026 May 28; 147(22):2610-2620. doi: 10.1182\/blood.2025031858","author":"Muffly L, Lee CJ, Gandhi A, Varma A, Scott BL, Patel SS, Shiraz P, Youn M, Yanagiba C, Arulprakasam J, Le A, Kwon HS, Long-Boyle J, Shizuru JA, Pang WW, Artz AS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785374"},{"title01":"L-Carnitine Regulates Regeneration of Human Hematopoietic Stem and Progenitor Cells.","title02":"L-Carnitine Regulates Regeneration of Human Hematopoietic Stem and Progenitor Cells.","journal":"Blood","issue":"2026 May 26. doi: 10.1182\/blood.2025032136. Online ahead of print","author":"Duan H, Wang B, Zheng Y, Lv Y, Lu T, Li H, Li P, Li R, Xie X, Yang Z, Sun G, Zhao X, Yang M, He Y, Xu C, Pu S, Zhang L, Shi J, Jiang E, Cheng T, Hu Z, Cheng H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42189862"},{"title01":"Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS.","title02":"Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS.","journal":"Blood","issue":"2026 May 28; 147(22):2610-2620. doi: 10.1182\/blood.2025031858","author":"Muffly L, Lee CJ, Gandhi A, Varma A, Scott BL, Patel SS, Shiraz P, Youn M, Yanagiba C, Arulprakasam J, Le A, Kwon HS, Long-Boyle J, Shizuru JA, Pang WW, Artz AS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785374"},{"title01":"Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.","title02":"Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.","journal":"Blood","issue":"2026 May 21. doi: 10.1182\/blood.2025032829. Online ahead of print","author":"Duployez N, Joudinaud R, Boudry A, Hunault M, Fenwarth L, Tavernier E, Pautas C, Bertoli S, Tavitian S, Raffoux E, Hospital MA, Marchand T, Heiblig M, Chantepie SP, Carre M, Peterlin P, Gallego-Hernanz MP, Guieze R, Simand C, Turlure P, Huynh A, Lemasle E, Gabellier L, Lambert J, Suarez F, Chraibi S, Sanhes L, Celli-Lebras K, Mineur A, Gardin C, Ifrah N, Vey N, Peffault de Latour R, Rigolot L, Luquet I, Penther D, Itzykson RA, Delabesse E, Hamel-Broza JF, de Botton S, Pigneux A, Dombret H, Recher C, Preudhomme C, Dumas PY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42166362"},{"title01":"Autoimmune cytopenias following alemtuzumab-induced renal transplant: clinical features and treatment outcomes.","title02":"Autoimmune cytopenias following alemtuzumab-induced renal transplant: clinical features and treatment outcomes.","journal":"Haematologica","issue":"2026 May 28. doi: 10.3324\/haematol.2025.288549. Online ahead of print","author":"Lucchini E, Kamuriwo L, Gleeson S, Ademokun C, Atta M, Luqmani A, Deplano S, Layton M, Hart A, Sohal M, Okoli S, Vladescu C, Paul D, Saputil R, Szydlo R, Kousios A, Charif R, Cooper N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42206430"},{"title01":"A multicentre randomized open-label phase 2 trial of dexamethasone plus glycyrrhizinate versus dexamethasone in newly diagnosed immune thrombocytopenia.","title02":"A multicentre randomized open-label phase 2 trial of dexamethasone plus glycyrrhizinate versus dexamethasone in newly diagnosed immune thrombocytopenia.","journal":"Br J Haematol","issue":"2026 May 24. doi: 10.1111\/bjh.70574. Online ahead of print","author":"Wang H, Wang R, Yuan C, Bi K, Xiao T, Teng Q, Wang H, Yu J, Hou M, Hou Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42178778"},{"title01":"Can machine learning identify inherited causes of thrombocytopenia? A feasibility study.","title02":"Can machine learning identify inherited causes of thrombocytopenia? A feasibility study.","journal":"Br J Haematol","issue":"2026 May 26. doi: 10.1111\/bjh.70585. Online ahead of print","author":"Gurumurthy G, Kisiel F, Reynolds L, Sutherland M, Thachil J, Grainger J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42189042"},{"title01":"Switching patients with immune thrombocytopenia (ITP) to avatrombopag from other thrombopoietin receptor agonists: The real-world experience of the Spanish ITP Group (GEPTI).","title02":"Switching patients with immune thrombocytopenia (ITP) to avatrombopag from other thrombopoietin receptor agonists: The real-world experience of the Spanish ITP Group (GEPTI).","journal":"Br J Haematol","issue":"2026 May 29. doi: 10.1111\/bjh.70595. Online ahead of print","author":"Pascual-Izquierdo C, Bastida JM, Valcarcel D, Sanchez-Gonzalez B, Mingot-Castellano ME, Canaro-Hirnyk M, Aguilar-Monserrate G, Ortiz-Lopez A, Carbonell S, Garcia-Lazaro S, Martin-Carrizosa A, Alonso-Martinez C, Alcalde-Mellado P, Pedrote-Amador B, Serrasolses-Alemany E, Remezal-Serrano M, Canet-Maldonado M, Gomez-Del-Castillo MD, Lasa-Eguialde M, Garcia-Jaen P, Carrasco-Macedo S, Gonzalez-Gascon-Y-Marin I, Zafra D, Fernandez-Canal C, Piernas-Fontanilla S, Hernandez-Vazquez L, Morales-Espino E, Cobo-Rodriguez T, Martinez-Carballeira D, Gonzalez-Marugan P, Bolanos-Caderon E, Caballero-Navarro G, Revilla-Calvo N, Arquero-Portero T, Cervera M, Rodriguez-Lopez M, Banon-Soria J, Ramirez-Lopez A, Alvarez-Roman MT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42216511"},{"title01":"Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson&#8217;s disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study.","title02":"Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson&#8217;s disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study.","journal":"Lancet","issue":"2026 May 30; 407(10544):2227-2240. doi: 10.1016\/S0140-6736(26)00865-2","author":"Nikolcheva T, Pagano G, Anzures-Cabrera J, Trundell D, Kustermann T, Simuni T, Marek K, Pavese N, Seppi K, Stocchi F, Postuma RB, Pross N, Monnet A, Respondek G, Schlegel V, Boak L, Rutten-Jacobs L, Kerchner GA, Brundin P, Svoboda H, Bonni A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42208564"},{"title01":"Venetoclax and azacytidine in childhood primary advanced myelodysplastic syndromes, refractory\/relapsed acute myeloid leukemia and therapy-related myeloid neoplasms.","title02":"Venetoclax and azacytidine in childhood primary advanced myelodysplastic syndromes, refractory\/relapsed acute myeloid leukemia and therapy-related myeloid neoplasms.","journal":"Haematologica","issue":"2026 May 21. doi: 10.3324\/haematol.2026.300775. Online ahead of print","author":"Baccelli F, Merli P, Pigazzi M, Buldini B, Becilli M, Girardi K, Paganelli V, Pagano G, Leardini D, Muratore E, Vendemini F, Beneduce G, Tumino M, Saglio F, Sieni E, Mastrodicasa E, Maffeis M, Tambaro FP, Masetti R, Locatelli F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42163725"},{"title01":"The true cost of red cell transfusion for patients with myelodysplastic syndromes: A time-driven activity-based costing study.","title02":"The true cost of red cell transfusion for patients with myelodysplastic syndromes: A time-driven activity-based costing study.","journal":"Br J Haematol","issue":"2026 May 21. doi: 10.1111\/bjh.70556. Online ahead of print","author":"Mo A, Haysom H, Carrandi A, de Albornoz SC, Guglielmino J, Rushford K, Ellison A, Andrew D, Jesurajah A, Hu E, Banahene P, Hoo LS, Higgins AM, Shortt J, Wood EM, McQuilten ZK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42167920"},{"title01":"Validation of ICC hierarchical classification in secondary AML.","title02":"Validation of ICC hierarchical classification in secondary AML.","journal":"Blood advances","issue":"2026 May 26; 10(10):3347-3356. doi: 10.1182\/bloodadvances.2025018188","author":"Attardi E, Cipriani M, Guarnera L, Savi A, Fabiani E, Mallegni F, Moretti F, Silvestrini G, Awada H, Durmaz A, Ferrari I, Maggioni G, Memoli M, Visconte V, Venditti A, Della Porta MG, Gurnari C, Piciocchi A, Maciejewski JP, Voso MT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785326"},{"title01":"Deferasirox 6 months after allo-HSCT in AML\/MDS: a prospective propensity-matched study.","title02":"Deferasirox 6 months after allo-HSCT in AML\/MDS: a prospective propensity-matched study.","journal":"Blood advances","issue":"2026 May 26; 10(10):3705-3714. doi: 10.1182\/bloodadvances.2025018894","author":"Buono R, Huynh A, Forcade E, Labussiere H, Ceballos P, Cornillon J, Cabrera Q, D'Aveni M, Robin M, Devillier R, Raus N, Michallet M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41811968"},{"title01":"A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS\/AML including TP53-mutated disease.","title02":"A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS\/AML including TP53-mutated disease.","journal":"Blood advances","issue":"2026 May 20. doi: 10.1182\/bloodadvances.2025019380. Online ahead of print","author":"Naji NS, Ahmedna TS, Zeng X, An Y, Hemani Y, Perkins B, Thompson Z, Nichakawade TD, Wang Y, Lee BS, Watson E, Chatzilygeroudi T, Luo LZ, Paun B, Klausner M, Supeanu TD, Gojo I, Ghiaur G, DeZern AE, Levis MJ, Resar LMS, Jones RJ, Peske JD, Karanika S, Paul S, Karantanos T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42160756"},{"title01":"Interpretable machine learning model using peripheral blood for non-invasive detection of moderate-to-severe myelofibrosis in JAK2 V617F-positive MPNs: A multicentre pilot proof-of-concept study.","title02":"Interpretable machine learning model using peripheral blood for non-invasive detection of moderate-to-severe myelofibrosis in JAK2 V617F-positive MPNs: A multicentre pilot proof-of-concept study.","journal":"Br J Haematol","issue":"2026 May 27. doi: 10.1111\/bjh.70552. Online ahead of print","author":"Hao Z, Song M, Wang H, Yan C, Cao S, Xia J, Zhang M, Zhang X, Feng J, Li S, Li C, Liu S, Wei Y, Ren F, Yang W, Ren H, Huang L, Bian S, Chen X, Wang H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42203504"},{"title01":"Prime time for the use of statins in MPNs: from comorbidity drugs to disease-modifying partners.","title02":"Prime time for the use of statins in MPNs: from comorbidity drugs to disease-modifying partners.","journal":"Blood advances","issue":"2026 May 26; 10(10):3587-3605. doi: 10.1182\/bloodadvances.2026019625","author":"Hasselbalch HC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41747195"},{"title01":"Phase 2 study of the lysine-specific demethylase 1 inhibitor bomedemstat for essential thrombocythemia.","title02":"Phase 2 study of the lysine-specific demethylase 1 inhibitor bomedemstat for essential thrombocythemia.","journal":"Blood advances","issue":"2026 May 26; 10(10):3494-3504. doi: 10.1182\/bloodadvances.2025017575","author":"Gill H, Palandri F, Ross DM, Gothert JR, Cochrane T, Larsen SR, Halpern AB, Shortt J, Rossetti JM, Liang J, Marchetti M, Wilson AJ, Innes AJ, Hanna M, Vianelli N, Stevenson WS, Vannucchi AM, Kleppe M, Flynn J, Natsoulis G, Harrison CN, Rienhoff HY Jr","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758981"},{"title01":"Plasmacytic markers as immunotherapeutic targets for primary CD20-negative aggressive B-cell lymphomas.","title02":"Plasmacytic markers as immunotherapeutic targets for primary CD20-negative aggressive B-cell lymphomas.","journal":"Br J Haematol","issue":"2026 May 21. doi: 10.1111\/bjh.70557. Online ahead of print","author":"Neumann F, Schormann C, Cetin O, Kos IA, Bewarder M, Schwarz EC, Lohse S, Maurer S, Staber PB, Bittenbring JT, Smola S, Christofyllakis K, Hoth M, Thurner L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42163640"},{"title01":"Long-term outcomes after allogeneic versus autologous haematopoietic stem cell transplantation for T-lymphoblastic lymphoma.","title02":"Long-term outcomes after allogeneic versus autologous haematopoietic stem cell transplantation for T-lymphoblastic lymphoma.","journal":"Br J Haematol","issue":"2026 May 24. doi: 10.1111\/bjh.70581. Online ahead of print","author":"Cheng Q, Zhu Y, Sheng K, Zhou J, You T, Wang Q, Lu Q, Chen J, Wu D, Huang H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42178614"},{"title01":"DNMT3A variants are associated with the development of nodal TFH cell lymphoma, angioimmunoblastic-type after solid tumour occurrence.","title02":"DNMT3A variants are associated with the development of nodal TFH cell lymphoma, angioimmunoblastic-type after solid tumour occurrence.","journal":"Br J Haematol","issue":"2026 May 24. doi: 10.1111\/bjh.70576. Online ahead of print","author":"Frutos Diaz-Alejo J, Diaz de la Pinta FJ, Pavia Pascual L, Manso R, Morillo D, Moreno-Delgado M, Garcia-Cosio M, Garcia-Hernandez S, Garcia Fernandez E, Rebollo-Gonzalez M, Rodriguez M, Rodriguez Pinilla SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42178623"},{"title01":"Optical genome mapping improves detection and characterisation of cytogenetic abnormalities in non-Hodgkin lymphomas.","title02":"Optical genome mapping improves detection and characterisation of cytogenetic abnormalities in non-Hodgkin lymphomas.","journal":"Br J Haematol","issue":"2026 May 24. doi: 10.1111\/bjh.70575. Online ahead of print","author":"Fall C, Daudignon A, Valmary-Degano S, Mondet J, Bussot L, Molina L, Chevalier S, Bonneville E, Aubert P, Tondeur S, Legrand C, Gaillard JB, Guermouche H, Emadali A, Carras S, Lefebvre C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42178745"},{"title01":"Atezolizumab for relapsed\/refractory extranodal NK\/T-cell lymphoma: the phase II NCCH1903\/ATTACK trial.","title02":"Atezolizumab for relapsed\/refractory extranodal NK\/T-cell lymphoma: the phase II NCCH1903\/ATTACK trial.","journal":"Blood advances","issue":"2026 May 20. doi: 10.1182\/bloodadvances.2026019929. Online ahead of print","author":"Makita S, Koya J, Suzuki Y, Nishikori M, Fukuhara N, Miyagi Maeshima A, Hirkawa A, Ito Y, Kogure Y, Chiba K, Okada A, Shiraishi Y, Kawashima S, Nagasaka Y, Fujimoto A, Nagai H, Takeuchi K, Kataoka K, Izutsu K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42160759"},{"title01":"Patterns of care and clinical outcomes in systemic peripheral T-cell lymphoma: the LEO-MER prospective cohort study.","title02":"Patterns of care and clinical outcomes in systemic peripheral T-cell lymphoma: the LEO-MER prospective cohort study.","journal":"Blood advances","issue":"2026 May 26; 10(10):3480-3493. doi: 10.1182\/bloodadvances.2025018455","author":"Ruan J, Chen Z, Larson MC, Bennani NN, Allen P, Mou E, Wallace D, Mehta-Shah N, Lossos IS, Malpica Castillo LE, Jaye DL, Vega F, Inghirami G, Pongas G, Akkad N, Casulo C, Martin P, Cohen JB, Habermann TM, Maurer MJ, Leonard JP, Friedberg JW, Kahl B, Cerhan JR, Flowers CR, Feldman AL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41707114"},{"title01":"A phase 1 trial of romidepsin, azacitidine, dexamethasone, and lenalidomide in relapsed or refractory T-cell lymphoma.","title02":"A phase 1 trial of romidepsin, azacitidine, dexamethasone, and lenalidomide in relapsed or refractory T-cell lymphoma.","journal":"Blood advances","issue":"2026 May 26; 10(10):3398-3408. doi: 10.1182\/bloodadvances.2025019186","author":"Gordon MJ, Miljkovic MD, Milhon P, Lakhotia R, Melani C, Johnson K, Bryant B, Pittaluga S, Jaffe ES, Conlon K, Staudt LM, Wilson WH, Roschewski M, Ng S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779512"},{"title01":"Proteogenomic features define subtypes of mantle cell lymphoma.","title02":"Proteogenomic features define subtypes of mantle cell lymphoma.","journal":"Blood advances","issue":"2026 May 26; 10(10):3529-3540. doi: 10.1182\/bloodadvances.2025018701","author":"Yan Y, Chen W, Ge X, Sun J, Yu L, Garcia-Mansfield K, Zhang X, Yu Y, Xiong W, Zou D, An G, Jia Z, Pirrotte P, Li JJ, Yu Z, Hao M, Qiu L, Qi J, Wang L, Yi S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785305"},{"title01":"Dynamic monitoring of circulating cell-free EBV-DNA for risk assessment in early-stage natural killer\/T-cell lymphoma.","title02":"Dynamic monitoring of circulating cell-free EBV-DNA for risk assessment in early-stage natural killer\/T-cell lymphoma.","journal":"Blood advances","issue":"2026 May 26; 10(10):3457-3466. doi: 10.1182\/bloodadvances.2025018855","author":"Chen Z, Huang H, Fang X, Tian Y, Weng H, Gale RP, Zou L, Zhang W, Li Z, Guo H, Ge J, Chen N, Liang Y, Hong H, Lin T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41824796"},{"title01":"Integrated multi-omic profiling reveals two distinct splenic marginal zone lymphoma subgroups with prognostic relevance.","title02":"Integrated multi-omic profiling reveals two distinct splenic marginal zone lymphoma subgroups with prognostic relevance.","journal":"Blood advances","issue":"2026 May 27. doi: 10.1182\/bloodadvances.2025019336. Online ahead of print","author":"Parker H, Mirandari A, Stevens B, Jaramillo-Oquendo C, Duran-Ferrer M, Buermann L, Amarasinghe HE, Thomas J, Carr L, Syeda S, Sakthipakan M, Parry M, Rose-Zerilli MJ, Davis ZA, McIver-Brown NR, Xochelli A, Ennis S, Scarfo L, Ghia P, Kalpadakis C, Pangalis GA, Rossi D, Gaidano G, Wagner SD, Ahearne MJ, Seifert M, Plass C, Weichenhan D, Kimby EK, Sutton LA, Rosenquist R, Amini RM, Ljungstrom V, Pratt G, Forconi F, Stamatopoulos K, Salido M, Ferrer A, Thieblemont C, Hilton LK, Morin RD, Walewska R, Martin-Subero JI, Oscier DG, Oakes CC, Gibson J, Bryant D, Strefford JC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42200578"},{"title01":"On the RAdR in relapsed T-cell lymphoma.","title02":"On the RAdR in relapsed T-cell lymphoma.","journal":"Blood advances","issue":"2026 May 26; 10(10):3435-3436. doi: 10.1182\/bloodadvances.2026019925","author":"Casan JML, Van Der Weyden C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42133365"},{"title01":"Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma.","title02":"Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma.","journal":"Blood advances","issue":"2026 May 26; 10(10):3565-3571. doi: 10.1182\/bloodadvances.2025018267","author":"Baek G, Varma G, Yamshon S, van Besien H, Bartlett NL, Watkins M, Shah HR, Baron K, Merryman RW, Falade AS, Svoboda J, Prischak S, D'Angelo C, Lukowski JD, Advani RH, Yeung AH, Rosenberg M, Voutsinas J, Di M, Lynch R, Poh C, Raghunathan V, Shadman M, Smith S, Till BG, Ujjani C, Diefenbach CS, Gopal AK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41855500"},{"title01":"Early steroid and anakinra use to manage axicabtagene ciloleucel toxicity reduces the total duration of CRS and ICANS.","title02":"Early steroid and anakinra use to manage axicabtagene ciloleucel toxicity reduces the total duration of CRS and ICANS.","journal":"Blood advances","issue":"2026 May 26; 10(10):3313-3323. doi: 10.1182\/bloodadvances.2025019031","author":"Wang WL, Lee D, Cheung E, Jensen A, Rana MS, Goyal A, Hamilton M, Ghalehsari N, Latchford T, Scott B, Mallampet J, Heng E, Khan H, Zarak MS, Lohman C, Sahaf B, Sidana S, Weng WK, Smith M, Bharadwaj S, Frank MJ, Miklos DB, Dahiya S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41855506"},{"title01":"IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.","title02":"IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.","journal":"Blood","issue":"2026 May 29. doi: 10.1182\/blood.2025029956. Online ahead of print","author":"Arribas AJ, Cannas E, Sartori G, Guidetti F, Cascione L, Napoli S, Forestieri G, Fuzio F, Pesenti EDS, Tarantelli C, Spriano F, Zucchetto A, Rossi FM, Bruscaggin A, Rinaldi A, Castro de Moura M, Jovic S, Raimondi A, Bordone Pittau R, Terzi di Bergamo L, Ye X, Stathis A, Ben-David Y, Pan-Hammarstrom Q, Simonetta F, Stussi G, Zucca E, Gattei V, Brown JR, Esteller M, Rossi D, Bertoni F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42213644"},{"title01":"DOT1L Shapes ncPRC1-Target Gene Repression to Maintain Germinal Center B Cell Identity of Diffuse Large B cell Lymphoma.","title02":"DOT1L Shapes ncPRC1-Target Gene Repression to Maintain Germinal Center B Cell Identity of Diffuse Large B cell Lymphoma.","journal":"Blood","issue":"2026 May 29. doi: 10.1182\/blood.2025031615. Online ahead of print","author":"Gobel C, Niccolai R, Gregoricchio S, de Groot MHP, Kneefel SFK, Kreft M, Kuiken HJ, Lieftink C, Eickhoff N, Hoekman L, Bleijerveld O, Zwart W, Beijersbergen RL, van Leeuwen F, Jacobs H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42213647"},{"title01":"Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.","title02":"Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.","journal":"N Engl J Med","issue":"2026 May 29. doi: 10.1056\/NEJMoa2603870. Online ahead of print","author":"Touzeau C, Mina R, Quach H, Hungria V, Bhutani D, Chen W, Kumar S, Chaulagain C, Dimopoulos MA, Bahlis NJ, Maral S, van de Donk NWCJ, Schmidt Filho J, Saja K, Teipel R, Ando M, Roeloffzen W, Annibali O, Augustson B, Botta C, Delforge M, Bourgeois E, Buda G, Hus M, Perrot A, Preis M, Beksac M, Pour L, Farmer S, Nunes M, Oriol A, Melchardt T, Hu Y, Flogegard M, Wang D, Pei L, Wroblewski S, Aries IM, Quijano Carde NA, Perova T, de Jager T, Yeh TM, Vanquickelberghe V, Shah P, Chastain K, Kobos R, Carson R, Landgren O","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42212933"},{"title01":"Redefining Early Relapse in Multiple Myeloma &#8211; Time to Change the Rules.","title02":"Redefining Early Relapse in Multiple Myeloma &#8211; Time to Change the Rules.","journal":"N Engl J Med","issue":"2026 May 29. doi: 10.1056\/NEJMe2605404. Online ahead of print","author":"Mateos MV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42212941"},{"title01":"Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1.","title02":"Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1.","journal":"J Clin Oncol","issue":"2026 May 20; 101200JCO2601139. doi: 10.1200\/JCO-26-01139. Online ahead of print","author":"Banerjee R, Cheung MC, Derman B, Messersmith H, Al Hadidi S, Bhella S, Chmielewski C, Ebraheem MS, Kennedy CT, Kumar S, Langerak A, Lipe B, Mian H, Riva E, Seth R, Subramanian L, Usmani SZ, Wildes TM, Zanwar S, Zhuo Y, Hicks LK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42160714"},{"title01":"Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.","title02":"Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.","journal":"J Clin Oncol","issue":"2026 May 21; JCO2502957. doi: 10.1200\/JCO-25-02957. Online ahead of print","author":"Jin JX, Ginde VR, Huhn S, Reichert P, Bertsch U, Fenk R, Besemer B, Boquoi A, Schroers R, von Metzler I, Hanel M, Mann C, Leypoldt LB, Heilmeier B, Scheid C, Peters-Regehr T, Blau IW, Muller-Tidow C, Luntz S, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Muller M, Shumilov E, Knauf W, Michel CS, Geer T, Riesenberg H, Lutz C, Raab MS, Weinhold N, Hoffmann M, Benner A, Findeisen P, Weisel KC, Salwender HJ, Mai EK, Goldschmidt H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42166704"},{"title01":"[(18)F]Fluorodeoxyglucose-PET\/MRI-based response assessment following BCMA-directed CAR-T-cell therapy with ciltacabtagene autoleucel in relapsed\/refractory multiple myeloma.","title02":"[(18)F]Fluorodeoxyglucose-PET\/MRI-based response assessment following BCMA-directed CAR-T-cell therapy with ciltacabtagene autoleucel in relapsed\/refractory multiple myeloma.","journal":"Haematologica","issue":"2026 May 21. doi: 10.3324\/haematol.2026.300672. Online ahead of print","author":"Teipel R, Trautmann-Grill K, Kleditsch L, Epp K, Bottcher S, Rollig C, Weidner H, Gottschalk A, Glauche I, Brogsitter C, Platzek I, Apolle R, Bonin MV, Bornhauser M, Winzer R, Miederer M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42163771"},{"title01":"A phase I\/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma.","title02":"A phase I\/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma.","journal":"Haematologica","issue":"2026 May 28. doi: 10.3324\/haematol.2026.300897. Online ahead of print","author":"Nadeem O, Redd RA, Barth PM, Bayliss TJ, Laubach JP, Bianchi G, Mo CC, Reagan JL, Midha S, Sperling AS, Liu Y, Hartley-Brown MA, Chuma MP, Nicholson T, Benjamin EJ, Distaso A, Regan E, Hof AMV, Dahill AJ, Goldbaum R, Mohammadi K, Lewis A, Poda R, Munshi NC, Anderson KC, Ghobrial IM, Richardson PG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42206445"},{"title01":"The challenge of defining and understanding monoclonal gammopathy of undetermined significance.","title02":"The challenge of defining and understanding monoclonal gammopathy of undetermined significance.","journal":"Br J Haematol","issue":"2026 May 18. doi: 10.1111\/bjh.70539. Online ahead of print","author":"Haslam A, Ramasamy K, Bunce C, Kristinsson SY, Pratt G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42150882"},{"title01":"Elevated desmoglein-2 expression in multiple myeloma is a prognostic marker across genomic subtypes with impact on high-risk cytogenetics and a distinct gene expression profile.","title02":"Elevated desmoglein-2 expression in multiple myeloma is a prognostic marker across genomic subtypes with impact on high-risk cytogenetics and a distinct gene expression profile.","journal":"Br J Haematol","issue":"2026 May 18. doi: 10.1111\/bjh.70554. Online ahead of print","author":"McClure BJ, Toubia J, Toomes CEJ, Best OG, Yong A, Lee CH, Bonder CS, Kok CH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42150891"},{"title01":"Recognising disease progression in MGUS and smouldering myeloma: Biomarkers, symptom monitoring and imaging.","title02":"Recognising disease progression in MGUS and smouldering myeloma: Biomarkers, symptom monitoring and imaging.","journal":"Br J Haematol","issue":"2026 May 20. doi: 10.1111\/bjh.70492. Online ahead of print","author":"Haslam A, Iqbal G, Drayson M, Pratt G, Yong K, Dunn J, Atkin C, Bunce C, Howe D, Bowcock S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42162568"},{"title01":"Treatment-specific differences in soluble B-cell maturation antigen levels at minimum residual disease negativity in multiple myeloma.","title02":"Treatment-specific differences in soluble B-cell maturation antigen levels at minimum residual disease negativity in multiple myeloma.","journal":"Br J Haematol","issue":"2026 May 24. doi: 10.1111\/bjh.70555. Online ahead of print","author":"Toho M, Tabata R, Shima K, Terunuma D, Nagao K, Fukuda N, Sakuma H, Fujii F, Uehara A, Narita K, Takeuchi M, Ikeda D, Takamatsu H, Matsue K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42178924"},{"title01":"Long-term outcomes after allogeneic versus autologous haematopoietic stem cell transplantation for T-lymphoblastic lymphoma.","title02":"Long-term outcomes after allogeneic versus autologous haematopoietic stem cell transplantation for T-lymphoblastic lymphoma.","journal":"Br J Haematol","issue":"2026 May 24. doi: 10.1111\/bjh.70581. Online ahead of print","author":"Cheng Q, Zhu Y, Sheng K, Zhou J, You T, Wang Q, Lu Q, Chen J, Wu D, Huang H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42178614"},{"title01":"Transplantation outcomes in patients with Down syndrome-associated acute lymphoblastic leukaemia: Implications for treatment intensity and the use of novel therapies.","title02":"Transplantation outcomes in patients with Down syndrome-associated acute lymphoblastic leukaemia: Implications for treatment intensity and the use of novel therapies.","journal":"Br J Haematol","issue":"2026 May 24. doi: 10.1111\/bjh.70583. Online ahead of print","author":"Ishida H, Okamoto Y, Sakaguchi H, Arai Y, Ueda T, Yamamoto S, Yano M, Yokosuka T, Okada K, Sato M, Karakawa S, Kobayashi R, Kato K, Koh K, Fujiki T, Goi K, Saito S, Takita J, Miyamura T, Koga Y, Yoshida N, Sato A, Hino M, Tabuchi K, Arakawa Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42178886"},{"title01":"Outcomes of an optimized ciclosporin-free haploidentical HSCT protocol in paediatric patients with cerebral adrenoleukodystrophy.","title02":"Outcomes of an optimized ciclosporin-free haploidentical HSCT protocol in paediatric patients with cerebral adrenoleukodystrophy.","journal":"Br J Haematol","issue":"2026 May 18. doi: 10.1111\/bjh.70561. Online ahead of print","author":"Ye F, Fu B, Chen K, Xia X, Li Y, Wang L, Yang H, Deng W, Wang Z, Yang L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42152527"},{"title01":"Advances in the diagnosis and classification of B-ALL: comparative insights from updated guidelines.","title02":"Advances in the diagnosis and classification of B-ALL: comparative insights from updated guidelines.","journal":"Blood advances","issue":"2026 May 26; 10(10):3640-3652. doi: 10.1182\/bloodadvances.2025017301","author":"Chen X, Yuan L, Ma X, Wang F, Zhang Y, Fang J, Cao P, Wang T, Chen J, Zhou X, Long J, Liu H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41886641"},{"title01":"BCL2 overexpression in donor lymphocytes reduces the risk of graft-versus-host disease.","title02":"BCL2 overexpression in donor lymphocytes reduces the risk of graft-versus-host disease.","journal":"Blood advances","issue":"2026 May 26; 10(10):3572-3586. doi: 10.1182\/bloodadvances.2025017700","author":"Bejarano-Garcia JA, Nufer M, Palacios-Barea MJ, Guijarro-Albaladejo B, Sierro-Martinez B, Bella A, Robles-Benitez C, Garcia-Guerrero E, Carrasco-Brocal I, Lara-Chica M, Sanoja-Flores L, Mendendez NV, Caballero-Velazquez T, Rodriguez-Gil A, Perez-Simon JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41915889"},{"title01":"Impact of iron overload on hematopoietic stem cell transplantation in pediatric patients with nonmalignant hematological disorders.","title02":"Impact of iron overload on hematopoietic stem cell transplantation in pediatric patients with nonmalignant hematological disorders.","journal":"Blood advances","issue":"2026 May 26; 10(10):3324-3334. doi: 10.1182\/bloodadvances.2025017942","author":"Gibson NM, Nguyen N, Amaral S, Hsu J, Haney M, Heimbruch KE, Sabulski A, Zurawel A, Davidow KA, Lind KT, Scanlon S, Alva H, Hall L, Bailey LC, Olson TS, Kwiatkowski JL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637630"},{"title01":"Pediatric-inspired regimens and HSCT for adolescents and young adults with acute lymphoblastic leukemia.","title02":"Pediatric-inspired regimens and HSCT for adolescents and young adults with acute lymphoblastic leukemia.","journal":"Blood advances","issue":"2026 May 26; 10(10):3664-3675. doi: 10.1182\/bloodadvances.2025018736","author":"Sereda Y, Mai HJ, Kanaan G, Melson JW, Terasawa T, Cheung MC, Stock W, Wolfson JA, Saldanha IJ, Balk EM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610329"},{"title01":"Patterns of care and clinical outcomes in systemic peripheral T-cell lymphoma: the LEO-MER prospective cohort study.","title02":"Patterns of care and clinical outcomes in systemic peripheral T-cell lymphoma: the LEO-MER prospective cohort study.","journal":"Blood advances","issue":"2026 May 26; 10(10):3480-3493. doi: 10.1182\/bloodadvances.2025018455","author":"Ruan J, Chen Z, Larson MC, Bennani NN, Allen P, Mou E, Wallace D, Mehta-Shah N, Lossos IS, Malpica Castillo LE, Jaye DL, Vega F, Inghirami G, Pongas G, Akkad N, Casulo C, Martin P, Cohen JB, Habermann TM, Maurer MJ, Leonard JP, Friedberg JW, Kahl B, Cerhan JR, Flowers CR, Feldman AL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41707114"},{"title01":"Immunologic Dream Team: BiTEs peri-allotransplant to redirect donor lymphocytes towards GVL.","title02":"Immunologic Dream Team: BiTEs peri-allotransplant to redirect donor lymphocytes towards GVL.","journal":"Blood advances","issue":"2026 May 20. doi: 10.1182\/bloodadvances.2026020530. Online ahead of print","author":"Iovino L, Shadman M, Milano F, Gopal AK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42160762"},{"title01":"Total body irradiation and smoking interact to increase lung cancer risk after blood or marrow transplantation.","title02":"Total body irradiation and smoking interact to increase lung cancer risk after blood or marrow transplantation.","journal":"Blood advances","issue":"2026 May 26; 10(10):3371-3382. doi: 10.1182\/bloodadvances.2025019391","author":"Balas N, Chen Y, Meng Q, Hageman L, Landier W, Richman J, Bosworth A, Wong FL, Bhatia R, Weisdorf DJ, Armenian SH, Bhatia S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41843797"},{"title01":"Deferasirox 6 months after allo-HSCT in AML\/MDS: a prospective propensity-matched study.","title02":"Deferasirox 6 months after allo-HSCT in AML\/MDS: a prospective propensity-matched study.","journal":"Blood advances","issue":"2026 May 26; 10(10):3705-3714. doi: 10.1182\/bloodadvances.2025018894","author":"Buono R, Huynh A, Forcade E, Labussiere H, Ceballos P, Cornillon J, Cabrera Q, D'Aveni M, Robin M, Devillier R, Raus N, Michallet M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41811968"},{"title01":"Baricitinib for refractory chronic graft-versus-host-disease: Results of a phase 1\/2 study.","title02":"Baricitinib for refractory chronic graft-versus-host-disease: Results of a phase 1\/2 study.","journal":"Blood advances","issue":"2026 May 27. doi: 10.1182\/bloodadvances.2025018898. Online ahead of print","author":"Holtzman NG, Im A, Curtis LM, Schulz E, Sharma R, Pirsl F, Berman A, Ostojic A, Magone MT, Cowen EW, Mays JW, Comis LE, Joe G, Peer CJ, Figg WD, Rose JJ, El Jurdi N, Pouzolles M, Hakim FT, Taylor N, Pavletic SZ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42200447"},{"title01":"Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML.","title02":"Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML.","journal":"Blood advances","issue":"2026 May 27. doi: 10.1182\/bloodadvances.2026019841. Online ahead of print","author":"Short NJ, Kantarjian HM, Daver NG, Azevedo RS, Karrar O, DiNardo CD, Kadia TM, Yilmaz M, Maroun MM, Hachem MCR, Borthakur G, Issa GC, Shpall EJ, Popat UR, Huang X, Qiao W, Nasr LF, Macaron W, Abramova R, Garcia-Manero G, Konopleva M, Ravandi F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42200455"},{"title01":"Refining busulfan exposure enhances pediatric ALL HSCT outcomes: insights from the International FORUM study.","title02":"Refining busulfan exposure enhances pediatric ALL HSCT outcomes: insights from the International FORUM study.","journal":"Blood advances","issue":"2026 May 26; 10(10):3719-3730. doi: 10.1182\/bloodadvances.2025019142","author":"Ben Hassine K, Gloor Y, Dupanloup I, Uppugunduri CRS, Mlakar V, Gonzales F, Gungor T, Ifversen M, Shaw PJ, Buechner J, Truong TH, Bittencourt H, Teague L, Toporski J, Sedlacek P, Poetschger U, Krajinovic M, Kalwak K, Balduzzi A, Algeri M, Bader P, Peters C, Dalle JH, Ansari M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779961"},{"title01":"Long-term MAPK inhibition of childhood refractory-Langerhans cell histiocytosis: an observational study of 288 patients.","title02":"Long-term MAPK inhibition of childhood refractory-Langerhans cell histiocytosis: an observational study of 288 patients.","journal":"Blood advances","issue":"2026 May 26; 10(10):3733-3743. doi: 10.1182\/bloodadvances.2025018651","author":"Donadieu J, Evseev D, Pegoraro F, Sieni E, Slater O, Hutter C, Astigarraga I, Lehrnbecher T, van den Bos C, Simonin M, Ahlmann M, Barkaoui M, Le Louet S, Chevallier A, Chalard F, Nguyen T, Holzhauer S, Beutel K, Haenicke H, Escherich G, Garcia-Obregon S, Valero-Arrese L, Ruano D, Moreno MA, Habes D, Lacaille F, McLin V, Bomken S, Bishop H, Penn A, Naeije L, Kabbara N, Milne P, Helias-Rodzewicz Z, Kolenova A, Renard C, Berard PM, Thalhammer J, Pagnier A, Salmon A, Aladjidi N, Olivier L, Saultier P, Blanc L, Gandemer V, Schneider P, Hessissen L, Golan M, Elitzur S, Ben Arush M, Lustig DA, Dvir R, Raciborska A, Malas Z, Diallo S, Levy G, Efremova V, Munthe-Kaas MC, von Bahr Greenwood T, Felizzia G, Braier J, Boudiaf H, Ben Fraj I, Svojgr K, Krenova Z, Bernard F, Adam C, Karaoli E, Kristensen IA, Dahl C, Trambusti I, Gaspari S, De Fusco C, Chiaravalli S, Corti P, Todesco A, Papadakis V, Luz I, Costa V, Osipova D, Lyudovskikh E, Maschan M, Bronin G, Burcev E, Idbaih A, Larabi IA, Bellouard M, Alvarez JC, Novosad O, Collin M, Henter JI, Emile JF, Heritier S, Minkov M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41678955"},{"title01":"Immunologic Dream Team: BiTEs peri-allotransplant to redirect donor lymphocytes towards GVL.","title02":"Immunologic Dream Team: BiTEs peri-allotransplant to redirect donor lymphocytes towards GVL.","journal":"Blood advances","issue":"2026 May 20. doi: 10.1182\/bloodadvances.2026020530. Online ahead of print","author":"Iovino L, Shadman M, Milano F, Gopal AK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42160762"},{"title01":"Deferasirox 6 months after allo-HSCT in AML\/MDS: a prospective propensity-matched study.","title02":"Deferasirox 6 months after allo-HSCT in AML\/MDS: a prospective propensity-matched study.","journal":"Blood advances","issue":"2026 May 26; 10(10):3705-3714. doi: 10.1182\/bloodadvances.2025018894","author":"Buono R, Huynh A, Forcade E, Labussiere H, Ceballos P, Cornillon J, Cabrera Q, D'Aveni M, Robin M, Devillier R, Raus N, Michallet M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41811968"},{"title01":"No overall increased risk of death in individuals with sickle cell trait: a study of 467 779 general population adults.","title02":"No overall increased risk of death in individuals with sickle cell trait: a study of 467 779 general population adults.","journal":"Blood","issue":"2026 May 21. doi: 10.1182\/blood.2025031872. Online ahead of print","author":"Warny M, Glenthoj A, Afzal S, Wei S, Petersen JB, Helby J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42166355"},{"title01":"CD117-targeted HCT preconditioning in AML and MDS.","title02":"CD117-targeted HCT preconditioning in AML and MDS.","journal":"Blood","issue":"2026 May 28; 147(22):2559-2560. doi: 10.1182\/blood.2026033642","author":"Manz MG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42207548"},{"title01":"A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS\/AML including TP53-mutated disease.","title02":"A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS\/AML including TP53-mutated disease.","journal":"Blood advances","issue":"2026 May 20. doi: 10.1182\/bloodadvances.2025019380. Online ahead of print","author":"Naji NS, Ahmedna TS, Zeng X, An Y, Hemani Y, Perkins B, Thompson Z, Nichakawade TD, Wang Y, Lee BS, Watson E, Chatzilygeroudi T, Luo LZ, Paun B, Klausner M, Supeanu TD, Gojo I, Ghiaur G, DeZern AE, Levis MJ, Resar LMS, Jones RJ, Peske JD, Karanika S, Paul S, Karantanos T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42160756"},{"title01":"Morphologic and flow cytometric features of menin inhibitor-induced pseudoprogression in KMT2A-rearranged acute myeloid leukemia.","title02":"Morphologic and flow cytometric features of menin inhibitor-induced pseudoprogression in KMT2A-rearranged acute myeloid leukemia.","journal":"Blood","issue":"2026 May 28; 147(22):2697. doi: 10.1182\/blood.2025033039","author":"Helman SR, Stonestrom AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42207547"},{"title01":"CD117-targeted HCT preconditioning in AML and MDS.","title02":"CD117-targeted HCT preconditioning in AML and MDS.","journal":"Blood","issue":"2026 May 28; 147(22):2559-2560. doi: 10.1182\/blood.2026033642","author":"Manz MG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42207548"},{"title01":"The fetal specific gene LIN28B is essential for human fetal B-lymphopoiesis and initiation of KMT2A::AFF1 infant leukemia.","title02":"The fetal specific gene LIN28B is essential for human fetal B-lymphopoiesis and initiation of KMT2A::AFF1 infant leukemia.","journal":"Blood","issue":"2026 May 29. doi: 10.1182\/blood.2025028877. Online ahead of print","author":"Ling RE, Welsh AM, Hamer L, Jackson T, Neil E, Elliott N, Cross JW, Wuppalapati AS, Smith AL, Chahrour C, Sevim O, Palmer DA, Bozhilov Y, Brown EJ, Olender L, Iskander D, Wang G, Rice S, O'Byrne S, Harman J, Ancliff P, Psaila B, Wilkinson AC, Morgan RG, Roberts IA, Milne TA, Roy A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42213620"},{"title01":"The GATA1 N terminus coordinates metabolic reprogramming in erythropoiesis.","title02":"The GATA1 N terminus coordinates metabolic reprogramming in erythropoiesis.","journal":"Blood","issue":"2026 May 28; 147(22):2666-2681. doi: 10.1182\/blood.2025030464","author":"Ling T, Bezavada L, Mehmood R, Zhang K, Cotton A, Crawford JC, Jin H, Sona S, Li L, Ju Y, Han L, Liu N, Tran T, Vu HS, Jin Y, Zhai J, Pruett-Miller SM, Bhoopalan SV, Xu J, Ni M, Crispino JD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587073"},{"title01":"Mutant IDH1 blocks neutropoiesis by repressing myeloid progenitor programs.","title02":"Mutant IDH1 blocks neutropoiesis by repressing myeloid progenitor programs.","journal":"Blood","issue":"2026 May 26. doi: 10.1182\/blood.2025031268. Online ahead of print","author":"Hakobyan M, Langstein J, Ramos Medina MJ, Kleinert E, Schonung M, Hartmann M, Rohdjess H, Wojtarowicz J, Staeble S, Ture M, Pobiedonoscew Y, Claus R, Bullinger L, Oakes CC, Zoldan K, Cross M, Platzbecker U, Kneisel N, Raffel S, Germing U, Hoermann G, Haas S, Rippe K, Frohling S, Pusch S, Plass C, Milsom MD, Lipka DB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42200677"},{"title01":"Venetoclax Plus Pediatric Regimen in Adolescents and Adults with Ph-Negative Acute Lymphoblastic Leukemia.","title02":"Venetoclax Plus Pediatric Regimen in Adolescents and Adults with Ph-Negative Acute Lymphoblastic Leukemia.","journal":"Blood","issue":"2026 May 21. doi: 10.1182\/blood.2026033577. Online ahead of print","author":"Gong X, Liu Y, Fang Q, Gu R, Liu K, Lin D, Zhou C, Zhang G, Gong B, Wei S, Li Y, Li S, Wang Y, Qiu S, Liu B, Wang Y, Mi Y, Wei H, Wang J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42166560"},{"title01":"Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.","title02":"Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.","journal":"Blood","issue":"2026 May 21. doi: 10.1182\/blood.2025032829. Online ahead of print","author":"Duployez N, Joudinaud R, Boudry A, Hunault M, Fenwarth L, Tavernier E, Pautas C, Bertoli S, Tavitian S, Raffoux E, Hospital MA, Marchand T, Heiblig M, Chantepie SP, Carre M, Peterlin P, Gallego-Hernanz MP, Guieze R, Simand C, Turlure P, Huynh A, Lemasle E, Gabellier L, Lambert J, Suarez F, Chraibi S, Sanhes L, Celli-Lebras K, Mineur A, Gardin C, Ifrah N, Vey N, Peffault de Latour R, Rigolot L, Luquet I, Penther D, Itzykson RA, Delabesse E, Hamel-Broza JF, de Botton S, Pigneux A, Dombret H, Recher C, Preudhomme C, Dumas PY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42166362"},{"title01":"Chromosome 5q deletion drives evolution of aneuploidy in myeloid neoplasms with complex karyotype.","title02":"Chromosome 5q deletion drives evolution of aneuploidy in myeloid neoplasms with complex karyotype.","journal":"Blood","issue":"2026 May 21. doi: 10.1182\/blood.2025031996. Online ahead of print","author":"Creamer JP 4th, Ray S, Stewart S, Gulsuner S, Saliba AN, Wu J, Huang FY, Leppa AM, Wang B, Abbas HA, Abkowitz JL, Appelbaum JS, Kaufmann SH, Becker PS, Trumpp A, Jobanputra V, Fang M, Swisher EM, Doulatov S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42166356"},{"title01":"High-dimensional spatiotemporal single-cell atlas and 3D imaging of the bone marrow microenvironment during CML progression.","title02":"High-dimensional spatiotemporal single-cell atlas and 3D imaging of the bone marrow microenvironment during CML progression.","journal":"Blood","issue":"2026 May 28; 147(22):2648-2665. doi: 10.1182\/blood.2025029824","author":"Li L, Rottmann I, Saeed BR, Ivison G, Wei H, Schroeder JC, Dunkel G, Greif K, Zhang Y, Makky A, Ochsenbein AF, Riether C, Goltsev Y, Nolan GP, Mayer AT, Weigelin B, Schurch CM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592325"},{"title01":"TCF3::HLF drives fatal B-ALL thriving on inflammation.","title02":"TCF3::HLF drives fatal B-ALL thriving on inflammation.","journal":"Blood","issue":"2026 May 21; 147(21):2420-2422. doi: 10.1182\/blood.2026033558","author":"Leveille E, Muschen M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42166200"},{"title01":"Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study.","title02":"Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study.","journal":"Blood","issue":"2026 May 19. doi: 10.1182\/blood.2026033559. Online ahead of print","author":"Muffly L, Frey NV, Roloff GW, Park JH, Dholaria B, Advani AS, Bachanova V, Cassaday RD, Daunov M, Dykes KC, Irizarry Gatell V, Grunwald MR, Hilal T, Hill LC, Jamy O, Kota VK, Kumaran M, Lin C, Logan AC, Luskin MR, O'Dwyer KM, Oliai C, Oluwole OO, Sasine JP, Schwartz MS, Solh MM, Stock W, Tsai SB, Ulrickson ML, Vasu S, Wang ES, Yalniz FF, Strickland SA, Leonard JT, Shah BD, Aldoss I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42154904"},{"title01":"Inhibition of the Atypical Kinase WNK1 as a Therapeutic Strategy in TAL-related T-cell Acute Lymphoblastic Leukemia.","title02":"Inhibition of the Atypical Kinase WNK1 as a Therapeutic Strategy in TAL-related T-cell Acute Lymphoblastic Leukemia.","journal":"Blood","issue":"2026 May 19. doi: 10.1182\/blood.2025029901. Online ahead of print","author":"Montanaro A, Monica G, Zamponi R, D'Antuono A, Andreani A, Andrei P, Su A, Ciringione A, Sammarelli G, Todaro G, Rosati R, La Starza R, Mecucci C, Elia L, Gherli A, Vento F, Simoncini E, Lorusso B, Lagastra CAM, Giaimo M, Pagliaro L, Marchesini M, Jimenez CR, Quaini F, Stegmaier K, Roti G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42154791"},{"title01":"Stag2 dependent chromatin remodeling enforces the erythroid-specific Gata1 cistrome.","title02":"Stag2 dependent chromatin remodeling enforces the erythroid-specific Gata1 cistrome.","journal":"Blood","issue":"2026 May 18. doi: 10.1182\/blood.2025030554. Online ahead of print","author":"Sudunagunta VS, Stewart EM, Chen Y, Yan H, Fernando S, Scoca V, Pantazi J, Deng R, Xu JJ, Mohandas N, Viny AD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42148659"},{"title01":"Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS.","title02":"Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS.","journal":"Blood","issue":"2026 May 28; 147(22):2610-2620. doi: 10.1182\/blood.2025031858","author":"Muffly L, Lee CJ, Gandhi A, Varma A, Scott BL, Patel SS, Shiraz P, Youn M, Yanagiba C, Arulprakasam J, Le A, Kwon HS, Long-Boyle J, Shizuru JA, Pang WW, Artz AS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785374"},{"title01":"Self-reinforcing IL-1beta signaling accelerates the development and recurrence of TCF3::HLF-positive B-ALL.","title02":"Self-reinforcing IL-1beta signaling accelerates the development and recurrence of TCF3::HLF-positive B-ALL.","journal":"Blood","issue":"2026 May 21; 147(21):2472-2488. doi: 10.1182\/blood.2025031521","author":"Suzuki A, Shigehiro T, Hirakawa M, Hirano R, Tamai M, Akahane K, Okamoto K, Takayanagi H, Terashima Y, Ueha S, Kitami T, Takagi M, Keino D, Kato K, Kawaguchi H, Hino M, Yoshimura A, Inukai T, Ikawa T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41774513"},{"title01":"Regulatory-like FOXP3+Helios+CD4+ T conventional cells correlate with T-cell activation after Orca-T immunotherapy.","title02":"Regulatory-like FOXP3+Helios+CD4+ T conventional cells correlate with T-cell activation after Orca-T immunotherapy.","journal":"Blood","issue":"2026 May 21; 147(21):2489-2502. doi: 10.1182\/blood.2025031545","author":"Bader CS, Killian S, Iliopoulou BP, Chen PI, Pathak S, Le CT, Villar-Prados A, Ji X, Jensen KP, Negrin RS, Meyer EH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758930"},{"title01":"A metabolism-specific drug-repurposing screen reveals itraconazole as a potent OXPHOS inhibitor in acute myeloid leukemia.","title02":"A metabolism-specific drug-repurposing screen reveals itraconazole as a potent OXPHOS inhibitor in acute myeloid leukemia.","journal":"Blood","issue":"2026 May 21; 147(21):2431-2447. doi: 10.1182\/blood.2024027853","author":"Himonas E, de Beauchamp L, Zerbst D, Desmares-Romain E, Sarnello D, Kalkman ER, Rattigan KM, James D, Shokry E, Copland M, Griessinger E, Recher C, De Mas V, Vergez F, Sumpton D, Schimmer AD, Minden MD, Gottlieb E, Shanks E, Sarry JE, Helgason GV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41734389"},{"title01":"Old drug, new parasite: targeting leukemia with antifungals.","title02":"Old drug, new parasite: targeting leukemia with antifungals.","journal":"Blood","issue":"2026 May 21; 147(21):2417-2418. doi: 10.1182\/blood.2026033393","author":"van Gastel N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42166204"},{"title01":"Moving beyond R-CHOP in large B-cell lymphoma.","title02":"Moving beyond R-CHOP in large B-cell lymphoma.","journal":"Lancet","issue":"2026 May 30. doi: 10.1016\/S0140-6736(26)01069-X. Online ahead of print","author":"Nijland M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42217459"},{"title01":"End of transplantation&#8217;s reign in mantle cell lymphoma.","title02":"End of transplantation&#8217;s reign in mantle cell lymphoma.","journal":"Lancet","issue":"2026 May 16; 407(10542):1897-1899. doi: 10.1016\/S0140-6736(26)00556-8","author":"Trotman J, Falconer J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42134341"},{"title01":"Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.","title02":"Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.","journal":"Lancet","issue":"2026 May 30. doi: 10.1016\/S0140-6736(26)00866-4. Online ahead of print","author":"Lenz G, Trneny M, Burke JM, Nowakowski GS, Fox CP, Chiappella A, Duell J, Jeon YW, Cheah CY, Westin J, Ye JZ, Caguioa PB, Belada D, Shin HJ, Oh SY, Amorim S, Ku M, Mocikova H, Jimenez JL, Gaidano G, Rosenwald A, Chiarle R, Colucci P, Ioannidis S, Cheng L, Vitolo U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42217458"},{"title01":"Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4.5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.","title02":"Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4.5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.","journal":"Lancet","issue":"2026 May 16; 407(10542):1953-1967. doi: 10.1016\/S0140-6736(26)00362-4","author":"Dreyling M, Doorduijn J, Gine E, Jerkeman M, Walewski J, Hutchings M, Mey U, Riise J, Trneny M, Vergote VKJ, Shpilberg O, da Silva MG, Leppa S, Jiang L, Stilgenbauer S, Kerkhoff A, Jachimowicz RD, Hess G, Meerten TV, Wirths S, Herhaus P, Novak U, Dierlamm J, Hanel M, Hanoun C, Sonnevi K, Visco C, Donnarumma D, Ferreri AJM, Patti C, Stefani PM, Pott C, Klapper W, Schmidt C, Unterhalt M, Tix T, Ladetto M, Hoster E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42134356"},{"title01":"Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed\/Refractory Peripheral T-Cell Lymphoma.","title02":"Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed\/Refractory Peripheral T-Cell Lymphoma.","journal":"J Clin Oncol","issue":"2026 May 20; JCO2503120. doi: 10.1200\/JCO-25-03120. Online ahead of print","author":"Mehta-Shah N, Zinzani PL, Jacobsen ED, Zain J, Mead M, Casulo C, Gritti G, Pinter-Brown L, Izutsu K, Sidransky D, Bentur OS, Pro B, Fox CP, Brammer JE, Horwitz SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42018969"},{"title01":"Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa study.","title02":"Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa study.","journal":"Haematologica","issue":"2026 May 28. doi: 10.3324\/haematol.2025.300166. Online ahead of print","author":"Lazarovici J, Amorim S, Bouabdallah K, Fournier M, Guidez S, Molina L, Morschhauser F, Delapierre B, Gastinne T, Laribi K, Launay V, Slama B, Belmecheri N, Casasnovas RO, Corby A, Durot E, Feugier P, Nicolas-Virelizie E, Sibon D, Berriolo-Riedinger A, Edeline V, Borght TV, Damotte D, Traverse-Glehen A, Ribrag V, Andre M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42206423"},{"title01":"An epigenetic Achilles&#8217; heel in extranodal NK\/T-cell lymphoma?","title02":"An epigenetic Achilles&#8217; heel in extranodal NK\/T-cell lymphoma?","journal":"Haematologica","issue":"2026 May 21. doi: 10.3324\/haematol.2026.301083. Online ahead of print","author":"Ahearne MJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42163723"},{"title01":"Prolonged survival with glofitamab in non-diffuse large B-cell lymphoma after CAR T-cell therapy relapse.","title02":"Prolonged survival with glofitamab in non-diffuse large B-cell lymphoma after CAR T-cell therapy relapse.","journal":"Haematologica","issue":"2026 May 21. doi: 10.3324\/haematol.2026.300537. Online ahead of print","author":"Sesques P, Houot R, Al Tabaa Y, Le Bras F, Ysebaert L, Choquet S, Jardin F, Bay JO, Gros FX, Morschhauser F, Rossi C, Gastinne T, Thieblemont C, Joris M, Ricard L, Regny C, La Rochelle LD, Feugier P, Marcais A, Griolet S, Tarte K, Laurent C, Cartron G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42163719"},{"title01":"Site-specific biology of tongue base aggressive B-cell lymphomas revealed by molecular subtype classification.","title02":"Site-specific biology of tongue base aggressive B-cell lymphomas revealed by molecular subtype classification.","journal":"Haematologica","issue":"2026 May 21. doi: 10.3324\/haematol.2026.300896. Online ahead of print","author":"Chizzoniti D, Cecchetti C, Melle F, Appio L, Zambrotta GMP, Canziani L, Latargia ML, Pavesi F, Lotesoriere I, Tartaglia A, Bertolli V, Santamaria C, Ballardini F, Ciambelli F, Tabanelli V, Todisco E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42163721"},{"title01":"Utility of combined CD39\/CD73\/CD38 expression for the detection of malignant T cells in Sezary syndrome.","title02":"Utility of combined CD39\/CD73\/CD38 expression for the detection of malignant T cells in Sezary syndrome.","journal":"Br J Haematol","issue":"2026 May 25. doi: 10.1111\/bjh.70562. Online ahead of print","author":"Marchisio S, Yakymiv Y, Lin L, Ortolan E, Pullano V, Ponti R, de Bie FJ, van der Sluijs-Gelling AJ, Zoutman WH, Pala V, Scheeren FA, Vermeer MH, Funaro A, Quaglino P, Roccuzzo G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42179066"},{"title01":"Immunologic Dream Team: BiTEs peri-allotransplant to redirect donor lymphocytes towards GVL.","title02":"Immunologic Dream Team: BiTEs peri-allotransplant to redirect donor lymphocytes towards GVL.","journal":"Blood advances","issue":"2026 May 20. doi: 10.1182\/bloodadvances.2026020530. Online ahead of print","author":"Iovino L, Shadman M, Milano F, Gopal AK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42160762"},{"title01":"Long-term outcomes of 40 Gy CCRT with weekly cisplatin and systemic chemotherapy in limited-stage ENKTL.","title02":"Long-term outcomes of 40 Gy CCRT with weekly cisplatin and systemic chemotherapy in limited-stage ENKTL.","journal":"Blood advances","issue":"2026 May 26; 10(10):3335-3346. doi: 10.1182\/bloodadvances.2025019130","author":"Yoon SE, Oh D, Ryu G, Cho J, Kim SJ, Kim WS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628317"},{"title01":"N6-methyladenosine reader IGF2BP2 in T-cell lymphoma.","title02":"N6-methyladenosine reader IGF2BP2 in T-cell lymphoma.","journal":"Blood","issue":"2026 May 21. doi: 10.1182\/blood.2026034186. Online ahead of print","author":"Hu S, Qin Y, Yi HM, Huang YH, Cheng S, Wang C, Li Y, Qiu YR, Cai MC, Zhao Y, Xu PP, Wang L, Xiong J, Zhao WL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42166364"},{"title01":"Multiomic study of cutaneous T-cell lymphoma reveals single-cell clonal evolution in progression and therapy resistance.","title02":"Multiomic study of cutaneous T-cell lymphoma reveals single-cell clonal evolution in progression and therapy resistance.","journal":"Blood","issue":"2026 May 21; 147(21):2503-2517. doi: 10.1182\/blood.2025029012","author":"Dorando HK, Andrews JM, Khatavkar OU, Borcherding NC, Korshunova Y, Hakeman G, Panigassi R, Vo P, Tu RY, Tran D, Quinn CC, Schmidt JA, Aluri J, Harmon MT, Watkins MP, Frank A, Cooper MA, Musiek AC, Mehta-Shah N, Payton JE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41662591"},{"title01":"CSNK1E sustains stemlike drug persistence in diffuse large B-cell lymphoma.","title02":"CSNK1E sustains stemlike drug persistence in diffuse large B-cell lymphoma.","journal":"Blood","issue":"2026 May 28; 147(22):2633-2647. doi: 10.1182\/blood.2025031156","author":"Li X, Liu M, Shi Q, Du ZS, Fu D, Fang Y, Zhao LJ, Dai Y, Zhang MC, Zhang F, Zhao Y, Yi HM, He Y, Cheng S, Xu PP, Wang L, Chen J, Zhao WL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758931"},{"title01":"CSNK1E as a key to unlocking drug persistence in DLBCL.","title02":"CSNK1E as a key to unlocking drug persistence in DLBCL.","journal":"Blood","issue":"2026 May 28; 147(22):2562-2563. doi: 10.1182\/blood.2026033531","author":"Knittel G, Reinhardt HC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42207551"},{"title01":"Unraveling cellular and molecular mechanisms of relapse in CD19\/CD22 dual-targeting chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia.","title02":"Unraveling cellular and molecular mechanisms of relapse in CD19\/CD22 dual-targeting chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 May 29. doi: 10.1038\/s41375-026-02978-3. Online ahead of print","author":"Tan J, He F, Hu H, Cao W, Wang N, Zuo X, Huang L, Zhou J, Wang QF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42215727"},{"title01":"Clonal dynamics and therapeutic pressure in myeloproliferative neoplasm with concomitant chronic myeloid leukemia: Potential implications of JAK2-directed therapy and additional mutations.","title02":"Clonal dynamics and therapeutic pressure in myeloproliferative neoplasm with concomitant chronic myeloid leukemia: Potential implications of JAK2-directed therapy and additional mutations.","journal":"Leukemia","issue":"2026 May 29. doi: 10.1038\/s41375-026-02983-6. Online ahead of print","author":"Fujita M, Ureshino H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42215726"},{"title01":"From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia.","title02":"From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia.","journal":"Leukemia","issue":"2026 May 22. doi: 10.1038\/s41375-026-02984-5. Online ahead of print","author":"Hochhaus A, Talpaz M, Saglio G, Cortes JE, Hughes T, Apperley J, Hantschel O, Rea D, Schuld P, Kantarjian H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42174092"},{"title01":"2001-2026: LEUKEMIA celebrates 25 years of tyrosine kinase inhibitors.","title02":"2001-2026: LEUKEMIA celebrates 25 years of tyrosine kinase inhibitors.","journal":"Leukemia","issue":"2026 May 22. doi: 10.1038\/s41375-026-02981-8. Online ahead of print","author":"Gale RP, Hochhaus A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42174091"},{"title01":"Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trial.","title02":"Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trial.","journal":"Lancet Haematol","issue":"2026 May 18. doi: 10.1016\/S2352-3026(26)00014-1. Online ahead of print","author":"Stein A, Wang Y, Malki MMA, Aldoss I, Ali H, Aribi A, Artz A, Ball B, Dandapani S, Farol L, Han C, Liu A, Pullarkat V, Radany E, Sahebi F, Sanchez JF, Sandhu K, Salhotra A, Smith E, Spielberger R, Hui S, Marcucci G, Nakamura R, Forman SJ, Palmer J, Wong J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42150590"},{"title01":"Novel tripartite CPSF7::RARG::CPSF7 fusion confers primary ATRA resistance in atypical acute promyelocytic leukemia.","title02":"Novel tripartite CPSF7::RARG::CPSF7 fusion confers primary ATRA resistance in atypical acute promyelocytic leukemia.","journal":"Haematologica","issue":"2026 May 28. doi: 10.3324\/haematol.2026.300904. Online ahead of print","author":"Zhou X, Zhang Z, Xu F, Jiang M, Zhang Y, Cao P, Fang J, Ma X, Wang F, Chen J, Chen X, Wu P, Wang T, Lu Y, Liu H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42206415"},{"title01":"Presentation and management of pediatric T-cell acute lymphoblastic leukemia with mediastinal mass and hyperleukocytosis.","title02":"Presentation and management of pediatric T-cell acute lymphoblastic leukemia with mediastinal mass and hyperleukocytosis.","journal":"Haematologica","issue":"2026 May 28. doi: 10.3324\/haematol.2026.300811. Online ahead of print","author":"Muller B, Su Y, Rule A, Hu Z, Holland AC, Choi JK, Klco J, Yang JJ, Mullighan C, Karol SE, Cheng C, Tang L, Jeha S, Pui CH, Inaba H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42206439"},{"title01":"Venetoclax and azacytidine in childhood primary advanced myelodysplastic syndromes, refractory\/relapsed acute myeloid leukemia and therapy-related myeloid neoplasms.","title02":"Venetoclax and azacytidine in childhood primary advanced myelodysplastic syndromes, refractory\/relapsed acute myeloid leukemia and therapy-related myeloid neoplasms.","journal":"Haematologica","issue":"2026 May 21. doi: 10.3324\/haematol.2026.300775. Online ahead of print","author":"Baccelli F, Merli P, Pigazzi M, Buldini B, Becilli M, Girardi K, Paganelli V, Pagano G, Leardini D, Muratore E, Vendemini F, Beneduce G, Tumino M, Saglio F, Sieni E, Mastrodicasa E, Maffeis M, Tambaro FP, Masetti R, Locatelli F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42163725"},{"title01":"Next generation sequencing-based measurable residual disease detection predicts outcomes in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.","title02":"Next generation sequencing-based measurable residual disease detection predicts outcomes in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.","journal":"Haematologica","issue":"2026 May 28. doi: 10.3324\/haematol.2025.300432. Online ahead of print","author":"Krauss SM, Holloway T, Weigert A, Bischof L, Backhaus D, Brauer D, Ussmann J, Franke GN, Vucinic V, Platzbecker U, Schwind S, Jentzsch M, Metzeler KH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42206448"},{"title01":"Lorlatinib-induced remission in refractory acute myeloid leukemia with an anaplastic lymphoma kinase fusion.","title02":"Lorlatinib-induced remission in refractory acute myeloid leukemia with an anaplastic lymphoma kinase fusion.","journal":"Haematologica","issue":"2026 May 28. doi: 10.3324\/haematol.2026.300893. Online ahead of print","author":"Boussi L, Ovalle NT, Imber BS, Ewalt MD, Glick M, Shaffer B, Stein EM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42206443"},{"title01":"Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in acute myeloid leukemia in first complete remission: CIBMTR analysis.","title02":"Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in acute myeloid leukemia in first complete remission: CIBMTR analysis.","journal":"Haematologica","issue":"2026 May 28. doi: 10.3324\/haematol.2026.300764. Online ahead of print","author":"Tettero JM, Zhang MJ, Liu W, Nawas MT, Milano F, Bejanyan N, Bachanova V, Broglie L, Saber W, Gui G, Dillon LW, Walter RB, Page KM, Hourigan CS, El Chaer F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42206435"},{"title01":"Is CPX-351 the best path to remission for older patients with treatment-related or myelodysplastic-related acute myeloid leukemia?","title02":"Is CPX-351 the best path to remission for older patients with treatment-related or myelodysplastic-related acute myeloid leukemia?","journal":"Haematologica","issue":"2026 May 28. doi: 10.3324\/haematol.2026.301020. Online ahead of print","author":"Yisraeli-Salman M, Ofran Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42206437"},{"title01":"The oncogenic DeltaNp73 isoform contributes to aggressiveness in acute promyelocytic leukemia.","title02":"The oncogenic DeltaNp73 isoform contributes to aggressiveness in acute promyelocytic leukemia.","journal":"Haematologica","issue":"2026 May 28. doi: 10.3324\/haematol.2025.288595. Online ahead of print","author":"Rojas CAO, Pereira-Martins DA, Thome CH, Ferreira GA, Bianco TM, Weinhauser I, Gouvea AS, Scheucher PS, Silva CLA, Huls G, Bermudez A, Garcia F, Pitteri S, Faca VM, Ammatuna E, Schuringa JJ, Gloria AB, Pagnano KBB, Nunes EC, Traina F, De Figueiredo-Pontes LL, Rego EM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42206432"},{"title01":"Azacitidine-venetoclax in unfit acute myeloid leukaemia: One size does not fit all.","title02":"Azacitidine-venetoclax in unfit acute myeloid leukaemia: One size does not fit all.","journal":"Br J Haematol","issue":"2026 May 20. doi: 10.1111\/bjh.70568. Online ahead of print","author":"Ferrara F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42163518"},{"title01":"Outcomes of patients with de novo and secondary acute myeloid leukaemia treated with front-line hypomethylating agents and venetoclax: A retrospective Italian study.","title02":"Outcomes of patients with de novo and secondary acute myeloid leukaemia treated with front-line hypomethylating agents and venetoclax: A retrospective Italian study.","journal":"Br J Haematol","issue":"2026 May 28. doi: 10.1111\/bjh.70587. Online ahead of print","author":"Tanasi I, Tamellini E, Marchetti E, De Bellis E, Ancora C, Angotzi F, Facchinelli D, Capraro F, Battaglia G, Sperotto A, Gottardi M, Leoncin M, Krampera M, Tiribelli M, Gurrieri C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42207150"},{"title01":"Transplantation outcomes in patients with Down syndrome-associated acute lymphoblastic leukaemia: Implications for treatment intensity and the use of novel therapies.","title02":"Transplantation outcomes in patients with Down syndrome-associated acute lymphoblastic leukaemia: Implications for treatment intensity and the use of novel therapies.","journal":"Br J Haematol","issue":"2026 May 24. doi: 10.1111\/bjh.70583. Online ahead of print","author":"Ishida H, Okamoto Y, Sakaguchi H, Arai Y, Ueda T, Yamamoto S, Yano M, Yokosuka T, Okada K, Sato M, Karakawa S, Kobayashi R, Kato K, Koh K, Fujiki T, Goi K, Saito S, Takita J, Miyamura T, Koga Y, Yoshida N, Sato A, Hino M, Tabuchi K, Arakawa Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42178886"},{"title01":"Acquired thiopurine resistance and mismatch repair aberrations in paediatric B-cell acute lymphoblastic leukaemia relapse: A real-world data integrating mutational signatures, clones and clinical thiopurine dosing patterns.","title02":"Acquired thiopurine resistance and mismatch repair aberrations in paediatric B-cell acute lymphoblastic leukaemia relapse: A real-world data integrating mutational signatures, clones and clinical thiopurine dosing patterns.","journal":"Br J Haematol","issue":"2026 May 26. doi: 10.1111\/bjh.70560. Online ahead of print","author":"Bhatia P, Sharun S, Palla S, Brady SW, Kirubanandhan S, Ansari S, Singh M, Sreedharanunni S, Das A, Trehan A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42189079"},{"title01":"Blinatumomab for treatment of children with acute lymphoblastic leukaemia in Hong Kong: A cost-effectiveness analysis.","title02":"Blinatumomab for treatment of children with acute lymphoblastic leukaemia in Hong Kong: A cost-effectiveness analysis.","journal":"Br J Haematol","issue":"2026 May 27. doi: 10.1111\/bjh.70582. Online ahead of print","author":"Rui M, Cheung YT, Zhang H, Wei Q, Wang Y, Shi J, Li CK, You JHS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42203433"},{"title01":"Identification of GSE1 as a PAX5 fusion partner and characterization of PAX5 fusion signature in B-cell acute lymphoblastic leukaemia.","title02":"Identification of GSE1 as a PAX5 fusion partner and characterization of PAX5 fusion signature in B-cell acute lymphoblastic leukaemia.","journal":"Br J Haematol","issue":"2026 May 27. doi: 10.1111\/bjh.70578. Online ahead of print","author":"Wang H, Xue J, Yan W, Gao Y, Zong X, Zhou D, Huang D, Liu H, Zhang X, Yan J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42204379"},{"title01":"A proposed refined definition of acute myeloid leukaemia patients ineligible for intensive therapy: The Integrated Comorbidity-ECOG-Age criteria.","title02":"A proposed refined definition of acute myeloid leukaemia patients ineligible for intensive therapy: The Integrated Comorbidity-ECOG-Age criteria.","journal":"Br J Haematol","issue":"2026 May 30. doi: 10.1111\/bjh.70592. Online ahead of print","author":"Weidl D, Boukovala M, Glaser D, Barthel B, Bullinger L, Heuser M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42216561"},{"title01":"Further insights into the application of the TFR prognostic score (TPS) in CML patients attempting TFR.","title02":"Further insights into the application of the TFR prognostic score (TPS) in CML patients attempting TFR.","journal":"Br J Haematol","issue":"2026 May 29. doi: 10.1111\/bjh.70571. Online ahead of print","author":"Claudiani S, Metelli S, Milojkovic D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42216510"},{"title01":"Low flow cytometry events in detecting CNS involvement in pediatric B-cell precursor ALL: NGS validation and prognostic significance.","title02":"Low flow cytometry events in detecting CNS involvement in pediatric B-cell precursor ALL: NGS validation and prognostic significance.","journal":"Blood advances","issue":"2026 May 26; 10(10):3505-3516. doi: 10.1182\/bloodadvances.2025018288","author":"Chou SW, Su YH, Lu MY, Chang HH, Yang YL, Du CJ, Yen HJ, Li MJ, Lee CY, Liew PT, Lin DT, Lin KH, Lin SW, Jou ST","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41719456"},{"title01":"Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML.","title02":"Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML.","journal":"Blood advances","issue":"2026 May 27. doi: 10.1182\/bloodadvances.2026019841. Online ahead of print","author":"Short NJ, Kantarjian HM, Daver NG, Azevedo RS, Karrar O, DiNardo CD, Kadia TM, Yilmaz M, Maroun MM, Hachem MCR, Borthakur G, Issa GC, Shpall EJ, Popat UR, Huang X, Qiao W, Nasr LF, Macaron W, Abramova R, Garcia-Manero G, Konopleva M, Ravandi F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42200455"},{"title01":"Refining busulfan exposure enhances pediatric ALL HSCT outcomes: insights from the International FORUM study.","title02":"Refining busulfan exposure enhances pediatric ALL HSCT outcomes: insights from the International FORUM study.","journal":"Blood advances","issue":"2026 May 26; 10(10):3719-3730. doi: 10.1182\/bloodadvances.2025019142","author":"Ben Hassine K, Gloor Y, Dupanloup I, Uppugunduri CRS, Mlakar V, Gonzales F, Gungor T, Ifversen M, Shaw PJ, Buechner J, Truong TH, Bittencourt H, Teague L, Toporski J, Sedlacek P, Poetschger U, Krajinovic M, Kalwak K, Balduzzi A, Algeri M, Bader P, Peters C, Dalle JH, Ansari M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779961"},{"title01":"Validation of ICC hierarchical classification in secondary AML.","title02":"Validation of ICC hierarchical classification in secondary AML.","journal":"Blood advances","issue":"2026 May 26; 10(10):3347-3356. doi: 10.1182\/bloodadvances.2025018188","author":"Attardi E, Cipriani M, Guarnera L, Savi A, Fabiani E, Mallegni F, Moretti F, Silvestrini G, Awada H, Durmaz A, Ferrari I, Maggioni G, Memoli M, Visconte V, Venditti A, Della Porta MG, Gurnari C, Piciocchi A, Maciejewski JP, Voso MT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785326"},{"title01":"CD19 CAR T-cell outcomes in relapsed\/refractory extramedullary B-ALL: a multisite, retrospective cohort review.","title02":"CD19 CAR T-cell outcomes in relapsed\/refractory extramedullary B-ALL: a multisite, retrospective cohort review.","journal":"Blood advances","issue":"2026 May 26; 10(10):3467-3479. doi: 10.1182\/bloodadvances.2025018604","author":"Rankin AW, Myers RM, Lamble AJ, Hsieh EM, Sankaran H, Chen L, Annesley C, DiNofia AM, Grupp SA, Pulsipher MA, Dolan JG, Bhojwani D, Gardner RA, Shah NN, Rheingold SR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41701972"},{"title01":"HMA + venetoclax triplet regimens for the initial treatment of AML in adults- CONTRA.","title02":"HMA + venetoclax triplet regimens for the initial treatment of AML in adults- CONTRA.","journal":"Blood advances","issue":"2026 May 21. doi: 10.1182\/bloodadvances.2025018556. Online ahead of print","author":"Stahl M, Stone RM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42166690"},{"title01":"Deferasirox 6 months after allo-HSCT in AML\/MDS: a prospective propensity-matched study.","title02":"Deferasirox 6 months after allo-HSCT in AML\/MDS: a prospective propensity-matched study.","journal":"Blood advances","issue":"2026 May 26; 10(10):3705-3714. doi: 10.1182\/bloodadvances.2025018894","author":"Buono R, Huynh A, Forcade E, Labussiere H, Ceballos P, Cornillon J, Cabrera Q, D'Aveni M, Robin M, Devillier R, Raus N, Michallet M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41811968"},{"title01":"Venetoclax retreatment in chronic lymphocytic leukemia is biologically rational and clinically effective.","title02":"Venetoclax retreatment in chronic lymphocytic leukemia is biologically rational and clinically effective.","journal":"Blood advances","issue":"2026 May 26; 10(10):3357-3366. doi: 10.1182\/bloodadvances.2026019871","author":"Castonguay M, Anderson MA, Thompson P, Seymour JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41843779"},{"title01":"IDH1- and IDH2-mutated myeloid neoplasms: mutational pattern, clonal hierarchy, and the role in AML transformation.","title02":"IDH1- and IDH2-mutated myeloid neoplasms: mutational pattern, clonal hierarchy, and the role in AML transformation.","journal":"Blood advances","issue":"2026 May 26; 10(10):3554-3564. doi: 10.1182\/bloodadvances.2025019387","author":"Huber S, Goessweiner F, Walter W, Summerer I, Meggendorfer M, Ordemann R, Pohlkamp C, Kneisel N, Haferlach C, Kern W, Haferlach T, Delic S, Hoermann G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41860384"},{"title01":"Advances in the diagnosis and classification of B-ALL: comparative insights from updated guidelines.","title02":"Advances in the diagnosis and classification of B-ALL: comparative insights from updated guidelines.","journal":"Blood advances","issue":"2026 May 26; 10(10):3640-3652. doi: 10.1182\/bloodadvances.2025017301","author":"Chen X, Yuan L, Ma X, Wang F, Zhang Y, Fang J, Cao P, Wang T, Chen J, Zhou X, Long J, Liu H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41886641"},{"title01":"BCL2 overexpression in donor lymphocytes reduces the risk of graft-versus-host disease.","title02":"BCL2 overexpression in donor lymphocytes reduces the risk of graft-versus-host disease.","journal":"Blood advances","issue":"2026 May 26; 10(10):3572-3586. doi: 10.1182\/bloodadvances.2025017700","author":"Bejarano-Garcia JA, Nufer M, Palacios-Barea MJ, Guijarro-Albaladejo B, Sierro-Martinez B, Bella A, Robles-Benitez C, Garcia-Guerrero E, Carrasco-Brocal I, Lara-Chica M, Sanoja-Flores L, Mendendez NV, Caballero-Velazquez T, Rodriguez-Gil A, Perez-Simon JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41915889"},{"title01":"CD19 CAR T cells for B-ALL with EMD.","title02":"CD19 CAR T cells for B-ALL with EMD.","journal":"Blood advances","issue":"2026 May 26; 10(10):3527-3528. doi: 10.1182\/bloodadvances.2026019818","author":"Llaurador Caraballo G, Steffin D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42138652"},{"title01":"Pediatric-inspired regimens and HSCT for adolescents and young adults with acute lymphoblastic leukemia.","title02":"Pediatric-inspired regimens and HSCT for adolescents and young adults with acute lymphoblastic leukemia.","journal":"Blood advances","issue":"2026 May 26; 10(10):3664-3675. doi: 10.1182\/bloodadvances.2025018736","author":"Sereda Y, Mai HJ, Kanaan G, Melson JW, Terasawa T, Cheung MC, Stock W, Wolfson JA, Saldanha IJ, Balk EM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610329"},{"title01":"DUSP1 is a Key Driver of Disease Persistence and Potential Therapeutic Target in Hairy Cell Leukemia.","title02":"DUSP1 is a Key Driver of Disease Persistence and Potential Therapeutic Target in Hairy Cell Leukemia.","journal":"Blood advances","issue":"2026 May 27. doi: 10.1182\/bloodadvances.2025019057. Online ahead of print","author":"Bohn JP, Scheiber A, Sturm G, Maurer T, Mair A, Kugler V, Feichtner A, Fritz A, Torres-Quesada O, Jaeger U, Huber RG, Daum S, Martowicz A, Redlinger N, Pircher A, Sopper S, Trajanoski Z, Stefan E, Salcher S, Wolf D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42200459"},{"title01":"Artificial intelligence-enhancement of flow cytometry data accelerates the identification of measurable residual chronic lymphocytic leukemia.","title02":"Artificial intelligence-enhancement of flow cytometry data accelerates the identification of measurable residual chronic lymphocytic leukemia.","journal":"Leukemia","issue":"2026 May 26. doi: 10.1038\/s41375-026-02986-3. Online ahead of print","author":"Chiu A, Seheult JN, Shi M, Jevremovic D, Jordan CE, Weybright MJ, Timm MM, Otteson GE, Olteanu H, Parikh SA, Horna P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42192141"},{"title01":"Allogeneic stem cell transplantation in T-cell prolymphocytic leukemia: final disappointment or a chance for cure?","title02":"Allogeneic stem cell transplantation in T-cell prolymphocytic leukemia: final disappointment or a chance for cure?","journal":"Haematologica","issue":"2026 May 28. doi: 10.3324\/haematol.2026.301173. Online ahead of print","author":"Shumilov E, Schmitz N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42206428"},{"title01":"A novel tripartite STAT5B::RARA::RP11-750B16.1 fusion in variant acute promyelocytic leukemia. Comment on: &#8220;Novel ligand-binding domain truncated CPSF7::RARA::CPSF7 tripartite fusion confers primary ATRA resistance in atypical acute promyelocytic leukemia&#8221;.","title02":"A novel tripartite STAT5B::RARA::RP11-750B16.1 fusion in variant acute promyelocytic leukemia. Comment on: &#8220;Novel ligand-binding domain truncated CPSF7::RARA::CPSF7 tripartite fusion confers primary ATRA resistance in atypical acute promyelocytic leukemia&#8221;.","journal":"Haematologica","issue":"2026 May 7. doi: 10.3324\/haematol.2026.301049. Online ahead of print","author":"Su Z, Feng X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42095250"},{"title01":"Is it time to increase the liposomal doxorubicin dosage for frontline therapy in young adults and adults with classic Hodgkin lymphoma? Comment on: &#8220;Is it time to reduce the doxorubicin dosage in Hodgkin lymphoma therapy?&#8221;.","title02":"Is it time to increase the liposomal doxorubicin dosage for frontline therapy in young adults and adults with classic Hodgkin lymphoma? Comment on: &#8220;Is it time to reduce the doxorubicin dosage in Hodgkin lymphoma therapy?&#8221;.","journal":"Haematologica","issue":"2026 May 7. doi: 10.3324\/haematol.2026.301044. Online ahead of print","author":"Picardi M, Vincenzi A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42095255"},{"title01":"Boosting &#8220;Treg-ulation&#8221;: a good way to treat chronic GVHD?","title02":"Boosting &#8220;Treg-ulation&#8221;: a good way to treat chronic GVHD?","journal":"Blood advances","issue":"2026 May 12; 10(9):3059-3060. doi: 10.1182\/bloodadvances.2026019728","author":"Boiko JR, Carpenter PA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42060316"},{"title01":"Anti-CD4 antibody-modulated transplants for GVHD prevention in hematopoietic cell transplantation.","title02":"Anti-CD4 antibody-modulated transplants for GVHD prevention in hematopoietic cell transplantation.","journal":"Blood","issue":"2026 May 14; 147(20):2402-2414. doi: 10.1182\/blood.2025031370","author":"Roth K, Loeffler D, Blumert C, Scholz A, Reiche K, Bauer M, Wickenhauser C, Schiefer D, Hilger N, Blaudszun AR, Thees J, Walter J, Tretbar US, Koehl U, Fricke S, Blache U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587074"},{"title01":"MLL3 and MLL4 sustain hematopoietic stem cell multipotency by opposing a B-cell default state.","title02":"MLL3 and MLL4 sustain hematopoietic stem cell multipotency by opposing a B-cell default state.","journal":"Blood","issue":"2026 May 12. doi: 10.1182\/blood.2025032969. Online ahead of print","author":"Wang HC, Chen R, Yang W, Muthukumar R, Hu T, Patel RM, Casey EB, Denby ED, Zhang R, Xie G, Ge K, Challen G, Bednarski JJ, Magee JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42118696"},{"title01":"Inflammatory bowel disease-induced inflammation augments clonal hematopoiesis of indeterminate potential through Ref-1.","title02":"Inflammatory bowel disease-induced inflammation augments clonal hematopoiesis of indeterminate potential through Ref-1.","journal":"Blood","issue":"2026 May 14; 147(20):2315-2327. doi: 10.1182\/blood.2025032339","author":"Kumar R, Li L, Urbut S, Uddin M, Niroula A, Kanumuri R, Ramdas B, Pasupuleti SK, Palam LR, Wang X, Ram Padam KS, Kelley M, Natarajan P, Yu Z, Kapur R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41746260"},{"title01":"Genetics and MRD for therapy allocation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.","title02":"Genetics and MRD for therapy allocation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.","journal":"Blood","issue":"2026 May 4. doi: 10.1182\/blood.2025032645. Online ahead of print","author":"Ribera JM, Torrent A, Morgades M, Barrena S, Ribera J, Genesca E, Gonzalez-Campos J, Martinez-Cibrian N, Montesinos P, Hernandez Sanchez A, Barba P, Zapico E Sr, Sanchez R, Novo A, Sitges M, Maluquer Artigal C, Such E, Botella C, Queipo de Llano MP, Cabrero M, Vicent A, Lopez de Ugarriza P, Tormo M, Gonzalez-Gonzalez BJ, Garcia-Cadenas I, Rodriguez-Medina C, Martinez Sanchez P, Bermudez A, Gomez-Centurion I, Herrero-Garcia M, Ciudad J, Navas-Acosta J, Hermosin L, Serrano J, Raposo-Puglia JA, Solan L, Roldan-Galiacho V, de Laiglesia A, Gomez-Perez L, Sole-Rodriguez M, Casado MS Sr, Llorente Gonzalez L, Barrios Decoud D, Vall-Llovera F, Algarra JL, Amador L, Garcia-Boyero R, Cladera A, Bergua Burgues JM, Calasanz MJJ, Granada I, Feliu E, Hernandez-Rivas JM, Orfao A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42081455"},{"title01":"Case 14-2026: A 50-Year-Old Woman with Vaginal Bleeding and Anemia.","title02":"Case 14-2026: A 50-Year-Old Woman with Vaginal Bleeding and Anemia.","journal":"N Engl J Med","issue":"2026 May 14; 394(19):1940-1951. doi: 10.1056\/NEJMcpc2517864","author":"Ziperstein JC, Barnawi RA, Al-Samkari H, Bolster MB, Heusinkveld LE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42127395"},{"title01":"Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease.","title02":"Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease.","journal":"N Engl J Med","issue":"2026 May 7; 394(18):1824-1835. doi: 10.1056\/NEJMoa2504835","author":"Gupta AO, Sharma A, Frangoul H, Kanter J, Mapara MY, Dalal J, Alavi A, Jaroscak JJ, Ayala E, DiPersio JF, Ziga ED, Eapen M, Rifkin-Zenenberg S, Minella AC, Chen Y, Chesler S, Ambati S, Bowman TS, Habtemariam B, Joseney-Antoine M, Chockalingam PS, Lin L, Goyal S, Simon A, Thompson AA, Heeney MM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41931046"},{"title01":"Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial.","title02":"Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial.","journal":"Lancet Oncol","issue":"2026 May; 27(5):614-624. doi: 10.1016\/S1470-2045(26)00014-8","author":"Morgans AK, Haresh KP, Jievaltas M, Olmos D, Shore ND, Vjaters E, Xing N, Mohamed AF, Littleton N, Srinivasan S, Verholen F, Saad F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41969015"},{"title01":"Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4\/6 inhibitor in HR+\/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial.","title02":"Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4\/6 inhibitor in HR+\/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial.","journal":"Lancet Oncol","issue":"2026 May; 27(5):580-591. doi: 10.1016\/S1470-2045(26)00059-8","author":"Wander SA, Lloyd MR, Keenan JC, Scott EC, Niemierko A, Spring LM, Fell GG, Shin J, Isakoff SJ, Moy B, Ryan L, Padden S, Fisher E, Newton A, Habin KR, Viscosi-Spieler ET, Scarpetti L, Varkaris A, Ellisen LW, Dubash T, Che D, Patel PS, de la Cruz FF, Sutaria DS, Sane RS, Micalizzi DS, Maheswaran S, Haber DA, Juric D, Bardia A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42061370"},{"title01":"Final Efficacy and Safety Data From the Phase I\/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.","title02":"Final Efficacy and Safety Data From the Phase I\/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.","journal":"J Clin Oncol","issue":"2026 May; 44(13):1190-1197. doi: 10.1200\/JCO-25-01489","author":"Besse B, Subbiah V, Curigliano G, Bowles DW, Doebele RC, Mansfield AS, Baik CS, de Lima Lopes G, Paz-Ares L, Taylor MH, Tan DSW, Alonso G, Gadgeel SM, Kalemkerian GP, Ou SI, van der Wekken AJ, Becerra CR, Evangelist M, Griesinger F, Liu SV, Lou Y, Mazieres J, Melear JM, Narang M, Saxena A, Thomas M, Wang S, Thomassen A, Lee DH, Kim DW, Gainor JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41886723"},{"title01":"Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE).","title02":"Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE).","journal":"J Clin Oncol","issue":"2026 May 7; JCO2502835. doi: 10.1200\/JCO-25-02835. Online ahead of print","author":"McKay RR, Xie W, Ajmera A, Araneta A, Jamieson C, Folefac E, Hussain A, Kyriakopoulos CE, Manning DK, Olson A, Parikh M, Parikh R, Saraiya B, Pasquina LW, Madison R, Clifford S, Childress M, Gasco A, Ivy P, Van Allen E, Kochupurakkal B, Shapiro GI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42096662"},{"title01":"Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I\/Ib Trial.","title02":"Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I\/Ib Trial.","journal":"J Clin Oncol","issue":"2026 May 8; JCO2502027. doi: 10.1200\/JCO-25-02027. Online ahead of print","author":"Hanna GJ, Zandberg DP, Wong DJ, Sherman E, Sacco AG, Yilmaz E, Hernando-Calvo A, Reiners RD, Bohr D, Salazar RL, O'Connell BC, Raben D, Schulten J, Chung CH, Kaczmar J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42102329"},{"title01":"Functional impact of a deep intronic variant in the RPS19 gene detected in a case of Diamond-Blackfan anemia syndrome.","title02":"Functional impact of a deep intronic variant in the RPS19 gene detected in a case of Diamond-Blackfan anemia syndrome.","journal":"Haematologica","issue":"2026 May 1; 111(5):1876-1880. doi: 10.3324\/haematol.2025.300131","author":"Kanezaki R, Toki T, Okuse R, Kobayashi A, Sato M, Kimura S, Kudo K, Sato T, Tanaka T, Yoshida K, Kawai Y, Tokunaga K, Takita J, Ogawa S, Terui K, Ito E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568468"},{"title01":"A multicentre analysis of efficacy, safety and molecular response correlates of fostamatinib in warm autoimmune haemolytic anaemia and Evans syndrome.","title02":"A multicentre analysis of efficacy, safety and molecular response correlates of fostamatinib in warm autoimmune haemolytic anaemia and Evans syndrome.","journal":"Br J Haematol","issue":"2026 May; 208(5):1878-1884. doi: 10.1111\/bjh.70434","author":"Ruiz Lopez JN, Shao L, Jiang D, Bailey LS, Bikkani T, Boothby A, Moore DC, Murakhovskaya I, Piatek CI, Pineda-Roman M, Jin P, Poston JN, Stolla M, Stroncek DF, Hudson KE, Bussel JB, Panch SR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41846299"},{"title01":"In-depth analysis of osmotic gradient ektacytometry parameters across different genotypes in hereditary spherocytosis.","title02":"In-depth analysis of osmotic gradient ektacytometry parameters across different genotypes in hereditary spherocytosis.","journal":"Br J Haematol","issue":"2026 May; 208(5):1785-1796. doi: 10.1111\/bjh.70457","author":"de Wilde JRA, Kuppens GZL, Boesveld ME, van Vuren AJ, van Solinge WW, Waanders E, van Beers EJ, Rab MAE, Bartels M, van Wijk R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41914049"},{"title01":"Contemporary global burden of sickle cell anaemia under-5 and under-20: A systematic review and meta-analysis.","title02":"Contemporary global burden of sickle cell anaemia under-5 and under-20: A systematic review and meta-analysis.","journal":"Br J Haematol","issue":"2026 May 3. doi: 10.1111\/bjh.70501. Online ahead of print","author":"Pimenta K, Edwards J, Ray M, Naser AM, Price C, Idassi O, Strong K, Were W, Piel FB, Hankins JS, Smeltzer M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42070793"},{"title01":"Halofuginone suppresses hepcidin by a heparan sulfate-dependent mechanism to treat iron disorders in mice.","title02":"Halofuginone suppresses hepcidin by a heparan sulfate-dependent mechanism to treat iron disorders in mice.","journal":"Blood advances","issue":"2026 May 12; 10(9):3020-3031. doi: 10.1182\/bloodadvances.2025017943","author":"Leal S, Denardo A, Van Echten A, Jungnickel H, Nelson CB, Sandoval D, Salvador JA, Shin J, Chung A, Brush MN, Bennett CP, Piermatteo A, Secrest PD, Jung CL, Ganz T, Poli M, Gordts PLSM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671472"},{"title01":"Hematologic malignancies in pediatric patients with RUNX1-familial platelet disorder with associated myeloid malignancy.","title02":"Hematologic malignancies in pediatric patients with RUNX1-familial platelet disorder with associated myeloid malignancy.","journal":"Blood advances","issue":"2026 May 12; 10(9):3075-3085. doi: 10.1182\/bloodadvances.2025017808","author":"Kajdic A, Deuitch NT, Bresciani E, Chong S, Craft K, Davis J, Bashtawi R, McReynolds LJ, Giri N, Young DJ, Liu PP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41616279"},{"title01":"Ferroportin inhibition attenuates pulmonary hypertension in hypoxic sickle cell disease mice.","title02":"Ferroportin inhibition attenuates pulmonary hypertension in hypoxic sickle cell disease mice.","journal":"Blood advances","issue":"2026 May 12; 10(9):3229-3242. doi: 10.1182\/bloodadvances.2025018680","author":"Lucero MJ, Setua S, Thangaraju K, Khan A, Lamb DR, Lisk C, Swindle D, Cendali FI, Dzieciatkowska M, Stephenson D, Pak DI, Tolson R, Zaeske S, Rana NK, Khan S, Westover N, Davizon-Castillo P, George G, Hassell K, Nuss R, D'Alessandro A, Manolova V, Irwin DC, Buehler PW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538305"},{"title01":"How I utilize somatic alterations in the diagnosis, risk stratification, and therapy of hypocellular bone marrow failure.","title02":"How I utilize somatic alterations in the diagnosis, risk stratification, and therapy of hypocellular bone marrow failure.","journal":"Blood","issue":"2026 May 7. doi: 10.1182\/blood.2025029923. Online ahead of print","author":"Groarke EM, Gutierrez-Rodrigues F, Patel BA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42095935"},{"title01":"Differentiating pathogenic from bystander autoantibodies in immune thrombocytopenia using intact glycoproteindeficient megakaryocytes.","title02":"Differentiating pathogenic from bystander autoantibodies in immune thrombocytopenia using intact glycoproteindeficient megakaryocytes.","journal":"Haematologica","issue":"2026 May 1; 111(5):1725-1734. doi: 10.3324\/haematol.2025.288832","author":"Zhang N, Uzun G, Bakchoul T, Curtis BR, Newman PJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376564"},{"title01":"CSF1R modulates megakaryopoiesis by targeting RUNX1 in immune thrombocytopenia.","title02":"CSF1R modulates megakaryopoiesis by targeting RUNX1 in immune thrombocytopenia.","journal":"Haematologica","issue":"2026 May 1; 111(5):1735-1746. doi: 10.3324\/haematol.2025.288511","author":"Han H, Zhou M, Qi J, Song X, Li X, Zhang Z, Pan T, Xu X, Guo M, Wu D, Han Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41414965"},{"title01":"Overuse of thrombopoietin receptor agonists driven by suboptimal response is associated with myelofibrosis in pediatric immune thrombocytopenia.","title02":"Overuse of thrombopoietin receptor agonists driven by suboptimal response is associated with myelofibrosis in pediatric immune thrombocytopenia.","journal":"Haematologica","issue":"2026 May 7. doi: 10.3324\/haematol.2026.300651. Online ahead of print","author":"Ma J, Chen Z, Cheng X, Hu Y, Jiang J, Ma J, Lian H, Zhang L, Ma X, Lin X, Dong S, Li C, Yao W, Zhao S, Wei Y, Wu R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42095249"},{"title01":"Dapsone response in immune thrombocytopenic purpura is associated with dapsone dose and mediated through reduction in haemoglobin: A longitudinal data analysis of 58 adult and paediatric ITP patients demonstrates efficacy and safety.","title02":"Dapsone response in immune thrombocytopenic purpura is associated with dapsone dose and mediated through reduction in haemoglobin: A longitudinal data analysis of 58 adult and paediatric ITP patients demonstrates efficacy and safety.","journal":"Br J Haematol","issue":"2026 May; 208(5):1768-1776. doi: 10.1111\/bjh.70414","author":"Shah SD, Vibhakar A, Shah RP, Rathod N, Modi G, Patel A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41802829"},{"title01":"Short- and long-term outcome of neonates with thrombocytopenia from maternal immune thrombocytopenia.","title02":"Short- and long-term outcome of neonates with thrombocytopenia from maternal immune thrombocytopenia.","journal":"Br J Haematol","issue":"2026 May; 208(5):1867-1872. doi: 10.1111\/bjh.70403","author":"Sorin B, Azzouguen B, Loustau V, Boutin E, Henique H, Graveleau J, Souchaud-Debouverie O, Pascal L, Gilardin L, Costedoat-Chalumeau N, Reynaud Q, Pan-Petesch B, Cheze S, Terriou L, Comont T, Sauvetre G, Royer B, Mahevas M, Michel M, Canoui-Poitrine F, Godeau B, Guillet S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41814575"},{"title01":"Integrated proteomic and metabolomic profiling reveals sex-stratified biomarkers predicting chronicity in paediatric primary immune thrombocytopenia.","title02":"Integrated proteomic and metabolomic profiling reveals sex-stratified biomarkers predicting chronicity in paediatric primary immune thrombocytopenia.","journal":"Br J Haematol","issue":"2026 May 3. doi: 10.1111\/bjh.70521. Online ahead of print","author":"Xue Y, Zhang R, Liang D, Xu Y, Tian Z, Dai X, Xu W, Cao Q, Zhu H, Wang Y, Yuan Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42070774"},{"title01":"Real-world treatment patterns and outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL-AVA 3.5 study.","title02":"Real-world treatment patterns and outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL-AVA 3.5 study.","journal":"Br J Haematol","issue":"2026 May 14. doi: 10.1111\/bjh.70531. Online ahead of print","author":"Piatek C, Oladapo A, Kolodny S, Vredenburg M, Lucht S, Bland E, Pathak P, Feinberg B, Maitland H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42136034"},{"title01":"Multicenter initiative to standardize management of pediatric immune thrombocytopenia improves adherence to guidelines.","title02":"Multicenter initiative to standardize management of pediatric immune thrombocytopenia improves adherence to guidelines.","journal":"Blood advances","issue":"2026 May 12; 10(9):3304-3312. doi: 10.1182\/bloodadvances.2025018690","author":"Gunn E, Angulo PA, Badawy SM, Davini M, Elkus H, Hillier K, Kaicker S, Lebensburger J, Luke N, Scott KE, Nakano TA, Remiker A, Rifkin-Zenenberg S, Schultz CL, Buissereth T, Carrier K, Durney J, Dekermanji A, Grace RF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643186"},{"title01":"Adherence to ITP guidelines and adequate immunotherapy.","title02":"Adherence to ITP guidelines and adequate immunotherapy.","journal":"Blood advances","issue":"2026 May 12; 10(9):3301-3303. doi: 10.1182\/bloodadvances.2026019919","author":"Imbach P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42118548"},{"title01":"U2af1(S34F) and U2af1(Q157R) myeloid neoplasm-associated hotspot mutations induce distinct hematopoietic phenotypes in mice.","title02":"U2af1(S34F) and U2af1(Q157R) myeloid neoplasm-associated hotspot mutations induce distinct hematopoietic phenotypes in mice.","journal":"Leukemia","issue":"2026 May 6. doi: 10.1038\/s41375-026-02974-7. Online ahead of print","author":"Alberti MO, Nonavinkere Srivatsan S, Shao J, Fei DL, Zhu M, Pastrana CC, Chavez M, Tarnawsky SP, Grieb S, Graubert TA, Abdel-Wahab O, Walter MJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42092046"},{"title01":"Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide.","title02":"Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide.","journal":"Leukemia","issue":"2026 May; 40(5):934-945. doi: 10.1038\/s41375-026-02907-4","author":"Smallbone P, Cao K, Saliba RM, Carmarzzi Y, Al-Atrash G, Alvarez M, Rondon G, Fingrut WB, Aljawai YM, Olson AL, Alousi AM, Chen GL, Tanner MR, Zou J, Ramdial JL, Champlin RE, Shpall EJ, Oran B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41803402"},{"title01":"IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy.","title02":"IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy.","journal":"Haematologica","issue":"2026 May 1; 111(5):1625-1633. doi: 10.3324\/haematol.2025.288743","author":"Hoff FW, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike O, Zeidner JF, Olin RL, Smith CC, Schiller GJ, Curran EK, Handa SV, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Byrd JC, Madanat YF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195510"},{"title01":"A novel GATA1 variant linking germline and somatic myelodysplastic syndrome in two patients.","title02":"A novel GATA1 variant linking germline and somatic myelodysplastic syndrome in two patients.","journal":"Haematologica","issue":"2026 May 1; 111(5):1896-1901. doi: 10.3324\/haematol.2025.289133","author":"Revilla N, Atance M, Grasa JM, Garcia-Ortego A, Soto C, Rodriguez-Pinilla SM, Arquero T, Perlado S, Ledesma S, Esquinas-Tarifa E, Serrano-Lopez J, Lopez-Lorenzo JL, Velasco-Rodriguez D, Alonso-Dominguez JM, Mata R, Llamas-Sillero P, Salgado RN, Rio-Machin A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437813"},{"title01":"Outcomes of patients diagnosed with myelodysplastic syndrome or acute myeloid leukemia following solid organ transplantation.","title02":"Outcomes of patients diagnosed with myelodysplastic syndrome or acute myeloid leukemia following solid organ transplantation.","journal":"Haematologica","issue":"2026 May 14. doi: 10.3324\/haematol.2026.300856. Online ahead of print","author":"Vegivinti CTR, Montalban-Bravo G, Chien K, Hammond D, Sasaki K, Bataller A, Bouligny I, Jen WY, Swaminathan M, Loghavi S, Popat U, Garcia-Manero G, Bazinet A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42131946"},{"title01":"Rethinking the effectiveness of hypomethylating agents in myelodysplastic syndromes: the 50%-2-year wall.","title02":"Rethinking the effectiveness of hypomethylating agents in myelodysplastic syndromes: the 50%-2-year wall.","journal":"Haematologica","issue":"2026 May 1; 111(5):1523-1525. doi: 10.3324\/haematol.2025.300405","author":"Oster H, Mittelman M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568531"},{"title01":"Myelodysplastic syndrome with concomitant SF3B1 mutation and deletion of chromosome 5 long arm: outcomes and response to treatment.","title02":"Myelodysplastic syndrome with concomitant SF3B1 mutation and deletion of chromosome 5 long arm: outcomes and response to treatment.","journal":"Haematologica","issue":"2026 May 7. doi: 10.3324\/haematol.2025.300396. Online ahead of print","author":"Komrokji R, Schwabkey Z, Komrokji Z, Al Ali N, Aguirre L, Stahl M, Ball S, Mason E, Savona M, Santini V, Consagra A, Platzbecker U, Kubasch AS, Madanat Y, Fenaux P, Zhao LP, Sekeres MA, Chandhok N, Porta MD, Lanino L, DeZern A, Sallman D, Padron E, Xie Z, Sasaki K, Takaoka K, Jain A, Gonzalez MDR, Campelo MD, Garcia-Manero G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42095239"},{"title01":"Decitabine plus all-trans retinoic acid versus decitabine monotherapy for myelodysplastic syndromes with excess blasts: a multicenter, randomized controlled trial.","title02":"Decitabine plus all-trans retinoic acid versus decitabine monotherapy for myelodysplastic syndromes with excess blasts: a multicenter, randomized controlled trial.","journal":"Haematologica","issue":"2026 May 1; 111(5):1683-1693. doi: 10.3324\/haematol.2025.288526","author":"Zhou X, Lin Y, Gao Y, Ge Z, Huang L, Zhang J, Cheng H, Ouyang G, Meng F, Tian Y, Kuang Y, Zhou F, Sheng L, Jin W, Xu G, Ma L, Ye L, Mei C, Li J, Jin J, Tong H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262042"},{"title01":"Impact of blood donor, component and recipient variables on antigen-specific alloantibodies.","title02":"Impact of blood donor, component and recipient variables on antigen-specific alloantibodies.","journal":"Br J Haematol","issue":"2026 May 13. doi: 10.1111\/bjh.70536. Online ahead of print","author":"Wang D, Zhou L, Hendrickson JE, Karafin MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42128430"},{"title01":"Non-infectious fever defines a subgroup of patients with poorer survival outcomes in high-risk myelodysplastic syndrome.","title02":"Non-infectious fever defines a subgroup of patients with poorer survival outcomes in high-risk myelodysplastic syndrome.","journal":"Br J Haematol","issue":"2026 May 10. doi: 10.1111\/bjh.70543. Online ahead of print","author":"Nakamura T, Okamoto H, Maekura C, Niiyama-Uchibori Y, Inoue Y, Fujino T, Tsukamoto T, Shimura Y, Mizutani S, Shimura K, Kaneko H, Nakao M, Ide D, Okano A, Takahashi R, Kuwahara-Ota S, Fuchida SI, Hayata H, Nishiyama D, Murao T, Kamitsuji Y, Uchiyama H, Sasaki N, Yamaguchi J, Kawata E, Uoshima N, Kuroda J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42108389"},{"title01":"Leveraging paired germline and somatic analysis to improve the classification of DDX41 variants.","title02":"Leveraging paired germline and somatic analysis to improve the classification of DDX41 variants.","journal":"Br J Haematol","issue":"2026 May; 208(5):1584-1595. doi: 10.1111\/bjh.70411","author":"George A, Rolf E, Domeradzka M, Ribeiro S, Mills B, Hallett A, Macmahon S, Proszek P, Shaikh R, Yuan L, Hubank M, Petrizan MV, McVeigh TP, Khorashad JS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41873058"},{"title01":"High frequency of CD95(+)\/CD45RA(-) regulatory T cells defines an immunosuppressive profile associated with MDS progression.","title02":"High frequency of CD95(+)\/CD45RA(-) regulatory T cells defines an immunosuppressive profile associated with MDS progression.","journal":"Br J Haematol","issue":"2026 May 4. doi: 10.1111\/bjh.70504. Online ahead of print","author":"Vazquez R, Deredec N, Boussaid I, Boncoeur P, Knosp C, Houvert A, Zalmai L, Friedrich C, Almire C, Dussiau C, Willems L, Birsen R, Decroocq J, Bouscary D, Kosmider O, Kordasti S, Fontenay M, Simoni Y, Chapuis N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42080308"},{"title01":"Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies.","title02":"Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies.","journal":"Br J Haematol","issue":"2026 May; 208(5):1734-1744. doi: 10.1111\/bjh.70384","author":"Savic A, Taylor A, Fenaux P, Symeonidis A, Cargo C, Mittelman M, Petzer V, Sanz G, Cermak J, Langemeijer S, Hellstrom-Lindberg E, Comont T, D'Aveni M, Culligan D, Kotsianidis I, Panagiotidis P, van Marrewijk C, Smith A, Crouch S, de Witte T, Malcovati L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41704134"},{"title01":"Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.","title02":"Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.","journal":"Br J Haematol","issue":"2026 May; 208(5):1724-1733. doi: 10.1111\/bjh.70303","author":"Kim DH, Park SY, Cho H, Byun JM, Shin DY, Koh Y, Kim I, Yoon SS, Hong J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437919"},{"title01":"Exposure to Agent Orange and association with myelodysplastic syndromes.","title02":"Exposure to Agent Orange and association with myelodysplastic syndromes.","journal":"Blood advances","issue":"2026 May 12; 10(9):3054-3058. doi: 10.1182\/bloodadvances.2025019262","author":"Sekeres MA, DeZern AE, Otterstatter M, Padron E, Al Baghdadi T, Foran JM, Komrokji RS, Abel GA, Saber W, Gore SD, Lee C, Bejar R, Liu JJ, Deeg HJ, Sherman S, Lindsley RC, Walter MJ, Gillis N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41734386"},{"title01":"How I utilize somatic alterations in the diagnosis, risk stratification, and therapy of hypocellular bone marrow failure.","title02":"How I utilize somatic alterations in the diagnosis, risk stratification, and therapy of hypocellular bone marrow failure.","journal":"Blood","issue":"2026 May 7. doi: 10.1182\/blood.2025029923. Online ahead of print","author":"Groarke EM, Gutierrez-Rodrigues F, Patel BA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42095935"},{"title01":"PU.1-activated genomic regions define low-risk MDS subsets characterized by immune dysregulation and disease progression.","title02":"PU.1-activated genomic regions define low-risk MDS subsets characterized by immune dysregulation and disease progression.","journal":"Blood","issue":"2026 May 14; 147(20):2358-2374. doi: 10.1182\/blood.2025030760","author":"Vallelonga V, Gandolfi F, Zampini M, Riva E, Maggioni G, Ventura D, Saba E, Termanini A, Polletti S, Prosperini E, Crisafulli L, Campagna A, Ferrari I, Pinocchio N, Todisco G, Pedretti S, Calvi M, Di Vito C, Mavilio D, Mitro N, Ficara F, Della Porta MG, Ghisletti S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538708"},{"title01":"PU.1 inflames lower-risk MDS.","title02":"PU.1 inflames lower-risk MDS.","journal":"Blood","issue":"2026 May 14; 147(20):2283-2285. doi: 10.1182\/blood.2026033252","author":"Thoms JAI, Pimanda JE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42133330"},{"title01":"Artificial intelligence differentiates prefibrotic primary myelofibrosis with thrombocytosis from essential thrombocythemia using digitized bone marrow biopsy images.","title02":"Artificial intelligence differentiates prefibrotic primary myelofibrosis with thrombocytosis from essential thrombocythemia using digitized bone marrow biopsy images.","journal":"Leukemia","issue":"2026 May; 40(5):1018-1026. doi: 10.1038\/s41375-026-02893-7","author":"Srisuwananukorn A, Loscocco GG, Dolezal JM, Kuykendall AT, Santi R, Zhang L, Singh AM, Guglielmelli P, Vannucchi AM, Salama ME, Pearson AT, Hoffman R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41721088"},{"title01":"Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes.","title02":"Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes.","journal":"Leukemia","issue":"2026 May; 40(5):946-954. doi: 10.1038\/s41375-026-02928-z","author":"Gagnon LL, Duminuco A, Stagno F, Sobas M, Fominykh M, Virchis A, Nicolini FE, Hildt J, Bentley H, Godfrey AL, Shih LY, Chee A, Mead A, Lewandowski K, Sobieralski P, Hannah G, Reyal Y, Cummin T, Piszcz J, Yip K, Frewin R, Narayanan S, Rahman D, Ajayi A, Cervi P, Byrne J, Taylor T, Lebowa W, Pavlu J, Arami S, Ceesay M, Chraniuk D, Delage R, Condorelli A, Santana C, Radia DH, de Lavallade H, Milojkovic D, Harrison C, Harrington P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41896663"},{"title01":"New insights into JAK2 germline variant-driven stromal cell alterations and proinflammatory bone marrow niche remodeling in myeloproliferative neoplasms.","title02":"New insights into JAK2 germline variant-driven stromal cell alterations and proinflammatory bone marrow niche remodeling in myeloproliferative neoplasms.","journal":"Leukemia","issue":"2026 May; 40(5):1058-1061. doi: 10.1038\/s41375-026-02937-y","author":"Nishimura K, Ono R, Nagaharu K, Ohya E, Tsuji T, Ikejiri M, Nakamura A, Nosaka T, Tawara I, Sugimoto Y, Ohishi K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41922799"},{"title01":"MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasms.","title02":"MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasms.","journal":"Leukemia","issue":"2026 May 5. doi: 10.1038\/s41375-026-02975-6. Online ahead of print","author":"Al-Ali HK, Heidel ST, Palandri F, Heidel FH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42086932"},{"title01":"Myeloproliferative neoplasms with clinically relevant paroxysmal nocturnal hemoglobinuria: clinical correlations and outcomes.","title02":"Myeloproliferative neoplasms with clinically relevant paroxysmal nocturnal hemoglobinuria: clinical correlations and outcomes.","journal":"Haematologica","issue":"2026 May 1; 111(5):1858-1862. doi: 10.3324\/haematol.2025.289078","author":"Faldu P, Abdelaziz R, Yousuf M, Pardanani A, Patnaik M, Tefferi A, Gangat N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307118"},{"title01":"Breaking barriers in rare disease research: a pilot trial of thromboprophylaxis with apixaban versus aspirin in JAK2-Positive myeloproliferative neoplasms.","title02":"Breaking barriers in rare disease research: a pilot trial of thromboprophylaxis with apixaban versus aspirin in JAK2-Positive myeloproliferative neoplasms.","journal":"Haematologica","issue":"2026 May 7. doi: 10.3324\/haematol.2026.301040. Online ahead of print","author":"Kimpton M, Cerquozzi S, Toupin D, Ianotto JC, Villleneuve P, Siegal DM, Carrier M, Delluc A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42095240"},{"title01":"Hyperplasia, dysplasia and neoplasia are unique pathological entities. Comment on: &#8220;Clonal megakaryocyte dysplasia with normal blood values: a covert, thrombosis-prone, early myeloproliferative neoplasm&#8221;.","title02":"Hyperplasia, dysplasia and neoplasia are unique pathological entities. Comment on: &#8220;Clonal megakaryocyte dysplasia with normal blood values: a covert, thrombosis-prone, early myeloproliferative neoplasm&#8221;.","journal":"Haematologica","issue":"2026 May 14. doi: 10.3324\/haematol.2026.301164. Online ahead of print","author":"Lichtman MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42131947"},{"title01":"Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.","title02":"Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.","journal":"Br J Haematol","issue":"2026 May 3. doi: 10.1111\/bjh.70511. Online ahead of print","author":"Rampotas A, Naylor-Layland G, Brown C, Alabdulkarim A, Ryan J, Wadelin F, Alimam S, Tun PWW, Lambert J, O'Sullivan J, Wilson AJ, Tafesh L, McGregor A, Claudiani S, Innes A, Booth E, Leveson J, Knapper S, Garg M, Dubey M, Vatopoulou T, Brierley C, Leung WKN, Greenfield G, McMullin MF, Khan A, Milne K, Brian D, Godfrey A, Harrison CN, Psaila B, Harrington P, Kirkwood A, Somervaille TCP, McLornan DP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42070782"},{"title01":"Single cell long read genotyping of transcripts reveals discrete mechanisms of clonal evolution in post-MPN AML.","title02":"Single cell long read genotyping of transcripts reveals discrete mechanisms of clonal evolution in post-MPN AML.","journal":"Blood advances","issue":"2026 May 7. doi: 10.1182\/bloodadvances.2025018902. Online ahead of print","author":"Grabek J, Straube JM, Cooper L, Halder R, Zhang R, Dulige I, Barker MA, Gatehouse W, Christensen H, Amor G, Ling VY, McNamara C, Ross DM, Perkins AC, Bywater MJ, Lane SW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42101375"},{"title01":"Preliminary investigation into the association of serum free kappa light chains with risk stratification, clonal evolution and precision therapy in multiple myeloma.","title02":"Preliminary investigation into the association of serum free kappa light chains with risk stratification, clonal evolution and precision therapy in multiple myeloma.","journal":"Br J Haematol","issue":"2026 May 11. doi: 10.1111\/bjh.70541. Online ahead of print","author":"Yang C, Xiao J, Zhao N, Liu X, Li Y, Huang Y, Zhang C, Chen K, Sun M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42108956"},{"title01":"Dysplastic plasma cells in multiple myeloma.","title02":"Dysplastic plasma cells in multiple myeloma.","journal":"Br J Haematol","issue":"2026 May; 208(5):1517-1518. doi: 10.1111\/bjh.70021","author":"Barros Pinto MP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41983265"},{"title01":"High-throughput monoclonal gammopathy community monitoring programme.","title02":"High-throughput monoclonal gammopathy community monitoring programme.","journal":"Br J Haematol","issue":"2026 May; 208(5):1826-1830. doi: 10.1111\/bjh.70366","author":"Agarwal G, Campbell L, Carty O, Larham J, Knight E, Moore S, Gooding S, Kothari J, Browning J, Evans J, Ferguson L, Vieira A, Swanborough L, Roberts P, Bateman E, Sadler R, Ramasamy K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41674337"},{"title01":"Serum free light chain concentration and ratio-based criterion for myeloma-defining event, in its current version, is untenable.","title02":"Serum free light chain concentration and ratio-based criterion for myeloma-defining event, in its current version, is untenable.","journal":"Br J Haematol","issue":"2026 May; 208(5):1555-1563. doi: 10.1111\/bjh.70427","author":"Singh G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41889201"},{"title01":"Non-ICANS neurological toxicities associated with BCMA-directed CAR T-cell therapy in patients with plasma cell dyscrasia: A systematic review and pooled analysis.","title02":"Non-ICANS neurological toxicities associated with BCMA-directed CAR T-cell therapy in patients with plasma cell dyscrasia: A systematic review and pooled analysis.","journal":"Br J Haematol","issue":"2026 May; 208(5):1854-1857. doi: 10.1111\/bjh.70382","author":"Saini M, Deeksha FNU, Jandial A, Jain A, Prakash G, Khadwal A, Chakraborty R, Malhotra P, Singh C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41705773"},{"title01":"Preferred standard-of-care carfilzomib dosing in multiple myeloma: An international survey of haematologists\/oncologists.","title02":"Preferred standard-of-care carfilzomib dosing in multiple myeloma: An international survey of haematologists\/oncologists.","journal":"Br J Haematol","issue":"2026 May; 208(5):1831-1835. doi: 10.1111\/bjh.70435","author":"Banerjee R, Dong S, McCaughan G, Mehra N, Wang B, Sperling AS, Cowan AJ, Anderson LD Jr, Rajkumar SV, Kaur G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41841734"},{"title01":"Changes in patient-reported distress and symptom burden during talquetamab therapy in multiple myeloma.","title02":"Changes in patient-reported distress and symptom burden during talquetamab therapy in multiple myeloma.","journal":"Br J Haematol","issue":"2026 May; 208(5):1836-1840. doi: 10.1111\/bjh.70428","author":"Aughey E, Estrada-Merly N, Akhtar OS, Dhakal B, Mohan M, Narra R, Pasquini MC, D'Souza A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41797476"},{"title01":"Incidence and mortality of multiple myeloma: Global, regional and national estimates and projections from the Global Burden of Disease Study 2021.","title02":"Incidence and mortality of multiple myeloma: Global, regional and national estimates and projections from the Global Burden of Disease Study 2021.","journal":"Br J Haematol","issue":"2026 May; 208(5):1641-1649. doi: 10.1111\/bjh.70415","author":"Qu F, Hui M, Yang F, He Y, Wang X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41796105"},{"title01":"Patients&#8217;, clinicians&#8217; and research&#8217;s priorities on important outcomes in multiple myeloma: A mixed-methods study.","title02":"Patients&#8217;, clinicians&#8217; and research&#8217;s priorities on important outcomes in multiple myeloma: A mixed-methods study.","journal":"Br J Haematol","issue":"2026 May; 208(5):1650-1659. doi: 10.1111\/bjh.70396","author":"Mainou M, Karagiannis T, Pagkalidou E, Liakos A, Malandrakis P, Hatjiharissi E, Chissan S, Mandala E, Van Oekelen O, Vlachaki E, Papaioannou M, Terpos E, Mohyuddin GR, Tsapas A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41747758"},{"title01":"Early diagnosis of AL amyloidosis in haematology, cardiology, neurology, renal and general clinics: A British Society for Haematology Guideline.","title02":"Early diagnosis of AL amyloidosis in haematology, cardiology, neurology, renal and general clinics: A British Society for Haematology Guideline.","journal":"Br J Haematol","issue":"2026 May 7. doi: 10.1111\/bjh.70472. Online ahead of print","author":"Garg M, Choudhuri S, Parrish C, Hawkins S, Lachmann H, Clayton L, Richardson J, Chan YLT, Wechalekar A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42099096"},{"title01":"Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma.","title02":"Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma.","journal":"Blood advances","issue":"2026 May 12; 10(9):2925-2936. doi: 10.1182\/bloodadvances.2025019050","author":"Atrash S, Symanowski J, Robinson M, Flynn C, Norek S, Cox R, Plott M, Bumgarner K, Rhinehardt D, Begic X, Ndiaye A, Robinson J, Friend R, Paul B, Varga C, Ferreri C, Pineda-Roman M, Foureau D, Bhutani M, Voorhees P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41719502"},{"title01":"Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis.","title02":"Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis.","journal":"Blood advances","issue":"2026 May 12; 10(9):2937-2946. doi: 10.1182\/bloodadvances.2025019231","author":"Tan CR, Usmani S, Derkach A, de Meneze Silva Corraes A, Parrondo R, Ailawadhi S, Asoori S, Dave M, Popat R, Morjaria O, Hajek R, Mihalyova J, Htut M, Janakiram M, Visram A, Kastritis E, Dimopoulos MA, Martinez-Lopez J, Nagarajan C, Bal S, Costa LJ, Einsele H, Steinbrunn T, Waldschmidt JM, Riedhammer C, Banerjee R, Chng WJ, Tso A, Lin Y, Martin T, Mian H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41734378"},{"title01":"Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONE.","title02":"Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONE.","journal":"Blood advances","issue":"2026 May 5. doi: 10.1182\/bloodadvances.2025019323. Online ahead of print","author":"Bahlis NJ, Facon T, San-Miguel JF, Usmani SZ, Dimopoulos MA, Moreau P, Zweegman S, Perrot A, Manier S, Chari A, Raje NS, Orlowski RZ, Goldschmidt H, Basu S, Hulin C, Weisel KC, Mohty M, Leleu X, Plesner T, Jakubowiak AJ, Cook G, Quach H, Venner CP, Cavo M, Ngo M, Bolyard K, Carson R, Borgsten F, Mateos MV, Kumar SK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42085642"},{"title01":"Feasibility of decentralized real-world monitoring of SARS-CoV-2 booster vaccines and COVID-19 outcomes in myeloma.","title02":"Feasibility of decentralized real-world monitoring of SARS-CoV-2 booster vaccines and COVID-19 outcomes in myeloma.","journal":"Blood advances","issue":"2026 May 12; 10(9):3094-3102. doi: 10.1182\/bloodadvances.2025018963","author":"Wood WA, Kumar SK, Semmel EA, James S, Schroeder MA, Chung DJ, Rosenberg A, Zonder J, Rubinstein S, D'Souza A, Martin T, Chari A, Vij R, Nooka AK, Anderson KC, Neuberg DS, Richard S, Torres K, Weiss BM, Pederson L, Derkach A, Geyer S, Usmani SZ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41734388"},{"title01":"Fiber intake associates with increased treatment response in patients with multiple myeloma along with changes in gut microbiome.","title02":"Fiber intake associates with increased treatment response in patients with multiple myeloma along with changes in gut microbiome.","journal":"Blood advances","issue":"2026 May 12; 10(9):3088-3093. doi: 10.1182\/bloodadvances.2025018598","author":"Sester LS, Galeeva I, de Castilhos J, Borisov V, Gambihler AK, Kilian M, Vonhoren D, Friedrich MJ, Poschet G, Steiger S, Chechenina A, Lettau K, Kohlberger CP, Prokoph N, Frenking J, John L, Huhn S, Reichert P, Mai EK, Rippe K, Sauer S, Muller-Tidow C, Weinhold N, Platten M, Goldschmidt H, Raab MS, Stein-Thoeringer CK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41734379"},{"title01":"Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.","title02":"Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.","journal":"Blood","issue":"2026 May 8. doi: 10.1182\/blood.2025030891. Online ahead of print","author":"Chen LY, Aleman A, Larrayoz M, Chiu H, Zhao J, Van Oekelen O, Kelly G, Kim-Schulze S, Lagana A, Jagannath S, Chow TT, Lozano T, Lasarte JJ, Hamley JC, Baker W, Ebert BL, Oppermann U, Amatangelo MD, Gandhi AK, Hagner PR, Martinez-Climent JA, Gooding S, Milne TA, Parekh S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42101964"},{"title01":"Mezigdomide reverses T-cell exhaustion through degradation of IKZF1\/IKZF3 and reinvigoration of cytokine production pathways.","title02":"Mezigdomide reverses T-cell exhaustion through degradation of IKZF1\/IKZF3 and reinvigoration of cytokine production pathways.","journal":"Blood","issue":"2026 May 12. doi: 10.1182\/blood.2025030873. Online ahead of print","author":"Chiu H, Zhao J, Basavanhally T, Hsu CC, Amatangelo MD, Jain G, Bjorklund CC, Huang TH, Chen LY, Milne TA, Gooding S, Parekh S, Gandhi AK, Ortiz Estevez M, Hagner PR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42118707"},{"title01":"How we prevent infections in adults receiving bispecific antibody therapies for advanced B-cell malignancies.","title02":"How we prevent infections in adults receiving bispecific antibody therapies for advanced B-cell malignancies.","journal":"Blood","issue":"2026 May 12. doi: 10.1182\/blood.2025032298. Online ahead of print","author":"Rejeski K, Banerjee R, Hill JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42118692"},{"title01":"Proteasome subunit PSMD1 is a key therapeutic target in multiple myeloma.","title02":"Proteasome subunit PSMD1 is a key therapeutic target in multiple myeloma.","journal":"Blood","issue":"2026 May 14; 147(20):2344-2357. doi: 10.1182\/blood.2025029358","author":"Du T, Fang T, Pillai S, Ray A, Wang M, Wan X, Wen K, Liu Y, Xu J, Musa MA, Liu X, Fulciniti M, Munshi NC, Garbicz F, Carrasco RD, Yao Y, Zhang Z, Song Y, Anderson KC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632828"},{"title01":"Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome.","title02":"Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome.","journal":"Blood","issue":"2026 May 7; 147(19):2226-2237. doi: 10.1182\/blood.2025031287","author":"Davidson-Swinton HR, Iyer S, Kolchinski A, Salem JA, DeBoy EA, Kilada AG, Hwang JS, Jain T, Keel SB, Gocke CD, Zou YS, Schratz KE, Armanios M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41564438"},{"title01":"Ruxolitinib for ciltacabtagene autoleucel-associated refractory diarrhea.","title02":"Ruxolitinib for ciltacabtagene autoleucel-associated refractory diarrhea.","journal":"Blood","issue":"2026 May 7; 147(19):2215-2225. doi: 10.1182\/blood.2025032347","author":"Blumenberg V, Birocchi F, Shih A, Escobar G, Mucci A, Armstrong A, Cirstea D, Harris DL, Bozym DJ, Puliafito BR, Newcomb R, Dhawale TM, Johnson PC, El-Jawahri A, Jeffrey R 3rd, Barselau AL, Li A, Emmanuel-Alejandro E, Cook D, Lindell K, Luk SO, Chaffee R, Yee AJ, Branagan A, Raje N, Graham CE, Hammond SP, Bushman FD, Roche AM, Reddy S, McFarland AG, Chen YB, Choi BD, Mount CW, Dougan M, Nardi V, Sohani AR, Gallagher KME, Maus MV, Frigault MJ, Leick MB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592291"},{"title01":"How I Treat Plasma Cell Leukemia.","title02":"How I Treat Plasma Cell Leukemia.","journal":"Blood","issue":"2026 May 1. doi: 10.1182\/blood.2025032145. Online ahead of print","author":"Al Hadidi S, van Rhee F, Anderson LD Jr","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42066212"},{"title01":"Chronic active Epstein-Barr virus disease in children: Clinical outcomes and prognostic risk factors from a 149-patient cohort.","title02":"Chronic active Epstein-Barr virus disease in children: Clinical outcomes and prognostic risk factors from a 149-patient cohort.","journal":"Br J Haematol","issue":"2026 May; 208(5):1704-1712. doi: 10.1111\/bjh.70454","author":"Zhang Q, Zhao YZ, Wang D, Ma HH, Cui L, Li WJ, Wang CJ, Li ZG, Zhang R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41905747"},{"title01":"Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.","title02":"Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.","journal":"Br J Haematol","issue":"2026 May; 208(5):1724-1733. doi: 10.1111\/bjh.70303","author":"Kim DH, Park SY, Cho H, Byun JM, Shin DY, Koh Y, Kim I, Yoon SS, Hong J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437919"},{"title01":"Clinical features and prognostic factors of adult systemic chronic active EBV disease: A retrospective analysis in Japan.","title02":"Clinical features and prognostic factors of adult systemic chronic active EBV disease: A retrospective analysis in Japan.","journal":"Br J Haematol","issue":"2026 May 10. doi: 10.1111\/bjh.70532. Online ahead of print","author":"Fuseya A, Yamamoto M, Nishio M, Kitabayashi R, Hirakawa A, Yasui H, Umezawa Y, Tanaka K, Tamai H, Uemura Y, Oshima K, Sano F, Mori T, Koike R, Ohga S, Arai A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42108635"},{"title01":"Ravulizumab for treatment of paroxysmal nocturnal hemoglobinuria during pregnancy.","title02":"Ravulizumab for treatment of paroxysmal nocturnal hemoglobinuria during pregnancy.","journal":"Blood advances","issue":"2026 May 12; 10(9):3067-3074. doi: 10.1182\/bloodadvances.2025019253","author":"Hochsmann B, Gerber GF, Leopold W, Patel BJ, Gavriilaki E, Hefter A, Kalhammer U, Opitz S, Marx-Hoffmann A, Knight DB, Brodsky RA, Marvaki A, Lalayanni C, Korper S, Babushok DV, Schrezenmeier H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610317"},{"title01":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory Richter transformation.","title02":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory Richter transformation.","journal":"Blood advances","issue":"2026 May 12; 10(9):3011-3019. doi: 10.1182\/bloodadvances.2025017914","author":"Lewis KL, Assouline SE, Baker R, Bartlett NL, El-Sharkawi D, Giri P, Ku M, Matasar M, Schuster S, Radford J, Wei MC, Yin S, Kwan A, To I, Raghavan V, Budde LE, Cheah CY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643182"},{"title01":"Metabolic Profiling and Perturbations of Human CD34+ Hematopoietic Stem and Progenitors to Regulate HSPC Function.","title02":"Metabolic Profiling and Perturbations of Human CD34+ Hematopoietic Stem and Progenitors to Regulate HSPC Function.","journal":"Blood advances","issue":"2026 May 6. doi: 10.1182\/bloodadvances.2025018876. Online ahead of print","author":"Yuan K, Xiong M, Yang R, Sun K, Zhang Z, Zhang S, Xiu Y, Cai B, Yang J, Ju Y, Yin H, Liang F, Sun Y, Zhao G, Zeng Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42090579"},{"title01":"Gilteritinib + chemotherapy in children with relapsed\/refractory FLT3-ITD AML: results from the phase 1\/2 SKIPPER trial.","title02":"Gilteritinib + chemotherapy in children with relapsed\/refractory FLT3-ITD AML: results from the phase 1\/2 SKIPPER trial.","journal":"Blood advances","issue":"2026 May 8. doi: 10.1182\/bloodadvances.2026020144. Online ahead of print","author":"Connor P, Ribeiro RC, Catala A, Norton A, Schundeln MM, Hasabou N, Delgado D, Heinloth AN, Hill JE, Gill SC, Bigirumurame T, Tasian SK, Locatelli F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42101908"},{"title01":"Outcome of second conditioned allogeneic stem cell transplant in children with non-SCID inborn errors of immunity.","title02":"Outcome of second conditioned allogeneic stem cell transplant in children with non-SCID inborn errors of immunity.","journal":"Blood advances","issue":"2026 May 12; 10(9):3207-3217. doi: 10.1182\/bloodadvances.2025015971","author":"Nademi Z, Lum SH, Gilbert P, Sirait T, Karakukcu M, Locatelli F, Schulz A, Gozdzik J, Ikinciogullari A, Kalwak K, Alsaedi H, Bierings M, Bader P, Diaz de Heredia C, Winiarski J, Masmas TN, Lankester AC, Gabriel M, Biffi A, Mitchell R, Ryhanen S, Kuskonmaz B, Corbacioglu S, Faraci M, Buechner J, Kerre T, Kulagin A, Lewalle P, Ghosh S, Schlegel PG, Eyrich M, Schwinger W, Wynn RF, Slatter M, Gennery AR, Albert MH, Neven B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41774850"},{"title01":"VLA-4 agonist promotes engraftment and immune reconstitution of allogeneic hematopoietic stem cells.","title02":"VLA-4 agonist promotes engraftment and immune reconstitution of allogeneic hematopoietic stem cells.","journal":"Blood advances","issue":"2026 May 12; 10(9):3103-3117. doi: 10.1182\/bloodadvances.2025017456","author":"He Q, Sun X, Chen LV, Yang J, Gao Y, Wan L, Cai Y, Zhou X, Shen L, Jiang P, Liu J, Ding X, Li L, Tong Y, Qiu H, Huang C, Dong B, Zhou K, Yang Y, Wang P, Liang X, Zhang Y, Zhou BO, Zhang F, Song X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758999"},{"title01":"Intensity of conditioning but not measurable residual disease status affects the outcomes of umbilical cord blood transplantation.","title02":"Intensity of conditioning but not measurable residual disease status affects the outcomes of umbilical cord blood transplantation.","journal":"Blood advances","issue":"2026 May 12; 10(9):3165-3169. doi: 10.1182\/bloodadvances.2025018519","author":"Chan LKL, Nicholson E, Chan LY, Taussig D, Potter M, Ethell M, Easdale S, Garnett C, Anthias C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41747186"},{"title01":"Long-term health outcomes in older recipients of blood or marrow transplantation: a report from the BMTSS.","title02":"Long-term health outcomes in older recipients of blood or marrow transplantation: a report from the BMTSS.","journal":"Blood advances","issue":"2026 May 12; 10(9):2951-2961. doi: 10.1182\/bloodadvances.2025018477","author":"Bhandari R, Meng Q, Hageman L, Francisco L, Ross ES, Balas N, Bosworth A, Bhatia R, Landier W, Weisdorf DJ, Wong FL, Bhatia S, Armenian SH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41734391"},{"title01":"How I Treat Plasma Cell Leukemia.","title02":"How I Treat Plasma Cell Leukemia.","journal":"Blood","issue":"2026 May 1. doi: 10.1182\/blood.2025032145. Online ahead of print","author":"Al Hadidi S, van Rhee F, Anderson LD Jr","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42066212"},{"title01":"Myeloid\/lymphoid neoplasms with FGFR1 rearrangement and pemigatinib.","title02":"Myeloid\/lymphoid neoplasms with FGFR1 rearrangement and pemigatinib.","journal":"Blood","issue":"2026 May 7; 147(19):2171-2175. doi: 10.1182\/blood.2025031016","author":"Vannucchi AM, Patel JL, Kiladjian JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779732"},{"title01":"Genetics and MRD for therapy allocation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.","title02":"Genetics and MRD for therapy allocation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.","journal":"Blood","issue":"2026 May 4. doi: 10.1182\/blood.2025032645. Online ahead of print","author":"Ribera JM, Torrent A, Morgades M, Barrena S, Ribera J, Genesca E, Gonzalez-Campos J, Martinez-Cibrian N, Montesinos P, Hernandez Sanchez A, Barba P, Zapico E Sr, Sanchez R, Novo A, Sitges M, Maluquer Artigal C, Such E, Botella C, Queipo de Llano MP, Cabrero M, Vicent A, Lopez de Ugarriza P, Tormo M, Gonzalez-Gonzalez BJ, Garcia-Cadenas I, Rodriguez-Medina C, Martinez Sanchez P, Bermudez A, Gomez-Centurion I, Herrero-Garcia M, Ciudad J, Navas-Acosta J, Hermosin L, Serrano J, Raposo-Puglia JA, Solan L, Roldan-Galiacho V, de Laiglesia A, Gomez-Perez L, Sole-Rodriguez M, Casado MS Sr, Llorente Gonzalez L, Barrios Decoud D, Vall-Llovera F, Algarra JL, Amador L, Garcia-Boyero R, Cladera A, Bergua Burgues JM, Calasanz MJJ, Granada I, Feliu E, Hernandez-Rivas JM, Orfao A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42081455"},{"title01":"Ruxolitinib for ciltacabtagene autoleucel-associated refractory diarrhea.","title02":"Ruxolitinib for ciltacabtagene autoleucel-associated refractory diarrhea.","journal":"Blood","issue":"2026 May 7; 147(19):2215-2225. doi: 10.1182\/blood.2025032347","author":"Blumenberg V, Birocchi F, Shih A, Escobar G, Mucci A, Armstrong A, Cirstea D, Harris DL, Bozym DJ, Puliafito BR, Newcomb R, Dhawale TM, Johnson PC, El-Jawahri A, Jeffrey R 3rd, Barselau AL, Li A, Emmanuel-Alejandro E, Cook D, Lindell K, Luk SO, Chaffee R, Yee AJ, Branagan A, Raje N, Graham CE, Hammond SP, Bushman FD, Roche AM, Reddy S, McFarland AG, Chen YB, Choi BD, Mount CW, Dougan M, Nardi V, Sohani AR, Gallagher KME, Maus MV, Frigault MJ, Leick MB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592291"},{"title01":"Anti-CD4 antibody-modulated transplants for GVHD prevention in hematopoietic cell transplantation.","title02":"Anti-CD4 antibody-modulated transplants for GVHD prevention in hematopoietic cell transplantation.","journal":"Blood","issue":"2026 May 14; 147(20):2402-2414. doi: 10.1182\/blood.2025031370","author":"Roth K, Loeffler D, Blumert C, Scholz A, Reiche K, Bauer M, Wickenhauser C, Schiefer D, Hilger N, Blaudszun AR, Thees J, Walter J, Tretbar US, Koehl U, Fricke S, Blache U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587074"},{"title01":"Local oxygen tension dictates hematopoietic cell growth and potency.","title02":"Local oxygen tension dictates hematopoietic cell growth and potency.","journal":"Leukemia","issue":"2026 May 15. doi: 10.1038\/s41375-026-02971-w. Online ahead of print","author":"Ropa J, Gutch S, Wathen L, Kim SJ, Park J, Newton J, Whitacre G, Aljoufi A, Cooper S, Van't Hof W, Kaplan MH, Capitano ML","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42135527"},{"title01":"Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide.","title02":"Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide.","journal":"Leukemia","issue":"2026 May; 40(5):934-945. doi: 10.1038\/s41375-026-02907-4","author":"Smallbone P, Cao K, Saliba RM, Carmarzzi Y, Al-Atrash G, Alvarez M, Rondon G, Fingrut WB, Aljawai YM, Olson AL, Alousi AM, Chen GL, Tanner MR, Zou J, Ramdial JL, Champlin RE, Shpall EJ, Oran B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41803402"},{"title01":"Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangement.","title02":"Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangement.","journal":"Leukemia","issue":"2026 May 12. doi: 10.1038\/s41375-026-02973-8. Online ahead of print","author":"Ducourneau B, Pages A, Struski S, Decamp M, Raffoux E, Berthon C, Fenwarth L, Marmouset V, Pautas C, Cluzeau T, Lebon D, Uzunov M, Pereyra P, Heiblig M, Malfuson JV, Farnault L, Dumas PY, Hieulle J, Bertoli S, Chantepie S, Auger N, Bidet A, Mozziconacci MJ, Boudry A, Luquet I, Chat L, Loyaux R, El-Mur L, Clappier E, Gardin C, Hunault M, De Botton S, Pigneux A, Penther D, Delabesse E, Itzykson R, Preudhomme C, Dombret H, Recher C, Duployez N, Micol JB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42120929"},{"title01":"MECOM promotes leukemia progression and inhibits mast cell differentiation through functional competition with GATA2.","title02":"MECOM promotes leukemia progression and inhibits mast cell differentiation through functional competition with GATA2.","journal":"Leukemia","issue":"2026 May 5. doi: 10.1038\/s41375-026-02977-4. Online ahead of print","author":"Iida K, Nakanishi M, Nakahara J, Asada S, Isobe T, Yabushita T, Fukushima T, Tanaka Y, Ozawa M, Yamada Y, Kitamura T, Yamamoto K, Goyama S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42086934"},{"title01":"Intracellular IL-23R is necessary for mitotic spindle formation and viability in AML.","title02":"Intracellular IL-23R is necessary for mitotic spindle formation and viability in AML.","journal":"Leukemia","issue":"2026 May; 40(5):906-917. doi: 10.1038\/s41375-026-02949-8","author":"Duong N, Khan DH, Thomas GE, Feng Y, Hurren R, Lee JB, St-Germain J, Drimmer L, Yan Y, Zhang LX, Fang KK, Ling D, Ma ML, MacLean N, Gronda M, Rondeau V, Brown BD, Matellan L, Jones CL, Chang H, Arruda A, Xie S, Pelletier L, Minden MD, Zhang L, Kornblau SM, Raught B, Jacobs K, Jacobs MG, Goede D, Spadavecchio V, Schimmer AD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41998300"},{"title01":"Haploidentical versus matched unrelated donor transplantation with post-transplant cyclophosphamide: a platform-dependent machine learning analysis of donor age.","title02":"Haploidentical versus matched unrelated donor transplantation with post-transplant cyclophosphamide: a platform-dependent machine learning analysis of donor age.","journal":"Leukemia","issue":"2026 May; 40(5):1009-1017. doi: 10.1038\/s41375-026-02903-8","author":"Mehta RS, Kanakry CG, Nawas M, Lazaryan A, Kanakry JA, Holtan S, Al-Juhaishi T, Rimando JC, Singh A, Saultz J, Mccurdy SR, Milano F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41986623"},{"title01":"Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX models.","title02":"Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX models.","journal":"Leukemia","issue":"2026 May; 40(5):918-924. doi: 10.1038\/s41375-026-02957-8","author":"Kandarpa M, Peterson LF, Potu H, Ramappan M, Liu Y, Polk A, Wang S, Talpaz M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41986621"},{"title01":"Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia.","title02":"Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 May; 40(5):1027-1034. doi: 10.1038\/s41375-026-02867-9","author":"Lecornec N, Rabian F, Dourthe ME, Chevillon F, Yakouben K, Chaillou D, Caillat-Zucman S, Cuffel A, Lesprit E, Arnould A, Naudin J, Roupret-Serzec J, Parquet N, Brignier A, Guerin-El Khourouj V, Lainey E, Caye-Eude A, Arfeuille C, Clappier E, Kim R, Mathis S, Chaix ML, Azoulay E, Dalle JH, Madelaine I, Larghero J, Baruchel A, Boissel N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41735483"},{"title01":"First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.","title02":"First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.","journal":"J Clin Oncol","issue":"2026 May 10; 44(14):1323-1336. doi: 10.1200\/JCO-25-01966","author":"Rettinger E, Heckl D, Hutter M, Salzmann-Manrique E, Luedtke M, Huenecke S, Bremm M, Cappel C, Bug G, Greil J, Meisel R, Wagner-Drouet EM, Serve H, Gungor T, Klusmann JH, Klingebiel T, Bader P, Bonig H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41941697"},{"title01":"Shifting paradigms from myeloablation to immune modulation: pre-transplant immune-suppression and post-transplant cyclophosphamide in human leucocyte antigen identical related donor hematopoietic stem cell transplantation for sickle cell disease.","title02":"Shifting paradigms from myeloablation to immune modulation: pre-transplant immune-suppression and post-transplant cyclophosphamide in human leucocyte antigen identical related donor hematopoietic stem cell transplantation for sickle cell disease.","journal":"Haematologica","issue":"2026 May 14. doi: 10.3324\/haematol.2026.300729. Online ahead of print","author":"Kharya G, Nirmal G, Chadha V, Ramalingam S, Gupta N, Baby E, Bakane A, Mukherjee S, Verma S, Jain A, Chowdhry M, Sharma S, Kuttappan S, Yadav H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42131937"},{"title01":"Impact of hematopoietic cell transplantation and quizartinib in patients with newly diagnosed FLT3-internal tandem duplication-negative acute myeloid leukemia: results from the QUIWI study.","title02":"Impact of hematopoietic cell transplantation and quizartinib in patients with newly diagnosed FLT3-internal tandem duplication-negative acute myeloid leukemia: results from the QUIWI study.","journal":"Haematologica","issue":"2026 May 14. doi: 10.3324\/haematol.2026.300855. Online ahead of print","author":"Lloret-Madrid P, Rodriguez-Veiga R, Bergua JM, Algarra JLA, Botella C, Rodriguez-Arboli E, Bernal T, Tormo M, Calbacho M, Salamero O, Serrano J, Noriega V, Lopez-Lopez JA, Vives S, Lopez-Lorenzo JL, Colorado M, Vidriales MB, Boyero RG, Olave MT, Herrera P, Arce O, Barrios M, Sayas MJ, Polo M, Gomez-Roncero MI, Barragan E, Ayala R, Chillon C, Calasanz MJ, Paiva B, Boluda B, Casas-Aviles I, Sanchez MJ, Rodriguez-Medina C, Cuevas L, Raposo-Puglia JA, Mateos MC, Olivares M, Martinez-Chamorro C, Alonso N, Suarez S, Sanchez-Vadillo I, Rodriguez MS, Gonzalez BJ, Martinez-Frances A, Cuello R, Fernandez A, Martinez-Cuadron D, Labrador J, Montesinos P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42131933"},{"title01":"Novel and emerging therapeutic strategies for clonal hematopoiesis.","title02":"Novel and emerging therapeutic strategies for clonal hematopoiesis.","journal":"Haematologica","issue":"2026 May 1; 111(5):1566-1577. doi: 10.3324\/haematol.2025.287443","author":"Hosseini M, Chan SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41230698"},{"title01":"Age-related differences in donor selection priorities for allogeneic hematopoietic transplantation.","title02":"Age-related differences in donor selection priorities for allogeneic hematopoietic transplantation.","journal":"Haematologica","issue":"2026 May 1; 111(5):1662-1672. doi: 10.3324\/haematol.2025.288004","author":"Kawamura K, Kanda J, Seo S, Kimura F, Hirayama M, Uchida N, Doki N, Takeda W, Nishida T, Katayama Y, Tanaka M, Sawa M, Yoshihara S, Eto T, Kawakita T, Nakamae H, Ota S, Ishimaru F, Fukuda T, Atsuta Y, Kanda Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931859"},{"title01":"Loss of endothelial miR-126 drives age-related decline in hematopoiesis.","title02":"Loss of endothelial miR-126 drives age-related decline in hematopoiesis.","journal":"Haematologica","issue":"2026 May 1; 111(5):1646-1661. doi: 10.3324\/haematol.2025.288736","author":"Zhao D, Nguyen LXT, Gong X, Chen F, Zhao X, Chen MH, Marcucci G, Zhang B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41342184"},{"title01":"Lipid dysregulation after hematopoietic stem cell transplant.","title02":"Lipid dysregulation after hematopoietic stem cell transplant.","journal":"Haematologica","issue":"2026 May 1; 111(5):1634-1645. doi: 10.3324\/haematol.2025.288933","author":"Koo J, Langenberg L, Zhao X, Setchell KR, Lake KE, Luebbering N, Walter E, Lane A, Myers KC, Reynaud D, Sabulski A, Teusink-Cross A, Jodele S, Davies SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437821"},{"title01":"Clonal hematopoiesis driver mutations: molecular mechanisms and clinical implications &#8211; inclusive fitness of pre-leukemic hematopoietic stem and progenitor cells through pro-inflammatory features of their progeny.","title02":"Clonal hematopoiesis driver mutations: molecular mechanisms and clinical implications &#8211; inclusive fitness of pre-leukemic hematopoietic stem and progenitor cells through pro-inflammatory features of their progeny.","journal":"Haematologica","issue":"2026 May 1; 111(5):1578-1583. doi: 10.3324\/haematol.2025.287480","author":"Bacharach T, Duek A, Shlush LI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609026"},{"title01":"Treosulfan-fludarabine conditioning in infants with severe combined immunodeficiencies: Extended study of the UK paediatric treosulfan study.","title02":"Treosulfan-fludarabine conditioning in infants with severe combined immunodeficiencies: Extended study of the UK paediatric treosulfan study.","journal":"Br J Haematol","issue":"2026 May; 208(5):1713-1723. doi: 10.1111\/bjh.70453","author":"Lum SH, Greener S, Memon IL, Amrolia P, Nademi Z, Chiesa R, Silva J, Young H, Owens S, Williams E, Ng KF, Flood T, Gennery AR, Hambleton S, Rao K, Slatter M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41958357"},{"title01":"An oncogenic, truncated FGFR1 variant cooperates with SPFQ\/NONO to regulate gene transcription in FGFR1-driven leukaemia.","title02":"An oncogenic, truncated FGFR1 variant cooperates with SPFQ\/NONO to regulate gene transcription in FGFR1-driven leukaemia.","journal":"Br J Haematol","issue":"2026 May; 208(5):1564-1571. doi: 10.1111\/bjh.70426","author":"Cowell JK, Fang X, Mori SF, Hu T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41830421"},{"title01":"Chronic active Epstein-Barr virus disease in children: Clinical outcomes and prognostic risk factors from a 149-patient cohort.","title02":"Chronic active Epstein-Barr virus disease in children: Clinical outcomes and prognostic risk factors from a 149-patient cohort.","journal":"Br J Haematol","issue":"2026 May; 208(5):1704-1712. doi: 10.1111\/bjh.70454","author":"Zhang Q, Zhao YZ, Wang D, Ma HH, Cui L, Li WJ, Wang CJ, Li ZG, Zhang R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41905747"},{"title01":"Serotherapy in transplant: Getting it right!","title02":"Serotherapy in transplant: Getting it right!","journal":"Br J Haematol","issue":"2026 May; 208(5):1885-1886. doi: 10.1111\/bjh.70456","author":"Wynn R, Admiraal R, Lindemans C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41937680"},{"title01":"Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies.","title02":"Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies.","journal":"Br J Haematol","issue":"2026 May; 208(5):1734-1744. doi: 10.1111\/bjh.70384","author":"Savic A, Taylor A, Fenaux P, Symeonidis A, Cargo C, Mittelman M, Petzer V, Sanz G, Cermak J, Langemeijer S, Hellstrom-Lindberg E, Comont T, D'Aveni M, Culligan D, Kotsianidis I, Panagiotidis P, van Marrewijk C, Smith A, Crouch S, de Witte T, Malcovati L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41704134"},{"title01":"Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.","title02":"Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.","journal":"Br J Haematol","issue":"2026 May; 208(5):1724-1733. doi: 10.1111\/bjh.70303","author":"Kim DH, Park SY, Cho H, Byun JM, Shin DY, Koh Y, Kim I, Yoon SS, Hong J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437919"},{"title01":"Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.","title02":"Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.","journal":"Br J Haematol","issue":"2026 May 3. doi: 10.1111\/bjh.70511. Online ahead of print","author":"Rampotas A, Naylor-Layland G, Brown C, Alabdulkarim A, Ryan J, Wadelin F, Alimam S, Tun PWW, Lambert J, O'Sullivan J, Wilson AJ, Tafesh L, McGregor A, Claudiani S, Innes A, Booth E, Leveson J, Knapper S, Garg M, Dubey M, Vatopoulou T, Brierley C, Leung WKN, Greenfield G, McMullin MF, Khan A, Milne K, Brian D, Godfrey A, Harrison CN, Psaila B, Harrington P, Kirkwood A, Somervaille TCP, McLornan DP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42070782"},{"title01":"High frequency of CD95(+)\/CD45RA(-) regulatory T cells defines an immunosuppressive profile associated with MDS progression.","title02":"High frequency of CD95(+)\/CD45RA(-) regulatory T cells defines an immunosuppressive profile associated with MDS progression.","journal":"Br J Haematol","issue":"2026 May 4. doi: 10.1111\/bjh.70504. Online ahead of print","author":"Vazquez R, Deredec N, Boussaid I, Boncoeur P, Knosp C, Houvert A, Zalmai L, Friedrich C, Almire C, Dussiau C, Willems L, Birsen R, Decroocq J, Bouscary D, Kosmider O, Kordasti S, Fontenay M, Simoni Y, Chapuis N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42080308"},{"title01":"Haematopoietic stem cell transplantation outcomes for teenage and young adult patients with acute leukaemia: A British Society of Blood and Marrow Transplantation and Cellular Therapy registry study.","title02":"Haematopoietic stem cell transplantation outcomes for teenage and young adult patients with acute leukaemia: A British Society of Blood and Marrow Transplantation and Cellular Therapy registry study.","journal":"Br J Haematol","issue":"2026 May; 208(5):1745-1757. doi: 10.1111\/bjh.70421","author":"McIlroy G, Carpenter B, Hough R, James B, Besley C, Nicholson E, Amrolia P, Mirci-Danicar O, Furness CL, Gibson B, Potter V, Pearce R, Lee J, Abamba C, Castleton A, Malladi R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41813254"},{"title01":"Clinical features and prognostic factors of adult systemic chronic active EBV disease: A retrospective analysis in Japan.","title02":"Clinical features and prognostic factors of adult systemic chronic active EBV disease: A retrospective analysis in Japan.","journal":"Br J Haematol","issue":"2026 May 10. doi: 10.1111\/bjh.70532. Online ahead of print","author":"Fuseya A, Yamamoto M, Nishio M, Kitabayashi R, Hirakawa A, Yasui H, Umezawa Y, Tanaka K, Tamai H, Uemura Y, Oshima K, Sano F, Mori T, Koike R, Ohga S, Arai A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42108635"},{"title01":"Predictors of renal response in AL amyloidosis following anti-plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotype.","title02":"Predictors of renal response in AL amyloidosis following anti-plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotype.","journal":"Br J Haematol","issue":"2026 May 10. doi: 10.1111\/bjh.70542. Online ahead of print","author":"Rees MJ, Yohannan B, Geyer S, Atallah-Yunes SA, Toumeh N, Gertz M, Dispenzieri A, Leung N, Hayman S, Buadi F, Cook J, Dingli D, Warsame R, Kapoor P, Binder M, Kourelis T, Gonsalves W, Rajkumar SV, Kumar S, Muchtar E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42108212"},{"title01":"Gilteritinib + chemotherapy in children with relapsed\/refractory FLT3-ITD AML: results from the phase 1\/2 SKIPPER trial.","title02":"Gilteritinib + chemotherapy in children with relapsed\/refractory FLT3-ITD AML: results from the phase 1\/2 SKIPPER trial.","journal":"Blood advances","issue":"2026 May 8. doi: 10.1182\/bloodadvances.2026020144. Online ahead of print","author":"Connor P, Ribeiro RC, Catala A, Norton A, Schundeln MM, Hasabou N, Delgado D, Heinloth AN, Hill JE, Gill SC, Bigirumurame T, Tasian SK, Locatelli F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42101908"},{"title01":"Outcome of second conditioned allogeneic stem cell transplant in children with non-SCID inborn errors of immunity.","title02":"Outcome of second conditioned allogeneic stem cell transplant in children with non-SCID inborn errors of immunity.","journal":"Blood advances","issue":"2026 May 12; 10(9):3207-3217. doi: 10.1182\/bloodadvances.2025015971","author":"Nademi Z, Lum SH, Gilbert P, Sirait T, Karakukcu M, Locatelli F, Schulz A, Gozdzik J, Ikinciogullari A, Kalwak K, Alsaedi H, Bierings M, Bader P, Diaz de Heredia C, Winiarski J, Masmas TN, Lankester AC, Gabriel M, Biffi A, Mitchell R, Ryhanen S, Kuskonmaz B, Corbacioglu S, Faraci M, Buechner J, Kerre T, Kulagin A, Lewalle P, Ghosh S, Schlegel PG, Eyrich M, Schwinger W, Wynn RF, Slatter M, Gennery AR, Albert MH, Neven B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41774850"},{"title01":"Metabolic Profiling and Perturbations of Human CD34+ Hematopoietic Stem and Progenitors to Regulate HSPC Function.","title02":"Metabolic Profiling and Perturbations of Human CD34+ Hematopoietic Stem and Progenitors to Regulate HSPC Function.","journal":"Blood advances","issue":"2026 May 6. doi: 10.1182\/bloodadvances.2025018876. Online ahead of print","author":"Yuan K, Xiong M, Yang R, Sun K, Zhang Z, Zhang S, Xiu Y, Cai B, Yang J, Ju Y, Yin H, Liang F, Sun Y, Zhao G, Zeng Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42090579"},{"title01":"Phase 1\/2 trials of donor regulatory T cells for the treatment of steroid-refractory chronic graft-versus-host disease.","title02":"Phase 1\/2 trials of donor regulatory T cells for the treatment of steroid-refractory chronic graft-versus-host disease.","journal":"Blood advances","issue":"2026 May 12; 10(9):2904-2915. doi: 10.1182\/bloodadvances.2025017996","author":"Soares MVD, Gomez VE, Azevedo RI, Pereira PNG, Velazquez TC, Mendes L, Alho AC, Garcia-Guerrero E, Garcia-Calderon CB, Tharmaratnam K, Cabral IA, Ribeiro AC, Juncal C, Roncon S, Pais AT, Gil AR, Espada E, Rodrigues A, Garcao A, Yaspo ML, Warnatz HJ, Lehrach H, Ward L, Barbosa-Morais NL, Quintas AM, Palmela P, Caldas C, Ferreira R, Leite L, Martins C, Lourenco F, Moreno R, Campilho F, Cheyne CP, Garcia-Finana M, Campos A, Baron F, Arpinati M, Hoffmann P, Edinger M, Koreth J, Ritz J, Vaz CP, Perez-Simon JA, Lacerda JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637631"},{"title01":"VLA-4 agonist promotes engraftment and immune reconstitution of allogeneic hematopoietic stem cells.","title02":"VLA-4 agonist promotes engraftment and immune reconstitution of allogeneic hematopoietic stem cells.","journal":"Blood advances","issue":"2026 May 12; 10(9):3103-3117. doi: 10.1182\/bloodadvances.2025017456","author":"He Q, Sun X, Chen LV, Yang J, Gao Y, Wan L, Cai Y, Zhou X, Shen L, Jiang P, Liu J, Ding X, Li L, Tong Y, Qiu H, Huang C, Dong B, Zhou K, Yang Y, Wang P, Liang X, Zhang Y, Zhou BO, Zhang F, Song X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758999"},{"title01":"How I utilize somatic alterations in the diagnosis, risk stratification, and therapy of hypocellular bone marrow failure.","title02":"How I utilize somatic alterations in the diagnosis, risk stratification, and therapy of hypocellular bone marrow failure.","journal":"Blood","issue":"2026 May 7. doi: 10.1182\/blood.2025029923. Online ahead of print","author":"Groarke EM, Gutierrez-Rodrigues F, Patel BA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42095935"},{"title01":"Procr+ endothelial progenitor cells govern hematopoiesis through fine-tuning mesenchymal stem cell niche signals.","title02":"Procr+ endothelial progenitor cells govern hematopoiesis through fine-tuning mesenchymal stem cell niche signals.","journal":"Blood","issue":"2026 May 8. doi: 10.1182\/blood.2025031474. Online ahead of print","author":"Xu C, Lv X, Yang S, Lv Y, Zheng Y, Wang YX, Hui Y, Sun G, Zhao X, Ma LY, Duan H, Zhang L, Pu S, Sun L, Li X, He Y, Fang W, Yang M, Suda T, Chen Q, Cheng T, Cheng H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42101967"},{"title01":"Erratum: Lenalidomide Plus Rituximab for Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.","title02":"Erratum: Lenalidomide Plus Rituximab for Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.","journal":"J Clin Oncol","issue":"2026 May 13; JCO2601085. doi: 10.1200\/JCO-26-01085. Online ahead of print","author":"Leonard JP, Trneny M, Zhang H, Nowakowski GS, Izutsu K, Fowler N, Thieblemont C, Zinzani PL, Gkasiamis A, Ahn JR, Gribben JG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42127332"},{"title01":"The development and preliminary validation of the CTCL-PRO-20: a novel quality of life survey for patients with cutaneous T-cell lymphoma.","title02":"The development and preliminary validation of the CTCL-PRO-20: a novel quality of life survey for patients with cutaneous T-cell lymphoma.","journal":"Haematologica","issue":"2026 May 7. doi: 10.3324\/haematol.2025.300426. Online ahead of print","author":"Akkad N, Jeffe DB, Krause A, Al-Hammadi N, Watkins M, Musiek A, Mehta-Shah N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42095261"},{"title01":"Optimizing bone health in lymphoma survivors: denosumab superiority to alendronate for R-CHOP-like therapy (the DENOSULY phase III randomized controlled trial).","title02":"Optimizing bone health in lymphoma survivors: denosumab superiority to alendronate for R-CHOP-like therapy (the DENOSULY phase III randomized controlled trial).","journal":"Haematologica","issue":"2026 May 7. doi: 10.3324\/haematol.2026.300564. Online ahead of print","author":"Kikuchi S, Negoro E, Horaguchi R, Fujihira T, Nabe Y, Minemura T, Ono K, Kamihara Y, Wada A, Dang NH, Masaki Y, Miyamoto T, Yamauchi T, Sato T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42095246"},{"title01":"SWI\/SNF alterations define a subgroup with poorer outcome among patients with aggressive forms of adult T-cell leukemia\/lymphoma.","title02":"SWI\/SNF alterations define a subgroup with poorer outcome among patients with aggressive forms of adult T-cell leukemia\/lymphoma.","journal":"Haematologica","issue":"2026 May 7. doi: 10.3324\/haematol.2026.300706. Online ahead of print","author":"Loyaux R, Chraibi S, Pesic M, Debus L, Suez-Panama V, Fuseau P, Hurlot Q, Danu A, Verge V, Meniane JC, Ghez D, Marzac C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42095244"},{"title01":"Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma.","title02":"Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma.","journal":"Br J Haematol","issue":"2026 May; 208(5):1535-1550. doi: 10.1111\/bjh.70374","author":"Hsu CM, Hsu JF, Huang JF, Liu YC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41721497"},{"title01":"Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.","title02":"Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.","journal":"Br J Haematol","issue":"2026 May; 208(5):1816-1820. doi: 10.1111\/bjh.70401","author":"Rigolin GM, Soddu S, Dondolin R, Frustaci AM, Scortechini I, Mauro FR, Angotzi F, Motta M, Scarfo L, Mengarelli A, Giordano A, Martinelli S, Patti C, Sportoletti P, Sanna A, Maschio N, Riccioni R, Vigano CV, Tafuri A, Piciocchi A, Fazi P, Luminari S, Ferreri AJM, Gini G, Ghia P, Cuneo A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41806221"},{"title01":"Is universal CAR T-cell referral absolutely required for transplant-ineligible patients with primary refractory or early relapsed DLBCL?","title02":"Is universal CAR T-cell referral absolutely required for transplant-ineligible patients with primary refractory or early relapsed DLBCL?","journal":"Br J Haematol","issue":"2026 May 15. doi: 10.1111\/bjh.70559. Online ahead of print","author":"Dimou M, Vassilakopoulos TP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42141731"},{"title01":"Impact of rituximab maintenance on survival in patients with mantle cell lymphoma: a population-based cohort study.","title02":"Impact of rituximab maintenance on survival in patients with mantle cell lymphoma: a population-based cohort study.","journal":"Blood advances","issue":"2026 May 12; 10(9):2916-2924. doi: 10.1182\/bloodadvances.2025018667","author":"Stedema F, Brink M, Huisman F, van Rijn R, Sijs-Szabo A, Nijhof I, Diepstra A, Vergote V, van Gorkum G, Flinsenberg T, Huls G, van Meerten T, Doorduijn J, Plattel W, Nijland M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637634"},{"title01":"HNRNPU Mutations Redirect Cell Cycle Control to E2F in MYC-Driven Lymphomas.","title02":"HNRNPU Mutations Redirect Cell Cycle Control to E2F in MYC-Driven Lymphomas.","journal":"Blood advances","issue":"2026 May 12. doi: 10.1182\/bloodadvances.2025019135. Online ahead of print","author":"Qureshi Q, Coyle KM, Brown C, Thomas N, Collinge B, Dreval K, Steidl C, Scott DW, Audas TE, Morin RD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42126254"},{"title01":"Prognostic Value of Combined Baseline FDG PET\/CT Radiomic Parameters in Primary Mediastinal B-Cell Lymphoma.","title02":"Prognostic Value of Combined Baseline FDG PET\/CT Radiomic Parameters in Primary Mediastinal B-Cell Lymphoma.","journal":"Blood advances","issue":"2026 May 12. doi: 10.1182\/bloodadvances.2026020168. Online ahead of print","author":"Decazes P, Rossi C, Sesques P, Becker S, Viennot M, Mihailescu SD, Lemonnier F, Durot E, Gower N, Willaume A, Oberic L, Paillassa J, Antier C, Renaud L, Tournilhac O, Thieblemont C, Besson C, Lebras L, Choquet S, Le Du K, Bonnet C, Bailly S, Damaj GL, Laribi K, Morineau N, Houot R, Chauchet A, Jardin F, Tilly H, Veresezan EL, Drieux F, Donzel M, Traverse-Glehen A, Tonnelet D, Camus V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42118857"},{"title01":"Molecular features of response and resistance to glofitamab, a T-cell engager for treatment of large B-cell lymphoma.","title02":"Molecular features of response and resistance to glofitamab, a T-cell engager for treatment of large B-cell lymphoma.","journal":"Blood advances","issue":"2026 May 12; 10(9):2977-2990. doi: 10.1182\/bloodadvances.2025016925","author":"Schmeing S, Nassiri S, Leclercq-Cohen G, Yanguez E, Husser T, Servera LA, Schlenker R, Sam J, Klein C, Umana P, Herter S, Bottos A, Bacac M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41569641"},{"title01":"Outcomes of patients over 70 years treated with brexu-cel for R\/R mantle cell lymphoma: a study from the CTIWP of EBMT.","title02":"Outcomes of patients over 70 years treated with brexu-cel for R\/R mantle cell lymphoma: a study from the CTIWP of EBMT.","journal":"Blood advances","issue":"2026 May 12; 10(9):3135-3142. doi: 10.1182\/bloodadvances.2025019367","author":"Santoro N, Mooyaart JE, Novak U, Protheroe R, Ayuk F, Dreger P, van Meerten T, Paneesha S, Sanderson R, Ram R, Northend M, Forcade E, Huynh A, Yakoub-Agha I, Hoogenboom JD, Coelho MHM, Pagliuca S, Malard F, Kuball J, Sureda A, Bazarbachi A, Ruggeri A, Rocha V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779968"},{"title01":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory Richter transformation.","title02":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory Richter transformation.","journal":"Blood advances","issue":"2026 May 12; 10(9):3011-3019. doi: 10.1182\/bloodadvances.2025017914","author":"Lewis KL, Assouline SE, Baker R, Bartlett NL, El-Sharkawi D, Giri P, Ku M, Matasar M, Schuster S, Radford J, Wei MC, Yin S, Kwan A, To I, Raghavan V, Budde LE, Cheah CY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643182"},{"title01":"LYP vs. advanced-stage CTCLs: Single-cell profiling reveals markers of self-limited vs. aggressive disease behavior.","title02":"LYP vs. advanced-stage CTCLs: Single-cell profiling reveals markers of self-limited vs. aggressive disease behavior.","journal":"Blood advances","issue":"2026 May 5. doi: 10.1182\/bloodadvances.2025017533. Online ahead of print","author":"Meledathu S, Chennareddy S, Naidu MP, Meehan SA, Adalsteinsson JA, Alkon N, Cohenour ER, Christensen G, Port LR, Fleischli A, Burnett A, Rindler K, Jonak C, Brunner PM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42085604"},{"title01":"Glofitamab crosses the blood-brain barrier and exhibits activity against primary and secondary CNS lymphoma.","title02":"Glofitamab crosses the blood-brain barrier and exhibits activity against primary and secondary CNS lymphoma.","journal":"Blood advances","issue":"2026 May 12; 10(9):3128-3132. doi: 10.1182\/bloodadvances.2025019322","author":"Neumann MA, Schneider J, Szameitat M, Schommers P, Borchmann S, Hallek M, Borchmann P, Heger JM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785308"},{"title01":"Field-testing the MALT-IPI in a single-center real-world cohort of patients with extranodal marginal zone lymphoma.","title02":"Field-testing the MALT-IPI in a single-center real-world cohort of patients with extranodal marginal zone lymphoma.","journal":"Blood advances","issue":"2026 May 12; 10(9):3186-3197. doi: 10.1182\/bloodadvances.2025019076","author":"Sunder-Plassmann V, Kiesewetter B, Simonitsch-Klupp I, Brand R, Dolak W, Mayerhoefer ME, Raderer M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41774849"},{"title01":"Persistence of PET scan positivity after chemoimmunotherapy for DLBCL.","title02":"Persistence of PET scan positivity after chemoimmunotherapy for DLBCL.","journal":"Blood advances","issue":"2026 May 12; 10(9):3061-3066. doi: 10.1182\/bloodadvances.2025019273","author":"Armitage JO, Lunning MA, Vose JM, Longo DL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41747191"},{"title01":"Long-term health outcomes in older recipients of blood or marrow transplantation: a report from the BMTSS.","title02":"Long-term health outcomes in older recipients of blood or marrow transplantation: a report from the BMTSS.","journal":"Blood advances","issue":"2026 May 12; 10(9):2951-2961. doi: 10.1182\/bloodadvances.2025018477","author":"Bhandari R, Meng Q, Hageman L, Francisco L, Ross ES, Balas N, Bosworth A, Bhatia R, Landier W, Weisdorf DJ, Wong FL, Bhatia S, Armenian SH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41734391"},{"title01":"Minimal disease detection by immunoglobulin high-throughput sequencing in pediatric Burkitt lymphoma.","title02":"Minimal disease detection by immunoglobulin high-throughput sequencing in pediatric Burkitt lymphoma.","journal":"Blood advances","issue":"2026 May 12; 10(9):2947-2950. doi: 10.1182\/bloodadvances.2025019436","author":"Craig SM, Okeson KR, Adlowitz DG, Baker C, Rock PJ, Burack R, Fries C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41734384"},{"title01":"Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM.","title02":"Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM.","journal":"Blood advances","issue":"2026 May 12; 10(9):2962-2966. doi: 10.1182\/bloodadvances.2025019303","author":"Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Ribrag V, Lin Y, Bhatnagar R, Braun R, Montheard S, Abramson JS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41707107"},{"title01":"Polatuzumab vedotin-containing regimens as bridge to CART: analysis from the CART-SIE study.","title02":"Polatuzumab vedotin-containing regimens as bridge to CART: analysis from the CART-SIE study.","journal":"Blood advances","issue":"2026 May 5. doi: 10.1182\/bloodadvances.2025018749. Online ahead of print","author":"Gabrielli G, Casadei B, Chiappella A, Tisi MC, Galli E, Cutini I, Di Rocco A, Donzelli L, Martino M, Policastro G, Crescimanno A, Petruzzellis G, Stella F, Visco C, Krampera M, Farina M, Angelillo P, Brunello L, Bruno B, Mannina D, Novo M, Grillo G, Argnani L, Bonifazi F, Corradini P, Zinzani PL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42085605"},{"title01":"Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed\/refractory B-cell non-Hodgkin lymphoma.","title02":"Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed\/refractory B-cell non-Hodgkin lymphoma.","journal":"Blood advances","issue":"2026 May 5. doi: 10.1182\/bloodadvances.2026020123. Online ahead of print","author":"McGuirk JP, Ghobadi A, Bachier CR, Shaughnessy PJ, Awan FT, Maakaron JE, Bishop MR, Ho PJ, Tam CS, Dickinson MJ, Darrah JM, Waller EK, Murthy HS, Ross A, Williams LM, Pan C, Stevens WN, Serwer L, Nguyen T, Terrett J, Kalaitzidis D, Ma A, Xu H, Benton MD, Weaver A, Cohen SB, Maziarz RT, Cheah CY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42085626"},{"title01":"Causes of excess nonlymphoma death in 58 000 patients with DLBCL diagnosed during 1997 to 2020 and followed for up to 25 years.","title02":"Causes of excess nonlymphoma death in 58 000 patients with DLBCL diagnosed during 1997 to 2020 and followed for up to 25 years.","journal":"Blood advances","issue":"2026 May 12; 10(9):3243-3254. doi: 10.1182\/bloodadvances.2025017966","author":"Challenger A, McGale P, Probert J, Barrett A, Broggio J, Collins GP, Harish KK, Roden L, Royston D, Wang Z, Darby SC, Cutter DJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779974"},{"title01":"MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay.","title02":"MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay.","journal":"Blood","issue":"2026 May 7; 147(19):2194-2202. doi: 10.1182\/blood.2025031089","author":"Heger JM, Mattlener J, Kaul H, Ferdinandus J, Schneider J, Schleifenbaum JK, Schneider G, Schaub V, Hanel M, Hellmuth JC, Dierlamm J, Martin S, Mathas S, Meissner J, Pegtel DM, Zijlstra JM, Ossowski A, Becker K, Hallek M, von Tresckow B, Borchmann P, Borchmann S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41662627"},{"title01":"Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.","title02":"Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.","journal":"Blood","issue":"2026 May 7; 147(19):2272-2277. doi: 10.1182\/blood.2025032307","author":"Dowling MR, Cliff ERS, Jeffrey A, Cashion C, Boyle S, Li J, Buss T, MacDonald R, Edelkina A, Scott HW, O'Leary NL, Keir MW, Belbachir S, Westerman DA, Tam CS, Ho PJ, Harrison SJ, Barraclough A, Inam S, Blyth E, Henden AS, Vanguru V, Dickinson MJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41701973"},{"title01":"Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome.","title02":"Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome.","journal":"Blood","issue":"2026 May 7; 147(19):2226-2237. doi: 10.1182\/blood.2025031287","author":"Davidson-Swinton HR, Iyer S, Kolchinski A, Salem JA, DeBoy EA, Kilada AG, Hwang JS, Jain T, Keel SB, Gocke CD, Zou YS, Schratz KE, Armanios M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41564438"},{"title01":"MRD testing in Hodgkin lymphoma: filling the knowledge gaps.","title02":"MRD testing in Hodgkin lymphoma: filling the knowledge gaps.","journal":"Blood","issue":"2026 May 7; 147(19):2159-2160. doi: 10.1182\/blood.2026033163","author":"Lossos IS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42096250"},{"title01":"Myeloid\/lymphoid neoplasms with FGFR1 rearrangement and pemigatinib.","title02":"Myeloid\/lymphoid neoplasms with FGFR1 rearrangement and pemigatinib.","journal":"Blood","issue":"2026 May 7; 147(19):2171-2175. doi: 10.1182\/blood.2025031016","author":"Vannucchi AM, Patel JL, Kiladjian JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779732"},{"title01":"Classic Hodgkin lymphoma with IGH::CCND1 rearrangement: evidence of clonal relation to preceding mantle cell lymphoma.","title02":"Classic Hodgkin lymphoma with IGH::CCND1 rearrangement: evidence of clonal relation to preceding mantle cell lymphoma.","journal":"Blood","issue":"2026 May 7; 147(19):2278. doi: 10.1182\/blood.2025032107","author":"Ahmed AA, Tadros S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42096246"},{"title01":"How we prevent infections in adults receiving bispecific antibody therapies for advanced B-cell malignancies.","title02":"How we prevent infections in adults receiving bispecific antibody therapies for advanced B-cell malignancies.","journal":"Blood","issue":"2026 May 12. doi: 10.1182\/blood.2025032298. Online ahead of print","author":"Rejeski K, Banerjee R, Hill JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42118692"},{"title01":"Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myeloma.","title02":"Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myeloma.","journal":"Leukemia","issue":"2026 May; 40(5):1054-1057. doi: 10.1038\/s41375-026-02941-2","author":"Waldschmidt J, Fandrei D, Hecker JS, Meggendorfer M, Truger M, Reinhard F, Shibru B, Hogner M, Gebauer A, Koppel M, Muller H, Jung J, Teschner D, Topp MS, Purcarea A, Vucinic V, Haferlach T, Bassermann F, Platzbecker U, Einsele H, Haferlach C, Kortum KM, Metzeler KH, Merz M, Gotze KS, Rasche L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41876727"},{"title01":"Smoldering multiple myeloma in transition: redefining early myeloma in the modern era.","title02":"Smoldering multiple myeloma in transition: redefining early myeloma in the modern era.","journal":"Leukemia","issue":"2026 May 5. doi: 10.1038\/s41375-026-02979-2. Online ahead of print","author":"Landgren O","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42086933"},{"title01":"Impact of frailty on infection risk in non-transplant eligible multiple myeloma patients: a systematic review and meta-analysis.","title02":"Impact of frailty on infection risk in non-transplant eligible multiple myeloma patients: a systematic review and meta-analysis.","journal":"Leukemia","issue":"2026 May; 40(5):1072-1075. doi: 10.1038\/s41375-026-02880-y","author":"Spataro F, Armentaro G, Di Gioia G, Meloni P, Rossi I, Williams M, Romiti GF, Talerico R, Villani R, Desantis V, Einsele H, Bencivenga L, Solimando AG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703031"},{"title01":"Pharmacokinetics of CAR T cells in multiple myeloma &#8211; the good, the bad, and the ugly.","title02":"Pharmacokinetics of CAR T cells in multiple myeloma &#8211; the good, the bad, and the ugly.","journal":"Leukemia","issue":"2026 May; 40(5):872-879. doi: 10.1038\/s41375-026-02933-2","author":"Merz M, Jurgens E, Fandrei D, Usmani SZ, Mailankody S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41917281"},{"title01":"CAR T-cell therapy at first relapse in myeloma &#8211; Authors&#8217; reply.","title02":"CAR T-cell therapy at first relapse in myeloma &#8211; Authors&#8217; reply.","journal":"Lancet Oncol","issue":"2026 May; 27(5):e233. doi: 10.1016\/S1470-2045(26)00181-6","author":"Einsele H, Popat R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42061376"},{"title01":"CAR T-cell therapy at first relapse in myeloma.","title02":"CAR T-cell therapy at first relapse in myeloma.","journal":"Lancet Oncol","issue":"2026 May; 27(5):e232. doi: 10.1016\/S1470-2045(26)00176-2","author":"Kim JL, Rajkumar SV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42061375"},{"title01":"From enrolment to authorship: racial and global disparities in phase 3 multiple myeloma clinical trials.","title02":"From enrolment to authorship: racial and global disparities in phase 3 multiple myeloma clinical trials.","journal":"Lancet Haematol","issue":"2026 May; 13(5):e271-e273. doi: 10.1016\/S2352-3026(26)00078-5","author":"Montelongo-Cepeda JE, Quezada-Ramirez SI, Gonzalez-Lopez GA, Noyola-Perez A, Leon AG, Gomez-Almaguer D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42069407"},{"title01":"An otherwise smouldering multiple myeloma with a solitary osteolytic lesion and soft-tissue mass.","title02":"An otherwise smouldering multiple myeloma with a solitary osteolytic lesion and soft-tissue mass.","journal":"Lancet Haematol","issue":"2026 May; 13(5):e351. doi: 10.1016\/S2352-3026(26)00015-3","author":"Piperidou A, Rondogianni P, Zorbala A, Korkolopoulou P, Kontogeorgakos V, Vassilakopoulos TP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41936370"},{"title01":"t(11;14) multiple myeloma patient: minimal residual disease after 10 years of follow-up &#8211; a case report.","title02":"t(11;14) multiple myeloma patient: minimal residual disease after 10 years of follow-up &#8211; a case report.","journal":"Haematologica","issue":"2026 May 1; 111(5):1881-1884. doi: 10.3324\/haematol.2025.288950","author":"Decheiver S, Schavgoulidze A, Maheo S, Vion PA, Lucidarme O, Corre J, Garderet L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437828"},{"title01":"Genetic alterations of SENP6 in multiple myeloma disrupt genome and proteome stability, sensitizing to proteasome inhibition.","title02":"Genetic alterations of SENP6 in multiple myeloma disrupt genome and proteome stability, sensitizing to proteasome inhibition.","journal":"Haematologica","issue":"2026 May 1; 111(5):1828-1834. doi: 10.3324\/haematol.2025.288863","author":"Herzberg F, Korenkov M, Isaakidis K, Zang C, Wirth M, Muller S, Keller U, Demel UM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41342169"},{"title01":"Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma.","title02":"Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma.","journal":"Br J Haematol","issue":"2026 May; 208(5):1535-1550. doi: 10.1111\/bjh.70374","author":"Hsu CM, Hsu JF, Huang JF, Liu YC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41721497"},{"title01":"Daratumumab, bortezomib and dexamethasone for previously treated myeloma-Real-world outcomes for 2545 patients treated in England.","title02":"Daratumumab, bortezomib and dexamethasone for previously treated myeloma-Real-world outcomes for 2545 patients treated in England.","journal":"Br J Haematol","issue":"2026 May; 208(5):1841-1845. doi: 10.1111\/bjh.70425","author":"Lawton SL, Bishton M, Thackray KE, Kipps E, Smith D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41846296"},{"title01":"A dexamethasone-free daratumumab-ixazomib regimen in frail elderly patients with relapsed or refractory multiple myeloma: Results of the IFM 2018-02 phase II study.","title02":"A dexamethasone-free daratumumab-ixazomib regimen in frail elderly patients with relapsed or refractory multiple myeloma: Results of the IFM 2018-02 phase II study.","journal":"Br J Haematol","issue":"2026 May 7. doi: 10.1111\/bjh.70512. Online ahead of print","author":"Bobin A, Macro M, Touzeau C, Mariette C, Manier S, Brechignac S, Vincent L, Hebraud B, Decaux O, Schulman S, Lenoir C, Godmer P, Parienti JJ, Paul LPS, Briant A, Leleu X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42097596"},{"title01":"Retreatment with talquetamab and pomalidomide in triple-class-BCMA-GPRC5D refractory myeloma.","title02":"Retreatment with talquetamab and pomalidomide in triple-class-BCMA-GPRC5D refractory myeloma.","journal":"Br J Haematol","issue":"2026 May 10. doi: 10.1111\/bjh.70540. Online ahead of print","author":"Rahbari KJ, Galarza Fortuna GM, Dholaria B, Sborov DW, Baljevic M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42108083"},{"title01":"Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape.","title02":"Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape.","journal":"Blood","issue":"2026 May 7; 147(19):2176-2193. doi: 10.1182\/blood.2025032536","author":"van de Donk NWCJ, Sonneveld P, Einsele H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610427"},{"title01":"PSMD1 and myeloma: striking the proteasome from a new angle.","title02":"PSMD1 and myeloma: striking the proteasome from a new angle.","journal":"Blood","issue":"2026 May 14; 147(20):2282-2283. doi: 10.1182\/blood.2025033018","author":"Milan E, Cenci S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42133328"},{"title01":"Local oxygen tension dictates hematopoietic cell growth and potency.","title02":"Local oxygen tension dictates hematopoietic cell growth and potency.","journal":"Leukemia","issue":"2026 May 15. doi: 10.1038\/s41375-026-02971-w. Online ahead of print","author":"Ropa J, Gutch S, Wathen L, Kim SJ, Park J, Newton J, Whitacre G, Aljoufi A, Cooper S, Van't Hof W, Kaplan MH, Capitano ML","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42135527"},{"title01":"Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia.","title02":"Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 May; 40(5):1027-1034. doi: 10.1038\/s41375-026-02867-9","author":"Lecornec N, Rabian F, Dourthe ME, Chevillon F, Yakouben K, Chaillou D, Caillat-Zucman S, Cuffel A, Lesprit E, Arnould A, Naudin J, Roupret-Serzec J, Parquet N, Brignier A, Guerin-El Khourouj V, Lainey E, Caye-Eude A, Arfeuille C, Clappier E, Kim R, Mathis S, Chaix ML, Azoulay E, Dalle JH, Madelaine I, Larghero J, Baruchel A, Boissel N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41735483"},{"title01":"Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangement.","title02":"Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangement.","journal":"Leukemia","issue":"2026 May 12. doi: 10.1038\/s41375-026-02973-8. Online ahead of print","author":"Ducourneau B, Pages A, Struski S, Decamp M, Raffoux E, Berthon C, Fenwarth L, Marmouset V, Pautas C, Cluzeau T, Lebon D, Uzunov M, Pereyra P, Heiblig M, Malfuson JV, Farnault L, Dumas PY, Hieulle J, Bertoli S, Chantepie S, Auger N, Bidet A, Mozziconacci MJ, Boudry A, Luquet I, Chat L, Loyaux R, El-Mur L, Clappier E, Gardin C, Hunault M, De Botton S, Pigneux A, Penther D, Delabesse E, Itzykson R, Preudhomme C, Dombret H, Recher C, Duployez N, Micol JB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42120929"},{"title01":"Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of acute myeloid leukemia.","title02":"Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of acute myeloid leukemia.","journal":"Leukemia","issue":"2026 May; 40(5):880-893. doi: 10.1038\/s41375-026-02930-5","author":"Li YR, Shen X, Chen Y, Zhu Y, Huang J, Oliai C, Yang L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41888396"},{"title01":"Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide.","title02":"Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide.","journal":"Leukemia","issue":"2026 May; 40(5):934-945. doi: 10.1038\/s41375-026-02907-4","author":"Smallbone P, Cao K, Saliba RM, Carmarzzi Y, Al-Atrash G, Alvarez M, Rondon G, Fingrut WB, Aljawai YM, Olson AL, Alousi AM, Chen GL, Tanner MR, Zou J, Ramdial JL, Champlin RE, Shpall EJ, Oran B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41803402"},{"title01":"First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.","title02":"First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.","journal":"J Clin Oncol","issue":"2026 May 10; 44(14):1323-1336. doi: 10.1200\/JCO-25-01966","author":"Rettinger E, Heckl D, Hutter M, Salzmann-Manrique E, Luedtke M, Huenecke S, Bremm M, Cappel C, Bug G, Greil J, Meisel R, Wagner-Drouet EM, Serve H, Gungor T, Klusmann JH, Klingebiel T, Bader P, Bonig H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41941697"},{"title01":"Stuck in traffic: a bispecific antibody-mediated immune re-engagement after allogeneic stem cell transplantation.","title02":"Stuck in traffic: a bispecific antibody-mediated immune re-engagement after allogeneic stem cell transplantation.","journal":"Haematologica","issue":"2026 May 14. doi: 10.3324\/haematol.2026.300890. Online ahead of print","author":"Boisclair S, Wallin M, Ko S, Gladstone DE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42131942"},{"title01":"Shifting paradigms from myeloablation to immune modulation: pre-transplant immune-suppression and post-transplant cyclophosphamide in human leucocyte antigen identical related donor hematopoietic stem cell transplantation for sickle cell disease.","title02":"Shifting paradigms from myeloablation to immune modulation: pre-transplant immune-suppression and post-transplant cyclophosphamide in human leucocyte antigen identical related donor hematopoietic stem cell transplantation for sickle cell disease.","journal":"Haematologica","issue":"2026 May 14. doi: 10.3324\/haematol.2026.300729. Online ahead of print","author":"Kharya G, Nirmal G, Chadha V, Ramalingam S, Gupta N, Baby E, Bakane A, Mukherjee S, Verma S, Jain A, Chowdhry M, Sharma S, Kuttappan S, Yadav H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42131937"},{"title01":"Lipid dysregulation after hematopoietic stem cell transplant.","title02":"Lipid dysregulation after hematopoietic stem cell transplant.","journal":"Haematologica","issue":"2026 May 1; 111(5):1634-1645. doi: 10.3324\/haematol.2025.288933","author":"Koo J, Langenberg L, Zhao X, Setchell KR, Lake KE, Luebbering N, Walter E, Lane A, Myers KC, Reynaud D, Sabulski A, Teusink-Cross A, Jodele S, Davies SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437821"},{"title01":"Age-related differences in donor selection priorities for allogeneic hematopoietic transplantation.","title02":"Age-related differences in donor selection priorities for allogeneic hematopoietic transplantation.","journal":"Haematologica","issue":"2026 May 1; 111(5):1662-1672. doi: 10.3324\/haematol.2025.288004","author":"Kawamura K, Kanda J, Seo S, Kimura F, Hirayama M, Uchida N, Doki N, Takeda W, Nishida T, Katayama Y, Tanaka M, Sawa M, Yoshihara S, Eto T, Kawakita T, Nakamae H, Ota S, Ishimaru F, Fukuda T, Atsuta Y, Kanda Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931859"},{"title01":"Treosulfan-fludarabine conditioning in infants with severe combined immunodeficiencies: Extended study of the UK paediatric treosulfan study.","title02":"Treosulfan-fludarabine conditioning in infants with severe combined immunodeficiencies: Extended study of the UK paediatric treosulfan study.","journal":"Br J Haematol","issue":"2026 May; 208(5):1713-1723. doi: 10.1111\/bjh.70453","author":"Lum SH, Greener S, Memon IL, Amrolia P, Nademi Z, Chiesa R, Silva J, Young H, Owens S, Williams E, Ng KF, Flood T, Gennery AR, Hambleton S, Rao K, Slatter M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41958357"},{"title01":"Predictors of renal response in AL amyloidosis following anti-plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotype.","title02":"Predictors of renal response in AL amyloidosis following anti-plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotype.","journal":"Br J Haematol","issue":"2026 May 10. doi: 10.1111\/bjh.70542. Online ahead of print","author":"Rees MJ, Yohannan B, Geyer S, Atallah-Yunes SA, Toumeh N, Gertz M, Dispenzieri A, Leung N, Hayman S, Buadi F, Cook J, Dingli D, Warsame R, Kapoor P, Binder M, Kourelis T, Gonsalves W, Rajkumar SV, Kumar S, Muchtar E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42108212"},{"title01":"Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.","title02":"Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.","journal":"Br J Haematol","issue":"2026 May 3. doi: 10.1111\/bjh.70511. Online ahead of print","author":"Rampotas A, Naylor-Layland G, Brown C, Alabdulkarim A, Ryan J, Wadelin F, Alimam S, Tun PWW, Lambert J, O'Sullivan J, Wilson AJ, Tafesh L, McGregor A, Claudiani S, Innes A, Booth E, Leveson J, Knapper S, Garg M, Dubey M, Vatopoulou T, Brierley C, Leung WKN, Greenfield G, McMullin MF, Khan A, Milne K, Brian D, Godfrey A, Harrison CN, Psaila B, Harrington P, Kirkwood A, Somervaille TCP, McLornan DP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42070782"},{"title01":"Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies.","title02":"Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies.","journal":"Br J Haematol","issue":"2026 May; 208(5):1734-1744. doi: 10.1111\/bjh.70384","author":"Savic A, Taylor A, Fenaux P, Symeonidis A, Cargo C, Mittelman M, Petzer V, Sanz G, Cermak J, Langemeijer S, Hellstrom-Lindberg E, Comont T, D'Aveni M, Culligan D, Kotsianidis I, Panagiotidis P, van Marrewijk C, Smith A, Crouch S, de Witte T, Malcovati L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41704134"},{"title01":"Serotherapy in transplant: Getting it right!","title02":"Serotherapy in transplant: Getting it right!","journal":"Br J Haematol","issue":"2026 May; 208(5):1885-1886. doi: 10.1111\/bjh.70456","author":"Wynn R, Admiraal R, Lindemans C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41937680"},{"title01":"Haematopoietic stem cell transplantation outcomes for teenage and young adult patients with acute leukaemia: A British Society of Blood and Marrow Transplantation and Cellular Therapy registry study.","title02":"Haematopoietic stem cell transplantation outcomes for teenage and young adult patients with acute leukaemia: A British Society of Blood and Marrow Transplantation and Cellular Therapy registry study.","journal":"Br J Haematol","issue":"2026 May; 208(5):1745-1757. doi: 10.1111\/bjh.70421","author":"McIlroy G, Carpenter B, Hough R, James B, Besley C, Nicholson E, Amrolia P, Mirci-Danicar O, Furness CL, Gibson B, Potter V, Pearce R, Lee J, Abamba C, Castleton A, Malladi R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41813254"},{"title01":"Phase 1\/2 trials of donor regulatory T cells for the treatment of steroid-refractory chronic graft-versus-host disease.","title02":"Phase 1\/2 trials of donor regulatory T cells for the treatment of steroid-refractory chronic graft-versus-host disease.","journal":"Blood advances","issue":"2026 May 12; 10(9):2904-2915. doi: 10.1182\/bloodadvances.2025017996","author":"Soares MVD, Gomez VE, Azevedo RI, Pereira PNG, Velazquez TC, Mendes L, Alho AC, Garcia-Guerrero E, Garcia-Calderon CB, Tharmaratnam K, Cabral IA, Ribeiro AC, Juncal C, Roncon S, Pais AT, Gil AR, Espada E, Rodrigues A, Garcao A, Yaspo ML, Warnatz HJ, Lehrach H, Ward L, Barbosa-Morais NL, Quintas AM, Palmela P, Caldas C, Ferreira R, Leite L, Martins C, Lourenco F, Moreno R, Campilho F, Cheyne CP, Garcia-Finana M, Campos A, Baron F, Arpinati M, Hoffmann P, Edinger M, Koreth J, Ritz J, Vaz CP, Perez-Simon JA, Lacerda JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637631"},{"title01":"Impact of rituximab maintenance on survival in patients with mantle cell lymphoma: a population-based cohort study.","title02":"Impact of rituximab maintenance on survival in patients with mantle cell lymphoma: a population-based cohort study.","journal":"Blood advances","issue":"2026 May 12; 10(9):2916-2924. doi: 10.1182\/bloodadvances.2025018667","author":"Stedema F, Brink M, Huisman F, van Rijn R, Sijs-Szabo A, Nijhof I, Diepstra A, Vergote V, van Gorkum G, Flinsenberg T, Huls G, van Meerten T, Doorduijn J, Plattel W, Nijland M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637634"},{"title01":"Haematopoietic stem cell transplantation outcomes for teenage and young adult patients with acute leukaemia: A British Society of Blood and Marrow Transplantation and Cellular Therapy registry study.","title02":"Haematopoietic stem cell transplantation outcomes for teenage and young adult patients with acute leukaemia: A British Society of Blood and Marrow Transplantation and Cellular Therapy registry study.","journal":"Br J Haematol","issue":"2026 May; 208(5):1745-1757. doi: 10.1111\/bjh.70421","author":"McIlroy G, Carpenter B, Hough R, James B, Besley C, Nicholson E, Amrolia P, Mirci-Danicar O, Furness CL, Gibson B, Potter V, Pearce R, Lee J, Abamba C, Castleton A, Malladi R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41813254"},{"title01":"Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.","title02":"Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.","journal":"Br J Haematol","issue":"2026 May; 208(5):1816-1820. doi: 10.1111\/bjh.70401","author":"Rigolin GM, Soddu S, Dondolin R, Frustaci AM, Scortechini I, Mauro FR, Angotzi F, Motta M, Scarfo L, Mengarelli A, Giordano A, Martinelli S, Patti C, Sportoletti P, Sanna A, Maschio N, Riccioni R, Vigano CV, Tafuri A, Piciocchi A, Fazi P, Luminari S, Ferreri AJM, Gini G, Ghia P, Cuneo A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41806221"},{"title01":"Introducing a prognostic score for successful treatment-free remission in chronic myeloid leukaemia.","title02":"Introducing a prognostic score for successful treatment-free remission in chronic myeloid leukaemia.","journal":"Br J Haematol","issue":"2026 May; 208(5):1660-1668. doi: 10.1111\/bjh.70409","author":"Claudiani S, Metelli S, Khan A, Hannah G, Byrne J, Gallipoli P, Bulley SJ, Horne GA, Rothwell K, Copland M, Clark RE, Fernando F, Innes AJ, Apperley JF, Milojkovic D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41797306"},{"title01":"Immunological features of acquired pure red cell aplasia: Specific human leucocyte antigen alleles, signal transducer and activator of transcription 3 mutations and a unique T-cell receptor beta motif.","title02":"Immunological features of acquired pure red cell aplasia: Specific human leucocyte antigen alleles, signal transducer and activator of transcription 3 mutations and a unique T-cell receptor beta motif.","journal":"Br J Haematol","issue":"2026 May; 208(5):1797-1805. doi: 10.1111\/bjh.70475","author":"Yamashita N, Kawakami T, Matsuzawa S, Miyairi S, Maruyama M, Kawakami F, Kojima S, Yanagisawa R, Higuchi Y, Makishima H, Nakazawa H, Ishida F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41943918"},{"title01":"Polycythaemic panmyelosis in chronic myeloid leukaemia.","title02":"Polycythaemic panmyelosis in chronic myeloid leukaemia.","journal":"Br J Haematol","issue":"2026 May; 208(5):1521-1522. doi: 10.1111\/bjh.70388","author":"Mason G, Hanamshet A, Kim S, Singh N, McIlroy K, Greenwood M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41793040"},{"title01":"Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.","title02":"Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.","journal":"Br J Haematol","issue":"2026 May; 208(5):1724-1733. doi: 10.1111\/bjh.70303","author":"Kim DH, Park SY, Cho H, Byun JM, Shin DY, Koh Y, Kim I, Yoon SS, Hong J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437919"},{"title01":"Clinical implications of RAS mutations in AML: Prognostic significance is based upon involved gene and mutation complexity.","title02":"Clinical implications of RAS mutations in AML: Prognostic significance is based upon involved gene and mutation complexity.","journal":"Blood advances","issue":"2026 May 12. doi: 10.1182\/bloodadvances.2025018699. Online ahead of print","author":"Colgan JN, Peplinski JH, Wang YC, Kirkey DC, Wallace L, Feng Y, Fan L, Connerty P, Ries RE, Lamble AJ, Huang BJ, Alonzo TA, Ma X, Tarlock K, Meshinchi S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42118855"},{"title01":"Revisiting KIR Restriction and CD94 Expression in Diagnostic Criteria for NK-Large Granular Lymphocytic Leukemia.","title02":"Revisiting KIR Restriction and CD94 Expression in Diagnostic Criteria for NK-Large Granular Lymphocytic Leukemia.","journal":"Blood advances","issue":"2026 May 8. doi: 10.1182\/bloodadvances.2026020572. Online ahead of print","author":"Seheult JN, Otteson GE, Jevremovic D, Morice WW, Timm MM, Hsi ED, Olteanu H, Horna P, Shi M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42102292"},{"title01":"Gilteritinib + chemotherapy in children with relapsed\/refractory FLT3-ITD AML: results from the phase 1\/2 SKIPPER trial.","title02":"Gilteritinib + chemotherapy in children with relapsed\/refractory FLT3-ITD AML: results from the phase 1\/2 SKIPPER trial.","journal":"Blood advances","issue":"2026 May 8. doi: 10.1182\/bloodadvances.2026020144. Online ahead of print","author":"Connor P, Ribeiro RC, Catala A, Norton A, Schundeln MM, Hasabou N, Delgado D, Heinloth AN, Hill JE, Gill SC, Bigirumurame T, Tasian SK, Locatelli F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42101908"},{"title01":"Single cell long read genotyping of transcripts reveals discrete mechanisms of clonal evolution in post-MPN AML.","title02":"Single cell long read genotyping of transcripts reveals discrete mechanisms of clonal evolution in post-MPN AML.","journal":"Blood advances","issue":"2026 May 7. doi: 10.1182\/bloodadvances.2025018902. Online ahead of print","author":"Grabek J, Straube JM, Cooper L, Halder R, Zhang R, Dulige I, Barker MA, Gatehouse W, Christensen H, Amor G, Ling VY, McNamara C, Ross DM, Perkins AC, Bywater MJ, Lane SW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42101375"},{"title01":"Interpreting next-generation immunosequencing results in children and young adults with acute lymphoblastic leukemia.","title02":"Interpreting next-generation immunosequencing results in children and young adults with acute lymphoblastic leukemia.","journal":"Blood advances","issue":"2026 May 12; 10(9):3281-3289. doi: 10.1182\/bloodadvances.2025018923","author":"Hamidi R, Kirsch I, Schultz L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41747190"},{"title01":"Mutations in isocitrate dehydrogenase portend a poor prognosis in adult patients with acute lymphoblastic leukemia.","title02":"Mutations in isocitrate dehydrogenase portend a poor prognosis in adult patients with acute lymphoblastic leukemia.","journal":"Blood advances","issue":"2026 May 12; 10(9):3276-3280. doi: 10.1182\/bloodadvances.2025019519","author":"Goulart H, Short NJ, Borthakur G, Jain N, DiNardo C, Loghavi S, Khouri R, Hachem M, Ravandi F, Daver N, Kadia TM, Yilmaz M, Issa G, Bazinet A, Swaminathan M, Montalban-Bravo G, Haddad F, Garris R, Kantarjian H, Jabbour E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41860396"},{"title01":"CRLF2 rearrangement and extramedullary disease in B-cell acute lymphoblastic leukemia: a possible link?","title02":"CRLF2 rearrangement and extramedullary disease in B-cell acute lymphoblastic leukemia: a possible link?","journal":"Blood advances","issue":"2026 May 12; 10(9):3044-3053. doi: 10.1182\/bloodadvances.2025018480","author":"Gava F, Yates B, Sun Z, Li G, O'Koren C, Adhikari B, Lugar S, Shalabi H, Mattison R, Turkbey EB, Yuan CM, Paietta E, Wang HW, Mullighan C, Silbert SK, Litzow M, Shah NN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41707115"},{"title01":"Anticoagulation, recurrent thrombosis, and major bleeding in antiphospholipid syndrome: UK multicenter observational study.","title02":"Anticoagulation, recurrent thrombosis, and major bleeding in antiphospholipid syndrome: UK multicenter observational study.","journal":"Blood advances","issue":"2026 May 12; 10(9):3264-3275. doi: 10.1182\/bloodadvances.2025019447","author":"Crossette-Thambiah C, Rajakaruna I, Odho Z, Doyle AJ, Breen KA, Laffan M, Arachchillage DJ, Simini G, Roberts L, Gameil A, Lamb G, Simpson K, Aung N, Chan LY, Booth E, Benton A, Duffell J, Power K, Dhawan S, James I, Lewis S, Anderson J, Bhagat S, Altohami M, Hmaid A, Abuqamar D, Goncalves P, Chunara Z, Salta S, Webster A, Challenor S, Nicholson P, Sutton D, Buka R, Joseph A, Ling V, Nkem J, Moss K, Ross A, Millen E, Bashford A, Pardeshi P, Mounter P, Tan J, Gyansah C, Dutt T, Badu S, Murphy F, Langridge A, Osama M, Glancy P, Chattree S, Langridge A, Musgrave K, Likupe B, Delaney A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41719455"},{"title01":"Toxicity from asparaginase during acute lymphoblastic leukemia induction: A report from the Children&#8217;s Oncology Group.","title02":"Toxicity from asparaginase during acute lymphoblastic leukemia induction: A report from the Children&#8217;s Oncology Group.","journal":"Blood advances","issue":"2026 May 5. doi: 10.1182\/bloodadvances.2026019870. Online ahead of print","author":"Orgel E, Maese LD, Devidas M, Militano O, Rau RE, Angiolillo A, McNeer J, Schore RJ, Borowitz MJ, Wood BL, Raetz EA, Silverman LB, Winick NJ, Larsen EC, Carroll WL, Winter SS, Dunsmore KP, Hunger SP, Loh ML","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42085640"},{"title01":"Genetics and MRD for therapy allocation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.","title02":"Genetics and MRD for therapy allocation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.","journal":"Blood","issue":"2026 May 4. doi: 10.1182\/blood.2025032645. Online ahead of print","author":"Ribera JM, Torrent A, Morgades M, Barrena S, Ribera J, Genesca E, Gonzalez-Campos J, Martinez-Cibrian N, Montesinos P, Hernandez Sanchez A, Barba P, Zapico E Sr, Sanchez R, Novo A, Sitges M, Maluquer Artigal C, Such E, Botella C, Queipo de Llano MP, Cabrero M, Vicent A, Lopez de Ugarriza P, Tormo M, Gonzalez-Gonzalez BJ, Garcia-Cadenas I, Rodriguez-Medina C, Martinez Sanchez P, Bermudez A, Gomez-Centurion I, Herrero-Garcia M, Ciudad J, Navas-Acosta J, Hermosin L, Serrano J, Raposo-Puglia JA, Solan L, Roldan-Galiacho V, de Laiglesia A, Gomez-Perez L, Sole-Rodriguez M, Casado MS Sr, Llorente Gonzalez L, Barrios Decoud D, Vall-Llovera F, Algarra JL, Amador L, Garcia-Boyero R, Cladera A, Bergua Burgues JM, Calasanz MJJ, Granada I, Feliu E, Hernandez-Rivas JM, Orfao A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42081455"},{"title01":"Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome.","title02":"Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome.","journal":"Blood","issue":"2026 May 7; 147(19):2226-2237. doi: 10.1182\/blood.2025031287","author":"Davidson-Swinton HR, Iyer S, Kolchinski A, Salem JA, DeBoy EA, Kilada AG, Hwang JS, Jain T, Keel SB, Gocke CD, Zou YS, Schratz KE, Armanios M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41564438"},{"title01":"Targeting PRMT9 Overcomes Venetoclax Resistance in AML by Modulating Splicing and Inhibiting Translation.","title02":"Targeting PRMT9 Overcomes Venetoclax Resistance in AML by Modulating Splicing and Inhibiting Translation.","journal":"Blood","issue":"2026 May 12. doi: 10.1182\/blood.2026034144. Online ahead of print","author":"Li Y, He X, Zhang L, Dong H, Wang X, Che Y, Yadav UP, Liu M, Zhang L, Ge S, Wu G, Fu YH, Chen W, Kuo YH, Chen L, Marcucci G, Wang S, Li L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42118690"},{"title01":"circPCMTD1: a protein-coding circular RNA that regulates DNA damage response in BCR\/ABL1-positive leukemias.","title02":"circPCMTD1: a protein-coding circular RNA that regulates DNA damage response in BCR\/ABL1-positive leukemias.","journal":"Blood","issue":"2026 May 14; 147(20):2375-2387. doi: 10.1182\/blood.2025031129","author":"Papaioannou D, Urs AP, Buisson R, Petri A, Liu M, Woodward L, Kulkarni R, Weislamle X, Ivashkiv O, Nicolet D, Goda C, Paraskevopoulou V, Bustos Y, Mrozek K, Eisfeld AK, Chandrasekharan MB, Behbehani GK, Kauppinen S, Aifantis I, Singh G, Dorrance AM, Garzon R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610425"},{"title01":"DHODH as a targetable metabolic Achilles&#8217; heel for chemotherapy-resistant B-ALL.","title02":"DHODH as a targetable metabolic Achilles&#8217; heel for chemotherapy-resistant B-ALL.","journal":"Blood","issue":"2026 May 14; 147(20):2328-2343. doi: 10.1182\/blood.2025029264","author":"Liu Y, Jiang H, Liu J, Stuani L, Merchant M, Jager A, Koladiya A, Chang TC, Domizi P, Sarno J, Wang A, Keyes T, Jedoui D, Meng J, Hartmann FJ, Hou R, Fries C, Pirillo C, Gao Q, Iacobucci I, Bendall SC, Huang M, Lacayo NJ, Sakamoto KM, Mullighan CG, Loh M, Yu J, Yang JJ, Ye J, Davis KL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41576347"},{"title01":"Circular RNA in chronic myeloid leukemia.","title02":"Circular RNA in chronic myeloid leukemia.","journal":"Blood","issue":"2026 May 14; 147(20):2285-2286. doi: 10.1182\/blood.2026033266","author":"Gambacorti-Passerini C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42133326"},{"title01":"Targeting of ibrutinib resistance-driving pathways by miR-28 in ABC-DLBCL.","title02":"Targeting of ibrutinib resistance-driving pathways by miR-28 in ABC-DLBCL.","journal":"Leukemia","issue":"2026 May; 40(5):894-905. doi: 10.1038\/s41375-026-02948-9","author":"Alvarez-Corrales E, Moreno-Palomares R, Gomez-Escolar C, Martinez M, Moral-Perez U, Laguna-Herrero M, Fuertes T, Estrada BS, Mur S, de Bonis A, Leiva M, Martinez-Martin N, Somoza A, Ramiro AR, de Yebenes VG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41951939"},{"title01":"Evolving therapeutic strategies in mantle cell lymphoma: advancements and future directions.","title02":"Evolving therapeutic strategies in mantle cell lymphoma: advancements and future directions.","journal":"Leukemia","issue":"2026 May; 40(5):857-871. doi: 10.1038\/s41375-026-02942-1","author":"Tavarozzi R, Maher N, Catania G, Zacchi G, D'Andrea F, Sofia A, Zanni M, Ladetto M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41986622"},{"title01":"KMT2A-rearranged B-lymphoblastic lymphomas are skewed towards a more mature developmental stage.","title02":"KMT2A-rearranged B-lymphoblastic lymphomas are skewed towards a more mature developmental stage.","journal":"Leukemia","issue":"2026 May; 40(5):1067-1071. doi: 10.1038\/s41375-026-02943-0","author":"Iaccarino I, Hartmann AM, Yalcin F, Mondal M, Bozzetti C, Wolgast N, Loeffen JLC, Boer JM, Bruggemann M, Baldus CD, Cario G, Klapper W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41872503"},{"title01":"Editorial Expression of Concern: Discovery of a BTK\/MNK dual inhibitor for lymphoma and leukemia.","title02":"Editorial Expression of Concern: Discovery of a BTK\/MNK dual inhibitor for lymphoma and leukemia.","journal":"Leukemia","issue":"2026 May 6. doi: 10.1038\/s41375-026-02980-9. Online ahead of print","author":"Wu H, Hu C, Wang A, Weisberg EL, Chen Y, Yun CH, Wang W, Liu Y, Liu X, Tian B, Wang J, Zhao Z, Liang Y, Li B, Wang L, Wang B, Chen C, Buhrlage SJ, Qi Z, Zou F, Nonami A, Li Y, Fernandes SM, Adamia S, Stone RM, Galinsky IA, Wang X, Yang G, Griffin JD, Brown JR, Eck MJ, Liu J, Gray NS, Liu Q","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42092047"},{"title01":"Validation of Prospective Cutaneous Lymphoma International Prognostic Index for advanced cutaneous lymphoma in a multicenter Chinese cohort.","title02":"Validation of Prospective Cutaneous Lymphoma International Prognostic Index for advanced cutaneous lymphoma in a multicenter Chinese cohort.","journal":"Leukemia","issue":"2026 May; 40(5):1040-1043. doi: 10.1038\/s41375-026-02927-0","author":"Chen Z, Ruan Y, Wang Y, Liu F, Sun J, Xiao Y, Wen Y, Lai P, Jiang Y, Li M, Yang C, Cui Z, Hong Z, Deng R, Ye C, Tong Z, Zhu Z, Shen X, Wang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41862596"},{"title01":"Protein-losing enteropathy in marginal zone lymphoma: tissue is the issue.","title02":"Protein-losing enteropathy in marginal zone lymphoma: tissue is the issue.","journal":"Lancet Haematol","issue":"2026 May; 13(5):e352. doi: 10.1016\/S2352-3026(26)00041-4","author":"Becking AL, Kusters PJH, Levenga H, Vos JMI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42069413"},{"title01":"Risks and benefits for patients with relapsed or refractory diffuse large B-cell lymphoma in early-phase clinical trials: a systematic review and meta-analysis.","title02":"Risks and benefits for patients with relapsed or refractory diffuse large B-cell lymphoma in early-phase clinical trials: a systematic review and meta-analysis.","journal":"Lancet Haematol","issue":"2026 May; 13(5):e297-e314. doi: 10.1016\/S2352-3026(26)00045-1","author":"Spanjaart AM, Bakker M, de Vries R, Hutten BA, van Nieuwenhuijzen N, Minnema MC, Kuipers MT, Kersten MJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42069410"},{"title01":"Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenstrom macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1\/2 BRUIN trial.","title02":"Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenstrom macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1\/2 BRUIN trial.","journal":"Lancet Haematol","issue":"2026 May; 13(5):e284-e296. doi: 10.1016\/S2352-3026(26)00037-2","author":"Palomba ML, Patel MR, Eyre TA, Jurczak W, Lewis D, Gastinne T, Ma S, Cohen JB, Patel K, Brown JR, Scarfo L, Munir T, Lech-Maranda E, Hoffmann MS, Ujjani CS, Fakhri B, Wang ML, Izutsu K, Nagai H, Tam CS, Rhodes JM, Vose J, McKinney M, Gerson JN, Barve MA, Kuss B, Koh Y, Barrett A, Treon SP, Castillo JJ, Seymour JF, Ruppert AS, McNeely SC, Walgren RA, Tsai DE, Bao K, Nair B, Woyach J, Cheah CY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42069409"},{"title01":"Very early [(18)F]FDG-PET-guided targeted therapy in untreated advanced-stage classic Hodgkin lymphoma (EORTC-1537-COBRA): primary results of a single-arm, multicentre, phase 2 trial.","title02":"Very early [(18)F]FDG-PET-guided targeted therapy in untreated advanced-stage classic Hodgkin lymphoma (EORTC-1537-COBRA): primary results of a single-arm, multicentre, phase 2 trial.","journal":"Lancet Haematol","issue":"2026 May; 13(5):e274-e283. doi: 10.1016\/S2352-3026(26)00068-2","author":"Hutchings M, Diepstra A, Sureda Balari A, Carvalho S, Vranovsky A, Noordzij W, Loft A, Arens A, Teesink S, Visser L, Stevens W, Aleman BMP, Woei-A-Jin FJSH, Viguria M, Saevels K, Te Boome L, Tonino S, Meijnders P, Domingo Domenech E, Hasselbalch Riley C, Musekera L, Nuyens S, Mallien C, Sents W, Buhrer E, Fortpied C, Plattel WJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42069408"},{"title01":"Two decades of phase 1 and 2 trials in relapsed or refractory diffuse large B-cell lymphoma.","title02":"Two decades of phase 1 and 2 trials in relapsed or refractory diffuse large B-cell lymphoma.","journal":"Lancet Haematol","issue":"2026 May; 13(5):e268-e269. doi: 10.1016\/S2352-3026(26)00070-0","author":"Baggio D, El-Galaly TC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42069405"},{"title01":"Prothrombotic genetic variants and cancer-associated venous thromboembolism: defining thrombotic risk across tumor types.","title02":"Prothrombotic genetic variants and cancer-associated venous thromboembolism: defining thrombotic risk across tumor types.","journal":"Haematologica","issue":"2026 May 7. doi: 10.3324\/haematol.2026.300579. Online ahead of print","author":"Stevens H, Ho WWH, Singh M, Canovas R, Xiang R, Tran H, Takeuchi F, Peter K, McFadyen JD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42095241"},{"title01":"Peripheral T-cell lymphoma in adult-onset familial hemophagocytic lymphohistiocytosis type 2 and heterozygous LRBA mutation.","title02":"Peripheral T-cell lymphoma in adult-onset familial hemophagocytic lymphohistiocytosis type 2 and heterozygous LRBA mutation.","journal":"Haematologica","issue":"2026 May 1; 111(5):1902-1906. doi: 10.3324\/haematol.2026.300514","author":"Tembrink M, Haverkamp T, Reinhardt HC, Hanoun M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41852350"},{"title01":"CD20 re-emergence in a patient with diffuse large b-cell lymphoma who experienced a CD20-negative relapse after glofitamab treatment.","title02":"CD20 re-emergence in a patient with diffuse large b-cell lymphoma who experienced a CD20-negative relapse after glofitamab treatment.","journal":"Haematologica","issue":"2026 May 14. doi: 10.3324\/haematol.2025.300182. Online ahead of print","author":"Gaddipati P, Ayad A, Epstein-Peterson Z, Palomba ML, Catillo M, Martinova A, Zhang H, Galera PK, Dogan A, Zhang Y, Salles G, Falchi L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42131932"},{"title01":"Comparative effectiveness of immunotherapy alone or with chemotherapy as first-line treatment for marginal zone lymphoma.","title02":"Comparative effectiveness of immunotherapy alone or with chemotherapy as first-line treatment for marginal zone lymphoma.","journal":"Haematologica","issue":"2026 May 1; 111(5):1840-1846. doi: 10.3324\/haematol.2025.288946","author":"Olszewski AJ, Ollila TA, Chihara D, Shouse G, Grover N, Karmali R, Torka P, Thomas C, Geethakumari PR, Barta SK, Bartlett NL, Epperla N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307133"},{"title01":"Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencing.","title02":"Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencing.","journal":"Haematologica","issue":"2026 May 14. doi: 10.3324\/haematol.2026.300569. Online ahead of print","author":"Osborne W, Haynes E, Wilson W, Ediriwickrema K, Paterson J, Menne T, El-Sharkawi D, Chan LY, Iyengar S, Davies AJ, Hiew HJ, Kanfer E, Foldes D, Chaganti S, Crosland H, Owen M, Follows G, Santarsieri A, Lawless S, Wilson M, McKay P, Osborn R, Tucker D, Thiebaud CM, Fox CP, Ambrose H, Gleeson M, Lam J, Broom A, Smith J, Wells M, Oldham L, Linton K, Jeffers L, Kuhnl A, Collins G, Qasim J, Shah N, McCulloch R, Baloch M, Cox C, Lewis D, Martin A, Maw KZD, Norman J, Deshani V, Stables V, Preston G, Culligan D, Willan J, Ahearne M, Motiwale R, Dunning L, Fawcett J, Kelsey P, Besley C, Lugthart S, Easton J, Gurung S, Ojie D, Mathew S, Auer R, Townsend W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42131938"},{"title01":"Marked survival gains in patients ","title02":"Marked survival gains in patients <\/= 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020.","journal":"Haematologica","issue":"2026 May 1; 111(5):1694-1704. doi: 10.3324\/haematol.2025.288929","author":"Jiang L, Ladetto M, Hermine O, Kluin-Nelemans JC, Walewski J, Doorduijn J, Vergote V, Gine E, Jerkeman M, Hutchings M, Trneny M, Mey U, Riise J, Shpilberg O, Da Silva MG, Ribrag V, Schmidt C, Klapper W, Unterhalt M, Dreyling M, Hoster E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41163573"},{"title01":"Transforming mantle cell lymphoma: the journey across eras.","title02":"Transforming mantle cell lymphoma: the journey across eras.","journal":"Haematologica","issue":"2026 May 1; 111(5):1526-1528. doi: 10.3324\/haematol.2025.300275","author":"Castonguay M, Seymour JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609054"},{"title01":"Rituximab, dexamethasone, etoposide, ifosfamide and carboplatin (R-DeVIC) in relapsed or refractory central nervous system lymphoma: a retrospective multicentre clinical study.","title02":"Rituximab, dexamethasone, etoposide, ifosfamide and carboplatin (R-DeVIC) in relapsed or refractory central nervous system lymphoma: a retrospective multicentre clinical study.","journal":"Haematologica","issue":"2026 May 1; 111(5):1792-1796. doi: 10.3324\/haematol.2025.287982","author":"Kama K, Treiber H, Kutilina A, Trefz S, Wollnitza S, Shumilov E, Finke J, Lenz G, Wulf G, Isbell LK, Aksoy A, Jensch A, Illerhaus G, Wendler J, Schorb E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376557"},{"title01":"Association between body mass index and outcomes in lymphoma-associated haemophagocytic lymphohistiocytosis: A retrospective multicentre cohort study of Jiangsu Cooperative Lymphoma Group (JCLG).","title02":"Association between body mass index and outcomes in lymphoma-associated haemophagocytic lymphohistiocytosis: A retrospective multicentre cohort study of Jiangsu Cooperative Lymphoma Group (JCLG).","journal":"Br J Haematol","issue":"2026 May; 208(5):1810-1815. doi: 10.1111\/bjh.70406","author":"Liu Y, Zhang J, Wang L, Liang Z, Gong Y, Gao L, Zhang W, Lu X, Wang C, Yu L, Sun M, Zhuang Y, Miao Y, Ni H, Xie X, Xu J, Zhang Y, Zhao M, Xu M, Zhuang W, Gu W, Lin G, Hua H, Zhu J, Xu M, Jia T, Zhai L, Shan H, Shen Q, Fan L, Xia Y, Li J, Li B, Miao Y, Shi W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41757549"},{"title01":"An atypical bilobed and binucleated splenic marginal zone lymphoma.","title02":"An atypical bilobed and binucleated splenic marginal zone lymphoma.","journal":"Br J Haematol","issue":"2026 May 7. doi: 10.1111\/bjh.70514. Online ahead of print","author":"Amiot Q, Dejean ALE, Navarrot JC, Arnautou P, Malfuson JV, Hejl C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42099024"},{"title01":"Statistical considerations in the comparison of immunotherapy and chemotherapy for POD24 follicular lymphoma.","title02":"Statistical considerations in the comparison of immunotherapy and chemotherapy for POD24 follicular lymphoma.","journal":"Br J Haematol","issue":"2026 May 7. doi: 10.1111\/bjh.70522. Online ahead of print","author":"Yan C, Liu J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42099098"},{"title01":"Response to &#8216;Statistical considerations in the comparison of immunotherapy and chemotherapy for POD24 follicular lymphoma&#8217;.","title02":"Response to &#8216;Statistical considerations in the comparison of immunotherapy and chemotherapy for POD24 follicular lymphoma&#8217;.","journal":"Br J Haematol","issue":"2026 May 11. doi: 10.1111\/bjh.70523. Online ahead of print","author":"Serna A, Navarro V, Abrisqueta P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42112530"},{"title01":"Population-based survival after mantle cell lymphoma in Norway and Denmark: Limited impact of earlier BTKi access.","title02":"Population-based survival after mantle cell lymphoma in Norway and Denmark: Limited impact of earlier BTKi access.","journal":"Br J Haematol","issue":"2026 May 12. doi: 10.1111\/bjh.70538. Online ahead of print","author":"Simonsen MR, Jerm MB, Johannesen TB, Enerstvedt L, El-Galaly T, Fossa A, Smeland K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42117309"},{"title01":"Predictive value of MRD monitoring by BCR clonality in the ZUMA-7 randomized clinical trial for CAR T therapy in r\/r lymphoma.","title02":"Predictive value of MRD monitoring by BCR clonality in the ZUMA-7 randomized clinical trial for CAR T therapy in r\/r lymphoma.","journal":"Br J Haematol","issue":"2026 May; 208(5):1850-1853. doi: 10.1111\/bjh.70375","author":"Miles B, Mao D, Vardhanabhuti S, Bedognetti D, Filosto S, Shen R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41735224"},{"title01":"Immune-related adverse events in the treatment of Hodgkin lymphoma with immune checkpoint inhibitors.","title02":"Immune-related adverse events in the treatment of Hodgkin lymphoma with immune checkpoint inhibitors.","journal":"Br J Haematol","issue":"2026 May; 208(5):1608-1616. doi: 10.1111\/bjh.70402","author":"Argnani L, Stefoni V, Casadei B, Pelusi C, Preiato VL, Pagotto U, Bugane A, Pellegrini C, Broccoli A, Zinzani PL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41744197"},{"title01":"Marked variation in eligibility criteria across registrational trials for relapsed diffuse large B-cell lymphoma limits applicability to clinical practice.","title02":"Marked variation in eligibility criteria across registrational trials for relapsed diffuse large B-cell lymphoma limits applicability to clinical practice.","journal":"Br J Haematol","issue":"2026 May 15. doi: 10.1111\/bjh.70550. Online ahead of print","author":"Goodall E, Palmer J, Martynchyk A, Waters N, Swain F, Giang TB, Marconi T, Brennan J, Gregory GP, Cheah C, Keane C, Hawkes EA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42141736"},{"title01":"Exploiting ALK inhibition in anaplastic large cell lymphoma: Biological rationale and therapeutic integration.","title02":"Exploiting ALK inhibition in anaplastic large cell lymphoma: Biological rationale and therapeutic integration.","journal":"Br J Haematol","issue":"2026 May; 208(5):1525-1534. doi: 10.1111\/bjh.70458","author":"Caserta S, Martino EA, Skafi M, Alvaro ME, Bruzzese A, Amodio N, Fiorillo M, Lucia E, Olivito V, Labanca C, Mendicino F, Vigna E, Morabito F, Gentile M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41905770"},{"title01":"Insights into the novel EEF1D::ALK fusion transcript in FISH-negative ALK-positive anaplastic large cell lymphoma.","title02":"Insights into the novel EEF1D::ALK fusion transcript in FISH-negative ALK-positive anaplastic large cell lymphoma.","journal":"Br J Haematol","issue":"2026 May; 208(5):1821-1825. doi: 10.1111\/bjh.70410","author":"Tuteja SK, Wlodaver A, Kirschmann D, Caparelli E, Yap KL, Schubert J, Zhong Y, Li MM, Leuer K, Gong S, Richardson AI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41773598"},{"title01":"Development and validation of a novel prognostic index for mantle cell lymphoma integrating TP53 mutations (MIPI53).","title02":"Development and validation of a novel prognostic index for mantle cell lymphoma integrating TP53 mutations (MIPI53).","journal":"Br J Haematol","issue":"2026 May 14. doi: 10.1111\/bjh.70535. Online ahead of print","author":"Bastos-Boente M, Medina-Herrera A, Navarro-Bailon A, Ferrero S, Sarasquete ME, Jimenez C, Garcia-Alvarez M, Anton A, Balanzategui A, Moia R, Re A, Boccomini C, Balzarotti M, Zilioli VR, da Silva MG, Diaz-Galvez FJ, Gonzalez-Mena B, Penarrubia MJ, Fernandez-Ferrero S, de Ramon C, Blanco O, Cabero A, Ladetto M, Garcia-Sanz R, Gutierrez NC, Martin Garcia-Sancho A, Alcoceba M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42134850"},{"title01":"Immunoprofiling, sex- and age-related determinants of treatment response in paediatric, adolescent and young adult Hodgkin lymphoma.","title02":"Immunoprofiling, sex- and age-related determinants of treatment response in paediatric, adolescent and young adult Hodgkin lymphoma.","journal":"Br J Haematol","issue":"2026 May; 208(5):1617-1630. doi: 10.1111\/bjh.70423","author":"De Re V, Lopci E, Brisotto G, Elia C, Vitullo A, Paduano V, De Zorzi M, Mussolin L, Quarello P, Bianchi S, Buffardi S, Garaventa A, Muggeo P, Pillon M, Sala A, Vinti L, d'Amore E, Mauz-Korholz C, Mascarin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41819087"},{"title01":"Family history of haematological malignancy and prognosis across non-Hodgkin lymphoma subtypes.","title02":"Family history of haematological malignancy and prognosis across non-Hodgkin lymphoma subtypes.","journal":"Br J Haematol","issue":"2026 May; 208(5):1631-1640. doi: 10.1111\/bjh.70397","author":"Cholack GA, Mwangi R, Vodicka P, Habermann TM, Hinder V, Robinson DP, Feldman AL, Witzig TE, Villasboas JC, Ansell SM, Link BK, Wang Y, Thompson CA, Slager SL, Maurer M, Novak AJ, Cerhan JR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41806244"},{"title01":"Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes.","title02":"Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes.","journal":"Leukemia","issue":"2026 May; 40(5):946-954. doi: 10.1038\/s41375-026-02928-z","author":"Gagnon LL, Duminuco A, Stagno F, Sobas M, Fominykh M, Virchis A, Nicolini FE, Hildt J, Bentley H, Godfrey AL, Shih LY, Chee A, Mead A, Lewandowski K, Sobieralski P, Hannah G, Reyal Y, Cummin T, Piszcz J, Yip K, Frewin R, Narayanan S, Rahman D, Ajayi A, Cervi P, Byrne J, Taylor T, Lebowa W, Pavlu J, Arami S, Ceesay M, Chraniuk D, Delage R, Condorelli A, Santana C, Radia DH, de Lavallade H, Milojkovic D, Harrison C, Harrington P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41896663"},{"title01":"Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of acute myeloid leukemia.","title02":"Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of acute myeloid leukemia.","journal":"Leukemia","issue":"2026 May; 40(5):880-893. doi: 10.1038\/s41375-026-02930-5","author":"Li YR, Shen X, Chen Y, Zhu Y, Huang J, Oliai C, Yang L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41888396"},{"title01":"Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemia.","title02":"Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemia.","journal":"Leukemia","issue":"2026 May; 40(5):970-981. doi: 10.1038\/s41375-026-02900-x","author":"Vasseur L, Duchmann M, Duployez N, Raffoux E, Berthon C, Heiblig M, Genthon A, Braun T, Leclerc M, Lebon D, Chantepie S, Micol JB, Lambert J, Recher C, Chretien ML, Iat A, Vaidie J, Malfuson JV, Uzunov M, Pigneux A, Peterlin P, Tarfi S, Hirsch P, Penther D, Jourdan E, Celli-Lebras K, Preudhomme C, Dombret H, Lambert J, Boissel N, Itzykson R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41888395"},{"title01":"Functional cooperation between the B-cell receptor and NOTCH1 in regulating metabolic reprogramming in chronic lymphocytic leukemia.","title02":"Functional cooperation between the B-cell receptor and NOTCH1 in regulating metabolic reprogramming in chronic lymphocytic leukemia.","journal":"Leukemia","issue":"2026 May; 40(5):982-995. doi: 10.1038\/s41375-026-02912-7","author":"Fasci A, Vallone FE, Nabelsi N, Viry E, Sana I, Morabito A, Seghezzi S, Pesce NA, Rovere M, Bertola N, Duculty C, Ravera S, Mouhssine S, Muzio M, Ghia P, Vitale C, Coscia M, Moussay E, Gaidano G, Allan J, Furman RR, Paggetti J, Vaisitti T, Deaglio S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41872504"},{"title01":"A Perturb-seq map of a differentiation hub reveals synergistic vulnerabilities in KMT2A-rearranged acute myeloid leukemia.","title02":"A Perturb-seq map of a differentiation hub reveals synergistic vulnerabilities in KMT2A-rearranged acute myeloid leukemia.","journal":"Leukemia","issue":"2026 May; 40(5):996-1008. doi: 10.1038\/s41375-026-02917-2","author":"Aryal S, Curtiss BM, Zhou X, Lu R, Cheng C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41882099"},{"title01":"Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia.","title02":"Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 May; 40(5):1027-1034. doi: 10.1038\/s41375-026-02867-9","author":"Lecornec N, Rabian F, Dourthe ME, Chevillon F, Yakouben K, Chaillou D, Caillat-Zucman S, Cuffel A, Lesprit E, Arnould A, Naudin J, Roupret-Serzec J, Parquet N, Brignier A, Guerin-El Khourouj V, Lainey E, Caye-Eude A, Arfeuille C, Clappier E, Kim R, Mathis S, Chaix ML, Azoulay E, Dalle JH, Madelaine I, Larghero J, Baruchel A, Boissel N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41735483"},{"title01":"Beyond mechanisms: toward patient-centered choices in BTKi-venetoclax fixed-duration therapy for CLL.","title02":"Beyond mechanisms: toward patient-centered choices in BTKi-venetoclax fixed-duration therapy for CLL.","journal":"Leukemia","issue":"2026 May; 40(5):1083-1085. doi: 10.1038\/s41375-026-02945-y","author":"Mauro FR, Allsup D, Molica S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41876726"},{"title01":"CSF3R-mutated chronic neutrophilic leukemia: a two-center study of 44 consecutive patients.","title02":"CSF3R-mutated chronic neutrophilic leukemia: a two-center study of 44 consecutive patients.","journal":"Haematologica","issue":"2026 May 14. doi: 10.3324\/haematol.2025.300040. Online ahead of print","author":"Bolarinwa AB, Szuber N, Caron-Lecuyer J, Al-Kali A, Hogan WJ, Shah M, Foran JM, Badar T, Reichard KK, He R, Gangat N, Mendoza CJZ, Elliott MA, Pardanani A, Tefferi A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42131931"},{"title01":"Impact of hematopoietic cell transplantation and quizartinib in patients with newly diagnosed FLT3-internal tandem duplication-negative acute myeloid leukemia: results from the QUIWI study.","title02":"Impact of hematopoietic cell transplantation and quizartinib in patients with newly diagnosed FLT3-internal tandem duplication-negative acute myeloid leukemia: results from the QUIWI study.","journal":"Haematologica","issue":"2026 May 14. doi: 10.3324\/haematol.2026.300855. Online ahead of print","author":"Lloret-Madrid P, Rodriguez-Veiga R, Bergua JM, Algarra JLA, Botella C, Rodriguez-Arboli E, Bernal T, Tormo M, Calbacho M, Salamero O, Serrano J, Noriega V, Lopez-Lopez JA, Vives S, Lopez-Lorenzo JL, Colorado M, Vidriales MB, Boyero RG, Olave MT, Herrera P, Arce O, Barrios M, Sayas MJ, Polo M, Gomez-Roncero MI, Barragan E, Ayala R, Chillon C, Calasanz MJ, Paiva B, Boluda B, Casas-Aviles I, Sanchez MJ, Rodriguez-Medina C, Cuevas L, Raposo-Puglia JA, Mateos MC, Olivares M, Martinez-Chamorro C, Alonso N, Suarez S, Sanchez-Vadillo I, Rodriguez MS, Gonzalez BJ, Martinez-Frances A, Cuello R, Fernandez A, Martinez-Cuadron D, Labrador J, Montesinos P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42131933"},{"title01":"Outcomes of patients diagnosed with myelodysplastic syndrome or acute myeloid leukemia following solid organ transplantation.","title02":"Outcomes of patients diagnosed with myelodysplastic syndrome or acute myeloid leukemia following solid organ transplantation.","journal":"Haematologica","issue":"2026 May 14. doi: 10.3324\/haematol.2026.300856. Online ahead of print","author":"Vegivinti CTR, Montalban-Bravo G, Chien K, Hammond D, Sasaki K, Bataller A, Bouligny I, Jen WY, Swaminathan M, Loghavi S, Popat U, Garcia-Manero G, Bazinet A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42131946"},{"title01":"ROCKing resistance: cytoskeletal-mitochondrial synergy in acute myeloid leukemia.","title02":"ROCKing resistance: cytoskeletal-mitochondrial synergy in acute myeloid leukemia.","journal":"Haematologica","issue":"2026 May 14. doi: 10.3324\/haematol.2026.300928. Online ahead of print","author":"Zheng W, Chen S, Liu M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42131954"},{"title01":"Long-term safety and efficacy of ponatinib in intolerant chronic myeloid leukemia: subanalysis of the observational study of Iclusig(R) (ponatinib) treatment in patients with chronic myeloid leukemia in Italy.","title02":"Long-term safety and efficacy of ponatinib in intolerant chronic myeloid leukemia: subanalysis of the observational study of Iclusig(R) (ponatinib) treatment in patients with chronic myeloid leukemia in Italy.","journal":"Haematologica","issue":"2026 May 14. doi: 10.3324\/haematol.2026.300586. Online ahead of print","author":"Breccia M, Iurlo A, Pane F, Scortechini AR, Rossi AR, Santoro M, Cerrano M, Lunghi F, Maggi A, Di Renzo N, Sargentini V, Piciocchi A, Tringali C, Malato A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42131958"},{"title01":"Mutational profiling in acute myeloid leukemia.","title02":"Mutational profiling in acute myeloid leukemia.","journal":"Haematologica","issue":"2026 May 1; 111(5):1511-1512. doi: 10.3324\/haematol.2026.289405","author":"DiNardo CD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42076976"},{"title01":"Menin inhibitor DS-1594b drives differentiation and induces synergistic lethality in combination with venetoclax in acute myeloid leukemia cells with rearranged mixed-lineage leukemia and mutated nucleophosmin-1.","title02":"Menin inhibitor DS-1594b drives differentiation and induces synergistic lethality in combination with venetoclax in acute myeloid leukemia cells with rearranged mixed-lineage leukemia and mutated nucleophosmin-1.","journal":"Haematologica","issue":"2026 May 1; 111(5):1610-1624. doi: 10.3324\/haematol.2024.286833","author":"Ciaurro V, Sharlandjieva V, Skwarska A, Chahrour C, Baran N, Zeng Z, Ramage C, Daver N, Carter BZ, Chaundhry S, Thandapani P, Martelli MP, Milne TA, Konopleva M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195508"},{"title01":"Integrative clinical and molecular characterization of an acute promyelocytic leukemia-like subgroup with high early death risk in newly diagnosed acute myeloid leukemia: a multicenter study.","title02":"Integrative clinical and molecular characterization of an acute promyelocytic leukemia-like subgroup with high early death risk in newly diagnosed acute myeloid leukemia: a multicenter study.","journal":"Haematologica","issue":"2026 May 1; 111(5):1797-1803. doi: 10.3324\/haematol.2025.288377","author":"Shu M, Ding W, Wang L, Wang Z, Wang L, Zhu M, Liu D, Shen H, Wang Y, Dou X, Ma X, Zhang Y, Xu Y, Wang Y, Xue S, Fu J, Qiu H, Tang X, Han Y, Huang J, Wu D, Dai H, Wen L, Chen S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307138"},{"title01":"Single-cell profiling of CD19-directed CAR T-cell phenotypes and immune system dynamics in pediatric B-cell acute lymphoblastic leukemia.","title02":"Single-cell profiling of CD19-directed CAR T-cell phenotypes and immune system dynamics in pediatric B-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 May 1; 111(5):1810-1815. doi: 10.3324\/haematol.2025.288397","author":"Oszer A, Pawlik B, Cwilichowska-Puslecka N, Marschollek P, Richert-Przygonska M, Mielcarek-Siedziuk M, Crawford JC, Mazurek M, Koladiya A, Kalwak K, Styczynski J, Janczar S, Poreba M, Velasquez MP, Davis KL, Mlynarski W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262045"},{"title01":"Common ancestral origin of indeterminate dendritic cell tumor and chronic myelomonocytic leukemia in clonal hematopoiesis.","title02":"Common ancestral origin of indeterminate dendritic cell tumor and chronic myelomonocytic leukemia in clonal hematopoiesis.","journal":"Haematologica","issue":"2026 May 1; 111(5):1885-1890. doi: 10.3324\/haematol.2025.288974","author":"Sato A, Yusa N, Takamori H, Shimizu E, Jimbo K, Kato S, Konuma T, Yokoyama K, Imoto S, Takahashi S, Nannya Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537315"},{"title01":"Silver bullets for the golden age: treating IDH-mutated acute myeloid leukemia in older patients.","title02":"Silver bullets for the golden age: treating IDH-mutated acute myeloid leukemia in older patients.","journal":"Haematologica","issue":"2026 May 1; 111(5):1515-1517. doi: 10.3324\/haematol.2025.300191","author":"Wolach O","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376578"},{"title01":"Is Bruton tyrosine kinase a potential target to treat mast cell neoplasms? Systemic mastocytosis associated with chronic lymphoid leukemia successfully treated with acalabrutinib monotherapy: a case report and review of the literature.","title02":"Is Bruton tyrosine kinase a potential target to treat mast cell neoplasms? Systemic mastocytosis associated with chronic lymphoid leukemia successfully treated with acalabrutinib monotherapy: a case report and review of the literature.","journal":"Haematologica","issue":"2026 May 1; 111(5):1891-1895. doi: 10.3324\/haematol.2025.289116","author":"Fazio M, Elena C, Ferrari J, Camilotto V, Stella S, Leotta D, Palumbo GA, Di Raimondo F, Romano A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376555"},{"title01":"Allopurinol increases DNA-thioguanine nucleotides during maintenance therapy in pediatric acute lymphoblastic leukemia.","title02":"Allopurinol increases DNA-thioguanine nucleotides during maintenance therapy in pediatric acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 May 1; 111(5):1835-1839. doi: 10.3324\/haematol.2025.288872","author":"Kallstrom J, Niinimaki R, Fredlund J, Vogt H, Korhonen LS, Castor A, Schmiegelow K, Thastrup M, Ek T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41342181"},{"title01":"Decitabine plus all-trans retinoic acid versus decitabine monotherapy for myelodysplastic syndromes with excess blasts: a multicenter, randomized controlled trial.","title02":"Decitabine plus all-trans retinoic acid versus decitabine monotherapy for myelodysplastic syndromes with excess blasts: a multicenter, randomized controlled trial.","journal":"Haematologica","issue":"2026 May 1; 111(5):1683-1693. doi: 10.3324\/haematol.2025.288526","author":"Zhou X, Lin Y, Gao Y, Ge Z, Huang L, Zhang J, Cheng H, Ouyang G, Meng F, Tian Y, Kuang Y, Zhou F, Sheng L, Jin W, Xu G, Ma L, Ye L, Mei C, Li J, Jin J, Tong H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262042"},{"title01":"Rapid and accurate identification of acute promyelocytic leukemia with a novel multiparametric flow cytometric scoring system.","title02":"Rapid and accurate identification of acute promyelocytic leukemia with a novel multiparametric flow cytometric scoring system.","journal":"Haematologica","issue":"2026 May 1; 111(5):1863-1868. doi: 10.3324\/haematol.2025.289104","author":"Lagana A, Fanciullo D, Kasmi D, Germano CA, Nardacci MG, Scalzulli E, Carmosino I, Bisegna ML, Minotti C, Nostro F, Milani ML, Buffolino S, Limongi MZ, Ielo C, Diverio D, Martelli M, Breccia M, De Propris MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41342176"},{"title01":"CPX-351 in secondary\/high-risk acute myeloid leukemia: a meta-analysis of randomized and real-world studies encompassing more than 3,200 patients.","title02":"CPX-351 in secondary\/high-risk acute myeloid leukemia: a meta-analysis of randomized and real-world studies encompassing more than 3,200 patients.","journal":"Haematologica","issue":"2026 May 1; 111(5):1774-1780. doi: 10.3324\/haematol.2025.300076","author":"Molica M, Giannarelli D, De Fazio L, Rossi M, Perrone S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376581"},{"title01":"Comments on &#8216;Dose-dependent impairment of brain functional and microstructural connectivity during leukaemia chemotherapy&#8217;.","title02":"Comments on &#8216;Dose-dependent impairment of brain functional and microstructural connectivity during leukaemia chemotherapy&#8217;.","journal":"Br J Haematol","issue":"2026 May 7. doi: 10.1111\/bjh.70537. Online ahead of print","author":"Liu J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42095398"},{"title01":"Clinical features and prognostic factors of adult systemic chronic active EBV disease: A retrospective analysis in Japan.","title02":"Clinical features and prognostic factors of adult systemic chronic active EBV disease: A retrospective analysis in Japan.","journal":"Br J Haematol","issue":"2026 May 10. doi: 10.1111\/bjh.70532. Online ahead of print","author":"Fuseya A, Yamamoto M, Nishio M, Kitabayashi R, Hirakawa A, Yasui H, Umezawa Y, Tanaka K, Tamai H, Uemura Y, Oshima K, Sano F, Mori T, Koike R, Ohga S, Arai A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42108635"},{"title01":"Dynamic improvement of the treatment-free remission prognostic score by prolonging MR4 duration in chronic myeloid leukaemia.","title02":"Dynamic improvement of the treatment-free remission prognostic score by prolonging MR4 duration in chronic myeloid leukaemia.","journal":"Br J Haematol","issue":"2026 May 11. doi: 10.1111\/bjh.70558. Online ahead of print","author":"Fujita M, Ureshino H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42109182"},{"title01":"Authors&#8217; reply to &#8216;Comments on dose-dependent impairment of brain functional and microstructural connectivity during leukaemia chemotherapy&#8217;.","title02":"Authors&#8217; reply to &#8216;Comments on dose-dependent impairment of brain functional and microstructural connectivity during leukaemia chemotherapy&#8217;.","journal":"Br J Haematol","issue":"2026 May 11. doi: 10.1111\/bjh.70544. Online ahead of print","author":"Scott AP, Lo A, Xia Y, Thompson K, Bodimeade H, Fazlollahi A, Weber N, Curley C, Hunt S, Morris K, McNamara C, Perera N, Subramoniapillai E, Lane SW, Kennedy GA, Salvado O, Urriola J, McMahon KL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42109200"},{"title01":"Invasive yeast infection in paediatric acute lymphoblastic leukaemia: A report from the multi-international clinical trial AIEOP-BFM ALL 2009.","title02":"Invasive yeast infection in paediatric acute lymphoblastic leukaemia: A report from the multi-international clinical trial AIEOP-BFM ALL 2009.","journal":"Br J Haematol","issue":"2026 May; 208(5):1846-1849. doi: 10.1111\/bjh.70405","author":"Groll AH, Cesaro S, Alten J, Attarbaschi A, Barbaric D, Ebrahimi-Fakhari D, Bodmer N, Conter V, Elitzur S, Moricke A, Schrappe M, Stary J, Zapotocka E, Zimmermann M, Lehrnbecher T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733132"},{"title01":"Leveraging paired germline and somatic analysis to improve the classification of DDX41 variants.","title02":"Leveraging paired germline and somatic analysis to improve the classification of DDX41 variants.","journal":"Br J Haematol","issue":"2026 May; 208(5):1584-1595. doi: 10.1111\/bjh.70411","author":"George A, Rolf E, Domeradzka M, Ribeiro S, Mills B, Hallett A, Macmahon S, Proszek P, Shaikh R, Yuan L, Hubank M, Petrizan MV, McVeigh TP, Khorashad JS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41873058"},{"title01":"Cost-effectiveness of blinatumomab as post-remission therapy in adults with measurable residual disease-negative, Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia.","title02":"Cost-effectiveness of blinatumomab as post-remission therapy in adults with measurable residual disease-negative, Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia.","journal":"Br J Haematol","issue":"2026 May; 208(5):1679-1691. doi: 10.1111\/bjh.70400","author":"Yamamoto C, Yamaguchi T, Honda S, Tominaga R, Yokoyama D, Furuki S, Noguchi A, Koyama S, Murahashi R, Nakashima H, Kawaguchi SI, Hyodo K, Toda Y, Umino K, Minakata D, Ashizawa M, Ueda M, Hatano K, Sato K, Ohmine K, Fujiwara SI, Kanda Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41792981"},{"title01":"Sweet&#8217;s syndrome in acute myeloid leukaemia.","title02":"Sweet&#8217;s syndrome in acute myeloid leukaemia.","journal":"Br J Haematol","issue":"2026 May; 208(5):1523-1524. doi: 10.1111\/bjh.70389","author":"Mon HT, Han KH, Nicholson E, Aguilar-Duran S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41814590"},{"title01":"Chemotherapy-driven expression of WNT ligands in bone marrow stromal cells contributes to chemoresistance in acute lymphoblastic leukaemia.","title02":"Chemotherapy-driven expression of WNT ligands in bone marrow stromal cells contributes to chemoresistance in acute lymphoblastic leukaemia.","journal":"Br J Haematol","issue":"2026 May; 208(5):1572-1583. doi: 10.1111\/bjh.70431","author":"Kalampalika F, Jimenez-Pompa A, Sanchez-Lanzas R, Patel B, Ganuza M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41841727"},{"title01":"An oncogenic, truncated FGFR1 variant cooperates with SPFQ\/NONO to regulate gene transcription in FGFR1-driven leukaemia.","title02":"An oncogenic, truncated FGFR1 variant cooperates with SPFQ\/NONO to regulate gene transcription in FGFR1-driven leukaemia.","journal":"Br J Haematol","issue":"2026 May; 208(5):1564-1571. doi: 10.1111\/bjh.70426","author":"Cowell JK, Fang X, Mori SF, Hu T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41830421"},{"title01":"Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab.","title02":"Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab.","journal":"Br J Haematol","issue":"2026 May; 208(5):1596-1607. doi: 10.1111\/bjh.70416","author":"Allsup DJ, Cairns DA, Samy EF, Duley L, Bloor A, Varghese A, Meads D, Dawkins B, Girvan S, Howard DR, Hockaday A, Brown JM, Jackson S, Greatorex N, Templeton P, Tupper M, Phillips D, Yaqub S, Mortimer D, Stones D, Patten PEM, Rawstron A, Hillmen P, Munir T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41912408"},{"title01":"Dose-dependent impairment of brain functional and microstructural connectivity during leukaemia chemotherapy.","title02":"Dose-dependent impairment of brain functional and microstructural connectivity during leukaemia chemotherapy.","journal":"Br J Haematol","issue":"2026 May; 208(5):1692-1703. doi: 10.1111\/bjh.70386","author":"Scott AP, Lo A, Xia Y, Thompson K, Bodimeade H, Fazlollahi A, Weber N, Curley C, Hunt S, Morris K, McNamara C, Perera N, Subramoniapillai E, Lane SW, Kennedy GA, Salvado O, Urriola J, McMahon KL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41821185"},{"title01":"Monocytic transition in B-lymphoblastic leukaemia with a DUX4 rearrangement.","title02":"Monocytic transition in B-lymphoblastic leukaemia with a DUX4 rearrangement.","journal":"Br J Haematol","issue":"2026 May; 208(5):1519-1520. doi: 10.1111\/bjh.70407","author":"Li J, Lorsbach RB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41793012"},{"title01":"Very long-term outcomes of chronic-phase chronic myeloid leukaemia patients treated with imatinib: A 25-year real-world cohort study.","title02":"Very long-term outcomes of chronic-phase chronic myeloid leukaemia patients treated with imatinib: A 25-year real-world cohort study.","journal":"Br J Haematol","issue":"2026 May; 208(5):1669-1678. doi: 10.1111\/bjh.70418","author":"Costa A, Scalzulli E, Carmosino I, Bisegna ML, Lagana A, Ielo C, Cappelli L, Martelli M, Breccia M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41820245"},{"title01":"Combining Menin and MEK inhibition to target poor prognosis KMT2A-rearranged RAS pathway-mutant acute myeloid leukemia.","title02":"Combining Menin and MEK inhibition to target poor prognosis KMT2A-rearranged RAS pathway-mutant acute myeloid leukemia.","journal":"Blood advances","issue":"2026 May 5. doi: 10.1182\/bloodadvances.2025016208. Online ahead of print","author":"Scheidegger NK, Schneider C, Alexe G, Wang YC, Alonzo TA, Basanthakumar A, Bourgeois WA, Dudkiewicz-Garbicz J, Khalid D, Merickel LA, Perry JA, Ries RE, Salhotra S, Taillon A, Gamis AS, Aplenc R, Harris MH, Wunderlich M, Armstrong SA, Pollard JA, Meshinchi S, Pikman Y, Stegmaier K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42085603"},{"title01":"PU.1-activated genomic regions define low-risk MDS subsets characterized by immune dysregulation and disease progression.","title02":"PU.1-activated genomic regions define low-risk MDS subsets characterized by immune dysregulation and disease progression.","journal":"Blood","issue":"2026 May 14; 147(20):2358-2374. doi: 10.1182\/blood.2025030760","author":"Vallelonga V, Gandolfi F, Zampini M, Riva E, Maggioni G, Ventura D, Saba E, Termanini A, Polletti S, Prosperini E, Crisafulli L, Campagna A, Ferrari I, Pinocchio N, Todisco G, Pedretti S, Calvi M, Di Vito C, Mavilio D, Mitro N, Ficara F, Della Porta MG, Ghisletti S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538708"},{"title01":"Next-generation IHC: identifying TP53 mutation origin in a bone marrow with concurrent CLL and AML.","title02":"Next-generation IHC: identifying TP53 mutation origin in a bone marrow with concurrent CLL and AML.","journal":"Blood","issue":"2026 May 14; 147(20):2415. doi: 10.1182\/blood.2025032949","author":"Hussain M, Loghavi S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42133324"},{"title01":"Nuclear transcriptional condensates as drivers and therapeutic targets in NPM1-mutated AML.","title02":"Nuclear transcriptional condensates as drivers and therapeutic targets in NPM1-mutated AML.","journal":"Blood","issue":"2026 May 14; 147(20):2291-2297. doi: 10.1182\/blood.2025031880","author":"Uckelmann HJ, Gadrey JY, Brunetti L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41949617"},{"title01":"Myeloid\/lymphoid neoplasms with FGFR1 rearrangement and pemigatinib.","title02":"Myeloid\/lymphoid neoplasms with FGFR1 rearrangement and pemigatinib.","journal":"Blood","issue":"2026 May 7; 147(19):2171-2175. doi: 10.1182\/blood.2025031016","author":"Vannucchi AM, Patel JL, Kiladjian JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779732"},{"title01":"How I Treat Plasma Cell Leukemia.","title02":"How I Treat Plasma Cell Leukemia.","journal":"Blood","issue":"2026 May 1. doi: 10.1182\/blood.2025032145. Online ahead of print","author":"Al Hadidi S, van Rhee F, Anderson LD Jr","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42066212"},{"title01":"MLL3 and MLL4 sustain hematopoietic stem cell multipotency by opposing a B-cell default state.","title02":"MLL3 and MLL4 sustain hematopoietic stem cell multipotency by opposing a B-cell default state.","journal":"Blood","issue":"2026 May 12. doi: 10.1182\/blood.2025032969. Online ahead of print","author":"Wang HC, Chen R, Yang W, Muthukumar R, Hu T, Patel RM, Casey EB, Denby ED, Zhang R, Xie G, Ge K, Challen G, Bednarski JJ, Magee JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42118696"},{"title01":"The adverse prognostic impact of HMGCLL1 gene variants can be abrogated by frontline second-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.","title02":"The adverse prognostic impact of HMGCLL1 gene variants can be abrogated by frontline second-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.","journal":"Leukemia","issue":"2026 May; 40(5):1080-1082. doi: 10.1038\/s41375-026-02921-6","author":"Perusini MA, Pagnano K, Pavlovsky C, Zackova D, Mayer J, Moiraghi B, Varela AI, Bianchini M, Pascoal Lopes AB, Duarte G, de Souza CA, Jeziskova I, Kvetkova A, Jurcek T, Won Lee H, Chang MH, Medeiros JJF, Abelson S, Kim DDH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41912912"},{"title01":"Discovery of a selective CDK7 PROTAC against acute leukemia with low platelet toxicity.","title02":"Discovery of a selective CDK7 PROTAC against acute leukemia with low platelet toxicity.","journal":"Leukemia","issue":"2026 May; 40(5):925-933. doi: 10.1038\/s41375-026-02925-2","author":"Tu Y, Cai X, Tao Z, Zhang R, Li X, Chen B, Zhang H, Hu X, Ke J, Chen X, Bai X, Li J, Xu T, Zhou Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41882098"},{"title01":"Intracellular IL-23R is necessary for mitotic spindle formation and viability in AML.","title02":"Intracellular IL-23R is necessary for mitotic spindle formation and viability in AML.","journal":"Leukemia","issue":"2026 May; 40(5):906-917. doi: 10.1038\/s41375-026-02949-8","author":"Duong N, Khan DH, Thomas GE, Feng Y, Hurren R, Lee JB, St-Germain J, Drimmer L, Yan Y, Zhang LX, Fang KK, Ling D, Ma ML, MacLean N, Gronda M, Rondeau V, Brown BD, Matellan L, Jones CL, Chang H, Arruda A, Xie S, Pelletier L, Minden MD, Zhang L, Kornblau SM, Raught B, Jacobs K, Jacobs MG, Goede D, Spadavecchio V, Schimmer AD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41998300"},{"title01":"Haploidentical versus matched unrelated donor transplantation with post-transplant cyclophosphamide: a platform-dependent machine learning analysis of donor age.","title02":"Haploidentical versus matched unrelated donor transplantation with post-transplant cyclophosphamide: a platform-dependent machine learning analysis of donor age.","journal":"Leukemia","issue":"2026 May; 40(5):1009-1017. doi: 10.1038\/s41375-026-02903-8","author":"Mehta RS, Kanakry CG, Nawas M, Lazaryan A, Kanakry JA, Holtan S, Al-Juhaishi T, Rimando JC, Singh A, Saultz J, Mccurdy SR, Milano F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41986623"},{"title01":"Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX models.","title02":"Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX models.","journal":"Leukemia","issue":"2026 May; 40(5):918-924. doi: 10.1038\/s41375-026-02957-8","author":"Kandarpa M, Peterson LF, Potu H, Ramappan M, Liu Y, Polk A, Wang S, Talpaz M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41986621"},{"title01":"Elevated levels of TNF and its targets characterize better-risk older acute myeloid leukemia patients.","title02":"Elevated levels of TNF and its targets characterize better-risk older acute myeloid leukemia patients.","journal":"Leukemia","issue":"2026 May; 40(5):1049-1053. doi: 10.1038\/s41375-026-02954-x","author":"Neelamraju Y, Rapaport F, Gandara JA, Paudel BB, DeWolf S, Dunham N, Fan H, Lee T, Mayo MW, Othman J, Sheridan C, Sol-Church K, Solga MD, Wang L, Cripe LD, Dillon R, Kleppe M, Carroll M, Mason CE, Roboz GJ, Sun Z, Tallman MS, Zhang Y, Paietta E, Levine R, Melnick AM, Bekiranov S, Garrett-Bakelman FE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41975002"},{"title01":"Adherence-enhancing intervention and relapse in childhood acute lymphoblastic leukemia: results from the Children&#8217;s Oncology Group randomized trial ACCL1033.","title02":"Adherence-enhancing intervention and relapse in childhood acute lymphoblastic leukemia: results from the Children&#8217;s Oncology Group randomized trial ACCL1033.","journal":"Leukemia","issue":"2026 May; 40(5):1062-1066. doi: 10.1038\/s41375-026-02951-0","author":"Bhatia S, Hageman L, Chen Y, Wadhwa A, Wong FL, McQuaid EL, Freyer DR, Mba N, Aristizabal P, Raetz E, Landier W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41975001"},{"title01":"Error-corrected next-generation sequencing for profiling the subclonal genetic architecture of juvenile myelomonocytic leukemia.","title02":"Error-corrected next-generation sequencing for profiling the subclonal genetic architecture of juvenile myelomonocytic leukemia.","journal":"Leukemia","issue":"2026 May; 40(5):1035-1039. doi: 10.1038\/s41375-026-02922-5","author":"Sajiki D, Muramatsu H, Wakamatsu M, Tsumura Y, Yamashita D, Yamamori A, Narita K, Kataoka S, Takahashi Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41942652"},{"title01":"Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide.","title02":"Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide.","journal":"Leukemia","issue":"2026 May; 40(5):934-945. doi: 10.1038\/s41375-026-02907-4","author":"Smallbone P, Cao K, Saliba RM, Carmarzzi Y, Al-Atrash G, Alvarez M, Rondon G, Fingrut WB, Aljawai YM, Olson AL, Alousi AM, Chen GL, Tanner MR, Zou J, Ramdial JL, Champlin RE, Shpall EJ, Oran B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41803402"},{"title01":"Testicular organoids formation from leukaemia-infiltrated prepubertal testicular tissue: implications for fertility preservation.","title02":"Testicular organoids formation from leukaemia-infiltrated prepubertal testicular tissue: implications for fertility preservation.","journal":"Leukemia","issue":"2026 May; 40(5):1044-1048. doi: 10.1038\/s41375-026-02938-x","author":"Cui Y, Lohi J, Lindskog C, Jahnukainen K, Stukenborg JB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41922798"},{"title01":"BCR::ABL1 tyrosine kinase inhibitors induce ribosome collisions to activate ZAK-dependent ribotoxic stress and apoptosis in chronic myeloid leukemia.","title02":"BCR::ABL1 tyrosine kinase inhibitors induce ribosome collisions to activate ZAK-dependent ribotoxic stress and apoptosis in chronic myeloid leukemia.","journal":"Leukemia","issue":"2026 May; 40(5):955-969. doi: 10.1038\/s41375-026-02916-3","author":"Park J, Kim SH, Park J, Park H, Kim H, Kim DW, Lim C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41912913"},{"title01":"Differential mitochondrial priming by BCR::ABL1 in B-cell precursor acute lymphoblastic leukemia.","title02":"Differential mitochondrial priming by BCR::ABL1 in B-cell precursor acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 May; 40(5):1076-1079. doi: 10.1038\/s41375-026-02944-z","author":"Kirchhoff H, Schoenherr C, Fleischer L, Talbot SR, Heidel FH, Bergmann AK, Eder M, Scherr M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41912910"},{"title01":"A novel CRLF2-targeted antibody-drug conjugate exhibits potent anti-leukemic activity against Ph-like acute lymphoblastic leukemia.","title02":"A novel CRLF2-targeted antibody-drug conjugate exhibits potent anti-leukemic activity against Ph-like acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 May 5. doi: 10.1038\/s41375-026-02976-5. Online ahead of print","author":"Mohamed SMA, Schofield P, Evans K, Friedrich KH, Christ D, Bayat N, Lock RB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42086931"},{"title01":"MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasms.","title02":"MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasms.","journal":"Leukemia","issue":"2026 May 5. doi: 10.1038\/s41375-026-02975-6. Online ahead of print","author":"Al-Ali HK, Heidel ST, Palandri F, Heidel FH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42086932"},{"title01":"MECOM promotes leukemia progression and inhibits mast cell differentiation through functional competition with GATA2.","title02":"MECOM promotes leukemia progression and inhibits mast cell differentiation through functional competition with GATA2.","journal":"Leukemia","issue":"2026 May 5. doi: 10.1038\/s41375-026-02977-4. Online ahead of print","author":"Iida K, Nakanishi M, Nakahara J, Asada S, Isobe T, Yabushita T, Fukushima T, Tanaka Y, Ozawa M, Yamada Y, Kitamura T, Yamamoto K, Goyama S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42086934"},{"title01":"Editorial Expression of Concern: Discovery of a BTK\/MNK dual inhibitor for lymphoma and leukemia.","title02":"Editorial Expression of Concern: Discovery of a BTK\/MNK dual inhibitor for lymphoma and leukemia.","journal":"Leukemia","issue":"2026 May 6. doi: 10.1038\/s41375-026-02980-9. Online ahead of print","author":"Wu H, Hu C, Wang A, Weisberg EL, Chen Y, Yun CH, Wang W, Liu Y, Liu X, Tian B, Wang J, Zhao Z, Liang Y, Li B, Wang L, Wang B, Chen C, Buhrlage SJ, Qi Z, Zou F, Nonami A, Li Y, Fernandes SM, Adamia S, Stone RM, Galinsky IA, Wang X, Yang G, Griffin JD, Brown JR, Eck MJ, Liu J, Gray NS, Liu Q","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42092047"},{"title01":"Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangement.","title02":"Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangement.","journal":"Leukemia","issue":"2026 May 12. doi: 10.1038\/s41375-026-02973-8. Online ahead of print","author":"Ducourneau B, Pages A, Struski S, Decamp M, Raffoux E, Berthon C, Fenwarth L, Marmouset V, Pautas C, Cluzeau T, Lebon D, Uzunov M, Pereyra P, Heiblig M, Malfuson JV, Farnault L, Dumas PY, Hieulle J, Bertoli S, Chantepie S, Auger N, Bidet A, Mozziconacci MJ, Boudry A, Luquet I, Chat L, Loyaux R, El-Mur L, Clappier E, Gardin C, Hunault M, De Botton S, Pigneux A, Penther D, Delabesse E, Itzykson R, Preudhomme C, Dombret H, Recher C, Duployez N, Micol JB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42120929"},{"title01":"Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial.","title02":"Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial.","journal":"Lancet Haematol","issue":"2026 May; 13(5):e315-e326. doi: 10.1016\/S2352-3026(26)00043-8","author":"Nicolini FE, Etienne G, Huguet F, Charbonnier A, Roth-Guepin G, Escoffre-Barbe M, Dubruille V, Johnson-Ansah H, Rousselot P, Legros L, Parry A, Roy L, Coiteux V, Lenain P, Ianotto JC, Doublet C, Orvain C, Simonet-Boissard M, Chretien ML, Penot A, Meunier M, Ame S, Hermet E, Quittet P, Lapusan S, Schwiertz V, Cayuela JM, Maute C, Rea D, Morisset S, Mahon FX, Dulucq S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42069411"},{"title01":"Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenstrom macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1\/2 BRUIN trial.","title02":"Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenstrom macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1\/2 BRUIN trial.","journal":"Lancet Haematol","issue":"2026 May; 13(5):e284-e296. doi: 10.1016\/S2352-3026(26)00037-2","author":"Palomba ML, Patel MR, Eyre TA, Jurczak W, Lewis D, Gastinne T, Ma S, Cohen JB, Patel K, Brown JR, Scarfo L, Munir T, Lech-Maranda E, Hoffmann MS, Ujjani CS, Fakhri B, Wang ML, Izutsu K, Nagai H, Tam CS, Rhodes JM, Vose J, McKinney M, Gerson JN, Barve MA, Kuss B, Koh Y, Barrett A, Treon SP, Castillo JJ, Seymour JF, Ruppert AS, McNeely SC, Walgren RA, Tsai DE, Bao K, Nair B, Woyach J, Cheah CY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42069409"},{"title01":"From Molecular Complexity to Personalized Care in Chronic Myelomonocytic Leukemia.","title02":"From Molecular Complexity to Personalized Care in Chronic Myelomonocytic Leukemia.","journal":"J Clin Oncol","issue":"2026 May 7; JCO2600635. doi: 10.1200\/JCO-26-00635. Online ahead of print","author":"Wiseman DH, Batta K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42096663"},{"title01":"First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.","title02":"First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.","journal":"J Clin Oncol","issue":"2026 May 10; 44(14):1323-1336. doi: 10.1200\/JCO-25-01966","author":"Rettinger E, Heckl D, Hutter M, Salzmann-Manrique E, Luedtke M, Huenecke S, Bremm M, Cappel C, Bug G, Greil J, Meisel R, Wagner-Drouet EM, Serve H, Gungor T, Klusmann JH, Klingebiel T, Bader P, Bonig H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41941697"},{"title01":"Altered immune and treatment response gene expression signatures among povertyexposed children with B-cell acute lymphoblastic leukemia.","title02":"Altered immune and treatment response gene expression signatures among povertyexposed children with B-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 May 7. doi: 10.3324\/haematol.2025.289187. Online ahead of print","author":"Guillaumet-Adkins A, Mehrabad EM, Sotudeh N, Potdar S, Vijaykumar T, Nair M, Dimitrova V, Frede J, Pikman Y, Harris M, Place AE, Silverman LB, Lohr JG, Bona K, Knoechel B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42095251"},{"title01":"Treatment of leukemic ocular infiltrations with intra-arterial chemotherapy in very early mixed relapse of B-cell acute lymphoblastic leukemia.","title02":"Treatment of leukemic ocular infiltrations with intra-arterial chemotherapy in very early mixed relapse of B-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 May 7. doi: 10.3324\/haematol.2026.300507. Online ahead of print","author":"Andrzejewska M, Deregowski M, Aniol Z, Dezor-Garus J, Stodolska A, Rutkowska S, Przybylowicz-Chalecka A, Zajac-Spychala O, Gotz-Wieckowska A, Derwich K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42095247"},{"title01":"Venetoclax and gilteritinib combination for FLT3-mutated relapsed\/refractory acute myeloid leukemia: a real-world single-center experience.","title02":"Venetoclax and gilteritinib combination for FLT3-mutated relapsed\/refractory acute myeloid leukemia: a real-world single-center experience.","journal":"Haematologica","issue":"2026 May 7. doi: 10.3324\/haematol.2026.300692. Online ahead of print","author":"Crupi F, Ciolli G, Piccini M, Scappini B, Fasano L, Quinti E, Pasquini A, Caroprese J, Gianfaldoni G, Motta G, Santi R, Maccari C, Guglielmelli P, Vannucchi AM, Mannelli F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42095262"},{"title01":"SWI\/SNF alterations define a subgroup with poorer outcome among patients with aggressive forms of adult T-cell leukemia\/lymphoma.","title02":"SWI\/SNF alterations define a subgroup with poorer outcome among patients with aggressive forms of adult T-cell leukemia\/lymphoma.","journal":"Haematologica","issue":"2026 May 7. doi: 10.3324\/haematol.2026.300706. Online ahead of print","author":"Loyaux R, Chraibi S, Pesic M, Debus L, Suez-Panama V, Fuseau P, Hurlot Q, Danu A, Verge V, Meniane JC, Ghez D, Marzac C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42095244"},{"title01":"IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy.","title02":"IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy.","journal":"Haematologica","issue":"2026 May 1; 111(5):1625-1633. doi: 10.3324\/haematol.2025.288743","author":"Hoff FW, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike O, Zeidner JF, Olin RL, Smith CC, Schiller GJ, Curran EK, Handa SV, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Byrd JC, Madanat YF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195510"},{"title01":"Fibrinogen promotes acute myelogenous leukemia progression via miR-486\/GPR153 axis.","title02":"Fibrinogen promotes acute myelogenous leukemia progression via miR-486\/GPR153 axis.","journal":"Haematologica","issue":"2026 May 7. doi: 10.3324\/haematol.2025.288109. Online ahead of print","author":"Yang M, You X, Zhao F, Tong H, Munir H, Wu K, Yu X, Bi L, Xiang J, Zhao M, Zhang S, Ling C, Zhu L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42095237"},{"title01":"Response to Comment on: &#8220;Reporting blast percentage for response assessment in acute leukemias: recommendations from an EHA\/ELN expert panel&#8221;.","title02":"Response to Comment on: &#8220;Reporting blast percentage for response assessment in acute leukemias: recommendations from an EHA\/ELN expert panel&#8221;.","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2026.300980. Online ahead of print","author":"Wang SA, Arenillas L, Buccisano F, Bruggemann M, Kern W, Menes M, Plesa A, Stone L, Wellnitz D, Westerman DA, Wood BL, Freeman SD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988756"},{"title01":"Not guilty by association: myelodysplasia-related mutations in AML.","title02":"Not guilty by association: myelodysplasia-related mutations in AML.","journal":"Leukemia","issue":"2026 April 22. doi: 10.1038\/s41375-026-02936-z. Online ahead of print","author":"Venugopal S, Sekeres MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42020780"},{"title01":"Chronic myelomonocytic leukemia beyond the marrow: biology, patterns, and management of extramedullary disease.","title02":"Chronic myelomonocytic leukemia beyond the marrow: biology, patterns, and management of extramedullary disease.","journal":"Leukemia","issue":"2026 April 27. doi: 10.1038\/s41375-026-02966-7. Online ahead of print","author":"Ahmidouch M, Deshpande P, Salib C, Brunner P, Heller P, Abdel Azim D, Ball S, Tremblay D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42045559"},{"title01":"How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?","title02":"How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?","journal":"Leukemia","issue":"2026 April 30. doi: 10.1038\/s41375-026-02939-w. Online ahead of print","author":"Montoro MJ, Acha P, Haferlach C, Chan O, Navarro V, Kubota Y, Schulz F, Briski R, Al Ali NH, Xicoy B, Palomo L, Lopez-Cadenas F, Bosch F, Meggendorfer M, Gonzalez T, Eder LN, Jerez A, Wang Y, Campagna A, Betz B, Santini V, Bernal T, Such E, Platzbecker AS, Kewan T, Gurnari C, Zindel C, Kulasekararaj A, Voso MT, Sekeres M, Diaz-Varela N, Al-Kali A, Polini A, Diral E, Memoli M, Platzbecker U, Haase D, Zeidan AM, Diez-Campelo M, Garcia-Manero G, Wiseman DH, Della Porta MG, Germing U, Maciejewski J, Komrokji RS, Sole F, Haferlach T, Fenaux P, Valcarcel D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42062555"},{"title01":"TP53 mutation analysis in myelodysplastic syndromes &#8211; long or short read sequencing?","title02":"TP53 mutation analysis in myelodysplastic syndromes &#8211; long or short read sequencing?","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2026.300932. Online ahead of print","author":"Mittelman M, Shlush L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988775"},{"title01":"Recovering from a therapeutic stall in higher-risk myelodysplastic syndromes: re-examining biology, backbones and study designs.","title02":"Recovering from a therapeutic stall in higher-risk myelodysplastic syndromes: re-examining biology, backbones and study designs.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2026.300560. Online ahead of print","author":"Tauro S, Tefferi A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021696"},{"title01":"Not all Tregs in MDS are created equal.","title02":"Not all Tregs in MDS are created equal.","journal":"Br J Haematol","issue":"2026 April 23. doi: 10.1111\/bjh.70503. Online ahead of print","author":"Selig M, Penter L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42025585"},{"title01":"Baseline IPSS-M vs pretransplant risk downstaging as prognostic determinants in MDS undergoing allogeneic transplantation.","title02":"Baseline IPSS-M vs pretransplant risk downstaging as prognostic determinants in MDS undergoing allogeneic transplantation.","journal":"Blood advances","issue":"2026 April 28; 10(8):2817-2828. doi: 10.1182\/bloodadvances.2025018431","author":"Aguirre LE, Kim HT, Elmariah H, Frumm SM, Kelkar AH, Ho V, Gooptu M, Koreth J, Shapiro RM, Romee R, Nikiforow S, Antin JH, Soiffer RJ, Shimony S, Luskin MR, Garcia JS, Chen EC, Wadleigh M, Winer ES, Stone RM, DeAngelo DJ, Al Ali N, Sallman D, Kuykendall A, Sweet K, Lancet JE, Padron E, Chan O, Xie Z, Cutler CS, Komrokji RS, Stahl M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587470"},{"title01":"A novel approach to defining progression in MDS and precursor myeloid conditions in the MDS Natural History Study.","title02":"A novel approach to defining progression in MDS and precursor myeloid conditions in the MDS Natural History Study.","journal":"Blood advances","issue":"2026 April 28; 10(8):2743-2753. doi: 10.1182\/bloodadvances.2025018770","author":"DeZern AE, Gillis N, Otterstatter M, Abel G, Padron E, Deeg HJ, Al Baghdadi T, Liu J, Xie Z, Zhang L, Moscinski L, Kroft S, Harrington A, Foran J, Komrokji R, Starczynowski D, Gore S, Saber W, Bejar R, Lindsley RC, Sherman S, Lee C, DiFronzo N, Walter M, Sekeres MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671442"},{"title01":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","title02":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","journal":"Blood","issue":"2026 April 23; 147(17):1914-1927. doi: 10.1182\/blood.2025031053","author":"Mushtaq MU, DiPersio JF, Azzi J, Cooper BW, Koehne G, Koura D, Maakaron J, Magenau J, McClune B, Rimando JC, Shah NN, Suh HC, Beuka K, Sturrock J, Nikam M, Berglund E, Hu J, Keschner Y, Etchin J, Lydeard JR, Vasquez M, O'Donnell D, Mundelboim G, Thosar S, Canesin G, Xavier-Ferrucio J, Hyzy SL, Lloyd DM, Spink K, Hummel D, Lee-Sundlov MM, Scherer J, Lin MI, Whangbo JS, Muffly LS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41636724"},{"title01":"Chronic myelomonocytic leukemia beyond the marrow: biology, patterns, and management of extramedullary disease.","title02":"Chronic myelomonocytic leukemia beyond the marrow: biology, patterns, and management of extramedullary disease.","journal":"Leukemia","issue":"2026 April 27. doi: 10.1038\/s41375-026-02966-7. Online ahead of print","author":"Ahmidouch M, Deshpande P, Salib C, Brunner P, Heller P, Abdel Azim D, Ball S, Tremblay D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42045559"},{"title01":"Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.","title02":"Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.","journal":"J Clin Oncol","issue":"2026 April 24; JCO2502351. doi: 10.1200\/JCO-25-02351. Online ahead of print","author":"Dierickx D, Heimovaara JH, Bellido M, Van Calsteren K, Cardonick E, Garcia AC, Baten A, Evens AM, Ferber A, Fumagalli M, Lampka E, Specht L, Vandecaveye V, Vogelius IR, Alber M, Amant F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42030539"},{"title01":"Prevalence, incidence, and risk factors of secondary malignancies in patients with polycythemia vera: A real-world study.","title02":"Prevalence, incidence, and risk factors of secondary malignancies in patients with polycythemia vera: A real-world study.","journal":"Blood advances","issue":"2026 April 29. doi: 10.1182\/bloodadvances.2025019349. Online ahead of print","author":"Pemmaraju N, Markova A, Masarova L, Reaven N, Funk SE, Ferguson TW, Bellamy LA, Dinh P, Oyuela P, Valone F, Molina A, Gupta S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42054546"},{"title01":"Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphoma.","title02":"Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphoma.","journal":"Blood advances","issue":"2026 April 28; 10(8):2767-2780. doi: 10.1182\/bloodadvances.2025018774","author":"Knorr F, Zimmermann M, Bader P, Lang P, Muller I, Basu O, Burkhardt B, Seidl J, Damm-Welk C, Pichler H, Attarbaschi A, Meissner B, Beier R, Woessmann W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632689"},{"title01":"Pregnancy after hematopoietic stem cell transplant: an international multicenter study.","title02":"Pregnancy after hematopoietic stem cell transplant: an international multicenter study.","journal":"Blood advances","issue":"2026 April 28; 10(8):2634-2645. doi: 10.1182\/bloodadvances.2025016977","author":"Salooja N, Eikema DJ, Michonneau D, Tichelli A, Apperley JF, Akhtar S, Bourhis JH, Maertens J, Maghfoor I, Massarotti C, Collin M, Mielke S, Raiola A, Schaap N, Sedlacek P, Socie G, van der Werf S, Aljurf M, Kalwak K, Basak G, Peric Z, Penack O, Schoemans H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41604618"},{"title01":"Long-read KIR genotyping reveals donor KIR\/HLA polymorphisms linked to posttransplant relapse in T-cell malignancies.","title02":"Long-read KIR genotyping reveals donor KIR\/HLA polymorphisms linked to posttransplant relapse in T-cell malignancies.","journal":"Blood advances","issue":"2026 April 17. doi: 10.1182\/bloodadvances.2025019066. Online ahead of print","author":"Morita-Fujita M, Kawaguchi S, Shindo T, Izumi K, Shimizu M, Inadomi Y, Kanda J, Watanabe M, Takahashi M, Tsujimura T, Tarumoto S, Yamamoto T, Kato K, Tanaka H, Morishima S, Morishima Y, Nakano N, Hayashi M, Miyazaki Y, Imada K, Higuchi Y, Yonezawa A, Suehiro Y, Yoshimitsu M, Doki N, Katayama Y, Hasegawa Y, Serizawa K, Ichinohe T, Fukuda T, Onizuka M, Atsuta Y, Takaori-Kondo A, Matsuda F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41995743"},{"title01":"GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study.","title02":"GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study.","journal":"Blood advances","issue":"2026 April 28; 10(8):2648-2660. doi: 10.1182\/bloodadvances.2025018626","author":"Yamasaki S, Yanada M, Mizuno S, Shimomura Y, Tobai T, Harada K, Uchida N, Tanaka M, Wake A, Onizuka M, Eto T, Uehara Y, Takahashi S, Izumi T, Doki N, Tokunaga M, Kawakita T, Nishida T, Sakata-Yanagimoto M, Ishimaru F, Kanda J, Atsuta Y, Konuma T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538306"},{"title01":"Tildrakizumab for the prophylaxis of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.","title02":"Tildrakizumab for the prophylaxis of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.","journal":"Blood advances","issue":"2026 April 28; 10(8):2698-2710. doi: 10.1182\/bloodadvances.2025019065","author":"Runaas L, Fank S, Palen K, Szabo A, Rein LE, Ying G, Salzman N, Samanas L, Abedin S, Chhabra S, Hamadani M, Longo W, Shah NN, Haber J, Gradissimo A, Waters N, Peled JU, Johnson B, Kearl T, Drobyski WR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632629"},{"title01":"HIV cure after HCT: seven horses seem to be on the mark.","title02":"HIV cure after HCT: seven horses seem to be on the mark.","journal":"Blood advances","issue":"2026 April 29. doi: 10.1182\/bloodadvances.2026019926. Online ahead of print","author":"Camargo JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42054547"},{"title01":"Endothelial Activation and Damage associated with Steroid-Refractory aGVHD is counteracted by Ruxolitinib.","title02":"Endothelial Activation and Damage associated with Steroid-Refractory aGVHD is counteracted by Ruxolitinib.","journal":"Blood advances","issue":"2026 April 28. doi: 10.1182\/bloodadvances.2026019704. Online ahead of print","author":"De Moner B, Martinez-Sanchez J, Escribano-Serrat S, Moreno-Castano AB, Charry P, Cid J, Lozano M, Arellano-Rodrigo E, Salas MQ, Rovira M, Martinez C, Escolar G, Carreras E, Alvarez-Larran A, Diaz-Ricart M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42048573"},{"title01":"Acquired nonpermissive BM microenvironment impairs HSC proliferation and maintenance, and B-cell development after HSCT.","title02":"Acquired nonpermissive BM microenvironment impairs HSC proliferation and maintenance, and B-cell development after HSCT.","journal":"Blood advances","issue":"2026 April 28; 10(8):2786-2800. doi: 10.1182\/bloodadvances.2025015915","author":"de Gier M, Korzhenevich J, Schmidt FM, Janowska I, van Ostaijen-Ten Dam MM, Pico-Knijnenburg I, Cats D, Keller F, Hadlova P, Kunze M, Markfeld-Erol F, Reising K, Mei H, Bredius RGM, Lankester AC, van der Burg M, Rizzi M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41544216"},{"title01":"The role of HLA transcription in unrelated hematopoietic cell transplantation.","title02":"The role of HLA transcription in unrelated hematopoietic cell transplantation.","journal":"Blood advances","issue":"2026 April 28; 10(8):2687-2697. doi: 10.1182\/bloodadvances.2025017945","author":"Morishima S, Shiina T, Azuma F, Tomori S, Doki N, Nishida T, Fukuda T, Eto T, Kataoka K, Hasegawa Y, Tanaka M, Ota S, Takada S, Katayama Y, Uchida N, Nakamae H, Kanda Y, Hiramoto N, Kanda J, Onizuka M, Ichinohe T, Atsuta Y, Morishima Y, Murata M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628351"},{"title01":"CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.","title02":"CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.","journal":"Blood advances","issue":"2026 April 28; 10(8):2854-2864. doi: 10.1182\/bloodadvances.2025019378","author":"Shimony S, Murdock HM, Keating J, Tsai HK, Sasi A, Gibson CJ, Faderl S, Wagner A, Dronamraju N, Lin TL, Prebet T, Cortes JE, Uy GL, Lancet JE, Reilly CR, Neuberg D, Stone RM, Lindsley RC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628350"},{"title01":"Nucleoplasmic ZNF467 condensates boost hematopoietic stem cell engraftment via ICAM1-mediated mechanical reprogramming.","title02":"Nucleoplasmic ZNF467 condensates boost hematopoietic stem cell engraftment via ICAM1-mediated mechanical reprogramming.","journal":"Blood","issue":"2026 April 30; 147(18):2064-2080. doi: 10.1182\/blood.2025031247","author":"Chen Y, Shen J, Lin Z, Ding Q, Zhang X, Zhang M, Yang H, Yao H, Liu S, Wan J, Liu S, Jia X, Wang X, Yu U, Hao S, Cao M, Jiang H, Guo B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671478"},{"title01":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","title02":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","journal":"Blood","issue":"2026 April 23; 147(17):1914-1927. doi: 10.1182\/blood.2025031053","author":"Mushtaq MU, DiPersio JF, Azzi J, Cooper BW, Koehne G, Koura D, Maakaron J, Magenau J, McClune B, Rimando JC, Shah NN, Suh HC, Beuka K, Sturrock J, Nikam M, Berglund E, Hu J, Keschner Y, Etchin J, Lydeard JR, Vasquez M, O'Donnell D, Mundelboim G, Thosar S, Canesin G, Xavier-Ferrucio J, Hyzy SL, Lloyd DM, Spink K, Hummel D, Lee-Sundlov MM, Scherer J, Lin MI, Whangbo JS, Muffly LS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41636724"},{"title01":"Nuclear architecture: a mechanical lever for HSC fitness.","title02":"Nuclear architecture: a mechanical lever for HSC fitness.","journal":"Blood","issue":"2026 April 30; 147(18):2023-2024. doi: 10.1182\/blood.2026033532","author":"Rezk R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42060330"},{"title01":"Development and validation of the predictive aplastic score system (PASS): a simplified tool to diagnose acquired aplastic anemia in adults.","title02":"Development and validation of the predictive aplastic score system (PASS): a simplified tool to diagnose acquired aplastic anemia in adults.","journal":"Leukemia","issue":"2026 April 27. doi: 10.1038\/s41375-026-02924-3. Online ahead of print","author":"Aleixo G, Cheon H, Zheng J, Soewito S, Lee J, Kaphan E, Kalakuntla N, Jen WY, Kotha S, Rupsee A, Djulbegovic M, Matthews JA, Kadia TM, Olson TS, Peffault de Latour R, Sicre De Fontbrune F, Bat T, DiNardo CD, Babushok DV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42045556"},{"title01":"Nivolumab +\/- Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial.","title02":"Nivolumab +\/- Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial.","journal":"J Clin Oncol","issue":"2026 April 20; 44(12):1120-1129. doi: 10.1200\/JCO-25-01657","author":"Walter TP, Mazieres J, Otto J, Lena H, Lepage C, Smith D, Madelaine J, Geriniere L, Egenod T, El Hajbi F, Ferru A, Clement-Duchene C, Madroszyk A, Brotelle T, Bouhier-Leporrier K, Desrame J, Ghiringhelli F, Paleiron N, Khalil A, Milot L, Chevallier O, Couvelard A, Lantuejoul S, Langlais A, Morin F, Duruisseaux M, Michel P, Louvet C, Westeel V, Girard N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41774886"},{"title01":"Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.","title02":"Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.","journal":"J Clin Oncol","issue":"2026 April 24; JCO2502351. doi: 10.1200\/JCO-25-02351. Online ahead of print","author":"Dierickx D, Heimovaara JH, Bellido M, Van Calsteren K, Cardonick E, Garcia AC, Baten A, Evens AM, Ferber A, Fumagalli M, Lampka E, Specht L, Vandecaveye V, Vogelius IR, Alber M, Amant F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42030539"},{"title01":"Immunosuppressive therapy for severe aplastic anemia in children under the age of 3 years yields a high response rate: a North American collaborative study.","title02":"Immunosuppressive therapy for severe aplastic anemia in children under the age of 3 years yields a high response rate: a North American collaborative study.","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2025.300232. Online ahead of print","author":"Dayagi TW, Willis L, Arnold SD, Boklan J, Cada M, Coates TD, Corriveau-Bourque C, Gamper CJ, Geddis AE, Glader B, Kupfer GM, Nakano TA, Olson TS, Rogers ZR, Shimamura A, Takemoto C, Thompson AA, Williams DA, Dror Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988768"},{"title01":"A genetic risk score based on BCL11A and HBS1L-MYB variants predicts clinical severity in Brazilian sickle cell anaemia patients.","title02":"A genetic risk score based on BCL11A and HBS1L-MYB variants predicts clinical severity in Brazilian sickle cell anaemia patients.","journal":"Br J Haematol","issue":"2026 April 16. doi: 10.1111\/bjh.70489. Online ahead of print","author":"Arcanjo GS, Silva AP, Diniz MV, Domingos IF, Pereira-Martins DA, Araujo AB, Franca TSS, Anjos AC, Araujo AS, Belini-Junior E, Saad STO, Costa FF, Lucena-Araujo AR, Bezerra MAC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41989145"},{"title01":"Circulating erythropoietin concentration associates with thromboembolism in sickle cell disease.","title02":"Circulating erythropoietin concentration associates with thromboembolism in sickle cell disease.","journal":"Br J Haematol","issue":"2026 April 29. doi: 10.1111\/bjh.70517. Online ahead of print","author":"Zhang X, Shah BN, Han J, Nouraie M, Zhang Y, Machado RF, Gladwin MT, Saraf SL, Gordeuk VR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42052798"},{"title01":"Allogeneic hematopoietic cell transplantation for aplastic anemia: a single institution experience across 6 decades.","title02":"Allogeneic hematopoietic cell transplantation for aplastic anemia: a single institution experience across 6 decades.","journal":"Blood advances","issue":"2026 April 28; 10(8):2661-2675. doi: 10.1182\/bloodadvances.2025018548","author":"Olivieri D, Othus M, Vo P, Walter RB, Manjappa S, Basom R, Storb R, Keel S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637641"},{"title01":"Clinical variability of ATP11C-related hemolytic anemia: expanding the phenotypic and diagnostic spectrum.","title02":"Clinical variability of ATP11C-related hemolytic anemia: expanding the phenotypic and diagnostic spectrum.","journal":"Blood advances","issue":"2026 April 22. doi: 10.1182\/bloodadvances.2025019161. Online ahead of print","author":"D'Onofrio V, Esposito FM, Marra R, Rosato BE, Nostroso A, Perrotta A, Matsell E, Manno M Sr, Iscaro A, Dionisi M Sr, Martone S, Arcioni F, Barbato A, Chiariotti L, Della Monica R, van Oirschot BA, van Wijk R, Molday RS, Iolascon A, Russo R, Andolfo I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42018644"},{"title01":"Erythroid-produced intact FGF23 is a paracrine inhibitor of erythropoiesis.","title02":"Erythroid-produced intact FGF23 is a paracrine inhibitor of erythropoiesis.","journal":"Blood","issue":"2026 April 21. doi: 10.1182\/blood.2025030634. Online ahead of print","author":"Courbon G, Thomas JJ, Duque EJ, Kentrup D, Spindler J, Semancheck W, Tracey E, Vaughan DE, Chang W, Creemers JWM, Ji P, Isakova T, Martin A, David V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42013007"},{"title01":"Refined classification and phenotype-driven analysis of PIEZO1 variants in hereditary red cell and iron disorders.","title02":"Refined classification and phenotype-driven analysis of PIEZO1 variants in hereditary red cell and iron disorders.","journal":"Blood","issue":"2026 April 21. doi: 10.1182\/blood.2025031632. Online ahead of print","author":"Rosato BE, Marra R, Martone S, Manno M Sr, Dionisi M Sr, Ribersani M 2nd, Pinto VM, Forni GL, Balocco M, Carrara P, Lamagna M, Morisco F, Guarino M, Cossiga V, Barbato A, Arcioni F, Iolascon A, Russo R, Andolfo I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42013021"},{"title01":"Ianalumab plus Eltrombopag in Immune Thrombocytopenia.","title02":"Ianalumab plus Eltrombopag in Immune Thrombocytopenia.","journal":"N Engl J Med","issue":"2026 April 16; 394(15):1503-1513. doi: 10.1056\/NEJMoa2515168","author":"Cuker A, Stauch T, Cooper N, Al-Samkari H, Michel M, Ghanima W, Urban P, Fronczek J, Foster M, Weill M, Zhang L, Hou M, Zander T, Sharif A, Sun J, Nath UK, Schutgens R, Rossi E, Deleu L, Cervinek L, Yoon JH, Chang H, Ruchutrakool T, Iino M, Goto T, Zaja F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363800"},{"title01":"Chimeric antigen receptor T cells for autoimmune diseases, in particular immune thrombocytopenia.","title02":"Chimeric antigen receptor T cells for autoimmune diseases, in particular immune thrombocytopenia.","journal":"Br J Haematol","issue":"2026 April 16. doi: 10.1111\/bjh.70482. Online ahead of print","author":"Soff SP, Ruder S, Bussel JB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41989015"},{"title01":"Anti-CD38 therapy in immune thrombocytopenia (ITP).","title02":"Anti-CD38 therapy in immune thrombocytopenia (ITP).","journal":"Br J Haematol","issue":"2026 April 23. doi: 10.1111\/bjh.70493. Online ahead of print","author":"Ghanima W, Hou Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021728"},{"title01":"The association of thrombocytopenia with haematological malignancy.","title02":"The association of thrombocytopenia with haematological malignancy.","journal":"Br J Haematol","issue":"2026 April 24. doi: 10.1111\/bjh.70498. Online ahead of print","author":"Vijenthira A, Frederiksen H, Sholzberg M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42031689"},{"title01":"HLA profile in paediatric ITP: Comparison with healthy controls and prognostic implications.","title02":"HLA profile in paediatric ITP: Comparison with healthy controls and prognostic implications.","journal":"Br J Haematol","issue":"2026 April 29. doi: 10.1111\/bjh.70483. Online ahead of print","author":"Gonzalez de Pablo J, Molina YL, Vicario JL, Moreno Hidalgo MA, de la Cruz A, Galan A, Zubicaray J, Lopez de Hontanar G, Sanz A, Marin L, Verdejo de Antonio J, Sevilla J, Sebastian E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42051172"},{"title01":"Predicting development of pediatric chronic immune thrombocytopenia at disease onset using a statistical risk model.","title02":"Predicting development of pediatric chronic immune thrombocytopenia at disease onset using a statistical risk model.","journal":"Blood","issue":"2026 April 16; 147(16):1863-1872. doi: 10.1182\/blood.2025028563","author":"Hillier K, Zobeck M, MacMath D, Chumsky J, Kirk SE, O'Farrell C, Lucari B, Ngwerume F, Gaerlan S, Konde P, Wang K, Lambert MP, Grace RF, Grimes AB, Kim TO","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632829"},{"title01":"CDK8\/CDK19 inhibition restores T-cell homeostasis in primary immune thrombocytopenia.","title02":"CDK8\/CDK19 inhibition restores T-cell homeostasis in primary immune thrombocytopenia.","journal":"Blood","issue":"2026 April 30; 147(18):2114-2131. doi: 10.1182\/blood.2025031332","author":"Wang YM, Zhou H, Leng SQ, Ma JJ, Li HY, Li GS, Sun T, Xu YT, Han SQ, Gu YF, Dong L, Yan ZY, Zhang L, Peng J, Liu XG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41770851"},{"title01":"Chronic ITP prediction model.","title02":"Chronic ITP prediction model.","journal":"Blood","issue":"2026 April 16; 147(16):1887. doi: 10.1182\/blood.2026033691","author":"No authors listed","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41989799"},{"title01":"Cloudy with a chance of platelets: forecasting chronic ITP.","title02":"Cloudy with a chance of platelets: forecasting chronic ITP.","journal":"Blood","issue":"2026 April 16; 147(16):1788-1789. doi: 10.1182\/blood.2025033013","author":"Shimano KA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41989800"},{"title01":"Platelet-derived TGF-beta1 and Treg maintenance in a murine model of ITP.","title02":"Platelet-derived TGF-beta1 and Treg maintenance in a murine model of ITP.","journal":"Blood","issue":"2026 April 20. doi: 10.1182\/blood.2026034039. Online ahead of print","author":"Ahamed J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42008373"},{"title01":"Toggling STAT to restore T-cell homeostasis in ITP.","title02":"Toggling STAT to restore T-cell homeostasis in ITP.","journal":"Blood","issue":"2026 April 30; 147(18):2028-2030. doi: 10.1182\/blood.2026033533","author":"Semple JW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42060329"},{"title01":"CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.","title02":"CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.","journal":"Blood advances","issue":"2026 April 28; 10(8):2854-2864. doi: 10.1182\/bloodadvances.2025019378","author":"Shimony S, Murdock HM, Keating J, Tsai HK, Sasi A, Gibson CJ, Faderl S, Wagner A, Dronamraju N, Lin TL, Prebet T, Cortes JE, Uy GL, Lancet JE, Reilly CR, Neuberg D, Stone RM, Lindsley RC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628350"},{"title01":"Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data.","title02":"Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data.","journal":"Br J Haematol","issue":"2026 April 23. doi: 10.1111\/bjh.70490. Online ahead of print","author":"Goel U, Dragomirescu C, Zanwar S, Cassano RC, Cicero KI, Cowan AJ, Banerjee R, Anwer F, Khouri J, Dima D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42023513"},{"title01":"Recombinant zoster vaccine induces superior immunogenicity compared with live varicella vaccine in allogeneic haematopoietic stem cell transplantation recipients.","title02":"Recombinant zoster vaccine induces superior immunogenicity compared with live varicella vaccine in allogeneic haematopoietic stem cell transplantation recipients.","journal":"Br J Haematol","issue":"2026 April 20. doi: 10.1111\/bjh.70500. Online ahead of print","author":"Ono T, Okada T, Ikeda R, Yamashita M, Koyauchi K, Takagi F, Adachi M, Takemura T, Mitsui K, Nagata Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42007689"},{"title01":"Reconsidering GVHD prophylaxis in cord blood transplantation.","title02":"Reconsidering GVHD prophylaxis in cord blood transplantation.","journal":"Blood advances","issue":"2026 April 28; 10(8):2727-2728. doi: 10.1182\/bloodadvances.2025019372","author":"Clara JA, Ballen K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41996199"},{"title01":"Endothelial Activation and Damage associated with Steroid-Refractory aGVHD is counteracted by Ruxolitinib.","title02":"Endothelial Activation and Damage associated with Steroid-Refractory aGVHD is counteracted by Ruxolitinib.","journal":"Blood advances","issue":"2026 April 28. doi: 10.1182\/bloodadvances.2026019704. Online ahead of print","author":"De Moner B, Martinez-Sanchez J, Escribano-Serrat S, Moreno-Castano AB, Charry P, Cid J, Lozano M, Arellano-Rodrigo E, Salas MQ, Rovira M, Martinez C, Escolar G, Carreras E, Alvarez-Larran A, Diaz-Ricart M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42048573"},{"title01":"Long-read KIR genotyping reveals donor KIR\/HLA polymorphisms linked to posttransplant relapse in T-cell malignancies.","title02":"Long-read KIR genotyping reveals donor KIR\/HLA polymorphisms linked to posttransplant relapse in T-cell malignancies.","journal":"Blood advances","issue":"2026 April 17. doi: 10.1182\/bloodadvances.2025019066. Online ahead of print","author":"Morita-Fujita M, Kawaguchi S, Shindo T, Izumi K, Shimizu M, Inadomi Y, Kanda J, Watanabe M, Takahashi M, Tsujimura T, Tarumoto S, Yamamoto T, Kato K, Tanaka H, Morishima S, Morishima Y, Nakano N, Hayashi M, Miyazaki Y, Imada K, Higuchi Y, Yonezawa A, Suehiro Y, Yoshimitsu M, Doki N, Katayama Y, Hasegawa Y, Serizawa K, Ichinohe T, Fukuda T, Onizuka M, Atsuta Y, Takaori-Kondo A, Matsuda F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41995743"},{"title01":"GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study.","title02":"GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study.","journal":"Blood advances","issue":"2026 April 28; 10(8):2648-2660. doi: 10.1182\/bloodadvances.2025018626","author":"Yamasaki S, Yanada M, Mizuno S, Shimomura Y, Tobai T, Harada K, Uchida N, Tanaka M, Wake A, Onizuka M, Eto T, Uehara Y, Takahashi S, Izumi T, Doki N, Tokunaga M, Kawakita T, Nishida T, Sakata-Yanagimoto M, Ishimaru F, Kanda J, Atsuta Y, Konuma T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538306"},{"title01":"IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM.","title02":"IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM.","journal":"Blood advances","issue":"2026 April 28; 10(8):2616-2625. doi: 10.1182\/bloodadvances.2025018537","author":"Maclachlan KH, Tan CR, Shekarkhand T, Rueda C, Derkach A, Hashmi H, Hassoun H, Shah UA, Hultcrantz M, Lesokhin AM, Mailankody S, Maura F, Merz M, Firestone R, Jurgens EM, Miller KC, Rajeeve S, Giralt S, Shah GL, Scordo M, Landau HJ, Zhang Y, Cimera R, Arcila ME, Korde N, Usmani SZ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41701976"},{"title01":"Allogeneic hematopoietic cell transplantation for aplastic anemia: a single institution experience across 6 decades.","title02":"Allogeneic hematopoietic cell transplantation for aplastic anemia: a single institution experience across 6 decades.","journal":"Blood advances","issue":"2026 April 28; 10(8):2661-2675. doi: 10.1182\/bloodadvances.2025018548","author":"Olivieri D, Othus M, Vo P, Walter RB, Manjappa S, Basom R, Storb R, Keel S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637641"},{"title01":"Pregnancy after hematopoietic stem cell transplant: an international multicenter study.","title02":"Pregnancy after hematopoietic stem cell transplant: an international multicenter study.","journal":"Blood advances","issue":"2026 April 28; 10(8):2634-2645. doi: 10.1182\/bloodadvances.2025016977","author":"Salooja N, Eikema DJ, Michonneau D, Tichelli A, Apperley JF, Akhtar S, Bourhis JH, Maertens J, Maghfoor I, Massarotti C, Collin M, Mielke S, Raiola A, Schaap N, Sedlacek P, Socie G, van der Werf S, Aljurf M, Kalwak K, Basak G, Peric Z, Penack O, Schoemans H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41604618"},{"title01":"Baseline IPSS-M vs pretransplant risk downstaging as prognostic determinants in MDS undergoing allogeneic transplantation.","title02":"Baseline IPSS-M vs pretransplant risk downstaging as prognostic determinants in MDS undergoing allogeneic transplantation.","journal":"Blood advances","issue":"2026 April 28; 10(8):2817-2828. doi: 10.1182\/bloodadvances.2025018431","author":"Aguirre LE, Kim HT, Elmariah H, Frumm SM, Kelkar AH, Ho V, Gooptu M, Koreth J, Shapiro RM, Romee R, Nikiforow S, Antin JH, Soiffer RJ, Shimony S, Luskin MR, Garcia JS, Chen EC, Wadleigh M, Winer ES, Stone RM, DeAngelo DJ, Al Ali N, Sallman D, Kuykendall A, Sweet K, Lancet JE, Padron E, Chan O, Xie Z, Cutler CS, Komrokji RS, Stahl M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587470"},{"title01":"How I select hematopoietic cell donors in the era of posttransplant cyclophosphamide.","title02":"How I select hematopoietic cell donors in the era of posttransplant cyclophosphamide.","journal":"Blood","issue":"2026 April 23; 147(17):1903-1913. doi: 10.1182\/blood.2025030823","author":"Shaffer BC, Lee SJ, Perales MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41746780"},{"title01":"Targeting donor XCR1+ and CD11b+ dendritic cells prevents Th1- and Th17-dependent GVHD within the gastrointestinal tract.","title02":"Targeting donor XCR1+ and CD11b+ dendritic cells prevents Th1- and Th17-dependent GVHD within the gastrointestinal tract.","journal":"Blood","issue":"2026 April 30; 147(18):2143-2155. doi: 10.1182\/blood.2025029431","author":"Takahashi S, Inoue T, Ensbey KS, Legg SRW, Sekiguchi T, Nelson E, Nemychenkov NS, Joshi T, Minnie SA, Yeh AC, Zhang P, Headley M, Paik J, Amory JK, Hill GR, Koyama M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41662631"},{"title01":"A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma.","title02":"A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma.","journal":"Blood","issue":"2026 April 30; 147(18):2041-2052. doi: 10.1182\/blood.2025029546","author":"Diefenbach CS, Jegede O, Wang V, Ansell SM, Kostakoglu L, Steidl C, Natkunam Y, Scott DW, Ambinder RF, David KA, Advani RH, Bartlett NL, Robertson MJ, Thomas SP, Cohen J, Ibrahimi S, Goyal G, Mehta-Shah N, Amengual JE, Forlenza CJ, Cole PD, Duan F, Kelly K, Kahl BS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41662628"},{"title01":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","title02":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","journal":"Blood","issue":"2026 April 23; 147(17):1914-1927. doi: 10.1182\/blood.2025031053","author":"Mushtaq MU, DiPersio JF, Azzi J, Cooper BW, Koehne G, Koura D, Maakaron J, Magenau J, McClune B, Rimando JC, Shah NN, Suh HC, Beuka K, Sturrock J, Nikam M, Berglund E, Hu J, Keschner Y, Etchin J, Lydeard JR, Vasquez M, O'Donnell D, Mundelboim G, Thosar S, Canesin G, Xavier-Ferrucio J, Hyzy SL, Lloyd DM, Spink K, Hummel D, Lee-Sundlov MM, Scherer J, Lin MI, Whangbo JS, Muffly LS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41636724"},{"title01":"Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.","title02":"Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.","journal":"Blood","issue":"2026 April 16; 147(16):1857-1862. doi: 10.1182\/blood.2025031952","author":"Bal S, Ravi G, Dhakal B, Callander NS, Medvedova E, Dholaria BR, Giri S, Godby KN, Silbermann RW, Mikhail FM, Huls F, Reddy V, Costa LJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592281"},{"title01":"Dendritic cells team up to drive gut GVHD.","title02":"Dendritic cells team up to drive gut GVHD.","journal":"Blood","issue":"2026 April 30; 147(18):2032-2034. doi: 10.1182\/blood.2026033361","author":"Babiker L, Maillard I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42060335"},{"title01":"Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma.","title02":"Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma.","journal":"Blood","issue":"2026 April 16; 147(16):1814-1827. doi: 10.1182\/blood.2025031455","author":"Alderuccio JP, Baggio D, Han S, Ghione P, Nizamuddin I, Khwaja J, Saha A, Dong N, Wang Y, Cherng HJ, Tolu S, Wagner-Johnston N, Ollila TA, Grover N, Koff JL, Desai A, Ramakrishnan Geethakumari P, Moyo TK, Sandoval-Sus J, Epperla N, Wallace DS, Kamdar M, Tavarozzi R, Danilov A, Tun H, Munoz J, Narkhede M, Rhodes JM, Prica A, Kuhnl A, Maraj A, Okosun J, Smith J, Osborne W, Calvert V, El-Sharkawi D, Hilali A, Collins GP, Linton K, Elmusharaf N, Santarsieri A, Karim F, Baidoun F, Monick SE, Trutzer IM, Can J, Ayers A, Calabrese De Feo J, Sharp J, Ghosh N, Treitman R, Kallam A, Okcu I, Abeyakoon C, Hann W, Barrett A, Deshani V, Kahl BS, Chavez JC, Olszewski AJ, Cwynarski K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490516"},{"title01":"Intracellular IL-23R is necessary for mitotic spindle formation and viability in AML.","title02":"Intracellular IL-23R is necessary for mitotic spindle formation and viability in AML.","journal":"Leukemia","issue":"2026 May; 40(5):906-917. doi: 10.1038\/s41375-026-02949-8","author":"Duong N, Khan DH, Thomas GE, Feng Y, Hurren R, Lee JB, St-Germain J, Drimmer L, Yan Y, Zhang LX, Fang KK, Ling D, Ma ML, MacLean N, Gronda M, Rondeau V, Brown BD, Matellan L, Jones CL, Chang H, Arruda A, Xie S, Pelletier L, Minden MD, Zhang L, Kornblau SM, Raught B, Jacobs K, Jacobs MG, Goede D, Spadavecchio V, Schimmer AD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41998300"},{"title01":"Imputing causality and clonal dynamics from single-cell transcriptomics in paroxysmal nocturnal hemoglobinuria.","title02":"Imputing causality and clonal dynamics from single-cell transcriptomics in paroxysmal nocturnal hemoglobinuria.","journal":"Leukemia","issue":"2026 April 22. doi: 10.1038\/s41375-026-02914-5. Online ahead of print","author":"Mizumaki H, Gao S, Wu Z, Gutierrez-Rodrigues F, Alemu L, Quinones Raffo D, Darden I, Rios O, Lotter J, Kajigaya S, Durrani J, Groarke EM, Patel BA, Young NS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42020783"},{"title01":"Multi-omics analysis of pediatric minimally differentiated acute myeloid leukemia reveals RUNX1-driven stemness and chemoresistance.","title02":"Multi-omics analysis of pediatric minimally differentiated acute myeloid leukemia reveals RUNX1-driven stemness and chemoresistance.","journal":"Leukemia","issue":"2026 April 29. doi: 10.1038\/s41375-026-02967-6. Online ahead of print","author":"Kamitori T, Saida S, Mitani K, Tsujimoto S, Goto H, Shibata H, Akazawa R, Isobe K, Ueno H, Kakiuchi N, Saito AM, Hiwatari M, Kudo K, Hirabayashi S, Fukuoka K, Koh K, Taga T, Kubota H, Kato I, Umeda K, Adachi S, Kawai T, Tomizawa D, Ikeda J, Shiba N, Hayashi Y, Ogawa S, Takita J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42056531"},{"title01":"Inherited HHV-6A reactivation linked to impaired immune reconstitution following hematopoietic stem cell transplantation.","title02":"Inherited HHV-6A reactivation linked to impaired immune reconstitution following hematopoietic stem cell transplantation.","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2026.300575. Online ahead of print","author":"Hannolainen L, Lang H, Pyoria L, Vepsalainen K, Vakkilainen S, Hedman K, Kekalainen E, Dickson Z, Ryhanen S, Perdomo MF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988785"},{"title01":"Long-term outcome of allogeneic hematopoietic cell transplantation for T-cell prolymphocytic leukemia &#8211; a study on behalf of the Chronic Malignancies Working Party of the EBMT.","title02":"Long-term outcome of allogeneic hematopoietic cell transplantation for T-cell prolymphocytic leukemia &#8211; a study on behalf of the Chronic Malignancies Working Party of the EBMT.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2025.288819. Online ahead of print","author":"Drozd-Sokolowska J, Gras L, Baaij LGA, Koster L, Nicholson E, Dreger P, Gedde-Dahl T, Mielke S, Salmenniemi U, Basak G, Chevallier P, Wulf GG, Schetelig J, Johansson JE, Nagler A, Quoc SN, Potter V, Sala E, Sandstedt AB, Koc Y, Zeiser R, Van Gelder M, Jedrzejczak WW, Raj K, McLornan DP, Tournilhac O","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021691"},{"title01":"SIRT3 deSUMOylation sustains hematopoietic stem cell activities under stressful conditions via the DHX58-IRF7 axis.","title02":"SIRT3 deSUMOylation sustains hematopoietic stem cell activities under stressful conditions via the DHX58-IRF7 axis.","journal":"Haematologica","issue":"2026 April 30. doi: 10.3324\/haematol.2025.300025. Online ahead of print","author":"He X, Yu J, Xu Y, Wang T, Lu Y, Wu J, Dan S, Xia Y, Mu X, Xie L, Chen C, Yu Z, Ye J, Gilson E, Zhang Y, Cheng J, Zheng J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42059296"},{"title01":"Day-30 IL1RL1, CXCL9 and REG3alpha are prognostic for survival after mismatched unrelated donor transplantation.","title02":"Day-30 IL1RL1, CXCL9 and REG3alpha are prognostic for survival after mismatched unrelated donor transplantation.","journal":"Br J Haematol","issue":"2026 April 28. doi: 10.1111\/bjh.70507. Online ahead of print","author":"Wang T, Ferreira AC, Hossain NM, Fu D, Hill EG, Jimenez Jimenez AM, Benjamin C, Komanduri KV, Paczesny S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42047487"},{"title01":"Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data.","title02":"Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data.","journal":"Br J Haematol","issue":"2026 April 23. doi: 10.1111\/bjh.70490. Online ahead of print","author":"Goel U, Dragomirescu C, Zanwar S, Cassano RC, Cicero KI, Cowan AJ, Banerjee R, Anwer F, Khouri J, Dima D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42023513"},{"title01":"Recombinant zoster vaccine induces superior immunogenicity compared with live varicella vaccine in allogeneic haematopoietic stem cell transplantation recipients.","title02":"Recombinant zoster vaccine induces superior immunogenicity compared with live varicella vaccine in allogeneic haematopoietic stem cell transplantation recipients.","journal":"Br J Haematol","issue":"2026 April 20. doi: 10.1111\/bjh.70500. Online ahead of print","author":"Ono T, Okada T, Ikeda R, Yamashita M, Koyauchi K, Takagi F, Adachi M, Takemura T, Mitsui K, Nagata Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42007689"},{"title01":"Prospective implementation of the HCT frailty scale in adults with lymphoproliferative syndromes candidates for autologous haematopoietic stem cell transplantation: Results from a multicentre GETH-TC study.","title02":"Prospective implementation of the HCT frailty scale in adults with lymphoproliferative syndromes candidates for autologous haematopoietic stem cell transplantation: Results from a multicentre GETH-TC study.","journal":"Br J Haematol","issue":"2026 April 29. doi: 10.1111\/bjh.70505. Online ahead of print","author":"Cornago J, Baile M, Acera M, Fox L, Del Mar Perez-Artigas M, Santamaria A, Del Carmen Quintela M, Sanchez-Salinas A, Salmeron JM, Illana V, Abdallahi-Lefdil Z, Pardo L, Solan L, Lopez-Lorenzo JL, Fernandez-Luis S, Vega LP, Villar S, Beorlegui-Murillo P, Molina M, Esquirol A, Izquierdo I, Ribes J, Mussetti A, Lavilla E, Alda O, Lopez-Marin J, Bento L, Filaferro S, Balsalobre P, Sureda A, Salas MQ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42056024"},{"title01":"Clinicogenetic characteristics and outcomes of children with NUP98-rearranged acute myeloid leukaemia: A single-centre cohort study of 32 cases.","title02":"Clinicogenetic characteristics and outcomes of children with NUP98-rearranged acute myeloid leukaemia: A single-centre cohort study of 32 cases.","journal":"Br J Haematol","issue":"2026 April 28. doi: 10.1111\/bjh.70497. Online ahead of print","author":"Zhang ZX, Zhang L, Lu AD, Zhang LP, Jia YP, Zeng HM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42047313"},{"title01":"Allogeneic hematopoietic cell transplantation for aplastic anemia: a single institution experience across 6 decades.","title02":"Allogeneic hematopoietic cell transplantation for aplastic anemia: a single institution experience across 6 decades.","journal":"Blood advances","issue":"2026 April 28; 10(8):2661-2675. doi: 10.1182\/bloodadvances.2025018548","author":"Olivieri D, Othus M, Vo P, Walter RB, Manjappa S, Basom R, Storb R, Keel S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637641"},{"title01":"Understanding the impact of social determinants of health in hematology: a scoping review of trends across journals and over time.","title02":"Understanding the impact of social determinants of health in hematology: a scoping review of trends across journals and over time.","journal":"Blood advances","issue":"2026 April 28; 10(8):2801-2816. doi: 10.1182\/bloodadvances.2025017559","author":"Lu B, Troyer J, Krause KJ, Lapite A, Aviles M, Della-Moretta S, Dobson D, Farrokhi K, Hasanali ZS, Pillai P, Taborda C, Villagomez L, Vo PT, Wang'ondu RW, Yui JC, Weyand AC, Fingrut WB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587417"},{"title01":"A compartmentalized inflammatory landscape and macrophage plasticity regulate Tet2+\/&#8211;mediated clonal hematopoiesis.","title02":"A compartmentalized inflammatory landscape and macrophage plasticity regulate Tet2+\/&#8211;mediated clonal hematopoiesis.","journal":"Blood","issue":"2026 April 16; 147(16):1828-1841. doi: 10.1182\/blood.2024028031","author":"Lee K, Hong CL, Dissanayake W, Kulzhanova G, Pfeffer AN, Li H, Sivakumar S, Yin Z, Quarato ER, Benoodt L, Bajaj J, Cao C, Wu CL, Calvi LM, Yeh SA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41525451"},{"title01":"Extended HLA Haplotypes and Transplant Survival.","title02":"Extended HLA Haplotypes and Transplant Survival.","journal":"Blood","issue":"2026 April 22. doi: 10.1182\/blood.2025033031. Online ahead of print","author":"Petersdorf EW, McKallor C, Malkki M, He M, Spellman SR, Gooley TA, Stevenson PA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42018610"},{"title01":"IFNgamma Drives Long-Term Bone Marrow Niche Dysfunction Following Doxorubicin-Based Chemotherapy.","title02":"IFNgamma Drives Long-Term Bone Marrow Niche Dysfunction Following Doxorubicin-Based Chemotherapy.","journal":"Blood","issue":"2026 April 20. doi: 10.1182\/blood.2025030946. Online ahead of print","author":"Li X, Aguilar-Navarro AG, Nader M, Jahangiri S, Lee HS, Edun G, Gower M, Yang D, Fernandez M, Lin B, Oh D, Farhat S, Phillips DM, Bartman S, Murray DI, Kaszuba CM, Kossinna P, Kamath M, Whyne C, Schwartz G, Bajaj J, Kislinger T, Zhou BO, Coutu DL, Akens MK, Changoor A, Mallevaey T, Gaiti F, Jones CL, Naik S, Minden MD, Arruda A, Hitzler JK, Lee KJ, Kim YM, Adams RH, Sivaraj KK, Tikhonova AN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42008378"},{"title01":"How I select hematopoietic cell donors in the era of posttransplant cyclophosphamide.","title02":"How I select hematopoietic cell donors in the era of posttransplant cyclophosphamide.","journal":"Blood","issue":"2026 April 23; 147(17):1903-1913. doi: 10.1182\/blood.2025030823","author":"Shaffer BC, Lee SJ, Perales MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41746780"},{"title01":"DC-SIGN binding to the surface immunoglobulin oligomannose-type glycans promotes follicular lymphoma cell adhesion and survival.","title02":"DC-SIGN binding to the surface immunoglobulin oligomannose-type glycans promotes follicular lymphoma cell adhesion and survival.","journal":"Blood","issue":"2026 April 30; 147(18):2089-2097. doi: 10.1182\/blood.2025030049","author":"Chiodin G, Tatterton DJ, Rock P, Del Rio L, Snook E, James S, Duriez PJ, Di Re M, Verdoes M, Lanham S, Hodson DJ, Burack R, Forconi F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41557914"},{"title01":"The singularity of IGHV4-34 links infection, autoimmunity, and B-cell tumors.","title02":"The singularity of IGHV4-34 links infection, autoimmunity, and B-cell tumors.","journal":"Blood","issue":"2026 April 16; 147(16):1793-1803. doi: 10.1182\/blood.2025032357","author":"Stevenson FK, Stamatopoulos K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41557911"},{"title01":"SIGN of the times: DC-SIGN and the follicular lymphoma niche.","title02":"SIGN of the times: DC-SIGN and the follicular lymphoma niche.","journal":"Blood","issue":"2026 April 30; 147(18):2025-2026. doi: 10.1182\/blood.2025032939","author":"Tobin JWD, Gandhi MK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42060334"},{"title01":"Gene expression-based dissemination score predicts early spread and poor outcomes in multiple myeloma.","title02":"Gene expression-based dissemination score predicts early spread and poor outcomes in multiple myeloma.","journal":"Leukemia","issue":"2026 April 22. doi: 10.1038\/s41375-026-02931-4. Online ahead of print","author":"Bohra A, Dasari S, Zanwar S, Gonsalves WI, Kapoor P, Binder M, Dispenzieri A, Timm MM, Buadi F, Jevremovic D, Rajkumar SV, Kumar S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42020784"},{"title01":"Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.","title02":"Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.","journal":"J Clin Oncol","issue":"2026 April 24; JCO2502351. doi: 10.1200\/JCO-25-02351. Online ahead of print","author":"Dierickx D, Heimovaara JH, Bellido M, Van Calsteren K, Cardonick E, Garcia AC, Baten A, Evens AM, Ferber A, Fumagalli M, Lampka E, Specht L, Vandecaveye V, Vogelius IR, Alber M, Amant F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42030539"},{"title01":"Inhibition of SUV39H1 as a potent therapeutic target in multiple myeloma.","title02":"Inhibition of SUV39H1 as a potent therapeutic target in multiple myeloma.","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2025.300333. Online ahead of print","author":"Alibert L, Ovejero S, Devin J, Thomas M, Kassambara A, Angles M, Requirand G, Robert N, Vincent L, Cartron G, Martinez AM, Herbaux C, Cavalli G, Moreaux J, Bret C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988779"},{"title01":"Prevalence and impact of frailty assessed using standard geriatrics tools in older adults with blood cancers.","title02":"Prevalence and impact of frailty assessed using standard geriatrics tools in older adults with blood cancers.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2025.300233. Online ahead of print","author":"DuMontier C, Cronin AM, Hshieh TT, Sanyal A, Mozessohn L, Abdallah MM, DeAngelo DJ, Munshi NC, Stone RM, Soiffer RJ, Driver JA, Abel GA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021681"},{"title01":"Bedaquiline amplifies proteasome inhibitor efficacy and overcomes resistance in multiple myeloma.","title02":"Bedaquiline amplifies proteasome inhibitor efficacy and overcomes resistance in multiple myeloma.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2025.300157. Online ahead of print","author":"Cumerlato M, Maccagno M, Labrador M, Luciano B, Mereu E, Porro M, Bandini C, Furlan M, Maisano D, D'Agostino M, Larocca A, Gay F, Tamburrini A, Anselmi F, Porporato PE, Oliviero S, Bruno B, Morelli E, Munshi N, Piva R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021688"},{"title01":"Effect of intravenous immunoglobulin on infections in multiple myeloma patients receiving daratumumab.","title02":"Effect of intravenous immunoglobulin on infections in multiple myeloma patients receiving daratumumab.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2025.289215. Online ahead of print","author":"Lancman G, Sastow D, Aslanova M, Moshier E, Cho HJ, Jagannath S, Parekh S, Richard S, Richter J, Rodriguez C, Rossi A, Sanchez L, Thibaud S, Chari A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021698"},{"title01":"Elranatamab therapy in relapsed refractory multiple myeloma patients with chronic kidney disease: A case series.","title02":"Elranatamab therapy in relapsed refractory multiple myeloma patients with chronic kidney disease: A case series.","journal":"Br J Haematol","issue":"2026 April 29. doi: 10.1111\/bjh.70510. Online ahead of print","author":"Marron G, Warrier N, Chan K, Augustson B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42051159"},{"title01":"A critical view of the BJH publication on the lack of benefit of second-line daratumumab in patients with functional high-risk multiple myeloma.","title02":"A critical view of the BJH publication on the lack of benefit of second-line daratumumab in patients with functional high-risk multiple myeloma.","journal":"Br J Haematol","issue":"2026 April 24. doi: 10.1111\/bjh.70516. Online ahead of print","author":"Schnog JB, Erjavec Z, Van Dijck R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42032249"},{"title01":"Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data.","title02":"Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data.","journal":"Br J Haematol","issue":"2026 April 23. doi: 10.1111\/bjh.70490. Online ahead of print","author":"Goel U, Dragomirescu C, Zanwar S, Cassano RC, Cicero KI, Cowan AJ, Banerjee R, Anwer F, Khouri J, Dima D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42023513"},{"title01":"Vestibular symptoms after talquetamab therapy in heavily pretreated multiple myeloma.","title02":"Vestibular symptoms after talquetamab therapy in heavily pretreated multiple myeloma.","journal":"Blood advances","issue":"2026 April 28; 10(8):2626-2628. doi: 10.1182\/bloodadvances.2025018974","author":"Di Palma-Grisi J, Biran N, Phull P, Vesole D, Siegel D, Parmar H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41701974"},{"title01":"IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM.","title02":"IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM.","journal":"Blood advances","issue":"2026 April 28; 10(8):2616-2625. doi: 10.1182\/bloodadvances.2025018537","author":"Maclachlan KH, Tan CR, Shekarkhand T, Rueda C, Derkach A, Hashmi H, Hassoun H, Shah UA, Hultcrantz M, Lesokhin AM, Mailankody S, Maura F, Merz M, Firestone R, Jurgens EM, Miller KC, Rajeeve S, Giralt S, Shah GL, Scordo M, Landau HJ, Zhang Y, Cimera R, Arcila ME, Korde N, Usmani SZ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41701976"},{"title01":"Improving Control Arms in 2026 U.S. Myeloma Trials.","title02":"Improving Control Arms in 2026 U.S. Myeloma Trials.","journal":"Blood advances","issue":"2026 April 17. doi: 10.1182\/bloodadvances.2026020329. Online ahead of print","author":"Ding K, Kunesh J, Neupane K, Mohyuddin GR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41995759"},{"title01":"A multi-center study of progression-risk and outcomes in solitary bone plasmacytoma with and without marrow involvement.","title02":"A multi-center study of progression-risk and outcomes in solitary bone plasmacytoma with and without marrow involvement.","journal":"Blood advances","issue":"2026 April 22. doi: 10.1182\/bloodadvances.2025019136. Online ahead of print","author":"Lim KJ, Steinhardt MJ, Rees MJ, Greipp PT, Kelemen K, Dispenzieri A, Jevremovic D, Baughn LB, Buadi FK, Dingli D, Hayman SR, Kapoor P, Muchtar E, Leung N, Fonder AL, Hobbs MA, Hwa YL, Warsame R, Kourelis TV, Cook J, Binder M, Abdallah N, Zanwar SS, Lin Y, Go RS, Siddiqui M, Parrondo RD, Ailawadhi S, Roy V, Cooke RE, Dun K, Zordan AC Mr, Ninkovic S, Best S, Alatorre G, Wiedmeier-Nutor JE, Kortum KM, Einsele H, Chhabra S, Bergsagel PL, Kyle RA, Gertz MA, Kumar SK, Rajkumar SV, Fonseca R, Gonsalves WI, Yadav U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42018661"},{"title01":"Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.","title02":"Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.","journal":"Blood","issue":"2026 April 16; 147(16):1857-1862. doi: 10.1182\/blood.2025031952","author":"Bal S, Ravi G, Dhakal B, Callander NS, Medvedova E, Dholaria BR, Giri S, Godby KN, Silbermann RW, Mikhail FM, Huls F, Reddy V, Costa LJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592281"},{"title01":"Immune biomarkers of increased infection risk in multiple myeloma.","title02":"Immune biomarkers of increased infection risk in multiple myeloma.","journal":"Blood","issue":"2026 April 30; 147(18):2081-2088. doi: 10.1182\/blood.2025031744","author":"Zabaleta A, Tamariz-Amador LE, Kostopoulos IV, Sklavenitis-Pistofidis R, Smits F, Rodriguez-Otero P, Roncal C, Aranha MP, Zihala D, Machu M, Tsakirakis N, Bakouros P, Tsitsilonis O, Solia I, Moreno C, Maia C, Martin-Sanchez E, Perez JJ, Encinas C, Rios-Tamayo R, Oriol A, Blanchard MJ, de Arriba F, Gonzalez ME, Lakhwani S, Sureda A, Cabanas V, Escalante F, Carrillo-Cruz E, Perez-Montana A, Ocio EM, Bargay J, Orfao A, Jelinek T, Ghobrial IM, Mutis T, Zweegman S, Terpos E, Kastritis E, Martinez-Lopez J, Lahuerta JJ, Fernandez de Larrea C, Rosinol L, Blade J, Mateos MV, San-Miguel J, Cedena MT, Puig N, Paiva B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610428"},{"title01":"Does minimal residual disease matter in t(11;14) myeloma?","title02":"Does minimal residual disease matter in t(11;14) myeloma?","journal":"Blood","issue":"2026 April 16; 147(16):1787-1788. doi: 10.1182\/blood.2025032941","author":"Touzeau C, Corre J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41989805"},{"title01":"Immune clues to infection risk in myeloma.","title02":"Immune clues to infection risk in myeloma.","journal":"Blood","issue":"2026 April 30; 147(18):2024-2025. doi: 10.1182\/blood.2026033248","author":"Ainley L, Yong K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42060327"},{"title01":"CD19 CAR T-Cell Therapy for Treatment of Chronic Graft-versus-Host Disease.","title02":"CD19 CAR T-Cell Therapy for Treatment of Chronic Graft-versus-Host Disease.","journal":"N Engl J Med","issue":"2026 April 30; 394(17):1759-1762. doi: 10.1056\/NEJMc2517629","author":"Sandhu KS, Cheng J, Mellors PW, Dainton-Smith H, Lao-Sirieix P, Brugger W, Clark MC, Budde E, Ritz J, Gill S, Forman SJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42054687"},{"title01":"A velocity-informed framework for resolving functional stratification in rare human stem cells.","title02":"A velocity-informed framework for resolving functional stratification in rare human stem cells.","journal":"Leukemia","issue":"2026 April 21. doi: 10.1038\/s41375-026-02956-9. Online ahead of print","author":"Jarczak J, Ratajczak MZ, Kucia M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42014860"},{"title01":"Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.","title02":"Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.","journal":"J Clin Oncol","issue":"2026 April 30; JCO2503104. doi: 10.1200\/JCO-25-03104. Online ahead of print","author":"Cutler C, Kim HT, El Banna H, Halloran E, Matozel E, Ho VT, Koreth J, Gooptu M, Shapiro R, Kelkar A, Gibson C, Nikiforow S, Nageshwar P, Reynolds C, Ansuinelli M, Tamada R, Au C, Panaro K, Gervais C, DeFilipp Z, El-Jawahri A, Chen YB, El Jurdi N, Weisdorf D, Couriel D, Lee C, Arai S, Sahaf B, Bacigalupi J, Ji K, Soiffer R, Miklos D, Antin JH, Ritz J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42060875"},{"title01":"Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.","title02":"Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.","journal":"J Clin Oncol","issue":"2026 April 27; JCO2503051. doi: 10.1200\/JCO-25-03051. Online ahead of print","author":"Stepan L, Ansari S, Abramson JS, Okal A, Dell'Aringa J, Thompson EG, Crotta A, Chow VA, Kamdar M, Solomon SR, Johnston PB, Glass B, Mutsaers P, Arnason J, Mielke S, Shadman M, Hernandez-Ilizaliturri F, Izutsu K, Bachanova V, Ibrahimi S, Chabon JJ, Kurtz DM, Alizadeh AA, Peiser L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42044466"},{"title01":"Safety and Clinical Outcomes of Pooled Donor, Nonengrafting Expanded Progenitor Cells in Single-Unit Cord Blood Transplantation.","title02":"Safety and Clinical Outcomes of Pooled Donor, Nonengrafting Expanded Progenitor Cells in Single-Unit Cord Blood Transplantation.","journal":"J Clin Oncol","issue":"2026 April 27; JCO2502510. doi: 10.1200\/JCO-25-02510. Online ahead of print","author":"Milano F, Dahlberg A, Pedersen J, Roberts L, Azure A, Martin L, Mazziotta F, Hadland B, Chapuis AG, Delaney C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42044462"},{"title01":"Favorable safety and efficacy profiles of alpha-1-antitrypsin in steroid- and ruxolitinib-refractory acute graft-versus-host disease of the gastrointestinal tract: a retrospective, single center study.","title02":"Favorable safety and efficacy profiles of alpha-1-antitrypsin in steroid- and ruxolitinib-refractory acute graft-versus-host disease of the gastrointestinal tract: a retrospective, single center study.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2026.300541. Online ahead of print","author":"Yehudai-Ofir D, Khatib H, Beyar-Katz O, Frisch A, Krayem B, Zuckerman T, Henig I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021699"},{"title01":"Inherited HHV-6A reactivation linked to impaired immune reconstitution following hematopoietic stem cell transplantation.","title02":"Inherited HHV-6A reactivation linked to impaired immune reconstitution following hematopoietic stem cell transplantation.","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2026.300575. Online ahead of print","author":"Hannolainen L, Lang H, Pyoria L, Vepsalainen K, Vakkilainen S, Hedman K, Kekalainen E, Dickson Z, Ryhanen S, Perdomo MF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988785"},{"title01":"Prospective implementation of the HCT frailty scale in adults with lymphoproliferative syndromes candidates for autologous haematopoietic stem cell transplantation: Results from a multicentre GETH-TC study.","title02":"Prospective implementation of the HCT frailty scale in adults with lymphoproliferative syndromes candidates for autologous haematopoietic stem cell transplantation: Results from a multicentre GETH-TC study.","journal":"Br J Haematol","issue":"2026 April 29. doi: 10.1111\/bjh.70505. Online ahead of print","author":"Cornago J, Baile M, Acera M, Fox L, Del Mar Perez-Artigas M, Santamaria A, Del Carmen Quintela M, Sanchez-Salinas A, Salmeron JM, Illana V, Abdallahi-Lefdil Z, Pardo L, Solan L, Lopez-Lorenzo JL, Fernandez-Luis S, Vega LP, Villar S, Beorlegui-Murillo P, Molina M, Esquirol A, Izquierdo I, Ribes J, Mussetti A, Lavilla E, Alda O, Lopez-Marin J, Bento L, Filaferro S, Balsalobre P, Sureda A, Salas MQ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42056024"},{"title01":"Day-30 IL1RL1, CXCL9 and REG3alpha are prognostic for survival after mismatched unrelated donor transplantation.","title02":"Day-30 IL1RL1, CXCL9 and REG3alpha are prognostic for survival after mismatched unrelated donor transplantation.","journal":"Br J Haematol","issue":"2026 April 28. doi: 10.1111\/bjh.70507. Online ahead of print","author":"Wang T, Ferreira AC, Hossain NM, Fu D, Hill EG, Jimenez Jimenez AM, Benjamin C, Komanduri KV, Paczesny S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42047487"},{"title01":"Clinicogenetic characteristics and outcomes of children with NUP98-rearranged acute myeloid leukaemia: A single-centre cohort study of 32 cases.","title02":"Clinicogenetic characteristics and outcomes of children with NUP98-rearranged acute myeloid leukaemia: A single-centre cohort study of 32 cases.","journal":"Br J Haematol","issue":"2026 April 28. doi: 10.1111\/bjh.70497. Online ahead of print","author":"Zhang ZX, Zhang L, Lu AD, Zhang LP, Jia YP, Zeng HM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42047313"},{"title01":"Impact of CD34(+) cell dose on outcomes of related allogeneic PBSCT in adult AML patients.","title02":"Impact of CD34(+) cell dose on outcomes of related allogeneic PBSCT in adult AML patients.","journal":"Br J Haematol","issue":"2026 April 28. doi: 10.1111\/bjh.70506. Online ahead of print","author":"Toda Y, Jo T, Arai Y, Harada K, Yanada M, Fukuda T, Yoshihara S, Doki N, Uchida N, Mori Y, Hasegawa Y, Kondo Y, Kawakita T, Eto T, Nishida T, Tanaka M, Onizuka M, Shono K, Hino M, Ichinohe T, Atsuta Y, Konuma T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42046860"},{"title01":"Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphoma.","title02":"Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphoma.","journal":"Blood advances","issue":"2026 April 28; 10(8):2767-2780. doi: 10.1182\/bloodadvances.2025018774","author":"Knorr F, Zimmermann M, Bader P, Lang P, Muller I, Basu O, Burkhardt B, Seidl J, Damm-Welk C, Pichler H, Attarbaschi A, Meissner B, Beier R, Woessmann W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632689"},{"title01":"Tildrakizumab for the prophylaxis of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.","title02":"Tildrakizumab for the prophylaxis of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.","journal":"Blood advances","issue":"2026 April 28; 10(8):2698-2710. doi: 10.1182\/bloodadvances.2025019065","author":"Runaas L, Fank S, Palen K, Szabo A, Rein LE, Ying G, Salzman N, Samanas L, Abedin S, Chhabra S, Hamadani M, Longo W, Shah NN, Haber J, Gradissimo A, Waters N, Peled JU, Johnson B, Kearl T, Drobyski WR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632629"},{"title01":"The role of HLA transcription in unrelated hematopoietic cell transplantation.","title02":"The role of HLA transcription in unrelated hematopoietic cell transplantation.","journal":"Blood advances","issue":"2026 April 28; 10(8):2687-2697. doi: 10.1182\/bloodadvances.2025017945","author":"Morishima S, Shiina T, Azuma F, Tomori S, Doki N, Nishida T, Fukuda T, Eto T, Kataoka K, Hasegawa Y, Tanaka M, Ota S, Takada S, Katayama Y, Uchida N, Nakamae H, Kanda Y, Hiramoto N, Kanda J, Onizuka M, Ichinohe T, Atsuta Y, Morishima Y, Murata M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628351"},{"title01":"B-lymphoblastic leukemia with synchronous KMT2A::TXNRD1 and IGH::CEBPD rearrangements.","title02":"B-lymphoblastic leukemia with synchronous KMT2A::TXNRD1 and IGH::CEBPD rearrangements.","journal":"Blood","issue":"2026 April 23; 147(17):2018. doi: 10.1182\/blood.2025032543","author":"Li Y, Shao H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42024392"},{"title01":"Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.","title02":"Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.","journal":"J Clin Oncol","issue":"2026 April 27; JCO2503051. doi: 10.1200\/JCO-25-03051. Online ahead of print","author":"Stepan L, Ansari S, Abramson JS, Okal A, Dell'Aringa J, Thompson EG, Crotta A, Chow VA, Kamdar M, Solomon SR, Johnston PB, Glass B, Mutsaers P, Arnason J, Mielke S, Shadman M, Hernandez-Ilizaliturri F, Izutsu K, Bachanova V, Ibrahimi S, Chabon JJ, Kurtz DM, Alizadeh AA, Peiser L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42044466"},{"title01":"Circulating tumor DNA at baseline as a prognostic marker in untreated follicular lymphoma.","title02":"Circulating tumor DNA at baseline as a prognostic marker in untreated follicular lymphoma.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2025.289111. Online ahead of print","author":"Lutterbeck C, Kaufman D, Bolen CR, Shin M, Akbari V, Mirebrahim H, Davies A, Knapp A, Nielsen T, Weigert O, Penuel E, Bogard PE, Bottos A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021704"},{"title01":"Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experience.","title02":"Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experience.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2025.300289. Online ahead of print","author":"Basile G, Neuville A, Martineau D, Delapierre B, Dubois S, Noel R, Durot E, Caillet A, Laboure G, Laribi K, Gros FX, Bernard S, Mineur A, Borel C, Chartier L, Damaj G, Bouabdallah K, Galtier J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021687"},{"title01":"Immune evasion in primary central nervous system lymphoma: macrophage and T cell roles in response to immunotherapy.","title02":"Immune evasion in primary central nervous system lymphoma: macrophage and T cell roles in response to immunotherapy.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2025.300015. Online ahead of print","author":"Pages-Geli C, Medina-Gil D, Fernandez-Guzman P, Hernandez C, Carabia J, Pujadas G, Weiskopf K, Bosch F, Crespo M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021682"},{"title01":"Prevalence and impact of frailty assessed using standard geriatrics tools in older adults with blood cancers.","title02":"Prevalence and impact of frailty assessed using standard geriatrics tools in older adults with blood cancers.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2025.300233. Online ahead of print","author":"DuMontier C, Cronin AM, Hshieh TT, Sanyal A, Mozessohn L, Abdallah MM, DeAngelo DJ, Munshi NC, Stone RM, Soiffer RJ, Driver JA, Abel GA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021681"},{"title01":"Myeloid neoplasms after follicular helper T-cell lymphomas: a real, but limited risk.","title02":"Myeloid neoplasms after follicular helper T-cell lymphomas: a real, but limited risk.","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2025.300464. Online ahead of print","author":"Messeant O, Lemonnier F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988765"},{"title01":"Gene expression profile of adult T-cell leukemia\/lymphoma with human T-cell lymphotropic virus type 1-infected Hodgkin and Reed-Sternberg-like cells is more similar to classic Hodgkin lymphoma than typical adult T-cell leukemia\/lymphoma.","title02":"Gene expression profile of adult T-cell leukemia\/lymphoma with human T-cell lymphotropic virus type 1-infected Hodgkin and Reed-Sternberg-like cells is more similar to classic Hodgkin lymphoma than typical adult T-cell leukemia\/lymphoma.","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2025.289270. Online ahead of print","author":"Miyagi S, Mori K, Miyawaki K, Shimo M, Tamaki T, Sakihama S, Takatori M, Akashi K, Karube K, Kato K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988767"},{"title01":"Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed\/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110\/ReBeL study.","title02":"Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed\/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110\/ReBeL study.","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2025.300152. Online ahead of print","author":"Kersten MJ, Dreyling M, Linton KM, Chitu D, Zwezerijnen GJC, Tonino SH, Kap M, Liu R, Van Hooije C, Chamuleau MED, Visser HPJ, De Jongh E, Marijt EAF, Leys MBL, Bilgin YM, Durig J, McKay P, Snijders T, Pettitt A, Minnema MC, Prange-Krex G, Cuijpers MLH, Bohmer LH, Tick LW, Florschutz A, Silbermann M, Fijnheer R, Beeker A, Tolboom N, Mitea C, Arens AIJ, Wiegers SE, Heymans MW, Klapper W, Coupland SE, De Jong D, Doorduijn JK, Zijlstra JM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988778"},{"title01":"Lymphocyte dynamics after CAR-T therapy for non-Hodgkin lymphoma.","title02":"Lymphocyte dynamics after CAR-T therapy for non-Hodgkin lymphoma.","journal":"Br J Haematol","issue":"2026 April 21. doi: 10.1111\/bjh.70502. Online ahead of print","author":"Dingli S, Rothweiler P, Corraes AMS, Atallah-Yunes A, Ansell SM, Bennani NN, Durani U, Johnston PB, Khurana A, Paludo J, Bisneto JCV, Wang Y, Lin Y, Erdman AG, Dingli D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42011548"},{"title01":"Real-world comparison of peripheral neuropathy and treatment delivery between Pola-R-CHP and R-CHOP in DLBCL.","title02":"Real-world comparison of peripheral neuropathy and treatment delivery between Pola-R-CHP and R-CHOP in DLBCL.","journal":"Br J Haematol","issue":"2026 April 29. doi: 10.1111\/bjh.70524. Online ahead of print","author":"Nakamura N, Ohata K, Aizaki T, Kaneda Y, Ikoma Y, Matsumoto T, Nakamura H, Matsuoka SB, Sadaka SH, Suzuki A, Kanemura N, Shimizu M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42052919"},{"title01":"Glofitamab in refractory Burkitt lymphoma-type post-transplant lymphoproliferative disorder.","title02":"Glofitamab in refractory Burkitt lymphoma-type post-transplant lymphoproliferative disorder.","journal":"Br J Haematol","issue":"2026 April 28. doi: 10.1111\/bjh.70519. Online ahead of print","author":"Lam HPJ, Arulogun S, Mikhaeel NG, Brady JL, Stanley K, Yuen L, Lennie C, Chowdhury P, Warbey V, Gleeson M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42049201"},{"title01":"Long-read KIR genotyping reveals donor KIR\/HLA polymorphisms linked to posttransplant relapse in T-cell malignancies.","title02":"Long-read KIR genotyping reveals donor KIR\/HLA polymorphisms linked to posttransplant relapse in T-cell malignancies.","journal":"Blood advances","issue":"2026 April 17. doi: 10.1182\/bloodadvances.2025019066. Online ahead of print","author":"Morita-Fujita M, Kawaguchi S, Shindo T, Izumi K, Shimizu M, Inadomi Y, Kanda J, Watanabe M, Takahashi M, Tsujimura T, Tarumoto S, Yamamoto T, Kato K, Tanaka H, Morishima S, Morishima Y, Nakano N, Hayashi M, Miyazaki Y, Imada K, Higuchi Y, Yonezawa A, Suehiro Y, Yoshimitsu M, Doki N, Katayama Y, Hasegawa Y, Serizawa K, Ichinohe T, Fukuda T, Onizuka M, Atsuta Y, Takaori-Kondo A, Matsuda F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41995743"},{"title01":"Aging cells, young patients: senescence in Hodgkin lymphoma.","title02":"Aging cells, young patients: senescence in Hodgkin lymphoma.","journal":"Blood advances","issue":"2026 April 28; 10(8):2765-2766. doi: 10.1182\/bloodadvances.2025019439","author":"Kong IY, Giulino-Roth L, Steidl C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41996198"},{"title01":"TCRVbeta-targeting antibody-drug conjugates as a novel strategy to eliminate malignant T cells in T cell cancers.","title02":"TCRVbeta-targeting antibody-drug conjugates as a novel strategy to eliminate malignant T cells in T cell cancers.","journal":"Blood advances","issue":"2026 April 29. doi: 10.1182\/bloodadvances.2026020282. Online ahead of print","author":"Vadivel CK, Norregaard KS, Perlado AM, Sorrosal LP, Zeng Z, Yan L, Namini MRJ, Gluud M, Buus TB, Engelholm LH, Behrendt N, Odum N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42054548"},{"title01":"Drivers of Temporal Improvement in CAR T-Cell Therapy for Large B-Cell Lymphoma: A Japanese Nationwide Registry Analysis.","title02":"Drivers of Temporal Improvement in CAR T-Cell Therapy for Large B-Cell Lymphoma: A Japanese Nationwide Registry Analysis.","journal":"Blood advances","issue":"2026 April 22. doi: 10.1182\/bloodadvances.2025019510. Online ahead of print","author":"Yagi Y, Kanemasa Y, Terao T, Kato M, Jo T, Shimoyama T, Kitawaki T, Hanajiri R, Doki N, Yoshihara S, Fujii N, Iwaki N, Yamamoto G, Sakurai M, Matsukawa T, Sakaida E, Nakashima Y, Umezawa Y, Kim H, Kataoka K, Goto H, Atsuta Y, Kato K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42018609"},{"title01":"Exploring the role of blinatumomab in pediatric B-lymphoblastic lymphoma (B-LLy).","title02":"Exploring the role of blinatumomab in pediatric B-lymphoblastic lymphoma (B-LLy).","journal":"Blood advances","issue":"2026 April 28; 10(8):2579-2581. doi: 10.1182\/bloodadvances.2025019473","author":"Devine KJ, Fries C, Wistinghausen B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643198"},{"title01":"Incidence, timing, and prognosis of heart failure after treatment for large B-cell lymphoma in Sweden during 2007-2022.","title02":"Incidence, timing, and prognosis of heart failure after treatment for large B-cell lymphoma in Sweden during 2007-2022.","journal":"Blood advances","issue":"2026 April 28; 10(8):2754-2764. doi: 10.1182\/bloodadvances.2025018515","author":"Godtfredsen SJ, Bergstrom F, Harrysson S, Kragholm K, El-Galaly TC, Smedby KE, Eloranta S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637561"},{"title01":"Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphoma.","title02":"Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphoma.","journal":"Blood advances","issue":"2026 April 28; 10(8):2767-2780. doi: 10.1182\/bloodadvances.2025018774","author":"Knorr F, Zimmermann M, Bader P, Lang P, Muller I, Basu O, Burkhardt B, Seidl J, Damm-Welk C, Pichler H, Attarbaschi A, Meissner B, Beier R, Woessmann W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632689"},{"title01":"An indirect comparison of zanubrutinib vs acalabrutinib plus venetoclax in patients with treatment-naive CLL.","title02":"An indirect comparison of zanubrutinib vs acalabrutinib plus venetoclax in patients with treatment-naive CLL.","journal":"Blood advances","issue":"2026 April 28; 10(8):2599-2607. doi: 10.1182\/bloodadvances.2025018536","author":"Shadman M, Tam CS, Brander DM, Lefebure M, Yang K, Xu S, Tian T, Kuptsova-Clarkson N, Williams R, Hirata J, Munir T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587482"},{"title01":"Disordered differentiation and cellular senescence in pediatric Hodgkin Reed-Sternberg cells.","title02":"Disordered differentiation and cellular senescence in pediatric Hodgkin Reed-Sternberg cells.","journal":"Blood advances","issue":"2026 April 28; 10(8):2711-2726. doi: 10.1182\/bloodadvances.2025016953","author":"Agrusa JE, Abdel Fattah E, Lin H, Velazquez J, Salinas SA, Abhyankar HA, Scull BP, Fleischmann R, Elghetany MT, Marcogliese AN, Curry CV, Punia JN, Ozuah NW, Eckstein OS, El-Mallawany NK, Gulati N, Lubega J, Horton TM, Kamdar KY, McClain KL, Man TK, Allen CE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538304"},{"title01":"Expression of cFLIP in B cells is essential for diffuse large B-cell lymphoma pathogenesis.","title02":"Expression of cFLIP in B cells is essential for diffuse large B-cell lymphoma pathogenesis.","journal":"Blood","issue":"2026 April 23. doi: 10.1182\/blood.2026033320. Online ahead of print","author":"Bariboloka KT, Serrano-Saenz S, Savcigil DP, Spoeck S, Poss RE, Schreurs LD, Lober J, Serin N, Valiulis J, Nugraha K, Gangarossa G, Lutz A, Reese M, Klein S, Enssle JC, Buttner R, Kashkar H, Peifer M, Chapuy B, Knittel G, Labi V, Villunger A, Nguyen PH, Scheich S, Oellerich T, Walczak H, Flumann R, Jachimowicz RD, Hallek MJ, Reinhardt HC, Annibaldi A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42024475"},{"title01":"Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.","title02":"Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.","journal":"Blood","issue":"2026 April 16; 147(16):1842-1856. doi: 10.1182\/blood.2025031409","author":"Carturan A, Angelos MG, Guruprasad P, Patel RP, Pajarillo R, Lee A, Espie D, Zhang Y, Chiang YH, Xie W, Rodriguez JL, Harris J, Devi P, Afolayan-Oloye OI, Xu J, Sussman JH, Elghawy O, Yang A, Barsouk A, Cho JH, Shaw CE, Singh E, Ugwuanyi O, Paruzzo L, Stella F, Liu S, Nason S, Imparato A, Rotolo A, Lemoine J, Barrett DM, Posey A, Rook AH, Pillai V, Bagg A, Pileri SA, Liu D, Tan K, Schuster SJ, Teachey DT, Porazzi P, Ruella M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490267"},{"title01":"Unfinished Business in Chronic Lymphocytic Leukemia: Translational and Clinical Priorities for a Cure.","title02":"Unfinished Business in Chronic Lymphocytic Leukemia: Translational and Clinical Priorities for a Cure.","journal":"Blood","issue":"2026 April 22. doi: 10.1182\/blood.2025032393. Online ahead of print","author":"Wu CJ, Caligaris-Cappio F, Chiorazzi N, Gribben JG, Hallek MJ, Wierda WG, Kipps TJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42018659"},{"title01":"Mosunetuzumab plus polatuzumab vedotin in relapsed\/refractory MCL after BTK inhibitor therapy: a phase 2 study.","title02":"Mosunetuzumab plus polatuzumab vedotin in relapsed\/refractory MCL after BTK inhibitor therapy: a phase 2 study.","journal":"Blood","issue":"2026 April 21. doi: 10.1182\/blood.2025032422. Online ahead of print","author":"Budde LE, Kamdar M, Assouline SE, Chavez JC, Ghosh N, Ollila TA, Hodson DJ, Modi D, Bastos-Oreiro M, Naik SG, Nakhoda SK, Batlevi CL MD, PhD, Wang J, Makadia S, Kwan A, Penuel E, Jing J, Wu H, Ead W, Pham S, To I, Wei MC, Wang M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42013019"},{"title01":"Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma.","title02":"Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma.","journal":"Blood","issue":"2026 April 16; 147(16):1814-1827. doi: 10.1182\/blood.2025031455","author":"Alderuccio JP, Baggio D, Han S, Ghione P, Nizamuddin I, Khwaja J, Saha A, Dong N, Wang Y, Cherng HJ, Tolu S, Wagner-Johnston N, Ollila TA, Grover N, Koff JL, Desai A, Ramakrishnan Geethakumari P, Moyo TK, Sandoval-Sus J, Epperla N, Wallace DS, Kamdar M, Tavarozzi R, Danilov A, Tun H, Munoz J, Narkhede M, Rhodes JM, Prica A, Kuhnl A, Maraj A, Okosun J, Smith J, Osborne W, Calvert V, El-Sharkawi D, Hilali A, Collins GP, Linton K, Elmusharaf N, Santarsieri A, Karim F, Baidoun F, Monick SE, Trutzer IM, Can J, Ayers A, Calabrese De Feo J, Sharp J, Ghosh N, Treitman R, Kallam A, Okcu I, Abeyakoon C, Hann W, Barrett A, Deshani V, Kahl BS, Chavez JC, Olszewski AJ, Cwynarski K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490516"},{"title01":"Single-day nonactivated IL-18-armed CAR T cells establish a durable, stemlike state with enhanced persistence.","title02":"Single-day nonactivated IL-18-armed CAR T cells establish a durable, stemlike state with enhanced persistence.","journal":"Blood","issue":"2026 April 16. doi: 10.1182\/blood.2026033460. Online ahead of print","author":"Durgin JS, Seo SH, Kazmi S, Valentic B, Leff C, Markovska M, Jin X, Shen F, Berjis A, Mukherjee N, Sannecy A, Plesa G, Gabunia K, Scholler J, Gill SI, O'Connor RS, June CH, Ghassemi S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41990270"},{"title01":"Mapping risk and therapy in secondary CNS lymphoma.","title02":"Mapping risk and therapy in secondary CNS lymphoma.","journal":"Blood","issue":"2026 April 16; 147(16):1783-1784. doi: 10.1182\/blood.2025032674","author":"Schorb E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41989802"},{"title01":"A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma.","title02":"A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma.","journal":"Blood","issue":"2026 April 30; 147(18):2041-2052. doi: 10.1182\/blood.2025029546","author":"Diefenbach CS, Jegede O, Wang V, Ansell SM, Kostakoglu L, Steidl C, Natkunam Y, Scott DW, Ambinder RF, David KA, Advani RH, Bartlett NL, Robertson MJ, Thomas SP, Cohen J, Ibrahimi S, Goyal G, Mehta-Shah N, Amengual JE, Forlenza CJ, Cole PD, Duan F, Kelly K, Kahl BS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41662628"},{"title01":"CCR4 expression defines a targetable subset of T-cell acute lymphoblastic leukemia.","title02":"CCR4 expression defines a targetable subset of T-cell acute lymphoblastic leukemia.","journal":"Blood advances","issue":"2026 April 28; 10(8):2676-2686. doi: 10.1182\/bloodadvances.2025018600","author":"Xu J, McCoy M, Martinez Z, Sussman JH, Gao D, Vincent T, Wang H, Ma C, Elghawy O, Chen GM, Yang AG, Polonen P, Natan K, Shraim R, Newman H, Hofmann TJ, Scoma S, DiNofia AM, Hunger SP, Yang JJ, Mullighan CG, Bernt KM, Hexner EO, Grupp SA, Watanabe K, June CH, Tan K, Teachey DT, Diorio C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671457"},{"title01":"Hypertension and CLL: a common and hazardous relationship.","title02":"Hypertension and CLL: a common and hazardous relationship.","journal":"Blood advances","issue":"2026 April 28; 10(8):2833-2835. doi: 10.1182\/bloodadvances.2026019633","author":"Mulligan SP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42008321"},{"title01":"GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study.","title02":"GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study.","journal":"Blood advances","issue":"2026 April 28; 10(8):2648-2660. doi: 10.1182\/bloodadvances.2025018626","author":"Yamasaki S, Yanada M, Mizuno S, Shimomura Y, Tobai T, Harada K, Uchida N, Tanaka M, Wake A, Onizuka M, Eto T, Uehara Y, Takahashi S, Izumi T, Doki N, Tokunaga M, Kawakita T, Nishida T, Sakata-Yanagimoto M, Ishimaru F, Kanda J, Atsuta Y, Konuma T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538306"},{"title01":"CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.","title02":"CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.","journal":"Blood advances","issue":"2026 April 28; 10(8):2854-2864. doi: 10.1182\/bloodadvances.2025019378","author":"Shimony S, Murdock HM, Keating J, Tsai HK, Sasi A, Gibson CJ, Faderl S, Wagner A, Dronamraju N, Lin TL, Prebet T, Cortes JE, Uy GL, Lancet JE, Reilly CR, Neuberg D, Stone RM, Lindsley RC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628350"},{"title01":"IFNgamma Drives Long-Term Bone Marrow Niche Dysfunction Following Doxorubicin-Based Chemotherapy.","title02":"IFNgamma Drives Long-Term Bone Marrow Niche Dysfunction Following Doxorubicin-Based Chemotherapy.","journal":"Blood","issue":"2026 April 20. doi: 10.1182\/blood.2025030946. Online ahead of print","author":"Li X, Aguilar-Navarro AG, Nader M, Jahangiri S, Lee HS, Edun G, Gower M, Yang D, Fernandez M, Lin B, Oh D, Farhat S, Phillips DM, Bartman S, Murray DI, Kaszuba CM, Kossinna P, Kamath M, Whyne C, Schwartz G, Bajaj J, Kislinger T, Zhou BO, Coutu DL, Akens MK, Changoor A, Mallevaey T, Gaiti F, Jones CL, Naik S, Minden MD, Arruda A, Hitzler JK, Lee KJ, Kim YM, Adams RH, Sivaraj KK, Tikhonova AN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42008378"},{"title01":"The singularity of IGHV4-34 links infection, autoimmunity, and B-cell tumors.","title02":"The singularity of IGHV4-34 links infection, autoimmunity, and B-cell tumors.","journal":"Blood","issue":"2026 April 16; 147(16):1793-1803. doi: 10.1182\/blood.2025032357","author":"Stevenson FK, Stamatopoulos K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41557911"},{"title01":"Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability.","title02":"Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability.","journal":"Blood","issue":"2026 April 23; 147(17):1941-1957. doi: 10.1182\/blood.2025029972","author":"Sekrecki M, Sekrecka A, Lattupally RR, Le K, Jin X, Mozes C, Dwyer BG, Zhuang Z, Romero BA, Pineda JMB, Cao X, Nguyen L, Chen V, Zhou CM, Wallace JA, Tanaka K, Tiwari C, Gabel A, Kim WJ, Stanley RF, Benbarche S, Thind J, Muruganandham A, Zhang TY, Greenberg PL, Gotlib JR, Mannis G, Shomali WE, Salmasi G, Kuo C, Shanafelt T, Singh I, Inoue D, Hansen FK, Gray NS, van Rechem C, Fakhri B, Zhang X, Lu SX","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587094"},{"title01":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","title02":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","journal":"Blood","issue":"2026 April 23; 147(17):1914-1927. doi: 10.1182\/blood.2025031053","author":"Mushtaq MU, DiPersio JF, Azzi J, Cooper BW, Koehne G, Koura D, Maakaron J, Magenau J, McClune B, Rimando JC, Shah NN, Suh HC, Beuka K, Sturrock J, Nikam M, Berglund E, Hu J, Keschner Y, Etchin J, Lydeard JR, Vasquez M, O'Donnell D, Mundelboim G, Thosar S, Canesin G, Xavier-Ferrucio J, Hyzy SL, Lloyd DM, Spink K, Hummel D, Lee-Sundlov MM, Scherer J, Lin MI, Whangbo JS, Muffly LS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41636724"},{"title01":"Donor T cells on double duty: VCAR33 for AML after transplant.","title02":"Donor T cells on double duty: VCAR33 for AML after transplant.","journal":"Blood","issue":"2026 April 23; 147(17):1889-1891. doi: 10.1182\/blood.2026033164","author":"Geyer MB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42024396"},{"title01":"NPM1-mutated acute myeloid leukemia with a hybrid granulocytic and monocytic phenotype.","title02":"NPM1-mutated acute myeloid leukemia with a hybrid granulocytic and monocytic phenotype.","journal":"Blood","issue":"2026 April 23; 147(17):2019. doi: 10.1182\/blood.2025032818","author":"Wang W, Fang H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42024393"},{"title01":"Single-day nonactivated IL-18-armed CAR T cells establish a durable, stemlike state with enhanced persistence.","title02":"Single-day nonactivated IL-18-armed CAR T cells establish a durable, stemlike state with enhanced persistence.","journal":"Blood","issue":"2026 April 16. doi: 10.1182\/blood.2026033460. Online ahead of print","author":"Durgin JS, Seo SH, Kazmi S, Valentic B, Leff C, Markovska M, Jin X, Shen F, Berjis A, Mukherjee N, Sannecy A, Plesa G, Gabunia K, Scholler J, Gill SI, O'Connor RS, June CH, Ghassemi S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41990270"},{"title01":"Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL.","title02":"Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL.","journal":"Blood","issue":"2026 April 23; 147(17):2011-2017. doi: 10.1182\/blood.2025031734","author":"Srinagesh HK, Gupta V, Zhang A, Grunwald M, Connor M, Kota VK, Boccucci J, Ulrickson M, Pradeep R, Hill L, Tsai SB, O'Connor T, Sandhu K, Advani AS, Reshef R, Gordillo CA, Luskin MR, Chen EC, Lin C, Cassaday RD, Kopmar NE, Majhail NS, Battiwalla M, Strickland SA, Lee CJ, Bobillo SO, Hilal T, Park JH, Valtis YK, Faramand R, Solh MM, Guzowski C, Vasu S, Leonard JT, Tan V, Wang ES, McCauley R, Sasine J, Tang K, Miller K, Sutherland KC, Daunov M, Mohty R, Jamy O, Kumaran MV, Hoeg RT, Dykes KC, Logan AC, Othman T, Stock W, Schwartz M, Byrd K, Yalniz F, Bachanova V, Tracy S, Yaghmour G, Irizarry Gatell VM, Jackson CW, Oluwole OO, Dholaria B, O'Dwyer KM, Moore J, Roloff GW, Frey NV, Aldoss I, Shah BD, Oliai CH, Muffly LS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643192"},{"title01":"Unfinished Business in Chronic Lymphocytic Leukemia: Translational and Clinical Priorities for a Cure.","title02":"Unfinished Business in Chronic Lymphocytic Leukemia: Translational and Clinical Priorities for a Cure.","journal":"Blood","issue":"2026 April 22. doi: 10.1182\/blood.2025032393. Online ahead of print","author":"Wu CJ, Caligaris-Cappio F, Chiorazzi N, Gribben JG, Hallek MJ, Wierda WG, Kipps TJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42018659"},{"title01":"The transposable element-PARP axis underpins synthetic lethality and immunogenic vulnerability in blood cancer.","title02":"The transposable element-PARP axis underpins synthetic lethality and immunogenic vulnerability in blood cancer.","journal":"Blood","issue":"2026 April 30; 147(18):2035-2040. doi: 10.1182\/blood.2025032216","author":"Zeisig BB, Karimi MM, So CWE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41812189"},{"title01":"A compartmentalized inflammatory landscape and macrophage plasticity regulate Tet2+\/&#8211;mediated clonal hematopoiesis.","title02":"A compartmentalized inflammatory landscape and macrophage plasticity regulate Tet2+\/&#8211;mediated clonal hematopoiesis.","journal":"Blood","issue":"2026 April 16; 147(16):1828-1841. doi: 10.1182\/blood.2024028031","author":"Lee K, Hong CL, Dissanayake W, Kulzhanova G, Pfeffer AN, Li H, Sivakumar S, Yin Z, Quarato ER, Benoodt L, Bajaj J, Cao C, Wu CL, Calvi LM, Yeh SA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41525451"},{"title01":"Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.","title02":"Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.","journal":"Blood","issue":"2026 April 16; 147(16):1842-1856. doi: 10.1182\/blood.2025031409","author":"Carturan A, Angelos MG, Guruprasad P, Patel RP, Pajarillo R, Lee A, Espie D, Zhang Y, Chiang YH, Xie W, Rodriguez JL, Harris J, Devi P, Afolayan-Oloye OI, Xu J, Sussman JH, Elghawy O, Yang A, Barsouk A, Cho JH, Shaw CE, Singh E, Ugwuanyi O, Paruzzo L, Stella F, Liu S, Nason S, Imparato A, Rotolo A, Lemoine J, Barrett DM, Posey A, Rook AH, Pillai V, Bagg A, Pileri SA, Liu D, Tan K, Schuster SJ, Teachey DT, Porazzi P, Ruella M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490267"},{"title01":"A targeted circulating tumor DNA landscape of copy number aberrations in large B-cell lymphomas.","title02":"A targeted circulating tumor DNA landscape of copy number aberrations in large B-cell lymphomas.","journal":"Leukemia","issue":"2026 April 22. doi: 10.1038\/s41375-026-02955-w. Online ahead of print","author":"Arffman M, Meriranta L, Jorgensen J, Karjalainen-Lindsberg ML, Beiske K, Pedersen M, Drott K, Fluge O, Jyrkkio S, Brown P, Holte H, Leppa S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42020781"},{"title01":"Hemophagocytic lymphohistiocytosis in HIV-related lymphomas: a multicentre retrospective cohort study.","title02":"Hemophagocytic lymphohistiocytosis in HIV-related lymphomas: a multicentre retrospective cohort study.","journal":"Leukemia","issue":"2026 April 23. doi: 10.1038\/s41375-026-02929-y. Online ahead of print","author":"Migaud P, Dalla Pria A, Drauz D, Dayalan N, Fulgenzi CA, Hosmann K, Leone AG, Muller M, Stocker H, Temple A, Hentrich M, Bower M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42026178"},{"title01":"PRMT5 inhibition sensitizes B-cell lymphoma cells to ferroptosis.","title02":"PRMT5 inhibition sensitizes B-cell lymphoma cells to ferroptosis.","journal":"Leukemia","issue":"2026 April 17. doi: 10.1038\/s41375-026-02932-3. Online ahead of print","author":"Liu Y, Chen R, Gao X, Zhu F, Ni Q, Bates PD, Wu S, Zai Z, Obernberger VA, Weerawardhene K, Tourdot TK, Petta S, Conyers MJ, Capitini CM, Rui L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41998301"},{"title01":"Lenalidomide Plus Rituximab for Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.","title02":"Lenalidomide Plus Rituximab for Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.","journal":"J Clin Oncol","issue":"2026 April 16; JCO2501770. doi: 10.1200\/JCO-25-01770. Online ahead of print","author":"Leonard JP, Trneny M, Zhang H, Nowakowski GS, Izutsu K, Fowler N, Thieblemont C, Zinzani PL, Gkasiamis A, Ahn JR, Gribben JG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41990300"},{"title01":"Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell Lymphoma.","title02":"Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell Lymphoma.","journal":"J Clin Oncol","issue":"2026 April 29; JCO2501928. doi: 10.1200\/JCO-25-01928. Online ahead of print","author":"Uppal M, Bhinder B, Marderstein AR, Lee Batlevi C, Falchi L, Hamlin P, Horwitz S, Kumar A, Noy A, Zelenetz AD, Lue JK, Torka P, Epstein-Peterson ZD, Arcila M, Dogan A, Imber B, Yahalom J, Vardhana SA, Intlekofer A, Raj S, Shouval R, Hodkinson B, Stokes ME, Kittai AS, Brody JD, Elemento O, Salles G, Joffe E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42054619"},{"title01":"Duvelisib Induces Deep Responses in PTCL: Final Results of the Phase 2 PRIMO Trial of Duvelisib in Relapsed\/Refractory Peripheral T-Cell Lymphoma.","title02":"Duvelisib Induces Deep Responses in PTCL: Final Results of the Phase 2 PRIMO Trial of Duvelisib in Relapsed\/Refractory Peripheral T-Cell Lymphoma.","journal":"J Clin Oncol","issue":"2026 April 22; 101200JCO2503120. doi: 10.1200\/JCO-25-03120. Online ahead of print","author":"Mehta-Shah N, Zinzani PL, Jacobsen ED, Zain J, Mead M, Casulo C, Gritti G, Pinter-Brown L, Izutsu K, Sidransky D, Bentur OS, Pro B, Fox CP, Brammer JE, Horwitz SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42018969"},{"title01":"Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.","title02":"Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.","journal":"J Clin Oncol","issue":"2026 April 24; JCO2502351. doi: 10.1200\/JCO-25-02351. Online ahead of print","author":"Dierickx D, Heimovaara JH, Bellido M, Van Calsteren K, Cardonick E, Garcia AC, Baten A, Evens AM, Ferber A, Fumagalli M, Lampka E, Specht L, Vandecaveye V, Vogelius IR, Alber M, Amant F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42030539"},{"title01":"Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.","title02":"Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.","journal":"J Clin Oncol","issue":"2026 April 24; JCO2502351. doi: 10.1200\/JCO-25-02351. Online ahead of print","author":"Dierickx D, Heimovaara JH, Bellido M, Van Calsteren K, Cardonick E, Garcia AC, Baten A, Evens AM, Ferber A, Fumagalli M, Lampka E, Specht L, Vandecaveye V, Vogelius IR, Alber M, Amant F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42030539"},{"title01":"Reply to: How to Interpret the Results in a Noninferiority Randomized Trial in Chronic Lymphocytic Leukemia.","title02":"Reply to: How to Interpret the Results in a Noninferiority Randomized Trial in Chronic Lymphocytic Leukemia.","journal":"J Clin Oncol","issue":"2026 April 20; JCO2600304. doi: 10.1200\/JCO-26-00304. Online ahead of print","author":"Wierda WG, Leow CC, Ruppert AS, Bian Y, Woyach JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42008785"},{"title01":"RBM15 and ZMYND8 shape acute myeloid leukemia response to BCL2 inhibitors.","title02":"RBM15 and ZMYND8 shape acute myeloid leukemia response to BCL2 inhibitors.","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2025.288972. Online ahead of print","author":"Cruz-Rodriguez N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988758"},{"title01":"RNA modification, leukemia stem cell, selective vulnerability.","title02":"RNA modification, leukemia stem cell, selective vulnerability.","journal":"Haematologica","issue":"2026 April 30. doi: 10.3324\/haematol.2026.301076. Online ahead of print","author":"Zhou F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42059285"},{"title01":"Myeloid blast phase of chronic myeloid leukemia with co-occurring t(11;12)(p15;q13)\/NUP98::HOXC12: a novel NUP98 fusion partner.","title02":"Myeloid blast phase of chronic myeloid leukemia with co-occurring t(11;12)(p15;q13)\/NUP98::HOXC12: a novel NUP98 fusion partner.","journal":"Haematologica","issue":"2026 April 30. doi: 10.3324\/haematol.2025.300433. Online ahead of print","author":"Khan A, Xu J, Thakral B, Toruner GA, Medeiros LJ, Qiu L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42059282"},{"title01":"Novel KAT6B::NUTM2B fusion oncogene in congenital acute myeloid leukemia and implications for menin inhibitor therapy.","title02":"Novel KAT6B::NUTM2B fusion oncogene in congenital acute myeloid leukemia and implications for menin inhibitor therapy.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2025.300350. Online ahead of print","author":"Voss RK, Qi W, Browne L, Wang'ondu RW, Khanlari M, Ma J, Ma X, Lott J, Barajas JM, Thomas Iii M, Loyola VBP, Cao H, Furtado LV, Naik S, Bami S, Karol SE, Rubnitz JE, Klco JM, Liu YC, Wang L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021697"},{"title01":"Durable deep molecular response via CD19 chimeric antigen receptor T-cell therapy combined with a third-generation tyrosine kinase inhibitor in acute leukemia of ambiguous lineage with the Philadelphia chromosome: a potential strategy for transplant-ineligible patients.","title02":"Durable deep molecular response via CD19 chimeric antigen receptor T-cell therapy combined with a third-generation tyrosine kinase inhibitor in acute leukemia of ambiguous lineage with the Philadelphia chromosome: a potential strategy for transplant-ineligible patients.","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2026.300521. Online ahead of print","author":"Zhang A, Gong B, Liu Y, Zhang G, Zhou C, Li S, Guo C, Yang H, Li Y, Wang L, Zhang B, Wei H, Wang J, Qiu S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988760"},{"title01":"Timing of microbial exposure and risk of infectionpromoted acute lymphoblastic leukemia.","title02":"Timing of microbial exposure and risk of infectionpromoted acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2025.289280. Online ahead of print","author":"Cazzaniga V, Shamsaei E, Procter J, John-Baptiste P, Ford AM, Greaves M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988764"},{"title01":"Efficacy of the kinase inhibitor CHZ868 against JAK2 rearrangements in pediatric acute lymphoblastic leukemia.","title02":"Efficacy of the kinase inhibitor CHZ868 against JAK2 rearrangements in pediatric acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2025.287840. Online ahead of print","author":"Quadri M, Saitta C, Palamini S, Rebellato S, Watrin T, Tu JW, Bhatia S, Borkhardt A, Palmi C, Biondi A, Cazzaniga G, Fazio G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988773"},{"title01":"Impact of CD34(+) cell dose on outcomes of related allogeneic PBSCT in adult AML patients.","title02":"Impact of CD34(+) cell dose on outcomes of related allogeneic PBSCT in adult AML patients.","journal":"Br J Haematol","issue":"2026 April 28. doi: 10.1111\/bjh.70506. Online ahead of print","author":"Toda Y, Jo T, Arai Y, Harada K, Yanada M, Fukuda T, Yoshihara S, Doki N, Uchida N, Mori Y, Hasegawa Y, Kondo Y, Kawakita T, Eto T, Nishida T, Tanaka M, Onizuka M, Shono K, Hino M, Ichinohe T, Atsuta Y, Konuma T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42046860"},{"title01":"Clinicogenetic characteristics and outcomes of children with NUP98-rearranged acute myeloid leukaemia: A single-centre cohort study of 32 cases.","title02":"Clinicogenetic characteristics and outcomes of children with NUP98-rearranged acute myeloid leukaemia: A single-centre cohort study of 32 cases.","journal":"Br J Haematol","issue":"2026 April 28. doi: 10.1111\/bjh.70497. Online ahead of print","author":"Zhang ZX, Zhang L, Lu AD, Zhang LP, Jia YP, Zeng HM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42047313"},{"title01":"Deacetylase inhibitors CM-444 and CM-1758 enhance chemotherapy response in AML via ALOX5.","title02":"Deacetylase inhibitors CM-444 and CM-1758 enhance chemotherapy response in AML via ALOX5.","journal":"Br J Haematol","issue":"2026 April 29. doi: 10.1111\/bjh.70520. Online ahead of print","author":"Gimenez-Camino N, San Jose-Eneriz E, Garate L, Miranda E, Saez E, Pineda-Lucena A, Prosper F, Agirre X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42052754"},{"title01":"A rare chain of events: Post-follicular therapy-related t(8;21) acute myeloid leukaemia with KIT D816Y mutation revealing systemic mastocytosis.","title02":"A rare chain of events: Post-follicular therapy-related t(8;21) acute myeloid leukaemia with KIT D816Y mutation revealing systemic mastocytosis.","journal":"Br J Haematol","issue":"2026 April 16. doi: 10.1111\/bjh.70442. Online ahead of print","author":"Assadi-Gazvini C, Amiot Q, Menier L, Bugier S, Li C, Konopacki J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41992504"},{"title01":"Improved survival with fludarabine-based therapies in mixed phenotype acute leukaemia: A population-based study using the WHO 2022 classification.","title02":"Improved survival with fludarabine-based therapies in mixed phenotype acute leukaemia: A population-based study using the WHO 2022 classification.","journal":"Br J Haematol","issue":"2026 April 17. doi: 10.1111\/bjh.70491. Online ahead of print","author":"Christensen LM, Simonsen MR, Jensen JF, Kristensen DT, Dybkaer K, Gronbaek K, El-Galaly TC, Ettrup MS, Ommen HB, Sorensen ALT, Hansen DL, Severinsen MT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41992976"},{"title01":"Flow cytometry-guided ex vivo drug sensitivity testing informs venetoclax-based therapy in acute undifferentiated leukaemia.","title02":"Flow cytometry-guided ex vivo drug sensitivity testing informs venetoclax-based therapy in acute undifferentiated leukaemia.","journal":"Br J Haematol","issue":"2026 April 17. doi: 10.1111\/bjh.70499. Online ahead of print","author":"Xu L, Wang J, Zhao W, Wang Y, Hu Y, Li Y, Lai W, Yong J, Gao C, Liu D, Gao X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41995597"},{"title01":"Hypertension affects survival and treatment in chronic lymphocytic leukemia.","title02":"Hypertension affects survival and treatment in chronic lymphocytic leukemia.","journal":"Blood advances","issue":"2026 April 28; 10(8):2729-2742. doi: 10.1182\/bloodadvances.2025018771","author":"Vainer N, Brieghel C, Rostgaard K, Daviethsson OB, Dietz JB, Frederiksen CM, da Cunha-Bang C, Hjalgrim H, Niemann CU, Rotbain EC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41604617"},{"title01":"Long-read KIR genotyping reveals donor KIR\/HLA polymorphisms linked to posttransplant relapse in T-cell malignancies.","title02":"Long-read KIR genotyping reveals donor KIR\/HLA polymorphisms linked to posttransplant relapse in T-cell malignancies.","journal":"Blood advances","issue":"2026 April 17. doi: 10.1182\/bloodadvances.2025019066. Online ahead of print","author":"Morita-Fujita M, Kawaguchi S, Shindo T, Izumi K, Shimizu M, Inadomi Y, Kanda J, Watanabe M, Takahashi M, Tsujimura T, Tarumoto S, Yamamoto T, Kato K, Tanaka H, Morishima S, Morishima Y, Nakano N, Hayashi M, Miyazaki Y, Imada K, Higuchi Y, Yonezawa A, Suehiro Y, Yoshimitsu M, Doki N, Katayama Y, Hasegawa Y, Serizawa K, Ichinohe T, Fukuda T, Onizuka M, Atsuta Y, Takaori-Kondo A, Matsuda F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41995743"},{"title01":"Acalabrutinib monotherapy as a first-line treatment for CLL: 3 years follow-up of the real-world EPIC study.","title02":"Acalabrutinib monotherapy as a first-line treatment for CLL: 3 years follow-up of the real-world EPIC study.","journal":"Blood advances","issue":"2026 April 29. doi: 10.1182\/bloodadvances.2026019978. Online ahead of print","author":"Eyre TA, Martinez-Calle N, Paneesha S, Norouzi M, Tucker DL, Walter HS, Boden A, Kilner M, Phillips N, Patten PE, Shah N, Ruparelia M, Oddy S, Tsawayo T, Forconi F, Wardle H, Gbemre T, Gregory C, Cook LBM, Allsup DJ, Morris A, Knechtli CJC, Davies J, Galani J, Marr H, Hutchinson C, Williams S, Hickey J, Harding H, Hunjan S, Blak BT, Walewska R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42054544"},{"title01":"An indirect comparison of zanubrutinib vs acalabrutinib plus venetoclax in patients with treatment-naive CLL.","title02":"An indirect comparison of zanubrutinib vs acalabrutinib plus venetoclax in patients with treatment-naive CLL.","journal":"Blood advances","issue":"2026 April 28; 10(8):2599-2607. doi: 10.1182\/bloodadvances.2025018536","author":"Shadman M, Tam CS, Brander DM, Lefebure M, Yang K, Xu S, Tian T, Kuptsova-Clarkson N, Williams R, Hirata J, Munir T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587482"},{"title01":"ENO1 promotes acute myeloid leukemia progression through SCD1-mediated lipid metabolism reprogramming.","title02":"ENO1 promotes acute myeloid leukemia progression through SCD1-mediated lipid metabolism reprogramming.","journal":"Blood advances","issue":"2026 April 28. doi: 10.1182\/bloodadvances.2025017973. Online ahead of print","author":"Wu Y, Gao L, Fang F, Li Z, Hu Y, Zhang Y, Yang C, Wei Z, Liu X, Yang Y, Zhang F, Zhang W, Sun K, Li Y, Yang C, Pan J, Hu S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42048629"},{"title01":"Common variants, rare disease: new insights into AML risk.","title02":"Common variants, rare disease: new insights into AML risk.","journal":"Blood","issue":"2026 April 23; 147(17):1894-1896. doi: 10.1182\/blood.2025032945","author":"Wen S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42024400"},{"title01":"Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia.","title02":"Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia.","journal":"Blood","issue":"2026 April 23; 147(17):1958-1969. doi: 10.1182\/blood.2025031266","author":"Ranasinghe D, Lin WY, Fordham SE, Alharbi A, Sunter NJ, Elstob C, Nahari MH, Xu Y, Park C, Hungate E, Quante A, Strauch K, Gieger C, Skol A, Rahman T, Sucheston-Campbell L, Hahn T, Clay-Gilmour AI, Jones GL, Marr HJ, Jackson GH, Menne T, Collin M, Ivey A, Hills RK, Burnett AK, Russell NH, Fitzgibbon J, Larson RA, Le Beau MM, Stock W, Heidenreich O, Enshaei A, Gunasinghe D, Hawking ZL, Heslop H, Nandana D, Di B, Plokhuta A, Brown IT, Allsup DJ, Houlston RS, Collins A, Milne P, Norden J, Dickinson AM, Lendrem C, Daly AK, Palm L, Piechocki K, Jeffries S, Bornhauser M, Rollig C, Altmann H, Ruhnke L, Kunadt D, Wagenfuhr L, Cordell HJ, Darlay R, Andersen MK, Fontana MC, Martinelli G, Marconi G, Sanz MA, Cervera J, Gomez-Segui I, Cluzeau T, Moreilhon C, Raynaud S, Sill H, Voso MT, Dombret H, Cheok M, Preudhomme C, Gale RE, Linch D, Weisinger J, Masszi A, Nowak D, Hofmann WK, Gilkes A, Porkka K, Milosevic Feenstra JD, Kralovics R, Wang J, Meggendorfer M, Haferlach T, Krizsan S, Bodor C, Parkin B, Malek SN, Stolzel F, Onel K, Allan JM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610418"},{"title01":"Multi-omics analysis of pediatric minimally differentiated acute myeloid leukemia reveals RUNX1-driven stemness and chemoresistance.","title02":"Multi-omics analysis of pediatric minimally differentiated acute myeloid leukemia reveals RUNX1-driven stemness and chemoresistance.","journal":"Leukemia","issue":"2026 April 29. doi: 10.1038\/s41375-026-02967-6. Online ahead of print","author":"Kamitori T, Saida S, Mitani K, Tsujimoto S, Goto H, Shibata H, Akazawa R, Isobe K, Ueno H, Kakiuchi N, Saito AM, Hiwatari M, Kudo K, Hirabayashi S, Fukuoka K, Koh K, Taga T, Kubota H, Kato I, Umeda K, Adachi S, Kawai T, Tomizawa D, Ikeda J, Shiba N, Hayashi Y, Ogawa S, Takita J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42056531"},{"title01":"Reduced-intensity reinduction for children and young persons with relapsed acute lymphoblastic leukemia.","title02":"Reduced-intensity reinduction for children and young persons with relapsed acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 April 30. doi: 10.1038\/s41375-026-02923-4. Online ahead of print","author":"Hodder A, Mishra A, Enshaei A, Baird S, Bhuller K, Castleton A, Clesham K, Connor P, Elbeshlawi I, Gattens M, George L, Heaney N, Ingham D, Jigoulina G, Lindsay K, Madni M, Malone A, Mitchell B, Motwani J, Nicholson E, Patrick K, Ramanathan S, Taylor G, Tewari S, Thakur I, Samrin L, McLelland V, Osborne C, Hogan LE, Cooper S, Ji L, Bhojwani D, Brown PA, Hunger SP, Loh ML, Bonney D, Cummins M, van Delft F, Ghorashian S, Halsey C, Hough R, Moorman A, Moppett J, Samarasinghe S, Vora A, O'Connor D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42056530"},{"title01":"Chronic myelomonocytic leukemia beyond the marrow: biology, patterns, and management of extramedullary disease.","title02":"Chronic myelomonocytic leukemia beyond the marrow: biology, patterns, and management of extramedullary disease.","journal":"Leukemia","issue":"2026 April 27. doi: 10.1038\/s41375-026-02966-7. Online ahead of print","author":"Ahmidouch M, Deshpande P, Salib C, Brunner P, Heller P, Abdel Azim D, Ball S, Tremblay D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42045559"},{"title01":"Blinatumomab in pediatric acute lymphoblastic leukemia: current and future use.","title02":"Blinatumomab in pediatric acute lymphoblastic leukemia: current and future use.","journal":"Leukemia","issue":"2026 April 27. doi: 10.1038\/s41375-026-02962-x. Online ahead of print","author":"Lertvivatpong N, Inaba H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42045557"},{"title01":"Prevalence and characterization of germline RAS pathway variants in children with chronic myeloid leukemia.","title02":"Prevalence and characterization of germline RAS pathway variants in children with chronic myeloid leukemia.","journal":"Leukemia","issue":"2026 April 24. doi: 10.1038\/s41375-026-02952-z. Online ahead of print","author":"Ghete T, Gaschler L, Krumbholz M, Sembill S, Behrens YL, Karow A, Wolfl M, Auer F, Hauer J, Carta MG, Ferrazzi F, Hutter S, Horn AHC, Sticht H, Schlegel PG, Metzler M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42032322"},{"title01":"ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors.","title02":"ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors.","journal":"Leukemia","issue":"2026 April 23. doi: 10.1038\/s41375-026-02965-8. Online ahead of print","author":"Hochhaus A, le Coutre P, Milojkovic D, Kim DDH, Lim SM, Pavlovsky C, Nguyen T, Nicolini FE, Moiraghi B, Grosicki S, Phu CD, Etienne G, Marco de Lucas F, Ayala Diaz RM, Breccia M, Chuah C, Abi Rached R, Pokhriyal H, Ic A, Schuld P, Pilipovic V, Alisch F, Boquimpani CM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42026180"},{"title01":"The spectrum of immunoglobulin heavy chain enhancer hijacking in chronic lymphocytic leukemia.","title02":"The spectrum of immunoglobulin heavy chain enhancer hijacking in chronic lymphocytic leukemia.","journal":"Leukemia","issue":"2026 April 23. doi: 10.1038\/s41375-026-02902-9. Online ahead of print","author":"Drewes C, Lopez C, Okeke N, Jebaraj B, Wiegreffe C, Kraus I, Hillebrecht S, Awada A, Bens S, Chteinberg E, Eichhorst B, Datismann S, Dyer MJS, Fischer A, Fischer K, Glaser S, Hallek M, Kretzmer H, Mottok A, Pfaff D, Schnitzler K, Meier-Kolthoff JP, Schlesner M, Schneider C, Britsch S, Ammerpohl O, Stilgenbauer S, Tausch E, Siebert R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42026179"},{"title01":"A transgenic zebrafish leukemia model driven by KMT2A::MLLT3 (MLL-AF9).","title02":"A transgenic zebrafish leukemia model driven by KMT2A::MLLT3 (MLL-AF9).","journal":"Leukemia","issue":"2026 April 22. doi: 10.1038\/s41375-026-02953-y. Online ahead of print","author":"Saberi M, Delfi O, Hall CJ, Madola DWKK, Browett PJ, Kakadia PM, Bohlander SK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42020782"},{"title01":"Not guilty by association: myelodysplasia-related mutations in AML.","title02":"Not guilty by association: myelodysplasia-related mutations in AML.","journal":"Leukemia","issue":"2026 April 22. doi: 10.1038\/s41375-026-02936-z. Online ahead of print","author":"Venugopal S, Sekeres MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42020780"},{"title01":"Genomic fusion breakpoints for DNA-based measurable residual disease monitoring in pediatric acute lymphoblastic leukemia.","title02":"Genomic fusion breakpoints for DNA-based measurable residual disease monitoring in pediatric acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 April 21. doi: 10.1038\/s41375-026-02958-7. Online ahead of print","author":"Houtman AH, Arfeuille C, Strullu M, Baruchel A, Cave H, Caye-Eude A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42014859"},{"title01":"Interstitial loss of heterozygosity at Chr19q13 in CD33-negative AML.","title02":"Interstitial loss of heterozygosity at Chr19q13 in CD33-negative AML.","journal":"Leukemia","issue":"2026 April 21. doi: 10.1038\/s41375-026-02963-w. Online ahead of print","author":"Shastri VM, Dai R, Zhang Y, Loken MR, Lamba JK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42014857"},{"title01":"Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies.","title02":"Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies.","journal":"Leukemia","issue":"2026 April 30. doi: 10.1038\/s41375-026-02970-x. Online ahead of print","author":"Wang Y, Li C, Gale RP, Liang Q, Kay NE, Huang Q, Song Y, Wang W, Liang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42062556"},{"title01":"How to Interpret the Results in a Noninferiority Randomized Trial in Chronic Lymphocytic Leukemia.","title02":"How to Interpret the Results in a Noninferiority Randomized Trial in Chronic Lymphocytic Leukemia.","journal":"J Clin Oncol","issue":"2026 April 20; JCO2503114. doi: 10.1200\/JCO-25-03114. Online ahead of print","author":"Levy V, Chevret S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42008784"},{"title01":"Safety and Clinical Outcomes of Pooled Donor, Nonengrafting Expanded Progenitor Cells in Single-Unit Cord Blood Transplantation.","title02":"Safety and Clinical Outcomes of Pooled Donor, Nonengrafting Expanded Progenitor Cells in Single-Unit Cord Blood Transplantation.","journal":"J Clin Oncol","issue":"2026 April 27; JCO2502510. doi: 10.1200\/JCO-25-02510. Online ahead of print","author":"Milano F, Dahlberg A, Pedersen J, Roberts L, Azure A, Martin L, Mazziotta F, Hadland B, Chapuis AG, Delaney C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42044462"},{"title01":"Allograft inflammatory factor -1 is essential for acute monocytic leukemia infiltration.","title02":"Allograft inflammatory factor -1 is essential for acute monocytic leukemia infiltration.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2025.300027. Online ahead of print","author":"Chen AL, Hu HY, Alamoudi D, Zhang JY, Yao SJ, Zhao BH, Song HY, Zhu HH, Wang QF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021693"},{"title01":"An unusual case of basophilic meningitis revealing a chronicphase chronic myeloid leukemia: a report after almost three years of follow-up.","title02":"An unusual case of basophilic meningitis revealing a chronicphase chronic myeloid leukemia: a report after almost three years of follow-up.","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2025.300120. Online ahead of print","author":"Rahme R, Dragani M, Fleury C, Tueur G, Bamba PM, Torres-Villaros H, Giocanti-Auregan A, Bangbotche R, Lazarian G, Baran-Marszak F, Gardin C, Braun T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988759"},{"title01":"Phase Ib\/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results.","title02":"Phase Ib\/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2026.300627. Online ahead of print","author":"Hochman MJ, Ruppert AS, Huang Y, Mims A, Borate U, Swords R, Traer E, Baer MR, Duong VH, Stock W, Odenike T, Patel P, Madanat Y, Stein E, Deininger MW, Schiller G, Pollyea DA, Foran JM, Olin R, Lin T, Boyiadzis MM, Handa S, Rueter B, Gana TJ, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus S, Rosenberg L, Druker B, Levine R, Burd A, Yocum AO, Byrd JC, Blum W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021690"},{"title01":"SQSTM1::RARA fusion in acute promyelocytic leukemia: the first case report and literature review.","title02":"SQSTM1::RARA fusion in acute promyelocytic leukemia: the first case report and literature review.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2025.300329. Online ahead of print","author":"Yin X, Li N, Cheng Z, Ai J, Liang H, Sun S, Zhu HH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021686"},{"title01":"Prevalence and impact of frailty assessed using standard geriatrics tools in older adults with blood cancers.","title02":"Prevalence and impact of frailty assessed using standard geriatrics tools in older adults with blood cancers.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2025.300233. Online ahead of print","author":"DuMontier C, Cronin AM, Hshieh TT, Sanyal A, Mozessohn L, Abdallah MM, DeAngelo DJ, Munshi NC, Stone RM, Soiffer RJ, Driver JA, Abel GA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021681"},{"title01":"Long-term outcome of allogeneic hematopoietic cell transplantation for T-cell prolymphocytic leukemia &#8211; a study on behalf of the Chronic Malignancies Working Party of the EBMT.","title02":"Long-term outcome of allogeneic hematopoietic cell transplantation for T-cell prolymphocytic leukemia &#8211; a study on behalf of the Chronic Malignancies Working Party of the EBMT.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2025.288819. Online ahead of print","author":"Drozd-Sokolowska J, Gras L, Baaij LGA, Koster L, Nicholson E, Dreger P, Gedde-Dahl T, Mielke S, Salmenniemi U, Basak G, Chevallier P, Wulf GG, Schetelig J, Johansson JE, Nagler A, Quoc SN, Potter V, Sala E, Sandstedt AB, Koc Y, Zeiser R, Van Gelder M, Jedrzejczak WW, Raj K, McLornan DP, Tournilhac O","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021691"},{"title01":"Gene expression profile of adult T-cell leukemia\/lymphoma with human T-cell lymphotropic virus type 1-infected Hodgkin and Reed-Sternberg-like cells is more similar to classic Hodgkin lymphoma than typical adult T-cell leukemia\/lymphoma.","title02":"Gene expression profile of adult T-cell leukemia\/lymphoma with human T-cell lymphotropic virus type 1-infected Hodgkin and Reed-Sternberg-like cells is more similar to classic Hodgkin lymphoma than typical adult T-cell leukemia\/lymphoma.","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2025.289270. Online ahead of print","author":"Miyagi S, Mori K, Miyawaki K, Shimo M, Tamaki T, Sakihama S, Takatori M, Akashi K, Karube K, Kato K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988767"},{"title01":"Origins of iAMP21 in children who later developed paediatric acute lymphoblastic leukemia: an investigation of neonatal blood spots.","title02":"Origins of iAMP21 in children who later developed paediatric acute lymphoblastic leukemia: an investigation of neonatal blood spots.","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2026.300813. Online ahead of print","author":"Leijonhufvud G, Ljungstrom V, Amini RM, Saft I, Ford AM, Gustafsson B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988772"},{"title01":"HDAC8 inhibition targets STAT3-MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute myeloid leukemia.","title02":"HDAC8 inhibition targets STAT3-MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute myeloid leukemia.","journal":"Leukemia","issue":"2026 April 21. doi: 10.1038\/s41375-026-02950-1. Online ahead of print","author":"Zhang L, Guo W, Fu YH, Wu D, Li M, Chen YC, Tseng CY, Hua WK, Nguyen LXT, He X, Dong H, Zhang L, Zhang B, Li L, Marcucci G, Kuo YH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42014858"},{"title01":"Intracellular IL-23R is necessary for mitotic spindle formation and viability in AML.","title02":"Intracellular IL-23R is necessary for mitotic spindle formation and viability in AML.","journal":"Leukemia","issue":"2026 May; 40(5):906-917. doi: 10.1038\/s41375-026-02949-8","author":"Duong N, Khan DH, Thomas GE, Feng Y, Hurren R, Lee JB, St-Germain J, Drimmer L, Yan Y, Zhang LX, Fang KK, Ling D, Ma ML, MacLean N, Gronda M, Rondeau V, Brown BD, Matellan L, Jones CL, Chang H, Arruda A, Xie S, Pelletier L, Minden MD, Zhang L, Kornblau SM, Raught B, Jacobs K, Jacobs MG, Goede D, Spadavecchio V, Schimmer AD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41998300"},{"title01":"How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?","title02":"How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?","journal":"Leukemia","issue":"2026 April 30. doi: 10.1038\/s41375-026-02939-w. Online ahead of print","author":"Montoro MJ, Acha P, Haferlach C, Chan O, Navarro V, Kubota Y, Schulz F, Briski R, Al Ali NH, Xicoy B, Palomo L, Lopez-Cadenas F, Bosch F, Meggendorfer M, Gonzalez T, Eder LN, Jerez A, Wang Y, Campagna A, Betz B, Santini V, Bernal T, Such E, Platzbecker AS, Kewan T, Gurnari C, Zindel C, Kulasekararaj A, Voso MT, Sekeres M, Diaz-Varela N, Al-Kali A, Polini A, Diral E, Memoli M, Platzbecker U, Haase D, Zeidan AM, Diez-Campelo M, Garcia-Manero G, Wiseman DH, Della Porta MG, Germing U, Maciejewski J, Komrokji RS, Sole F, Haferlach T, Fenaux P, Valcarcel D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42062555"},{"title01":"Response to Comment on: &#8220;Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with hematological malignancies&#8221;.","title02":"Response to Comment on: &#8220;Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with hematological malignancies&#8221;.","journal":"Haematologica","issue":"2026 April 1; 111(4):1507-1508. doi: 10.3324\/haematol.2025.289053","author":"Rees MJ, Quach H, Jardine D, Thompson A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931863"},{"title01":"HBV infection in the era of T-cell engagers in multiple myeloma: unresolved challenges and unmet needs. Comment on: &#8220;Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with hematological malignancies&#8221;.","title02":"HBV infection in the era of T-cell engagers in multiple myeloma: unresolved challenges and unmet needs. Comment on: &#8220;Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with hematological malignancies&#8221;.","journal":"Haematologica","issue":"2026 April 1; 111(4):1505-1506. doi: 10.3324\/haematol.2025.288942","author":"Rago A, Ridola L, Di Toritto TC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905098"},{"title01":"Erratum to: &#8220;Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial&#8221;.","title02":"Erratum to: &#8220;Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial&#8221;.","journal":"Haematologica","issue":"2026 April 1; 111(4):1509-1510. doi: 10.3324\/haematol.2025.289379","author":"Schlenk RF, Montesinos P, Kim HJ, Romero-Aguilar A, Vrhovac R, Patkowska E, Zak P, Wang PN, Hanyok J, Liu L, Kamel YM, Imadalou K, Lesegretain A, Cortes J, Sekeres MA, Dombret H, Amadori S, Wang J, Perl AE, Levis MJ, Erba HP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41919560"},{"title01":"Response to Comment on: &#8220;Prognostic implications of myelodysplasia-related gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis&#8221;.","title02":"Response to Comment on: &#8220;Prognostic implications of myelodysplasia-related gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis&#8221;.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2026.300922. Online ahead of print","author":"Chang YS, Hou HA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924903"},{"title01":"Response to Comment on: &#8220;Prognostic implications of myelodysplasia-related gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis&#8221;.","title02":"Response to Comment on: &#8220;Prognostic implications of myelodysplasia-related gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis&#8221;.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2026.300922. Online ahead of print","author":"Chang YS, Hou HA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924903"},{"title01":"The &#8220;Sweet&#8221; crosstalk between refractory leukemia cells and vascular niche.","title02":"The &#8220;Sweet&#8221; crosstalk between refractory leukemia cells and vascular niche.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2026.300820. Online ahead of print","author":"Cheng H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924906"},{"title01":"Implications of the EHA\/ELN guidelines for reporting blast percentage. Comment on: &#8220;Reporting blast percentage for response assessment in acute leukemias: recommendations from an EHA\/ELN expert panel&#8221;.","title02":"Implications of the EHA\/ELN guidelines for reporting blast percentage. Comment on: &#8220;Reporting blast percentage for response assessment in acute leukemias: recommendations from an EHA\/ELN expert panel&#8221;.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2026.300842. Online ahead of print","author":"Przepiorka D, Jen EY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924912"},{"title01":"Erratum to: &#8220;Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial&#8221;.","title02":"Erratum to: &#8220;Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial&#8221;.","journal":"Haematologica","issue":"2026 April 1; 111(4):1509-1510. doi: 10.3324\/haematol.2025.289379","author":"Schlenk RF, Montesinos P, Kim HJ, Romero-Aguilar A, Vrhovac R, Patkowska E, Zak P, Wang PN, Hanyok J, Liu L, Kamel YM, Imadalou K, Lesegretain A, Cortes J, Sekeres MA, Dombret H, Amadori S, Wang J, Perl AE, Levis MJ, Erba HP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41919560"},{"title01":"Equal outcomes after human leukocyte antigen-matched unrelated versus sibling donor transplants-Results of the AML SCT-BFM 2007 trial and consecutive &#8216;real-world routine&#8217;.","title02":"Equal outcomes after human leukocyte antigen-matched unrelated versus sibling donor transplants-Results of the AML SCT-BFM 2007 trial and consecutive &#8216;real-world routine&#8217;.","journal":"Br J Haematol","issue":"2026 April; 208(4):1472-1476. doi: 10.1111\/bjh.70324","author":"Sauer MG, Lang PJ, Albert MH, Bader P, Eyrich M, Gruhn B, Klingebiel T, Mauz-Korholz C, Meisel R, Muller I, Niemeyer CM, Peters C, Burkhardt B, Reinhardt D, Sedlacek P, Strahm B, Woessmann W, Handgretinger R, Zimmermann M, Borkhardt A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41502109"},{"title01":"Navigating through uncertainty-Experience from the UK national VEXAS MDT.","title02":"Navigating through uncertainty-Experience from the UK national VEXAS MDT.","journal":"Br J Haematol","issue":"2026 April; 208(4):1306-1313. doi: 10.1111\/bjh.70365","author":"Pietsch D, Kulasekararaj A, Savic S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41735226"},{"title01":"Mycosis fungoides and Sezary syndrome.","title02":"Mycosis fungoides and Sezary syndrome.","journal":"Br J Haematol","issue":"2026 April; 208(4):1207-1210. doi: 10.1111\/bjh.70392","author":"Martins F, Calvao J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41711246"},{"title01":"Utility of transplant conditioning intensity score in allogeneic haematopoietic stem cell transplantation for genetic disorders.","title02":"Utility of transplant conditioning intensity score in allogeneic haematopoietic stem cell transplantation for genetic disorders.","journal":"Br J Haematol","issue":"2026 April; 208(4):1369-1379. doi: 10.1111\/bjh.70381","author":"Kawaguchi K, Miyamoto S, Yoshida N, Yamamoto S, Koike T, Okada S, Kajiwara M, Takahashi Y, Ishimura M, Sakaguchi H, Hama A, Cho Y, Sato M, Kato K, Okada K, Matsumoto K, Kato K, Hashii Y, Tabuchi K, Atsuta Y, Umeda K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41705788"},{"title01":"Antigen-specific T cell responses to SARS-CoV-2 vaccination after Hematopoietic Cell Transplant or CAR T cell Therapy.","title02":"Antigen-specific T cell responses to SARS-CoV-2 vaccination after Hematopoietic Cell Transplant or CAR T cell Therapy.","journal":"Blood advances","issue":"2026 April 6. doi: 10.1182\/bloodadvances.2026019614. Online ahead of print","author":"Einarsdottir S, Fei T, Singh KH, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Shahid Z, Armistead PM, Westervelt P, McCarty J, McGuirk JP, Hamadani M, Sharon E, Spahn A, Toor AA, Waldvogel SL, Greenberger LM, Auletta JJ, Horowitz MM, Riches M, Hosszu K, Hill JA, DeWolf S, Perales MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41941698"},{"title01":"In Utero Hematopoietic Cell Transplantation in Fetuses with Alpha Thalassemia Major: A Phase 1 Clinical Trial.","title02":"In Utero Hematopoietic Cell Transplantation in Fetuses with Alpha Thalassemia Major: A Phase 1 Clinical Trial.","journal":"Blood advances","issue":"2026 April 15. doi: 10.1182\/bloodadvances.2026019655. Online ahead of print","author":"MacKenzie TC, Lianoglou BR, Gonzalez J MD, Dvorak CC, Kharbanda S, Herzeg A, Canepa E, Kreger EM, Frascoli M, Sper R, Gupta A, Leung J, Tang Q, Sinha R, Worthington AK, Gano D, Coco Bakkour S, Chafets D, Keller RL, Shimotake J, Lal A, Glenn OA, Moon-Grady A, Vichinsky EP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41984996"},{"title01":"Quizartinib in newly diagnosed patients with FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.","title02":"Quizartinib in newly diagnosed patients with FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.","journal":"Blood advances","issue":"2026 April 8. doi: 10.1182\/bloodadvances.2025017738. Online ahead of print","author":"Levis MJ, Erba HP, Montesinos P, Patkowska E, Cortes JE, Perl AE, Dombret H, Amadori S, Wang J, Schlenk RF, Liu L, Mostafa Kamel Y, Imadalou K, Laadem A, Burns K, Sekeres MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41949390"},{"title01":"Nonmyeloablative HLA-identical sibling transplant for sickle cell disease in children: A multicenter prospective study.","title02":"Nonmyeloablative HLA-identical sibling transplant for sickle cell disease in children: A multicenter prospective study.","journal":"Blood advances","issue":"2026 April 7. doi: 10.1182\/bloodadvances.2025019567. Online ahead of print","author":"Nickel RS, Abraham AA, Chiang KY, Ali M, Rangarajan HG, Chaudhury S, Kent M, Odinakachukwu MC, Kukadiya D, Malloy J, Zhang A, Hardy SJ, Guilcher GMT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41945757"},{"title01":"A Pilot Randomized Clinical Trial of a Peer Support Intervention for Hematopoietic Stem Cell Transplantation.","title02":"A Pilot Randomized Clinical Trial of a Peer Support Intervention for Hematopoietic Stem Cell Transplantation.","journal":"Blood advances","issue":"2026 April 7. doi: 10.1182\/bloodadvances.2025018918. Online ahead of print","author":"Amonoo HL, Keane EP, Guo M, Gudenkauf LM, Boardman AC, Larizza IS, Wolfe ED, Mate-Kole MN, Healy BC, Cutler CS, Jim HS, Lee SJ, Greer JA, Huffman JC, El-Jawahri A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41945755"},{"title01":"Differential effects of GVHD therapies on intestinal epithelium.","title02":"Differential effects of GVHD therapies on intestinal epithelium.","journal":"Blood advances","issue":"2026 April 14; 10(7):2431-2440. doi: 10.1182\/bloodadvances.2025017189","author":"Utrero-Rico A, Kapoor U, Berrios B, Morales G, Levine JE, Prado-Acosta M, Ferrara JLM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643175"},{"title01":"The bone marrow niche and hematopoietic system are distinctly remodeled by CD45-targeted astatine-211 radioimmunotherapy.","title02":"The bone marrow niche and hematopoietic system are distinctly remodeled by CD45-targeted astatine-211 radioimmunotherapy.","journal":"Blood advances","issue":"2026 April 14; 10(7):2452-2469. doi: 10.1182\/bloodadvances.2025017065","author":"Hagen MW, Setiawan NJ, Dexter S, Woodruff KA, Gaerlan FK, Billings TM, Orozco JJ, Termini CM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671449"},{"title01":"HCT Pre-App program: a telemedicine-based prehabilitation for allogeneic hematopoietic cell transplant candidates.","title02":"HCT Pre-App program: a telemedicine-based prehabilitation for allogeneic hematopoietic cell transplant candidates.","journal":"Blood advances","issue":"2026 April 14; 10(7):2232-2243. doi: 10.1182\/bloodadvances.2025018378","author":"Salinas Gonzalez RS, Guardia L, Sole B, Moreno C, de Llobet N, Cascos E, Martinez-Sanchez J, Diaz-Ricart M, Carreras E, Antonio M, Suarez-Lledo M, Rosinol L, Closa C, Sebio R, Martinez C, Fernandez-Aviles F, Rovira M, Salas MQ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41544211"},{"title01":"Supportive Care Interventions in Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis.","title02":"Supportive Care Interventions in Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis.","journal":"Blood advances","issue":"2026 April 2. doi: 10.1182\/bloodadvances.2026019724. Online ahead of print","author":"Schaefer DA, Guo M, Keane EP, Song MT, Larizza IS, Adri F, Wolfe ED, Saadeh N, Boardman AC, Acharya NB, Waldman LP, Monahan JA, Ramirez-Gamero AF, Diaz Gonzalez-Colmenero F, Watson J, Cronin AE, Celano CM, Brown L, Lee SJ, Stoto MA, Gudenkauf LM, Amonoo HL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41925563"},{"title01":"CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia. Reply.","title02":"CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia. Reply.","journal":"N Engl J Med","issue":"2026 April 9; 394(14):1455. doi: 10.1056\/NEJMc2602059","author":"Xiong H, Li R, Shi J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41950486"},{"title01":"CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia.","title02":"CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia.","journal":"N Engl J Med","issue":"2026 April 9; 394(14):1455. doi: 10.1056\/NEJMc2602059","author":"Yang S, Lu Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41950485"},{"title01":"[(177)Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b\/2 study.","title02":"[(177)Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b\/2 study.","journal":"Lancet Oncol","issue":"2026 April; 27(4):470-479. doi: 10.1016\/S1470-2045(26)00017-3","author":"Sandhu S, Joshua AM, Emmett L, Bressel M, Anton A, Spain L, Horvath LG, Pasam A, Tolmeijer SH, Akhurst TJ, Alipour R, Banks P, Buteau JP, Cassidy E, Crumbaker M, Dhiantravan N, Xu W, Chan J, Hitchen N, Scalzo M, Ravi Kumar AS, Kong G, Wallace R, Williams N, Williams S, Haynes NM, Neeson P, Wyatt AW, Hicks RJ, Hofman MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41926961"},{"title01":"Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial.","title02":"Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial.","journal":"Lancet Oncol","issue":"2026 April 9. doi: 10.1016\/S1470-2045(26)00014-8. Online ahead of print","author":"Morgans AK, Haresh KP, Jievaltas M, Olmos D, Shore ND, Vjaters E, Xing N, Mohamed AF, Littleton N, Srinivasan S, Verholen F, Saad F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41969015"},{"title01":"Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1\/2 trial.","title02":"Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1\/2 trial.","journal":"Lancet Oncol","issue":"2026 April; 27(4):491-501. doi: 10.1016\/S1470-2045(25)00733-8","author":"Johnson ML, Patel MR, Falchook GS, Koyama T, Gutierrez M, Awad MM, Piha-Paul SA, Friedman CF, Satoh T, Okamoto N, Singh J, Yoshizuka N, Windish HP, Qian M, Tran BP, Doi T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41926962"},{"title01":"Implications of changes in WHO haemoglobin elevation adjustment guidelines on global, regional, and national anaemia burden, 1990-2023: a population-based modelling study.","title02":"Implications of changes in WHO haemoglobin elevation adjustment guidelines on global, regional, and national anaemia burden, 1990-2023: a population-based modelling study.","journal":"Lancet Haematol","issue":"2026 April; 13(4):e227-e240. doi: 10.1016\/S2352-3026(26)00013-X","author":"Teply CJ, Gardner WM, Noyes TS, McHugh TA, Tandiono HA, Gusti Ayu Nanditha N, Harris AA, Perumal N, Markt-Maloney J, Howatt BC, Taylor HJ, Humphrey K, Bhutta ZA, Girelli D, Hay SI, Murray CJL, Musallam KM, Nnodu O, Suchdev PS, Kassebaum NJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41934993"},{"title01":"Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.","title02":"Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.","journal":"Lancet","issue":"2026 April 10. doi: 10.1016\/S0140-6736(26)00462-9. Online ahead of print","author":"Lorusso D, Gladieff L, O'Malley DM, Kim JW, Garbaos G, Fagotti A, Gilbert L, Mileshkin L, Quesada S, Hopp E, Lee YJ, Oaknin A, Scaranti M, Kim BG, Clamp A, Prillaman C, Diakos C, Bagameri A, Leiser AL, Salutari V, Monk BJ, Follana P, McClung E, Carbone V, Slomovitz B, Giudice E, Cannizzaro MC, Gavoille L, Devaux A, Scollo P, Scandurra G, Cassani C, Artioli G, Van Gorp T, Santaballa A, Dreiling LK, Kesner-Hays A, Tudor IC, Jubb AM, Colombo N, Olawaiye AB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41974149"},{"title01":"Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.","title02":"Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.","journal":"J Clin Oncol","issue":"2026 April; 44(10):893-902. doi: 10.1200\/JCO-25-01929","author":"Zhou H, Zhao H, Hou X, Wang Y, He Z, Li Y, Ma Y, Zhao Y, Huang Y, Chen L, Xiao S, Zhu H, Zhu Y, Fang W, Zhang L, Yang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779981"},{"title01":"Impact of horse anti-thymocyte globulin on graft-versus-host disease after human leukocyte antigen-matched related bone marrow transplantation for severe aplastic anemia.","title02":"Impact of horse anti-thymocyte globulin on graft-versus-host disease after human leukocyte antigen-matched related bone marrow transplantation for severe aplastic anemia.","journal":"Haematologica","issue":"2026 April 9. doi: 10.3324\/haematol.2026.300746. Online ahead of print","author":"Olivieri DJ, Gooley T, Manjappa S, Walter RB, Keel S, Flowers M, Storb R, Vo P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952636"},{"title01":"Clinical features and maternal-fetal outcome of pregnancy with aplastic anaemia: A single-centre retrospective study.","title02":"Clinical features and maternal-fetal outcome of pregnancy with aplastic anaemia: A single-centre retrospective study.","journal":"Br J Haematol","issue":"2026 April 5. doi: 10.1111\/bjh.70464. Online ahead of print","author":"Wu X, Yang Z, Zhang X, Lu S, Sun A, Wu D, Zhou H, Miao M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41937249"},{"title01":"Short-course blood transfusion therapy with hydroxyurea, a functional strategy in the management of stroke in children with sickle cell disease.","title02":"Short-course blood transfusion therapy with hydroxyurea, a functional strategy in the management of stroke in children with sickle cell disease.","journal":"Br J Haematol","issue":"2026 April 5. doi: 10.1111\/bjh.70399. Online ahead of print","author":"Temiye E, Akinsete A, Joacquim A, Fakile U, Ashefor O, Ogamba C, Ogbenna A, Adeyemo N, Okodugha O, Edokpolo E, Elemo O, Salako A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41937419"},{"title01":"Suboptimal screening and correction of maternal iron deficiency anaemia in the general population and in inherited bleeding disorders: A population-based cohort study.","title02":"Suboptimal screening and correction of maternal iron deficiency anaemia in the general population and in inherited bleeding disorders: A population-based cohort study.","journal":"Br J Haematol","issue":"2026 April; 208(4):1389-1397. doi: 10.1111\/bjh.70348","author":"Alam AU, Kaul P, Jain V, Wu C, Sun HL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41589617"},{"title01":"Transthyretin V122I Variant and Protein Affects Cardiac Severity and Mortality in Sickle Cell Disease.","title02":"Transthyretin V122I Variant and Protein Affects Cardiac Severity and Mortality in Sickle Cell Disease.","journal":"Blood advances","issue":"2026 April 1. doi: 10.1182\/bloodadvances.2026019698. Online ahead of print","author":"Li H, Gao S, Wang X, Asomaning N, Conrey A, Kruah B, Joo J, Wu CO, Sachdev V, Thein SL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41921073"},{"title01":"Lipid metabolism transcriptomic signature of defective erythropoiesis in Diamond Blackfan anemia syndrome.","title02":"Lipid metabolism transcriptomic signature of defective erythropoiesis in Diamond Blackfan anemia syndrome.","journal":"Blood advances","issue":"2026 April 14; 10(7):2272-2285. doi: 10.1182\/bloodadvances.2025017318","author":"Deng K, Wang Y, Min JC, Liu X, Ueharu H, Myers G, Yu L, Hammoud S, Adam A, Saba R, Natogi V, Drysdale C, Chen B, Yee J, Kitzman JO, Lyssiotis CA, Mishina Y, Jones M, Kaartinen V, Guan Y, Khoriaty R, Engel JD, Singh SA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41576344"},{"title01":"Growth and puberty in African children with sickle cell anemia treated with hydroxyurea.","title02":"Growth and puberty in African children with sickle cell anemia treated with hydroxyurea.","journal":"Blood advances","issue":"2026 April 9. doi: 10.1182\/bloodadvances.2025019511. Online ahead of print","author":"Backeljauw P, Tomlinson G, Smart LR, Tshilolo LMM, Williams TN, Santos B, Olupot-Olupot P, Stuber SE, Lane A, Latham TS, Ware RE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41954645"},{"title01":"Atrial fibrillation prevalence and its management in aging, transfusion-dependent patients with thalassemia: the FATHAL study.","title02":"Atrial fibrillation prevalence and its management in aging, transfusion-dependent patients with thalassemia: the FATHAL study.","journal":"Blood advances","issue":"2026 April 14; 10(7):2291-2301. doi: 10.1182\/bloodadvances.2025017577","author":"Di Stefano V, Gianesin B, Orecchia V, Longo F, Barella S, Barone A, Culcasi M, Denotti AR, Costantini S, Ferrara F, Foggetti I, Gigante A, Manca MR, Mazzi F, Pasanisi A, Pisaniello M, Ricchi P, Serra M, Origa R, Bertini M, Motta I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41569798"},{"title01":"Epo and hypoxia accelerate a pattern of gradual cell cycle shortening in BFU-e and CFU-e erythroid progenitors in vivo.","title02":"Epo and hypoxia accelerate a pattern of gradual cell cycle shortening in BFU-e and CFU-e erythroid progenitors in vivo.","journal":"Blood advances","issue":"2026 April 14; 10(7):2257-2271. doi: 10.1182\/bloodadvances.2025017907","author":"Winward A, Lalonde L, Nair D, Socolovsky M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41441873"},{"title01":"A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia.","title02":"A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia.","journal":"N Engl J Med","issue":"2026 April 9; 394(14):1388-1398. doi: 10.1056\/NEJMoa2513120","author":"Kuter DJ, Miura K, Patriarca A, Pulanic D, Radinoff A, Sapunarova K, Syrigou A, Yang R, Nguyen VA, Skelton E, Wang S, Yee DL, Patwari P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41950473"},{"title01":"Thrombosis in immune thrombocytopenia.","title02":"Thrombosis in immune thrombocytopenia.","journal":"Br J Haematol","issue":"2026 April 9. doi: 10.1111\/bjh.70474. Online ahead of print","author":"Garabet L, Ghanima W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952648"},{"title01":"MicroRNAs as potential architects of immune dysregulation and megakaryocytic failure in immune thrombocytopenia.","title02":"MicroRNAs as potential architects of immune dysregulation and megakaryocytic failure in immune thrombocytopenia.","journal":"Br J Haematol","issue":"2026 April 15. doi: 10.1111\/bjh.70485. Online ahead of print","author":"Liu Z, Rebetz J, Garabet L, Ghanima W, Xu P, Wadenvik H, Provan D, Kapur R, Semple JW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41983341"},{"title01":"Pre-diagnostic clonal hematopoiesis of indeterminate potential among patients with a primary cancer and risk of second cancers.","title02":"Pre-diagnostic clonal hematopoiesis of indeterminate potential among patients with a primary cancer and risk of second cancers.","journal":"Leukemia","issue":"2026 April 14. doi: 10.1038\/s41375-026-02946-x. Online ahead of print","author":"Liu X, Adami HO, Boberg E, Smedby KE, Wei H, Fang F, Liu Q","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41981103"},{"title01":"A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia.","title02":"A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia.","journal":"Leukemia","issue":"2026 April; 40(4):717-729. doi: 10.1038\/s41375-026-02883-9","author":"Chakraborty S, Morganti C, Zaldana K, Rivera Pena B, Zhang H, Verma D, Gitego N, Ma F, Aluri S, Pradhan K, Gordon-Mitchell S, Mantzaris I, Goldfinger M, Feldman E, Gritsman K, Shi Y, Hubner S, Qiu YH, Brown BD, Khasawneh A, Skwarska A, de Camargo Magalhaes ES, Verma A, Konopleva M, Tabe Y, Gavathiotis E, Colla S, Gollob J, Dey J, Kornblau SM, Koralov SB, Ito K, Shastri A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703028"},{"title01":"Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing.","title02":"Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing.","journal":"Leukemia","issue":"2026 April; 40(4):783-793. doi: 10.1038\/s41375-026-02892-8","author":"Jutzi JS, Crosse E, Kim CJ, van Gasteren B, Laurore C, Rolles B, Kramer F, Tishena A, Rocha AV, Wazir M, Weeks LD, How J, Stahl M, Luskin MR, Lindsley RC, Pozdnyakova O, Rai S, Graubert TA, Bradley RK, Mullally A, Marneth AE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41748695"},{"title01":"TGFbeta-activated kinase-1 knockdown in hematopoietic stem-progenitor cells causes PANoptosis and myelodysplastic syndrome-like disease in mice.","title02":"TGFbeta-activated kinase-1 knockdown in hematopoietic stem-progenitor cells causes PANoptosis and myelodysplastic syndrome-like disease in mice.","journal":"Haematologica","issue":"2026 April 1; 111(4):1355-1367. doi: 10.3324\/haematol.2025.287951","author":"Zhang L, Li W, Thalla R, Ma R, Mack R, Kini AR, Runde A, Hagen PA, Barton K, Kosti-Schwartz J, Breslin P, Ji HL, Zhang J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41163575"},{"title01":"Clinical outcomes of WHO2022 and ICC MDS entities with risk stratification by IPSS-R and IPSS-M.","title02":"Clinical outcomes of WHO2022 and ICC MDS entities with risk stratification by IPSS-R and IPSS-M.","journal":"Haematologica","issue":"2026 April 1; 111(4):1422-1426. doi: 10.3324\/haematol.2025.288090","author":"Kwag D, Bae B, Jung J, Kim HS, Lee JM, Ahn A, Yoon JS, Park SY, Park S, Kim M, Kim YJ, Kim Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41163580"},{"title01":"Azacitidine for MDS and CMML.","title02":"Azacitidine for MDS and CMML.","journal":"Haematologica","issue":"2026 April 1; 111(4):1147-1148. doi: 10.3324\/haematol.2026.289398","author":"Martin ES, Patnaik MM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41919559"},{"title01":"Treatment of TP53-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclax.","title02":"Treatment of TP53-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclax.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2026.300534. Online ahead of print","author":"Goldfinger M, Mantzaris I, Shastri A, Rockwell B, Saunthararajah Y, Yin S, Levitz D, Gritsman K, Sica AR, Kornblum N, Shapiro LC, Gupta R, Peeke S, Shah N, Pradhan K, Munoz A, Dhawan A, Verceles JA, Fehn K, Comas M, Shah L, Shi Y, Jonas BA, Cooper DL, Konopleva M, Feldman EJ, Verma A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924907"},{"title01":"Improvement in survival of patients with higher risk but not lower risk myelodysplastic syndromes over 20 years: A retrospective study from Nagasaki, Japan.","title02":"Improvement in survival of patients with higher risk but not lower risk myelodysplastic syndromes over 20 years: A retrospective study from Nagasaki, Japan.","journal":"Br J Haematol","issue":"2026 April; 208(4):1443-1447. doi: 10.1111\/bjh.70345","author":"Furumoto T, Ando K, Toriyama E, Hata T, Sakamoto H, Chiwata M, Kitanosono H, Nakashima J, Kato T, Taguchi M, Horai M, Itonaga H, Sato S, Sawayama Y, Imanishi D, Imaizumi Y, Jo T, Yoshida S, Moriuchi Y, Miyazaki Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41582419"},{"title01":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: A 25-year nationwide study.","title02":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: A 25-year nationwide study.","journal":"Br J Haematol","issue":"2026 April 5. doi: 10.1111\/bjh.70463. Online ahead of print","author":"Itonaga H, Miyazaki Y, Tachi N, Kurosawa S, Marumo A, Konuma T, Ebina T, Doki N, Uchida N, Fukuda T, Nishida T, Katayama Y, Asada N, Sakurai M, Maeda T, Eto T, Tanaka M, Nakamae H, Onizuka M, Kawamura K, Kanda Y, Atsuta Y, Tachibana T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41937388"},{"title01":"Contrasting impacts of pretransplant cytoreduction and post-transplant maintenance on outcomes of allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromes: Real-world multicentre evidence.","title02":"Contrasting impacts of pretransplant cytoreduction and post-transplant maintenance on outcomes of allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromes: Real-world multicentre evidence.","journal":"Br J Haematol","issue":"2026 April 10. doi: 10.1111\/bjh.70477. Online ahead of print","author":"Chen Y, Zhang X, Shen N, Zhang J, Guo R, Xing H, Han L, Liu Y, Tian W, Wang M, Xie X, Jiang Z, Wan D, Zhou X, Xu H, Qin L, Shi W, Cao W, Bian Z","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41960892"},{"title01":"The ASH HematOmics Program supports integrative analysis of genomic and clinical data in hematologic diseases.","title02":"The ASH HematOmics Program supports integrative analysis of genomic and clinical data in hematologic diseases.","journal":"Blood","issue":"2026 April 6. doi: 10.1182\/blood.2025032031. Online ahead of print","author":"Lu C, Matt GY, Paul R, Wang J, Sioson E, Gangwani K, Acic A, Willems A, Zaldivar Peraza A, Reilly C, Polonen P, Gao Q, Li Q, Pounds SB, Zeng AGX, Li S, Nadarajah N, Brady SW, Iacobucci I, Haferlach T, Rose MC, Mullighan CG, Zhou X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41940951"},{"title01":"Risk stratification of patients with TP53-mutated myeloproliferative neoplasms.","title02":"Risk stratification of patients with TP53-mutated myeloproliferative neoplasms.","journal":"Leukemia","issue":"2026 April; 40(4):773-782. doi: 10.1038\/s41375-026-02885-7","author":"Rolles B, Filho CMO, Fergusson N, Bewersdorf JP, Keating J, Perkins C, Schwede M, England J, Luskin MR, DeAngelo DJ, Shimony S, Faiz M, Hillerbrand AC, Kim C, Weeks LD, Waldman L, Wazir M, How J, Marneth AE, Liu Y, Aryee MJ, Rampal R, Tsai HK, Gotlib J, Gupta V, Stahl M, Mullally A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41735484"},{"title01":"Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing.","title02":"Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing.","journal":"Leukemia","issue":"2026 April; 40(4):783-793. doi: 10.1038\/s41375-026-02892-8","author":"Jutzi JS, Crosse E, Kim CJ, van Gasteren B, Laurore C, Rolles B, Kramer F, Tishena A, Rocha AV, Wazir M, Weeks LD, How J, Stahl M, Luskin MR, Lindsley RC, Pozdnyakova O, Rai S, Graubert TA, Bradley RK, Mullally A, Marneth AE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41748695"},{"title01":"New insights into JAK2 germline variant-driven stromal cell alterations and proinflammatory bone marrow niche remodeling in myeloproliferative neoplasms.","title02":"New insights into JAK2 germline variant-driven stromal cell alterations and proinflammatory bone marrow niche remodeling in myeloproliferative neoplasms.","journal":"Leukemia","issue":"2026 April 1. doi: 10.1038\/s41375-026-02937-y. Online ahead of print","author":"Nishimura K, Ono R, Nagaharu K, Ohya E, Tsuji T, Ikejiri M, Nakamura A, Nosaka T, Tawara I, Sugimoto Y, Ohishi K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41922799"},{"title01":"A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alpha.","title02":"A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alpha.","journal":"Leukemia","issue":"2026 April 8. doi: 10.1038\/s41375-026-02882-w. Online ahead of print","author":"Silver RT, Hasselbalch HC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41951941"},{"title01":"Pre-diagnostic clonal hematopoiesis of indeterminate potential among patients with a primary cancer and risk of second cancers.","title02":"Pre-diagnostic clonal hematopoiesis of indeterminate potential among patients with a primary cancer and risk of second cancers.","journal":"Leukemia","issue":"2026 April 14. doi: 10.1038\/s41375-026-02946-x. Online ahead of print","author":"Liu X, Adami HO, Boberg E, Smedby KE, Wei H, Fang F, Liu Q","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41981103"},{"title01":"Loss of KDEL function from a calreticulin frameshift mutation drives expression of an immature, mutant calreticulin-dependent form of the thrombopoietin receptor MPL.","title02":"Loss of KDEL function from a calreticulin frameshift mutation drives expression of an immature, mutant calreticulin-dependent form of the thrombopoietin receptor MPL.","journal":"Haematologica","issue":"2026 April 1; 111(4):1368-1379. doi: 10.3324\/haematol.2025.287585","author":"Masubuchi N, Yang Y, Imai M, Kihara Y, Morishita S, Edahiro Y, Komatsu N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195513"},{"title01":"JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.","title02":"JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.","journal":"Haematologica","issue":"2026 April 1; 111(4):1179-1197. doi: 10.3324\/haematol.2025.288654","author":"Vachhani P, Mesa R, Mascarenhas J, Rampal R, Oh ST, Vannucchi AM, Fox ML, Palandri F, Passamonti F, Kiladjian JJ, Azimi M, Harrison C, Bose P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262043"},{"title01":"Clonal megakaryocyte dysplasia with normal blood values: a covert, thrombosis-prone, early myeloproliferative neoplasm.","title02":"Clonal megakaryocyte dysplasia with normal blood values: a covert, thrombosis-prone, early myeloproliferative neoplasm.","journal":"Haematologica","issue":"2026 April 1; 111(4):1380-1388. doi: 10.3324\/haematol.2025.288681","author":"Barosi G, Rosti V, Campanelli R, Massa M, Abba C, Carolei A, Catarsi P, Inzoli A, Pergola L, Barbui T, Tatarelli C, Finazzi MC, Condorelli A, Salmoiraghi S, Rambaldi A, Gianatti A, De Stefano V, Galli A, Gandossini M, Bardelli M, Gale RP, Malcovati L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262049"},{"title01":"Changes in neutrophil-to-lymphocyte ratio in patients with polycythemia vera treated with ruxolitinib reflect JAK2 variant allele frequency.","title02":"Changes in neutrophil-to-lymphocyte ratio in patients with polycythemia vera treated with ruxolitinib reflect JAK2 variant allele frequency.","journal":"Haematologica","issue":"2026 April 9. doi: 10.3324\/haematol.2025.300245. Online ahead of print","author":"Guglielmelli P, Paoli C, Borgi G, Fagiolo L, Bianchini S, Loscocco GG, Gesullo F, Di Vaio F, Matteoli C, Pancani F, Danesi S, Pestelli S, Barbui T, Vannucchi AM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952646"},{"title01":"Somatic and germline genetic testing pathways in haematological malignancies: Best practice consensus guidelines from the 2025 national meeting organised by UK Cancer Genetics Group (UKCGG), CanGene-CanVar and the NHS England Haematological Oncology Working Group.","title02":"Somatic and germline genetic testing pathways in haematological malignancies: Best practice consensus guidelines from the 2025 national meeting organised by UK Cancer Genetics Group (UKCGG), CanGene-CanVar and the NHS England Haematological Oncology Working Group.","journal":"Br J Haematol","issue":"2026 April; 208(4):1211-1222. doi: 10.1111\/bjh.70404","author":"Speight B, Hamblin A, Talley P, Tsoulaki O, Robinson R, Dean P, Khorashad J, Kulasekararaj A, Godfrey AL, Mead AJ, McVeigh TP, Snape K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41773566"},{"title01":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: A 25-year nationwide study.","title02":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: A 25-year nationwide study.","journal":"Br J Haematol","issue":"2026 April 5. doi: 10.1111\/bjh.70463. Online ahead of print","author":"Itonaga H, Miyazaki Y, Tachi N, Kurosawa S, Marumo A, Konuma T, Ebina T, Doki N, Uchida N, Fukuda T, Nishida T, Katayama Y, Asada N, Sakurai M, Maeda T, Eto T, Tanaka M, Nakamae H, Onizuka M, Kawamura K, Kanda Y, Atsuta Y, Tachibana T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41937388"},{"title01":"MPN-FIT: a randomized controlled pilot trial of supervised exercise in myeloproliferative neoplasms.","title02":"MPN-FIT: a randomized controlled pilot trial of supervised exercise in myeloproliferative neoplasms.","journal":"Blood advances","issue":"2026 April 14; 10(7):2142-2152. doi: 10.1182\/bloodadvances.2025018682","author":"Ouellet M, Rizzolo A, Venne C, Moussa H, Bilodeau K, Mollica L, Chabot-Roy G, Huynh-Trudeau G, Lesage S, Harnois M, Busque L, Sirhan S, Szuber N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41499761"},{"title01":"Ropeginterferon alfa-2b has minimal transplacental passage and breastmilk secretion in pregnant patients with MPN.","title02":"Ropeginterferon alfa-2b has minimal transplacental passage and breastmilk secretion in pregnant patients with MPN.","journal":"Blood advances","issue":"2026 April 14; 10(7):2168-2172. doi: 10.1182\/bloodadvances.2025018811","author":"Tashi T, Shih LY, Yo YT, Sullivan AE, Chueh HY, Kuo MC, Smith A, Kim SJ, Parsegov B, Reeves BN, Song J, Prchal JT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587484"},{"title01":"Thrombosis in primary myelofibrosis: the influence of cohort composition and disease biology.","title02":"Thrombosis in primary myelofibrosis: the influence of cohort composition and disease biology.","journal":"Blood advances","issue":"2026 April 14; 10(7):2521-2524. doi: 10.1182\/bloodadvances.2026019668","author":"Barbui T, De Stefano V, Tefferi A, Vannucchi AM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41678834"},{"title01":"Ultraprecision therapy for type 1 vs type 2 CALR+ MPN by dual epitope targeting that restores ruxolitinib sensitivity.","title02":"Ultraprecision therapy for type 1 vs type 2 CALR+ MPN by dual epitope targeting that restores ruxolitinib sensitivity.","journal":"Blood","issue":"2026 April 2; 147(14):1611-1623. doi: 10.1182\/blood.2024027897","author":"Thompson-Peach CAL, Thomas D, Dottore M, Lim K, Stomski F, Panagopoulos RA, Fosselteder J, Reinisch A, Chandrakanthan V, Jenkner S, Bland L, Paton S, Gronthos S, Hercus TR, Wardill HR, Kan WL, Kamel MM, Moretti PA, Pitson SM, Burbury K, Ross DM, Nair PC, Lopez AF, Tvorogov D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41481383"},{"title01":"Treosulfan-fludarabine conditioning in infants with severe combined immunodeficiencies: Extended study of the UK paediatric treosulfan study.","title02":"Treosulfan-fludarabine conditioning in infants with severe combined immunodeficiencies: Extended study of the UK paediatric treosulfan study.","journal":"Br J Haematol","issue":"2026 April 10. doi: 10.1111\/bjh.70453. Online ahead of print","author":"Lum SH, Greener S, Memon IL, Amrolia P, Nademi Z, Chiesa R, Silva J, Young H, Owens S, Williams E, Ng KF, Flood T, Gennery AR, Hambleton S, Rao K, Slatter M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41958357"},{"title01":"Endothelial activation and stress index score as a predictor of transplant-associated thrombotic microangiopathy in patients with sickle cell disease.","title02":"Endothelial activation and stress index score as a predictor of transplant-associated thrombotic microangiopathy in patients with sickle cell disease.","journal":"Br J Haematol","issue":"2026 April 2. doi: 10.1111\/bjh.70465. Online ahead of print","author":"Krishnan R, Sankaran H, Jacobsohn D, Nickel R, Snelling K, Vatsayan A, Dreyzin A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924942"},{"title01":"Contrasting impacts of pretransplant cytoreduction and post-transplant maintenance on outcomes of allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromes: Real-world multicentre evidence.","title02":"Contrasting impacts of pretransplant cytoreduction and post-transplant maintenance on outcomes of allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromes: Real-world multicentre evidence.","journal":"Br J Haematol","issue":"2026 April 10. doi: 10.1111\/bjh.70477. Online ahead of print","author":"Chen Y, Zhang X, Shen N, Zhang J, Guo R, Xing H, Han L, Liu Y, Tian W, Wang M, Xie X, Jiang Z, Wan D, Zhou X, Xu H, Qin L, Shi W, Cao W, Bian Z","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41960892"},{"title01":"Inclusion of Thiotepa in Myeloablative Regimens Improves Donor Chimerism in Children with Inborn Errors of Immunity or Inherited Metabolic Disorders.","title02":"Inclusion of Thiotepa in Myeloablative Regimens Improves Donor Chimerism in Children with Inborn Errors of Immunity or Inherited Metabolic Disorders.","journal":"Br J Haematol","issue":"2026 April 15. doi: 10.1111\/bjh.70486. Online ahead of print","author":"McComb C, Pai V, Stanek J, Rankin AW, Lamb M, Bhunia N, Bajwa R, Abu-Arja R, Rangarajan HG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41983326"},{"title01":"Serotherapy in transplant: Getting it right!","title02":"Serotherapy in transplant: Getting it right!","journal":"Br J Haematol","issue":"2026 April 6. doi: 10.1111\/bjh.70456. Online ahead of print","author":"Wynn R, Admiraal R, Lindemans C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41937680"},{"title01":"Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.","title02":"Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.","journal":"Br J Haematol","issue":"2026 April; 208(4):1359-1368. doi: 10.1111\/bjh.70380","author":"Desai N, Althobaiti M, Chen C, Al-Shaibani E, Moya TA, Novitzky-Basso I, Pasic I, Michelis FV, Kim DD, Kumar R, Mattsson J, Law AD, Viswabandya A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41747740"},{"title01":"Navigating through uncertainty-Experience from the UK national VEXAS MDT.","title02":"Navigating through uncertainty-Experience from the UK national VEXAS MDT.","journal":"Br J Haematol","issue":"2026 April; 208(4):1306-1313. doi: 10.1111\/bjh.70365","author":"Pietsch D, Kulasekararaj A, Savic S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41735226"},{"title01":"Utility of transplant conditioning intensity score in allogeneic haematopoietic stem cell transplantation for genetic disorders.","title02":"Utility of transplant conditioning intensity score in allogeneic haematopoietic stem cell transplantation for genetic disorders.","journal":"Br J Haematol","issue":"2026 April; 208(4):1369-1379. doi: 10.1111\/bjh.70381","author":"Kawaguchi K, Miyamoto S, Yoshida N, Yamamoto S, Koike T, Okada S, Kajiwara M, Takahashi Y, Ishimura M, Sakaguchi H, Hama A, Cho Y, Sato M, Kato K, Okada K, Matsumoto K, Kato K, Hashii Y, Tabuchi K, Atsuta Y, Umeda K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41705788"},{"title01":"Efficacy of immune checkpoint inhibitors in paediatric, adolescent and young adults with primary refractory or relapsed classical Hodgkin lymphoma: A national multicentre real-world study.","title02":"Efficacy of immune checkpoint inhibitors in paediatric, adolescent and young adults with primary refractory or relapsed classical Hodgkin lymphoma: A national multicentre real-world study.","journal":"Br J Haematol","issue":"2026 April; 208(4):1331-1338. doi: 10.1111\/bjh.70379","author":"Pouthier M, Garnier N, Leruste A, Rigaud C, Curtillet C, Ducassou S, Poiree M, Dourthe ME, Pochon C, Couec ML, Bonneau-Lagacherie J, Montravers F, Boudjemaa S, Jonca B, Haouy S, Leblanc T, Parker JL, Simonin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41704060"},{"title01":"Equal outcomes after human leukocyte antigen-matched unrelated versus sibling donor transplants-Results of the AML SCT-BFM 2007 trial and consecutive &#8216;real-world routine&#8217;.","title02":"Equal outcomes after human leukocyte antigen-matched unrelated versus sibling donor transplants-Results of the AML SCT-BFM 2007 trial and consecutive &#8216;real-world routine&#8217;.","journal":"Br J Haematol","issue":"2026 April; 208(4):1472-1476. doi: 10.1111\/bjh.70324","author":"Sauer MG, Lang PJ, Albert MH, Bader P, Eyrich M, Gruhn B, Klingebiel T, Mauz-Korholz C, Meisel R, Muller I, Niemeyer CM, Peters C, Burkhardt B, Reinhardt D, Sedlacek P, Strahm B, Woessmann W, Handgretinger R, Zimmermann M, Borkhardt A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41502109"},{"title01":"Dose de-escalation of alemtuzumab in matched unrelated donor haematopoietic stem cell transplantation.","title02":"Dose de-escalation of alemtuzumab in matched unrelated donor haematopoietic stem cell transplantation.","journal":"Br J Haematol","issue":"2026 April; 208(4):1477-1481. doi: 10.1111\/bjh.70318","author":"Madkhali MM, Mitchell A, Wright C, Pearce K, Aku S, Pagan S, Duncan L, Lam J, Macdonald J, Milne P, Publicover A, Hurst E, Bigley V, Hale G, Collin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41508744"},{"title01":"Nonmyeloablative HLA-identical sibling transplant for sickle cell disease in children: A multicenter prospective study.","title02":"Nonmyeloablative HLA-identical sibling transplant for sickle cell disease in children: A multicenter prospective study.","journal":"Blood advances","issue":"2026 April 7. doi: 10.1182\/bloodadvances.2025019567. Online ahead of print","author":"Nickel RS, Abraham AA, Chiang KY, Ali M, Rangarajan HG, Chaudhury S, Kent M, Odinakachukwu MC, Kukadiya D, Malloy J, Zhang A, Hardy SJ, Guilcher GMT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41945757"},{"title01":"A Pilot Randomized Clinical Trial of a Peer Support Intervention for Hematopoietic Stem Cell Transplantation.","title02":"A Pilot Randomized Clinical Trial of a Peer Support Intervention for Hematopoietic Stem Cell Transplantation.","journal":"Blood advances","issue":"2026 April 7. doi: 10.1182\/bloodadvances.2025018918. Online ahead of print","author":"Amonoo HL, Keane EP, Guo M, Gudenkauf LM, Boardman AC, Larizza IS, Wolfe ED, Mate-Kole MN, Healy BC, Cutler CS, Jim HS, Lee SJ, Greer JA, Huffman JC, El-Jawahri A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41945755"},{"title01":"Bone marrow transplantation for sickle cell disease using posttransplantation cyclophosphamide and 400 cGy TBI.","title02":"Bone marrow transplantation for sickle cell disease using posttransplantation cyclophosphamide and 400 cGy TBI.","journal":"Blood advances","issue":"2026 April 14; 10(7):2202-2217. doi: 10.1182\/bloodadvances.2025017413","author":"Goldenberg M, Varadhan R, Gamper CJ, Cooke KR, Ambinder AJ, Symons HJ, Pecker LH, Jones RJ, Brodsky RA, Bolanos-Meade J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41569644"},{"title01":"Supportive Care Interventions in Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis.","title02":"Supportive Care Interventions in Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis.","journal":"Blood advances","issue":"2026 April 2. doi: 10.1182\/bloodadvances.2026019724. Online ahead of print","author":"Schaefer DA, Guo M, Keane EP, Song MT, Larizza IS, Adri F, Wolfe ED, Saadeh N, Boardman AC, Acharya NB, Waldman LP, Monahan JA, Ramirez-Gamero AF, Diaz Gonzalez-Colmenero F, Watson J, Cronin AE, Celano CM, Brown L, Lee SJ, Stoto MA, Gudenkauf LM, Amonoo HL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41925563"},{"title01":"Targeting Aurora kinase A to prevent GVHD and relapse after myeloablative allogeneic hematopoietic cell transplantation.","title02":"Targeting Aurora kinase A to prevent GVHD and relapse after myeloablative allogeneic hematopoietic cell transplantation.","journal":"Blood advances","issue":"2026 April 14; 10(7):2190-2201. doi: 10.1182\/bloodadvances.2025017360","author":"Holtan SG, Grover P, Walton K, El Jurdi N, Quinones V, Maakaron JE, Juckett MB, Bachanova V, Hou JH, Terezakis S, Myers TJ, Paradiso LJ, DeFor TE, Cao Q, Betts BC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592279"},{"title01":"Allogeneic hematopoietic stem cell transplantation in ERCC6L2 disease.","title02":"Allogeneic hematopoietic stem cell transplantation in ERCC6L2 disease.","journal":"Blood advances","issue":"2026 April 14; 10(7):2525-2537. doi: 10.1182\/bloodadvances.2025018349","author":"Hakkarainen M, Sicre de Fontbrune F, Kaaja I, Douglas S, Dalle JH, Risitano AM, Kulasekararaj A, Alsultan A, Cutler C, Ho VT, Hellstrom-Lindberg E, Mielke S, Myhre AE, Rihani R, Shanap MA, Hashem H, Shimamura A, Rowe RG, Auer F, Beier F, Desnica L, Hough R, Ali Jafri SR, Ayas M, Jardine L, Mellid EF, Corrales I, Richardson D, Ozbek NY, Zaniewska-Tekieli A, Gozdzik J, Ryhanen S, Niinimaki R, Jahnukainen K, Salmenniemi U, Kilpivaara O, Wartiovaara-Kautto U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628318"},{"title01":"Differential effects of GVHD therapies on intestinal epithelium.","title02":"Differential effects of GVHD therapies on intestinal epithelium.","journal":"Blood advances","issue":"2026 April 14; 10(7):2431-2440. doi: 10.1182\/bloodadvances.2025017189","author":"Utrero-Rico A, Kapoor U, Berrios B, Morales G, Levine JE, Prado-Acosta M, Ferrara JLM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643175"},{"title01":"In Utero Hematopoietic Cell Transplantation in Fetuses with Alpha Thalassemia Major: A Phase 1 Clinical Trial.","title02":"In Utero Hematopoietic Cell Transplantation in Fetuses with Alpha Thalassemia Major: A Phase 1 Clinical Trial.","journal":"Blood advances","issue":"2026 April 15. doi: 10.1182\/bloodadvances.2026019655. Online ahead of print","author":"MacKenzie TC, Lianoglou BR, Gonzalez J MD, Dvorak CC, Kharbanda S, Herzeg A, Canepa E, Kreger EM, Frascoli M, Sper R, Gupta A, Leung J, Tang Q, Sinha R, Worthington AK, Gano D, Coco Bakkour S, Chafets D, Keller RL, Shimotake J, Lal A, Glenn OA, Moon-Grady A, Vichinsky EP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41984996"},{"title01":"Gastrin for the treatment of acute graft-versus-host disease of the stomach.","title02":"Gastrin for the treatment of acute graft-versus-host disease of the stomach.","journal":"Blood","issue":"2026 April 9; 147(15):1763-1778. doi: 10.1182\/blood.2025031080","author":"Gawron J, Czech M, Ruckert T, Holzmuller V, Andreev G, Burk AC, Hartmann A, Chatterjee S, Andrieux G, Marquard FE, Baur AS, Stell AV, Krausz M, Braun LM, Osswald N, Melchinger W, Wertheimer T, Proano-Vasco AI, Maas-Bauer K, Schmitt-Graeff A, Boerries M, Kohler N, Ayuk F, Schell C, Quante M, Zeiser R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41511880"},{"title01":"GVHD fails the acid test.","title02":"GVHD fails the acid test.","journal":"Blood","issue":"2026 April 9; 147(15):1660-1662. doi: 10.1182\/blood.2025032810","author":"Chakraverty R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41954963"},{"title01":"CD28(+) CD8(+) Tem cells with a STAT1-dependent glucocorticoid receptor deficit contribute to steroid-refractory acute GVHD.","title02":"CD28(+) CD8(+) Tem cells with a STAT1-dependent glucocorticoid receptor deficit contribute to steroid-refractory acute GVHD.","journal":"Blood","issue":"2026 April 14. doi: 10.1182\/blood.2025032587. Online ahead of print","author":"Pan Z, Deng Y, Huang J, Bian H, Chen Y, Huang A, Jiang C, Wang L, Zhang Z, Lu H, Li S, Yin T, Yu S, Zhu J, Zhao WL, Wang J, Ji J, Xu Y, Cheng H, Chen J, Hu H, Hu X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41980031"},{"title01":"Chronic active Epstein-Barr virus disease: molecular pathogenesis, evolving concepts, and emerging therapies.","title02":"Chronic active Epstein-Barr virus disease: molecular pathogenesis, evolving concepts, and emerging therapies.","journal":"Blood","issue":"2026 April 2; 147(14):1562-1573. doi: 10.1182\/blood.2025032277","author":"Kimura H, Cohen JI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490284"},{"title01":"CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat beta-Thalassemia.","title02":"CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat beta-Thalassemia.","journal":"N Engl J Med","issue":"2026 April 2; 394(13):1292-1301. doi: 10.1056\/NEJMoa2501277","author":"Frangoul H, Hanna R, Walters MC, Kao RL, Carroll C, McManus M, Chang KH, Jaskolka MC, Kim K, Yu Q, Badamosi N, Mei B, Afonja O, Thompson A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41931048"},{"title01":"CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease.","title02":"CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease.","journal":"N Engl J Med","issue":"2026 April 2; 394(13):1281-1291. doi: 10.1056\/NEJMoa2415550","author":"Hanna R, Frangoul H, Pineiro L, McKinney C, Mapara M, Dalal J, Rangarajan HG, Atkins H, Sharma A, Chang KH, Jaskolka MC, Kim K, Yu Q, Mei B, Afonja O, Walters MC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41931047"},{"title01":"Haploidentical versus matched unrelated donor transplantation with post-transplant cyclophosphamide: a platform-dependent machine learning analysis of donor age.","title02":"Haploidentical versus matched unrelated donor transplantation with post-transplant cyclophosphamide: a platform-dependent machine learning analysis of donor age.","journal":"Leukemia","issue":"2026 April 15. doi: 10.1038\/s41375-026-02903-8. Online ahead of print","author":"Mehta RS, Kanakry CG, Nawas M, Lazaryan A, Kanakry JA, Holtan S, Al-Juhaishi T, Rimando JC, Singh A, Saultz J, Mccurdy SR, Milano F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41986623"},{"title01":"Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX models.","title02":"Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX models.","journal":"Leukemia","issue":"2026 April 15. doi: 10.1038\/s41375-026-02957-8. Online ahead of print","author":"Kandarpa M, Peterson LF, Potu H, Ramappan M, Liu Y, Polk A, Wang S, Talpaz M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41986621"},{"title01":"Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.","title02":"Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.","journal":"Lancet Haematol","issue":"2026 April; 13(4):e241-e253. doi: 10.1016\/S2352-3026(26)00011-6","author":"Dytfeld D, Wrobel T, Jamroziak K, Kubicki T, Robak P, Pula A, Walter-Croneck A, Czyz J, Tyczynska A, Druzd-Sitek A, Giannopoulos K, Nowicki A, Szczepaniak T, Lojko-Dankowska A, Matuszak M, Gil L, Pula B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski L, Konska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Lahoud OB, Zonder JA, Cooperrider JH, Derman BA, Karrison T, Jakubowiak AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41831471"},{"title01":"Maintenance intensification after autologous HSCT: refining selection.","title02":"Maintenance intensification after autologous HSCT: refining selection.","journal":"Lancet Haematol","issue":"2026 April; 13(4):e189-e191. doi: 10.1016\/S2352-3026(26)00064-5","author":"Perrot A, Frenzel L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41831470"},{"title01":"Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant.","title02":"Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant.","journal":"J Clin Oncol","issue":"2026 April 10; 44(11):1003-1015. doi: 10.1200\/JCO-25-01591","author":"Liberio N, Allbee-Johnson M, Ahn KW, Moskop A, Phelan R, Shaw BE, Page KM, Schultz KR, Phillips CL, Mehta PA, Qayed M, Sharma A, Lipsitt AE, Symons H, Bolanos-Meade J, Kharbanda S, Dvorak CC, Kapoor N, Doherty EE, Chavan RS, Broglie L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41740085"},{"title01":"First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.","title02":"First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.","journal":"J Clin Oncol","issue":"2026 April 6; JCO2501966. doi: 10.1200\/JCO-25-01966. Online ahead of print","author":"Rettinger E, Heckl D, Hutter M, Salzmann-Manrique E, Luedtke M, Huenecke S, Bremm M, Cappel C, Bug G, Greil J, Meisel R, Wagner-Drouet EM, Serve H, Gungor T, Klusmann JH, Klingebiel T, Bader P, Bonig H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41941697"},{"title01":"Preemptive hematopoietic stem cell transplantation in RUNX1 familial platelet disorder: a shared decision-making framework.","title02":"Preemptive hematopoietic stem cell transplantation in RUNX1 familial platelet disorder: a shared decision-making framework.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2025.300403. Online ahead of print","author":"Olson TS, Ericson K, Antin JH, Babbitt L, Babich M, Deuitch NT, DiNardo C, Ford PJ, Obeng EA, Stewart BL, Xiao W, Shimamura A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924923"},{"title01":"The comprehensive landscape of TTMV::RARA fusiondriven acute myeloid leukemia: from viral integration mechanisms to clinical outcomes.","title02":"The comprehensive landscape of TTMV::RARA fusiondriven acute myeloid leukemia: from viral integration mechanisms to clinical outcomes.","journal":"Haematologica","issue":"2026 April 1; 111(4):1254-1264. doi: 10.3324\/haematol.2025.288721","author":"Sun S, Liu Y, Xu QY, Wang J, Chen L, Cheng Z, Gao W, Wang H, Yang B, Wang H, Wen L, Xiao J, Lou J, Yu H, Li N, Wang F, Xie Y, Wang J, Wang X, Xue H, Chen K, Wu Y, Zhang L, Li K, Shen S, Chen S, Wang HY, Wang K, Huang J, Zhu HH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41230695"},{"title01":"Understanding drug resistance in chronic myeloid leukemia through the lens of leukemic stem cell states: insights from single-cell analyses.","title02":"Understanding drug resistance in chronic myeloid leukemia through the lens of leukemic stem cell states: insights from single-cell analyses.","journal":"Haematologica","issue":"2026 April 9. doi: 10.3324\/haematol.2025.287767. Online ahead of print","author":"Krishnan V, Shyamsunder P, Ong TS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952641"},{"title01":"JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.","title02":"JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.","journal":"Haematologica","issue":"2026 April 1; 111(4):1179-1197. doi: 10.3324\/haematol.2025.288654","author":"Vachhani P, Mesa R, Mascarenhas J, Rampal R, Oh ST, Vannucchi AM, Fox ML, Palandri F, Passamonti F, Kiladjian JJ, Azimi M, Harrison C, Bose P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262043"},{"title01":"Human cytomegalovirus control in allogeneic stem cell transplant recipients in the letermovir era &#8211; emerging humoral and cellular players.","title02":"Human cytomegalovirus control in allogeneic stem cell transplant recipients in the letermovir era &#8211; emerging humoral and cellular players.","journal":"Haematologica","issue":"2026 April 1; 111(4):1265-1279. doi: 10.3324\/haematol.2025.288237","author":"Lauruschkat CD, Gorge H, Knies K, Weissbrich B, Dolken L, Kochel C, Imhof N, Huber M, Hengel H, Einsele H, Wurster S, Kraus S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307128"},{"title01":"Role of donor regulatory T-cell adoptive immunotherapy in B-cell immunity after hematopoietic cell transplantation.","title02":"Role of donor regulatory T-cell adoptive immunotherapy in B-cell immunity after hematopoietic cell transplantation.","journal":"Haematologica","issue":"2026 April 1; 111(4):1404-1410. doi: 10.3324\/haematol.2024.286905","author":"Piccinelli S, Limongello R, Viglione V, Hohxa E, Zei T, Ostini RI, Bigerna B, Tabarrini A, Sembenico R, Tricarico S, Zorutti F, Martelli MP, Carotti A, Martelli MF, Velardi A, Ruggeri L, Mancusi A, Pierini A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195519"},{"title01":"Proteomic analysis of pericardial effusions in hematopoietic stem cell transplant recipients.","title02":"Proteomic analysis of pericardial effusions in hematopoietic stem cell transplant recipients.","journal":"Haematologica","issue":"2026 April 1; 111(4):1484-1489. doi: 10.3324\/haematol.2025.289076","author":"Koo J, Webster A, Lake KE, Luebbering N, Dandoy C, Jodele S, Ryan TD, Davies SM, Sabulski A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195509"},{"title01":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: A 25-year nationwide study.","title02":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: A 25-year nationwide study.","journal":"Br J Haematol","issue":"2026 April 5. doi: 10.1111\/bjh.70463. Online ahead of print","author":"Itonaga H, Miyazaki Y, Tachi N, Kurosawa S, Marumo A, Konuma T, Ebina T, Doki N, Uchida N, Fukuda T, Nishida T, Katayama Y, Asada N, Sakurai M, Maeda T, Eto T, Tanaka M, Nakamae H, Onizuka M, Kawamura K, Kanda Y, Atsuta Y, Tachibana T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41937388"},{"title01":"Inclusion of Thiotepa in Myeloablative Regimens Improves Donor Chimerism in Children with Inborn Errors of Immunity or Inherited Metabolic Disorders.","title02":"Inclusion of Thiotepa in Myeloablative Regimens Improves Donor Chimerism in Children with Inborn Errors of Immunity or Inherited Metabolic Disorders.","journal":"Br J Haematol","issue":"2026 April 15. doi: 10.1111\/bjh.70486. Online ahead of print","author":"McComb C, Pai V, Stanek J, Rankin AW, Lamb M, Bhunia N, Bajwa R, Abu-Arja R, Rangarajan HG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41983326"},{"title01":"Serotherapy in transplant: Getting it right!","title02":"Serotherapy in transplant: Getting it right!","journal":"Br J Haematol","issue":"2026 April 6. doi: 10.1111\/bjh.70456. Online ahead of print","author":"Wynn R, Admiraal R, Lindemans C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41937680"},{"title01":"Precision immune-guided management of cytomegalovirus (CMV) after allogeneic haematopoietic stem cell transplantation in the letermovir era: A pragmatic framework.","title02":"Precision immune-guided management of cytomegalovirus (CMV) after allogeneic haematopoietic stem cell transplantation in the letermovir era: A pragmatic framework.","journal":"Br J Haematol","issue":"2026 April; 208(4):1482-1485. doi: 10.1111\/bjh.70327","author":"Jiang X, Xu Z, Wang H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41536163"},{"title01":"Dose de-escalation of alemtuzumab in matched unrelated donor haematopoietic stem cell transplantation.","title02":"Dose de-escalation of alemtuzumab in matched unrelated donor haematopoietic stem cell transplantation.","journal":"Br J Haematol","issue":"2026 April; 208(4):1477-1481. doi: 10.1111\/bjh.70318","author":"Madkhali MM, Mitchell A, Wright C, Pearce K, Aku S, Pagan S, Duncan L, Lam J, Macdonald J, Milne P, Publicover A, Hurst E, Bigley V, Hale G, Collin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41508744"},{"title01":"Treosulfan-fludarabine conditioning in infants with severe combined immunodeficiencies: Extended study of the UK paediatric treosulfan study.","title02":"Treosulfan-fludarabine conditioning in infants with severe combined immunodeficiencies: Extended study of the UK paediatric treosulfan study.","journal":"Br J Haematol","issue":"2026 April 10. doi: 10.1111\/bjh.70453. Online ahead of print","author":"Lum SH, Greener S, Memon IL, Amrolia P, Nademi Z, Chiesa R, Silva J, Young H, Owens S, Williams E, Ng KF, Flood T, Gennery AR, Hambleton S, Rao K, Slatter M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41958357"},{"title01":"Contrasting impacts of pretransplant cytoreduction and post-transplant maintenance on outcomes of allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromes: Real-world multicentre evidence.","title02":"Contrasting impacts of pretransplant cytoreduction and post-transplant maintenance on outcomes of allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromes: Real-world multicentre evidence.","journal":"Br J Haematol","issue":"2026 April 10. doi: 10.1111\/bjh.70477. Online ahead of print","author":"Chen Y, Zhang X, Shen N, Zhang J, Guo R, Xing H, Han L, Liu Y, Tian W, Wang M, Xie X, Jiang Z, Wan D, Zhou X, Xu H, Qin L, Shi W, Cao W, Bian Z","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41960892"},{"title01":"Immune-related toxicity profile after haematopoietic stem cell transplantation in patients with B-ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab.","title02":"Immune-related toxicity profile after haematopoietic stem cell transplantation in patients with B-ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab.","journal":"Br J Haematol","issue":"2026 April; 208(4):1462-1466. doi: 10.1111\/bjh.70350","author":"Okeleji O, McCall D, Cuglievan B, Gibson A, Petropoulos D, Tewari P, Connors J, Sheikh IN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41582414"},{"title01":"Targeting Aurora kinase A to prevent GVHD and relapse after myeloablative allogeneic hematopoietic cell transplantation.","title02":"Targeting Aurora kinase A to prevent GVHD and relapse after myeloablative allogeneic hematopoietic cell transplantation.","journal":"Blood advances","issue":"2026 April 14; 10(7):2190-2201. doi: 10.1182\/bloodadvances.2025017360","author":"Holtan SG, Grover P, Walton K, El Jurdi N, Quinones V, Maakaron JE, Juckett MB, Bachanova V, Hou JH, Terezakis S, Myers TJ, Paradiso LJ, DeFor TE, Cao Q, Betts BC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592279"},{"title01":"Allogeneic hematopoietic stem cell transplantation in ERCC6L2 disease.","title02":"Allogeneic hematopoietic stem cell transplantation in ERCC6L2 disease.","journal":"Blood advances","issue":"2026 April 14; 10(7):2525-2537. doi: 10.1182\/bloodadvances.2025018349","author":"Hakkarainen M, Sicre de Fontbrune F, Kaaja I, Douglas S, Dalle JH, Risitano AM, Kulasekararaj A, Alsultan A, Cutler C, Ho VT, Hellstrom-Lindberg E, Mielke S, Myhre AE, Rihani R, Shanap MA, Hashem H, Shimamura A, Rowe RG, Auer F, Beier F, Desnica L, Hough R, Ali Jafri SR, Ayas M, Jardine L, Mellid EF, Corrales I, Richardson D, Ozbek NY, Zaniewska-Tekieli A, Gozdzik J, Ryhanen S, Niinimaki R, Jahnukainen K, Salmenniemi U, Kilpivaara O, Wartiovaara-Kautto U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628318"},{"title01":"Gastrin for the treatment of acute graft-versus-host disease of the stomach.","title02":"Gastrin for the treatment of acute graft-versus-host disease of the stomach.","journal":"Blood","issue":"2026 April 9; 147(15):1763-1778. doi: 10.1182\/blood.2025031080","author":"Gawron J, Czech M, Ruckert T, Holzmuller V, Andreev G, Burk AC, Hartmann A, Chatterjee S, Andrieux G, Marquard FE, Baur AS, Stell AV, Krausz M, Braun LM, Osswald N, Melchinger W, Wertheimer T, Proano-Vasco AI, Maas-Bauer K, Schmitt-Graeff A, Boerries M, Kohler N, Ayuk F, Schell C, Quante M, Zeiser R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41511880"},{"title01":"Turning off SP140 to turn on HSCs.","title02":"Turning off SP140 to turn on HSCs.","journal":"Blood","issue":"2026 April 2; 147(14):1511-1513. doi: 10.1182\/blood.2025032459","author":"Juster S, Gottgens B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41926141"},{"title01":"Chronic active Epstein-Barr virus disease: molecular pathogenesis, evolving concepts, and emerging therapies.","title02":"Chronic active Epstein-Barr virus disease: molecular pathogenesis, evolving concepts, and emerging therapies.","journal":"Blood","issue":"2026 April 2; 147(14):1562-1573. doi: 10.1182\/blood.2025032277","author":"Kimura H, Cohen JI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490284"},{"title01":"CD28(+) CD8(+) Tem cells with a STAT1-dependent glucocorticoid receptor deficit contribute to steroid-refractory acute GVHD.","title02":"CD28(+) CD8(+) Tem cells with a STAT1-dependent glucocorticoid receptor deficit contribute to steroid-refractory acute GVHD.","journal":"Blood","issue":"2026 April 14. doi: 10.1182\/blood.2025032587. Online ahead of print","author":"Pan Z, Deng Y, Huang J, Bian H, Chen Y, Huang A, Jiang C, Wang L, Zhang Z, Lu H, Li S, Yin T, Yu S, Zhu J, Zhao WL, Wang J, Ji J, Xu Y, Cheng H, Chen J, Hu H, Hu X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41980031"},{"title01":"Transient SP140 inhibition unlocks hematopoietic stem cell fate from human pluripotent stem cells.","title02":"Transient SP140 inhibition unlocks hematopoietic stem cell fate from human pluripotent stem cells.","journal":"Blood","issue":"2026 April 2; 147(14):1584-1597. doi: 10.1182\/blood.2025032084","author":"Liu X, Zhang Z, Cui X, Guo R, Ding X, Ma L, Liu P, Yu Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41397285"},{"title01":"Charting human developmental hematopoiesis in vitro to open new routes for regenerative medicine.","title02":"Charting human developmental hematopoiesis in vitro to open new routes for regenerative medicine.","journal":"Blood","issue":"2026 April 9; 147(15):1680-1692. doi: 10.1182\/blood.2024028063","author":"Castiglioni C, Piussi R, Ditadi A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41481376"},{"title01":"Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing.","title02":"Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing.","journal":"Leukemia","issue":"2026 April; 40(4):783-793. doi: 10.1038\/s41375-026-02892-8","author":"Jutzi JS, Crosse E, Kim CJ, van Gasteren B, Laurore C, Rolles B, Kramer F, Tishena A, Rocha AV, Wazir M, Weeks LD, How J, Stahl M, Luskin MR, Lindsley RC, Pozdnyakova O, Rai S, Graubert TA, Bradley RK, Mullally A, Marneth AE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41748695"},{"title01":"Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease.","title02":"Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease.","journal":"N Engl J Med","issue":"2026 April 1. doi: 10.1056\/NEJMoa2504835. Online ahead of print","author":"Gupta AO, Sharma A, Frangoul H, Kanter J, Mapara MY, Dalal J, Alavi A, Jaroscak JJ, Ayala E, DiPersio JF, Ziga ED, Eapen M, Rifkin-Zenenberg S, Minella AC, Chen Y, Chesler S, Ambati S, Bowman TS, Habtemariam B, Joseney-Antoine M, Chockalingam PS, Lin L, Goyal S, Simon A, Thompson AA, Heeney MM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41931046"},{"title01":"Updated anaemia estimates: implications for global monitoring.","title02":"Updated anaemia estimates: implications for global monitoring.","journal":"Lancet Haematol","issue":"2026 April; 13(4):e188-e189. doi: 10.1016\/S2352-3026(26)00040-2","author":"Leung S, Pasricha SR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41934986"},{"title01":"Pyruvate kinase activators in hereditary haemolytic anaemias: current evidence and clinical potential.","title02":"Pyruvate kinase activators in hereditary haemolytic anaemias: current evidence and clinical potential.","journal":"Lancet","issue":"2026 April 4; 407(10536):1383-1396. doi: 10.1016\/S0140-6736(26)00150-9","author":"Doeven T, Glenthoj A, Grace RF, van Beers EJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41833294"},{"title01":"Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant.","title02":"Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant.","journal":"Blood","issue":"2026 April 14. doi: 10.1182\/blood.2025032757. Online ahead of print","author":"Zent CS, Tiacci E, Kreitman RJ, Tadmor T, Tallman MS, Wormann BJ, Andritsos LA, Arons E, Banerji V, Barrientos JC, Bhat SA, Blachly JS, Broccoli A, Call TG, Dearden C, Demeter J, Dietrich S, El-Sharkawi D, Fagarasanu A, Falini B, Forconi F, Gerrie AS, Gladstone DE, Gozzetti A, Hampel PJ, Hermel DJ, Iyengar S, Johnston JB, Juliusson G, Kipps TJ, Lauria F, Lozanski G, Parikh SA, Park JH, Polliack A, Quest G, Rai KR, Ravandi F, Robak T Prof, Rogers KA, Saven A, Seymour JF, Tam CS, Troussard X, Zenz T, Zinzani PL, Grever MR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41980020"},{"title01":"Clonal hematopoiesis and lymphoma-associated mutations in hematopoietic progenitors in B-cell non-Hodgkin lymphoma.","title02":"Clonal hematopoiesis and lymphoma-associated mutations in hematopoietic progenitors in B-cell non-Hodgkin lymphoma.","journal":"Blood","issue":"2026 April 9; 147(15):1723-1734. doi: 10.1182\/blood.2025030489","author":"Wiegand L, Silva P, Noerenberg D, Christen F, Kopp K, Locher BN, Lowe P, Tilgner M, Altwasser R, Storzer V, Stein CM, Briest F, Arends CM, Frick M, Ihlow J, Dolnik A, Ishaque N, Keller U, Na IK, Penter L, Bullinger L, Hablesreiter R, Damm F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490454"},{"title01":"Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma.","title02":"Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma.","journal":"Blood","issue":"2026 April 9; 147(15):1713-1722. doi: 10.1182\/blood.2025030190","author":"Abramson JS, Straus DJ, Bartlett NL, Burke JM, Lynch RC, Domingo Domenech E, Hess B, Schuster SR, Linhares Y, Gandhi M, Shah HR, Jurczak W, Re A, Hahn U, Prince HM, Guo W, Davis G, Ho L, Fanale M, Yasenchak CA, Lee HJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41460964"},{"title01":"The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.","title02":"The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.","journal":"Leukemia","issue":"2026 April; 40(4):730-738. doi: 10.1038\/s41375-026-02889-3","author":"Riedhammer C, Truger M, Lee H, Leypoldt LB, Meggendorfer M, Hutter S, Muller H, Mersi J, Kadel SK, Buchwald T, Kosch R, Helal M, Afrin N, Rosenwald A, Gerhard-Hartmann E, Brioli A, Kronke J, Haferlach T, Haferlach C, Weisel KC, Neri P, Einsele H, Kortum KM, Waldschmidt JM, Bahlis N, Weinhold N, Rasche L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703032"},{"title01":"An otherwise smouldering multiple myeloma with a solitary osteolytic lesion and soft-tissue mass.","title02":"An otherwise smouldering multiple myeloma with a solitary osteolytic lesion and soft-tissue mass.","journal":"Lancet Haematol","issue":"2026 April 2. doi: 10.1016\/S2352-3026(26)00015-3. Online ahead of print","author":"Piperidou A, Rondogianni P, Zorbala A, Korkolopoulou P, Kontogeorgakos V, Vassilakopoulos TP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41936370"},{"title01":"Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.","title02":"Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.","journal":"Lancet Haematol","issue":"2026 April; 13(4):e241-e253. doi: 10.1016\/S2352-3026(26)00011-6","author":"Dytfeld D, Wrobel T, Jamroziak K, Kubicki T, Robak P, Pula A, Walter-Croneck A, Czyz J, Tyczynska A, Druzd-Sitek A, Giannopoulos K, Nowicki A, Szczepaniak T, Lojko-Dankowska A, Matuszak M, Gil L, Pula B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski L, Konska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Lahoud OB, Zonder JA, Cooperrider JH, Derman BA, Karrison T, Jakubowiak AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41831471"},{"title01":"Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).","title02":"Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).","journal":"J Clin Oncol","issue":"2026 April 10; 44(11):992-1002. doi: 10.1200\/JCO-25-01969","author":"Yan W, Du C, Lv R, Zou H, Zhang S, Yu T, Yan Y, Zhang Y, Peng S, Wang T, Deng S, Huang W, Yi S, Zou D, Cheng T, Wang J, Chang AH, Qiu L, An G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41759038"},{"title01":"Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.","title02":"Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.","journal":"J Clin Oncol","issue":"2026 April; 44(10):914-941. doi: 10.1200\/JCO-25-02587","author":"Hicks LK, Messersmith HJ, Al Hadidi S, Banerjee R, Derman BA, Kumar S, Wildes TM, Bal S, Bhella S, Chmielewski C, Costello C, Dabney R, Hartley-Brown M, Langerak A, Lipe B, Martin T, McCurdy A, Mian H, Riva E, Seth R, Subramanian L, Mikhael J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41494138"},{"title01":"Past, Present, and Future of Dexamethasone in Multiple Myeloma and AL Amyloidosis.","title02":"Past, Present, and Future of Dexamethasone in Multiple Myeloma and AL Amyloidosis.","journal":"J Clin Oncol","issue":"2026 April; 44(10):903-913. doi: 10.1200\/JCO-25-01713","author":"Banerjee R, King T, Faiman B, Harding S, Rosenberg AS, Sanchorawala V, Mikhael JR, Cowan AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592262"},{"title01":"The genetic landscape of extramedullary plasmacytoma: a comparative analysis with extramedullary disease of multiple myeloma.","title02":"The genetic landscape of extramedullary plasmacytoma: a comparative analysis with extramedullary disease of multiple myeloma.","journal":"Haematologica","issue":"2026 April 9. doi: 10.3324\/haematol.2025.300201. Online ahead of print","author":"Vogelsberg A, Salmeron-Villalobos J, Wilhelmi AL, Otto F, Schneider A, Mankel B, Bag E, Colmenero A, Dettmer MS, Narbaitz M, Tzankov A, Salaverria I, Bonzheim I, Fend F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952616"},{"title01":"Therapeutic inhibition of myeloperoxidase with AZD5904 attenuates disease progression in mouse models of early-stage and relapsed multiple myeloma.","title02":"Therapeutic inhibition of myeloperoxidase with AZD5904 attenuates disease progression in mouse models of early-stage and relapsed multiple myeloma.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2025.300383. Online ahead of print","author":"Williams CMD, Noll JE, Harnas D, Parkinson HB, Hewett DR, Zannettino ACW, Vandyke K, Cox TR, Panagopoulos V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924905"},{"title01":"Phenotypic evolution of circulating plasma cells from early precursor stages to multiple myeloma.","title02":"Phenotypic evolution of circulating plasma cells from early precursor stages to multiple myeloma.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2025.300105. Online ahead of print","author":"Pietzsch M, Beer SA, Kimmich LM, Windsor C, Gekeler S, Besemer B, Stanger AMP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924901"},{"title01":"TE-1146, a novel anti-CD38-antibody-lenalidomide conjugate, demonstrates potent ex vivo anti-myeloma activity.","title02":"TE-1146, a novel anti-CD38-antibody-lenalidomide conjugate, demonstrates potent ex vivo anti-myeloma activity.","journal":"Haematologica","issue":"2026 April 1; 111(4):1474-1477. doi: 10.3324\/haematol.2025.288692","author":"Cheng SS, Jiang JG, Lin SC, Yu YH, Chang TW, Lim C, Yu YB, Chu HM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195521"},{"title01":"Single-cell analysis unveils distinct transcriptional alterations and cellular origins in IgD multiple myeloma.","title02":"Single-cell analysis unveils distinct transcriptional alterations and cellular origins in IgD multiple myeloma.","journal":"Haematologica","issue":"2026 April 1; 111(4):1449-1454. doi: 10.3324\/haematol.2025.288418","author":"Luo T, Zhou X, Chen X, Liu J, Yang Y, Hu X, Li J, Du J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41163585"},{"title01":"Ixazomib maintenance therapy in transplant-eligible multiple myeloma: real-world evidence from three large German centers.","title02":"Ixazomib maintenance therapy in transplant-eligible multiple myeloma: real-world evidence from three large German centers.","journal":"Haematologica","issue":"2026 April 1; 111(4):1432-1435. doi: 10.3324\/haematol.2025.288320","author":"May P, Rassner M, Hoegner M, Shahbaz W, Wasch R, Martinez AMG, Schmidt B, Theurich S, Engelhardt M, Bassermann F, Jung J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41098101"},{"title01":"Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial.","title02":"Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial.","journal":"Br J Haematol","issue":"2026 April 14. doi: 10.1111\/bjh.70479. Online ahead of print","author":"Delimpasi S, Spicka I, Butler JP, Stevens DA, Mesa MG, Bygrave C, Merlo GM, la Porte C, Dimopoulos MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41978554"},{"title01":"Venous thromboembolism in patients with multiple myeloma treated with B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy: A systematic review.","title02":"Venous thromboembolism in patients with multiple myeloma treated with B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy: A systematic review.","journal":"Br J Haematol","issue":"2026 April; 208(4):1454-1457. doi: 10.1111\/bjh.70356","author":"Las Casas PHFDC, Marco-Ayala J, Lefkou EE, Soares TS, Baghdadi MA, Kempaiah P, Fareed J, Vandreden P, Hungria V, Marchetti M, Falanga A, Garderet L, Gerotziafas G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41622574"},{"title01":"Daratumumab or active observation for asymptomatic biochemical relapse in patients with multiple myeloma.","title02":"Daratumumab or active observation for asymptomatic biochemical relapse in patients with multiple myeloma.","journal":"Br J Haematol","issue":"2026 April; 208(4):1314-1323. doi: 10.1111\/bjh.70373","author":"Jamroziak K, Dytfeld D, Kubicki T, Dutka M, Wrobel T, Giannopoulos K, Konska A, Druzd-Sitek A, Tyczynska A, Olszewska-Szopa M, Morawska M, Szeremet A, Kopinska A, Wisniewski K, Czyz J, Helbig G, Gil L, Zaucha JM, Kruk-Kwapisz D, Walewski J, Gorecki T, Pula B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41704058"},{"title01":"Resumption of bone-modifying agents in relapsed multiple myeloma does not improve outcomes: A real-world analysis.","title02":"Resumption of bone-modifying agents in relapsed multiple myeloma does not improve outcomes: A real-world analysis.","journal":"Br J Haematol","issue":"2026 April; 208(4):1324-1330. doi: 10.1111\/bjh.70395","author":"Su M, Khan AM, Cowan AJ, Anderson LD Jr, Kaur G, Banerjee R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733330"},{"title01":"The shape-shifting plasma cell: Multiple myeloma with CKS1B amplification.","title02":"The shape-shifting plasma cell: Multiple myeloma with CKS1B amplification.","journal":"Br J Haematol","issue":"2026 April; 208(4):1179-1180. doi: 10.1111\/bjh.70376","author":"Amiot Q, Assadi-Gazvini C, Bugier S, Arnautou P, Maillot J, Malfuson JV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41797264"},{"title01":"Biochemical bone biomarkers in plasma cell dyscrasias for the British Journal of Haematology.","title02":"Biochemical bone biomarkers in plasma cell dyscrasias for the British Journal of Haematology.","journal":"Br J Haematol","issue":"2026 April 8. doi: 10.1111\/bjh.70467. Online ahead of print","author":"Nador G, Vijjhalwar R, Javaid MK, Edwards CM, Ramasamy K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41948808"},{"title01":"HAT-PCR is non-inferior to NGS when quantifying measurable residual disease for myeloma.","title02":"HAT-PCR is non-inferior to NGS when quantifying measurable residual disease for myeloma.","journal":"Br J Haematol","issue":"2026 April 8. doi: 10.1111\/bjh.70478. Online ahead of print","author":"Hughes E, Blombery P, Kannan S, Khong T, Spencer A, Morley A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41947647"},{"title01":"Cytomegalovirus reactivation in multiple myeloma patients receiving bispecific antibodies.","title02":"Cytomegalovirus reactivation in multiple myeloma patients receiving bispecific antibodies.","journal":"Blood advances","issue":"2026 April 6. doi: 10.1182\/bloodadvances.2025019563. Online ahead of print","author":"Sastre-Escola E, Reynolds GK, Yong MK, Zhu V, Harrison SJ, Khot AS, Slavin MA, Teh BW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41941693"},{"title01":"Point: CAR-T therapy is the preferred option in relapsed\/refractory multiple myeloma.","title02":"Point: CAR-T therapy is the preferred option in relapsed\/refractory multiple myeloma.","journal":"Blood advances","issue":"2026 April 13. doi: 10.1182\/bloodadvances.2026019898. Online ahead of print","author":"Banerjee R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41973829"},{"title01":"IL-6-driven POU2AF1 and ELL2 are key regulators of multiple myeloma-distinct transcriptional and splicing programs.","title02":"IL-6-driven POU2AF1 and ELL2 are key regulators of multiple myeloma-distinct transcriptional and splicing programs.","journal":"Blood advances","issue":"2026 April 2. doi: 10.1182\/bloodadvances.2025018710. Online ahead of print","author":"Ohguchi Y, Ajiro M, Ogiya D, Masuda T, Kawano Y, Usuki S, Koga T, Hino S Dr, Harada T, Takahashi S, Okada S, Yasunaga JI, Sashida G, Ohtsuki S, Nakao M, Minami T, Yoshimi A, Ohguchi H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41925579"},{"title01":"Significant burden of low-grade infections in patients treated with T-cell-engaging therapies for multiple myeloma.","title02":"Significant burden of low-grade infections in patients treated with T-cell-engaging therapies for multiple myeloma.","journal":"Blood advances","issue":"2026 April 14; 10(7):2244-2248. doi: 10.1182\/bloodadvances.2025017889","author":"Mersi J, Burow L, Zhou X, Eisele F, Fante M, Riedhammer C, Stich A, Isberner N, Afrin N, Duell J, Topp MS, Einsele H, Waldschmidt J, Kortum KM, Rasche L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610311"},{"title01":"BCMA\/CD19 dual-targeting CAR T cell therapy in older patients with newly diagnosed multiple myeloma: a phase I study.","title02":"BCMA\/CD19 dual-targeting CAR T cell therapy in older patients with newly diagnosed multiple myeloma: a phase I study.","journal":"Blood advances","issue":"2026 April 2. doi: 10.1182\/bloodadvances.2025019036. Online ahead of print","author":"Liu J, Fan X, Peng L, Liu J, He H, Qiang W, Jin L, Shi L, Lu J, Guo P, Shah N, Zhang Q, Shen L, Du J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41925575"},{"title01":"Breaking new ground with antibody-drug conjugates in myeloma.","title02":"Breaking new ground with antibody-drug conjugates in myeloma.","journal":"Blood","issue":"2026 April 2; 147(14):1510-1511. doi: 10.1182\/blood.2025032443","author":"Usmani SZ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41926146"},{"title01":"Venetoclax in myeloma: t(11;14) and what else?","title02":"Venetoclax in myeloma: t(11;14) and what else?","journal":"Blood","issue":"2026 April 2; 147(14):1513-1515. doi: 10.1182\/blood.2025032670","author":"Pellat-Deceunynck C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41926144"},{"title01":"Tunneling Nanotube-Mediated Filamin A Transport Mechanosensitively Programs Osteoclastogenesis in Myeloma Bone Disease.","title02":"Tunneling Nanotube-Mediated Filamin A Transport Mechanosensitively Programs Osteoclastogenesis in Myeloma Bone Disease.","journal":"Blood","issue":"2026 April 8. doi: 10.1182\/blood.2025031627. Online ahead of print","author":"Guo J, Wang J, Xie Y, Wang Y, Peng Z, Wang M, Cheng H, Li T, Jia L, Xu H, Su D, Qiao M, Liu H, Li X, Li W, Wu D, Huang J, Bergsagel PL, Li F, Zhao Z, Liu Z","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41950002"},{"title01":"Phase 1\/1b study of BCMA-targeting bispecific T-cell engager pavurutamab in relapsed\/refractory multiple myeloma.","title02":"Phase 1\/1b study of BCMA-targeting bispecific T-cell engager pavurutamab in relapsed\/refractory multiple myeloma.","journal":"Blood","issue":"2026 April 8. doi: 10.1182\/blood.2025032044. Online ahead of print","author":"Lee HC, Plattel WJ, Harrison SJ, Sborov DW, Lentzsch S, Spencer A, Niesvizky R, Trudel S, Mollee P, Vij R, Minnema MC, Rasche L, Upreti VV, Zhou D, Xia Q, Talpes M, Eggert T, Kapoor P, Ailawadhi S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41950113"},{"title01":"Belantamab mafodotin, lenalidomide, and dexamethasone for intermediate-fit and frail patients with newly diagnosed myeloma.","title02":"Belantamab mafodotin, lenalidomide, and dexamethasone for intermediate-fit and frail patients with newly diagnosed myeloma.","journal":"Blood","issue":"2026 April 2; 147(14):1574-1583. doi: 10.1182\/blood.2025031629","author":"Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Malandrakis P, Fotiou D, Kanellias N, Migkou M, Theodorakakou F, Spiliopoulou V, Solia E, Eleutherakis-Papaiakovou E, Psarros G, Kastritis E, Dimopoulos MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41346230"},{"title01":"Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH).","title02":"Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH).","journal":"Blood","issue":"2026 April 2; 147(14):1598-1610. doi: 10.1182\/blood.2025029996","author":"Kaddoura M, Wiedmeier-Nutor JE, Gupta VA, Jelinek T, Ziccheddu B, Shivaram S, Tang H, Owens RW, Sevcikova T, Fonseca R, Durante M, Diamond B, Zhao L, Zhu YX, Shi CX, Matulis SM, Mitsiades CS, Landgren O, Usmani S, Hajek R, Chesi M, Bergsagel PL, Braggio E, Boise LH, Fonseca R, Kumar S, Maura F, Baughn LB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41481388"},{"title01":"CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease.","title02":"CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease.","journal":"N Engl J Med","issue":"2026 April 2; 394(13):1281-1291. doi: 10.1056\/NEJMoa2415550","author":"Hanna R, Frangoul H, Pineiro L, McKinney C, Mapara M, Dalal J, Rangarajan HG, Atkins H, Sharma A, Chang KH, Jaskolka MC, Kim K, Yu Q, Mei B, Afonja O, Walters MC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41931047"},{"title01":"Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.","title02":"Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.","journal":"Lancet Haematol","issue":"2026 April; 13(4):e241-e253. doi: 10.1016\/S2352-3026(26)00011-6","author":"Dytfeld D, Wrobel T, Jamroziak K, Kubicki T, Robak P, Pula A, Walter-Croneck A, Czyz J, Tyczynska A, Druzd-Sitek A, Giannopoulos K, Nowicki A, Szczepaniak T, Lojko-Dankowska A, Matuszak M, Gil L, Pula B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski L, Konska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Lahoud OB, Zonder JA, Cooperrider JH, Derman BA, Karrison T, Jakubowiak AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41831471"},{"title01":"First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.","title02":"First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.","journal":"J Clin Oncol","issue":"2026 April 6; JCO2501966. doi: 10.1200\/JCO-25-01966. Online ahead of print","author":"Rettinger E, Heckl D, Hutter M, Salzmann-Manrique E, Luedtke M, Huenecke S, Bremm M, Cappel C, Bug G, Greil J, Meisel R, Wagner-Drouet EM, Serve H, Gungor T, Klusmann JH, Klingebiel T, Bader P, Bonig H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41941697"},{"title01":"Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).","title02":"Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).","journal":"J Clin Oncol","issue":"2026 April 10; 44(11):992-1002. doi: 10.1200\/JCO-25-01969","author":"Yan W, Du C, Lv R, Zou H, Zhang S, Yu T, Yan Y, Zhang Y, Peng S, Wang T, Deng S, Huang W, Yi S, Zou D, Cheng T, Wang J, Chang AH, Qiu L, An G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41759038"},{"title01":"Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm.","title02":"Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm.","journal":"J Clin Oncol","issue":"2026 April; 44(10):861-873. doi: 10.1200\/JCO-25-02083","author":"Pemmaraju N, Marconi G, Montesinos P, Lane AA, Mazzarella L, Sallman DA, Ulrickson ML, Schiller GJ, Erba HP, Wang ES, Walter RB, Deconinck E, Aribi A, Legrand O, Lebon D, Maisano V, Martinelli G, DeAngelo DJ, Derenzini E, Du Y, Lakshmikanthan S, Potluri J, Kantarjian HM, Daver NG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671533"},{"title01":"Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant.","title02":"Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant.","journal":"J Clin Oncol","issue":"2026 April 10; 44(11):1003-1015. doi: 10.1200\/JCO-25-01591","author":"Liberio N, Allbee-Johnson M, Ahn KW, Moskop A, Phelan R, Shaw BE, Page KM, Schultz KR, Phillips CL, Mehta PA, Qayed M, Sharma A, Lipsitt AE, Symons H, Bolanos-Meade J, Kharbanda S, Dvorak CC, Kapoor N, Doherty EE, Chavan RS, Broglie L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41740085"},{"title01":"Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor.","title02":"Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor.","journal":"Haematologica","issue":"2026 April 1; 111(4):1246-1253. doi: 10.3324\/haematol.2025.288553","author":"Short NJ, Loghavi S, Yilmaz M, Karrar O, Kim K, Dinardo CD, Kadia TM, Maroun M, Borthakur G, Issa GC, Jabbour J, Oran B, Shpall EJ, Popat U, Patel KP, Routbort M, Konopleva M, Ravandi F, Kantarjian H, Daver N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41035402"},{"title01":"Relapsed classic Hodgkin lymphoma; should all patients receive an autologous stem cell transplant? &#8211; the PRO.","title02":"Relapsed classic Hodgkin lymphoma; should all patients receive an autologous stem cell transplant? &#8211; the PRO.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2026.300574. Online ahead of print","author":"Abeyakoon C, Kuruvilla J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924908"},{"title01":"Relapsed Hodgkin disease: Should all patients receive an autologous stem cell transplant? &#8211; the CON.","title02":"Relapsed Hodgkin disease: Should all patients receive an autologous stem cell transplant? &#8211; the CON.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2026.300566. Online ahead of print","author":"Moskowitz AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924918"},{"title01":"Preemptive hematopoietic stem cell transplantation in RUNX1 familial platelet disorder: a shared decision-making framework.","title02":"Preemptive hematopoietic stem cell transplantation in RUNX1 familial platelet disorder: a shared decision-making framework.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2025.300403. Online ahead of print","author":"Olson TS, Ericson K, Antin JH, Babbitt L, Babich M, Deuitch NT, DiNardo C, Ford PJ, Obeng EA, Stewart BL, Xiao W, Shimamura A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924923"},{"title01":"Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R.","title02":"Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R.","journal":"Haematologica","issue":"2026 April 1; 111(4):1389-1395. doi: 10.3324\/haematol.2025.288232","author":"Hess B, Moskowitz A, Davis JA, Strati P, Sawalha Y, Bakos J, Sorrell M, Ferreira AC, Escribano-Serrat S, De Castro M, Brooks TR, Hill BT, Shah GL, Falade AS, Merryman R, Kamdar M, Ip A, Nachar V, Bennett JG, Lux N, Ahmed N, Hoffmann M, LaCasce A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41163564"},{"title01":"Impact of horse anti-thymocyte globulin on graft-versus-host disease after human leukocyte antigen-matched related bone marrow transplantation for severe aplastic anemia.","title02":"Impact of horse anti-thymocyte globulin on graft-versus-host disease after human leukocyte antigen-matched related bone marrow transplantation for severe aplastic anemia.","journal":"Haematologica","issue":"2026 April 9. doi: 10.3324\/haematol.2026.300746. Online ahead of print","author":"Olivieri DJ, Gooley T, Manjappa S, Walter RB, Keel S, Flowers M, Storb R, Vo P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952636"},{"title01":"Human cytomegalovirus control in allogeneic stem cell transplant recipients in the letermovir era &#8211; emerging humoral and cellular players.","title02":"Human cytomegalovirus control in allogeneic stem cell transplant recipients in the letermovir era &#8211; emerging humoral and cellular players.","journal":"Haematologica","issue":"2026 April 1; 111(4):1265-1279. doi: 10.3324\/haematol.2025.288237","author":"Lauruschkat CD, Gorge H, Knies K, Weissbrich B, Dolken L, Kochel C, Imhof N, Huber M, Hengel H, Einsele H, Wurster S, Kraus S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307128"},{"title01":"JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.","title02":"JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.","journal":"Haematologica","issue":"2026 April 1; 111(4):1179-1197. doi: 10.3324\/haematol.2025.288654","author":"Vachhani P, Mesa R, Mascarenhas J, Rampal R, Oh ST, Vannucchi AM, Fox ML, Palandri F, Passamonti F, Kiladjian JJ, Azimi M, Harrison C, Bose P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262043"},{"title01":"The comprehensive landscape of TTMV::RARA fusiondriven acute myeloid leukemia: from viral integration mechanisms to clinical outcomes.","title02":"The comprehensive landscape of TTMV::RARA fusiondriven acute myeloid leukemia: from viral integration mechanisms to clinical outcomes.","journal":"Haematologica","issue":"2026 April 1; 111(4):1254-1264. doi: 10.3324\/haematol.2025.288721","author":"Sun S, Liu Y, Xu QY, Wang J, Chen L, Cheng Z, Gao W, Wang H, Yang B, Wang H, Wen L, Xiao J, Lou J, Yu H, Li N, Wang F, Xie Y, Wang J, Wang X, Xue H, Chen K, Wu Y, Zhang L, Li K, Shen S, Chen S, Wang HY, Wang K, Huang J, Zhu HH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41230695"},{"title01":"Proteomic analysis of pericardial effusions in hematopoietic stem cell transplant recipients.","title02":"Proteomic analysis of pericardial effusions in hematopoietic stem cell transplant recipients.","journal":"Haematologica","issue":"2026 April 1; 111(4):1484-1489. doi: 10.3324\/haematol.2025.289076","author":"Koo J, Webster A, Lake KE, Luebbering N, Dandoy C, Jodele S, Ryan TD, Davies SM, Sabulski A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195509"},{"title01":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: A 25-year nationwide study.","title02":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: A 25-year nationwide study.","journal":"Br J Haematol","issue":"2026 April 5. doi: 10.1111\/bjh.70463. Online ahead of print","author":"Itonaga H, Miyazaki Y, Tachi N, Kurosawa S, Marumo A, Konuma T, Ebina T, Doki N, Uchida N, Fukuda T, Nishida T, Katayama Y, Asada N, Sakurai M, Maeda T, Eto T, Tanaka M, Nakamae H, Onizuka M, Kawamura K, Kanda Y, Atsuta Y, Tachibana T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41937388"},{"title01":"Transplant outcomes in adolescents and young adults with Philadelphia-positive B-cell acute lymphoblastic leukaemia.","title02":"Transplant outcomes in adolescents and young adults with Philadelphia-positive B-cell acute lymphoblastic leukaemia.","journal":"Br J Haematol","issue":"2026 April; 208(4):1467-1471. doi: 10.1111\/bjh.70347","author":"Aleid M, Fakih RE, Hanbali A, Alfraih F, Alothaimeen H, Elhassan T, Alahmari A, Rasheed W, Almohareb F, Chaudhri N, Alotaibi S, Alsharif F, Shaheen M, Alhayli S, Alkhaldi H, Alyamany R, Alshaibani A, Alotaibi AS, Alamer A, Albabtain AA, Ahmed SO, Alzahrani H, Aljurf M, Saad A, Alfayez M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41582435"},{"title01":"Immune-related toxicity profile after haematopoietic stem cell transplantation in patients with B-ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab.","title02":"Immune-related toxicity profile after haematopoietic stem cell transplantation in patients with B-ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab.","journal":"Br J Haematol","issue":"2026 April; 208(4):1462-1466. doi: 10.1111\/bjh.70350","author":"Okeleji O, McCall D, Cuglievan B, Gibson A, Petropoulos D, Tewari P, Connors J, Sheikh IN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41582414"},{"title01":"Precision immune-guided management of cytomegalovirus (CMV) after allogeneic haematopoietic stem cell transplantation in the letermovir era: A pragmatic framework.","title02":"Precision immune-guided management of cytomegalovirus (CMV) after allogeneic haematopoietic stem cell transplantation in the letermovir era: A pragmatic framework.","journal":"Br J Haematol","issue":"2026 April; 208(4):1482-1485. doi: 10.1111\/bjh.70327","author":"Jiang X, Xu Z, Wang H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41536163"},{"title01":"Mycosis fungoides and Sezary syndrome.","title02":"Mycosis fungoides and Sezary syndrome.","journal":"Br J Haematol","issue":"2026 April; 208(4):1207-1210. doi: 10.1111\/bjh.70392","author":"Martins F, Calvao J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41711246"},{"title01":"HLA-E single-chain trimer shields gene-edited allogeneic CAR T Cells from NK cell attack.","title02":"HLA-E single-chain trimer shields gene-edited allogeneic CAR T Cells from NK cell attack.","journal":"Blood advances","issue":"2026 April 7. doi: 10.1182\/bloodadvances.2025016927. Online ahead of print","author":"Apodaca K, Xu C, Stanton KL, Baroja ML, Alfaro Doblado AR, Engel NW, Wellhauusen N, Cox A, Berjis A, Ji MQ, Bushara O, Melendez D, Welch C, Banerjee E, Assenmacher CA, Sheppard NC, Scholler J, June CH, Carreno BM, Linette GP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41945756"},{"title01":"Allogeneic hematopoietic stem cell transplantation in ERCC6L2 disease.","title02":"Allogeneic hematopoietic stem cell transplantation in ERCC6L2 disease.","journal":"Blood advances","issue":"2026 April 14; 10(7):2525-2537. doi: 10.1182\/bloodadvances.2025018349","author":"Hakkarainen M, Sicre de Fontbrune F, Kaaja I, Douglas S, Dalle JH, Risitano AM, Kulasekararaj A, Alsultan A, Cutler C, Ho VT, Hellstrom-Lindberg E, Mielke S, Myhre AE, Rihani R, Shanap MA, Hashem H, Shimamura A, Rowe RG, Auer F, Beier F, Desnica L, Hough R, Ali Jafri SR, Ayas M, Jardine L, Mellid EF, Corrales I, Richardson D, Ozbek NY, Zaniewska-Tekieli A, Gozdzik J, Ryhanen S, Niinimaki R, Jahnukainen K, Salmenniemi U, Kilpivaara O, Wartiovaara-Kautto U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628318"},{"title01":"Diagnosis and management of immune effector cell-associated enterocolitis (IEC-EC) following ciltacabtagene autoleucel.","title02":"Diagnosis and management of immune effector cell-associated enterocolitis (IEC-EC) following ciltacabtagene autoleucel.","journal":"Blood advances","issue":"2026 April 10. doi: 10.1182\/bloodadvances.2025018853. Online ahead of print","author":"Lim KJ, Lee HE, Chen ZE, Bledsoe A, Parrondo RD, Chhabra S, Dooley K, De Menezes Silva Corraes A, Gertz MA, Hwa YL, Stephens H, Kapoor P, Tan MS, Kourelis TV, Warsame R, Cook J, Binder M, Bergsagel PL, Yadav U, Wiedmeier-Nutor JE, Geyer S, Ailawadhi S, Fonseca R, Kumar SK, Chowla N, Lin Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41961998"},{"title01":"Quizartinib in newly diagnosed patients with FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.","title02":"Quizartinib in newly diagnosed patients with FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.","journal":"Blood advances","issue":"2026 April 8. doi: 10.1182\/bloodadvances.2025017738. Online ahead of print","author":"Levis MJ, Erba HP, Montesinos P, Patkowska E, Cortes JE, Perl AE, Dombret H, Amadori S, Wang J, Schlenk RF, Liu L, Mostafa Kamel Y, Imadalou K, Laadem A, Burns K, Sekeres MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41949390"},{"title01":"Patient characteristics and treatment outcomes in marginal zone lymphoma: results of the prospective German MZL registry.","title02":"Patient characteristics and treatment outcomes in marginal zone lymphoma: results of the prospective German MZL registry.","journal":"Leukemia","issue":"2026 April; 40(4):845-850. doi: 10.1038\/s41375-026-02869-7","author":"Grunenberg A, Schmelzle B, Gokeler J, Mund H, Viardot A, Dreyhaupt J, Nagel G, Reiser M, Gabrysiak T, Braulke F, Dunst J, Schlag R, Gaska T, Runde V, Kraemer D, Weber T, Mueller L, Johansson P, Ziske C, Hess G, Liersch R, Buske C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41792439"},{"title01":"Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma.","title02":"Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma.","journal":"Leukemia","issue":"2026 April; 40(4):759-772. doi: 10.1038\/s41375-026-02868-8","author":"Filip D, Litzmanova K, Michaelou A, Kledus F, Devan J, Boudny M, Hoferkova E, Sharma S, Seda V, Zeni PF, Borsky M, Matulova K, Kren L, Oppelt J, Blavet N, Hejret V, Urik M, Mareckova A, Rimsza LM, Kamaradova K, Belada D, Sykorova A, Mocikova H, Trneny M, Prouzova Z, Evans AG, Danilov A, Horn H, Ott G, Staber P, Mayer J, Friedberg JW, Janikova A, Mraz M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41714403"},{"title01":"Pre-diagnostic clonal hematopoiesis of indeterminate potential among patients with a primary cancer and risk of second cancers.","title02":"Pre-diagnostic clonal hematopoiesis of indeterminate potential among patients with a primary cancer and risk of second cancers.","journal":"Leukemia","issue":"2026 April 14. doi: 10.1038\/s41375-026-02946-x. Online ahead of print","author":"Liu X, Adami HO, Boberg E, Smedby KE, Wei H, Fang F, Liu Q","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41981103"},{"title01":"Targeting of ibrutinib resistance-driving pathways by miR-28 in ABC-DLBCL.","title02":"Targeting of ibrutinib resistance-driving pathways by miR-28 in ABC-DLBCL.","journal":"Leukemia","issue":"2026 April 8. doi: 10.1038\/s41375-026-02948-9. Online ahead of print","author":"Alvarez-Corrales E, Moreno-Palomares R, Gomez-Escolar C, Martinez M, Moral-Perez U, Laguna-Herrero M, Fuertes T, Estrada BS, Mur S, de Bonis A, Leiva M, Martinez-Martin N, Somoza A, Ramiro AR, de Yebenes VG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41951939"},{"title01":"CD40\/PI3K\/FOXO1 axis rewiring drives microenvironment-dependent BIM silencing to sustain lymphoma growth and survival.","title02":"CD40\/PI3K\/FOXO1 axis rewiring drives microenvironment-dependent BIM silencing to sustain lymphoma growth and survival.","journal":"Leukemia","issue":"2026 April; 40(4):739-750. doi: 10.1038\/s41375-026-02894-6","author":"Madiot C, Bellanger C, Dousset C, Decombis S, Thirouard L, Papin A, Baron E, Barc J, Le Bris Y, Gomez-Bougie P, Moreau-Aubry A, Tessoulin B, Pellat-Deceunynck C, Chiron D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41714404"},{"title01":"Evolving therapeutic strategies in mantle cell lymphoma: advancements and future directions.","title02":"Evolving therapeutic strategies in mantle cell lymphoma: advancements and future directions.","journal":"Leukemia","issue":"2026 April 15. doi: 10.1038\/s41375-026-02942-1. Online ahead of print","author":"Tavarozzi R, Maher N, Catania G, Zacchi G, D'Andrea F, Sofia A, Zanni M, Ladetto M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41986622"},{"title01":"Relapsed classic Hodgkin lymphoma; should all patients receive an autologous stem cell transplant? &#8211; the PRO.","title02":"Relapsed classic Hodgkin lymphoma; should all patients receive an autologous stem cell transplant? &#8211; the PRO.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2026.300574. Online ahead of print","author":"Abeyakoon C, Kuruvilla J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924908"},{"title01":"Mapping the immune orchestra of zamtocabtagene autoleucel in primary CNS lymphoma.","title02":"Mapping the immune orchestra of zamtocabtagene autoleucel in primary CNS lymphoma.","journal":"Haematologica","issue":"2026 April 1; 111(4):1176-1178. doi: 10.3324\/haematol.2025.289294","author":"Lee D, Dahiya S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437826"},{"title01":"Advances in biomarkers for mantle cell lymphoma in the era of targeted therapies.","title02":"Advances in biomarkers for mantle cell lymphoma in the era of targeted therapies.","journal":"Haematologica","issue":"2026 April 1; 111(4):1198-1214. doi: 10.3324\/haematol.2025.288185","author":"Loh Z, Yeh P, Keane C, Hawkes EA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195522"},{"title01":"Relapse as a return, not a reinvention &#8211; genomic stability and pre-existing resistance in mantle cell lymphoma.","title02":"Relapse as a return, not a reinvention &#8211; genomic stability and pre-existing resistance in mantle cell lymphoma.","journal":"Haematologica","issue":"2026 April 9. doi: 10.3324\/haematol.2025.289129. Online ahead of print","author":"Pott C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952644"},{"title01":"UV-induced mutations accumulate during early clonal expansion in aneuploid subtypes of pediatric B-cell precursor acute lymphoblastic leukemia.","title02":"UV-induced mutations accumulate during early clonal expansion in aneuploid subtypes of pediatric B-cell precursor acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 April 9. doi: 10.3324\/haematol.2025.300118. Online ahead of print","author":"Suurenbroek LC, Van der Ham CG, Boer JM, Derks LLM, Hagelaar R, Van Roosmalen MJ, Klamer P, Sonneveld E, Den Boer ML, Van Boxtel R, Van Leeuwen FN, Loeffen JLC, Kuiper RP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952634"},{"title01":"Anti-CD19 CAR T-cell therapy in relapsed\/refractory T-cell\/histiocyte-rich large B-cell lymphoma: insights from the French DESCAR-T registry, a LYSA study.","title02":"Anti-CD19 CAR T-cell therapy in relapsed\/refractory T-cell\/histiocyte-rich large B-cell lymphoma: insights from the French DESCAR-T registry, a LYSA study.","journal":"Haematologica","issue":"2026 April 9. doi: 10.3324\/haematol.2025.289196. Online ahead of print","author":"Andre A, Bourbon E, Cartron G, Morschhauser F, Fayard A, Ricard L, Di Blasi R, Chauchet A, Guidez S, Castilla-Llorente C, Brisou G, Bories P, Houot R, Cuozzo A, Gat E, Lemonnier F, Laurent C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952624"},{"title01":"An AI-based IHC quantification technique for assisting in the differentiation of MCL from CLL\/SLL.","title02":"An AI-based IHC quantification technique for assisting in the differentiation of MCL from CLL\/SLL.","journal":"Br J Haematol","issue":"2026 April; 208(4):1287-1295. doi: 10.1111\/bjh.70383","author":"Tian Z, Deng Z, Han F, Yu L, Jiang Y, Peng H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733051"},{"title01":"Pembrolizumab and pralatrexate for relapsed or refractory peripheral T-cell lymphomas.","title02":"Pembrolizumab and pralatrexate for relapsed or refractory peripheral T-cell lymphomas.","journal":"Br J Haematol","issue":"2026 April; 208(4):1429-1432. doi: 10.1111\/bjh.70361","author":"Poh C, Zain J, Godfrey J, Querfeld C, Puverel S, Chen L, Allen P, Herrera AF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41693089"},{"title01":"Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naive follicular lymphoma: Results from the phase II &#8216;FLUORO&#8217; study.","title02":"Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naive follicular lymphoma: Results from the phase II &#8216;FLUORO&#8217; study.","journal":"Br J Haematol","issue":"2026 April 8. doi: 10.1111\/bjh.70468. Online ahead of print","author":"Martynchyk A, Chong G, Khor R, Lee D, Lee ST, Scott AM, Grobler AC, Campbell BA, Thachil T, Manos K, Douglas G, Romano A, Palmer JB, Burgess M, Keane C, Hawkes EA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41949430"},{"title01":"Zanubrutinib, lenalidomide, rituximab, temozolomide +\/- methotrexate as first-line treatment for primary central nervous system lymphoma: A prospective, open-label, multicentre clinical trial.","title02":"Zanubrutinib, lenalidomide, rituximab, temozolomide +\/- methotrexate as first-line treatment for primary central nervous system lymphoma: A prospective, open-label, multicentre clinical trial.","journal":"Br J Haematol","issue":"2026 April; 208(4):1424-1428. doi: 10.1111\/bjh.70335","author":"Song J, Jiang H, Ding K, Liu H, Wang Y, Gao S, Ren Y, Liu Z, Zhuo J, Li B, Wang G, Jiao Z, Gao D, Fu R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41582824"},{"title01":"Prognostic role of PET\/CT volumetric parameters in paediatric Hodgkin lymphoma: A systematic review and expert recommendations from the International SEARCH for CAYAHL Group.","title02":"Prognostic role of PET\/CT volumetric parameters in paediatric Hodgkin lymphoma: A systematic review and expert recommendations from the International SEARCH for CAYAHL Group.","journal":"Br J Haematol","issue":"2026 April; 208(4):1185-1195. doi: 10.1111\/bjh.70329","author":"Gowdy SC, Flerlage JE, Seelisch J, Palese M, Bradshaw T, Castellino SM, Cho S, Dieckmann K, Hoppe BS, Howard S, Kelly KM, Kurch L, Lai HA, Lopci E, Lucas JT Jr, Mauz-Korholz C, McCarten KM, Pandit-Taskar N, Schoder H, Steglich J, Stoevesandt D, Voss SD, Milgrom SA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41535222"},{"title01":"From genetic variants to therapeutic targets: A study reveals MMS19 and HLA genes in Hodgkin lymphoma pathogenesis.","title02":"From genetic variants to therapeutic targets: A study reveals MMS19 and HLA genes in Hodgkin lymphoma pathogenesis.","journal":"Br J Haematol","issue":"2026 April; 208(4):1419-1423. doi: 10.1111\/bjh.70326","author":"Fu YC, Liu LP, Zhou YP, Yang MH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41787912"},{"title01":"Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival.","title02":"Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival.","journal":"Br J Haematol","issue":"2026 April; 208(4):1347-1358. doi: 10.1111\/bjh.70357","author":"O'Reilly MA, Wilson W, Maybury B, Kuhnl A, Roddie C, Uttenthal B, Johnson R, Alajangi R, Creasey T, Abdulgawad A, Arias CG, Iyengar S, Ferguson G, Panopoulou K, Delaney A, Pryce A, Rubio L, Jones C, Lambert J, Gupta S, Mathew A, Kasivisvanathan S, Awofisayo O, Hanmantgad S, Collins GP, Besley C, Seymour F, Sanderson R, Chaganti S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41796018"},{"title01":"Prognostic impact of treatment-related and geriatric factors in older patients with classic Hodgkin lymphoma: A real-life cohort study.","title02":"Prognostic impact of treatment-related and geriatric factors in older patients with classic Hodgkin lymphoma: A real-life cohort study.","journal":"Br J Haematol","issue":"2026 April; 208(4):1296-1305. doi: 10.1111\/bjh.70390","author":"Ligia S, Assanto GM, Soriano T, Cappelli LV, Passucci M, Annechini G, D'Elia GM, Pulsoni A, Martelli M, Del Giudice I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41721535"},{"title01":"Decreased renal function predicts severe cytokine release syndrome after CAR-T-cell therapy for large B-cell lymphoma.","title02":"Decreased renal function predicts severe cytokine release syndrome after CAR-T-cell therapy for large B-cell lymphoma.","journal":"Br J Haematol","issue":"2026 April 15. doi: 10.1111\/bjh.70488. Online ahead of print","author":"Arai Y, Jo T, Sato T, Sakurai M, Kaji D, Kitawaki T, Shimada K, Shimoyama T, Yoshihara S, Makita S, Fujii N, Yamamoto G, Kataoka K, Sakaida E, Goto H, Nakashima Y, Yoshida A, Umezawa Y, Kim H, Kato M, Atsuta Y, Kato K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41986280"},{"title01":"Distribution of adult T-cell leukaemia\/lymphoma subtypes and survival outcomes across geographical regions: An international retrospective cohort study.","title02":"Distribution of adult T-cell leukaemia\/lymphoma subtypes and survival outcomes across geographical regions: An international retrospective cohort study.","journal":"Br J Haematol","issue":"2026 April 15. doi: 10.1111\/bjh.70494. Online ahead of print","author":"Valcarcel B, Utsunomiya A, Otsuka M, Miyahara M, Ishitsuka K, Takamatsu Y, Suzumiya J, Tamura K, Vasquez JF, Enriquez-Vera D, Beltran BE, Castro D, Runciman T, Idrobo H, Arrieta E, Arias O, Gotuzzo E, Garrido-Pinzas G, Rivera V, Rosa D, Pena C, Fiad L, Ramos JC, Sandoval-Sus J, Sica A, Bell BN, Cook LB, Leataud V, Miranda ECM, Chiattone C, Katsuya H, Malpica L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41986288"},{"title01":"Mycosis fungoides and Sezary syndrome.","title02":"Mycosis fungoides and Sezary syndrome.","journal":"Br J Haematol","issue":"2026 April; 208(4):1207-1210. doi: 10.1111\/bjh.70392","author":"Martins F, Calvao J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41711246"},{"title01":"Efficacy of immune checkpoint inhibitors in paediatric, adolescent and young adults with primary refractory or relapsed classical Hodgkin lymphoma: A national multicentre real-world study.","title02":"Efficacy of immune checkpoint inhibitors in paediatric, adolescent and young adults with primary refractory or relapsed classical Hodgkin lymphoma: A national multicentre real-world study.","journal":"Br J Haematol","issue":"2026 April; 208(4):1331-1338. doi: 10.1111\/bjh.70379","author":"Pouthier M, Garnier N, Leruste A, Rigaud C, Curtillet C, Ducassou S, Poiree M, Dourthe ME, Pochon C, Couec ML, Bonneau-Lagacherie J, Montravers F, Boudjemaa S, Jonca B, Haouy S, Leblanc T, Parker JL, Simonin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41704060"},{"title01":"Zanubrutinib and pirtobrutinib show synergistic killing and suppression of BTK signaling in MYD88-mutated lymphoma cells.","title02":"Zanubrutinib and pirtobrutinib show synergistic killing and suppression of BTK signaling in MYD88-mutated lymphoma cells.","journal":"Blood advances","issue":"2026 April 15. doi: 10.1182\/bloodadvances.2025018126. Online ahead of print","author":"Pizzarella D, Kofides A, Hatcher JM, Liu X, Guijosa A, Tsakmaklis N, Peachey A, Wang J, Guerrera ML, Patterson CJ, Hunter ZR, Sun H, Sarosiek S, Castillo JJ, Buhrlage S, Dhe-Paganon S, Branagan AR, Treon SP, Liu S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41985014"},{"title01":"LySeqST: A targeted sequencing assay for robust genomic classification of diffuse large B-cell lymphoma.","title02":"LySeqST: A targeted sequencing assay for robust genomic classification of diffuse large B-cell lymphoma.","journal":"Blood advances","issue":"2026 April 15. doi: 10.1182\/bloodadvances.2026020105. Online ahead of print","author":"Hilton LK, Gillis S, Yahyaei-Moayyed F, Bridgers J, Alduaij W, Jiang A, Ben-Neriah S, Collinge B, Wong JCH, Boyle M, Meissner B, Slack GW, Farinha P, Craig JW, Gerrie AS, Villa D, Savage KJ, Sehn LH, Karsan A, Wright G, Staudt LM, Morin RD, Steidl C, Scott DW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41985007"},{"title01":"Risk factor analysis of 115 children and adolescents with primary mediastinal B-cell lymphoma treated with DA-EPOCH-R.","title02":"Risk factor analysis of 115 children and adolescents with primary mediastinal B-cell lymphoma treated with DA-EPOCH-R.","journal":"Blood advances","issue":"2026 April 14. doi: 10.1182\/bloodadvances.2025019553. Online ahead of print","author":"Meyer-Wentrup F, Jonas SF, Knorr F, Auperin A, Alexander S, Andres M, Attarbaschi A, Burke GAA, Burkhardt B, Ceppi F, Gross TG, Kabickova E, Klapper W, Miles RR, Taj MM, Zimmermann M, Minard-Colin V, Woessmann W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41979343"},{"title01":"Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.","title02":"Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.","journal":"Blood advances","issue":"2026 April 14. doi: 10.1182\/bloodadvances.2026020012. Online ahead of print","author":"Flerlage JE, Eichenauer DA, Fuchs M, Hartmann S, Eich HT, Savage KJ, Lo AC, Skinnider B, Akhtar S, Rauf MS, Maghfoor I, Pinnix CC, Steiner RE, Milgrom SA, Vega F, Alomari M, Zhang XY, Collins GP, Advani RH, Kumar P, Dickinson MJ, Wirth A, Tsang R, Prica A, Major A, Smith SM, Hendrickson PG, Kelsey CR, Hopkins D, McKay P, Ng AK, Koenig JL, Constine LS, Casulo C, Sakthivel G, Baron JA, Plastaras JP, Roberts KB, Gao S, Al Kendi J, Al Rahbi N, Balogh AG Jr, Levis M, Ricardi U, Sridhar A, Torka P, Specht L, De Silva R, Shah N, Pickard K, Osborne W, Blazin LJ, Henry M, Chang I, Smith CM, Halperin D, Miall F, Brady JL, Mikhaeel NG, Brennan B, Penn A, Senchenko M, Volchkov EV, Reeves M, Hoppe BS, Terezakis SA, Talaulikar D, Della Pepa R, Picardi M, Kirova Y, Fergusson P, Northend M, Hawkes EA, Lee D, Wong Doo N, Barraclough A, Opat S, Cheah CY, Salvaris R, Ku M, Hamad N, Mutsando H, Tedjaseputra A, Gilbertson M, Marconi T, Viiala N, Palese M, Shankar AG, Maurer MJ, Natkunam Y, Kelly KM, Borchmann P, Hoppe RT, Binkley MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41979337"},{"title01":"Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study.","title02":"Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study.","journal":"Blood advances","issue":"2026 April 14. doi: 10.1182\/bloodadvances.2025019108. Online ahead of print","author":"Camus V, Krzisch D, Bruscaggin A, Leveque E, Viennot M, Fornecker LM, Cheminant M, Bailly S, Morschhauser F, Feugier P, Choquet S, Durot E, Carras S, Delette C, Damaj G, Waultier Rascalou A, Lebreton P, Le Du K, Galtier J, Houot R, Morineau N, Laribi K, Lebras L, Oberic L, Amorim S, Bocchetta S, Viailly PJ, Rainville V, Ruminy P, Caillot M, Terzi di Bergamo L, Piffaretti D, Pirosa MC, Salehi M, Forestieri G, Drieux F, Veresezan EL, Traverse-Glehen A, Donzel M, Burel L, Bohers E, Lanic MD, Penther D, Becker S, Decazes P, Tonnelet D, Draye-Carbonnier S, Tilly H, Jardin F, Rossi D, Sesques P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41979332"},{"title01":"Invasive Fungal Infections Following Bruton Tyrosine Kinase Inhibitor Treatment: A Systematic Review and Meta-analysis.","title02":"Invasive Fungal Infections Following Bruton Tyrosine Kinase Inhibitor Treatment: A Systematic Review and Meta-analysis.","journal":"Blood advances","issue":"2026 April 9. doi: 10.1182\/bloodadvances.2025019221. Online ahead of print","author":"Srisurapanont K, Meejun T, Manothummetha K, Li LX, Baddley JW, Schulz CA, Dioverti MV, Zhang SX, Avery RK, Kates OS, Permpalung N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41954633"},{"title01":"POD24 is a novel determinant of prognosis in patients with Waldenstrom macroglobulinemia.","title02":"POD24 is a novel determinant of prognosis in patients with Waldenstrom macroglobulinemia.","journal":"Blood advances","issue":"2026 April 14; 10(7):2322-2327. doi: 10.1182\/bloodadvances.2025017751","author":"Zanwar S, Abeykoon J, D'Sa S, Roos-Weil D, Larson DR, Colby CL, Durot E, Kastritis E, Uppal E, Tomkins O, Morel P, Mondello P, Montes L, Paludo J, Ailawadhi S, Sarosiek S, Ogunbiyi O, Cornillet-Lefebvre P, Rajkumar SV, Quinquenel A, Dispenzieri A, Fonseca R, Gertz MA, Kumar S, Dimopoulos MA, Ansell SM, Treon S, Castillo JJ, Kapoor P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41499755"},{"title01":"Zamtocabtagene autoleucel in relapsed\/refractory B-NHL: 5-year follow-up of a CD20\/19 tandem CAR T-cell phase 1 trial.","title02":"Zamtocabtagene autoleucel in relapsed\/refractory B-NHL: 5-year follow-up of a CD20\/19 tandem CAR T-cell phase 1 trial.","journal":"Blood advances","issue":"2026 April 14; 10(7):2395-2405. doi: 10.1182\/bloodadvances.2025018073","author":"Balke-Want H, Godel P, Schmid C, Ayuk F, Friedrichs B, van Heteren P, Holtkamp S, Zadoyan G, Brillant C, Costa J, Hanssens L, Holzer T, Wohle C, Biedermann S, Burger I, Orentas R, Overstijns T, Scheid C, Holtick U, Miltenyi S, Hallek M, Borchmann P, Kutsch N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41512222"},{"title01":"ASH ISTH 2026 guidelines for Anticoagulant Prophylaxis of Pediatric Patients at Risk of Venous Thromboembolism.","title02":"ASH ISTH 2026 guidelines for Anticoagulant Prophylaxis of Pediatric Patients at Risk of Venous Thromboembolism.","journal":"Blood advances","issue":"2026 April 8. doi: 10.1182\/bloodadvances.2025019415. Online ahead of print","author":"Betensky M, Azzam M, Bercovitz RS, Bhat R, Biss TT, Branchford BR, Brandao LR, Chan AK, Faustino EVS, Hamarsha Q, Jaffray J, Jones SE, Kawtharany H, Kerlin BA, Khawandi J, Krider G, Kucine N, Kumar R, Male C, Monagle P, Pelland-Marcotte MC, Raffini L, Raulji CM, Sartain SE, Takemoto CM, Tarango C, van Ommen CH, Velez MC, Vesely SK, Wiernikowski JT, Williams S, Wilson HP, Woods G, Mustafa RA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41949461"},{"title01":"Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R\/R marginal zone lymphoma: phase 1\/2 BRUIN study.","title02":"Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R\/R marginal zone lymphoma: phase 1\/2 BRUIN study.","journal":"Blood advances","issue":"2026 April 14; 10(7):2441-2451. doi: 10.1182\/bloodadvances.2025017489","author":"Patel K, Vose JM, Nasta SD, Brown JR, Maddocks KJ, Woyach JA, Shah NN, Fakhri B, Tessoulin B, Ma S, Jagadeesh D, Lech-Maranda E, Coombs CC, Patel MR, Rhodes JM, Ujjani C, Hoffmann MS, Cheah CY, Munir T, Lewis D, Scarfo L, Eyre TA, Alencar A, Cohen JB, Zelenetz AD, Tsai DE, Li M, Bian Y, Abada P, Balbas M, Zinzani PL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41544219"},{"title01":"Improved survival and health care use with CAR-T vs historical care in relapsed\/refractory large B-cell lymphoma.","title02":"Improved survival and health care use with CAR-T vs historical care in relapsed\/refractory large B-cell lymphoma.","journal":"Blood advances","issue":"2026 April 14; 10(7):2304-2313. doi: 10.1182\/bloodadvances.2025017401","author":"Kordbacheh T, Chan KKW, Crump M, Ante Z, Liu N, Aminilari M, Gong IY, Bhella S, Vijenthira A, Kuruvilla J, Kridel R, Chen C, Kukreti V, Yang C, Hodgson D, Prica A, Rodin D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41544221"},{"title01":"Serum free fatty acid promotes tumor progression and predicts golidocitinib sensitivity in peripheral T-cell lymphoma.","title02":"Serum free fatty acid promotes tumor progression and predicts golidocitinib sensitivity in peripheral T-cell lymphoma.","journal":"Blood advances","issue":"2026 April 14; 10(7):2125-2141. doi: 10.1182\/bloodadvances.2025017682","author":"Qin Y, Xia PH, Huang YH, Cheng S, Liu JY, Gao X, Cai MC, Wang C, Qiu YR, Hu S, Shi Q, Yang HX, Zhao JY, Wang L, Xiong J, Zhao WL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41564436"},{"title01":"AVD is an effective chemotherapy backbone in first-line treatment of older patients with classical Hodgkin lymphoma.","title02":"AVD is an effective chemotherapy backbone in first-line treatment of older patients with classical Hodgkin lymphoma.","journal":"Blood advances","issue":"2026 April 1. doi: 10.1182\/bloodadvances.2025018954. Online ahead of print","author":"Overgaard N, Lia K, Collin J, Asdahl PH, Wikman P, Glimelius I, Lagerlof I, Johansson AS, Hansson L, Enblad G, Linderoth J, Goldkuhl C, Jerlstrom U, Fossa A, Kamper P, Molin D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41921203"},{"title01":"Treatment and survival outcomes for patients with follicular lymphoma and POD24: a systematic review and meta-analysis.","title02":"Treatment and survival outcomes for patients with follicular lymphoma and POD24: a systematic review and meta-analysis.","journal":"Blood advances","issue":"2026 April 14; 10(7):2495-2505. doi: 10.1182\/bloodadvances.2025018474","author":"Shen J, Zhang J, Zhu Z, Ma H, Zhang J, Zhou F, Tian H, Liu J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587420"},{"title01":"Early CAR T-cell therapy in relapsed\/refractory large B-cell lymphoma is associated with lower hematotoxicity burden.","title02":"Early CAR T-cell therapy in relapsed\/refractory large B-cell lymphoma is associated with lower hematotoxicity burden.","journal":"Blood advances","issue":"2026 April 14; 10(7):2186-2189. doi: 10.1182\/bloodadvances.2025018353","author":"Zeremski V, Aydilek E, Behringer A, Brunner F, Haage TR, Haenel M, Kos I, Krueger W, Lenz G, Lesan V, Schneider J, Schultze-Florey C, Shumilov E, Weber T, Wulf G, Vucinic V, Mougiakakos D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41411524"},{"title01":"Primary refractory disease in large B-cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trial.","title02":"Primary refractory disease in large B-cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trial.","journal":"Blood advances","issue":"2026 April 14; 10(7):2249-2253. doi: 10.1182\/bloodadvances.2025018491","author":"Gong IY, Kuruvilla J, Prica A, Olney H, Fraser G, Buckstein R, Skrabek P, Keating MM, Hay A, Shepherd L, Chen BE, Crump M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587423"},{"title01":"Gonadal Function and Fertility after Hodgkin Lymphoma Treatment with Nivolumab-AVD in the Phase II GHSG NIVAHL Trial.","title02":"Gonadal Function and Fertility after Hodgkin Lymphoma Treatment with Nivolumab-AVD in the Phase II GHSG NIVAHL Trial.","journal":"Blood","issue":"2026 April 2. doi: 10.1182\/blood.2025031809. Online ahead of print","author":"Robertz AS, Buhnen I, Meissner J, Trautmann-Grill K, Herhaus P, Halbsguth T, Schaub V, Kerkhoff A, Mathas S, Bormann M, Dickhut A, Jaworek CP, Fuchs M, Kobe C, Baues C, Borchmann P, von Tresckow B, Behringer K, Brockelmann PJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41926569"},{"title01":"Digging deep for the roots of lymphoma.","title02":"Digging deep for the roots of lymphoma.","journal":"Blood","issue":"2026 April 9; 147(15):1657-1658. doi: 10.1182\/blood.2025032718","author":"Schroers-Martin JG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41954960"},{"title01":"Targeted therapy in early-stage classical Hodgkin lymphoma.","title02":"Targeted therapy in early-stage classical Hodgkin lymphoma.","journal":"Blood","issue":"2026 April 9; 147(15):1655-1657. doi: 10.1182\/blood.2025032560","author":"Aoki T, Kuruvilla J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41954961"},{"title01":"Chronic active Epstein-Barr virus disease: molecular pathogenesis, evolving concepts, and emerging therapies.","title02":"Chronic active Epstein-Barr virus disease: molecular pathogenesis, evolving concepts, and emerging therapies.","journal":"Blood","issue":"2026 April 2; 147(14):1562-1573. doi: 10.1182\/blood.2025032277","author":"Kimura H, Cohen JI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490284"},{"title01":"Diagnosis-to-Treatment Interval Is Associated With Outcomes in Follicular Lymphoma Treated with Immunochemotherapy.","title02":"Diagnosis-to-Treatment Interval Is Associated With Outcomes in Follicular Lymphoma Treated with Immunochemotherapy.","journal":"Blood","issue":"2026 April 14. doi: 10.1182\/blood.2026033090. Online ahead of print","author":"Vodicka P, El-Galaly TC, Prochazka V, Flowers CR, Villa D, Dietrich CE, Jakobsen LH, Ghesquieres H, Clausen MR, Kridel R, Cheah CY, Hawkes EA, Wahlin BE, Gandhi MK, Larson MC, Cahn EJ, Friedberg JW, Martin P, Chihara D, Cohen JB, Habermann TM, Casulo C, Wang Y, Brown PN, Mou E, Belada D, Janikova A, Mocikova H, Burack R, Lossos IS, Kahl BS, Smedby KE, Sehn LH, Trneny M, Cerhan JR, Maurer MJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41980013"},{"title01":"The impact of daratumumab-containing induction on stem cell mobilization, collection and engraftment in newly diagnosed multiple myeloma: results of the prospective DILEMMA study.","title02":"The impact of daratumumab-containing induction on stem cell mobilization, collection and engraftment in newly diagnosed multiple myeloma: results of the prospective DILEMMA study.","journal":"Haematologica","issue":"2026 April 1; 111(4):1443-1448. doi: 10.3324\/haematol.2025.288411","author":"Valentini CG, Pellegrino C, Chiusolo P, Rossi E, Ladiana R, Za T, Sica S, Pagano L, De Stefano V, Teofili L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41126731"},{"title01":"Clinical and genomic features of macrofocal multiple myeloma: a distinct profile.","title02":"Clinical and genomic features of macrofocal multiple myeloma: a distinct profile.","journal":"Haematologica","issue":"2026 April 1; 111(4):1462-1468. doi: 10.3324\/haematol.2025.288535","author":"Liu J, Fan J, Zhou X, Chen X, Hu X, He H, Jin L, Fu W, Hou J, Du J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41126728"},{"title01":"From myeloma to POEMS: extending the potential of T-cell redirecting therapies.","title02":"From myeloma to POEMS: extending the potential of T-cell redirecting therapies.","journal":"Haematologica","issue":"2026 April 1; 111(4):1173-1175. doi: 10.3324\/haematol.2025.288466","author":"Cook J, Dispenzieri A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40963394"},{"title01":"Talquetamab, a GPRC5DxCD3 bispecific antibody, in Chinese patients with relapsed\/refractory multiple myeloma: efficacy and safety from the phase 1\/2 MonumenTAL-1 study.","title02":"Talquetamab, a GPRC5DxCD3 bispecific antibody, in Chinese patients with relapsed\/refractory multiple myeloma: efficacy and safety from the phase 1\/2 MonumenTAL-1 study.","journal":"Haematologica","issue":"2026 April 1; 111(4):1411-1416. doi: 10.3324\/haematol.2025.287334","author":"An G, Jin J, Cai Z, Jing H, Fu C, He P, Xia Z, Liu R, Li L, Gai X, Zhang H, Zhu D, Luo X, Sun B, Xu H, Zhou L, Campagna M, Masterson TJ, Lau BW, Renaud T, Heuck C, Singh I, Vishwamitra D, Qiu L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41063704"},{"title01":"An AI-based IHC quantification technique for assisting in the differentiation of MCL from CLL\/SLL.","title02":"An AI-based IHC quantification technique for assisting in the differentiation of MCL from CLL\/SLL.","journal":"Br J Haematol","issue":"2026 April; 208(4):1287-1295. doi: 10.1111\/bjh.70383","author":"Tian Z, Deng Z, Han F, Yu L, Jiang Y, Peng H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733051"},{"title01":"Selective small molecule targeting of KDM4 as a therapeutic strategy to reduce proliferation of acute myeloid leukaemia.","title02":"Selective small molecule targeting of KDM4 as a therapeutic strategy to reduce proliferation of acute myeloid leukaemia.","journal":"Br J Haematol","issue":"2026 April; 208(4):1240-1251. doi: 10.1111\/bjh.70351","author":"Monaghan L, Bunschoten RP, Bittencourt-Silvestre J, Park T, Gannon S, Pirvan PA, Hoose A, Wheadon H, Liskamp RMJ, Huang X, Jorgensen HG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41622589"},{"title01":"Epigenetic silencing and pharmacological inhibition of EIF5A2 foster venetoclax sensitivity in acute myeloid leukaemia.","title02":"Epigenetic silencing and pharmacological inhibition of EIF5A2 foster venetoclax sensitivity in acute myeloid leukaemia.","journal":"Br J Haematol","issue":"2026 April; 208(4):1437-1442. doi: 10.1111\/bjh.70339","author":"Crespo-Garcia E, Quero-Dotor C, Noguera-Castells A, Sancho-Vila L, Martinez-Verbo L, Esteller M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41606290"},{"title01":"Short and complex-Telomeres and genomes in CLL.","title02":"Short and complex-Telomeres and genomes in CLL.","journal":"Br J Haematol","issue":"2026 April; 208(4):1503-1504. doi: 10.1111\/bjh.70430","author":"Jebaraj BMC, Stilgenbauer S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41814451"},{"title01":"Optical genome mapping detects cryptic high-risk and targetable abnormalities in adult AML.","title02":"Optical genome mapping detects cryptic high-risk and targetable abnormalities in adult AML.","journal":"Br J Haematol","issue":"2026 April; 208(4):1232-1239. doi: 10.1111\/bjh.70349","author":"Bidet A, Laharanne E, Dos Santos M, De Grande AC, Leguay T, Pigneux A, Frison E, Achard S, Dupont-Moufakkir S, Klein E, Dumas PY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41622767"},{"title01":"Blinatumomab limits humoral antibody response despite boosting the influenza vaccine schedule in children with B-ALL.","title02":"Blinatumomab limits humoral antibody response despite boosting the influenza vaccine schedule in children with B-ALL.","journal":"Blood advances","issue":"2026 April 14; 10(7):2425-2428. doi: 10.1182\/bloodadvances.2025018688","author":"Chiu SK, Furlong E, Fox A, McKinnon EJ, Ovando SS, McLean-Tooke A, Oommen J, Yeoh DK, Cheung LC, Gottardo NG, Kotecha RS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628313"},{"title01":"Prospective feasibility study of peripheral blood for MRD detection in acute myeloid leukemia by flow cytometry.","title02":"Prospective feasibility study of peripheral blood for MRD detection in acute myeloid leukemia by flow cytometry.","journal":"Blood advances","issue":"2026 April 14; 10(7):2470-2478. doi: 10.1182\/bloodadvances.2025018607","author":"Li S, Short NJ, Wang W, Ling J, Qiu L, Xu J, Wang WJ, Jia F, Tang G, Karrar O, Maroun M, Medeiros LJ, Ravandi F, Wang SA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41649796"},{"title01":"Exercise-mobilized lymphocytes enhance the function of cytokine-induced memory-like NK cells against myeloid leukemia.","title02":"Exercise-mobilized lymphocytes enhance the function of cytokine-induced memory-like NK cells against myeloid leukemia.","journal":"Blood advances","issue":"2026 April 14; 10(7):2565-2577. doi: 10.1182\/bloodadvances.2025018345","author":"Batatinha H, Valenzuela AM, Filioglou D, Wilde P, Leite G, Kistner TM, Baker FL, Katsanis E, Simpson RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538301"},{"title01":"Synthetic lethality of decitabine plus ATR inhibition for TP53-mutated AML.","title02":"Synthetic lethality of decitabine plus ATR inhibition for TP53-mutated AML.","journal":"Blood advances","issue":"2026 April 14; 10(7):2506-2520. doi: 10.1182\/bloodadvances.2025018369","author":"Baeten JT, Agashe S, Tabet I, Wooldridge JT, Carter A, Butler JN, Miller CA, Helton N, Quinet A, Johansson KB, Yang Y, Uy GL, Vindigni A, Link DC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610325"},{"title01":"ASH ISTH 2026 guidelines for Anticoagulant Prophylaxis of Pediatric Patients at Risk of Venous Thromboembolism.","title02":"ASH ISTH 2026 guidelines for Anticoagulant Prophylaxis of Pediatric Patients at Risk of Venous Thromboembolism.","journal":"Blood advances","issue":"2026 April 8. doi: 10.1182\/bloodadvances.2025019415. Online ahead of print","author":"Betensky M, Azzam M, Bercovitz RS, Bhat R, Biss TT, Branchford BR, Brandao LR, Chan AK, Faustino EVS, Hamarsha Q, Jaffray J, Jones SE, Kawtharany H, Kerlin BA, Khawandi J, Krider G, Kucine N, Kumar R, Male C, Monagle P, Pelland-Marcotte MC, Raffini L, Raulji CM, Sartain SE, Takemoto CM, Tarango C, van Ommen CH, Velez MC, Vesely SK, Wiernikowski JT, Williams S, Wilson HP, Woods G, Mustafa RA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41949461"},{"title01":"No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d positive CLL mainly expressed in trisomy 12.","title02":"No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d positive CLL mainly expressed in trisomy 12.","journal":"Blood advances","issue":"2026 April 2. doi: 10.1182\/bloodadvances.2025018640. Online ahead of print","author":"Laurenti L, Guglielmi F, Mosca A, Vitale C, Montalbano MC, Favrin G, Ferrarini I, Galitzia A, Pasquale R, Moratti M, Catania G, Murru R, Giannarelli D, Martino EA, Moia R, Zucchetto A, Tissino E, Autore F, Tomasso A, Stirparo L, Quaranta T, Abbate PL, Gattei V, Gaidano G, Gentile M, Krampera M, Farina G, Visentin A, Innao V, Varettoni M, Coscia M, Innocenti I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41925576"},{"title01":"Similar androgen receptor expression in male and female AML.","title02":"Similar androgen receptor expression in male and female AML.","journal":"Blood advances","issue":"2026 April 1. doi: 10.1182\/bloodadvances.2026020008. Online ahead of print","author":"Prabhu KS, Qian F, Sarkar D, Zheng H, Paulson RF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41921074"},{"title01":"Quizartinib in newly diagnosed patients with FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.","title02":"Quizartinib in newly diagnosed patients with FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.","journal":"Blood advances","issue":"2026 April 8. doi: 10.1182\/bloodadvances.2025017738. Online ahead of print","author":"Levis MJ, Erba HP, Montesinos P, Patkowska E, Cortes JE, Perl AE, Dombret H, Amadori S, Wang J, Schlenk RF, Liu L, Mostafa Kamel Y, Imadalou K, Laadem A, Burns K, Sekeres MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41949390"},{"title01":"DLK1 is a GATA1s-Driven Dependency and Therapeutic Target in Down Syndrome-Associated Myeloid Leukemia.","title02":"DLK1 is a GATA1s-Driven Dependency and Therapeutic Target in Down Syndrome-Associated Myeloid Leukemia.","journal":"Blood advances","issue":"2026 April 7. doi: 10.1182\/bloodadvances.2025018830. Online ahead of print","author":"Verboon L, Barwe SP, Tavenner M, Faust JR, Issa H, Goncalves-Dias J, Schuschel K, Bhayadia R, van Berkel PH, Sebastian A, Ries RE, Paczesny S, Meshinchi S, Hitzler JK, Pikman Y, Kolb EA, Heckl D, Klusmann JH, Gopalakrishnapillai A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41945753"},{"title01":"Genotype-immunophenotype relationships in NPM1-mutated AML clonal evolution uncovered by single-cell multiomic analysis.","title02":"Genotype-immunophenotype relationships in NPM1-mutated AML clonal evolution uncovered by single-cell multiomic analysis.","journal":"Blood","issue":"2026 April 8. doi: 10.1182\/blood.2025030772. Online ahead of print","author":"Drucker M, Lee D, Bowman MS, Zhang X, Kain BN, Nicolet D, Bandopadhyay R, Singh V, Wang Z, Stone RM, Saygin C, Mrozek K, Carroll AJ, Starczynowski DT, Levine RL, Byrd JC, Salomonis N, Skuli SJ, Grimes HL, Eisfeld AK, Bowman RL, Miles LA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41950000"},{"title01":"A tumor suppressor role of the miR-15b\/16-2 cluster in T-cell acute lymphoblastic leukemia.","title02":"A tumor suppressor role of the miR-15b\/16-2 cluster in T-cell acute lymphoblastic leukemia.","journal":"Blood","issue":"2026 April 8. doi: 10.1182\/blood.2025030670. Online ahead of print","author":"Toribio ML, Garcia-Leon MJ, Garcia-Peydro M, Fuentes P, Alcain J, Martin-Gayo E, Croce CM, Garzon R, Gonzalez-Garcia S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41949997"},{"title01":"Polycomb repressive complex 2 insufficiency underlies myeloid leukemia in Down syndrome.","title02":"Polycomb repressive complex 2 insufficiency underlies myeloid leukemia in Down syndrome.","journal":"Blood","issue":"2026 April 8. doi: 10.1182\/blood.2025032083. Online ahead of print","author":"Suzuki Y, Nakajima-Takagi Y, Oshima M, Ochi Y, Tsuchiya A, Koide S, Yokomizo-Nakano T, Kurosawa S, Rizq O, Kon A, Miyano S, Rahmutulla B, Kaneda A, Nakayama M, Koseki H, Yu E, Toki T, Ito E, Ogawa S, Iwama A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41949996"},{"title01":"Chronic active Epstein-Barr virus disease: molecular pathogenesis, evolving concepts, and emerging therapies.","title02":"Chronic active Epstein-Barr virus disease: molecular pathogenesis, evolving concepts, and emerging therapies.","journal":"Blood","issue":"2026 April 2; 147(14):1562-1573. doi: 10.1182\/blood.2025032277","author":"Kimura H, Cohen JI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490284"},{"title01":"Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel.","title02":"Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel.","journal":"Blood","issue":"2026 April 2; 147(14):1532-1561. doi: 10.1182\/blood.2024027904","author":"Zwaan CM, Tasian SK, Aplenc R, Brodersen LE, Buldini B, De Moerloose B, Dworzak MN, Fogelstrand L, Gibson BES, Goemans BF, Hasle H, Hirsch BA, Kaspers GJL, Klusmann JH, Kutny MA, Lehrnbecher T, Locatelli F, Meshinchi S, Petit A, Pigazzi M, Tierens A, Kolb EA, Reinhardt D, Tomizawa D, Cooper TM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41105890"},{"title01":"A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study.","title02":"A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study.","journal":"Blood","issue":"2026 April 9; 147(15):1702-1712. doi: 10.1182\/blood.2025029971","author":"Itsara A, Rogness VM, Samples L, Yuan CM, Wang HW, Ahn IE, Farooqui MZH, Tian X, Sun C, Tomasulo E, Soto S, Superata J, Bezkorovaynaya L, Hughes TE, Nierman P, Wiestner A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41405491"},{"title01":"Das not enough in CBF AML.","title02":"Das not enough in CBF AML.","journal":"Blood","issue":"2026 April 9; 147(15):1658-1659. doi: 10.1182\/blood.2025032734","author":"Stone RM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41954958"},{"title01":"Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant.","title02":"Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant.","journal":"Blood","issue":"2026 April 14. doi: 10.1182\/blood.2025032757. Online ahead of print","author":"Zent CS, Tiacci E, Kreitman RJ, Tadmor T, Tallman MS, Wormann BJ, Andritsos LA, Arons E, Banerji V, Barrientos JC, Bhat SA, Blachly JS, Broccoli A, Call TG, Dearden C, Demeter J, Dietrich S, El-Sharkawi D, Fagarasanu A, Falini B, Forconi F, Gerrie AS, Gladstone DE, Gozzetti A, Hampel PJ, Hermel DJ, Iyengar S, Johnston JB, Juliusson G, Kipps TJ, Lauria F, Lozanski G, Parikh SA, Park JH, Polliack A, Quest G, Rai KR, Ravandi F, Robak T Prof, Rogers KA, Saven A, Seymour JF, Tam CS, Troussard X, Zenz T, Zinzani PL, Grever MR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41980020"},{"title01":"Inhibition of high CXCR4 with Motixafortide and absence of single-cell MRD predict outcome after AML consolidation.","title02":"Inhibition of high CXCR4 with Motixafortide and absence of single-cell MRD predict outcome after AML consolidation.","journal":"Blood","issue":"2026 April 14. doi: 10.1182\/blood.2025032033. Online ahead of print","author":"Ceran E, Jaramillo S, Merbach AK, Rohde C, Wass M, Schaffrath J, Durruthy-Durruthy R, Arribas-Layton M, Sciambi A, Rieger K, Nogai A, Hanel M, Herbst RT, Stolzel F, Rollig C, Jost E, Schlenk R, Lotze M, Noppeney R, Brandts CH, Krug U, Gotze KS, Buske S, Florschutz A, Schubert JEA, Opitz B, Esseling E, von Witzendorff S, Subklewe M, Kaufmann M, Frickhofen N, Scholz CW, Schafer-Eckart K, Kunzmann V, Schmidt-Hieber M, Sayer HG, Rank A, Hemmati PG, Schuler F, Scheller M, Kowoll S, Steighardt J, Edemir B, Ludwig-Kraus B, Mueller LP, Edemir S, Vainstein-Haras A, Sorani E, Gliko-Kabir I Mrs, Kadosh S, Tavor S, Gromann C, Wienke A, Bauer M, Wickenhauser C, Baldus CD, Platzbecker U, Cerwenka A, Serve H, Bornhauser M, Junghanss C, Muller-Tidow C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41980027"},{"title01":"T cells dressed up with a dual HLA-restricted TCR targeting cathepsin G drive effective AML eradication.","title02":"T cells dressed up with a dual HLA-restricted TCR targeting cathepsin G drive effective AML eradication.","journal":"Blood","issue":"2026 April 14. doi: 10.1182\/blood.2025030579. Online ahead of print","author":"Marzuttini F, Potenza A, Celli L, Simioni A, Conte L, Camisa B, Magnani ZI, Sergi Sergi L, Mohammadi N, Scaramuzza S, El Khoury R, Improta CM, Ugolini A, Spiga M, Remiddi E, Grometto A, Carnevale E, Cavallaro V, Veronese S, Scola A, Toffalori C, Abbati D, Sanvito F, Ponzoni M, Lupo Stanghellini MT, Themeli M, Casucci M, Degano M, Vago L, Merelli I, Ciceri F, Bonini C, Ruggiero E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41980033"},{"title01":"Bone marrow failure, somatic rescue by p53 inactivation, and enhanced leukemogenesis in germ line ERCC6L2 disease.","title02":"Bone marrow failure, somatic rescue by p53 inactivation, and enhanced leukemogenesis in germ line ERCC6L2 disease.","journal":"Blood","issue":"2026 April 9; 147(15):1663-1679. doi: 10.1182\/blood.2025030230","author":"Schimmer RR, Klemm N, Fullin J, Topcu E, Treacy M, Zielinska KA, Doerdelmann C, Devesa-Serrano D, Lock M, Caiado F, Koch C, Dietliker N, Schwotzer R, Buhler M, Myllymaki M, Kurppa KJ, Manz MG, Lopes M, Boettcher S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490322"},{"title01":"A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.","title02":"A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.","journal":"Blood","issue":"2026 April 9; 147(15):1735-1748. doi: 10.1182\/blood.2025030722","author":"Dohner H, Spath D, Saadati M, Fiedler W, Gotze K, Koller E, Westermann J, Vogel W, Heuser M, Lubbert M, Tischler HJ, Germing U, Teichmann LL, Fransecky L, Wolfler A, Nachbaur D, Hertenstein B, Schroers R, Martens U, von Harsdorf S, Radsak M, Aschauer G, Weisshaar S, Corbacioglu A, Schrade A, Gaidzik VI, Thol F, Paschka P, Bullinger L, Benner A, Dohner K, Ganser A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490515"},{"title01":"The ASH HematOmics Program supports integrative analysis of genomic and clinical data in hematologic diseases.","title02":"The ASH HematOmics Program supports integrative analysis of genomic and clinical data in hematologic diseases.","journal":"Blood","issue":"2026 April 6. doi: 10.1182\/blood.2025032031. Online ahead of print","author":"Lu C, Matt GY, Paul R, Wang J, Sioson E, Gangwani K, Acic A, Willems A, Zaldivar Peraza A, Reilly C, Polonen P, Gao Q, Li Q, Pounds SB, Zeng AGX, Li S, Nadarajah N, Brady SW, Iacobucci I, Haferlach T, Rose MC, Mullighan CG, Zhou X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41940951"},{"title01":"Breast hairy cell leukemia mimicking lobular breast carcinoma.","title02":"Breast hairy cell leukemia mimicking lobular breast carcinoma.","journal":"Blood","issue":"2026 April 2; 147(14):1648. doi: 10.1182\/blood.2025032411","author":"Tsvetnov IV, Lyapichev KA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41926137"},{"title01":"CML mimicker: a myeloid neoplasm with BCR::FGFR1 fusion without peripheral blood eosinophilia or basophilia.","title02":"CML mimicker: a myeloid neoplasm with BCR::FGFR1 fusion without peripheral blood eosinophilia or basophilia.","journal":"Blood","issue":"2026 April 9; 147(15):1780. doi: 10.1182\/blood.2025032576","author":"Wang HY, Mangan JK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41954956"},{"title01":"Old methods, lasting impact in relapsed\/refractory primary mediastinal B-cell lymphoma.","title02":"Old methods, lasting impact in relapsed\/refractory primary mediastinal B-cell lymphoma.","journal":"Haematologica","issue":"2026 April 1; 111(4):1171-1172. doi: 10.3324\/haematol.2025.289153","author":"Ringelstein-Harlev S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41230691"},{"title01":"Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed\/refractory large B-cell lymphoma.","title02":"Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed\/refractory large B-cell lymphoma.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2025.300063. Online ahead of print","author":"Shumilov E, Wurm-Kuczera R, Kauer J, Wang M, Mazzeo P, Boyadzhiev H, Gebauer N, Holtick U, Holscher A, Teichert M, Nierychlewska PM, Kimmich C, Berning P, Melchardt T, Zeremski V, Wirths C, Nakov P, Schultze-Florey C, Velazquez GF, Lesan V, Kramer I, Kaiser F, Vehling-Kaiser U, Ossami-Saidy A, Huber H, Behringer A, Bentz M, Scholz JK, Godel P, Schnetzke U, Vucinic V, Shorb E, Ghandili S, Kerkhoff A, Scheich S, Aydin S, Mayer K, Bacher U, Wille K, Glass B, Oellerich T, Ayuk F, Heidel F, Thurner L, Lutz M, Hanel M, Scholz CW, Tometten M, Pott C, Dreger P, Mougiakakos D, Dietrich S, Derenzini E, Chapuy B, Tresckow BV, Pabst T, Muller F, Lenz G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924925"},{"title01":"First-year results of the International Leukemia\/Lymphoma Target Board for pediatric relapsed and refractory hematological malignancies.","title02":"First-year results of the International Leukemia\/Lymphoma Target Board for pediatric relapsed and refractory hematological malignancies.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2025.300154. Online ahead of print","author":"Ilan U, Boer JM, Luesink M, Bautista F, Hofmans M, Vedi A, Egyed B, Geoerger B, Tuckuviene R, Als-Nielsen B, Velasco P, Fuster JL, Rubio A, Tasian SK, Delft FV, Irving JAE, Erdely DJ, Schmiegelow K, De Moerloose B, Baruchel A, Den Boer ML, Zwaan MC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924922"},{"title01":"Azacitidine-induced remission enables allogeneic transplantation in TET2\/BCOR-mutant relapsed extranodal natural killer\/T-cell lymphoma: a case report.","title02":"Azacitidine-induced remission enables allogeneic transplantation in TET2\/BCOR-mutant relapsed extranodal natural killer\/T-cell lymphoma: a case report.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2025.300314. Online ahead of print","author":"Ortiz CR, Abouzeid H, De Bernardi C, Durham A, Mathoux G, Masouridi S, Mckee TA, Sibon D, Hermine O, Weinstock DM, Egervari K, Tamburini J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924921"},{"title01":"CAR-T therapy for relapsed\/refractory large B-cell lymphoma in people living with HIV: efficacy, toxicity and treatment considerations.","title02":"CAR-T therapy for relapsed\/refractory large B-cell lymphoma in people living with HIV: efficacy, toxicity and treatment considerations.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2025.300151. Online ahead of print","author":"Hwang A, Kirkwood AA, Hardefeldt P, Amrith M, O'Reilly M, Kuhnl A, Northend M, Maciocia P, Chaganti S, Cwynarski K, Sanderson R, Roddie C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924913"},{"title01":"Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R.","title02":"Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R.","journal":"Haematologica","issue":"2026 April 1; 111(4):1389-1395. doi: 10.3324\/haematol.2025.288232","author":"Hess B, Moskowitz A, Davis JA, Strati P, Sawalha Y, Bakos J, Sorrell M, Ferreira AC, Escribano-Serrat S, De Castro M, Brooks TR, Hill BT, Shah GL, Falade AS, Merryman R, Kamdar M, Ip A, Nachar V, Bennett JG, Lux N, Ahmed N, Hoffmann M, LaCasce A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41163564"},{"title01":"CNS infiltration by zamtocabtagene autoleucel tandem CD20\/CD19 CAR T cells leading to complete remission in a patient with primary CNS lymphoma.","title02":"CNS infiltration by zamtocabtagene autoleucel tandem CD20\/CD19 CAR T cells leading to complete remission in a patient with primary CNS lymphoma.","journal":"Haematologica","issue":"2026 April 1; 111(4):1494-1499. doi: 10.3324\/haematol.2025.288856","author":"Hardy NM, Yared JA, Luetkens T, Ahmad H, Mulatu R, Yamoah D, Fan X, Weeks S, Bredar SA, Gelin A, Baker JM, Dietze KA, Matsangos A, Fromowitz A, Theruvath J, Wirthlin L, Kaleta R, Wijatyk A, Koka R, Kallen ME, Hankey KG, Rapoport AP, Atanackovic D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41098100"},{"title01":"Clonal haematopoiesis in T-follicular helper cell lymphoma: A prognostic biomarker and early event in lymphoma evolution.","title02":"Clonal haematopoiesis in T-follicular helper cell lymphoma: A prognostic biomarker and early event in lymphoma evolution.","journal":"Br J Haematol","issue":"2026 April; 208(4):1223-1231. doi: 10.1111\/bjh.70363","author":"Wei C, Zhang Y, Zhao D, Zhang W, Zhou D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41668589"},{"title01":"UV-induced mutations accumulate during early clonal expansion in aneuploid subtypes of pediatric B-cell precursor acute lymphoblastic leukemia.","title02":"UV-induced mutations accumulate during early clonal expansion in aneuploid subtypes of pediatric B-cell precursor acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 April 9. doi: 10.3324\/haematol.2025.300118. Online ahead of print","author":"Suurenbroek LC, Van der Ham CG, Boer JM, Derks LLM, Hagelaar R, Van Roosmalen MJ, Klamer P, Sonneveld E, Den Boer ML, Van Boxtel R, Van Leeuwen FN, Loeffen JLC, Kuiper RP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952634"},{"title01":"Hypomethylating agents plus venetoclax versus intensive chemotherapy prior to transplant in high-risk acute myeloid leukemia.","title02":"Hypomethylating agents plus venetoclax versus intensive chemotherapy prior to transplant in high-risk acute myeloid leukemia.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2025.300202. Online ahead of print","author":"Berton G, Bewersdorf JP, Gilhodes J, Iat A, Soua A, DeAngelo DJ, Boussi L, Shallis RM, Zucenka A, Bystrom RP, Ling K, Aguirre LE, Stone RM, Luskin MR, Garcia JS, Winer ES, Chen EC, Wadleigh M, Mendez L, Podoltsev N, Tauveron-Jalenques U, Lanino L, Stein E, Zeidan AM, Forcade E, Cluzeau T, Dumas PY, Heiblig M, Devillier R, Shimony S, Goldberg AD, Stahl M, Garciaz S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924924"},{"title01":"SLC25A1 reprograms mitochondrial and fatty acid metabolism to promote the progression of acute myeloid leukemia.","title02":"SLC25A1 reprograms mitochondrial and fatty acid metabolism to promote the progression of acute myeloid leukemia.","journal":"Haematologica","issue":"2026 April 1; 111(4):1220-1234. doi: 10.3324\/haematol.2024.287269","author":"Chen M, Li W, Tao Y, Hu C, Ge R, Kang S, Yue P, Man CH, Wang L, Yan X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905075"},{"title01":"Clinical and germline risk factors for multiple treatmentrelated toxicities in pediatric acute lymphoblastic leukemia.","title02":"Clinical and germline risk factors for multiple treatmentrelated toxicities in pediatric acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 April 1; 111(4):1478-1483. doi: 10.3324\/haematol.2025.288939","author":"Mateos MK, Mayoh C, Sullivan P, Barbaro PM, Quinn MCJ, George C, Sutton R, Revesz T, Giles JE, Barbaric D, Alvaro F, Conyers R, Catchpoole D, MacGregor S, Kotecha RS, Dalla-Pozza L, Trahair TN, Marshall GM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41163570"},{"title01":"Combined asciminib and olverembatinib in blast-phase chronic myeloid leukemia.","title02":"Combined asciminib and olverembatinib in blast-phase chronic myeloid leukemia.","journal":"Haematologica","issue":"2026 April 1; 111(4):1500-1504. doi: 10.3324\/haematol.2025.289085","author":"Cheng F, Li W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376545"},{"title01":"Identification of a novel MYO1F::MLLT10 fusion in adult acute monocytic leukemia.","title02":"Identification of a novel MYO1F::MLLT10 fusion in adult acute monocytic leukemia.","journal":"Haematologica","issue":"2026 April 1; 111(4):1427-1431. doi: 10.3324\/haematol.2025.288255","author":"Shah B, Francis R, Pei J, Neumann-Domer R, Mackrides N, Testa JR, Nejati R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262051"},{"title01":"The comprehensive landscape of TTMV::RARA fusiondriven acute myeloid leukemia: from viral integration mechanisms to clinical outcomes.","title02":"The comprehensive landscape of TTMV::RARA fusiondriven acute myeloid leukemia: from viral integration mechanisms to clinical outcomes.","journal":"Haematologica","issue":"2026 April 1; 111(4):1254-1264. doi: 10.3324\/haematol.2025.288721","author":"Sun S, Liu Y, Xu QY, Wang J, Chen L, Cheng Z, Gao W, Wang H, Yang B, Wang H, Wen L, Xiao J, Lou J, Yu H, Li N, Wang F, Xie Y, Wang J, Wang X, Xue H, Chen K, Wu Y, Zhang L, Li K, Shen S, Chen S, Wang HY, Wang K, Huang J, Zhu HH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41230695"},{"title01":"An emerging triplet option for newly diagnosed FLT3-mutated acute myeloid leukemia.","title02":"An emerging triplet option for newly diagnosed FLT3-mutated acute myeloid leukemia.","journal":"Haematologica","issue":"2026 April 1; 111(4):1162-1164. doi: 10.3324\/haematol.2025.289066","author":"Boussi L, Goldberg AD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41230690"},{"title01":"All patients with AML and FLT3-ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? &#8211; the PRO.","title02":"All patients with AML and FLT3-ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? &#8211; the PRO.","journal":"Haematologica","issue":"2026 April 1; 111(4):1149-1152. doi: 10.3324\/haematol.2025.288785","author":"Kayser S, Schlenk RF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537334"},{"title01":"All patients with acute myeloid leukemia and FLT3-ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? &#8211; the CON.","title02":"All patients with acute myeloid leukemia and FLT3-ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? &#8211; the CON.","journal":"Haematologica","issue":"2026 April 1; 111(4):1153-1158. doi: 10.3324\/haematol.2025.288786","author":"Russell NH, Lewis KD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537333"},{"title01":"Patient-centered care strategies for Jehovah&#8217;s Witnesses with acute leukemia and high-grade myeloid neoplasms.","title02":"Patient-centered care strategies for Jehovah&#8217;s Witnesses with acute leukemia and high-grade myeloid neoplasms.","journal":"Haematologica","issue":"2026 April 1; 111(4):1469-1473. doi: 10.3324\/haematol.2025.288622","author":"Zarka J, Al-Kali A, Alkhateeb HB, Matin A, Gangat N, Hogan WJ, Foran J, Murthy H, Yi CA, Prasad DK, Mina S, Litzow MR, Begna KH, Saliba AN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41163567"},{"title01":"Children with chronic-phase chronic myeloid leukemia: characteristics and outcomes from the International Registry of Childhood CML.","title02":"Children with chronic-phase chronic myeloid leukemia: characteristics and outcomes from the International Registry of Childhood CML.","journal":"Haematologica","issue":"2026 April 1; 111(4):1280-1288. doi: 10.3324\/haematol.2025.288283","author":"Millot F, De Keizer J, Metzler M, Kalwak K, Gunes AM, De Moerloose B, Luesink M, Honrubia AM, Sedlacek P, Yajima J, Ampatzidou M, Dworzak M, Lausen B, Borisevich M, Li CK, Kolenova A, Jakovljevic G, Farah R, Durocher L, Baruchel A, Suttorp M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41126742"},{"title01":"Age-specific mutation profiles and their prognostic implications in pediatric KMT2A-rearranged acute myeloid leukemia.","title02":"Age-specific mutation profiles and their prognostic implications in pediatric KMT2A-rearranged acute myeloid leukemia.","journal":"Haematologica","issue":"2026 April 1; 111(4):1235-1245. doi: 10.3324\/haematol.2025.288481","author":"Shoji K, Yoshida K, Iyoda S, Ishikawa M, Tanaka M, Nobe M, Saito N, Shino Y, Nannya Y, Yamato G, Tsujimoto S, Shiba N, Hayashi Y, Shiozawa Y, Shiraishi Y, Chiba K, Okada A, Tanaka H, Miyano S, Koga Y, Goto H, Terui K, Ito E, Kiyokawa N, Tomizawa D, Taga T, Moritake H, Tawa A, Takita J, Nishikori M, Adachi S, Ogawa S, Matsuo H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41126738"},{"title01":"Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor.","title02":"Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor.","journal":"Haematologica","issue":"2026 April 1; 111(4):1246-1253. doi: 10.3324\/haematol.2025.288553","author":"Short NJ, Loghavi S, Yilmaz M, Karrar O, Kim K, Dinardo CD, Kadia TM, Maroun M, Borthakur G, Issa GC, Jabbour J, Oran B, Shpall EJ, Popat U, Patel KP, Routbort M, Konopleva M, Ravandi F, Kantarjian H, Daver N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41035402"},{"title01":"Genetic characterization of AML defined by differentiation shows a high frequency of DDX41 mutations.","title02":"Genetic characterization of AML defined by differentiation shows a high frequency of DDX41 mutations.","journal":"Br J Haematol","issue":"2026 April 14. doi: 10.1111\/bjh.70484. Online ahead of print","author":"Huber S, Kornauth C, Hutter S, Meggendorfer M, Summerer I, Kern W, Haferlach T, Pohlkamp C, Hoermann G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41979368"},{"title01":"Distribution of adult T-cell leukaemia\/lymphoma subtypes and survival outcomes across geographical regions: An international retrospective cohort study.","title02":"Distribution of adult T-cell leukaemia\/lymphoma subtypes and survival outcomes across geographical regions: An international retrospective cohort study.","journal":"Br J Haematol","issue":"2026 April 15. doi: 10.1111\/bjh.70494. Online ahead of print","author":"Valcarcel B, Utsunomiya A, Otsuka M, Miyahara M, Ishitsuka K, Takamatsu Y, Suzumiya J, Tamura K, Vasquez JF, Enriquez-Vera D, Beltran BE, Castro D, Runciman T, Idrobo H, Arrieta E, Arias O, Gotuzzo E, Garrido-Pinzas G, Rivera V, Rosa D, Pena C, Fiad L, Ramos JC, Sandoval-Sus J, Sica A, Bell BN, Cook LB, Leataud V, Miranda ECM, Chiattone C, Katsuya H, Malpica L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41986288"},{"title01":"Plasma calprotectin to assess susceptibility to bloodstream infections during paediatric acute lymphoblastic leukaemia induction treatment.","title02":"Plasma calprotectin to assess susceptibility to bloodstream infections during paediatric acute lymphoblastic leukaemia induction treatment.","journal":"Br J Haematol","issue":"2026 April; 208(4):1339-1346. doi: 10.1111\/bjh.70393","author":"Eriksen JVN, de Pietri S, Rathe M, Hasle H, Enevold C, Nielsen CH, Schmigelow K, Moser C, Muller K, Weischendorff S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733102"},{"title01":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: A 25-year nationwide study.","title02":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: A 25-year nationwide study.","journal":"Br J Haematol","issue":"2026 April 5. doi: 10.1111\/bjh.70463. Online ahead of print","author":"Itonaga H, Miyazaki Y, Tachi N, Kurosawa S, Marumo A, Konuma T, Ebina T, Doki N, Uchida N, Fukuda T, Nishida T, Katayama Y, Asada N, Sakurai M, Maeda T, Eto T, Tanaka M, Nakamae H, Onizuka M, Kawamura K, Kanda Y, Atsuta Y, Tachibana T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41937388"},{"title01":"Equal outcomes after human leukocyte antigen-matched unrelated versus sibling donor transplants-Results of the AML SCT-BFM 2007 trial and consecutive &#8216;real-world routine&#8217;.","title02":"Equal outcomes after human leukocyte antigen-matched unrelated versus sibling donor transplants-Results of the AML SCT-BFM 2007 trial and consecutive &#8216;real-world routine&#8217;.","journal":"Br J Haematol","issue":"2026 April; 208(4):1472-1476. doi: 10.1111\/bjh.70324","author":"Sauer MG, Lang PJ, Albert MH, Bader P, Eyrich M, Gruhn B, Klingebiel T, Mauz-Korholz C, Meisel R, Muller I, Niemeyer CM, Peters C, Burkhardt B, Reinhardt D, Sedlacek P, Strahm B, Woessmann W, Handgretinger R, Zimmermann M, Borkhardt A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41502109"},{"title01":"BRAF inhibitor plus rituximab in classical hairy cell leukaemia: A retrospective multicentre real-life study.","title02":"BRAF inhibitor plus rituximab in classical hairy cell leukaemia: A retrospective multicentre real-life study.","journal":"Br J Haematol","issue":"2026 April 9. doi: 10.1111\/bjh.70476. Online ahead of print","author":"Tauveron-Jalenques U, Inchiappa L, Paillassa J, Maitre E, Willems L, Stocker N, Merabet F, Lok A, Lara D, Bijou F, Herbaux C, Ramos I, Guieze R, Tomowiak C, Troussard X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41958072"},{"title01":"Selective DHCR7 inhibition versus AEBS modulation: Mechanistic implications for tamoxifen effects in AML.","title02":"Selective DHCR7 inhibition versus AEBS modulation: Mechanistic implications for tamoxifen effects in AML.","journal":"Br J Haematol","issue":"2026 April; 208(4):1501-1502. doi: 10.1111\/bjh.70420","author":"Poirot M, de Medina P, Silvente-Poirot S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41804099"},{"title01":"Identification of cellular hierarchy in paediatric acute myeloid leukaemia: The Japan Children&#8217;s Cancer Group trial (JCCG AML-12).","title02":"Identification of cellular hierarchy in paediatric acute myeloid leukaemia: The Japan Children&#8217;s Cancer Group trial (JCCG AML-12).","journal":"Br J Haematol","issue":"2026 April; 208(4):1252-1262. doi: 10.1111\/bjh.70355","author":"Komori T, Kawai T, Okuno Y, Tsujimoto S, Kato S, Kamitori T, Saida S, Ikeda J, Ohki K, Kato M, Tomizawa D, Taga T, Takita J, Horibe K, Adachi S, Hayashi Y, Ito S, Shiba N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41631723"},{"title01":"DHCR7 drives AML development through the IL6\/JAK2\/STAT3 signalling pathway.","title02":"DHCR7 drives AML development through the IL6\/JAK2\/STAT3 signalling pathway.","journal":"Br J Haematol","issue":"2026 April; 208(4):1263-1277. doi: 10.1111\/bjh.70346","author":"Dai X, Wu Z, Zhang W, Chen S, Zhao X, Lu Y, Ma Y, Zheng W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41608869"},{"title01":"Transplant outcomes in adolescents and young adults with Philadelphia-positive B-cell acute lymphoblastic leukaemia.","title02":"Transplant outcomes in adolescents and young adults with Philadelphia-positive B-cell acute lymphoblastic leukaemia.","journal":"Br J Haematol","issue":"2026 April; 208(4):1467-1471. doi: 10.1111\/bjh.70347","author":"Aleid M, Fakih RE, Hanbali A, Alfraih F, Alothaimeen H, Elhassan T, Alahmari A, Rasheed W, Almohareb F, Chaudhri N, Alotaibi S, Alsharif F, Shaheen M, Alhayli S, Alkhaldi H, Alyamany R, Alshaibani A, Alotaibi AS, Alamer A, Albabtain AA, Ahmed SO, Alzahrani H, Aljurf M, Saad A, Alfayez M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41582435"},{"title01":"Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.","title02":"Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.","journal":"Br J Haematol","issue":"2026 April; 208(4):1359-1368. doi: 10.1111\/bjh.70380","author":"Desai N, Althobaiti M, Chen C, Al-Shaibani E, Moya TA, Novitzky-Basso I, Pasic I, Michelis FV, Kim DD, Kumar R, Mattsson J, Law AD, Viswabandya A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41747740"},{"title01":"Immune-related toxicity profile after haematopoietic stem cell transplantation in patients with B-ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab.","title02":"Immune-related toxicity profile after haematopoietic stem cell transplantation in patients with B-ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab.","journal":"Br J Haematol","issue":"2026 April; 208(4):1462-1466. doi: 10.1111\/bjh.70350","author":"Okeleji O, McCall D, Cuglievan B, Gibson A, Petropoulos D, Tewari P, Connors J, Sheikh IN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41582414"},{"title01":"Second primary malignancies in Asian chronic lymphocytic leukaemia patients: A Taiwan Cancer Registry Study.","title02":"Second primary malignancies in Asian chronic lymphocytic leukaemia patients: A Taiwan Cancer Registry Study.","journal":"Br J Haematol","issue":"2026 April; 208(4):1278-1286. doi: 10.1111\/bjh.70353","author":"Lee YW, Chiang CJ, Lin YC, Tzeng HE, Chuang YT, Yang YW, Lee WC, Wu SJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41608915"},{"title01":"PTP4A2 Promotes Leukemogenesis through Inhibiting the p53 Tumor Suppressor Signaling Pathway in Leukemia-initiating Cells.","title02":"PTP4A2 Promotes Leukemogenesis through Inhibiting the p53 Tumor Suppressor Signaling Pathway in Leukemia-initiating Cells.","journal":"Blood advances","issue":"2026 April 15. doi: 10.1182\/bloodadvances.2025018908. Online ahead of print","author":"Xiao S, Kopbayashi M, Bai Y, Cai W, Barajas S, Amin MA, Vemula S, Yao C, Yang Y, Borchers C, Mays TM, Sotelo M, Pan H, Jia Y, Shen J, Hu SKK, Ali M, Veranga S, Ogino J, Eggleston SG, Liu H, Perlman H, Li L, Altman JK, Abaza Y, Eklund EA, Ji P, Zhang CR, Khan I, Mayo LD, Mulloy JC, Sukhanova M, Dou Y, Platanias LC, Zhang ZY, Chen H, Liu Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41985006"},{"title01":"Chromosome 15q deletions confer inferior outcomes among children with ETV6::RUNX1 B-Cell Acute Lymphoblastic Leukemia.","title02":"Chromosome 15q deletions confer inferior outcomes among children with ETV6::RUNX1 B-Cell Acute Lymphoblastic Leukemia.","journal":"Blood advances","issue":"2026 April 15. doi: 10.1182\/bloodadvances.2026019599. Online ahead of print","author":"Wang'ondu RW, Kairalla JA, Shago M, Angiolillo A, Breidenbach HM, Burke MJ, Carroll AJ, Rabin KR, Salzer W, Schore RJ, Wang C, Hunger SP, Teachey DT, Raetz EA, Loh ML, Davis KL, Rau RE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41985005"},{"title01":"Adding Induction Intrathecal Cytarabine in Newly Diagnosed CNS2 B-Acute Lymphoblastic Leukemia Does Not Improve Outcomes.","title02":"Adding Induction Intrathecal Cytarabine in Newly Diagnosed CNS2 B-Acute Lymphoblastic Leukemia Does Not Improve Outcomes.","journal":"Blood advances","issue":"2026 April 15. doi: 10.1182\/bloodadvances.2026019660. Online ahead of print","author":"Lee-Miller CA, Kairalla JA, Hibbitts E, Winick NJ, Rabin KR, Angiolillo A, Schore RJ, Salzer W, Burke MJ, Loh ML, Raetz EA, Hunger SP, Devidas M, Teachey DT, Gupta S, McNeer J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41984995"},{"title01":"Advancing precision therapy in pediatric acute myeloid leukemia through PDX models and mitochondrial targeting.","title02":"Advancing precision therapy in pediatric acute myeloid leukemia through PDX models and mitochondrial targeting.","journal":"Blood advances","issue":"2026 April 14; 10(7):2153-2167. doi: 10.1182\/bloodadvances.2025018002","author":"Da Ros A, Peloso A, Longo G, Benetton M, Indio V, Cairo S, Sandri M, Buldini B, Bresolin S, Rosato A, Pession A, Tregnago C, Locatelli F, Pigazzi M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41576348"},{"title01":"Clinical outcomes of older patients with NPM1-mutated or KMT2A-rearranged AML before menin inhibitors: a Beat AML report.","title02":"Clinical outcomes of older patients with NPM1-mutated or KMT2A-rearranged AML before menin inhibitors: a Beat AML report.","journal":"Blood advances","issue":"2026 April 14; 10(7):2328-2332. doi: 10.1182\/bloodadvances.2025019153","author":"Zeidner JF, Jain J, Welkie RL, Huang Y, Swords RT, Traer E, Stein EM, Lin TL, Madanat YF, Collins RH, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike O, Olin RL, Smith CC, Foran JM, Schiller GJ, Curran EK, Handa S, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Mims AS, Byrd JC, Borate U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632633"},{"title01":"Mining single-cell transcriptomic data reveals distinct T-cell population in pediatric B-ALL and AML at diagnosis.","title02":"Mining single-cell transcriptomic data reveals distinct T-cell population in pediatric B-ALL and AML at diagnosis.","journal":"Blood advances","issue":"2026 April 14. doi: 10.1182\/bloodadvances.2025019565. Online ahead of print","author":"Tian L, Gottschalk S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41979357"},{"title01":"Haploidentical versus matched unrelated donor transplantation with post-transplant cyclophosphamide: a platform-dependent machine learning analysis of donor age.","title02":"Haploidentical versus matched unrelated donor transplantation with post-transplant cyclophosphamide: a platform-dependent machine learning analysis of donor age.","journal":"Leukemia","issue":"2026 April 15. doi: 10.1038\/s41375-026-02903-8. Online ahead of print","author":"Mehta RS, Kanakry CG, Nawas M, Lazaryan A, Kanakry JA, Holtan S, Al-Juhaishi T, Rimando JC, Singh A, Saultz J, Mccurdy SR, Milano F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41986623"},{"title01":"Error-corrected next-generation sequencing for profiling the subclonal genetic architecture of juvenile myelomonocytic leukemia.","title02":"Error-corrected next-generation sequencing for profiling the subclonal genetic architecture of juvenile myelomonocytic leukemia.","journal":"Leukemia","issue":"2026 April 7. doi: 10.1038\/s41375-026-02922-5. Online ahead of print","author":"Sajiki D, Muramatsu H, Wakamatsu M, Tsumura Y, Yamashita D, Yamamori A, Narita K, Kataoka S, Takahashi Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41942652"},{"title01":"Correction: Peripheral blood flow cytometry-based definition of plasma cell leukemia.","title02":"Correction: Peripheral blood flow cytometry-based definition of plasma cell leukemia.","journal":"Leukemia","issue":"2026 April; 40(4):854. doi: 10.1038\/s41375-026-02897-3","author":"Bohra A, Hassan R, Zanwar S, Jevremovic D, Olteanu H, Gonsalves WI, Otteson G, Horna P, Rajkumar SV, Kumar S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41741799"},{"title01":"Correction: Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis.","title02":"Correction: Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis.","journal":"Leukemia","issue":"2026 April; 40(4):855. doi: 10.1038\/s41375-026-02909-2","author":"Setiawan T, Muhammad JA, Julianto NM, Wirawan LM, Jun N, Sari IN, Oehler VG, Kim DW, Kwon HY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41787068"},{"title01":"Enhancing tyrosine kinase inhibitor sensitivity by restoring IKAROS activity on GLUT1 expression and glycolysis in Philadelphia chromosome-positive acute lymphoblastic leukemia.","title02":"Enhancing tyrosine kinase inhibitor sensitivity by restoring IKAROS activity on GLUT1 expression and glycolysis in Philadelphia chromosome-positive acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 April; 40(4):794-805. doi: 10.1038\/s41375-026-02898-2","author":"Zhang L, Han Q, Xiang H, Lapalombella R, Eisfeld AK, Hanel WG, Brammer JE, Mims AS, Woyach JA, Song C, Ge Z","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41792440"},{"title01":"Does stringent cytoreduction improve survival in advanced proliferative chronic myelomonocytic leukemia?","title02":"Does stringent cytoreduction improve survival in advanced proliferative chronic myelomonocytic leukemia?","journal":"Leukemia","issue":"2026 April; 40(4):806-815. doi: 10.1038\/s41375-026-02901-w","author":"Selimoglu-Buet D, Chevret S, Santini V, Thepot S, Morabito M, Ades L, Laplane L, Giagounidis A, Droin N, Lubbert M, Sapena R, Nimubona S, Torregrosa-Diaz JM, Germing U, Pelizzari AM, Park S, Jaekel N, Metzgeroth G, Onida F, Paul F, Patriarca A, Stamatoullas A, Gotze K, Chermat F, Platzbecker U, Fenaux P, Solary E, Itzykson R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41803403"},{"title01":"High-risk molecular features may eclipse genomic complexity in predicting chronic lymphocytic leukemia outcomes; UK clinical trial insights.","title02":"High-risk molecular features may eclipse genomic complexity in predicting chronic lymphocytic leukemia outcomes; UK clinical trial insights.","journal":"Leukemia","issue":"2026 April; 40(4):816-826. doi: 10.1038\/s41375-026-02906-5","author":"Parker H, Carr L, Norris K, Nilsson-Takeuchi A, Stevens B, Amarasinghe H, Kadalayil L, Else M, Clifford R, Pettitt A, Munir T, Schuh A, Walewska R, Baird DM, Oscier DG, Pepper C, Bryant D, Gibson J, Strefford JC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41814015"},{"title01":"Correction: BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML.","title02":"Correction: BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML.","journal":"Leukemia","issue":"2026 April; 40(4):856. doi: 10.1038\/s41375-026-02911-8","author":"Birdwell CE, Fiskus W, Mill CP, Kadia TM, Daver N, DiNardo CD, Sasaki K, Davis JA, Das K, Hou H, Jain A, Malovannaya A, Flores LB, Pourebrahim R, Yuan S, Su X, Ceribelli M, Bhalla KN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41814016"},{"title01":"Chronic myeloid leukaemia: have basophils gone the way of the Dodo bird?","title02":"Chronic myeloid leukaemia: have basophils gone the way of the Dodo bird?","journal":"Leukemia","issue":"2026 April; 40(4):713-716. doi: 10.1038\/s41375-026-02910-9","author":"Turcsanyi L, Zhang XS, Kudelka M, Kubikova K, Radvansky M, Yang S, Kriegova E, Juranova J, Mayer J, Klamova H, Belohlavkova P, Karas M, Stejskal L, Cmunt E, Othus M, Gale RP, Jiang Q, Faber E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41840226"},{"title01":"Testicular organoids formation from leukaemia-infiltrated prepubertal testicular tissue: implications for fertility preservation.","title02":"Testicular organoids formation from leukaemia-infiltrated prepubertal testicular tissue: implications for fertility preservation.","journal":"Leukemia","issue":"2026 April 1. doi: 10.1038\/s41375-026-02938-x. Online ahead of print","author":"Cui Y, Lohi J, Lindskog C, Jahnukainen K, Stukenborg JB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41922798"},{"title01":"Development of a prognostic scoring system for chronic myeloid leukemia in blast phase.","title02":"Development of a prognostic scoring system for chronic myeloid leukemia in blast phase.","journal":"Leukemia","issue":"2026 April; 40(4):751-758. doi: 10.1038\/s41375-026-02875-9","author":"Lauseker M, Sacha T, Klamova H, Yakoleva J, Lomaia E, Milojkovic D, Fabisch C, Nicolini FE, Olsson-Stromberg U, Zackova D, Lewandowski K, Ernst P, Castagnetti F, Hirschbuhl K, Zupan I, Voskanyan A, Golos A, Frietsch JJ, Gil J, Faber E, Krause SW, Parry A, Saussele S, Heibl S, Franke GN, Casado LF, Paczkowska E, Hebart H, Eder M, Anhut P, Trautmann-Grill K, Szczepanek E, Sudhoff T, Patkowska E, Kiani A, Ernst T, Apperley J, Mayer J, Hochhaus A, Pfirrmann M, Brioli A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41714405"},{"title01":"A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia.","title02":"A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia.","journal":"Leukemia","issue":"2026 April; 40(4):717-729. doi: 10.1038\/s41375-026-02883-9","author":"Chakraborty S, Morganti C, Zaldana K, Rivera Pena B, Zhang H, Verma D, Gitego N, Ma F, Aluri S, Pradhan K, Gordon-Mitchell S, Mantzaris I, Goldfinger M, Feldman E, Gritsman K, Shi Y, Hubner S, Qiu YH, Brown BD, Khasawneh A, Skwarska A, de Camargo Magalhaes ES, Verma A, Konopleva M, Tabe Y, Gavathiotis E, Colla S, Gollob J, Dey J, Kornblau SM, Koralov SB, Ito K, Shastri A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703028"},{"title01":"Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX models.","title02":"Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX models.","journal":"Leukemia","issue":"2026 April 15. doi: 10.1038\/s41375-026-02957-8. Online ahead of print","author":"Kandarpa M, Peterson LF, Potu H, Ramappan M, Liu Y, Polk A, Wang S, Talpaz M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41986621"},{"title01":"Elevated levels of TNF and its targets characterize better-risk older acute myeloid leukemia patients.","title02":"Elevated levels of TNF and its targets characterize better-risk older acute myeloid leukemia patients.","journal":"Leukemia","issue":"2026 April 13. doi: 10.1038\/s41375-026-02954-x. Online ahead of print","author":"Neelamraju Y, Rapaport F, Gandara JA, Paudel BB, DeWolf S, Dunham N, Fan H, Lee T, Mayo MW, Othman J, Sheridan C, Sol-Church K, Solga MD, Wang L, Cripe LD, Dillon R, Kleppe M, Carroll M, Mason CE, Roboz GJ, Sun Z, Tallman MS, Zhang Y, Paietta E, Levine R, Melnick AM, Bekiranov S, Garrett-Bakelman FE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41975002"},{"title01":"Adherence-enhancing intervention and relapse in childhood acute lymphoblastic leukemia: results from the Children&#8217;s Oncology Group randomized trial ACCL1033.","title02":"Adherence-enhancing intervention and relapse in childhood acute lymphoblastic leukemia: results from the Children&#8217;s Oncology Group randomized trial ACCL1033.","journal":"Leukemia","issue":"2026 April 13. doi: 10.1038\/s41375-026-02951-0. Online ahead of print","author":"Bhatia S, Hageman L, Chen Y, Wadhwa A, Wong FL, McQuaid EL, Freyer DR, Mba N, Aristizabal P, Raetz E, Landier W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41975001"},{"title01":"mRNA vaccination targeting AML1::ETO fusion gene eliminates leukemia cells via activating T cells.","title02":"mRNA vaccination targeting AML1::ETO fusion gene eliminates leukemia cells via activating T cells.","journal":"Leukemia","issue":"2026 April 10. doi: 10.1038\/s41375-026-02940-3. Online ahead of print","author":"Zhou C, Bian S, Pang J, Bian H, Cheng T, Koyama H, Liu B, Li B, Tse W, Liu S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41963593"},{"title01":"Overcoming MEN1-mediated resistance with menin inhibitor switching in KMT2A-rearranged acute myeloid leukemia.","title02":"Overcoming MEN1-mediated resistance with menin inhibitor switching in KMT2A-rearranged acute myeloid leukemia.","journal":"Leukemia","issue":"2026 April 10. doi: 10.1038\/s41375-026-02959-6. Online ahead of print","author":"Chin KK, Abdul-Hay M, Shukla M, Geyer MB, Tamari R, Ko KH, Xiao W, Stein EM, Cai SF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41963592"},{"title01":"Concomitant or sequential lower intensity triplet therapy in AML.","title02":"Concomitant or sequential lower intensity triplet therapy in AML.","journal":"Lancet Haematol","issue":"2026 April; 13(4):e197-e198. doi: 10.1016\/S2352-3026(26)00031-1","author":"Senapati J, Daver NG, Jain J, Mims AS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41934991"},{"title01":"Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65\/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.","title02":"Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65\/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.","journal":"Lancet","issue":"2026 April 10. doi: 10.1016\/S0140-6736(26)00602-1. Online ahead of print","author":"Colombo N, Zsiros E, Parma G, Rulli E, Sebastianelli A, Bidzinski M, Gallardo C, Matanes E, Hasegawa K, Kose F, Magallanes-Maciel M, Herbertson RA, Ananda S, Kroep JR, de Melo AC, Debruyne PR, Kim JW, Sehouli J, Pierre ME, Hietanen S, Zamagni C, Lu X, Monk BJ, Coleman RL, Peng X, Yamada K, Bogusz AM, De La Motte Rouge T, Wu X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41974150"},{"title01":"First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.","title02":"First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.","journal":"J Clin Oncol","issue":"2026 April 6; JCO2501966. doi: 10.1200\/JCO-25-01966. Online ahead of print","author":"Rettinger E, Heckl D, Hutter M, Salzmann-Manrique E, Luedtke M, Huenecke S, Bremm M, Cappel C, Bug G, Greil J, Meisel R, Wagner-Drouet EM, Serve H, Gungor T, Klusmann JH, Klingebiel T, Bader P, Bonig H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41941697"},{"title01":"Conditioning for acute myeloid leukemia: looking beyond intensity.","title02":"Conditioning for acute myeloid leukemia: looking beyond intensity.","journal":"Haematologica","issue":"2026 April 9. doi: 10.3324\/haematol.2026.300787. Online ahead of print","author":"Gilbert JS, Milano F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952631"},{"title01":"Gatekeepers of mitochondrial metabolism: the emerging role of the SLC25 family in leukemia.","title02":"Gatekeepers of mitochondrial metabolism: the emerging role of the SLC25 family in leukemia.","journal":"Haematologica","issue":"2026 April 1; 111(4):1159-1161. doi: 10.3324\/haematol.2025.288787","author":"Haran A, Nachmias B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40994341"},{"title01":"Novel ligand-binding domain truncated CPSF7::RARA::CPSF7 tripartite fusion confers primary ATRA resistance in atypical acute promyelocytic leukemia.","title02":"Novel ligand-binding domain truncated CPSF7::RARA::CPSF7 tripartite fusion confers primary ATRA resistance in atypical acute promyelocytic leukemia.","journal":"Haematologica","issue":"2026 April 9. doi: 10.3324\/haematol.2026.300631. Online ahead of print","author":"Dong K, An Z, Dong C, Jin Z, Wang X, Qiao B, Ning Y, Sun Z, Qianni J, Ren F, Zhang Y, Chang J, Guo L, Zhou X, Liu H, Xu Z, Wang H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952642"},{"title01":"Azacitidine for MDS and CMML.","title02":"Azacitidine for MDS and CMML.","journal":"Haematologica","issue":"2026 April 1; 111(4):1147-1148. doi: 10.3324\/haematol.2026.289398","author":"Martin ES, Patnaik MM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41919559"},{"title01":"Understanding drug resistance in chronic myeloid leukemia through the lens of leukemic stem cell states: insights from single-cell analyses.","title02":"Understanding drug resistance in chronic myeloid leukemia through the lens of leukemic stem cell states: insights from single-cell analyses.","journal":"Haematologica","issue":"2026 April 9. doi: 10.3324\/haematol.2025.287767. Online ahead of print","author":"Krishnan V, Shyamsunder P, Ong TS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952641"},{"title01":"Disease course of FLT3 mutated extramedullary acute myeloid leukemia and efficacy of gilteritinib.","title02":"Disease course of FLT3 mutated extramedullary acute myeloid leukemia and efficacy of gilteritinib.","journal":"Haematologica","issue":"2026 April 9. doi: 10.3324\/haematol.2026.300540. Online ahead of print","author":"Angotzi F, Borlenghi E, Sartor C, Giannini MB, Marconi G, Tamellini E, Turrini M, Loscocco F, Audisio E, Federico V, Vetro C, Grimaldi F, Visentin A, Ferrara F, Trentin L, Gurrieri C, Lessi F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952620"},{"title01":"Treatment of TP53-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclax.","title02":"Treatment of TP53-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclax.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2026.300534. Online ahead of print","author":"Goldfinger M, Mantzaris I, Shastri A, Rockwell B, Saunthararajah Y, Yin S, Levitz D, Gritsman K, Sica AR, Kornblum N, Shapiro LC, Gupta R, Peeke S, Shah N, Pradhan K, Munoz A, Dhawan A, Verceles JA, Fehn K, Comas M, Shah L, Shi Y, Jonas BA, Cooper DL, Konopleva M, Feldman EJ, Verma A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924907"},{"title01":"Pharmacological blockade of rho kinase enhances venetoclax responses in translational models of acute myeloid leukemia.","title02":"Pharmacological blockade of rho kinase enhances venetoclax responses in translational models of acute myeloid leukemia.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2025.289041. Online ahead of print","author":"Golla U, Bhalodia R, Annageldiyev C, Patel S, Bollu VS, Tan SF, Cabot MC, Feith DJ, Loughran TP Jr, Levine RL, Mineishi S, Zheng H, Minagawa K, Hengst J, Sholler GLS, Desai D, Dovat S, Fisher-Wellman KH, Claxton DF, Sharma A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924919"},{"title01":"First-year results of the International Leukemia\/Lymphoma Target Board for pediatric relapsed and refractory hematological malignancies.","title02":"First-year results of the International Leukemia\/Lymphoma Target Board for pediatric relapsed and refractory hematological malignancies.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2025.300154. Online ahead of print","author":"Ilan U, Boer JM, Luesink M, Bautista F, Hofmans M, Vedi A, Egyed B, Geoerger B, Tuckuviene R, Als-Nielsen B, Velasco P, Fuster JL, Rubio A, Tasian SK, Delft FV, Irving JAE, Erdely DJ, Schmiegelow K, De Moerloose B, Baruchel A, Den Boer ML, Zwaan MC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924922"},{"title01":"Bipartite NUP98::RARA-E412* fusion with a cis-aligned ligand binding domain truncation mutation in atypical acute promyelocytic leukemia.","title02":"Bipartite NUP98::RARA-E412* fusion with a cis-aligned ligand binding domain truncation mutation in atypical acute promyelocytic leukemia.","journal":"Haematologica","issue":"2026 April 9. doi: 10.3324\/haematol.2025.300368. Online ahead of print","author":"Liu Q, Chen J, Zhou X, Teng Q, Chen X, Cao P, Fang J, Wang X, Zhang C, Ma X, Wang Z, Wang F, Zhang Y, Xin L, Liu H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952639"},{"title01":"Immunological features of acquired pure red cell aplasia: Specific human leucocyte antigen alleles, signal transducer and activator of transcription 3 mutations and a unique T-cell receptor beta motif.","title02":"Immunological features of acquired pure red cell aplasia: Specific human leucocyte antigen alleles, signal transducer and activator of transcription 3 mutations and a unique T-cell receptor beta motif.","journal":"Br J Haematol","issue":"2026 April 7. doi: 10.1111\/bjh.70475. Online ahead of print","author":"Yamashita N, Kawakami T, Matsuzawa S, Miyairi S, Maruyama M, Kawakami F, Kojima S, Yanagisawa R, Higuchi Y, Makishima H, Nakazawa H, Ishida F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41943918"}]